2021-01-28 10:45:37 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': False, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': '/binfl/lv71502/clang/fairseq/mBART_termeval/fp16_overepoch40_maxtok768x4/checkpoint_nl_comma/checkpoint_last.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': 'fp16_overepoch40_maxtok768x4/out_fp32/nl_comma_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 1024, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 1024, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_comma', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=False, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=1024, max_tokens_valid=1024, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='/binfl/lv71502/clang/fairseq/mBART_termeval/fp16_overepoch40_maxtok768x4/checkpoint_nl_comma/checkpoint_last.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='fp16_overepoch40_maxtok768x4/out_fp32/nl_comma_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-28 10:45:38 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-28 10:45:38 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-28 10:45:38 | INFO | fairseq_cli.generate | loading model(s) from /binfl/lv71502/clang/fairseq/mBART_termeval/fp16_overepoch40_maxtok768x4/checkpoint_nl_comma/checkpoint_last.pt
2021-01-28 10:46:02 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.src
2021-01-28 10:46:02 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.label
2021-01-28 10:46:02 | INFO | fairseq.tasks.translation | ./postprocessed/en_comma test src-label 2024 examples
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-0.6087672114372253	▁Sham - opera ted ▁animals
D-1339	-0.6087672114372253	Sham-operated animals
P-1339	-0.1750 -0.3924 -0.2146 -1.4290 -1.3227 -0.4104 -0.3173
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-1.2789102792739868	▁policy
D-312	-1.2789102792739868	policy
P-312	-2.3740 -1.1624 -0.3003
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-0.6364845633506775	
D-1125	-0.6364845633506775	
P-1125	-0.9586 -0.3144
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.438370019197464	
D-1399	-0.438370019197464	
P-1399	-0.5736 -0.3032
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.5006254315376282	
D-885	-0.5006254315376282	
P-885	-0.6616 -0.3396
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.3954874277114868	
D-311	-0.3954874277114868	
P-311	-0.5169 -0.2741
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients ; followed up
H-825	-0.34079501032829285	
D-825	-0.34079501032829285	
P-825	-0.4351 -0.2464
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-0.6462527513504028	▁treatment
D-749	-0.6462527513504028	treatment
P-749	-1.3079 -0.3697 -0.2611
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.36427295207977295	
D-1754	-0.36427295207977295	
P-1754	-0.4563 -0.2722
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart failure
H-1886	-0.9475160241127014	▁Heart ▁failure ▁; ▁uk
D-1886	-0.9475160241127014	Heart failure ; uk
P-1886	-2.2367 -1.0800 -0.4193 -1.0348 -0.5109 -0.4033
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-0.3944701850414276	▁CHF
D-673	-0.3944701850414276	CHF
P-673	-0.4522 -0.4088 -0.3224
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air ; heart failure
H-1805	-0.50176602602005	▁air ▁pollution ▁; ▁heart ▁failure
D-1805	-0.50176602602005	air pollution ; heart failure
P-1805	-0.2218 -0.6251 -0.3179 -1.0776 -0.4759 -0.4662 -0.3278
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise ; cardiovascular
H-1900	-1.0238932371139526	▁voordelen ▁; ▁exercise ▁; ▁cardiovascular ▁system
D-1900	-1.0238932371139526	voordelen ; exercise ; cardiovascular system
P-1900	-2.9413 -0.3258 -2.9000 -0.4328 -0.4534 -0.4478 -0.4021 -0.2880
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.331783652305603	
D-228	-0.331783652305603	
P-228	-0.4063 -0.2572
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.5245818495750427	
D-664	-0.5245818495750427	
P-664	-0.7477 -0.3014
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient ; hf
H-364	-1.1487758159637451	HF
D-364	-1.1487758159637451	HF
P-364	-2.6273 -0.4402 -0.3789
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.3686474859714508	▁eh
D-1528	-0.3686474859714508	eh
P-1528	-0.3303 -0.3902 -0.3855
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-0.48939579725265503	
D-1451	-0.48939579725265503	
P-1451	-0.6872 -0.2916
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.4029272198677063	
D-133	-0.4029272198677063	
P-133	-0.5527 -0.2532
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic ; heart failure ; outcomes
H-1198	-1.1585348844528198	▁di ure tic ▁; ▁heart ▁failure
D-1198	-1.1585348844528198	diuretic ; heart failure
P-1198	-2.4461 -1.9145 -1.2592 -1.3260 -1.0821 -0.6024 -0.3666 -0.2714
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse events
H-1988	-0.7073158621788025	
D-1988	-0.7073158621788025	
P-1988	-1.1451 -0.2696
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-0.6288241744041443	
D-1685	-0.6288241744041443	
P-1685	-0.9537 -0.3039
S-949	No major complications occurred during follow-up.<unk>
T-949	complications ; follow-up
H-949	-0.24457375705242157	▁follow - up
D-949	-0.24457375705242157	follow-up
P-949	-0.1081 -0.4002 -0.0602 -0.3606 -0.2938
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting ; cell ; anand
H-1037	-0.20826776325702667	▁Cell ▁; ▁Anand
D-1037	-0.20826776325702667	Cell ; Anand
P-1037	-0.2559 -0.1936 -0.0388 -0.3385 -0.2145
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin ; injected
H-957	-0.28993210196495056	▁do xor ubi cin
D-957	-0.28993210196495056	doxorubicin
P-957	-0.3391 -0.0638 -0.0786 -0.4598 -0.4384 -0.3598
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors ; blood transfusions
H-1684	-0.683165967464447	▁blood ▁trans fusion s
D-1684	-0.683165967464447	blood transfusions
P-1684	-2.2296 -0.0861 -0.2093 -0.5361 -0.6364 -0.4015
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart failure ; patients ; bisphosphonates
H-1534	-0.5381832122802734	▁Heart ▁failure ▁; ▁bis phos phon ates
D-1534	-0.5381832122802734	Heart failure ; bisphosphonates
P-1534	-1.2541 -0.3250 -0.3825 -0.2644 -0.0897 -0.4911 -1.1507 -0.5152 -0.3710
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox proportional hazards models
H-712	-0.5223509669303894	▁co x ▁proportion al ▁hazard s
D-712	-0.5223509669303894	cox proportional hazards
P-712	-0.3724 -0.7682 -0.1075 -0.1901 -0.4687 -1.5141 -0.4948 -0.2631
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 ; gene expression ; heart failure
H-169	-0.3741787374019623	▁Cas pas e -3 ▁gene ▁expression ▁; ▁heart ▁failure
D-169	-0.3741787374019623	Caspase-3 gene expression ; heart failure
P-169	-0.0518 -0.0324 -0.1260 -0.1708 -0.8939 -0.3083 -0.2501 -0.9172 -0.5825 -0.4663 -0.3164
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute right heart failure ; pulmonary hypertension
H-1090	-0.7723901271820068	▁right ▁heart ▁failure ▁; ▁pulmonar y ▁hyper tension
D-1090	-0.7723901271820068	right heart failure ; pulmonary hypertension
P-1090	-4.0259 -1.4181 -0.5548 -0.2758 -0.0132 -0.6639 -0.1035 -0.0789 -0.3354 -0.2544
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective cohort study
H-1712	-0.43202337622642517	
D-1712	-0.43202337622642517	
P-1712	-0.5894 -0.2746
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise ; cardiovascular ; health
H-1897	-1.1164907217025757	▁exercise ▁; ▁cardiovascular ▁health
D-1897	-1.1164907217025757	exercise ; cardiovascular health
P-1897	-2.9831 -0.4347 -0.1727 -2.4337 -0.3620 -0.3128
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute care surgery ; heart transplant
H-1279	-1.1684051752090454	cute ▁care ▁surgery ▁; ▁heart ▁transplant ▁recipient s
D-1279	-1.1684051752090454	cute care surgery ; heart transplant recipients
P-1279	-3.8949 -3.3135 -0.4414 -0.4344 -1.2211 -0.1614 -0.4567 -0.9824 -0.3992 -0.3790
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary end point ; inhospital ; mortality
H-190	-0.9006304740905762	
D-190	-0.9006304740905762	
P-190	-1.4254 -0.3758
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal artery stenosis
H-1592	-0.5196791291236877	▁Ren al ▁arter y ▁sten osis
D-1592	-0.5196791291236877	Renal artery stenosis
P-1592	-1.5231 -0.2557 -0.0709 -1.3925 -0.0069 -0.0854 -0.4710 -0.3521
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse events
H-1916	-0.4318259060382843	
D-1916	-0.4318259060382843	
P-1916	-0.5496 -0.3140
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf ; pna
H-1699	-1.1528123617172241	HF ▁; ▁p NA
D-1699	-1.1528123617172241	HF ; pNA
P-1699	-2.6077 -0.3670 -0.5904 -2.7275 -0.3747 -0.2496
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.2797674834728241	▁molecular ▁mechanism
D-1607	-0.2797674834728241	molecular mechanism
P-1607	-0.3918 -0.0576 -0.3667 -0.3030
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.6613830327987671	▁tertia ry ▁refer ral ▁centre
D-1497	-0.6613830327987671	tertiary referral centre
P-1497	-0.2080 -2.8273 -0.0612 -0.1973 -0.4727 -0.4376 -0.4255
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-0.5242853164672852	▁ec
D-256	-0.5242853164672852	ec
P-256	-0.8392 -0.4776 -0.2560
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.38554108142852783	
D-307	-0.38554108142852783	
P-307	-0.5005 -0.2706
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver disease
H-233	-0.6816080212593079	
D-233	-0.6816080212593079	
P-233	-1.0616 -0.3016
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.6474997997283936	▁d XA
D-1496	-0.6474997997283936	dXA
P-1496	-0.5585 -1.2117 -0.4932 -0.3266
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.482952356338501	▁FM
D-18	-0.482952356338501	FM
P-18	-0.7431 -0.4501 -0.2556
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart failure
H-1066	-0.7090741991996765	▁devices ▁; ▁heart ▁failure
D-1066	-0.7090741991996765	devices ; heart failure
P-1066	-1.0695 -0.5127 -1.4736 -0.3865 -0.4810 -0.3312
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate models
H-241	-0.49704691767692566	
D-241	-0.49704691767692566	
P-241	-0.6724 -0.3217
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.3886878490447998	
D-1944	-0.3886878490447998	
P-1944	-0.5214 -0.2560
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.4290503263473511	
D-796	-0.4290503263473511	
P-796	-0.5450 -0.3131
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.4359961748123169	
D-589	-0.4359961748123169	
P-589	-0.5235 -0.3485
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart failure ; latin america
H-1788	-0.8490170240402222	▁heart ▁failure ▁; ▁Latin ▁America
D-1788	-0.8490170240402222	heart failure ; Latin America
P-1788	-2.0161 -0.5290 -0.3387 -0.9983 -1.3622 -0.4077 -0.2911
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-1.1544899940490723	▁ HF
D-346	-1.1544899940490723	HF
P-346	-2.9691 -0.7569 -0.5356 -0.3563
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational cohort study
H-811	-0.3819462060928345	
D-811	-0.3819462060928345	
P-811	-0.5353 -0.2286
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective cohort
H-211	-0.420951783657074	
D-211	-0.420951783657074	
P-211	-0.5310 -0.3109
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic breathing ; heart beat
H-1345	-0.8085491061210632	▁breath ing ▁; ▁heart ▁beat
D-1345	-0.8085491061210632	breathing ; heart beat
P-1345	-1.8944 -0.5029 -0.4482 -1.8232 -0.1627 -0.5305 -0.2980
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.4059799313545227	
D-1982	-0.4059799313545227	
P-1982	-0.5076 -0.3044
S-422	Heart rate was minimally altered.<unk>
T-422	heart rate
H-422	-0.7716948390007019	▁Heart ▁rate
D-422	-0.7716948390007019	Heart rate
P-422	-1.3228 -0.9243 -0.4828 -0.3569
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.4150765836238861	
D-44	-0.4150765836238861	
P-44	-0.5326 -0.2976
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.4798072874546051	
D-1846	-0.4798072874546051	
P-1846	-0.6805 -0.2791
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.6845992207527161	
D-1686	-0.6845992207527161	
P-1686	-1.1161 -0.2531
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart failure
H-1356	-0.7268860340118408	▁Nutrition ▁; ▁heart ▁failure
D-1356	-0.7268860340118408	Nutrition ; heart failure
P-1356	-2.0101 -0.3149 -1.0335 -0.3124 -0.3989 -0.2915
S-1620	SETTING: Northwest United States.<unk>
T-1620	united states
H-1620	-0.7821081876754761	▁north west ▁United ▁States
D-1620	-0.7821081876754761	northwest United States
P-1620	-0.7879 -0.0582 -2.6556 -0.4990 -0.4455 -0.2465
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-0.4202554523944855	
D-795	-0.4202554523944855	
P-795	-0.5208 -0.3197
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.4808567762374878	
D-1595	-0.4808567762374878	
P-1595	-0.6821 -0.2796
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.4134303331375122	
D-363	-0.4134303331375122	
P-363	-0.5207 -0.3062
S-1683	She is going into heart failure.<unk>
T-1683	heart failure
H-1683	-1.0256340503692627	▁heart ▁failure
D-1683	-1.0256340503692627	heart failure
P-1683	-2.0508 -1.2623 -0.4366 -0.3529
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-1.512830376625061	▁INTER ven TIONS
D-798	-1.512830376625061	INTERvenTIONS
P-798	-3.0423 -0.8076 -3.0684 -0.3845 -0.2615
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.4447898268699646	
D-1249	-0.4447898268699646	
P-1249	-0.5273 -0.3623
S-979	Heart failure in the young.<unk>
T-979	heart failure
H-979	-0.6952422261238098	▁Heart
D-979	-0.6952422261238098	Heart
P-979	-0.7427 -0.9971 -0.3460
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.39704430103302	
D-1687	-0.39704430103302	
P-1687	-0.5147 -0.2794
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.44963595271110535	▁c lin
D-1246	-0.44963595271110535	clin
P-1246	-0.5761 -0.3296 -0.5206 -0.3723
S-1248	Sci.<unk>
T-1248	
H-1248	-0.4315110743045807	
D-1248	-0.4315110743045807	
P-1248	-0.5254 -0.3376
S-1247	Trans.<unk>
T-1247	
H-1247	-1.0330532789230347	▁trans
D-1247	-1.0330532789230347	trans
P-1247	-0.3243 -2.3998 -0.3751
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.41966667771339417	
D-32	-0.41966667771339417	
P-32	-0.5602 -0.2792
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.3692863881587982	
D-804	-0.3692863881587982	
P-804	-0.4659 -0.2726
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.6021303534507751	▁interne ▁; ▁Cro n bach
D-786	-0.6021303534507751	interne ; Cronbach
P-786	-0.7267 -1.1492 -1.2188 -0.1050 -0.0862 -0.5995 -0.3295
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients ; hypertension
H-1889	-0.5135482549667358	▁hyper tension
D-1889	-0.5135482549667358	hypertension
P-1889	-1.2011 -0.1792 -0.3531 -0.3208
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.7103635668754578	
D-1616	-0.7103635668754578	
P-1616	-1.1019 -0.3188
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end point
H-266	-0.42310628294944763	
D-266	-0.42310628294944763	
P-266	-0.6088 -0.2374
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard ratios ; cox regression analysis
H-1770	-0.5059723854064941	▁co x ▁re gression ▁analysis
D-1770	-0.5059723854064941	cox regression analysis
P-1770	-1.4176 -0.4900 -0.0958 -0.1607 -0.5909 -0.4585 -0.3282
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.44844579696655273	▁implant ed ▁monitoring ▁devices
D-156	-0.44844579696655273	implanted monitoring devices
P-156	-0.4061 -0.7478 -0.0613 -0.7480 -0.4205 -0.3069
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.7730207443237305	
D-1469	-0.7730207443237305	
P-1469	-1.2539 -0.2922
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient ; conditions
H-0	-0.5961912870407104	
D-0	-0.5961912870407104	
P-0	-0.8149 -0.3775
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea ; afterload
H-518	-1.1361531019210815	▁HR ▁; ▁Ea
D-518	-1.1361531019210815	HR ; Ea
P-518	-3.5911 -0.2154 -1.1239 -0.4360 -0.3144
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths ; strokes
H-778	-0.9538180828094482	▁stroke s
D-778	-0.9538180828094482	strokes
P-778	-2.6987 -0.4902 -0.3721 -0.2542
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty ; heart failure
H-1000	-0.6056468486785889	▁fra il ty ▁; ▁heart ▁failure
D-1000	-0.6056468486785889	frailty ; heart failure
P-1000	-0.1230 -0.2917 -0.7607 -0.7563 -1.8090 -0.2777 -0.4827 -0.3441
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-0.3545772135257721	
D-677	-0.3545772135257721	
P-677	-0.4102 -0.2990
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise ; quality of life ; heart failure
H-612	-1.246205449104309	▁exercise ▁; ▁heart ▁failure
D-612	-1.246205449104309	exercise ; heart failure
P-612	-2.3383 -0.5098 -2.9310 -0.7558 -0.5650 -0.3773
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras ; atherosclerosis
H-1594	-0.679916262626648	RAS ▁; ▁at hero sc ler osis
D-1594	-0.679916262626648	RAS ; atherosclerosis
P-1594	-0.1639 -0.2588 -1.8777 -0.1287 -0.0579 -2.6592 -0.2277 -0.4241 -0.3212
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas ; heart failure ; disease
H-1479	-0.44968920946121216	▁micro RNA s ▁; ▁heart ▁failure ▁; ▁disease ▁management
D-1479	-0.44968920946121216	microRNAs ; heart failure ; disease management
P-1479	-0.0595 -0.2413 -0.4937 -0.4436 -1.3972 -0.4432 -0.3246 -0.7322 -0.1837 -0.4056 -0.2220
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss ; exercise ; training ; outcomes
H-1932	-0.5248902440071106	▁ps s s
D-1932	-0.5248902440071106	psss
P-1932	-0.3507 -0.4518 -1.1104 -0.4137 -0.2978
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart failure with preserved ejection fraction
H-1885	-0.4248047173023224	▁management ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1885	-0.4248047173023224	management ; heart failure ; ejection fraction
P-1885	-1.3787 -0.3078 -1.2005 -0.2156 -0.2744 -0.2914 -0.3076 -0.0933 -0.2835 -0.0168 -0.4443 -0.2838
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology ; bromodomain ; halts ; heart failure
H-1033	-0.5530745983123779	▁Card i ology ▁; ▁bro modo main ▁inhibi tion ▁; ▁heart ▁failure
D-1033	-0.5530745983123779	Cardiology ; bromodomain inhibition ; heart failure
P-1033	-1.0697 -1.4477 -0.0867 -0.2738 -0.1532 -0.1190 -0.2480 -0.1095 -1.4380 -0.2418 -1.4361 -0.4214 -0.4715 -0.2267
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.4028724431991577	
D-1759	-0.4028724431991577	
P-1759	-0.5086 -0.2972
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart failure ; hospitalization ; cardiovascular death
H-410	-1.1374825239181519	▁heart ▁failure ▁; ▁hospital ization ▁; ▁cardiovascular ▁death
D-410	-1.1374825239181519	heart failure ; hospitalization ; cardiovascular death
P-410	-2.2960 -0.6087 -0.7590 -4.1757 -1.0885 -0.4310 -0.2561 -0.9804 -0.4787 -0.3007
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary outcomes ; quality of life
H-1654	-0.6561528444290161	▁cognitive ▁function
D-1654	-0.6561528444290161	cognitive function
P-1654	-1.1529 -0.3370 -0.7465 -0.3883
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated ; mixed linear models
H-325	-0.7287676334381104	▁co ▁; ▁mix ed ▁linear ▁models
D-325	-0.7287676334381104	co ; mixed linear models
P-325	-0.4832 -1.1786 -1.3787 -0.3080 -0.1701 -1.4793 -0.5025 -0.3297
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin ; congestive heart failure
H-633	-0.6626734137535095	▁vaso press in ▁; ▁con ges tive ▁heart ▁failure
D-633	-0.6626734137535095	vasopressin ; congestive heart failure
P-633	-0.2260 -0.2069 -0.8125 -0.3171 -0.2356 -0.4650 -3.0096 -0.9117 -0.3736 -0.4626 -0.2690
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral stenosis ; medical treatment ; heart failure
H-332	-1.015674352645874	▁mit ral ▁sten osis ▁; ▁medical ▁; ▁heart ▁failure
D-332	-1.015674352645874	mitral stenosis ; medical ; heart failure
P-332	-3.6456 -0.3921 -0.0185 -0.1583 -0.4376 -1.8218 -1.1663 -1.9047 -0.6486 -0.6084 -0.3705
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended criteria cardiac transplantation
H-707	-0.775850772857666	▁cardiac ▁transplant ation
D-707	-0.775850772857666	cardiac transplantation
P-707	-0.3716 -0.2457 -2.4358 -0.5114 -0.3147
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient ; medical ; conditions
H-1688	-0.7027806043624878	▁in patient ▁medical ▁conditions
D-1688	-0.7027806043624878	inpatient medical conditions
P-1688	-0.1994 -0.0817 -1.0730 -2.0501 -0.4551 -0.3575
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty ; hf
H-624	-1.1883667707443237	▁ HF
D-624	-1.1883667707443237	HF
P-624	-3.0158 -1.0061 -0.4285 -0.3030
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.5257520079612732	
D-1963	-0.5257520079612732	
P-1963	-0.6724 -0.3791
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv fibrosis
H-280	-0.9255266189575195	▁LV ▁fibro sis ▁; ANS ▁mi ce
D-280	-0.9255266189575195	LV fibrosis ;ANS mice
P-280	-0.4927 -0.2647 -0.9467 -0.4765 -3.9035 -1.1777 -0.3504 -0.4231 -0.2943
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.4990193545818329	
D-392	-0.4990193545818329	
P-392	-0.6572 -0.3409
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.2430615872144699	▁do d son
D-205	-0.2430615872144699	dodson
P-205	-0.3215 -0.0891 -0.0906 -0.4658 -0.2483
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end point
H-1763	-0.46166154742240906	
D-1763	-0.46166154742240906	
P-1763	-0.6348 -0.2885
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.7655130624771118	▁CHF
D-222	-0.7655130624771118	CHF
P-222	-0.5400 -1.4214 -0.3351
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient ; hospital ; heart failure
H-1960	-1.4569759368896484	▁heart ▁failure
D-1960	-1.4569759368896484	heart failure
P-1960	-4.7365 -0.3796 -0.4164 -0.2954
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.902895987033844	▁inter media te ▁fra il ty
D-1005	-0.902895987033844	intermediate frailty
P-1005	-2.9911 -1.5575 -0.3781 -0.0723 -0.4283 -1.0056 -0.5022 -0.2881
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral growth
H-511	-1.1579971313476562	▁competitive
D-511	-1.1579971313476562	competitive
P-511	-2.1961 -0.9441 -0.3339
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.4087927043437958	
D-126	-0.4087927043437958	
P-126	-0.5411 -0.2765
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic balance
H-1375	-0.43667492270469666	▁autonomi c ▁balance
D-1375	-0.43667492270469666	autonomic balance
P-1375	-0.1409 -0.6368 -0.6681 -0.4386 -0.2990
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.9430028796195984	▁ HF p EF
D-1078	-0.9430028796195984	HFpEF
P-1078	-2.9364 -1.1475 -0.0320 -0.8335 -0.4220 -0.2865
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness ; anemia
H-1679	-1.451974868774414	▁Jehovah ▁; ▁wit ness ▁; ▁an emia
D-1679	-1.451974868774414	Jehovah ; witness ; anemia
P-1679	-0.0228 -4.8404 -1.0475 -3.4889 -0.3827 -1.7654 -0.8152 -0.4013 -0.3036
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 ; functional capacity
H-702	-0.39032742381095886	▁ST 2
D-702	-0.39032742381095886	ST2
P-702	-0.5308 -0.3281 -0.3958 -0.3065
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart failure ; mortality
H-204	-0.5932890176773071	▁Heart ▁failure ▁; ▁cognitive ▁im pair ment ▁; ▁mortal iteit
D-204	-0.5932890176773071	Heart failure ; cognitive impairment ; mortaliteit
P-204	-0.8387 -0.3894 -0.2398 -0.4374 -0.5808 -0.0866 -1.3603 -0.3633 -0.3935 -1.8512 -0.3193 -0.2591
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology ; hospital
H-812	-0.7410134673118591	▁card i ology ▁; ▁university ▁hospital
D-812	-0.7410134673118591	cardiology ; university hospital
P-812	-0.9228 -0.4688 -0.2127 -0.5977 -2.4692 -0.6019 -0.3622 -0.2928
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up duration
H-495	-0.29954394698143005	▁follow - up
D-495	-0.29954394698143005	follow-up
P-495	-0.0595 -0.5259 -0.1352 -0.4824 -0.2947
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf ; hf
H-1309	-0.974966824054718	current ▁; HF ▁; ▁ HF
D-1309	-0.974966824054718	current ;HF ; HF
P-1309	-1.4172 -1.0026 -1.2725 -0.3753 -2.0575 -0.6727 -0.6828 -0.3192
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.45312491059303284	
D-575	-0.45312491059303284	
P-575	-0.6286 -0.2776
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary outcomes ; hemostasis
H-1116	-0.3773137629032135	▁hemos tas is
D-1116	-0.3773137629032135	hemostasis
P-1116	-0.2262 -0.3415 -0.4505 -0.4965 -0.3720
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal support
H-1296	-0.28387612104415894	
D-1296	-0.28387612104415894	
P-1296	-0.3599 -0.2079
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart failure ; disease ; therapeutics
H-1073	-0.7883201241493225	▁Heart ▁failure ▁; ▁disease
D-1073	-0.7883201241493225	Heart failure ; disease
P-1073	-1.2063 -0.4913 -0.3976 -1.5225 -0.7729 -0.3393
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf ; mi
H-1101	-1.2758383750915527	HF ▁; ▁MI
D-1101	-1.2758383750915527	HF ; MI
P-1101	-2.4082 -0.4328 -2.1467 -1.0628 -0.3287
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective matched cohort study
H-1619	-0.45153287053108215	
D-1619	-0.45153287053108215	
P-1619	-0.6107 -0.2923
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote ischemic conditioning ; patients ; heart failure
H-53	-0.7205962538719177	▁Remote ▁ ische mic ▁condition ing ▁; ▁heart ▁failure
D-53	-0.7205962538719177	Remote ischemic conditioning ; heart failure
P-53	-1.1600 -0.3816 -0.1454 -1.4971 -0.0450 -0.2648 -0.3660 -2.9773 -0.3511 -0.4592 -0.2790
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart rate variability ; risk stratification ; cardiac ; patients
H-1584	-0.8741128444671631	▁Heart ▁rate ▁; ▁cardiac ▁patients
D-1584	-0.8741128444671631	Heart rate ; cardiac patients
P-1584	-1.3178 -1.0665 -0.8224 -0.8464 -1.2192 -0.4543 -0.3922
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients ; cardiovascular disease
H-247	-0.8002228736877441	▁cardiovascular ▁disease
D-247	-0.8002228736877441	cardiovascular disease
P-247	-1.5372 -0.8545 -0.4784 -0.3308
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs ; expenditures
H-1238	-1.3074522018432617	▁ar rhythm ia - related ▁kosten
D-1238	-1.3074522018432617	arrhythmia-related kosten
P-1238	-3.1944 -0.5330 -1.8630 -0.2871 -0.3965 -3.0602 -0.7774 -0.3480
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-0.497766375541687	
D-150	-0.497766375541687	
P-150	-0.7019 -0.2936
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 ; hf
H-1211	-0.7722095847129822	▁p de 2 ▁; HF
D-1211	-0.7722095847129822	pde2 ;HF
P-1211	-1.5618 -0.7645 -0.1109 -0.2602 -2.0616 -0.3688 -0.2776
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality ; sts
H-159	-0.9425811171531677	▁mortal iteit ▁; ▁s ts ▁ HM
D-159	-0.9425811171531677	mortaliteit ; sts HM
P-159	-1.2829 -2.0702 -0.3682 -0.9283 -1.5599 -0.7878 -0.7920 -0.4041 -0.2898
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician ; hospital ; physician
H-1726	-0.5644773244857788	
D-1726	-0.5644773244857788	
P-1726	-0.7800 -0.3489
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication ; sst2
H-403	-1.2282898426055908	
D-403	-1.2282898426055908	
P-403	-2.1166 -0.3400
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart failure ; public ; health
H-1606	-1.2025244235992432	▁Heart ▁failure ▁; ▁public ▁health ▁problem
D-1606	-1.2025244235992432	Heart failure ; public health problem
P-1606	-2.3859 -0.8304 -0.3008 -1.0814 -1.4083 -2.5350 -0.6529 -0.4255
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative ; albumin
H-539	-0.38795286417007446	▁album in ▁level
D-539	-0.38795286417007446	albumin level
P-539	-0.6970 -0.3607 -0.1885 -0.4223 -0.2713
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.5657853484153748	▁media n ▁follow - up
D-1758	-0.5657853484153748	median follow-up
P-1758	-2.3229 -0.2110 -0.0719 -0.4767 -0.0840 -0.4837 -0.3103
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality of life
H-1919	-1.1238536834716797	
D-1919	-1.1238536834716797	
P-1919	-1.9308 -0.3169
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-0.23441894352436066	▁follow - up
D-1839	-0.23441894352436066	follow-up
P-1839	-0.1407 -0.3244 -0.0850 -0.3761 -0.2459
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable hf
H-481	-1.1151598691940308	HF
D-481	-1.1151598691940308	HF
P-481	-2.6692 -0.3887 -0.2876
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital ; coprimary outcome
H-1651	-0.48381850123405457	▁hospital
D-1651	-0.48381850123405457	hospital
P-1651	-0.7129 -0.4298 -0.3088
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-1.063156008720398	▁ET ▁; ▁CHF
D-261	-1.063156008720398	ET ; CHF
P-261	-3.5566 -0.4765 -0.5473 -0.4284 -0.3070
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular scaffolds ; heart ; pathology
H-989	-0.910973072052002	▁e RK ▁; ▁molecular ▁sc af fold s ▁; ▁heart ▁path ology
D-989	-0.910973072052002	eRK ; molecular scaffolds ; heart pathology
P-989	-3.0803 -0.2174 -1.6437 -0.2420 -1.3023 -2.0305 -0.7734 -0.5110 -0.3744 -1.1288 -0.2942 -0.2817 -0.4975 -0.3764
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone ; systolic heart failure
H-437	-0.3097584545612335	▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
D-437	-0.3097584545612335	spironolactone ; systolic heart failure
P-437	-0.0781 -0.1815 -0.1580 -0.1476 -0.3900 -0.0590 -0.2458 -0.2502 -0.8959 -0.4898 -0.5132 -0.3082
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate adjustment ; cox proportional hazards models
H-785	-0.7462878227233887	▁co x ▁proportion al ▁hazard s
D-785	-0.7462878227233887	cox proportional hazards
P-785	-0.0964 -2.8074 -0.0975 -0.1061 -0.1815 -1.5442 -0.7888 -0.3484
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart failure ; hf ; leading ; mortality ; society
H-1034	-0.6028041839599609	▁Heart ▁failure ▁; HF ▁; ▁mortal iteit ▁; ▁society
D-1034	-0.6028041839599609	Heart failure ;HF ; mortaliteit ; society
P-1034	-1.1939 -0.2580 -0.2585 -0.6684 -0.3524 -0.6425 -1.5920 -0.4332 -0.5993 -0.3417 -0.2910
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology ; chronic heart failure ; bisoprolol
H-645	-0.8443443179130554	▁chronic ▁heart ▁failure ▁; ▁bis o pro lol
D-645	-0.8443443179130554	chronic heart failure ; bisoprolol
P-645	-3.5330 -2.0930 -0.4203 -0.2589 -0.1375 -0.4485 -0.3522 -0.4611 -0.4142 -0.3246
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional ms ; reported ; patients ; degenerative mr
H-339	-0.7570198774337769	▁function al ▁MS ▁; ▁de genera tive ▁MR
D-339	-0.7570198774337769	functional MS ; degenerative MR
P-339	-2.3609 -0.3796 -0.6060 -0.3251 -1.3973 -0.0136 -1.4186 -0.2582 -0.5087 -0.3023
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.7873758673667908	
D-1261	-0.7873758673667908	
P-1261	-1.2128 -0.3620
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet ; aortic pressure
H-581	-0.6961843967437744	▁l VET ▁; ▁a or tic ▁pressure ▁cur ve
D-581	-0.6961843967437744	lVET ; aortic pressure curve
P-581	-1.8294 -0.4892 -0.3041 -0.2724 -0.1794 -1.4580 -1.1879 -0.9407 -0.2857 -0.4446 -0.2667
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac ; symptoms ; congenital ; lesions
H-983	-0.6093177199363708	▁Card iac ▁symptoms ▁; ▁children
D-983	-0.6093177199363708	Cardiac symptoms ; children
P-983	-1.2506 -0.4105 -0.5181 -0.3769 -1.1025 -0.2928 -0.3138
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart failure ; hf ; therapy
H-1067	-0.43468958139419556	▁Device s ▁; ▁heart ▁failure ▁; HF ▁; ▁ therapy
D-1067	-0.43468958139419556	Devices ; heart failure ;HF ; therapy
P-1067	-0.4955 -0.3255 -0.4721 -1.4519 -0.2785 -0.3461 -0.7526 -0.3419 -0.1145 -0.0426 -0.3271 -0.2679
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity ; patients ; breast cancer
H-669	-1.0281327962875366	▁Tras tuz um ab - related ▁cardio toxic iteit ▁; ▁breast ▁cancer
D-669	-1.0281327962875366	Trastuzumab-related cardiotoxiciteit ; breast cancer
P-669	-1.9850 -0.2500 -0.6642 -1.7696 -0.5376 -0.7560 -0.1065 -0.9879 -2.7632 -0.4817 -2.8130 -0.3735 -0.5082 -0.3974
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician ; outcomes ; discharge
H-1414	-0.8859556317329407	▁physician ▁continu iteit ▁; ▁dis charge
D-1414	-0.8859556317329407	physician continuiteit ; discharge
P-1414	-1.2429 -0.7617 -2.2961 -0.3998 -1.3157 -0.3394 -0.4027 -0.3293
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.6057658195495605	
D-145	-0.6057658195495605	
P-145	-0.9231 -0.2884
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan ; vasopressin type 2 receptor antagonist
H-1195	-0.37222951650619507	▁Tol va p tan ▁; ▁vaso press in ▁; ▁receptor
D-1195	-0.37222951650619507	Tolvaptan ; vasopressin ; receptor
P-1195	-0.1695 -0.1005 -0.1959 -0.2541 -0.4156 -0.2091 -0.0619 -0.7213 -0.4537 -0.0459 -1.4803 -0.3591
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.753187358379364	▁ metric ▁; ▁read mission ▁metri cs
D-134	-0.753187358379364	metric ; readmission metrics
P-134	-0.6822 -0.2851 -0.3198 -0.7409 -1.5985 -0.2539 -2.1368 -0.4080 -0.3536
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.7001209259033203	
D-1998	-0.7001209259033203	
P-1998	-1.0893 -0.3110
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.9644811749458313	▁pro pens iteit
D-1837	-0.9644811749458313	propensiteit
P-1837	-0.3941 -0.2494 -3.5300 -0.3615 -0.2875
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-0.5353605151176453	
D-958	-0.5353605151176453	
P-958	-0.7769 -0.2938
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-0.9307963252067566	▁black
D-1634	-0.9307963252067566	black
P-1634	-0.4247 -2.0398 -0.3279
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology ; diagnosed
H-352	-1.052728533744812	▁MR ▁; ▁MS ▁; ▁functional
D-352	-1.052728533744812	MR ; MS ; functional
P-352	-3.2130 -0.3349 -0.5542 -0.6091 -2.1475 -0.2697 -0.2407
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac amyloidosis
H-997	-0.42167508602142334	▁Card iac ▁a my lo idos is
D-997	-0.42167508602142334	Cardiac amyloidosis
P-997	-1.1856 -0.2274 -0.2364 -0.2913 -0.0702 -0.3172 -0.7095 -0.4868 -0.2707
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection fraction ; bnp
H-194	-0.7349085807800293	▁e je ction ▁ fraction ▁; ▁b NP
D-194	-0.7349085807800293	ejection fraction ; bNP
P-194	-1.1574 -0.3886 -0.0648 -0.2314 -0.0727 -0.2640 -2.3949 -2.1215 -0.3879 -0.2660
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients ; hfpef
H-787	-0.6819161772727966	▁ HF p EF
D-787	-0.6819161772727966	HFpEF
P-787	-1.2928 -0.8246 -0.0639 -1.0607 -0.4851 -0.3645
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients ; therapy ; beta blockade
H-1736	-0.9107576608657837	▁beta ▁block ade
D-1736	-0.9107576608657837	beta blockade
P-1736	-3.2291 -0.2543 -0.3615 -0.3678 -0.3411
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients ; functional capacity ; symptoms
H-550	-1.2505546808242798	▁significant
D-550	-1.2505546808242798	significant
P-550	-0.6799 -2.7377 -0.3341
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training ; heart failure ; patients
H-1911	-1.0233631134033203	▁Robot - assist ed ▁training ▁; ▁heart ▁failure ▁patients
D-1911	-1.0233631134033203	Robot-assisted training ; heart failure patients
P-1911	-3.1939 -0.5744 -0.0479 -0.5602 -1.7341 -0.5218 -1.8135 -0.5292 -1.3788 -0.5600 -0.3433
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary outcomes ; functional capacity ; quality of life
H-616	-0.7164024710655212	▁functional ▁capacity
D-616	-0.7164024710655212	functional capacity
P-616	-0.4963 -1.5319 -0.5306 -0.3068
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic hf ; death
H-1796	-0.35928604006767273	▁Chro nic ▁ HF
D-1796	-0.35928604006767273	Chronic HF
P-1796	-0.3219 -0.4739 -0.3590 -0.3098 -0.3858 -0.3054
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up ; patients
H-1009	-0.6789424419403076	▁follow - up
D-1009	-0.6789424419403076	follow-up
P-1009	-0.7988 -0.3823 -0.0634 -1.8407 -0.3095
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic ; medication ; death
H-507	-0.5185359120368958	▁Pig s ▁; ▁anti ar rhythm ic ▁medication
D-507	-0.5185359120368958	Pigs ; antiarrhythmic medication
P-507	-0.8702 -0.5628 -0.5095 -0.0584 -0.1603 -0.1939 -0.2666 -0.4293 -1.8003 -0.3341
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart rate ; arterial pressure
H-424	-0.8088091015815735	▁Heart ▁rate ▁; ▁arterial ▁pressure
D-424	-0.8088091015815735	Heart rate ; arterial pressure
P-424	-1.7014 -1.1314 -0.3731 -0.5906 -1.1169 -0.4812 -0.2671
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb ; correlated ; baseline ; hrqol
H-840	-0.9972445964813232	▁h gb ▁level ▁; ▁HR Qo L
D-840	-0.9972445964813232	hgb level ; HRQoL
P-840	-0.3961 -1.0743 -1.9134 -0.2786 -1.7332 -0.0282 -2.8243 -0.4236 -0.3035
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved ejection fraction ; outcomes
H-1464	-0.33938494324684143	▁e je ction ▁ fraction ▁outcome s ▁trial
D-1464	-0.33938494324684143	ejection fraction outcomes trial
P-1464	-0.2527 -0.4902 -0.1128 -0.2015 -0.0531 -0.8896 -0.1119 -0.5282 -0.4937 -0.2601
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed ; mortality ; random-effects models
H-64	-0.9341859221458435	▁mortal iteit
D-64	-0.9341859221458435	mortaliteit
P-64	-0.2318 -2.5459 -0.5218 -0.4373
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients ; cardiac ; inflammatory ; biomarkers
H-1914	-0.39498385787010193	▁cardiac ▁; ▁infla mma tory ▁bio mark ers
D-1914	-0.39498385787010193	cardiac ; inflammatory biomarkers
P-1914	-0.2408 -0.6576 -0.1951 -0.6448 -0.5141 -0.0508 -0.2731 -0.5458 -0.4273 -0.4005
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated hf ; cardiovascular ; hospitalization
H-1797	-0.7944872379302979	▁ HF ▁; ▁cardiovascular ▁hospital ization
D-1797	-0.7944872379302979	HF ; cardiovascular hospitalization
P-1797	-2.4445 -0.8002 -0.2645 -0.2526 -0.9472 -0.9048 -0.3963 -0.3458
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf ; patients ; intubated
H-219	-0.48610520362854004	▁CHF ▁; ▁in tuba ted
D-219	-0.48610520362854004	CHF ; intubated
P-219	-0.3185 -0.4054 -0.1468 -0.4014 -1.4317 -0.3938 -0.3051
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical ; hypothermic circulatory arrest
H-598	-0.2648041546344757	▁circula tory ▁arrest
D-598	-0.2648041546344757	circulatory arrest
P-598	-0.0724 -0.3247 -0.2122 -0.3993 -0.3153
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic ; biomarkers ; chronic heart failure
H-1471	-0.4676867425441742	▁bio mark ers ▁; ▁chronic ▁heart ▁failure
D-1471	-0.4676867425441742	biomarkers ; chronic heart failure
P-1471	-0.1409 -0.3288 -0.3896 -0.4234 -0.5364 -1.2767 -0.3299 -0.4723 -0.3111
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes ; patients ; heart failure ; emergency department
H-461	-0.836499035358429	▁heart ▁failure ▁; ▁emergency ▁department
D-461	-0.836499035358429	heart failure ; emergency department
P-461	-3.0184 -0.5669 -0.8635 -0.5573 -0.1234 -0.4446 -0.2814
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected ; patients ; systolic dysfunction
H-1069	-0.29324665665626526	▁sy sto lic ▁dys function
D-1069	-0.29324665665626526	systolic dysfunction
P-1069	-0.3975 -0.3425 -0.3396 -0.0374 -0.1233 -0.4989 -0.3135
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american ; hf
H-1843	-0.8195008635520935	▁ HF
D-1843	-0.8195008635520935	HF
P-1843	-1.0224 -1.4232 -0.5080 -0.3244
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north america
H-75	-0.873580813407898	▁north ▁America
D-75	-0.873580813407898	north America
P-75	-0.7233 -2.0276 -0.4972 -0.2462
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute heart failure
H-1014	-0.5090211629867554	▁a cute ▁heart ▁failure ▁trial s
D-1014	-0.5090211629867554	acute heart failure trials
P-1014	-0.5062 -0.1809 -0.8726 -0.3007 -1.1095 -0.4331 -0.3879 -0.2813
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.4243079423904419	
D-1576	-0.4243079423904419	
P-1576	-0.5373 -0.3113
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.6449535489082336	▁ therapy
D-1965	-0.6449535489082336	therapy
P-1965	-1.6376 -0.2599 -0.3559 -0.3264
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha ; esc
H-1908	-1.1597493886947632	AHA ▁; ▁ESC
D-1908	-1.1597493886947632	AHA ; ESC
P-1908	-2.3798 -0.3976 -2.2045 -0.4248 -0.3920
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.5759073495864868	▁c PG s
D-1848	-0.5759073495864868	cPGs
P-1848	-0.5954 -1.3788 -0.1984 -0.4007 -0.3062
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient ; circulation
H-1824	-0.5087559819221497	
D-1824	-0.5087559819221497	
P-1824	-0.6605 -0.3570
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.3796344995498657	▁MS ▁; ▁surgery
D-372	-0.3796344995498657	MS ; surgery
P-372	-0.5829 -0.3818 -0.1447 -0.5225 -0.2662
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic blood pressure
H-1048	-1.0451067686080933	▁system ic ▁blood ▁pressure
D-1048	-1.0451067686080933	systemic blood pressure
P-1048	-2.8945 -0.4136 -0.9545 -1.3332 -0.3877 -0.2870
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients ; heart failure
H-1821	-1.6966538429260254	▁patients ▁; ▁heart ▁failure
D-1821	-1.6966538429260254	patients ; heart failure
P-1821	-5.3227 -1.7206 -1.8924 -0.5218 -0.3854 -0.3370
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic ; hf
H-1072	-1.0359346866607666	▁stand - a lone ▁diagnostic ▁devices ▁; HF
D-1072	-1.0359346866607666	stand-alone diagnostic devices ;HF
P-1072	-3.0227 -0.2867 -1.0600 -0.2947 -1.7888 -0.4481 -0.3653 -2.4490 -0.3273 -0.3168
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end stage heart failure
H-1669	-1.5369447469711304	▁end ▁stage ▁heart ▁failure
D-1669	-1.5369447469711304	end stage heart failure
P-1669	-6.0230 -0.3645 -1.4913 -0.6005 -0.4561 -0.2863
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician ; hf
H-1732	-1.0487465858459473	▁ HF
D-1732	-1.0487465858459473	HF
P-1732	-2.4754 -0.7903 -0.5743 -0.3549
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity ; outcomes
H-709	-0.8805652856826782	
D-709	-0.8805652856826782	
P-709	-1.4374 -0.3238
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.3887043595314026	▁significant
D-1881	-0.3887043595314026	significant
P-1881	-0.0432 -0.8269 -0.2960
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient ; postoperatively ; multiorgan failure ; sepsis
H-551	-0.6966710090637207	▁se psis
D-551	-0.6966710090637207	sepsis
P-551	-2.0858 -0.0405 -0.3957 -0.2646
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized ; walking ; patients ; severe heart failure
H-567	-1.5180048942565918	▁Nordic ▁walking ▁; ▁heart ▁failure
D-567	-1.5180048942565918	Nordic walking ; heart failure
P-567	-1.4318 -2.4893 -0.3626 -4.8527 -0.5651 -0.5613 -0.3633
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric ; self-care of heart failure index version 6.2
H-1503	-0.5779517292976379	▁Psycho metric ▁testing ▁; ▁Self - car e ▁of ▁Heart ▁Fail ure ▁index
D-1503	-0.5779517292976379	Psychometric testing ; Self-care of Heart Failure index
P-1503	-1.0360 -0.1066 -1.2447 -0.3272 -0.3563 -0.0658 -1.1943 -0.5669 -0.8203 -0.7138 -0.3005 -0.6411 -0.5733 -0.4285 -0.2937
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping ; baseline ; heart failure
H-1059	-0.877877950668335	▁heart ▁failure ▁scan s
D-1059	-0.877877950668335	heart failure scans
P-1059	-2.7878 -0.7720 -0.5725 -0.3514 -0.4435 -0.3400
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients ; acute kidney injury ; postoperatively
H-975	-0.6028313040733337	▁a cute ▁ki dne y ▁injury
D-975	-0.6028313040733337	acute kidney injury
P-975	-1.7101 -0.4030 -0.0491 -1.1034 -0.3848 -0.4195 -0.4244 -0.3284
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive statistics ; cox proportional hazards models
H-675	-0.42659255862236023	▁co x ▁proportion al ▁hazard s
D-675	-0.42659255862236023	cox proportional hazards
P-675	-0.0924 -0.4571 -0.0705 -0.0672 -0.1731 -1.2310 -1.0035 -0.3179
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial function ; flow-mediated dilatation
H-253	-0.6335505247116089	
D-253	-0.6335505247116089	
P-253	-1.0221 -0.2450
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart failure ; cox proportional hazard analyses
H-1537	-0.5160612463951111	▁heart ▁failure ▁; ▁co x ▁proportion al ▁hazard ▁analyse s
D-1537	-0.5160612463951111	heart failure ; cox proportional hazard analyses
P-1537	-2.4312 -0.7180 -0.2843 -0.0471 -0.4462 -0.0847 -0.0856 -0.2540 -0.8068 -0.4595 -0.3270 -0.2483
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient ; surgery ; echocardiography
H-358	-0.45693445205688477	▁MS ▁; ▁surgery ▁; ▁e cho card i ography
D-358	-0.45693445205688477	MS ; surgery ; echocardiography
P-358	-0.6828 -0.3513 -1.2219 -0.3119 -0.2349 -0.3261 -0.3158 -0.6202 -0.2512 -0.3842 -0.3259
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological ; acute heart failure
H-1465	-1.0183018445968628	▁Pharma c ological ▁; ▁a cute ▁heart ▁failure ▁; ▁treatment
D-1465	-1.0183018445968628	Pharmacological ; acute heart failure ; treatment
P-1465	-5.2959 -0.4141 -0.8712 -0.6468 -0.3965 -0.1630 -1.3456 -0.3224 -0.4145 -1.6669 -0.3825 -0.3002
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.9462707042694092	▁voordelen
D-1028	-0.9462707042694092	voordelen
P-1028	-2.1071 -0.4782 -0.2536
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.9438124895095825	▁ab normal ▁cardiac ▁t 2 ▁; ▁treatment
D-746	-0.9438124895095825	abnormal cardiac t2 ; treatment
P-746	-3.2606 -0.4743 -0.1246 -1.2797 -0.0676 -0.3654 -2.1595 -0.4720 -0.2906
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.39788538217544556	
D-591	-0.39788538217544556	
P-591	-0.4615 -0.3342
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart failure
H-1204	-1.1320641040802002	▁heart ▁failure
D-1204	-1.1320641040802002	heart failure
P-1204	-2.9167 -0.7679 -0.5191 -0.3246
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-0.9190623760223389	▁health care ▁programme s
D-603	-0.9190623760223389	healthcare programmes
P-603	-3.6252 -0.2552 -0.3599 -0.4242 -0.4320 -0.4178
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.32992470264434814	▁bio mark ers
D-70	-0.32992470264434814	biomarkers
P-70	-0.0827 -0.2386 -0.3882 -0.5447 -0.3953
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome ; tug test
H-799	-1.1076468229293823	AIN ▁o UTC OME ▁; ▁tu g ▁test
D-799	-1.1076468229293823	AIN oUTCOME ; tug test
P-799	-3.4552 -0.5042 -0.2751 -0.2426 -1.1522 -0.6072 -3.8674 -0.3249 -0.4112 -0.2365
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.3396123945713043	
D-800	-0.3396123945713043	
P-800	-0.4353 -0.2439
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.4991612434387207	
D-1923	-0.4991612434387207	
P-1923	-0.6722 -0.3261
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.360274076461792	
D-1854	-0.360274076461792	
P-1854	-0.4494 -0.2712
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug ; japan
H-1197	-0.8749720454216003	▁drug ▁; ▁japan
D-1197	-0.8749720454216003	drug ; japan
P-1197	-2.1700 -0.3411 -1.1801 -0.4149 -0.2688
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-0.44899487495422363	
D-1206	-0.44899487495422363	
P-1206	-0.6049 -0.2931
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max ; significance
H-1255	-0.6122918725013733	▁VO 2 max
D-1255	-0.6122918725013733	VO2max
P-1255	-1.2183 -0.7470 -0.3481 -0.4310 -0.3171
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise ; life expectancy
H-1902	-1.2296357154846191	
D-1902	-1.2296357154846191	
P-1902	-2.0920 -0.3673
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary angiography ; lesions
H-349	-0.7602241635322571	▁Corona ry ▁ang i ography
D-349	-0.7602241635322571	Coronary angiography
P-349	-0.2420 -2.7384 -0.5593 -0.5156 -0.4542 -0.4986 -0.3135
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis ; patients ; implantation
H-913	-0.6352497935295105	▁di al ysis ▁; ▁device ▁implant ation
D-913	-0.6352497935295105	dialysis ; device implantation
P-913	-0.4751 -0.0806 -0.1315 -0.7949 -2.0061 -0.1419 -1.1371 -0.6012 -0.3489
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal ; heartmate ii
H-772	-0.4888516068458557	▁off - pump ▁; ▁ster nal ▁spar ing ▁; ▁Heart Mate ▁i ▁exchange
D-772	-0.4888516068458557	off-pump ; sternal sparing ; HeartMate i exchange
P-772	-0.0383 -0.2419 -0.4303 -0.5768 -0.1493 -1.6352 -0.0889 -0.1870 -1.6390 -0.3408 -0.1843 -0.8177 -0.1397 -0.5640 -0.2996
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic phenotype ; fontan
H-223	-0.3093958795070648	▁Hem o dynamic ▁ph eno type ▁; ▁Font an
D-223	-0.3093958795070648	Hemodynamic phenotype ; Fontan
P-223	-0.8696 -0.5845 -0.0476 -0.3958 -0.1368 -0.0220 -0.2773 -0.1715 -0.0931 -0.5392 -0.2660
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients ; esrd
H-394	-1.8934143781661987	▁ES RD
D-394	-1.8934143781661987	ESRD
P-394	-4.3058 -2.1294 -0.7263 -0.4121
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle heart failure model
H-2011	-0.549588143825531	▁Seattle ▁Heart ▁Fail ure ▁model
D-2011	-0.549588143825531	Seattle Heart Failure model
P-2011	-0.1084 -0.9741 -0.3480 -0.2781 -1.4895 -0.3966 -0.2525
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate analyses
H-826	-1.1806432008743286	
D-826	-1.1806432008743286	
P-826	-2.0056 -0.3557
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated ; hf
H-608	-0.8156331181526184	▁HR ▁; HF
D-608	-0.8156331181526184	HR ;HF
P-608	-1.5906 -0.3072 -1.5328 -0.3774 -0.2702
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart failure with preserved left ventricular ejection fraction
H-1299	-0.5327527523040771	▁Heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-1299	-0.5327527523040771	Heart failure ; left ventricular ejection fraction
P-1299	-0.5355 -0.5745 -0.2810 -1.6640 -0.1935 -1.4611 -0.7755 -0.3542 -0.3351 -0.2346 -0.2232 -0.0169 -0.5369 -0.2726
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients ; surgical
H-547	-1.2891831398010254	▁AI ▁; ▁sur g ical
D-547	-1.2891831398010254	AI ; surgical
P-547	-1.8174 -1.2860 -1.9880 -0.4875 -1.3245 -1.8039 -0.3170
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute heart failure
H-468	-0.5336794853210449	▁a cute ▁heart ▁failure
D-468	-0.5336794853210449	acute heart failure
P-468	-0.7176 -0.1379 -1.3983 -0.2539 -0.3812 -0.3132
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity pathway analysis
H-875	-0.6182490587234497	▁significant
D-875	-0.6182490587234497	significant
P-875	-0.0266 -1.4502 -0.3779
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad ai
H-543	-0.8473459482192993	▁algorithm s ▁; ▁post - ▁l VAD ▁AI
D-543	-0.8473459482192993	algorithms ; post- lVAD AI
P-543	-1.8311 -0.9202 -0.4356 -0.1947 -0.0620 -2.3465 -0.5516 -1.2294 -0.5467 -0.3556
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing ; nursing
H-1397	-0.8142522573471069	
D-1397	-0.8142522573471069	
P-1397	-1.2170 -0.4115
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise ; training ; outcomes
H-1640	-0.725990355014801	
D-1640	-0.725990355014801	
P-1640	-1.1548 -0.2972
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia ; patients ; heart disease
H-39	-1.249219298362732	▁voordelen ▁; ▁an emia ▁treatment ▁; ▁heart ▁disease
D-39	-1.249219298362732	voordelen ; anemia treatment ; heart disease
P-39	-2.2500 -0.4322 -1.0788 -0.9309 -3.5444 -0.4187 -2.3732 -0.7122 -0.4518 -0.2999
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort study
H-1829	-0.492484450340271	
D-1829	-0.492484450340271	
P-1829	-0.7061 -0.2789
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs duration
H-888	-0.7629572749137878	▁QR s ▁; ▁benefit
D-888	-0.7629572749137878	QRs ; benefit
P-888	-0.7792 -1.7531 -0.3351 -1.1150 -0.3437 -0.2515
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients ; hospitals
H-3	-0.7025841474533081	
D-3	-0.7025841474533081	
P-3	-1.0667 -0.3384
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control ; outcomes
H-1232	-0.9335775375366211	▁ Rhythm - ▁; ▁rate - control
D-1232	-0.9335775375366211	Rhythm- ; rate-control
P-1232	-2.9541 -0.4540 -0.4280 -2.7013 -0.4223 -0.5042 -0.0527 -0.6068 -0.2789
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.2499537318944931	▁follow - up
D-1165	-0.2499537318944931	follow-up
P-1165	-0.0510 -0.4780 -0.0959 -0.3643 -0.2607
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public reporting ; patients ; hospitals
H-1689	-0.9504069685935974	▁Public ▁report ing ▁; ▁hospital s
D-1689	-0.9504069685935974	Public reporting ; hospitals
P-1689	-2.1482 -0.2000 -0.1534 -0.4442 -3.0403 -0.7983 -0.4865 -0.3323
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus rhythm ; adverse outcomes
H-1644	-0.42258700728416443	▁sinus ▁ rhythm ▁; ▁AF
D-1644	-0.42258700728416443	sinus rhythm ; AF
P-1644	-0.6383 -0.3568 -0.5466 -0.3454 -0.4331 -0.3913 -0.2466
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal ; diagnostic ; filling pressures
H-490	-0.6372618079185486	▁diagnostic ▁; ▁fill ing ▁pressure s
D-490	-0.6372618079185486	diagnostic ; filling pressures
P-490	-2.2388 -0.6136 -0.3537 -0.2702 -0.3419 -0.4971 -0.4801 -0.3025
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth ; longitudinal ; medicare
H-1617	-0.5652599930763245	▁care ▁management ▁; ▁tele health ▁; ▁medica re
D-1617	-0.5652599930763245	care management ; telehealth ; medicare
P-1617	-2.8563 -0.2472 -0.2561 -0.3103 -0.5548 -0.3263 -0.0358 -0.1920 -0.5293 -0.3444
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative ; operative ; outcomes
H-299	-0.38510560989379883	
D-299	-0.38510560989379883	
P-299	-0.5035 -0.2667
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit index
H-1006	-0.35565823316574097	▁deficit ▁index
D-1006	-0.35565823316574097	deficit index
P-1006	-0.7383 -0.0698 -0.3350 -0.2795
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians ; patients ; hf
H-1724	-1.1304714679718018	▁ HF
D-1724	-1.1304714679718018	HF
P-1724	-2.9269 -0.8827 -0.4053 -0.3071
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients ; heart failure ; cardiac rehabilitation
H-568	-0.9841495752334595	▁heart ▁failure ▁; ▁cardiac ▁rehabilita tion
D-568	-0.9841495752334595	heart failure ; cardiac rehabilitation
P-568	-3.8230 -0.7651 -0.4175 -0.2550 -0.2166 -1.5757 -0.5069 -0.3133
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone ; severe heart failure
H-1701	-0.4647284150123596	▁Race ▁; ▁spi rono lac tone ▁; ▁heart ▁failure
D-1701	-0.4647284150123596	Race ; spironolactone ; heart failure
P-1701	-0.4165 -0.2355 -0.0598 -0.0925 -0.1845 -0.1966 -0.3138 -2.6112 -0.3391 -0.3680 -0.2946
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial infarction
H-1137	-0.6781094670295715	▁My o card ial ▁in far ction ▁; ▁Wi star ▁rat s
D-1137	-0.6781094670295715	Myocardial infarction ; Wistar rats
P-1137	-1.6137 -0.4746 -0.7453 -1.5307 -0.0762 -0.7656 -0.6129 -0.3864 -1.7258 -0.1941 -0.2327 -0.3424 -0.4649 -0.3283
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse events
H-1263	-0.38954612612724304	
D-1263	-0.38954612612724304	
P-1263	-0.5493 -0.2298
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf ; chromatin hyperacetylation
H-1036	-0.6355636119842529	▁molecular ▁level ▁; HF ▁; ▁chr omat in ▁hyper ace ty lation
D-1036	-0.6355636119842529	molecular level ;HF ; chromatin hyperacetylation
P-1036	-2.3232 -0.7847 -0.2411 -1.9657 -0.2881 -0.1253 -0.0942 -0.6015 -0.0882 -0.3390 -1.1739 -0.2669 -0.3588 -0.2470
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-0.8656838536262512	▁mortal iteit
D-1696	-0.8656838536262512	mortaliteit
P-1696	-0.2226 -2.4709 -0.4050 -0.3642
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-0.7907586097717285	▁g LS ▁; ▁CV ▁; ▁AF
D-810	-0.7907586097717285	gLS ; CV ; AF
P-810	-0.3761 -2.1711 -0.3080 -0.7015 -1.0570 -1.0407 -0.3969 -0.2747
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-0.7370398044586182	▁MS ▁; ▁surgery
D-370	-0.7370398044586182	MS ; surgery
P-370	-2.1134 -0.7460 -0.1702 -0.3588 -0.2967
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.36278036236763	
D-1855	-0.36278036236763	
P-1855	-0.4647 -0.2609
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication ; resting hemodynamics
H-828	-0.632357656955719	▁medication ▁; ▁hem o dynamic s
D-828	-0.632357656955719	medication ; hemodynamics
P-828	-1.0169 -0.3324 -1.4220 -0.9970 -0.0490 -0.4622 -0.4469 -0.3325
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome ; all-cause readmissions
H-1580	-1.3817228078842163	
D-1580	-1.3817228078842163	
P-1580	-2.4704 -0.2930
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis ; pathophysiological
H-1276	-0.5733680129051208	
D-1276	-0.5733680129051208	
P-1276	-0.8429 -0.3038
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence ; systolic hf
H-1798	-0.3339765965938568	▁sy sto lic ▁ HF
D-1798	-0.3339765965938568	systolic HF
P-1798	-0.2087 -0.3391 -0.0962 -0.5184 -0.4169 -0.4722 -0.2864
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation ; postsystolic function
H-331	-0.4030640721321106	▁posts y sto lic ▁function
D-331	-0.4030640721321106	postsystolic function
P-331	-0.8949 -0.6754 -0.2487 -0.0878 -0.1728 -0.4363 -0.3056
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients ; lvad ; implantation
H-545	-0.7723809480667114	▁l VAD ▁implant ation
D-545	-0.7723809480667114	lVAD implantation
P-545	-0.4236 -0.2727 -1.3021 -1.6923 -0.5624 -0.3812
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission ; hospital ; heart failure ; discharge
H-147	-0.816757321357727	▁hospital ▁; ▁heart ▁failure ▁; ▁dis charge
D-147	-0.816757321357727	hospital ; heart failure ; discharge
P-147	-3.1010 -0.4258 -1.4178 -0.4423 -0.9361 -0.2299 -0.1869 -0.3109 -0.2999
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income ; expenditure ; health
H-1792	-0.9425854086875916	▁gross ▁income ▁; ▁ex pendi ture ▁; ▁health
D-1792	-0.9425854086875916	gross income ; expenditure ; health
P-1792	-2.1228 -1.1621 -0.3148 -0.1497 -0.2454 -2.9397 -0.4064 -1.2545 -0.5380 -0.2925
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary outcome ; patient ; post
H-617	-0.4923737645149231	
D-617	-0.4923737645149231	
P-617	-0.6806 -0.3041
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac ; cardiac hypertrophy
H-1782	-0.7427892684936523	▁a ac ▁; ▁cardiac ▁hyper trop hy
D-1782	-0.7427892684936523	aac ; cardiac hypertrophy
P-1782	-1.2340 -1.5862 -0.3090 -0.2260 -0.2880 -0.0692 -2.3582 -0.3381 -0.2764
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician ; outcomes ; patients ; heart failure
H-1720	-1.7623366117477417	▁heart ▁failure
D-1720	-1.7623366117477417	heart failure
P-1720	-5.4223 -0.7023 -0.5238 -0.4009
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal muscle ; exercise capacity ; fontan circulation
H-1491	-0.7979691624641418	kelet al ▁muscle ▁; ▁exercise ▁capacity ▁; ▁Font an ▁circulation
D-1491	-0.7979691624641418	keletal muscle ; exercise capacity ; Fontan circulation
P-1491	-3.0922 -0.4579 -0.8064 -1.8968 -0.7662 -0.3566 -0.3015 -0.6488 -0.3788 -0.1233 -0.4460 -0.3010
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease ; lead ; hypertension ; kidney failure
H-1598	-0.6125994324684143	▁progressive ▁; ▁hyper tension ▁; ▁ki dne y ▁failure
D-1598	-0.6125994324684143	progressive ; hypertension ; kidney failure
P-1598	-2.4111 -1.4408 -0.2758 -0.1124 -0.2271 -0.1464 -0.8649 -0.3505 -0.2094 -0.4375 -0.2626
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients ; chronic kidney disease ; ckd
H-898	-0.7561905980110168	▁chronic ▁ki dne y ▁disease ▁; CK d
D-898	-0.7561905980110168	chronic kidney disease ;CKd
P-898	-1.4511 -0.2678 -1.2302 -0.6506 -0.5889 -0.2372 -1.5538 -0.8744 -0.3786 -0.3293
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations ; hospital ; longitudinal ; change
H-143	-0.6490343809127808	▁hospital
D-143	-0.6490343809127808	hospital
P-143	-1.2650 -0.3542 -0.3280
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic ; anaerobic threshold ; heart failure
H-1752	-0.5014041066169739	▁ana ero bic ▁thre s hold ▁; ▁heart ▁failure
D-1752	-0.5014041066169739	anaerobic threshold ; heart failure
P-1752	-0.5244 -1.0856 -0.8548 -0.0322 -0.3407 -0.4586 -0.2678 -0.8833 -0.2915 -0.5049 -0.2716
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral regurgitation ; hf ; symptoms ; surgery
H-362	-0.9809352159500122	ral ▁re gur gi tation ▁; ▁ HF ▁; ▁surgery
D-362	-0.9809352159500122	ral regurgitation ; HF ; surgery
P-362	-4.8417 -0.3513 -0.2960 -0.6749 -0.3763 -0.3245 -2.0885 -0.5748 -1.1633 -0.5131 -0.3009 -0.2661
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf ; unilateral renal dnx ; cardiac ; autonomic balance
H-1372	-0.4159436523914337	▁CHF ▁; ▁unilateral ▁renal ▁DN x ▁; ▁cardiac ▁autonomi c ▁balance
D-1372	-0.4159436523914337	CHF ; unilateral renal DNx ; cardiac autonomic balance
P-1372	-0.2871 -0.3580 -0.0441 -0.0795 -2.0746 -0.1473 -0.3225 -0.1405 -0.0426 -0.5589 -0.6234 -0.4842 -0.2447
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone system inhibitors ; heart failure
H-1486	-0.469368040561676	▁re nin - angi oten sin - al do ster one ▁system ▁inhibi tors ▁; ▁heart ▁failure
D-1486	-0.469368040561676	renin-angiotensin-aldosterone system inhibitors ; heart failure
P-1486	-0.6828 -0.5464 -0.1060 -0.0038 -0.4726 -2.3980 -0.2735 -0.0449 -0.0971 -0.1786 -1.2330 -0.1245 -0.2157 -0.2820 -0.3426 -0.5798 -0.4348 -0.5146 -0.3871
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr variability ; cardiac death
H-1589	-1.0954179763793945	▁ab normal ▁HR ▁variabil iteit ▁; ▁cardiac ▁death
D-1589	-1.0954179763793945	abnormal HR variabiliteit ; cardiac death
P-1589	-4.3743 -0.3619 -1.3246 -0.1089 -2.3453 -0.2284 -0.3367 -1.0889 -0.4736 -0.3117
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin ; inflammation ; metabolism ; heart disease
H-940	-0.5706124901771545	▁ inflammation ▁; ▁metabolism ▁; ▁heart ▁disease
D-940	-0.5706124901771545	inflammation ; metabolism ; heart disease
P-940	-0.6467 -0.6902 -0.3329 -0.0929 -0.3825 -1.3878 -0.8980 -0.3700 -0.3346
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart block ; pulmonary artery ; bivp
H-322	-0.8314921855926514	▁Heart ▁block ▁; ▁pulmonar y ▁arter y ▁; ▁Bi VP
D-322	-0.8314921855926514	Heart block ; pulmonary artery ; BiVP
P-322	-1.9302 -0.3271 -0.2922 -0.1006 -0.8703 -0.0240 -1.8134 -1.1888 -2.2645 -0.5039 -0.3954 -0.2675
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital ; heart ; lesions
H-985	-0.5687848329544067	▁con geni tal ▁heart ▁les ions
D-985	-0.5687848329544067	congenital heart lesions
P-985	-0.5160 -0.0729 -0.1170 -0.8943 -1.4498 -0.8705 -0.3638 -0.2660
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical ; patients ; functional ms
H-373	-1.1160656213760376	▁functional ▁MS
D-373	-1.1160656213760376	functional MS
P-373	-3.3189 -0.3695 -0.4626 -0.3132
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients ; patients ; echocardiographic
H-813	-0.896279513835907	▁AF ▁; ▁e cho car dio graphic ▁examina tion
D-813	-0.896279513835907	AF ; echocardiographic examination
P-813	-0.9385 -0.4263 -1.0882 -0.5318 -0.1821 -1.4703 -1.1666 -0.3500 -2.9401 -0.4257 -0.3395
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray ; genes ; heart failure
H-1605	-0.8710374236106873	▁bio informati c ▁; ▁micro arra y ▁; ▁gene s ▁; ▁heart ▁failure
D-1605	-0.8710374236106873	bioinformatic ; microarray ; genes ; heart failure
P-1605	-0.4277 -0.3583 -0.6920 -2.1610 -0.0938 -0.0727 -0.3765 -1.8932 -2.6298 -0.7407 -0.4921 -1.7588 -0.5915 -0.4794 -0.2981
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up ; cardiovascular events ; deaths
H-974	-0.5058834552764893	▁follow - up ▁; ▁cardiovascular ▁events ▁; ▁death s
D-974	-0.5058834552764893	follow-up ; cardiovascular events ; deaths
P-974	-0.1020 -0.3801 -0.0791 -0.3586 -0.2985 -0.4984 -0.9863 -1.5424 -0.7409 -0.3340 -0.2445
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic ; outcomes ; hf
H-1202	-0.9369741082191467	▁di ure tic ▁; HF
D-1202	-0.9369741082191467	diuretic ;HF
P-1202	-0.7202 -0.6404 -0.9547 -2.0095 -1.5948 -0.3789 -0.2603
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad ; systolic hf ; prognostic
H-1183	-0.2747276723384857	▁CAD ▁; ▁sy sto lic ▁ HF
D-1183	-0.2747276723384857	CAD ; systolic HF
P-1183	-0.3385 -0.2872 -0.0674 -0.1773 -0.1047 -0.4375 -0.2024 -0.6055 -0.2521
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf ; pb
H-1349	-0.8189232349395752	▁ pv f ▁; ▁p b
D-1349	-0.8189232349395752	pvf ; pb
P-1349	-1.7045 -0.1648 -3.2956 -0.2460 -0.2681 -0.2881 -0.3426 -0.2417
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses ; patients ; disease
H-2020	-1.6069790124893188	▁Nur ses ▁; ▁patients
D-2020	-1.6069790124893188	Nurses ; patients
P-2020	-4.3076 -2.9281 -0.5213 -0.7054 -0.8702 -0.3093
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients ; diabetes ; eo-cfus ; functional capacity
H-132	-0.7463701963424683	▁diabetes ▁; ▁e EO - c FU s ▁; ▁functional ▁capacity
D-132	-0.7463701963424683	diabetes ; eEO-cFUs ; functional capacity
P-132	-0.3296 -0.3961 -0.6689 -3.8797 -0.0751 -0.5684 -0.9907 -0.4789 -0.5344 -0.2983 -0.8956 -0.3233 -0.2639
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute walk distance ; peak vo2 ; baseline
H-1636	-0.553209125995636	▁black s ▁; ▁VO 2
D-1636	-0.553209125995636	blacks ; VO2
P-1636	-0.8619 -0.6344 -0.3199 -0.9295 -0.1023 -0.7258 -0.2987
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate models ; odds ratios ; accounting ; hospital
H-191	-0.3262401521205902	▁odds ▁ratio s ▁; ▁account ing ▁; ▁hospital ▁cluster ing
D-191	-0.3262401521205902	odds ratios ; accounting ; hospital clustering
P-191	-0.6352 -0.0540 -0.6297 -0.3333 -0.0720 -0.2174 -0.3399 -0.6238 -0.0495 -0.2522 -0.3755 -0.3323
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change ; lvet ; admission ; follow-up ; outcome
H-588	-0.5161459445953369	▁l VET ▁; ▁follow - up ▁measure ment
D-588	-0.5161459445953369	lVET ; follow-up measurement
P-588	-0.4247 -1.2592 -0.2917 -0.3211 -0.2840 -0.1104 -0.5461 -1.2719 -0.3583 -0.2940
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl ; hno ; acute ; heart failure
H-412	-0.8005989789962769	▁ni tro x yl ▁; ▁h no ▁; ▁a cute ▁treatment ▁; ▁heart ▁failure
D-412	-0.8005989789962769	nitroxyl ; hno ; acute treatment ; heart failure
P-412	-0.2922 -0.0329 -0.1303 -0.1122 -0.2401 -1.2059 -1.6443 -0.2768 -4.4336 -0.1764 -1.6775 -0.4094 -0.9631 -0.4865 -0.4200 -0.3085
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician ; death ; readmission ; discharge ; patients ; heart failure
H-1412	-1.0531909465789795	▁physician ▁; ▁death ▁; ▁urgent ▁read mission ▁; ▁dis charge ▁; ▁heart ▁failure
D-1412	-1.0531909465789795	physician ; death ; urgent readmission ; discharge ; heart failure
P-1412	-1.7271 -0.3812 -2.6216 -0.3249 -0.4103 -2.5290 -1.0207 -1.0872 -0.9121 -0.4728 -0.4179 -2.5190 -0.5461 -0.4919 -0.3359
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref ; hfpef ; patients ; regression line
H-497	-1.0028194189071655	▁h Fr EF ▁; ▁ HF p EF
D-497	-1.0028194189071655	hFrEF ; HFpEF
P-497	-1.8005 -2.7944 -1.6094 -0.2751 -0.5641 -0.8455 -0.0757 -1.0330 -0.7257 -0.3048
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life ; patients
H-161	-0.9231871962547302	▁Care ▁package s
D-161	-0.9231871962547302	Care packages
P-161	-2.2552 -0.9408 -0.5089 -0.5834 -0.3276
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home ; hospital ; readmission ; congestive heart failure
H-1573	-0.8599222898483276	▁hospital - to - Home ▁; ▁hospital ▁; ▁read mission ▁re duction ▁; ▁con ges tive ▁heart ▁failure
D-1573	-0.8599222898483276	hospital-to-Home ; hospital ; readmission reduction ; congestive heart failure
P-1573	-0.9171 -0.2550 -0.2601 -0.2078 -0.6715 -0.4941 -2.3816 -0.4179 -1.0234 -1.6080 -0.2233 -0.3104 -1.8085 -0.3360 -0.7019 -3.3721 -0.8821 -0.4224 -0.5635 -0.3417
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic ; accounting ; cost
H-1582	-0.8430156707763672	▁economische ▁; ▁kosten
D-1582	-0.8430156707763672	economische ; kosten
P-1582	-1.8666 -0.2946 -1.4196 -0.3577 -0.2767
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-1.1928402185440063	HF
D-556	-1.1928402185440063	HF
P-556	-2.7942 -0.4888 -0.2956
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt ; patients
H-905	-0.760400116443634	▁c RT ▁; ▁di al ysis - dependent ▁patients
D-905	-0.760400116443634	cRT ; dialysis-dependent patients
P-905	-0.6430 -3.8946 -0.4100 -0.5817 -0.1065 -0.0718 -0.3534 -0.1837 -1.3078 -0.4574 -0.3545
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf ; surgical
H-353	-0.8680922389030457	▁significant ▁; ▁MS ▁; HF ▁; ▁sur g ical ▁indica tion ▁; ▁MS
D-353	-0.8680922389030457	significant ; MS ;HF ; surgical indication ; MS
P-353	-0.0802 -0.5098 -2.0887 -0.2874 -1.5823 -0.3482 -3.9447 -0.3481 -0.7066 -0.2304 -1.1735 -0.3135 -0.8007 -0.3779 -0.2293
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance ; attrition
H-1319	-0.3551776707172394	
D-1319	-0.3551776707172394	
P-1319	-0.4440 -0.2664
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu ; mortality
H-582	-1.2972055673599243	ICU ▁mortal iteit
D-582	-1.2972055673599243	ICU mortaliteit
P-582	-1.3658 -1.8758 -2.4862 -0.4349 -0.3233
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac function ; catheter
H-1143	-0.4860647916793823	▁Card iac ▁function ▁; ▁pressure - volu me ▁conduct ance ▁cat heter ▁system
D-1143	-0.4860647916793823	Cardiac function ; pressure-volume conductance catheter system
P-1143	-1.3000 -1.2499 -0.1956 -0.2627 -0.7098 -0.1315 -0.0403 -0.2261 -0.0210 -0.5946 -1.4832 -0.1124 -0.3091 -0.4067 -0.2482
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-0.40046167373657227	▁RM
D-163	-0.40046167373657227	RM
P-163	-0.4708 -0.4375 -0.2930
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.36677253246307373	▁beta - block ers
D-865	-0.36677253246307373	beta-blockers
P-865	-0.3755 -0.1607 -0.4791 -0.3995 -0.4891 -0.2968
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf ; patients
H-217	-0.6409669518470764	▁CHF
D-217	-0.6409669518470764	CHF
P-217	-0.4815 -1.1397 -0.3016
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 ; therapy
H-401	-0.7375102043151855	▁s st 2 ▁; ▁benefit ▁; ▁BB ▁ therapy
D-401	-0.7375102043151855	sst2 ; benefit ; BB therapy
P-401	-0.0602 -3.0940 -0.2367 -1.2908 -1.5093 -0.3203 -0.6067 -0.2402 -0.0687 -0.3872 -0.2986
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence ; idiopathic dilated cardiomyopathy
H-1741	-0.3015117645263672	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1741	-0.3015117645263672	idiopathic dilated cardiomyopathy
P-1741	-0.6834 -0.1493 -0.1288 -0.7546 -0.2103 -0.1730 -0.0621 -0.5359 -0.1726 -0.0210 -0.4473 -0.2799
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia ; prognostic ; patients ; heart failure
H-529	-0.7257694602012634	▁Hypo album in emia ▁; ▁heart ▁failure
D-529	-0.7257694602012634	Hypoalbuminemia ; heart failure
P-529	-1.8363 -0.1276 -0.2089 -0.6231 -0.3283 -2.0948 -0.6081 -0.4269 -0.2780
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient ; diagnosed ; hypertensive lv dysfunction
H-350	-0.2946018576622009	▁hyper tensi ve ▁LV ▁dys function ▁; ▁MR ▁; ▁significant ▁MS
D-350	-0.2946018576622009	hypertensive LV dysfunction ; MR ; significant MS
P-350	-1.0221 -0.2521 -0.2499 -0.0316 -0.0395 -0.1270 -0.2293 -0.5232 -0.2665 -0.0059 -0.5308 -0.3358 -0.2161
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis ; hf ; etiologies
H-1795	-0.7391272783279419	▁ HF ▁; ▁et i ologie s
D-1795	-0.7391272783279419	HF ; etiologies
P-1795	-3.2875 -1.3818 -0.3983 -0.0821 -0.3395 -0.0267 -0.4499 -0.3993 -0.2871
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin receptor neprilysin inhibitor ; heart failure
H-1461	-0.7465117573738098	▁ang io ten sin ▁receptor ▁; ▁nepri ly sin ▁inhibi tor ▁; ▁heart ▁failure
D-1461	-0.7465117573738098	angiotensin receptor ; neprilysin inhibitor ; heart failure
P-1461	-1.6456 -2.0471 -0.1807 -2.7006 -0.1458 -0.4985 -0.0613 -0.5562 -1.6557 -0.0805 -0.1428 -0.4574 -0.5707 -0.2974 -0.5663 -0.3376
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western blot ; immunohistochemistry ; electron microscopy
H-1252	-0.5075516700744629	▁Western ▁blot ▁analysis ▁; ▁immun oh isto che mist ry ▁; ▁electro n ▁micro s copy
D-1252	-0.5075516700744629	Western blot analysis ; immunohistochemistry ; electron microscopy
P-1252	-0.3334 -0.1095 -1.5949 -0.2971 -0.0488 -0.2724 -0.8120 -0.3359 -0.5601 -1.6697 -0.3422 -0.0093 -0.0770 -0.0344 -0.8790 -0.9418 -0.5002 -0.3181
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic dysfunction ; patients ; peripheral artery disease
H-1566	-0.4664773941040039	▁dia sto lic ▁dys function ▁; ▁per i pher al ▁arter y ▁disease
D-1566	-0.4664773941040039	diastolic dysfunction ; peripheral artery disease
P-1566	-0.0286 -0.2797 -0.1203 -0.0724 -0.1785 -0.3288 -1.2754 -0.2906 -0.1734 -0.3141 -0.1674 -2.2373 -0.6033 -0.6149 -0.3124
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded protein response ; cardiac sodium ; systolic ; heart failure
H-1079	-0.396307110786438	▁un fold ed ▁protein ▁response ▁; ▁cardiac ▁so dium ▁current ▁; ▁sy sto lic ▁human ▁heart ▁failure
D-1079	-0.396307110786438	unfolded protein response ; cardiac sodium current ; systolic human heart failure
P-1079	-0.2178 -0.0077 -0.3433 -0.8156 -0.4408 -0.4620 -0.2729 -0.1293 -0.0178 -0.2634 -0.2324 -0.0575 -0.0948 -0.0913 -1.7961 -0.9018 -0.5596 -0.4997 -0.3262
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic cardiomyopathy ; mortality
H-67	-0.8183836340904236	▁cardio my o pathy ▁; ▁male ▁sex ▁; ▁mortal iteit
D-67	-0.8183836340904236	cardiomyopathy ; male sex ; mortaliteit
P-67	-1.5520 -0.7507 -0.2932 -0.0423 -0.2902 -2.6426 -0.6212 -0.2938 -0.2411 -2.3723 -0.3874 -0.3337
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise intolerance ; chronic heart failure ; prognosis
H-1273	-0.8139879703521729	▁Exerci se ▁in tolerance ▁; ▁chronic ▁heart ▁failure
D-1273	-0.8139879703521729	Exercise intolerance ; chronic heart failure
P-1273	-2.1385 -0.5697 -0.0369 -0.2193 -0.2944 -1.9673 -1.6449 -0.5001 -0.4800 -0.2886
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit index ; biological phenotype ; mortality
H-1012	-0.4942539632320404	▁deficit ▁index ▁; ▁bi ological ▁ph eno type ▁; ▁mortal iteit
D-1012	-0.4942539632320404	deficit index ; biological phenotype ; mortaliteit
P-1012	-0.7894 -0.0571 -0.1998 -0.4451 -0.4225 -0.3898 -0.2482 -0.0104 -0.2917 -0.3085 -2.6431 -0.3209 -0.2989
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise ; training ; endothelial function
H-248	-0.58992999792099	▁exercise ▁training ▁; ET ▁; ▁en dot heli al ▁function
D-248	-0.58992999792099	exercise training ;ET ; endothelial function
P-248	-2.3344 -0.7607 -0.2570 -2.2206 -0.3531 -0.1357 -0.2190 -0.0968 -0.0457 -0.0407 -0.3688 -0.2466
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death ; stroke ; hospitalisation ; heart failure
H-815	-0.6439234018325806	▁CV ▁; ▁death ▁; ▁non - fa tal ▁stroke ▁; ▁hospital isation ▁; ▁heart ▁failure
D-815	-0.6439234018325806	CV ; death ; non-fatal stroke ; hospitalisation ; heart failure
P-815	-0.7019 -0.3175 -4.8825 -0.3203 -0.5188 -0.0703 -0.3884 -0.0934 -0.2849 -0.2850 -0.9578 -0.1163 -0.2873 -0.7173 -0.2534 -0.4561 -0.2955
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd ; vvd ; free wall rs
H-328	-0.8062421083450317	▁AV d ▁; ▁VVD ▁; ▁free ▁wall ▁; ▁RS
D-328	-0.8062421083450317	AVd ; VVD ; free wall ; RS
P-328	-0.9146 -0.5224 -0.2929 -2.7010 -0.4096 -0.5367 -0.9574 -1.2161 -0.6959 -0.3715 -0.2506
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia ; right ventricle ; heart failure
H-1457	-0.4395468831062317	▁Fat ▁; ▁cache xia ▁; ▁right ▁vent ric le ▁; ▁heart ▁failure
D-1457	-0.4395468831062317	Fat ; cachexia ; right ventricle ; heart failure
P-1457	-0.4508 -0.1958 -0.0814 -0.1477 -0.3003 -1.2455 -0.1281 -0.9626 -0.5212 -0.2821 -0.9788 -0.2805 -0.3305 -0.2485
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial fibrillation ; patients ; heart failure
H-1231	-0.8478268980979919	▁At rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure
D-1231	-0.8478268980979919	Atrial fibrillation ;AF ; heart failure
P-1231	-3.4629 -0.2887 -0.6633 -0.1070 -0.3774 -0.3513 -2.1827 -0.3704 -1.1168 -0.4044 -0.5420 -0.3072
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct ; heart failure ; therapy ; patients
H-718	-0.9302688241004944	▁ec t ▁; ▁advanced ▁heart ▁failure ▁ therapy
D-718	-0.9302688241004944	ect ; advanced heart failure therapy
P-718	-0.6884 -2.3763 -0.4166 -2.4894 -1.3901 -0.4224 -0.5046 -0.1420 -0.5153 -0.3577
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart transplantation ; left ventricular assist device
H-306	-1.1225072145462036	▁heart ▁transplant ation ▁; ▁left ▁vent ri cular ▁assist ▁device
D-306	-1.1225072145462036	heart transplantation ; left ventricular assist device
P-306	-2.9453 -0.3345 -2.7343 -0.3992 -1.2371 -0.2595 -2.3760 -0.3819 -1.0867 -0.6271 -0.7775 -0.3109
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary disease ; leading ; heart failure
H-981	-1.0409481525421143	▁corona ry ▁disease ▁; ▁heart ▁failure
D-981	-1.0409481525421143	coronary disease ; heart failure
P-981	-0.8769 -3.4749 -0.8117 -0.2734 -1.6459 -0.5436 -0.3843 -0.3170
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications ; dialysis ; patients
H-908	-0.6845542192459106	▁complica tions ▁; ▁di al ysis ▁patients
D-908	-0.6845542192459106	complications ; dialysis patients
P-908	-0.7875 -2.5103 -0.2883 -0.6149 -0.0879 -0.0773 -0.9907 -0.4743 -0.3297
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right ventricular function ; prognosis ; heart failure
H-1157	-0.99936443567276	▁right ▁vent ri cular ▁function ▁; ▁body ▁composition ▁; ▁advanced ▁heart ▁failure
D-1157	-0.99936443567276	right ventricular function ; body composition ; advanced heart failure
P-1157	-2.1628 -0.4270 -1.6069 -0.5773 -0.3086 -0.3186 -3.3733 -0.2092 -0.2545 -2.5099 -0.9390 -0.5031 -0.4941 -0.3069
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ; ecgs ; electrocardiographers
H-884	-0.6546451449394226	▁e CG s ▁; ▁electro car dio graph ers
D-884	-0.6546451449394226	eCGs ; electrocardiographers
P-884	-0.6571 -2.2197 -0.3522 -0.2363 -0.0338 -0.1276 -0.9116 -1.1114 -0.8898 -0.3927 -0.2690
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left ventricular assist device ; right ventricular support
H-293	-0.7426398992538452	▁left ▁vent ri cular ▁assist ▁device ▁; ▁right ▁vent ri cular ▁support
D-293	-0.7426398992538452	left ventricular assist device ; right ventricular support
P-293	-0.6476 -0.3193 -1.9488 -0.4566 -0.8286 -0.3947 -0.3149 -1.1387 -0.1525 -2.1872 -0.4088 -0.7969 -0.5125 -0.2897
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence ; esrd ; outpatients ; hf
H-388	-1.2519272565841675	▁ES RD ▁; ▁out patient s ▁; HF
D-388	-1.2519272565841675	ESRD ; outpatients ;HF
P-388	-3.8666 -1.8682 -0.2673 -2.8677 -0.0743 -0.2678 -0.2563 -2.3903 -0.4075 -0.2534
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon matched-pairs signed-rank tests
H-923	-0.8353443145751953	▁Wil co xon
D-923	-0.8353443145751953	Wilcoxon
P-923	-2.3145 -0.0628 -0.6870 -0.7437 -0.3687
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical ; atherosclerosis ; linear models
H-1557	-1.105067253112793	▁at hero sc ler osis ▁; ▁linear
D-1557	-1.105067253112793	atherosclerosis ; linear
P-1557	-4.3213 -0.4196 -0.0594 -2.5244 -0.2006 -0.4329 -0.0952 -1.5529 -0.3393
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical ; connected ; elevated ; resistin ; heart failure
H-929	-1.0779619216918945	▁resist in ▁levels ▁; ▁heart ▁failure
D-929	-1.0779619216918945	resistin levels ; heart failure
P-929	-3.4028 -0.8223 -1.9420 -0.2658 -0.9892 -0.4937 -0.4521 -0.2558
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ; ffm ; stable
H-20	-1.1845306158065796	▁f m ▁; ▁FM ▁; ▁body ▁weight ▁; ▁CC
D-20	-1.1845306158065796	fm ; FM ; body weight ; CC
P-20	-0.9338 -2.0545 -0.4168 -3.4587 -0.3680 -3.4296 -0.3182 -0.3218 -1.1505 -0.3052 -0.2727
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal artery stenosis ; ras ; peripheral arterial disease
H-1593	-0.4818359911441803	▁Ren al ▁arter y ▁sten osis ▁; RAS ▁; ▁per i pher al ▁arterial ▁disease
D-1593	-0.4818359911441803	Renal artery stenosis ;RAS ; peripheral arterial disease
P-1593	-2.2520 -0.2437 -0.0742 -1.4902 -0.0055 -0.1291 -0.2042 -0.2087 -0.1731 -0.4209 -0.2307 -0.1940 -0.2347 -0.1940 -1.4059 -0.4238 -0.3064
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end point ; neurological ; cardiovascular events
H-1872	-0.8488059043884277	▁neurologi cal ▁; ▁cardiovascular ▁events
D-1872	-0.8488059043884277	neurological ; cardiovascular events
P-1872	-0.6880 -1.8691 -0.5885 -0.1071 -1.9234 -0.4690 -0.2965
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling pathways ; cardiac remodelling
H-992	-0.7937964200973511	▁signal ling ▁path ways ▁; ▁cardiac ▁remodel ling
D-992	-0.7937964200973511	signalling pathways ; cardiac remodelling
P-992	-1.4972 -1.2429 -0.5163 -0.8491 -0.5561 -1.7933 -0.1304 -0.5385 -0.4986 -0.3157
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome ; hdl
H-254	-0.7312683463096619	▁prote ome ▁; ▁HD l ▁parti cles ▁; ▁shot gun ▁; ▁l c - MS ▁; MS
D-254	-0.7312683463096619	proteome ; HDl particles ; shotgun ; lc-MS ;MS
P-254	-0.7208 -0.3086 -0.3127 -1.4311 -2.3732 -0.1410 -0.1457 -0.4698 -0.2698 -0.3339 -0.3120 -0.1613 -2.0675 -0.1509 -1.3875 -0.4761 -2.2537 -0.3088 -0.2699
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart rate
H-1446	-1.1201428174972534	▁heart ▁rate ▁variation
D-1446	-1.1201428174972534	heart rate variation
P-1446	-3.0795 -1.0702 -0.7289 -0.3707 -0.3515
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise ; exercise
H-1931	-1.468889832496643	▁social ▁; ▁exercise ▁; ▁exercise ▁time
D-1931	-1.468889832496643	social ; exercise ; exercise time
P-1931	-4.2869 -1.9435 -1.9189 -0.3983 -0.8579 -1.5895 -0.4710 -0.2852
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-0.7071024179458618	▁re hospital ization
D-1711	-0.7071024179458618	rehospitalization
P-1711	-1.6040 -0.1134 -1.1339 -0.3874 -0.2968
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac cachexia
H-9	-0.5915267467498779	▁Card iac ▁cache xia ▁; cc ▁; ▁body ▁composition
D-9	-0.5915267467498779	Cardiac cachexia ;cc ; body composition
P-9	-1.7361 -0.1014 -0.0365 -0.2000 -0.2695 -0.2814 -0.4082 -2.7324 -0.1421 -0.3325 -0.2667
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery ; mva
H-361	-0.6870101690292358	▁MS ▁; ▁significant ▁; ▁m VA
D-361	-0.6870101690292358	MS ; significant ; mVA
P-361	-1.1793 -0.2898 -0.0612 -0.4293 -0.3771 -2.5324 -0.3513 -0.2757
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins ; tac
H-872	-1.133705735206604	▁protein s ▁; TAC
D-872	-1.133705735206604	proteins ;TAC
P-872	-2.5541 -0.9858 -0.4183 -2.2266 -0.3282 -0.2892
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.6139355897903442	▁Mediterrane an ▁; ▁DAS h ▁; ▁die t ▁score s
D-688	-0.6139355897903442	Mediterranean ; DASh ; diet scores
P-688	-1.2822 -1.0995 -0.2619 -0.1613 -0.2464 -0.4498 -1.1068 -0.3613 -0.3523 -0.3048 -1.3885 -0.3525
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart failure ; nurse
H-84	-0.7061260938644409	▁heart ▁failure ▁guidelines ▁; ▁nurse ▁leaders
D-84	-0.7061260938644409	heart failure guidelines ; nurse leaders
P-84	-2.2877 -0.3107 -1.5038 -0.4418 -0.2220 -0.1558 -0.4349 -0.2924
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty ; hf
H-632	-0.79697585105896	▁ HF
D-632	-0.79697585105896	HF
P-632	-1.3933 -0.7824 -0.7152 -0.2971
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota ; hf
H-1003	-0.7590391635894775	▁south e a stern ▁Minnesota ▁; ▁ HF
D-1003	-0.7590391635894775	southeastern Minnesota ; HF
P-1003	-2.6706 -0.0977 -0.3172 -0.2986 -0.3096 -0.3366 -2.0145 -0.9090 -0.3841 -0.2524
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left bundle branch block
H-1153	-0.7525178790092468	▁left ▁; ▁bran ch ▁block ▁; ▁electric al ▁activa tion ▁se que nce
D-1153	-0.7525178790092468	left ; branch block ; electrical activation sequence
P-1153	-0.6366 -0.9184 -0.4247 -0.7200 -0.3208 -0.3337 -0.3448 -0.4530 -0.0190 -1.8766 -0.9534 -1.9135 -1.6398 -0.4591 -0.2743
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4 inhibitors ; drugs
H-1834	-0.562627375125885	▁h HF ▁; ▁d PP -4 ▁inhibi tors ▁; ▁drugs
D-1834	-0.562627375125885	hHF ; dPP-4 inhibitors ; drugs
P-1834	-0.0250 -2.6086 -0.3152 -0.0766 -1.7169 -0.1123 -0.1132 -0.5895 -0.3506 -0.1006 -0.4257 -0.3172
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical ; hfpef
H-943	-0.9708541035652161	▁AF ▁; ▁h bf
D-943	-0.9708541035652161	AF ; hbf
P-943	-1.0242 -0.3316 -0.7973 -2.4744 -0.8897 -0.3079
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients ; heart transplant ; ecct
H-714	-1.2500489950180054	▁heart ▁transplant ▁; ▁ec t
D-714	-1.2500489950180054	heart transplant ; ect
P-714	-3.9912 -0.3239 -0.4000 -0.2777 -2.9547 -0.4744 -0.3284
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.8078013062477112	▁c RF
D-1769	-0.8078013062477112	cRF
P-1769	-0.7058 -1.7476 -0.5089 -0.2690
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk stratification ; death ; all-cause hospitalization ; heart failure ; clinic ; outpatients
H-377	-0.9130338430404663	▁death ▁; ▁heart ▁failure ▁clinic ▁; ▁out patient s
D-377	-0.9130338430404663	death ; heart failure clinic ; outpatients
P-377	-4.2455 -0.3826 -1.4309 -0.3320 -0.2920 -0.5368 -1.5573 -0.0710 -0.3713 -0.4839 -0.3402
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization therapy ; heart failure ; narrow qrs complex
H-844	-0.6517713665962219	▁Card iac - re syn chron ization ▁ therapy ▁; ▁heart ▁failure ▁; ▁QR s ▁complex
D-844	-0.6517713665962219	Cardiac-resynchronization therapy ; heart failure ; QRs complex
P-844	-1.3723 -0.3629 -0.1509 -0.3680 -0.4237 -0.0214 -2.7920 -0.8299 -0.1143 -0.3825 -1.5469 -0.4789 -0.2971 -0.2993 -0.9129 -0.6518 -0.4569 -0.2703
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing ; medications ; heart failure
H-1121	-1.2861541509628296	▁medication s ▁; ▁adults ▁; ▁heart ▁failure
D-1121	-1.2861541509628296	medications ; adults ; heart failure
P-1121	-2.5131 -0.5119 -0.4338 -4.4812 -1.0100 -1.4019 -0.3456 -0.5652 -0.3127
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas ; cardiac ; pathogenesis
H-1484	-0.3693602681159973	▁mi RNA s ▁; ▁cardiac ▁path ogen es is
D-1484	-0.3693602681159973	miRNAs ; cardiac pathogenesis
P-1484	-1.0329 -0.2069 -0.3198 -0.3248 -0.1785 -0.4618 -0.4572 -0.1737 -0.2183 -0.4038 -0.2853
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart failure ; readmission ; outcome
H-1030	-1.3366260528564453	▁heart ▁failure ▁; ▁care
D-1030	-1.3366260528564453	heart failure ; care
P-1030	-2.5084 -0.3567 -1.5853 -2.7974 -0.4466 -0.3254
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt ; dt ; implantation
H-315	-0.9135535955429077	▁b t ▁; ▁d t
D-315	-0.9135535955429077	bt ; dt
P-315	-1.8472 -0.9837 -0.3494 -1.9041 -0.6325 -0.3906 -0.2875
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient ; mortality ; therapeutic
H-1667	-1.0424422025680542	▁mortal iteit
D-1667	-1.0424422025680542	mortaliteit
P-1667	-0.8017 -1.9820 -1.0675 -0.3187
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary heart disease ; stroke ; heart failure
H-1564	-1.022257685661316	▁corona ry ▁heart ▁disease ▁; ▁stroke ▁; ▁heart ▁failure
D-1564	-1.022257685661316	coronary heart disease ; stroke ; heart failure
P-1564	-0.7912 -3.6512 -1.3636 -1.6852 -0.3031 -0.3921 -0.2757 -1.4847 -0.5820 -0.4098 -0.3064
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality of life ; mlhf questionnaire
H-1991	-0.7652834057807922	▁significant ▁; ▁ ML HF ▁Question naire
D-1991	-0.7652834057807922	significant ; MLHF Questionnaire
P-1991	-0.0191 -0.6848 -2.1167 -0.5841 -2.4903 -0.4102 -0.0525 -0.2387 -0.2910
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions ; septal ; surgical
H-984	-1.3997591733932495	▁sur g ical ▁intervention
D-984	-1.3997591733932495	surgical intervention
P-984	-3.8906 -0.6791 -1.3813 -1.7439 -0.4205 -0.2833
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis ; mortality ; patients
H-61	-0.7956823706626892	▁mortal iteit ▁; ▁i CD - HF ▁patients
D-61	-0.7956823706626892	mortaliteit ; iCD-HF patients
P-61	-0.6076 -2.3496 -0.3529 -0.6679 -0.6371 -0.1882 -0.2799 -2.1557 -0.3651 -0.3528
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up ; hf
H-288	-0.6230862736701965	▁follow - up ▁; HF
D-288	-0.6230862736701965	follow-up ;HF
P-288	-0.0571 -0.3610 -0.0785 -0.3230 -2.8964 -0.3943 -0.2514
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse event ; hypotension
H-1970	-0.3344351351261139	▁hypo tension
D-1970	-0.3344351351261139	hypotension
P-1970	-0.3526 -0.2392 -0.4509 -0.2950
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative ; clinical ; mortality
H-532	-0.8702377080917358	▁mortal iteit
D-532	-0.8702377080917358	mortaliteit
P-532	-0.2002 -2.5698 -0.4118 -0.2991
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing ; β-blocker ; sst2
H-400	-0.6877685785293579	▁β - block er ▁; bb ▁; ▁s ST 2
D-400	-0.6877685785293579	β-blocker ;bb ; sST2
P-400	-0.3349 -0.2044 -0.8375 -0.4703 -0.4578 -1.3897 -0.5783 -0.0509 -2.2232 -0.2494 -1.1073 -0.3495
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients ; discharge ; follow-up ; medication
H-730	-0.8148327469825745	▁dis charge ▁; ▁follow - up ▁medication
D-730	-0.8148327469825745	discharge ; follow-up medication
P-730	-2.9649 -0.4650 -0.3534 -0.0436 -0.2780 -0.0679 -0.8330 -1.9843 -0.3435
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient ; asymptomatic ; follow-up
H-599	-0.4875126779079437	
D-599	-0.4875126779079437	
P-599	-0.7242 -0.2509
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients ; extubated ; blood ; transfusion
H-777	-0.6248032450675964	▁ex tuba ted ▁; ▁blood ▁loss ▁; ▁trans fusion ▁requirements
D-777	-0.6248032450675964	extubated ; blood loss ; transfusion requirements
P-777	-0.2155 -0.4481 -1.7352 -0.4031 -1.2397 -0.4259 -0.3230 -0.0147 -0.0835 -1.8948 -0.4636 -0.2504
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate ii ; lvads ; patients
H-776	-0.6960638165473938	▁techniek ▁; ▁Heart Mate ▁i i ▁; ▁l VAD s
D-776	-0.6960638165473938	techniek ; HeartMate ii ; lVADs
P-776	-1.1611 -0.3850 -2.6904 -0.2994 -0.6551 -0.4510 -1.0389 -0.1195 -0.1768 -0.5364 -0.4996 -0.3396
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart failure ; hf ; cardiovascular ; hospitalization
H-1074	-0.6362164616584778	▁Heart ▁failure ▁; HF ▁; ▁cardiovascular ▁hospital ization
D-1074	-0.6362164616584778	Heart failure ;HF ; cardiovascular hospitalization
P-1074	-1.5621 -0.3084 -0.2520 -0.6736 -0.2785 -0.3886 -0.9323 -0.8181 -0.7610 -0.3875
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 ; patients ; plasma
H-699	-0.3983273208141327	▁ST 2 ▁; ▁plasma ▁sample s
D-699	-0.3983273208141327	ST2 ; plasma samples
P-699	-0.5549 -0.3806 -0.3584 -0.4433 -0.2711 -0.3880 -0.4760 -0.3143
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf inhibition ; cardiac function ; remodeling
H-458	-1.0226384401321411	▁VE GF ▁inhibi tion ▁; ▁cardiac ▁function ▁; ▁remodel ing
D-458	-1.0226384401321411	VEGF inhibition ; cardiac function ; remodeling
P-458	-2.7007 -1.4390 -0.1197 -2.0201 -0.2799 -1.6491 -0.1789 -3.0035 -0.0645 -0.2837 -0.3319 -0.2006
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers ; hf
H-1475	-0.45892632007598877	▁bio mark ers ▁; HF
D-1475	-0.45892632007598877	biomarkers ;HF
P-1475	-0.0359 -0.2657 -0.3933 -0.3989 -1.4209 -0.3907 -0.3070
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf ; patients
H-671	-1.0227420330047607	▁tras tuz um ab - related ▁CHF
D-671	-1.0227420330047607	trastuzumab-related CHF
P-671	-1.2130 -0.2390 -0.5556 -2.5097 -0.6592 -1.0488 -0.5162 -2.0500 -0.4133
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy ; engage ; exercise
H-1903	-0.9567686319351196	▁Health ▁; ▁aero bic ▁exercise
D-1903	-0.9567686319351196	Health ; aerobic exercise
P-1903	-3.6363 -1.2833 -0.0464 -0.3851 -0.7248 -0.3171 -0.3044
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-1.2790237665176392	▁hospital s
D-1694	-1.2790237665176392	hospitals
P-1694	-3.1894 -1.3145 -0.3145 -0.2977
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes ; hospitalization
H-566	-0.49319931864738464	
D-566	-0.49319931864738464	
P-566	-0.6663 -0.3201
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients ; transplants
H-2000	-0.5390103459358215	▁transplant s ▁; ▁die d
D-2000	-0.5390103459358215	transplants ; died
P-2000	-0.4301 -1.0086 -0.5610 -0.8191 -0.2641 -0.3982 -0.2920
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-0.9521180391311646	
D-1	-0.9521180391311646	
P-1	-1.5610 -0.3433
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak vo2
H-1498	-0.7412310242652893	▁VO 2
D-1498	-0.7412310242652893	VO2
P-1498	-1.6095 -0.4617 -0.5350 -0.3587
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals ; outcome
H-1690	-0.7166144847869873	▁hospital s
D-1690	-0.7166144847869873	hospitals
P-1690	-0.8818 -1.2107 -0.4688 -0.3052
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.6650519371032715	
D-948	-0.6650519371032715	
P-948	-1.0451 -0.2850
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain proteins
H-1042	-0.38191890716552734	bro modo main ▁protein s
D-1042	-0.38191890716552734	bromodomain proteins
P-1042	-0.5142 -0.4592 -0.1965 -0.2583 -0.5516 -0.4154 -0.2783
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients ; condition ; economic
H-1575	-0.7897188663482666	▁significant ▁; ▁economische
D-1575	-0.7897188663482666	significant ; economische
P-1575	-1.0700 -1.2755 -0.8140 -0.4515 -0.3375
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-1.6398075819015503	▁financier s
D-1955	-1.6398075819015503	financiers
P-1955	-2.9073 -2.0343 -1.3060 -0.3117
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative ; hypoalbuminemia ; prognosis ; lvad ; surgery
H-538	-0.35056620836257935	▁hypo album in emia ▁; ▁l VAD ▁surgery
D-538	-0.35056620836257935	hypoalbuminemia ; lVAD surgery
P-538	-0.2691 -0.2453 -0.1982 -1.0771 -0.3757 -0.1519 -0.0893 -0.4118 -0.3848 -0.3026
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade ; holosystolic murmur ; third heart sound ; apex
H-342	-0.498199462890625	▁holo sy sto lic ▁mur mur ▁; ▁heart
D-342	-0.498199462890625	holosystolic murmur ; heart
P-342	-0.0145 -1.2608 -0.6178 -0.1047 -0.2535 -0.1986 -0.2949 -1.4641 -0.4889 -0.2842
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis ; atherosclerosis ; cardiovascular events ; rotterdam study
H-1554	-0.8309056758880615	▁psoriasis ▁; ▁at hero sc ler osis ▁; ▁cardiovascular ▁events ▁; ▁Rotterdam ▁Study
D-1554	-0.8309056758880615	psoriasis ; atherosclerosis ; cardiovascular events ; Rotterdam Study
P-1554	-1.6845 -1.1932 -1.2531 -0.1169 -0.0563 -2.4387 -0.0790 -0.2643 -0.2869 -0.4268 -0.2447 -2.1782 -1.5666 -0.4189 -0.2553
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary artery disease ; cad ; systolic heart failure ; hf
H-1182	-0.6393933296203613	▁Corona ry ▁arter y ▁disease ▁; CAD ▁; ▁sy sto lic ▁heart ▁failure ▁; HF
D-1182	-0.6393933296203613	Coronary artery disease ;CAD ; systolic heart failure ;HF
P-1182	-0.1592 -2.2520 -0.0799 -1.2775 -0.6774 -0.2343 -1.7462 -0.2893 -0.0709 -0.1002 -0.2672 -0.9465 -0.5723 -0.2636 -1.2899 -0.3648 -0.2785
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality ; hf ; hospital ; admissions ; transplant ; ventricular assist device
H-125	-0.8210813403129578	▁mortal iteit ▁; HF ▁; ▁hospital ▁ad missions ▁; ▁transplant ▁; ▁vent ri cular ▁assist ▁device
D-125	-0.8210813403129578	mortaliteit ;HF ; hospital admissions ; transplant ; ventricular assist device
P-125	-0.7969 -1.8110 -0.3151 -2.0304 -0.5424 -3.2501 -1.7316 -0.1611 -0.2106 -0.1272 -0.2495 -0.0706 -1.4955 -0.4523 -0.6067 -0.2099 -0.4254 -0.2931
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart failure ; patients ; rheumatoid arthritis ; tnf antagonist
H-600	-0.5658444166183472	▁Heart ▁failure ▁; ▁rhe um ato id ▁ar thri tis ▁; ▁t NF ▁anta gon ist
D-600	-0.5658444166183472	Heart failure ; rheumatoid arthritis ; tNF antagonist
P-600	-1.3481 -0.7194 -0.5140 -0.2734 -0.2149 -0.6360 -0.2584 -0.1660 -0.3722 -1.2090 -0.3721 -0.8769 -0.8326 -0.9760 -0.0097 -0.5024 -0.5499 -0.3542
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling ; hf ; haemodynamic ; neuronal stressors
H-1039	-0.4221002757549286	HF ▁; ▁ha emo dynamic ▁; ▁neuron al ▁stress ors
D-1039	-0.4221002757549286	HF ; haemodynamic ; neuronal stressors
P-1039	-2.4802 -0.2733 -0.0193 -0.1314 -0.0181 -0.1888 -0.2022 -0.1752 -0.2341 -0.6628 -0.4252 -0.2546
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients ; lvad ; implantation
H-531	-0.5718218088150024	▁l VAD ▁implant ation
D-531	-0.5718218088150024	lVAD implantation
P-531	-0.2200 -0.2599 -0.4461 -1.6850 -0.4718 -0.3482
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal dysfunction ; morbidity
H-719	-0.43864506483078003	▁renal ▁dys function ▁; ▁post - trans plant ▁morbi d iteit
D-719	-0.43864506483078003	renal dysfunction ; post-transplant morbiditeit
P-719	-0.4460 -0.1343 -0.3923 -0.2895 -0.2212 -0.1113 -0.0596 -0.1479 -0.5027 -0.2644 -2.4324 -0.3929 -0.3077
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna ; genotyped
H-1454	-0.45525577664375305	▁germ line ▁DNA ▁; ▁geno type d
D-1454	-0.45525577664375305	germline DNA ; genotyped
P-1454	-1.2906 -0.2741 -0.6380 -0.8336 -0.0796 -0.0184 -0.2507 -0.4516 -0.2607
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart failure ; disease ; medical
H-2008	-1.0121427774429321	▁Heart ▁failure ▁; ▁disease ▁management ▁; ▁medical ▁resource
D-2008	-1.0121427774429321	Heart failure ; disease management ; medical resource
P-2008	-1.7651 -0.5368 -0.4535 -0.9988 -0.3938 -1.3283 -0.9834 -0.9301 -2.4028 -0.3288
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal dnx ; plasma
H-1381	-0.4306846261024475	▁Ren al ▁DN x ▁; ▁circula ting ▁plasma ▁; ▁rabbi ts
D-1381	-0.4306846261024475	Renal DNx ; circulating plasma ; rabbits
P-1381	-1.5764 -0.0820 -1.2792 -0.2627 -0.3141 -0.0172 -0.4975 -0.1344 -0.2337 -0.2707 -0.2138 -0.4146 -0.3028
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient ; clinical ; symptoms
H-1468	-1.3772426843643188	▁treatment
D-1468	-1.3772426843643188	treatment
P-1468	-3.3232 -0.4887 -0.3199
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients ; trastuzumab
H-676	-0.44601258635520935	▁tras tuz um ab
D-676	-0.44601258635520935	trastuzumab
P-676	-0.3986 -0.4113 -0.2275 -0.8389 -0.4635 -0.3363
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses ; patients
H-1021	-0.6253455281257629	▁ NP ▁assessment ▁; ▁ED ▁patients
D-1021	-0.6253455281257629	NP assessment ; ED patients
P-1021	-0.8026 -0.7754 -0.2192 -0.2279 -0.3663 -1.8926 -0.4007 -0.3181
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac hypertrophy ; energy metabolism
H-1778	-0.7138153314590454	▁Card iac ▁hyper trop hy ▁; ▁energy ▁metabolism
D-1778	-0.7138153314590454	Cardiac hypertrophy ; energy metabolism
P-1778	-1.7830 -0.4657 -0.1217 -0.0463 -1.9226 -0.2826 -1.6562 -0.0890 -0.4765 -0.2946
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow up ; hf
H-627	-1.2527722120285034	HF
D-627	-1.2527722120285034	HF
P-627	-3.0187 -0.4728 -0.2668
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients ; blood ; medication
H-729	-1.2046151161193848	▁blood ▁work ▁; ▁medication
D-729	-1.2046151161193848	blood work ; medication
P-729	-1.6488 -0.7701 -1.7169 -1.3555 -1.3718 -0.3646
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 ; prognosis ; heart failure
H-399	-1.329487919807434	▁heart ▁failure
D-399	-1.329487919807434	heart failure
P-399	-3.9765 -0.5736 -0.4659 -0.3019
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart ; heart failure ; arrhythmias
H-747	-0.8153324127197266	▁Heart ▁t 2 ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
D-747	-0.8153324127197266	Heart t2 ; heart failure ; arrhythmias
P-747	-1.4928 -1.3050 -0.0164 -0.3297 -2.8777 -0.6566 -0.3076 -0.1171 -0.3805 -1.5427 -0.4958 -0.2620
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase ; myocardium
H-171	-0.5734824538230896	▁activa ted ▁Cas pas e ▁; ▁my o car dium
D-171	-0.5734824538230896	activated Caspase ; myocardium
P-171	-0.0866 -1.5654 -0.0693 -0.0649 -0.2676 -0.2674 -3.5111 -0.1312 -0.0327 -0.1573 -0.4294 -0.2987
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty ; heart failure ; health
H-621	-1.005771517753601	▁heart ▁failure ▁; ▁older ▁adults ▁; ▁body ▁composition
D-621	-1.005771517753601	heart failure ; older adults ; body composition
P-621	-3.8237 -0.5618 -0.2528 -0.5765 -0.7804 -0.3680 -2.7870 -0.0703 -0.6021 -0.2351
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin ; sitagliptin
H-1828	-0.8265430927276611	▁h HF ▁; ▁sax ag lip tin ▁; ▁si tag lip tin
D-1828	-0.8265430927276611	hHF ; saxagliptin ; sitagliptin
P-1828	-0.0276 -3.6966 -0.2375 -0.1939 -0.0284 -0.4999 -2.2885 -0.3296 -1.5937 -0.0973 -0.1278 -1.7309 -0.4582 -0.2616
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up ; hf ; deaths
H-1771	-0.6512817740440369	▁follow - up ▁; ▁ HF
D-1771	-0.6512817740440369	follow-up ; HF
P-1771	-0.4505 -0.2921 -0.0738 -0.3539 -2.0491 -1.1056 -0.5508 -0.3344
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations ; acr ; cms
H-140	-0.6060687303543091	▁a cr ▁; ▁CMS
D-140	-0.6060687303543091	acr ; CMS
P-140	-1.2020 -0.3139 -0.3657 -0.3760 -1.0589 -0.3200
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.9073456525802612	▁HD L - bound ▁malo ndi alde hy de ▁; ▁ec
D-252	-0.9073456525802612	HDL-bound malondialdehyde ; ec
P-252	-2.7786 -3.2908 -0.1629 -0.5892 -0.3099 -0.3088 -0.1387 -1.5234 -0.4316 -0.3973 -1.0848 -0.4833 -0.2962
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations ; congestive heart failure
H-208	-0.6735655069351196	▁ED ▁; ▁in tuba tions ▁; ▁con ges tive ▁heart ▁failure
D-208	-0.6735655069351196	ED ; intubations ; congestive heart failure
P-208	-0.6225 -0.5635 -0.0616 -0.7270 -1.2696 -0.3971 -0.2968 -0.3937 -2.3954 -0.8228 -0.4784 -0.4529 -0.2750
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients ; cad ; cad
H-1189	-0.5624871253967285	▁deriva tion ▁co hor t ▁; ▁CAD ▁; ▁CAD
D-1189	-0.5624871253967285	derivation cohort ; CAD ; CAD
P-1189	-0.5951 -1.3572 -0.0358 -1.0368 -0.1497 -0.3475 -0.4372 -0.3415 -1.2690 -0.3160 -0.3015
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-0.36889365315437317	
D-154	-0.36889365315437317	
P-154	-0.4616 -0.2762
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients ; randomized
H-1874	-0.5959717631340027	
D-1874	-0.5959717631340027	
P-1874	-0.8808 -0.3112
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital ; discharge
H-302	-1.1398860216140747	▁hospital ▁dis charge
D-302	-1.1398860216140747	hospital discharge
P-302	-3.1974 -1.2043 -0.5922 -0.3901 -0.3154
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.9951693415641785	
D-1713	-0.9951693415641785	
P-1713	-1.6571 -0.3333
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia ; heart disease
H-40	-1.1218433380126953	▁voordelen ▁; ▁an emia ▁; ▁adults ▁; ▁heart ▁disease
D-40	-1.1218433380126953	voordelen ; anemia ; adults ; heart disease
P-40	-3.0160 -0.3318 -2.5731 -0.9841 -0.3297 -2.0024 -0.7984 -1.1174 -0.5573 -0.3831 -0.2470
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients ; heart failure ; diagnostic ; medication ; follow-up
H-732	-1.02613365650177	▁heart ▁failure ▁; ▁diagnose ▁; ▁medication ▁; ▁follow - up
D-732	-1.02613365650177	heart failure ; diagnose ; medication ; follow-up
P-732	-3.1366 -0.8937 -0.5291 -2.9318 -0.8380 -0.1510 -0.8761 -0.0441 -0.1823 -0.0407 -2.3954 -0.2947
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression ; type i regulatory subunit ; ri ; hf
H-1429	-0.9320409893989563	▁regulator y ▁sub un it ▁; RI ▁; HF
D-1429	-0.9320409893989563	regulatory subunit ;RI ;HF
P-1429	-1.2216 -0.8643 -0.4073 -0.9000 -0.5299 -0.3105 -2.6955 -0.3763 -2.3150 -0.3589 -0.2732
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient ; heart failure with reduced ejection fraction
H-1203	-0.5649775862693787	▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1203	-0.5649775862693787	heart failure ; ejection fraction
P-1203	-2.8952 -0.3807 -0.3290 -0.4869 -0.2382 -0.0900 -0.3067 -0.0260 -0.6213 -0.2757
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet ; exercise rehabilitation ; patients ; chf
H-1884	-0.9913071990013123	▁c PET ▁; ▁gu iding ▁exercise ▁rehabilita tion ▁; ▁CHF
D-1884	-0.9913071990013123	cPET ; guiding exercise rehabilitation ; CHF
P-1884	-1.2160 -3.7647 -0.3817 -1.5929 -0.1518 -1.1792 -0.2397 -1.7689 -0.3735 -0.5675 -0.3790 -0.2809
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
H-638	-0.4788411557674408	▁n fat ▁; ▁mi r -25 ▁; ▁tran scription ▁factor ▁; ▁hand 2 ▁; ▁heart ▁failure
D-638	-0.4788411557674408	nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
P-638	-1.6804 -0.2958 -0.2811 -0.7159 -1.8087 -0.1776 -0.4592 -0.0570 -0.0621 -0.3800 -0.2707 -0.3235 -0.1330 -0.3643 -0.5321 -0.2981 -0.4395 -0.3402
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart failure ; hf ; morbidity ; mortality
H-199	-0.8495830297470093	▁Pediatri c ▁heart ▁failure ▁; HF
D-199	-0.8495830297470093	Pediatric heart failure ;HF
P-199	-2.7492 -0.4242 -1.0583 -0.3940 -0.2763 -0.8877 -0.6921 -0.3148
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone ; primary composite endpoint
H-1227	-0.3618640601634979	▁e pler en one
D-1227	-0.3618640601634979	eplerenone
P-1227	-0.3328 -0.0421 -0.1111 -0.9258 -0.4388 -0.3206
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral renal denervation ; autonomic balance ; chronic heart failure
H-1369	-0.7006791234016418	▁renal ▁den er va tion ▁; ▁autonomi c ▁balance ▁; ▁rabbi ts ▁; ▁chronic ▁heart ▁failure
D-1369	-0.7006791234016418	renal denervation ; autonomic balance ; rabbits ; chronic heart failure
P-1369	-1.0344 -2.4704 -0.8116 -0.2250 -1.2713 -0.4441 -0.1111 -0.5895 -0.7335 -0.3934 -0.3980 -0.2020 -0.3406 -1.1283 -1.3159 -0.3862 -0.4621 -0.2948
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change ; readmissions ; follow-up ; heart failure ; readmission
H-720	-0.8067271113395691	▁read missions ▁; ▁follow - up ▁visit s ▁; ▁heart ▁failure ▁; ▁read mission ▁quality
D-720	-0.8067271113395691	readmissions ; follow-up visits ; heart failure ; readmission quality
P-720	-1.4539 -0.6182 -0.3227 -0.0406 -0.3988 -0.0500 -0.5438 -0.3005 -0.4493 -1.2660 -0.2745 -0.5725 -1.4661 -1.6272 -1.6303 -2.3587 -0.3412
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation ; resistin ; correlated ; ejection fraction
H-938	-0.3919106125831604	▁resist in ▁; ▁e je ction ▁ fraction
D-938	-0.3919106125831604	resistin ; ejection fraction
P-938	-0.2079 -0.4806 -0.2885 -0.2115 -0.2818 -0.0966 -0.3101 -0.0376 -1.7027 -0.3018
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right atrial myxoma ; pulmonary embolism ; right heart failure
H-592	-0.7003538608551025	▁Right ▁at rial ▁my xo ma ▁; ▁pulmonar y ▁e mbol ism ▁; ▁right ▁heart ▁failure
D-592	-0.7003538608551025	Right atrial myxoma ; pulmonary embolism ; right heart failure
P-592	-0.7836 -0.8588 -0.5075 -1.3285 -0.1551 -1.0191 -0.4274 -0.0551 -1.0416 -0.3005 -0.0779 -2.0997 -0.3609 -1.1091 -1.0522 -0.6443 -0.5021 -0.2831
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic heart transplantation ; oht ; end-stage heart failure
H-1280	-1.184303879737854	▁Ort ho topic ▁heart ▁transplant ation ▁; ▁o w t ▁; ▁treatment ▁; ▁heart ▁failure
D-1280	-1.184303879737854	Orthotopic heart transplantation ; owt ; treatment ; heart failure
P-1280	-1.8201 -0.4383 -0.4449 -1.6780 -0.2217 -1.6821 -0.3519 -0.2962 -4.8876 -0.0228 -0.3087 -3.7657 -0.4002 -2.3508 -0.7139 -0.4643 -0.2860
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas ; right atrium ; embolize ; pulmonary arterial vasculature
H-594	-0.5569695234298706	▁My xo mas ▁; ▁right ▁at rium ▁; ▁pulmonar y ▁arterial ▁vas cula ture
D-594	-0.5569695234298706	Myxomas ; right atrium ; pulmonary arterial vasculature
P-594	-1.0728 -0.0646 -1.3891 -0.3481 -0.4310 -1.1965 -0.0435 -0.3903 -0.0275 -1.1996 -0.0460 -0.1273 -0.0915 -1.7662 -0.3665 -0.3509
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline ; outcomes ; ecct ; cardiac transplant
H-711	-0.6939443945884705	▁ec t ▁; ▁cardiac ▁transplant ▁recipient s
D-711	-0.6939443945884705	ect ; cardiac transplant recipients
P-711	-0.6175 -2.7161 -0.3935 -0.2467 -0.2140 -0.5470 -0.7313 -0.4577 -0.3217
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit index
H-1008	-0.6760518550872803	▁deficit ▁index ▁; SD
D-1008	-0.6760518550872803	deficit index ;SD
P-1008	-0.4920 -0.1012 -0.4036 -2.4962 -0.2785 -0.2848
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-0.5565349459648132	▁Diet ▁score ▁; ▁vegetables ▁; ▁nu ts ▁; ▁whole ▁grain ▁in take ▁; ▁mortal iteit
D-692	-0.5565349459648132	Diet score ; vegetables ; nuts ; whole grain intake ; mortaliteit
P-692	-2.1393 -0.5564 -0.2756 -0.8897 -0.3209 -0.2014 -0.1135 -0.3114 -0.1289 -0.1543 -0.0604 -1.0892 -0.3120 -0.2778 -2.0392 -0.3244 -0.2666
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-0.4890691936016083	▁benefit
D-619	-0.4890691936016083	benefit
P-619	-0.7769 -0.4100 -0.2802
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-0.4927833080291748	
D-1508	-0.4927833080291748	
P-1508	-0.6403 -0.3453
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.38388022780418396	▁ir on
D-49	-0.38388022780418396	iron
P-49	-0.2797 -0.2160 -0.7434 -0.2964
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-0.6229979395866394	▁ED ▁; ▁CHF
D-216	-0.6229979395866394	ED ; CHF
P-216	-1.6064 -0.4940 -0.2787 -0.4404 -0.2955
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic ; right ventricular contractile reserve ; patients ; pulmonary hypertension
H-821	-0.511687695980072	▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension
D-821	-0.511687695980072	right ventricular contractile reserve ; pulmonary hypertension
P-821	-1.4918 -0.4877 -1.7101 -0.2971 -0.0705 -0.1360 -0.1822 -0.2571 -0.3764 -1.2548 -0.1639 -0.0999 -0.4186 -0.2176
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal bleeding ; patients ; ventricular assist devices ; cardiac ; nurse
H-1656	-0.7644774317741394	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse
D-1656	-0.7644774317741394	Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
P-1656	-0.6345 -1.8233 -3.0682 -0.3137 -0.2098 -1.4329 -0.3029 -0.4835 -0.2082 -2.0074 -0.4026 -0.9211 -0.3128 -0.4369 -0.0701 -0.2560 -0.5629 -0.3138
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ; ambulatory ; patients ; heart failure ; functional capacity ; outcomes
H-695	-0.7545782327651978	▁Solu ble ▁ST 2 ▁; ▁ambula tory ▁patients ▁; ▁heart ▁failure ▁; ▁functional ▁capacity
D-695	-0.7545782327651978	Soluble ST2 ; ambulatory patients ; heart failure ; functional capacity
P-695	-0.5431 -1.4566 -0.4630 -0.1769 -0.4300 -0.8463 -1.2410 -1.3501 -1.1125 -1.5535 -0.5692 -0.4175 -0.3131 -0.9093 -0.3945 -0.2965
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline ; echocardiograms ; evidence ; reverse remodeling
H-907	-0.39571547508239746	▁e cho card i ogram s
D-907	-0.39571547508239746	echocardiograms
P-907	-0.2415 -0.4061 -0.3131 -0.5016 -0.0287 -0.9409 -0.4725 -0.2613
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin hypophosphorylation ; myocardial dd
H-771	-0.8306878209114075	▁Tit in ▁hypo phos phor y lation ▁; ▁my o card ial ▁ DD
D-771	-0.8306878209114075	Titin hypophosphorylation ; myocardial DD
P-771	-0.7282 -0.9223 -0.8385 -0.4050 -1.4364 -2.0216 -0.2820 -0.3089 -1.9658 -0.2029 -0.8877 -1.3327 -0.6732 -0.6092 -0.3633 -0.3132
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote monitoring ; hospital ; discharge ; patients ; heart failure ; meta-analysis
H-146	-0.9581006169319153	▁remote ▁monitoring ▁; ▁hospital ▁dis charge ▁; ▁heart ▁failure
D-146	-0.9581006169319153	remote monitoring ; hospital discharge ; heart failure
P-146	-0.7048 -0.1349 -0.3809 -2.0167 -0.9699 -0.5471 -0.3750 -4.1729 -0.5377 -0.3998 -0.2995
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck stent ; chronic myocardial ischemia ; heart failure
H-502	-0.40859898924827576	▁bottle ne ck ▁sten t ▁; ▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure ▁; ▁pig s
D-502	-0.40859898924827576	bottleneck stent ; chronic myocardial ischemia ; heart failure ; pigs
P-502	-0.3145 -0.2132 -0.0704 -0.0156 -0.0978 -0.2831 -0.9200 -1.8788 -0.2391 -0.4361 -1.0068 -0.2346 -0.1429 -0.3951 -0.2522 -1.0109 -0.1629 -0.2498 -0.1142 -0.3123 -0.4033 -0.2355
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt intervals ; sd of all qt intervals ; sdqt
H-1439	-0.8425371646881104	▁ QT ▁interval s ▁; ▁SD ▁; ▁ QT ▁interval s ▁; SD t
D-1439	-0.8425371646881104	QT intervals ; SD ; QT intervals ;SDt
P-1439	-0.3123 -1.2048 -0.0839 -0.3399 -0.3149 -0.9686 -0.5454 -0.1943 -1.7937 -0.1089 -0.2996 -0.3240 -3.1372 -3.2449 -0.3397 -0.2686
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv filling pressure ; stable ; severe systolic hf
H-489	-0.42005056142807007	▁LV ▁; ▁fill ing ▁pressure ▁; ▁severe ▁sy sto lic ▁ HF
D-489	-0.42005056142807007	LV ; filling pressure ; severe systolic HF
P-489	-0.6077 -0.2936 -0.4711 -0.3705 -0.8648 -0.2390 -1.1685 -0.0807 -0.1122 -0.1126 -0.4445 -0.4715 -0.3810 -0.2630
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline ; embase ; cinahl
H-62	-1.1962047815322876	▁med Line ▁; EMBA se ▁; ▁c INA HL
D-62	-1.1962047815322876	medLine ;EMBAse ; cINAHL
P-62	-0.9448 -2.1671 -0.2861 -0.3167 -1.7241 -0.3015 -3.1881 -1.8854 -1.6466 -0.4819 -0.2159
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker ; uptitration ; hfpef
H-183	-0.9054014682769775	▁benefit ▁; ▁β - block er ▁up tit ration ▁; ▁ HF p EF
D-183	-0.9054014682769775	benefit ; β-blocker uptitration ; HFpEF
P-183	-0.5802 -0.2785 -0.7122 -0.1847 -0.4886 -0.3055 -1.9254 -1.4069 -2.1991 -0.3656 -1.9089 -1.4280 -0.0701 -2.0991 -0.3035 -0.2301
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs ; functional capacity ; peak vo2
H-123	-0.8372862339019775	▁c ▁pc s ▁; ▁functional ▁capacity ▁; ▁VO 2
D-123	-0.8372862339019775	c pcs ; functional capacity ; VO2
P-123	-0.4004 -3.7931 -0.2524 -0.4469 -0.1880 -0.7278 -0.4170 -1.6194 -0.6518 -0.4026 -0.3107
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction ; pump ; driveline ; pump ; curative
H-774	-0.7366722822189331	▁pump ▁; ▁drive line ▁injury ▁; ▁isola ted ▁pump ▁replace ment
D-774	-0.7366722822189331	pump ; driveline injury ; isolated pump replacement
P-774	-2.3629 -1.7148 -0.4203 -0.1219 -0.3229 -0.3563 -0.0586 -0.5501 -1.4977 -0.3333 -1.0581 -0.4461 -0.3337
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic ; inflammatory ; abdominal
H-1285	-0.9644832611083984	▁ ische mic ▁; ▁in flam ma tory ▁abdominal ▁problems ▁; ▁MT
D-1285	-0.9644832611083984	ischemic ; inflammatory abdominal problems ; MT
P-1285	-0.2171 -0.6706 -1.1270 -0.9883 -0.7312 -0.2312 -2.8240 -0.6207 -0.5436 -2.8912 -0.3219 -1.1265 -0.9080 -0.3016
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical ; outcomes ; hfpef
H-1525	-0.6949489116668701	▁eh ▁; ▁ HF p EF
D-1525	-0.6949489116668701	eh ; HFpEF
P-1525	-0.3403 -0.2681 -1.6654 -1.6055 -0.0563 -0.9478 -0.3857 -0.2906
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham heart study ; hf ; ef
H-1103	-0.637365996837616	▁Fram ing ham ▁Heart ▁Study ▁; HF ▁; ▁EF
D-1103	-0.637365996837616	Framingham Heart Study ;HF ; EF
P-1103	-0.3093 -0.2835 -0.2738 -0.7226 -0.3275 -0.3723 -1.5092 -0.3291 -2.1472 -0.4506 -0.2860
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil ; orally ; doxorubicin
H-959	-0.7253103256225586	▁Nico rand il ▁; ▁oral ly ▁; ▁do xor ubi cin ▁treatment
D-959	-0.7253103256225586	Nicorandil ; orally ; doxorubicin treatment
P-959	-0.0535 -0.0426 -0.3050 -0.3909 -2.6095 -2.2989 -0.3656 -0.2939 -0.0761 -0.1602 -0.6600 -2.1325 -0.4963 -0.2694
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based ; therapies ; patients ; fes
H-1333	-1.6766977310180664	▁f es
D-1333	-1.6766977310180664	fes
P-1333	-4.3221 -1.6365 -0.4453 -0.3028
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence ; acp ; clinical practice guidelines
H-35	-1.264995813369751	▁guide line ▁; ▁a CP
D-35	-1.264995813369751	guideline ; aCP
P-35	-4.2178 -0.2776 -0.3078 -1.9470 -1.3862 -0.4171 -0.3013
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics ; symptoms ; patients ; heart failure ; hf
H-1199	-0.7487074732780457	▁di ure tics ▁; ▁con ges tive ▁symptoms ▁; ▁heart ▁failure ▁; HF
D-1199	-0.7487074732780457	diuretics ; congestive symptoms ; heart failure ;HF
P-1199	-1.1694 -1.0518 -0.4073 -0.4930 -0.2107 -0.4626 -2.5765 -0.4732 -0.3855 -1.1405 -0.3324 -0.3080 -1.5624 -0.3908 -0.2667
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis ; chronic heart failure ; tachycardia
H-164	-0.7623370885848999	▁chronic ▁heart ▁failure ▁; ▁ta chy car dia
D-164	-0.7623370885848999	chronic heart failure ; tachycardia
P-164	-2.6089 -2.1365 -0.4591 -0.3106 -0.9930 -0.2178 -0.0576 -0.1097 -0.4254 -0.3047
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas ; bridge to transplantation ; destination therapy
H-1999	-0.7648863792419434	▁l VAS ▁; ▁transplant ation
D-1999	-0.7648863792419434	lVAS ; transplantation
P-1999	-0.3249 -0.9201 -0.5938 -0.1362 -1.7685 -1.3471 -0.2636
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac overexpression ; mammalian enabled ; mena ; heart failure
H-1809	-0.5859777927398682	▁Card iac ▁; ▁Mamma lian ▁enabled ▁; Men a ▁; ▁heart ▁failure
D-1809	-0.5859777927398682	Cardiac ; Mammalian enabled ;Mena ; heart failure
P-1809	-0.9342 -0.2494 -0.7649 -0.2659 -0.3747 -0.7135 -0.1847 -1.6949 -0.0422 -0.2760 -1.7194 -0.2827 -0.4207 -0.2804
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east ; rhythm control therapy ; cardiovascular ; complications
H-1648	-0.5905788540840149	▁e ast ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁cardiovascular ▁complica tions ▁; ▁AF
D-1648	-0.5905788540840149	east ; rhythm control therapy ; cardiovascular complications ; AF
P-1648	-0.9072 -2.0216 -0.3198 -0.4240 -0.5915 -0.7652 -0.5774 -0.0857 -0.3167 -0.2135 -0.0389 -1.6160 -0.2698 -0.5806 -0.4092 -0.3121
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients ; clinical ; radiological ; hf ; hospitalization
H-560	-1.1015069484710693	▁ HF
D-560	-1.1015069484710693	HF
P-560	-2.9141 -0.7269 -0.4245 -0.3405
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise ; adverse events ; coronary artery disease ; cad
H-1899	-0.8374484181404114	▁corona ry ▁arter y ▁disease ▁; CAD
D-1899	-0.8374484181404114	coronary artery disease ;CAD
P-1899	-0.8277 -2.4210 -0.0683 -1.4815 -0.5122 -0.2729 -1.3455 -0.3622 -0.2456
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc ; outcomes ; outcome ; admission ; discharge
H-1401	-1.2794102430343628	▁no c
D-1401	-1.2794102430343628	noc
P-1401	-1.4994 -2.1618 -1.1409 -0.3155
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol ; exercise ; training ; baseline ; hgb
H-843	-1.0287234783172607	▁HR Qo l ▁; ▁exercise ▁training ▁; ▁base line ▁h gb
D-843	-1.0287234783172607	HRQol ; exercise training ; baseline hgb
P-843	-2.3569 -0.1188 -3.2314 -0.2991 -0.6604 -1.3836 -0.2848 -2.9928 -0.0894 -0.3979 -0.8736 -0.3825 -0.3022
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal muscle ; correlated ; vo2 max
H-1500	-0.7229657173156738	▁skelet al ▁muscle ▁mass ▁; ▁VO 2
D-1500	-0.7229657173156738	skeletal muscle mass ; VO2
P-1500	-1.8192 -0.3298 -1.4199 -0.2614 -0.4221 -1.2980 -0.2157 -0.4447 -0.2959
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients ; atrial fibrillation ; pacemaker
H-883	-0.5527878999710083	▁at rial ▁fi bril lation ▁; ▁pace maker
D-883	-0.5527878999710083	atrial fibrillation ; pacemaker
P-883	-2.4994 -0.3568 -0.5122 -0.1854 -0.4659 -0.3834 -0.1442 -0.1889 -0.5108 -0.2810
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient ; patients ; discharged ; hf
H-1400	-1.1134448051452637	▁in patient ▁records ▁; HF
D-1400	-1.1134448051452637	inpatient records ;HF
P-1400	-1.2644 -0.3133 -1.5689 -0.3270 -3.6130 -0.3908 -0.3167
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized ; double-blind ; active ; placebo
H-77	-0.5583229064941406	▁active ▁treatment ▁; ▁place bo
D-77	-0.5583229064941406	active treatment ; placebo
P-77	-1.2148 -0.7115 -0.7497 -0.5622 -0.0555 -0.3353 -0.2793
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac resynchronization therapy ; patients ; heart failure
H-903	-0.5314298868179321	▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure
D-903	-0.5314298868179321	cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
P-903	-0.3392 -0.3044 -0.1952 -0.0454 -2.1612 -0.5245 -0.0803 -0.3721 -0.6233 -0.0712 -0.0771 -0.2404 -0.1219 -1.5225 -0.9823 -1.0529 -0.4863 -0.5377 -0.3593
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients ; pneumonia ; surgical ; conditions
H-5	-0.9410558342933655	▁pneu monia ▁; ▁sur g ical ▁conditions
D-5	-0.9410558342933655	pneumonia ; surgical conditions
P-5	-0.7820 -1.8951 -0.3103 -1.1594 -1.0110 -1.7009 -0.9257 -0.3864 -0.2988
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic failure ; cardiomyopathic
H-986	-0.34173619747161865	▁dia sto lic ▁failure ▁; ▁cardio my o pathi c ▁restriction ▁; ▁flow
D-986	-0.34173619747161865	diastolic failure ; cardiomyopathic restriction ; flow
P-986	-0.0632 -0.2206 -0.1209 -0.2775 -0.2838 -0.0869 -1.0922 -0.3019 -0.0849 -0.3783 -0.7435 -0.6305 -0.1740 -0.3927 -0.2751
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition ; compliance ; exercise ; injections ; patients
H-1321	-0.6822582483291626	▁inject ions
D-1321	-0.6822582483291626	injections
P-1321	-1.2942 -0.7813 -0.3786 -0.2748
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump ; pump ; pump thrombosis ; hemolysis
H-2004	-0.5031397342681885	▁pump ▁exchange s ▁; ▁pump ▁mal function s ▁; ▁pump ▁ thro mbo sis ▁; ▁hem ol ysis ▁events
D-2004	-0.5031397342681885	pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
P-2004	-0.7150 -0.1639 -0.2838 -0.3285 -0.8403 -1.6996 -0.0759 -0.3502 -0.3210 -0.9509 -0.8864 -0.2190 -0.7397 -1.0900 -0.2814 -0.3368 -0.2415 -0.1647 -0.1469 -0.4443 -0.2862
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac catheterization ; patient ; extubated ; transferred
H-1297	-0.7159298062324524	▁cardiac ▁cat heter ization ▁; ▁ex tuba ted
D-1297	-0.7159298062324524	cardiac catheterization ; extubated
P-1297	-1.8370 -0.8660 -0.0868 -1.4816 -0.4164 -0.0615 -0.2313 -1.0343 -0.9133 -0.2310
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial ; exercise ; training ; heart failure ; hf ; patients
H-1925	-1.057754635810852	▁psycho social ▁factors ▁; ▁exercise ▁training ▁; ▁heart ▁failure ▁; HF
D-1925	-1.057754635810852	psychosocial factors ; exercise training ; heart failure ;HF
P-1925	-2.4000 -2.8704 -1.4885 -0.4459 -0.6649 -1.5050 -0.3832 -0.9095 -0.4288 -0.3230 -0.9896 -1.0273 -0.3147
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis ; medical ; heart failure ; canadian cardiovascular society
H-198	-1.0439496040344238	▁heart ▁failure ▁; ▁children ▁; ▁Canadian ▁Card io vas cular ▁Society ▁; ▁guidelines
D-198	-1.0439496040344238	heart failure ; children ; Canadian Cardiovascular Society ; guidelines
P-198	-5.0431 -0.4523 -0.2597 -0.8227 -0.2683 -0.7072 -1.4400 -2.1179 -0.7083 -0.6508 -0.8425 -0.9872 -0.7345 -0.3666 -0.2581
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ; ventricular-arterial coupling
H-526	-0.5436651110649109	▁e es ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁SV
D-526	-0.5436651110649109	ees ; ventricular-arterial coupling ; SV
P-526	-0.5905 -0.6919 -0.3846 -0.1169 -1.9481 -0.4967 -0.4044 -0.1000 -0.3668 -0.2047 -1.1673 -0.4816 -0.4420 -0.4793 -0.2801
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-0.7708704471588135	▁benefit ▁; ▁QR s
D-892	-0.7708704471588135	benefit ; QRs
P-892	-1.4752 -0.4199 -0.3534 -1.7776 -0.3458 -0.2534
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic nervous system ; activity ; qtv
H-1436	-0.958450198173523	▁autonomi c ▁ner vous ▁system ▁activity ▁; ▁ nc w
D-1436	-0.958450198173523	autonomic nervous system activity ; ncw
P-1436	-0.0809 -0.9583 -0.5844 -1.4195 -0.2119 -2.2820 -0.2590 -2.6855 -1.9735 -0.3702 -0.4124 -0.2637
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients ; implantation ; crt
H-848	-1.0995168685913086	▁device ▁implant ation ▁; ▁c RT
D-848	-1.0995168685913086	device implantation ; cRT
P-848	-1.1281 -0.3909 -1.9880 -0.3653 -0.5847 -3.0567 -0.9977 -0.2847
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report ; aric ; hf
H-290	-0.8943033814430237	▁a RIC ▁ HF
D-290	-0.8943033814430237	aRIC HF
P-290	-0.9825 -1.8322 -0.6447 -1.0333 -0.5694 -0.3038
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.4208639860153198	
D-1852	-0.4208639860153198	
P-1852	-0.5700 -0.2717
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical ; change
H-792	-0.4165690243244171	
D-792	-0.4165690243244171	
P-792	-0.5747 -0.2584
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs ; osprey
H-1611	-0.8419115543365479	▁de g s ▁; ▁o spre y
D-1611	-0.8419115543365479	degs ; osprey
P-1611	-0.2476 -5.3952 -0.6089 -0.3471 -0.0696 -0.1384 -0.2209 -0.2983 -0.2512
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis ; therapy
H-1467	-0.7605165839195251	▁ therapy
D-1467	-0.7605165839195251	therapy
P-1467	-2.0939 -0.2023 -0.3957 -0.3501
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world health organization ; hf
H-1791	-1.5471488237380981	▁world ▁health ▁Organization ▁; ▁ HF ▁; ▁LA
D-1791	-1.5471488237380981	world health Organization ; HF ; LA
P-1791	-1.5488 -1.6893 -1.1962 -0.3226 -3.6881 -1.7241 -0.3768 -2.9976 -1.6741 -0.2539
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare ; policy
H-1716	-0.5822482705116272	▁Medica re ▁; ▁post - a cute ▁care ▁transfer ▁policy
D-1716	-0.5822482705116272	Medicare ; post-acute care transfer policy
P-1716	-0.3752 -0.4761 -0.4530 -0.1617 -0.0715 -0.3192 -0.1596 -1.8571 -0.4885 -1.7614 -0.5401 -0.3237
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients ; therapy ; hospitalized ; cardiovascular
H-1223	-0.8552109599113464	▁cardiovascular ▁reason
D-1223	-0.8552109599113464	cardiovascular reason
P-1223	-2.4507 -0.3330 -0.3415 -0.2957
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease ; accounting ; cardiac transplants
H-982	-0.42457035183906555	▁pa e dia tric ▁cardiac ▁transplant s
D-982	-0.42457035183906555	paediatric cardiac transplants
P-982	-0.4002 -0.3114 -0.0971 -0.5167 -0.0580 -0.2634 -0.7452 -1.0416 -0.3876
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter ablation ; sinus rhythm
H-945	-0.4804210960865021	▁cat heter ▁ab lation ▁; ▁sinus ▁ rhythm
D-945	-0.4804210960865021	catheter ablation ; sinus rhythm
P-945	-1.6651 -0.1549 -0.0519 -0.3457 -0.3039 -0.3754 -0.2711 -0.8791 -0.4443 -0.3129
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body mass index ; crf ; exercise
H-1768	-0.5950831174850464	▁body ▁mass ▁index ▁; ▁c RF ▁; ▁tre ad m ill ▁; ▁exercise ▁testing
D-1768	-0.5950831174850464	body mass index ; cRF ; treadmill ; exercise testing
P-1768	-2.2469 -0.1754 -0.0286 -0.2945 -0.5237 -1.9117 -0.3329 -0.3932 -0.0851 -0.5353 -0.4857 -1.1438 -0.2674 -0.3389 -0.4560 -0.3025
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial tissue ; pka
H-1426	-0.8381184935569763	▁my o card ial ▁tissu e ▁; ▁p ka ▁sub un its
D-1426	-0.8381184935569763	myocardial tissue ; pka subunits
P-1426	-2.7142 -0.3247 -0.5353 -0.9497 -0.1525 -0.2098 -0.3424 -0.7744 -2.2680 -2.1684 -0.4199 -0.1297 -0.4653 -0.2795
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis ; mortality ; patients
H-68	-0.9972445964813232	▁mortal iteit ▁; ▁i CD - HF
D-68	-0.9972445964813232	mortaliteit ; iCD-HF
P-68	-0.5726 -2.7855 -1.0472 -0.7127 -1.1423 -0.1564 -0.3915 -1.7562 -0.4108
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1 mapping ; clinically ; myocardial fibrosis
H-1065	-0.6981040835380554	▁t 1 ▁ma pping ▁; ▁significant ▁; ▁my o card ial ▁fibro sis
D-1065	-0.6981040835380554	t1 mapping ; significant ; myocardial fibrosis
P-1065	-0.7698 -1.0827 -0.2710 -0.4629 -0.3228 -0.4085 -0.8486 -1.5257 -0.3155 -1.2571 -1.2990 -0.0421 -1.1812 -0.3941 -0.2904
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical ; therapeutic
H-1368	-0.6263373494148254	
D-1368	-0.6263373494148254	
P-1368	-0.9524 -0.3003
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare ; hospitalizations
H-1714	-0.6523453593254089	▁Medica re ▁; ▁hospital ization s
D-1714	-0.6523453593254089	Medicare ; hospitalizations
P-1714	-0.3725 -0.4258 -1.4666 -0.9193 -0.7658 -0.5721 -0.3505 -0.3461
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.5549430847167969	
D-1862	-0.5549430847167969	
P-1862	-0.8242 -0.2857
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-0.6502699851989746	▁white
D-626	-0.6502699851989746	white
P-626	-1.3356 -0.3215 -0.2937
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-1.0598472356796265	SD ▁; ▁die t ▁ad her ence ▁; SD
D-1983	-1.0598472356796265	SD ; diet adherence ;SD
P-1983	-0.4318 -0.4007 -0.6676 -0.2110 -1.0571 -2.7564 -3.5402 -0.4901 -1.3481 -0.4187 -0.3367
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients ; prognosis
H-1315	-0.5860313773155212	
D-1315	-0.5860313773155212	
P-1315	-0.8798 -0.2923
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics rounds
H-1681	-0.880197286605835	thi cs ▁Round s
D-1681	-0.880197286605835	thics Rounds
P-1681	-2.6482 -1.4801 -0.2191 -0.3455 -0.3081 -0.2802
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.4557952880859375	
D-2013	-0.4557952880859375	
P-2013	-0.6134 -0.2982
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic ; patients ; heart failure
H-1740	-1.5089482069015503	▁ therapeut ic ▁; ▁heart ▁failure
D-1740	-1.5089482069015503	therapeutic ; heart failure
P-1740	-3.4605 -0.5271 -0.4879 -0.9748 -5.3550 -0.4440 -0.5073 -0.3150
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf ; intubation
H-221	-0.7395625114440918	▁ED ▁; ▁CHF ▁; ▁in tub ation ▁rates
D-221	-0.7395625114440918	ED ; CHF ; intubation rates
P-221	-1.7088 -0.7931 -0.8260 -0.3501 -0.0582 -0.1880 -2.0422 -0.7844 -0.3798 -0.2650
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol ; mortality
H-650	-0.6654021143913269	▁bis o pro lol ▁; ▁mortal iteit
D-650	-0.6654021143913269	bisoprolol ; mortaliteit
P-650	-0.1310 -0.3888 -0.3709 -1.1959 -0.3460 -0.6359 -2.2527 -0.3768 -0.2906
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health buddy program ; telehealth
H-1622	-0.49834054708480835	▁Health ▁Budd y ▁Program ▁; ▁tele health ▁system ▁; ▁care ▁management
D-1622	-0.49834054708480835	Health Buddy Program ; telehealth system ; care management
P-1622	-1.6923 -0.0610 -0.2059 -1.2287 -0.3149 -0.5298 -0.3409 -0.1934 -0.2863 -0.6859 -0.1917 -0.4384 -0.3092
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome ; heart failure ; fontan
H-1493	-0.4237910509109497	▁muscle - was ting ▁syndrome ▁; ▁acquire d ▁heart ▁failure ▁; ▁Font an
D-1493	-0.4237910509109497	muscle-wasting syndrome ; acquired heart failure ; Fontan
P-1493	-1.0453 -0.2209 -0.0699 -0.0873 -0.0495 -0.3234 -1.8569 -0.1256 -1.0754 -0.3218 -0.2984 -0.2688 -0.0748 -0.2934 -0.2452
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty ; health ; outcomes
H-623	-1.0268659591674805	
D-623	-1.0268659591674805	
P-623	-1.7625 -0.2912
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart rate reduction ; ivabradine ; left ventricle ; heart failure ; patients
H-515	-0.7035170197486877	▁heart ▁rate ▁re duction ▁; ▁i va bra dine ▁un load s ▁; ▁left ▁vent ric le ▁; ▁heart ▁failure
D-515	-0.7035170197486877	heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
P-515	-3.5020 -0.9158 -1.0399 -0.4499 -0.4053 -0.1000 -0.0185 -0.6212 -0.7433 -0.5788 -0.1012 -0.4750 -0.6795 -0.5096 -0.1226 -1.0049 -0.6241 -0.3834 -1.1091 -0.4018 -1.3523 -0.3390
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo ; bivp ; correlated ; rs synchrony
H-327	-1.001272439956665	▁v rv PO ▁; ▁Bi VP ▁; ▁RS ▁synchron y ▁; ▁CS
D-327	-1.001272439956665	vrvPO ; BiVP ; RS synchrony ; CS
P-327	-1.6366 -1.4823 -2.2857 -0.2907 -0.7435 -1.1553 -0.3556 -3.0245 -0.0099 -1.6330 -0.3030 -0.4254 -0.3734 -0.2989
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia ; patients ; heart disease ; clinical practice guideline ; american college of physicians
H-29	-1.2201777696609497	▁an emia ▁; ▁heart ▁disease ▁; American ▁college ▁of ▁Physic ians
D-29	-1.2201777696609497	anemia ; heart disease ;American college of Physicians
P-29	-1.2375 -0.6844 -0.3660 -2.7378 -0.4984 -0.3375 -3.9353 -2.5286 -1.4892 -0.5711 -0.8502 -0.3297 -0.2966
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular death ; hf ; hospitalization ; exercise ; training ; patients ; btes
H-1933	-1.1180691719055176	▁cardiovascular ▁death ▁; HF ▁; ▁exercise ▁training ▁; ▁b tes
D-1933	-1.1180691719055176	cardiovascular death ;HF ; exercise training ; btes
P-1933	-0.7347 -1.8516 -0.2775 -2.2346 -0.4530 -1.9046 -1.4940 -0.3234 -2.2086 -1.2187 -0.4184 -0.2977
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise ; training ; patients ; chronic heart failure ; high-density lipoprotein
H-245	-1.5320812463760376	▁regelmatig ▁; ▁heart ▁failure ▁; ▁lipo prote in ▁functional ▁properties
D-245	-1.5320812463760376	regelmatig ; heart failure ; lipoprotein functional properties
P-245	-7.4929 -2.0922 -2.2832 -0.4022 -0.3954 -1.4148 -0.2133 -0.7445 -0.7885 -1.8623 -0.4274 -0.2683
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart rate ; aortic ; blood flow ; doxorubicin
H-960	-0.606460452079773	▁Heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁do xor ubi cin
D-960	-0.606460452079773	Heart rate ; aortic blood flow ; doxorubicin
P-960	-1.8238 -1.9461 -0.2787 -0.3660 -0.1072 -1.1868 -0.7837 -0.4214 -0.3935 -0.2247 -0.0869 -0.1669 -0.6977 -0.3838 -0.2295
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical ; outcomes ; hospitalisations ; readmissions ; mortality
H-1850	-0.5213622450828552	
D-1850	-0.5213622450828552	
P-1850	-0.6633 -0.3794
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial ; pde2 ; expression ; activity ; hf
H-1213	-1.0524286031723022	▁My o card ial ▁p de 2 ▁; ▁ HF
D-1213	-1.0524286031723022	Myocardial pde2 ; HF
P-1213	-1.6444 -0.3877 -0.5448 -1.3315 -1.7540 -1.0369 -0.2013 -0.7030 -2.7317 -1.5844 -0.4080 -0.3015
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin ; acute ; anthracycline-induced cardiotoxicity
H-931	-0.9472804069519043	▁resist in ▁; ▁a cute ▁an thra cycli ne - indu ced ▁cardio toxic iteit
D-931	-0.9472804069519043	resistin ; acute anthracycline-induced cardiotoxiciteit
P-931	-1.0907 -0.4995 -0.2323 -1.8830 -1.0516 -1.8731 -0.2563 -0.5342 -2.1920 -0.4300 -0.1749 -0.9679 -0.0765 -0.8638 -3.1842 -0.4514 -0.3423
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute ; autonomic nervous system ; qtv ; hf ; patients
H-1447	-0.8092548847198486	▁a cute ▁autonomi c ▁ner vous ▁system ▁modul ation ▁; ▁Q t ▁; ▁ HF
D-1447	-0.8092548847198486	acute autonomic nervous system modulation ; Qt ; HF
P-1447	-0.8014 -0.1510 -0.1093 -0.6080 -0.5636 -1.1517 -0.1288 -0.4636 -1.2430 -0.2249 -1.8043 -2.3997 -0.2868 -2.2435 -0.9898 -0.3660 -0.2220
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat ; sympathetic outflow ; parasympathetic activity
H-1869	-0.7728891372680664	▁BAT ▁; ▁sympa the tic ▁out flow ▁; ▁para sy mpa the tic ▁activity
D-1869	-0.7728891372680664	BAT ; sympathetic outflow ; parasympathetic activity
P-1869	-0.0901 -0.2709 -0.1297 -0.8737 -1.3133 -3.3592 -0.7339 -0.2933 -0.1218 -0.4397 -0.5858 -1.4022 -1.3904 -0.6291 -0.4723 -0.2608
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence ; end-stage renal disease ; outpatients ; systolic heart failure
H-386	-0.6277040839195251	▁renal ▁disease ▁; ▁out patient s ▁; ▁sy sto lic ▁heart ▁failure
D-386	-0.6277040839195251	renal disease ; outpatients ; systolic heart failure
P-386	-0.5132 -0.9241 -0.2770 -3.6196 -0.0856 -0.2120 -0.3736 -0.1797 -0.1266 -0.3334 -0.9398 -0.3998 -0.5154 -0.2879
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal ; pathophysiology ; congestive heart failure ; chf
H-634	-0.885913074016571	▁Neuro hormon al ▁ab normal ities ▁; ▁pat ho phy si ology ▁; ▁con ges tive ▁heart ▁failure ▁; ▁chw
D-634	-0.885913074016571	Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ; chw
P-634	-0.5489 -0.1865 -0.1514 -0.0399 -0.3833 -4.0259 -0.3305 -0.3414 -0.0726 -0.3927 -1.4331 -0.1494 -0.3168 -0.2143 -0.4743 -3.1241 -1.2502 -0.4228 -0.2746 -4.3632 -0.7069 -0.2872
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
H-426	-0.3638548254966736	▁e cho car dio graphic ▁; ▁rever se ▁remodel ing ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-426	-0.3638548254966736	echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
P-426	-1.5217 -0.3183 -0.0995 -0.6952 -0.5761 -0.3840 -0.1438 -0.0792 -0.0847 -0.3178 -0.3127 -0.0799 -0.1166 -0.0846 -0.0124 -1.4554 -0.2180 -0.0520 -0.4208 -0.3043
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic neurotransmission ; acetylcholinesterase inhibition
H-1135	-0.7505939602851868	▁para sy mpa the tic ▁neuro trans mission ▁; ▁a ce tyl cho line ster ase ▁inhibi tion
D-1135	-0.7505939602851868	parasympathetic neurotransmission ; acetylcholinesterase inhibition
P-1135	-0.0736 -0.4266 -1.1871 -1.2186 -1.5566 -0.2654 -0.0586 -1.3507 -0.2594 -0.4706 -0.9941 -1.1475 -0.7303 -0.1596 -0.8588 -1.3726 -0.0498 -2.0776 -0.4475 -0.3070
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal dnx ; cardiac ; autonomic balance ; chf ; sympathetic tone
H-1382	-0.42986825108528137	▁renal ▁DN x ▁; ▁cardiac ▁autonomi c ▁balance ▁; ▁CHF ▁; ▁sympa the tic ▁tone
D-1382	-0.42986825108528137	renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
P-1382	-0.4900 -1.1999 -0.2373 -0.3642 -0.2458 -0.0714 -0.5434 -0.7075 -0.3827 -0.2719 -0.3263 -0.0487 -0.5900 -1.0511 -0.1268 -0.4151 -0.2356
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart failure ; pathophysiology ; diagnosis ; medical treatment ; nursing
H-2018	-0.5810657143592834	▁Heart ▁Fail ure ▁; ▁Path o phy si ology ▁; ▁Medical ▁Treatment ▁Guide lines ▁; ▁Nur sing ▁management
D-2018	-0.5810657143592834	Heart Failure ; Pathophysiology ; Medical Treatment Guidelines ; Nursing management
P-2018	-0.8109 -0.3459 -1.6012 -0.2505 -0.5265 -1.2263 -0.1276 -1.4019 -0.0875 -0.2563 -1.3588 -1.0178 -0.3436 -0.2872 -0.3272 -0.2008 -0.0707 -0.7383 -0.3759 -0.2665
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
H-13	-0.3133352994918823	▁bio mark ers ▁; ▁neuro hormon al ▁stimul ation ▁; ▁ inflammation ▁; ▁en dot heli al ▁dys function
D-13	-0.3133352994918823	biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
P-13	-0.8822 -0.4433 -0.3036 -0.2473 -0.1131 -0.1023 -0.2124 -0.1129 -1.5658 -0.2670 -0.1509 -0.5071 -0.3102 -0.0629 -0.3349 -0.1756 -0.0384 -0.0212 -0.0872 -0.3606 -0.2811
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle cohort study ; canada
H-1951	-0.8003642559051514	▁Canada
D-1951	-0.8003642559051514	Canada
P-1951	-1.7065 -0.4116 -0.2830
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary outcome ; sympathetic activity ; myocardial washout
H-1115	-1.522305965423584	▁my o card ial ▁was hout
D-1115	-1.522305965423584	myocardial washout
P-1115	-6.4896 -0.7162 -1.0603 -0.8950 -1.1702 -1.0552 -0.4760 -0.3159
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right ventricle ; rv ; cardiac function ; medical
H-1091	-0.6372309327125549	▁right ▁vent ric le ▁; ▁v n ▁; ▁cardiac ▁function
D-1091	-0.6372309327125549	right ventricle ; vn ; cardiac function
P-1091	-0.8275 -0.1736 -0.9224 -0.8171 -0.3727 -1.9648 -0.8741 -0.3645 -0.2629 -0.1907 -0.5956 -0.2807
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes ; costs ; patients ; heart failure ; hf
H-1721	-1.1191502809524536	▁kosten ▁; ▁heart ▁failure ▁; HF
D-1721	-1.1191502809524536	kosten ; heart failure ;HF
P-1721	-3.2102 -0.4254 -1.8072 -0.4800 -0.3531 -1.9941 -0.4054 -0.2778
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical ; radiological ; hf ; quality of life
H-565	-1.3815727233886719	▁ HF
D-565	-1.3815727233886719	HF
P-565	-3.7650 -1.0187 -0.3956 -0.3470
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital ; mortality ; patients ; bnp ; mortality
H-195	-1.2765138149261475	▁mortal iteit ▁; ▁b NP ▁; ▁mortal iteit
D-195	-1.2765138149261475	mortaliteit ; bNP ; mortaliteit
P-195	-2.1362 -2.4847 -0.3295 -0.8904 -2.2181 -0.8823 -0.3864 -2.8048 -0.3408 -0.2920
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary ; exercise ; prognostically ; heart failure
H-1274	-1.2698290348052979	▁cardio pul mon ary ▁exercise ▁; ▁heart ▁failure
D-1274	-1.2698290348052979	cardiopulmonary exercise ; heart failure
P-1274	-0.7462 -1.5356 -3.0604 -1.5439 -2.1015 -0.2361 -2.2997 -0.3931 -0.5078 -0.2741
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv dysfunction ; correlated ; lean body mass
H-1164	-0.6133739948272705	▁ rv ▁dys function ▁; ▁weight ▁loss ▁; ▁fat ▁; lean ▁body ▁mass ▁ratio
D-1164	-0.6133739948272705	rv dysfunction ; weight loss ; fat ;lean body mass ratio
P-1164	-2.5728 -0.7485 -0.1148 -0.2016 -0.2734 -0.6171 -0.6959 -0.2852 -0.5508 -0.4254 -0.6317 -1.7350 -0.2135 -0.1129 -0.3551 -0.2803
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin subproteome ; diseased ; heart
H-99	-0.3744949698448181	▁chr omat in ▁sub prote ome ▁; ▁mouse ▁heart
D-99	-0.3744949698448181	chromatin subproteome ; mouse heart
P-99	-0.2606 -0.1432 -0.9202 -0.3983 -0.1185 -0.0716 -0.2461 -0.3924 -0.9078 -0.3813 -0.2793
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr reduction ; beta blockers ; exercise capacity ; hfref
H-1937	-0.7362179160118103	▁HR ▁; ▁beta ▁block ers ▁; ▁exercise ▁capacity ▁; ▁h Fr EF
D-1937	-0.7362179160118103	HR ; beta blockers ; exercise capacity ; hFrEF
P-1937	-1.8629 -0.8368 -0.5131 -0.3487 -0.2891 -0.3520 -0.3407 -0.2802 -0.3489 -0.5995 -1.6987 -2.1500 -0.4199 -0.2667
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein kinase a ; guanylate cyclase ; contractile response
H-418	-0.7848979234695435	▁protein ▁kina se ▁; ▁solu ble ▁gua ny late ▁cy cla se ▁; ▁contract ile ▁response
D-418	-0.7848979234695435	protein kinase ; soluble guanylate cyclase ; contractile response
P-418	-1.1093 -0.1266 -0.4070 -1.8016 -1.1668 -3.1426 -0.0476 -1.6710 -1.2677 -0.3401 -0.1053 -0.7975 -0.3273 -0.0334 -0.2390 -0.6193 -0.5510 -0.3751
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student t test ; confidence intervals ; cis ; regression analyses
H-215	-0.5982732176780701	▁student ▁t ▁test ▁; ▁confidence ▁interval s ▁; CI s ▁; ▁re gression ▁analyse s
D-215	-0.5982732176780701	student t test ; confidence intervals ;CIs ; regression analyses
P-215	-2.2006 -0.1089 -0.6516 -0.3914 -1.7988 -0.1182 -0.3519 -0.2443 -1.8590 -0.3862 -0.4771 -0.1278 -0.0668 -0.4574 -0.3062 -0.3232 -0.3014
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs ; functional capacity ; outcomes ; heart failure ; hf
H-121	-0.7803294062614441	▁c ▁pc s ▁; ▁functional ▁capacity ▁; ▁heart ▁failure ▁; HF
D-121	-0.7803294062614441	c pcs ; functional capacity ; heart failure ;HF
P-121	-0.9589 -3.6449 -0.2974 -0.2855 -0.2761 -0.4144 -0.3175 -0.7701 -0.4398 -0.2605 -1.8536 -0.3451 -0.2805
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity ; mortality ; quality of life ; patients ; hf
H-2023	-0.7956751585006714	▁morbi d iteit ▁; ▁mortal iteit ▁; HF
D-2023	-0.7956751585006714	morbiditeit ; mortaliteit ;HF
P-2023	-0.5966 -0.1919 -2.1562 -0.3031 -0.1133 -2.0565 -0.3261 -1.5623 -0.3429 -0.3079
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality ; deaths ; acs ; consultation ; operation
H-1287	-1.665143609046936	▁ corrupt ie ▁; ▁a CS
D-1287	-1.665143609046936	corruptie ; aCS
P-1287	-2.7601 -3.6527 -0.4085 -0.4578 -1.7341 -3.6190 -0.3760 -0.3130
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss ; btes ; exercise
H-1928	-1.085455298423767	▁ps s s ▁; ▁social ▁support ▁; ▁b tes
D-1928	-1.085455298423767	psss ; social support ; btes
P-1928	-0.4786 -0.4018 -1.3410 -0.3305 -1.5070 -2.8554 -0.3797 -2.5417 -1.1050 -0.6892 -0.3102
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt ; nt-probnp ; hf
H-291	-0.7466877102851868	▁c t n t ▁; ▁NT - pro b NP ▁; ▁significant ▁; ▁ HF
D-291	-0.7466877102851868	ctnt ; NT-probNP ; significant ; HF
P-291	-1.3562 -0.1681 -0.0910 -0.3019 -0.2968 -0.4377 -0.1093 -0.0904 -1.9044 -1.1638 -0.3640 -0.0198 -2.3300 -1.7173 -0.8723 -1.1482 -0.3225
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness ; sickle cell disease ; anemia
H-1682	-1.120070457458496	▁Jehovah ' s ▁Wit ness ▁; ▁sick le ▁cell ▁disease ▁; ▁an emia
D-1682	-1.120070457458496	Jehovah's Witness ; sickle cell disease ; anemia
P-1682	-0.0192 -6.5554 -0.4984 -2.2083 -2.5818 -0.4056 -0.1981 -0.2693 -0.5586 -0.3793 -0.3281 -1.3653 -0.5864 -0.4729 -0.3743
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas ; therapeutic ; heart failure
H-1485	-0.5224273204803467	▁mi RNA s ▁; ▁ therapeut ic ▁target s ▁; ▁heart ▁failure
D-1485	-0.5224273204803467	miRNAs ; therapeutic targets ; heart failure
P-1485	-1.0595 -0.1534 -0.4547 -0.3644 -1.4552 -0.3437 -0.5344 -0.2515 -0.3528 -0.3396 -1.0406 -0.2925 -0.4037 -0.2680
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician ; conditions ; hospital ; discharge
H-1422	-0.8233944177627563	▁physician ▁continu iteit ▁; ▁hospital ▁dis charge
D-1422	-0.8233944177627563	physician continuiteit ; hospital discharge
P-1422	-0.7297 -0.6841 -2.8823 -0.3665 -0.8840 -0.8562 -0.4402 -0.2863 -0.2812
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad variant ; congestive heart failure
H-1670	-0.9678961038589478	tent ▁inhibi tion ▁; ▁l - type ▁ca 2 + ▁current s ▁; ▁Rad ▁variant ▁; ▁con ges tive ▁heart ▁failure
D-1670	-0.9678961038589478	tent inhibition ; l-type ca2+ currents ; Rad variant ; congestive heart failure
P-1670	-4.3394 -0.2716 -2.3732 -0.3890 -0.6416 -0.1926 -0.0214 -0.2285 -0.1823 -2.9303 -0.0488 -0.4044 -0.3667 -1.3068 -1.6074 -0.5041 -0.2694 -0.5728 -3.0368 -0.9480 -0.8083 -0.4996 -0.3185
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive heart failure ; chf
H-209	-1.2844154834747314	▁con ges tive ▁heart ▁failure ▁; ▁ nc w
D-209	-1.2844154834747314	congestive heart failure ; ncw
P-209	-2.4296 -0.5369 -2.4649 -1.3134 -0.5113 -0.3258 -2.8722 -2.0413 -0.9177 -0.4200 -0.2955
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health buddy program ; hospital ; hospitalized
H-1626	-0.7820999622344971	▁Health ▁Budd y ▁Program ▁; ▁ED ▁; ▁hospital ▁days
D-1626	-0.7820999622344971	Health Buddy Program ; ED ; hospital days
P-1626	-1.2091 -0.0598 -0.4392 -1.1601 -0.3870 -0.6685 -0.7007 -0.5617 -1.6770 -1.4386 -0.3013
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri scanner ; baseline ; heart failure
H-1057	-0.7923623919487	▁m RI ▁scanner ▁; ▁heart ▁failure
D-1057	-0.7923623919487	mRI scanner ; heart failure
P-1057	-0.9841 -0.8943 -0.0863 -0.3756 -2.8317 -0.4210 -0.4220 -0.3238
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac stress ; β-ar ; drive
H-1219	-0.4913243353366852	▁cardiac ▁stress ▁; ▁β - AR ▁drive
D-1219	-0.4913243353366852	cardiac stress ; β-AR drive
P-1219	-1.0038 -0.7084 -0.3032 -0.4950 -0.1033 -0.9341 -0.2524 -0.3343 -0.2874
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left pulmonary artery ; right pulmonary artery
H-597	-0.7130745649337769	▁left ▁pulmonar y ▁arter y ▁; ▁right ▁pulmonar y ▁arter y
D-597	-0.7130745649337769	left pulmonary artery ; right pulmonary artery
P-597	-0.6299 -0.2107 -0.8966 -0.1275 -1.9436 -0.2872 -1.6987 -0.1197 -0.8324 -0.0830 -1.7472 -0.3993 -0.2941
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine ; furosemide ; outcome
H-586	-0.49337849020957947	▁do bu tamine ▁; ▁fur os em ide ▁dose ▁; ▁oxygen ▁flow
D-586	-0.49337849020957947	dobutamine ; furosemide dose ; oxygen flow
P-586	-1.6196 -0.0860 -0.2280 -0.3652 -0.6305 -0.4550 -0.1453 -0.0696 -1.7146 -0.2200 -0.3946 -0.2922 -0.4637 -0.2230
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential effect ; lvef ; mortality
H-118	-1.2891921997070312	▁LV EF ▁; ▁mortal iteit
D-118	-1.2891921997070312	LVEF ; mortaliteit
P-118	-0.8614 -2.3478 -0.4149 -2.3494 -2.3344 -0.3806 -0.3359
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash ; mortality ; heart failure ; health
H-684	-1.0058599710464478	▁Mediterrane an ▁; ▁DAS h ▁; ▁die t ▁score s ▁; ▁mortal iteit ▁; ▁women ▁; ▁heart ▁failure ▁; ▁Women ' s ▁Health ▁Initiative
D-684	-1.0058599710464478	Mediterranean ; DASh ; diet scores ; mortaliteit ; women ; heart failure ; Women's Health Initiative
P-684	-2.2492 -1.0252 -0.2936 -0.1827 -0.3362 -0.2961 -1.4272 -0.1085 -0.1350 -0.1949 -0.3601 -0.3938 -1.3673 -0.3422 -4.6574 -1.6118 -0.7870 -0.4348 -0.2779 -1.5595 -4.7511 -0.4709 -1.7504 -0.3937 -0.4358 -0.3098
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs ; outcomes ; patients ; diabetes
H-130	-0.9960376024246216	▁c ▁pc s ▁; ▁diabetes
D-130	-0.9960376024246216	c pcs ; diabetes
P-130	-0.7077 -4.0911 -0.2546 -0.3626 -0.6347 -0.5349 -0.3866
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin ; breast cancer ; patients ; cardiotoxicity
H-936	-1.0958266258239746	▁an thra cycli ne - tre ated ▁breast ▁cancer ▁; ▁cardio toxic iteit
D-936	-1.0958266258239746	anthracycline-treated breast cancer ; cardiotoxiciteit
P-936	-4.2025 -0.3389 -0.7388 -2.0829 -0.3299 -0.1169 -1.8463 -0.2850 -0.2227 -1.7151 -0.0477 -0.6708 -3.0988 -0.4271 -0.3141
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed up ; adverse events ; death ; transplantation ; circulatory assist device
H-1162	-0.51936936378479	▁death ▁; ▁transplant ation ▁; ▁circula tory ▁assist ▁device
D-1162	-0.51936936378479	death ; transplantation ; circulatory assist device
P-1162	-1.9902 -0.3496 -0.0732 -1.3129 -0.3806 -0.0166 -0.3722 -0.2590 -0.3069 -0.3969 -0.2549
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome ; change ; hospitalized ; heart failure
H-1395	-1.115470051765442	▁Nur sing - sensitiv e ▁outcome ▁change ▁score s ▁; ▁older ▁adults ▁; ▁heart ▁failure
D-1395	-1.115470051765442	Nursing-sensitive outcome change scores ; older adults ; heart failure
P-1395	-6.9372 -0.8851 -0.1779 -0.0046 -0.1350 -0.7174 -1.1687 -0.7757 -0.2451 -0.4648 -1.6238 -1.5024 -1.1605 -1.6716 -0.6663 -0.4687 -0.3581
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic ; diagnostic ; fluid overload
H-1071	-0.9342490434646606	▁devices ▁; ▁diagnostic ▁features ▁; ▁fluid ▁over load
D-1071	-0.9342490434646606	devices ; diagnostic features ; fluid overload
P-1071	-3.7892 -0.3947 -1.5907 -2.0919 -0.3316 -0.0240 -0.0317 -0.4156 -0.3743 -0.2988
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise ; clinical ; outcomes
H-1926	-0.3979814052581787	
D-1926	-0.3979814052581787	
P-1926	-0.5104 -0.2856
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter ; invasive ; surgery
H-553	-0.42432814836502075	▁trans cat heter ▁; ▁surgery
D-553	-0.42432814836502075	transcatheter ; surgery
P-553	-0.0410 -0.6362 -0.1768 -0.3016 -0.9777 -0.5040 -0.3331
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin ; heart failure ; breast cancer
H-927	-0.8879783153533936	▁resist in ▁; ▁che mo therapy - indu ced ▁heart ▁failure ▁; ▁breast ▁cancer
D-927	-0.8879783153533936	resistin ; chemotherapy-induced heart failure ; breast cancer
P-927	-3.9888 -0.4880 -0.3087 -0.5215 -0.4432 -0.0953 -0.3564 -0.4392 -1.0696 -1.2882 -0.2613 -0.3492 -3.5014 -0.4076 -0.3885 -0.3009
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression models ; comorbidities
H-662	-0.5764378309249878	▁insurance ▁status
D-662	-0.5764378309249878	insurance status
P-662	-0.8585 -0.6325 -0.4662 -0.3486
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up ; outcomes ; mortality
H-1637	-0.5355901122093201	▁black ▁race ▁; ▁mortal iteit
D-1637	-0.5355901122093201	black race ; mortaliteit
P-1637	-0.0918 -0.4833 -0.5779 -0.1587 -1.8862 -0.2994 -0.2518
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation ; heart iron
H-748	-0.9244031310081482	▁che lation ▁regime ns ▁; ▁heart ▁ir on
D-748	-0.9244031310081482	chelation regimens ; heart iron
P-748	-0.4315 -0.1638 -0.4685 -1.5849 -0.3787 -5.1647 -0.2726 -0.1080 -0.4275 -0.2438
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients ; chronic organ failure
H-793	-1.1394166946411133	▁Time ▁Up ▁; ▁Go ▁test ▁; ▁chronic ▁organ ▁failure
D-793	-1.1394166946411133	Time Up ; Go test ; chronic organ failure
P-793	-0.8645 -2.0172 -1.9598 -1.8183 -0.6916 -0.3623 -3.3934 -0.1604 -0.4337 -0.4853 -0.3471
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome ; death ; hospitalization ; heart failure
H-849	-0.998073935508728	▁death ▁; ▁heart ▁failure
D-849	-0.998073935508728	death ; heart failure
P-849	-2.2201 -0.2836 -2.3045 -0.5299 -0.3769 -0.2734
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline ; st2 ; interquartile range
H-701	-0.4274125397205353	▁ST 2 ▁level ▁; inter quart ile ▁range
D-701	-0.4274125397205353	ST2 level ;interquartile range
P-701	-0.9973 -0.3365 -0.2447 -0.4059 -1.2221 -0.1441 -0.1070 -0.0194 -0.4913 -0.3058
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure ulcers ; surgical ; patients
H-6	-0.5778018236160278	▁pressure ▁ul cer s ▁; ▁sur g ical ▁patients
D-6	-0.5778018236160278	pressure ulcers ; surgical patients
P-6	-0.6687 -0.0760 -0.1398 -0.6596 -0.3477 -1.4247 -0.3611 -1.0100 -0.9036 -0.4601 -0.3046
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf ; valve plasty ; mva
H-369	-0.8711182475090027	▁ HF ▁; ▁val ve ▁plast y ▁; ▁MS ▁; ▁significant ▁; ▁m VA
D-369	-0.8711182475090027	HF ; valve plasty ; MS ; significant ; mVA
P-369	-2.5213 -1.6890 -0.3380 -1.9996 -0.1715 -0.1534 -1.9190 -0.3835 -0.7411 -0.2941 -0.0495 -0.4026 -0.2511 -2.3789 -0.3913 -0.2539
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd ; congestive heart failure ; chf
H-902	-0.8621545433998108	▁PD ▁; ▁re frac tory ▁; ▁end - s tage ▁con ges tive ▁heart ▁failure ▁; ▁chw
D-902	-0.8621545433998108	PD ; refractory ; end-stage congestive heart failure ; chw
P-902	-1.1782 -0.2905 -0.2373 -0.2463 -0.2976 -0.3975 -2.5210 -0.1692 -0.3496 -0.1014 -0.1128 -0.7352 -2.4209 -1.2848 -0.4070 -0.2887 -4.3835 -0.6807 -0.2786
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms ; patients ; nyha
H-1893	-0.9133811593055725	▁w ha ▁; ▁functional ▁assessment
D-1893	-0.9133811593055725	wha ; functional assessment
P-1893	-3.7865 -1.2951 -0.3875 -0.1753 -0.1251 -0.3059 -0.3183
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta blockers ; mortality ; patients ; heart failure
H-649	-0.8981925249099731	▁beta ▁block ers ▁; ▁mortal iteit ▁; ▁heart ▁failure
D-649	-0.8981925249099731	beta blockers ; mortaliteit ; heart failure
P-649	-0.9381 -0.6668 -0.4500 -0.3784 -1.8854 -1.9394 -0.3314 -2.0893 -0.4929 -0.4327 -0.2756
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients ; consultation ; abdominal
H-1284	-1.0116337537765503	▁MT ▁; ▁abdominal ▁problems
D-1284	-1.0116337537765503	MT ; abdominal problems
P-1284	-1.3981 -0.5090 -0.3789 -2.9894 -0.4994 -0.2950
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.4528043568134308	▁follow - up ▁visit s
D-727	-0.4528043568134308	follow-up visits
P-727	-0.1297 -0.2969 -0.0973 -1.4419 -0.5717 -0.3363 -0.2958
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-0.9614571928977966	▁mortal iteit
D-2001	-0.9614571928977966	mortaliteit
P-2001	-0.8659 -2.2786 -0.4202 -0.2812
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-0.33014345169067383	▁fut ility ▁; ▁safety ▁monitoring ▁board
D-850	-0.33014345169067383	futility ; safety monitoring board
P-850	-0.2305 -0.4597 -0.4316 -0.5652 -0.1306 -0.2373 -0.3123 -0.2739
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic ; complication
H-1661	-1.3509461879730225	▁diagnose s ▁; ▁treatment s
D-1661	-1.3509461879730225	diagnoses ; treatments
P-1661	-3.4062 -1.2987 -0.3603 -2.8468 -0.5738 -0.6662 -0.3046
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress doppler echocardiography ; prognostic ; pulmonary hypertension ; patients
H-832	-0.6231813430786133	▁Stress ▁; ▁do pp ler ▁e cho card i ography ▁; ▁pulmonar y ▁hyper tension
D-832	-0.6231813430786133	Stress ; doppler echocardiography ; pulmonary hypertension
P-832	-0.9364 -1.8215 -0.4938 -0.1655 -1.8040 -0.2487 -0.4802 -0.4921 -0.6744 -0.3501 -0.3081 -0.0929 -1.0583 -0.1523 -0.1785 -1.0191 -0.3182
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection fraction ; clinical ; cardiac resynchronization therapy ; mild heart failure
H-750	-0.42082396149635315	▁e je ction ▁ fraction ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁mild ▁heart ▁failure
D-750	-0.42082396149635315	ejection fraction ; cardiac resynchronization therapy ; mild heart failure
P-750	-0.1386 -0.2596 -0.0847 -0.3583 -0.0495 -0.3221 -0.0871 -0.1386 -0.1112 -0.0157 -1.2520 -0.4230 -0.1070 -0.2883 -2.5532 -0.7622 -0.3978 -0.3899 -0.2568
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated ; septal ; wall ; avd ; free wall cs ; vvd
H-329	-1.2126094102859497	▁co ▁; ▁sept al ▁wall ▁; ▁v d ▁; ▁free ▁wall ▁; ▁CS ▁; ▁v n
D-329	-1.2126094102859497	co ; septal wall ; vd ; free wall ; CS ; vn
P-329	-1.7724 -0.5318 -0.4814 -0.2656 -0.6273 -0.6786 -4.7092 -1.3420 -0.3966 -0.6900 -0.8120 -0.6392 -3.1633 -0.3600 -3.5163 -1.0847 -0.4479 -0.3085
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv strain ; strain ; echocardiography ; baseline ; ablation
H-946	-0.45778316259384155	▁strain ▁; ▁strain ▁rate ▁; ▁e cho card i ography ▁; ▁base line ▁; ▁ab lation
D-946	-0.45778316259384155	strain ; strain rate ; echocardiography ; baseline ; ablation
P-946	-1.1331 -0.3464 -0.2434 -0.9174 -0.4756 -0.2897 -0.2280 -0.4182 -0.5953 -0.3371 -0.4536 -1.3370 -0.1338 -0.4758 -0.0158 -0.2065 -0.3596 -0.2738
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating progenitor cells ; outcome ; heart failure ; patients ; longitudinal
H-119	-0.5815243721008301	▁circula ting ▁pro gen itor ▁cell s ▁; ▁heart ▁failure ▁patients
D-119	-0.5815243721008301	circulating progenitor cells ; heart failure patients
P-119	-0.0355 -0.4085 -0.4229 -0.1297 -0.8164 -0.5339 -0.4542 -0.3778 -1.6340 -0.3841 -1.6851 -0.3909 -0.2869
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic ; acute rv failure ; left ventricular dysfunction
H-1092	-0.48282745480537415	▁et i ologic ▁; ▁a cute ▁ RV ▁failure ▁; ▁left ▁vent ri cular ▁dys function
D-1092	-0.48282745480537415	etiologic ; acute RV failure ; left ventricular dysfunction
P-1092	-1.1112 -0.2140 -0.2079 -0.6243 -0.5554 -0.1007 -0.3487 -0.9729 -0.2966 -0.2956 -0.7586 -0.1704 -1.6951 -0.3784 -0.0340 -0.2091 -0.3980 -0.3199
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic ; diastolic mitral leaflet motions ; organic ; lesion
H-351	-0.42593443393707275	▁sy sto lic ▁; ▁dia sto lic ▁mit ral ▁le a flet ▁; ▁motion s
D-351	-0.42593443393707275	systolic ; diastolic mitral leaflet ; motions
P-351	-0.3673 -0.3983 -0.1690 -0.5528 -0.0249 -0.3301 -0.2934 -1.1332 -0.3022 -1.3479 -0.1217 -0.2211 -0.3037 -0.3707 -0.4460 -0.5057 -0.3528
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial diastolic dysfunction ; dd ; collagen deposition ; titin
H-761	-0.7255138158798218	▁my o card ial ▁dia sto lic ▁dys function ▁; ▁d d ▁; ▁collage n ▁de position
D-761	-0.7255138158798218	myocardial diastolic dysfunction ; dd ; collagen deposition
P-761	-1.7684 -0.4031 -1.0722 -2.0675 -0.0364 -0.1125 -0.1242 -0.0192 -0.1179 -0.2575 -0.3386 -2.0085 -1.3617 -0.1632 -0.2074 -0.3818 -0.2390 -2.8536 -0.2522
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
H-576	-0.5564115047454834	▁vent ri cular ▁e je ction ▁time ▁; ▁a cute ▁heart ▁failure ▁; ▁pre cap illa ry ▁pulmonar y ▁hyper tension
D-576	-0.5564115047454834	ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
P-576	-0.9774 -1.7074 -0.4209 -0.2223 -0.2660 -0.1055 -1.2764 -0.3058 -1.2853 -0.1339 -0.7851 -0.2692 -0.3005 -0.9207 -0.2965 -0.1857 -1.3135 -0.0309 -0.9184 -0.1668 -0.0916 -0.5069 -0.3109
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical ; aortic valve insufficiency ; left ventricular assist device ; implantation
H-541	-0.7350853085517883	▁a or tic ▁val ve ▁insu ffi cie ncy ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁implant ation
D-541	-0.7350853085517883	aortic valve insufficiency ; left ventricular assist device ; implantation
P-541	-1.5771 -0.1461 -1.2813 -0.7491 -0.3561 -1.1028 -0.0839 -1.7529 -0.1809 -0.3431 -0.5858 -0.1499 -1.4844 -0.2664 -0.9101 -0.5878 -1.9632 -0.1127 -1.0607 -0.4620 -0.2803
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular pacing ; left heart twist ; strain ; right heart failure
H-318	-0.7947673201560974	▁bi ven tri cular ▁pa cing ▁; ▁left ▁heart ▁; ▁twist ▁; ▁strain ▁; ▁por cine ▁model ▁; ▁right ▁heart ▁failure
D-318	-0.7947673201560974	biventricular pacing ; left heart ; twist ; strain ; porcine model ; right heart failure
P-318	-2.7989 -0.2052 -2.1579 -0.6508 -0.1216 -0.2996 -0.5358 -1.9436 -1.3864 -0.2483 -0.7450 -0.2989 -0.0411 -0.3444 -1.4995 -0.4316 -1.0543 -0.3928 -0.8874 -0.9792 -0.4784 -0.4683 -0.3106
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac ; nurses
H-1662	-0.38325029611587524	▁cardiac ▁nurse s
D-1662	-0.38325029611587524	cardiac nurses
P-1662	-0.1835 -0.7153 -0.2878 -0.4105 -0.3191
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients ; randomization
H-851	-0.37198665738105774	
D-851	-0.37198665738105774	
P-851	-0.4786 -0.2654
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c statistics
H-383	-1.1524252891540527	▁UM ▁; ▁va - RT
D-383	-1.1524252891540527	UM ; va-RT
P-383	-1.5528 -1.7970 -0.2847 -1.1970 -2.5626 -0.3680 -0.3048
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart failure
H-1539	-0.8658557534217834	▁heart ▁failure
D-1539	-0.8658557534217834	heart failure
P-1539	-2.2075 -0.5801 -0.4034 -0.2724
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-1.2588225603103638	▁health ▁; ▁benefits
D-614	-1.2588225603103638	health ; benefits
P-614	-3.9362 -0.6603 -0.9999 -0.4089 -0.2887
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech republic
H-1972	-0.8185548782348633	▁Czech ▁Republic
D-1972	-0.8185548782348633	Czech Republic
P-1972	-1.8784 -0.6976 -0.3965 -0.3018
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac catheterization ; thrombotic obstruction ; right coronary artery
H-1292	-0.8841225504875183	▁investering ▁; ▁cardiac ▁cat heter ization ▁; ▁ thro mbo tic ▁ob struct ion ▁; ▁right ▁corona ry ▁arter y
D-1292	-0.8841225504875183	investering ; cardiac catheterization ; thrombotic obstruction ; right coronary artery
P-1292	-4.6545 -1.1917 -0.2698 -0.4542 -0.0649 -1.3744 -0.3002 -0.2745 -0.2792 -1.2089 -1.9284 -0.4758 -0.1576 -0.1502 -0.2971 -0.9725 -0.2221 -2.0810 -0.0327 -2.3373 -0.4345 -0.2893
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western blots ; monoclonal antibodies ; ser83 ; phosphorylation ; hf
H-1431	-0.7940880656242371	▁Western ▁blot s ▁; ▁mono clo nal ▁anti bo dies ▁; ▁Ser 83 ▁ phos phor y lation ▁; HF
D-1431	-0.7940880656242371	Western blots ; monoclonal antibodies ; Ser83 phosphorylation ;HF
P-1431	-0.3501 -0.0427 -0.5937 -0.2747 -0.0065 -0.5854 -2.8971 -0.0643 -0.0676 -2.5697 -0.3054 -1.0018 -1.1525 -0.1885 -0.0768 -1.7888 -2.1096 -0.2350 -0.2801 -2.2466 -0.3595 -0.2735
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef ; sodium ; ventricular ; vascular stiffness
H-917	-0.7593567967414856	▁h bf ▁; ▁so dium ▁restriction ▁; ▁vent ri cular ▁; ▁vas cular
D-917	-0.7593567967414856	hbf ; sodium restriction ; ventricular ; vascular
P-917	-0.9142 -2.4191 -1.5266 -0.5128 -0.0567 -0.4484 -0.2023 -0.1363 -1.3300 -0.3537 -0.2423 -0.4648 -0.5195 -1.9698 -0.2938
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical ; echocardiographic ; invasive ; hemodynamic ; outcome
H-1527	-0.403195858001709	▁e cho car dio graphic ▁; ▁invasi ve ▁hem o dynamic
D-1527	-0.403195858001709	echocardiographic ; invasive hemodynamic
P-1527	-0.1455 -0.3551 -0.1318 -0.6835 -0.9633 -0.3163 -0.2402 -0.8061 -0.2911 -0.4836 -0.0439 -0.5019 -0.2793
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic heart failure ; chf ; sympathetic tone ; autonomic imbalance
H-1370	-0.7071275115013123	▁chronic ▁heart ▁failure ▁; ▁chw ▁; ▁sympa the tic ▁tone ▁; ▁autonomi c ▁im balance
D-1370	-0.7071275115013123	chronic heart failure ; chw ; sympathetic tone ; autonomic imbalance
P-1370	-1.0507 -1.4995 -0.3499 -0.2946 -3.5014 -0.7639 -0.2147 -0.5265 -0.6073 -0.1492 -0.3062 -0.0809 -0.9060 -0.8209 -0.2306 -0.4258 -0.2930
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california office of statewide health planning and development patient discharge data nonpublic file
H-136	-0.9603188037872314	▁cali for nia ▁; ▁office ▁of ▁State wide ▁health plan ning ▁and ▁development ▁; ▁Patient ▁Dis charge
D-136	-0.9603188037872314	california ; office of Statewide healthplanning and development ; Patient Discharge
P-136	-0.6858 -0.1636 -0.4552 -2.6229 -1.4411 -0.3079 -1.9582 -0.1759 -1.6437 -0.7133 -0.0545 -1.8753 -0.9929 -1.9596 -0.6433 -1.6197 -0.0892 -0.5518 -0.2923
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right atrium ; prolapse ; tricuspid valve ; stenotic physiology
H-596	-0.3685820400714874	▁right ▁at rium ▁mass ▁; ▁tri cus pid ▁val ve ▁; ▁ste no tic ▁physio log y
D-596	-0.3685820400714874	right atrium mass ; tricuspid valve ; stenotic physiology
P-596	-0.3604 -1.1889 -0.0948 -0.5307 -0.2798 -0.1797 -0.3084 -0.1513 -0.4624 -0.3730 -0.3154 -0.0847 -0.1643 -0.6081 -0.1846 -0.2476 -0.8926 -0.3444 -0.2321
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative ; serum albumin ; patients ; left ventricular assist device ; implantation
H-528	-0.8436774015426636	▁se rum ▁album in ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁implant ation
D-528	-0.8436774015426636	serum albumin ; left ventricular assist device ; implantation
P-528	-0.4800 -0.7755 -1.0918 -0.2539 -0.4211 -2.9094 -0.2059 -2.0674 -0.2613 -0.7766 -0.3892 -2.0283 -0.1508 -0.9915 -0.4149 -0.2813
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary outcome ; functional capacity ; 6-minute walk test ; 6mwt
H-571	-0.5596225261688232	▁functional ▁capacity ▁; ▁mw t
D-571	-0.5596225261688232	functional capacity ; mwt
P-571	-0.5871 -0.6731 -0.3887 -1.4484 -0.1275 -0.3791 -0.3135
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing ; outcomes ; hospitalized ; hf
H-1402	-1.2369449138641357	▁older ▁adults ▁; ▁ HF
D-1402	-1.2369449138641357	older adults ; HF
P-1402	-2.5092 -0.8558 -0.2942 -3.0502 -1.2913 -0.3551 -0.3028
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf ; atrial explants ; cells ; explants
H-1341	-0.5980567336082458	▁CHF ▁; ▁at rial ▁ex plant s ▁; ▁sham ▁ex plant s
D-1341	-0.5980567336082458	CHF ; atrial explants ; sham explants
P-1341	-0.5091 -0.8070 -2.4356 -0.4208 -0.1647 -0.2583 -0.6832 -0.3636 -0.7148 -0.3078 -0.1938 -0.6741 -0.4985 -0.3415
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine ; dilated cardiomyopathy ; patients ; heart failure
H-1257	-0.6290106177330017	▁Chinese ▁herbal ▁medicine ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure
D-1257	-0.6290106177330017	Chinese herbal medicine ; dilated cardiomyopathy ; heart failure
P-1257	-2.0027 -0.3484 -0.5384 -0.3556 -1.3197 -0.5205 -0.0473 -0.7659 -0.3157 -0.0815 -0.3397 -1.4339 -0.4388 -0.5828 -0.3443
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient ; implantable cardioverter-defibrillator
H-1856	-0.5891312956809998	▁implant able ▁; ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1856	-0.5891312956809998	implantable ; cardioverter-defibrillator deactivation
P-1856	-1.1015 -0.5761 -1.5469 -0.0714 -0.1918 -0.6477 -0.2311 -0.1038 -0.2574 -1.4529 -0.2970 -0.1839 -0.3375 -0.1981 -2.0162 -0.4627 -0.3391
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype ; perioperative ; deaths
H-279	-0.3210849463939667	
D-279	-0.3210849463939667	
P-279	-0.3649 -0.2773
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic ; patients ; heart failure ; québec ; canada
H-1233	-0.9615645408630371	▁economische ▁; ▁AF ▁; ▁heart ▁failure ▁; ▁Québec ▁; ▁Canada
D-1233	-0.9615645408630371	economische ; AF ; heart failure ; Québec ; Canada
P-1233	-1.9422 -0.4290 -1.6580 -0.3782 -1.1739 -0.5942 -0.4289 -1.8767 -0.2661 -2.0988 -0.4310 -0.2617
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac ; mena deletion ; cardiac dysfunction ; hypertrophy
H-1811	-0.5410817861557007	▁cardiac ▁Men a ▁dele tion ▁; ▁cardiac ▁dys function ▁; ▁con duction ▁ab normal ities ▁; ▁hyper trop hy
D-1811	-0.5410817861557007	cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
P-1811	-0.2642 -1.8629 -0.0890 -0.0814 -0.8820 -0.3111 -0.2173 -0.0700 -0.0536 -0.2338 -0.5746 -0.0893 -0.0231 -0.3337 -2.8775 -0.2691 -0.0750 -0.0321 -2.4332 -0.3463 -0.2436
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical delay ; dyssynchronous heart failure
H-1146	-0.7096327543258667	▁electro me chan ical ▁de lay ▁; ▁dys syn chron ous ▁heart ▁failure ▁; ▁computa tional ▁study
D-1146	-0.7096327543258667	electromechanical delay ; dyssynchronous heart failure ; computational study
P-1146	-4.3123 -0.2521 -0.0729 -1.1758 -0.0949 -0.1254 -0.3947 -0.0673 -0.0565 -0.0137 -2.0221 -1.6538 -0.4794 -0.7136 -0.0104 -0.1221 -1.0995 -0.4650 -0.3516
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients ; trastuzumab ; cardiac ; comorbidities
H-682	-0.610463559627533	▁tras tuz um ab ▁; ▁cardiac ▁como rbi di ties
D-682	-0.610463559627533	trastuzumab ; cardiac comorbidities
P-682	-0.6614 -0.2556 -0.1329 -1.0693 -0.4501 -0.1058 -2.5811 -0.0291 -0.7978 -0.2033 -0.6948 -0.3442
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left bundle-branch block ; lbbb
H-886	-0.7763363122940063	▁bund le - bran ch ▁block ▁; ▁l bb ▁; ▁non - LB bb
D-886	-0.7763363122940063	bundle-branch block ; lbb ; non-LBbb
P-886	-0.0146 -0.9118 -0.2425 -0.1661 -1.0632 -0.2214 -0.2812 -0.6053 -1.6843 -0.5155 -2.0102 -0.1163 -1.1663 -2.7078 -0.3650 -0.3500
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan failure ; systolic ventricular function ; liver disease
H-224	-0.44022703170776367	▁Font ▁failure ▁; ▁sy sto lic ▁vent ri cular ▁function ▁; ▁significant ▁ liver ▁disease
D-224	-0.44022703170776367	Font failure ; systolic ventricular function ; significant liver disease
P-224	-0.5565 -1.7601 -0.2477 -0.0672 -0.1229 -0.1627 -0.0683 -1.3034 -0.2811 -0.2239 -0.2534 -0.0348 -0.4107 -0.4860 -0.7318 -0.4794 -0.2941
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated ; cardiac filling pressures ; adverse outcomes
H-1532	-0.5479636192321777	▁eh ▁; ▁CH ▁; ▁cardiac ▁fill ing ▁pressure s
D-1532	-0.5479636192321777	eh ; CH ; cardiac filling pressures
P-1532	-0.3892 -0.2394 -2.0315 -0.4301 -0.2490 -0.5757 -0.3538 -0.6232 -0.4277 -0.4232 -0.2849
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein ; genes ; western blot ; dna fragmentation ; tunel
H-167	-0.6176266074180603	▁protein ▁levels ▁; ▁Western ▁blot ▁; ▁DNA ▁fragment ation ▁; ▁tu nel ▁method ▁; ▁auto psy ▁sample s
D-167	-0.6176266074180603	protein levels ; Western blot ; DNA fragmentation ; tunel method ; autopsy samples
P-167	-0.8409 -2.8035 -0.2896 -1.2307 -0.0899 -0.3289 -0.4857 -0.0879 -1.2340 -0.3423 -0.3559 -1.2995 -1.4841 -0.3666 -0.1785 -0.0455 -0.0775 -0.2208 -0.3508 -0.2398
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal membrane oxygenation ; refractory right heart failure
H-1290	-0.4198218584060669	▁extra corp o real ▁membran e ▁; ▁oxygen ation ▁; ▁ bridge ▁; ▁in far ction - related ▁re frac tory ▁right ▁heart ▁failure
D-1290	-0.4198218584060669	extracorporeal membrane ; oxygenation ; bridge ; infarction-related refractory right heart failure
P-1290	-0.9251 -0.0757 -0.2329 -0.6374 -0.0685 -0.0807 -1.0779 -0.2888 -0.7004 -0.3375 -0.4887 -0.0087 -0.9895 -0.6201 -0.3343 -0.2723 -0.2458 -0.1826 -0.0932 -0.0392 -0.3194 -1.0182 -0.8040 -0.4524 -0.3785 -0.2432
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis ; pacing-induced dilated cardiomyopathy
H-165	-1.1681674718856812	▁dil ated ▁cardio my o pathy
D-165	-1.1681674718856812	dilated cardiomyopathy
P-165	-6.4262 -0.7414 -0.0773 -0.8580 -0.3371 -0.0586 -0.4627 -0.3842
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart failure ; leading ; mortality ; western ; society ; cardiovascular diseases
H-1480	-0.8600594401359558	▁Heart ▁failure ▁; ▁mortal iteit ▁; ▁Western ▁society ▁; ▁cardiovascular ▁disease s
D-1480	-0.8600594401359558	Heart failure ; mortaliteit ; Western society ; cardiovascular diseases
P-1480	-1.8853 -0.7223 -0.2373 -2.0287 -1.6161 -0.2620 -2.1710 -0.5022 -0.2616 -0.3255 -1.0752 -0.3723 -0.3393 -0.2420
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully magnetically levitated left ventricular assist system ; hf
H-1992	-0.6300443410873413	▁magnet ically ▁Lev itate d ▁le ft ▁vent ri cular ▁Assist ▁system ▁; ▁Tre ating ▁Advanced ▁ HF
D-1992	-0.6300443410873413	magnetically Levitated left ventricular Assist system ; Treating Advanced HF
P-1992	-0.1409 -0.6799 -0.1059 -4.0843 -0.0731 -0.7993 -0.1477 -0.6859 -1.0418 -0.1591 -0.2531 -0.5230 -0.2853 -1.8200 -0.0809 -0.3485 -0.2214 -0.5926 -0.3414 -0.2167
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation ; therapy ; heart disease ; rate control
H-1652	-0.6052453517913818	▁antico ag ulation ▁; ▁ therapy ▁; ▁heart ▁disease ▁; ▁rate ▁control
D-1652	-0.6052453517913818	anticoagulation ; therapy ; heart disease ; rate control
P-1652	-0.2063 -0.2481 -0.3675 -0.3168 -2.1944 -0.1348 -0.3833 -1.4869 -0.7225 -0.2285 -0.5592 -0.8661 -0.4637 -0.2954
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic effect ; beta blockers ; heart failure
H-648	-0.4889320135116577	▁in o tropi c ▁effect ▁; ▁beta ▁block ers ▁; ▁heart ▁failure
D-648	-0.4889320135116577	inotropic effect ; beta blockers ; heart failure
P-648	-0.2156 -0.7102 -0.0615 -0.3307 -0.0525 -0.3738 -0.3341 -0.5061 -0.3551 -0.3297 -2.4194 -0.4322 -0.4302 -0.2939
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients ; pad ; ankle-brachial index
H-1568	-0.4699805974960327	PAD ▁; ▁an kle - bra chi al ▁index
D-1568	-0.4699805974960327	PAD ; ankle-brachial index
P-1568	-0.3757 -0.4286 -0.5943 -0.8284 -0.4037 -0.4590 -1.0946 -0.2443 -0.0298 -0.4355 -0.2760
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr reduction ; ivabradine ; tac ; ea
H-525	-1.0210514068603516	▁HR ▁; ▁i va bra dine ▁; ▁ TAC ▁; ▁Ea
D-525	-1.0210514068603516	HR ; ivabradine ; TAC ; Ea
P-525	-4.6083 -0.4505 -0.2099 -0.0265 -0.5116 -1.1990 -0.3413 -1.2040 -0.8073 -0.4557 -2.6560 -0.4710 -0.3327
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp ; circulation ; hf ; patients
H-1513	-0.8406263589859009	▁NT - pro b NP ▁; ▁circulation ▁; ▁ HF
D-1513	-0.8406263589859009	NT-probNP ; circulation ; HF
P-1513	-0.8400 -0.1013 -0.0836 -1.9327 -1.8131 -0.3444 -0.5509 -0.2723 -1.0323 -1.0690 -1.6984 -0.3494
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy metabolism ; heart failure ; hypertrophied ; heart
H-1779	-0.6028286218643188	▁energy ▁metabolism ▁; ▁heart ▁failure ▁; ▁hyper trop hi ed ▁heart
D-1779	-0.6028286218643188	energy metabolism ; heart failure ; hypertrophied heart
P-1779	-1.4196 -0.2205 -0.2475 -1.7342 -0.6134 -0.2534 -0.1675 -0.0759 -0.0843 -0.7665 -1.7321 -0.2888 -0.2332
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality ; morbidity ; health-care ; budget
H-1075	-0.8353608846664429	▁cancer s ▁; ▁budget
D-1075	-0.8353608846664429	cancers ; budget
P-1075	-2.7926 -0.8803 -0.2845 -0.3173 -0.4141 -0.3234
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline ; mechanical cardiac support ; renal function
H-1388	-0.5026370286941528	▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function
D-1388	-0.5026370286941528	mechanical cardiac support ; renal function
P-1388	-1.3315 -0.1826 -0.1455 -1.1954 -0.3511 -0.2224 -0.3943 -0.4165 -0.2844
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients ; systolic function ; therapeutic
H-1070	-0.4341866970062256	▁sy sto lic ▁function ▁; ▁ therapeut ic
D-1070	-0.4341866970062256	systolic function ; therapeutic
P-1070	-0.5507 -0.3063 -0.1589 -0.1131 -0.9963 -0.2895 -0.3049 -0.6434 -0.6847 -0.2940
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ; ecmo ; patients ; vad ; ecmo ; vad
H-1390	-1.6267527341842651	▁ec mo ▁; ▁ VAD ▁; ▁ec mo + VAD
D-1390	-1.6267527341842651	ecmo ; VAD ; ecmo+VAD
P-1390	-1.5090 -3.1866 -1.2684 -2.5844 -0.4253 -0.3379 -1.1377 -3.3184 -3.8349 -0.6041 -0.9598 -0.3544
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis ; patients ; diastolic blood pressure ; body mass index
H-1560	-0.7904688119888306	▁psoriasis asis ▁; ▁smo ked ▁; ▁dia sto lic ▁blood ▁pressure ▁; ▁body ▁mass ▁index
D-1560	-0.7904688119888306	psoriasisasis ; smoked ; diastolic blood pressure ; body mass index
P-1560	-2.1144 -3.3695 -0.3213 -0.9018 -1.6005 -0.3697 -0.0321 -0.1478 -0.1586 -0.6457 -1.2961 -0.3012 -1.0785 -0.1267 -0.0301 -0.6484 -0.2954
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol ; linear mixed models ; intention-to-treat
H-838	-1.572339653968811	▁HR Qo l ▁; ▁linear
D-838	-1.572339653968811	HRQol ; linear
P-838	-4.0909 -0.0881 -2.6188 -1.6906 -0.5466 -1.6934 -0.2780
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients ; physicians ; hospitals ; new jersey ; new york
H-212	-0.8624843955039978	▁ED ▁physician s ▁; ▁New ▁Jersey ▁; ▁New ▁York
D-212	-0.8624843955039978	ED physicians ; New Jersey ; New York
P-212	-1.2682 -1.6519 -0.3158 -0.3177 -2.0498 -0.7578 -0.3051 -1.2337 -0.8943 -0.4199 -0.2733
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations ; cox models ; st2 ; functional capacity ; outcomes
H-700	-0.37009841203689575	▁co x ▁; ▁ST 2 ▁; ▁functional ▁capacity
D-700	-0.37009841203689575	cox ; ST2 ; functional capacity
P-700	-0.0636 -0.4100 -0.4287 -0.7115 -0.1582 -0.4256 -0.0708 -0.8141 -0.3266 -0.2918
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional ms ; lv dilatation ; functional ms
H-368	-1.0745995044708252	▁MS ▁; ▁functional ▁; ▁MS
D-368	-1.0745995044708252	MS ; functional ; MS
P-368	-2.3298 -0.3449 -2.3134 -0.7104 -1.1884 -0.3343 -0.3010
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion ; mortality
H-50	-0.692150354385376	▁trans fusion ▁thre s hold s ▁; ▁mortal iteit ▁rates
D-50	-0.692150354385376	transfusion thresholds ; mortaliteit rates
P-50	-0.0614 -0.4866 -0.0678 -0.4622 -0.9437 -0.4720 -0.3458 -0.3799 -2.6351 -1.5862 -0.5274 -0.3377
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause hospitalisations ; sts
H-160	-0.6074070930480957	▁TM ▁; ▁s ts
D-160	-0.6074070930480957	TM ; sts
P-160	-0.3441 -0.5136 -0.4201 -1.6030 -0.4344 -0.3292
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up ; patients ; hf
H-1106	-1.0859193801879883	▁ HF
D-1106	-1.0859193801879883	HF
P-1106	-2.8772 -0.7125 -0.4382 -0.3157
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality of life ; seattle heart failure model
H-2012	-0.46034786105155945	▁Seattle ▁Heart ▁Fail ure
D-2012	-0.46034786105155945	Seattle Heart Failure
P-2012	-0.1082 -0.6942 -0.5171 -0.5625 -0.6400 -0.2403
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients ; madit-crt
H-858	-1.3067047595977783	▁MAD t - c RT ▁; ▁device
D-858	-1.3067047595977783	MADt-cRT ; device
P-858	-0.2213 -3.8978 -0.1107 -0.8479 -3.9518 -1.1496 -0.9096 -0.3613 -0.3103
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological ; cardiovascular ; bound
H-1875	-0.8930656313896179	▁neurologi cal ▁; ▁cardiovascular
D-1875	-0.8930656313896179	neurological ; cardiovascular
P-1875	-0.2945 -1.2254 -0.5250 -0.1012 -2.9770 -0.2353
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets ; tac ; hf
H-1050	-0.77442866563797	▁bet s ▁; ▁mouse ▁ TAC ▁; ▁human ▁ HF
D-1050	-0.77442866563797	bets ; mouse TAC ; human HF
P-1050	-2.0401 -0.5511 -0.3046 -0.2383 -1.0910 -0.5625 -0.3194 -1.2109 -0.9875 -1.4512 -0.2862 -0.2503
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical ; nitrite ; vascular
H-414	-0.48286277055740356	▁nit rite
D-414	-0.48286277055740356	nitrite
P-414	-0.1428 -1.1151 -0.3533 -0.3202
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ; ahf ; risk stratification
H-58	-1.421899437904358	▁a HF
D-58	-1.421899437904358	aHF
P-58	-1.8681 -2.8449 -0.5965 -0.3781
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations ; patients ; patients
H-1282	-0.45104503631591797	
D-1282	-0.45104503631591797	
P-1282	-0.6328 -0.2693
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation ; flow-mediated dilatation
H-259	-0.80839604139328	▁no ▁; ▁flow - media ted ▁di la tation ▁; ▁ET
D-259	-0.80839604139328	no ; flow-mediated dilatation ; ET
P-259	-3.3825 -1.2016 -0.4651 -0.1226 -0.2215 -1.6325 -0.6204 -0.4047 -0.2419 -0.5389 -1.1011 -0.3231 -0.2533
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized ; dopamine ; nesiritide
H-76	-0.4181283712387085	▁dop amine ▁; ▁nesi riti de
D-76	-0.4181283712387085	dopamine ; nesiritide
P-76	-0.0364 -0.3026 -0.3218 -0.0923 -0.1469 -0.1626 -1.9775 -0.3050
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp ; sensitivity
H-271	-1.0780078172683716	▁cut off ▁level
D-271	-1.0780078172683716	cutoff level
P-271	-0.5215 -1.7695 -0.8695 -1.9157 -0.3138
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart failure ; protein kinase a ; expression
H-1423	-0.8259676694869995	▁heart ▁failure ▁; ▁protein ▁kina se
D-1423	-0.8259676694869995	heart failure ; protein kinase
P-1423	-3.9415 -0.7507 -0.3609 -0.5755 -0.0257 -0.2030 -0.4274 -0.3231
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox regression ; cardiovascular events ; psoriasis
H-1558	-0.2775900959968567	▁co x ▁re gression ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
D-1558	-0.2775900959968567	cox regression ; cardiovascular events ; psoriasis
P-1558	-0.0593 -0.4033 -0.1195 -0.1916 -0.3274 -0.2842 -0.6754 -0.3270 -0.0539 -0.3418 -0.2700
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective studies ; cpg ; hf
H-1845	-1.2778174877166748	▁c p ▁; HF
D-1845	-1.2778174877166748	cp ;HF
P-1845	-1.1325 -2.1144 -0.3443 -3.3467 -0.4511 -0.2779
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change ; paco2 ; cerebral ; blood flow ; perfusion ; carotid
H-1350	-0.41456618905067444	▁Paco 2 ▁; ▁cerebral ▁blood ▁flow ▁; ▁per fusion ▁; ▁caro tid ▁bo dies
D-1350	-0.41456618905067444	Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
P-1350	-0.0861 -0.2114 -0.3451 -0.2331 -1.2521 -0.7376 -0.2480 -0.7136 -0.0650 -0.3587 -0.0470 -0.3353 -0.0502 -1.3125 -0.3398 -0.2974
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional ms ; medical treatment ; surgical
H-376	-0.9809662103652954	▁function al ▁MS ▁; ▁medical ▁; ▁treatment ▁; ▁sur g ical
D-376	-0.9809662103652954	functional MS ; medical ; treatment ; surgical
P-376	-2.4953 -0.3200 -0.7838 -0.3175 -1.2407 -0.8917 -1.7376 -0.3636 -2.1120 -0.4480 -1.1390 -0.6473 -0.2561
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf ; epidemiology ; health ; hf
H-1790	-1.118336796760559	▁ HF ▁; ▁health ▁service ▁provision ▁; ▁ HF ▁; ▁LA
D-1790	-1.118336796760559	HF ; health service provision ; HF ; LA
P-1790	-2.4258 -0.9954 -0.3439 -1.4421 -1.0628 -0.9850 -0.2185 -2.6003 -1.0823 -0.3367 -2.2153 -0.5175 -0.3127
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes ; heart failure ; hf
H-555	-1.3465290069580078	▁heart ▁failure ▁; HF
D-555	-1.3465290069580078	heart failure ;HF
P-555	-4.9394 -0.4408 -0.2720 -1.7578 -0.3925 -0.2767
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal dysfunction ; mechanical cardiac support
H-1394	-0.44362759590148926	▁renal ▁dys function ▁; ▁mechanic al ▁cardiac ▁support
D-1394	-0.44362759590148926	renal dysfunction ; mechanical cardiac support
P-1394	-0.5509 -0.1355 -0.1137 -0.3013 -1.1364 -0.1995 -0.1022 -1.1839 -0.4413 -0.2715
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart failure ; hf ; chronic ; disease
H-2019	-0.6545277237892151	▁Heart ▁failure ▁; HF ▁; ▁chronic ▁disease
D-2019	-0.6545277237892151	Heart failure ;HF ; chronic disease
P-2019	-1.5048 -0.3324 -0.2477 -0.8222 -0.2932 -0.6192 -1.3682 -0.4140 -0.2891
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular assist devices ; therapies
H-203	-0.5199841856956482	▁vent ri cular ▁assist ▁devices ▁; ▁device ▁ therapie s
D-203	-0.5199841856956482	ventricular assist devices ; device therapies
P-203	-0.1572 -1.9634 -0.3912 -0.8212 -0.6109 -0.3601 -0.3487 -0.3752 -0.1371 -0.2925 -0.4313 -0.3510
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin ; health ; outcomes
H-43	-1.0050075054168701	▁hem o glob in ▁levels
D-43	-1.0050075054168701	hemoglobin levels
P-43	-0.9339 -0.8153 -0.3639 -1.1975 -2.8409 -0.5895 -0.2940
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory factor analysis ; cfa
H-1506	-0.8568539023399353	▁explora tory ▁factor ▁analysis ▁; ▁c FA
D-1506	-0.8568539023399353	exploratory factor analysis ; cFA
P-1506	-0.3680 -0.2753 -0.4860 -1.3236 -0.4937 -0.7086 -3.2499 -0.4523 -0.3542
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic ; clinicians ; patients
H-1124	-0.8571183681488037	
D-1124	-0.8571183681488037	
P-1124	-1.4169 -0.2973
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients ; heart failure ; systolic heart failure
H-725	-0.8256118893623352	▁heart ▁failure ▁; ▁sy sto lic ▁heart ▁failure
D-725	-0.8256118893623352	heart failure ; systolic heart failure
P-725	-3.5104 -0.6365 -0.3518 -0.2406 -0.1880 -0.3529 -1.6416 -0.5514 -0.4817 -0.3012
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline ; rhythm-control ; rate-control
H-1237	-0.5535396933555603	▁ rhythm - control ▁; ▁rate - control
D-1237	-0.5535396933555603	rhythm-control ; rate-control
P-1237	-0.3166 -1.8573 -0.5331 -0.1080 -0.3864 -1.0472 -0.3497 -0.1005 -0.5031 -0.3336
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up ; lvad ; patients ; heart failure
H-548	-0.9098914265632629	▁follow - up ▁; cf ▁l VAD ▁; ▁AI ▁; ▁heart ▁failure
D-548	-0.9098914265632629	follow-up ;cf lVAD ; AI ; heart failure
P-548	-1.1038 -0.3027 -0.0580 -0.3405 -3.3754 -0.6763 -0.1818 -0.4026 -2.7985 -0.3179 -1.8215 -0.4871 -0.5231 -0.3493
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade ; evidence ; anemia ; patients ; heart disease
H-38	-0.9640629887580872	▁an emia ▁; ▁heart ▁disease
D-38	-0.9640629887580872	anemia ; heart disease
P-38	-2.0334 -0.7101 -0.3338 -2.2809 -0.7047 -0.3502 -0.3353
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients ; left ventricular dilatation ; dysfunction
H-1746	-0.9216747879981995	▁left ▁vent ri cular ▁di la tation
D-1746	-0.9216747879981995	left ventricular dilatation
P-1746	-2.0741 -0.3568 -1.9370 -0.7381 -1.1783 -0.6245 -0.4640 -0.6033 -0.3190
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates ; coagulability
H-1113	-0.6885823011398315	▁se rum ▁factors ▁; ▁coa gul ability
D-1113	-0.6885823011398315	serum factors ; coagulability
P-1113	-0.1800 -0.9448 -0.2700 -0.4080 -0.5228 -0.9535 -2.2726 -0.3573 -0.2884
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted ; patients ; adverse events ; follow-up
H-1956	-0.8059465289115906	▁device ▁; ▁implant ed ▁; ▁follow - up
D-1956	-0.8059465289115906	device ; implanted ; follow-up
P-1956	-1.7164 -0.7247 -1.3854 -2.5298 -0.5591 -0.1145 -0.4261 -0.0567 -0.2912 -0.2554
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb ; patients ; hf
H-1351	-0.8442914485931396	▁p b ▁; ▁ HF
D-1351	-0.8442914485931396	pb ; HF
P-1351	-0.5009 -0.3818 -0.2994 -2.2825 -1.0805 -1.0481 -0.3168
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd ; patients
H-65	-0.8740742802619934	▁i CD
D-65	-0.8740742802619934	iCD
P-65	-0.7720 -1.9249 -0.4090 -0.3904
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients ; patients
H-267	-0.6629620790481567	
D-267	-0.6629620790481567	
P-267	-1.0083 -0.3176
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-1.424072027206421	▁ HF
D-1002	-1.424072027206421	HF
P-1002	-1.7761 -1.2794 -2.2970 -0.3438
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions ; hospital
H-144	-0.8224055767059326	▁computing ▁read missions ▁; ▁hospital ▁ranking s
D-144	-0.8224055767059326	computing readmissions ; hospital rankings
P-144	-0.4250 -2.1769 -0.2934 -0.2678 -1.3183 -1.7395 -0.2994 -0.5329 -0.3485
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients ; clinical ; echocardiography ; baseline ; shunt ; implantation
H-1954	-0.6358572840690613	▁e cho card i ography ▁; ▁shu nt ▁implant ation
D-1954	-0.6358572840690613	echocardiography ; shunt implantation
P-1954	-0.1933 -0.3347 -0.4392 -0.4792 -0.3531 -0.4601 -2.7471 -0.2233 -0.1540 -1.5083 -0.4352 -0.3029
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse correlation ; pro-adrenomedullin ; mr-proadm ; ffm
H-15	-0.5724949836730957	▁pro - ad re nom edu llin ▁; MR - pro ad m ▁; ▁f m
D-15	-0.5724949836730957	pro-adrenomedullin ;MR-proadm ; fm
P-15	-0.1416 -0.1344 -0.1141 -0.1531 -1.2068 -0.4438 -1.9140 -0.3805 -0.7525 -0.0550 -0.1199 -1.6489 -0.2440 -0.3861 -0.3577 -1.2347 -0.7318 -0.2862
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new york heart association classification ; 6-min walk test ; quality-of-life
H-2005	-1.0224717855453491	▁New ▁York ▁Heart ▁association ▁; ▁walk ▁test ▁; ▁quality - of - life
D-2005	-1.0224717855453491	New York Heart association ; walk test ; quality-of-life
P-2005	-1.3289 -2.0093 -1.7822 -0.5505 -0.3957 -2.9171 -1.7241 -0.3241 -0.3510 -0.1731 -0.0268 -0.4041 -0.5458 -2.4896 -0.3148
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional ms ; ring annuloplasty ; ischemic mr ; lv dilatation
H-366	-0.4335421919822693	▁functional ▁; ▁MS ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁MR ▁; ▁LV ▁di la tation
D-366	-0.4335421919822693	functional ; MS ; ring annuloplasty ; ischemic MR ; LV dilatation
P-366	-0.4683 -1.2324 -1.0823 -0.3098 -0.0400 -0.7394 -0.1622 -0.3013 -1.5107 -0.3357 -0.1005 -0.1249 -0.2417 -0.2715 -0.2717 -0.1739 -0.6863 -0.1818 -0.1451 -0.4750 -0.2500
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise intolerance ; heart failure ; exercise ; diagnosis ; prognosis ; therapeutic
H-1272	-0.8094440698623657	▁Exerci se ▁in tolerance ▁; ▁heart ▁failure ▁; ▁exercise ▁parameter s
D-1272	-0.8094440698623657	Exercise intolerance ; heart failure ; exercise parameters
P-1272	-1.7714 -1.0898 -0.0444 -0.1407 -0.3089 -1.6164 -0.5002 -0.3621 -2.2360 -1.1601 -0.3377 -0.6798 -0.2753
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology ; hf ; diagnosis ; medical ; nursing
H-2021	-0.7514131665229797	▁pat ho phy si ology ▁; HF ▁; ▁medical ▁management
D-2021	-0.7514131665229797	pathophysiology ;HF ; medical management
P-2021	-0.8764 -0.3678 -0.5348 -1.9705 -0.1676 -0.2665 -2.1460 -0.5845 -1.1024 -0.2630 -0.4467 -0.2907
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
H-1383	-0.49513089656829834	▁vent ri cular ▁assist ▁device ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁renal ▁function ▁; ▁heart ▁failure
D-1383	-0.49513089656829834	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
P-1383	-0.1452 -1.4997 -0.3173 -0.6950 -0.4616 -0.3214 -0.2293 -0.1197 -0.1446 -0.3255 -0.0946 -0.0789 -0.7144 -1.9083 -0.3556 -0.0656 -0.1965 -0.2874 -1.7523 -0.4617 -0.4416 -0.2770
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin receptor ; st2 ; beta-blocker ; therapy ; chronic heart failure
H-398	-0.575190007686615	▁inter le u kin ▁receptor ▁family ▁; ▁ST 2 ▁; ▁beta - block er ▁ therapy ▁; ▁chronic ▁heart ▁failure
D-398	-0.575190007686615	interleukin receptor family ; ST2 ; beta-blocker therapy ; chronic heart failure
P-398	-0.1603 -0.4055 -0.0926 -4.9792 -0.0279 -0.7476 -1.2618 -0.4863 -0.0984 -0.3228 -0.3104 -0.1281 -0.2439 -0.1183 -0.2076 -0.0547 -0.3268 -0.4988 -0.9941 -0.4692 -0.4215 -0.2983
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp ; nt-probnp ; diagnostic ; prognostic ; biomarkers ; patients ; heart failure
H-1365	-0.9278088808059692	▁b NP ▁; ▁NT - pro b NP ▁; ▁bio mark ers ▁; ▁heart ▁failure
D-1365	-0.9278088808059692	bNP ; NT-probNP ; biomarkers ; heart failure
P-1365	-0.9564 -2.3141 -0.3318 -0.3557 -0.1482 -0.0413 -1.0138 -1.9419 -0.3885 -2.8993 -0.6375 -0.5377 -0.3537 -2.4867 -0.6151 -0.4293 -0.3217
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory fitness ; body mass index ; heart failure ; mortality ; cooper center longitudinal study
H-1765	-0.8101356029510498	▁Card i ore spira tory ▁fitness ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁mortal iteit ▁; ▁Cooper ▁Center ▁Long itud in al ▁Study
D-1765	-0.8101356029510498	Cardiorespiratory fitness ; body mass index ; heart failure mortaliteit ; Cooper Center Longitudinal Study
P-1765	-2.6509 -0.6836 -1.5525 -0.1296 -0.2845 -3.0327 -0.2788 -1.1444 -0.1140 -0.0256 -0.3366 -0.8501 -0.5396 -0.5562 -2.1003 -0.2974 -0.9058 -1.8272 -0.6005 -0.1660 -0.3108 -0.0526 -1.0630 -0.4698 -0.2809
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin receptor antagonist ; tolvaptan ; heart failure ; patients
H-1194	-0.622143566608429	▁vaso press in ▁receptor ▁anta gon ist ▁; ▁to lv ap tan ▁; ▁Japanese ▁heart ▁failure ▁patients
D-1194	-0.622143566608429	vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure patients
P-1194	-0.2752 -0.1352 -0.4548 -0.0184 -0.0903 -0.0127 -1.1000 -0.3288 -0.1190 -0.3456 -0.7876 -0.1262 -0.3494 -3.1457 -1.0010 -0.4196 -2.3790 -0.4378 -0.2945
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-1.4838647842407227	▁die t ▁; ▁exercise ▁; ▁attention ▁control ▁; ▁telephone
D-1979	-1.4838647842407227	diet ; exercise ; attention control ; telephone
P-1979	-5.3065 -0.1472 -0.3219 -0.6246 -0.3284 -1.5710 -1.1038 -0.6899 -0.3041 -5.6158 -0.3092
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.8897433876991272	
D-142	-0.8897433876991272	
P-142	-1.4250 -0.3544
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute hf
H-1018	-0.6913299560546875	▁a cute ▁ HF
D-1018	-0.6913299560546875	acute HF
P-1018	-2.1341 -0.1195 -0.5038 -0.7098 -0.4052 -0.2756
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration ; chf
H-683	-0.8290517926216125	▁administration ▁; ▁tras tuz um ab - related ▁CHF
D-683	-0.8290517926216125	administration ; trastuzumab-related CHF
P-683	-2.9040 -0.2805 -0.2750 -0.3908 -0.5471 -1.8609 -0.6506 -0.6364 -0.8492 -0.4368 -0.2882
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.4448958933353424	
D-272	-0.4448958933353424	
P-272	-0.5753 -0.3145
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac death
H-1905	-0.7049473524093628	▁cardiac ▁death
D-1905	-0.7049473524093628	cardiac death
P-1905	-0.6061 -1.4737 -0.4787 -0.2613
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.45824652910232544	
D-1476	-0.45824652910232544	
P-1476	-0.5767 -0.3398
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital ; mortality
H-1692	-0.9113579988479614	▁hospital ▁mortal iteit
D-1692	-0.9113579988479614	hospital mortaliteit
P-1692	-0.9341 -0.3910 -2.5326 -0.3513 -0.3478
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-0.9452584385871887	▁medical ▁records
D-1131	-0.9452584385871887	medical records
P-1131	-1.8377 -0.6833 -0.9491 -0.3109
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection fraction ; ef ; infarct ; collateral growth ; myocardial perfusion
H-506	-0.7993996739387512	▁e je ction ▁ fraction ▁; EF ▁; ▁in far ct ▁; ▁col lateral ▁growth ▁; ▁my o card ial ▁per fusion
D-506	-0.7993996739387512	ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
P-506	-0.7288 -0.4874 -0.1065 -0.3835 -0.0358 -0.2670 -1.5812 -0.2766 -3.2615 -0.6931 -1.8889 -2.0917 -0.2218 -0.0155 -1.0744 -0.2897 -1.6430 -0.2779 -0.6440 -1.7011 -0.6482 -0.1370 -0.4003 -0.3304
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart failure ; hf ; elevated ; sympathetic activity ; parasympathetic control ; heart
H-1133	-0.7951550483703613	▁Heart ▁failure ▁; HF ▁; ▁sympa the tic ▁activity ▁; ▁para sy mpa the tic ▁control ▁; ▁heart
D-1133	-0.7951550483703613	Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
P-1133	-1.3400 -0.2743 -0.2235 -0.9529 -0.2622 -0.1866 -0.7468 -1.0180 -1.5977 -0.2483 -0.1726 -0.4145 -0.4200 -1.5679 -1.2623 -1.5247 -0.2066 -2.8454 -0.3698 -0.2691
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical ; activity ; cardiovascular ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
H-1898	-0.7186133861541748	▁physical ▁activity ▁; ▁cardiovascular ▁risk ▁factors ▁; ▁obes iteit ▁; ▁diabetes ▁mell itus ▁; ▁hyper tension ▁; ▁hyper li pida emia
D-1898	-0.7186133861541748	physical activity ; cardiovascular risk factors ; obesiteit ; diabetes mellitus ; hypertension ; hyperlipidaemia
P-1898	-3.6066 -2.4806 -0.6101 -0.5717 -1.1420 -0.5216 -0.2743 -0.3640 -3.5841 -0.2571 -0.0375 -0.0079 -0.0298 -0.2082 -0.0602 -0.1289 -0.1821 -0.0933 -0.1585 -0.4552 -1.1020 -0.3865 -0.2659
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure ; patients
H-1510	-0.6134969592094421	▁circula ting ▁fragment s ▁; ▁na tri ure tic ▁pe pti des ▁; ▁plasma ▁; ▁heart ▁failure ▁patients
D-1510	-0.6134969592094421	circulating fragments ; natriuretic peptides ; plasma ; heart failure patients
P-1510	-0.1856 -0.3391 -0.7703 -0.8990 -0.4013 -0.2846 -0.8879 -0.5047 -2.1160 -0.7479 -0.4756 -0.4014 -0.4346 -0.0721 -0.3560 -0.4763 -0.1703 -1.9461 -0.4617 -0.3394
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients ; heart failure ; hf ; preserved left ventricular ejection fraction ; hfpef
H-1300	-0.6966842412948608	▁heart ▁failure ▁; HF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; HF p EF
D-1300	-0.6966842412948608	heart failure ;HF ; left ventricular ejection fraction ;HFpEF
P-1300	-2.7416 -0.3640 -0.2897 -0.8964 -0.3201 -1.6918 -0.2410 -1.5095 -0.7961 -0.2558 -0.3237 -0.2419 -0.2990 -0.0337 -0.3599 -1.9818 -0.0493 -0.8795 -0.3764 -0.2824
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
H-1230	-0.6122431755065918	rial ▁fi bril lation ▁; ▁con ges tive ▁heart ▁failure ▁; ▁cost ▁; ▁ rhythm - control ▁; ▁rate - control
D-1230	-0.6122431755065918	rial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
P-1230	-1.5567 -0.4304 -0.0991 -0.3942 -0.3209 -0.2076 -0.5561 -2.8880 -0.8300 -0.3671 -0.3731 -1.3762 -0.6210 -0.2103 -1.0567 -0.2609 -0.0390 -0.2750 -0.8152 -0.3116 -0.0297 -0.7523 -0.3105
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf ; symptom ; cardiac murmurs ; blood pressure
H-356	-0.5926629304885864	▁ HF ▁; ▁cardiac ▁mur mur s ▁; ▁blood ▁pressure ▁; ▁h g
D-356	-0.5926629304885864	HF ; cardiac murmurs ; blood pressure ; hg
P-356	-2.3088 -0.8581 -0.2870 -0.3484 -0.1392 -0.0960 -0.6493 -0.3078 -1.0829 -1.1476 -0.3186 -0.5419 -0.1915 -0.3243 -0.2886
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp ; xo-mediated ros ; mitochondrial respiration ; contractile function
H-471	-0.4620246887207031	▁ATP ▁demand ▁; ▁ XO - media ted ▁ ROS ▁; ▁mito cho ndri al ▁respira tion ▁; ▁contract ile ▁function
D-471	-0.4620246887207031	ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile function
P-471	-1.4060 -1.0818 -0.2214 -0.3898 -0.2861 -0.0840 -0.0751 -0.9574 -0.2493 -0.3649 -0.3264 -0.1179 -0.9393 -0.7532 -0.2336 -0.5908 -1.2593 -0.3175 -0.0142 -0.1497 -0.0881 -0.4336 -0.2872
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
H-454	-0.8505731225013733	▁b ▁; ▁cardiac ▁ang io gene sis ▁; ▁in ▁vivo ▁corona ry ▁per fusion ▁; ▁cardiac ▁fibro sis
D-454	-0.8505731225013733	b ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
P-454	-2.5544 -1.2016 -2.5784 -1.1041 -1.3357 -0.4116 -1.5287 -0.3454 -0.5125 -0.0697 -0.2737 -2.0748 -0.8903 -0.0920 -0.2535 -0.2596 -0.0903 -0.8062 -0.3918 -0.2372
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization ; patients ; heart failure ; ventricular tachycardia
H-1434	-0.8335348963737488	▁heart ▁failure ▁; ▁pro ne ▁; ▁vent ri cular ▁ta chy car dia
D-1434	-0.8335348963737488	heart failure ; prone ; ventricular tachycardia
P-1434	-3.2415 -0.5073 -0.2877 -1.5406 -0.5442 -1.8599 -0.1247 -1.9885 -0.4630 -0.4408 -0.3463 -0.0795 -0.1248 -0.6163 -0.3378
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug test ; patients ; copd ; chf ; crf
H-806	-0.9794149398803711	▁tu g ▁test ▁; ▁COP d ▁; ▁CHF ▁; ▁c RF
D-806	-0.9794149398803711	tug test ; COPd ; CHF ; cRF
P-806	-1.3851 -3.8505 -0.6326 -0.3260 -1.0681 -0.7959 -0.3300 -0.0946 -0.3797 -1.1007 -2.0560 -0.4016 -0.3115
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling pathways ; pressure-overload-induced heart failure
H-877	-0.8581110239028931	▁pressure - over load - indu ced ▁heart ▁failure
D-877	-0.8581110239028931	pressure-overload-induced heart failure
P-877	-4.4131 -0.2109 -0.0583 -0.1797 -0.2646 -0.5904 -1.2891 -1.2520 -0.4474 -0.4107 -0.3231
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing ; mandate ; accountable ; outcomes ; nursing
H-1396	-0.9398559331893921	▁Nur sing ▁; ▁social ▁mandat e ▁; ▁nur sing ▁care
D-1396	-0.9398559331893921	Nursing ; social mandate ; nursing care
P-1396	-1.7866 -0.3594 -0.3254 -2.0872 -0.4703 -0.1598 -0.3798 -2.8200 -0.3359 -1.8205 -0.3857 -0.3475
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients ; hf ; spontaneous vt ; qt intervals
H-1445	-0.6818769574165344	HF ▁; ▁v t ▁; ▁beat - to - beat ▁ QT ▁interval s
D-1445	-0.6818769574165344	HF ; vt ; beat-to-beat QT intervals
P-1445	-3.2056 -0.3538 -1.0095 -1.2574 -0.4201 -0.0853 -0.2617 -0.6045 -0.3239 -0.3194 -0.6966 -0.8452 -0.3776 -0.3720 -0.4610 -0.3163
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular dysfunction ; outcome ; patients ; heartmate ii
H-305	-0.7933667898178101	▁bi ven tri cular ▁dys function ▁; ▁isola ted ▁Heart Mate ▁i i
D-305	-0.7933667898178101	biventricular dysfunction ; isolated HeartMate ii
P-305	-1.8515 -0.4175 -3.9153 -1.5085 -0.0915 -0.3987 -0.2946 -0.1394 -0.5957 -0.5640 -0.4289 -0.8851 -0.0531 -0.4280 -0.3287
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical ; patient ; hemodynamically ; cpr
H-1294	-1.2307698726654053	▁economische ▁; ▁hem o dynamic ally ▁uns table ▁; ▁c PR
D-1294	-1.2307698726654053	economische ; hemodynamically unstable ; cPR
P-1294	-7.8969 -0.2943 -0.2923 -0.4075 -0.0537 -1.5533 -0.6233 -0.5723 -0.3043 -0.6446 -2.7130 -0.3978 -0.2465
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients ; end-stage heart failure ; implantation ; ventricular assist device
H-1657	-0.9724481105804443	▁heart ▁failure ▁; ▁implant ation ▁; ▁vent ri cular ▁assist ▁device
D-1657	-0.9724481105804443	heart failure ; implantation ; ventricular assist device
P-1657	-4.1961 -0.6063 -0.3572 -1.6035 -1.3222 -0.3981 -0.1832 -1.8682 -0.3799 -0.5805 -0.3173 -0.5079 -0.3215
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine ; myocyte ; collagen ; left ventricle
H-1141	-0.4767504334449768	▁Pyr ido stig mine ▁; ▁my o cy te ▁diameter ▁; ▁collage n ▁den s ity ▁; ▁left ▁vent ric le
D-1141	-0.4767504334449768	Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
P-1141	-0.1131 -0.0296 -0.0032 -0.6249 -0.2723 -1.2287 -0.1965 -0.0870 -0.0790 -0.8662 -0.2394 -0.0482 -0.1823 -0.6356 -0.5534 -2.7064 -0.2558 -0.6108 -0.0542 -0.7558 -0.7614 -0.3826 -0.2788
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol ; cxl-1020 ; myocytes ; hearts
H-419	-0.4976038932800293	▁iso prot eren ol ▁; ▁c XL -10 20 ▁; ▁my o cy tes ▁; ▁heart s
D-419	-0.4976038932800293	isoproterenol ; cXL-1020 ; myocytes ; hearts
P-419	-0.1056 -0.0867 -0.2015 -0.6860 -0.3501 -0.3249 -1.9306 -0.1508 -0.5182 -0.3988 -1.6068 -0.2365 -0.1303 -0.1544 -0.3054 -1.0155 -0.4136 -0.5140 -0.3250
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise intolerance ; symptom ; chronic hfpef ; quality of life ; qol
H-1975	-1.2460540533065796	▁Exerci se ▁in tolerance ▁; ▁chronic ▁h FP EF ▁; ▁ nc w
D-1975	-1.2460540533065796	Exercise intolerance ; chronic hFPEF ; ncw
P-1975	-1.2617 -0.8100 -0.0521 -0.1574 -0.3009 -2.5737 -1.5595 -2.8154 -1.4705 -0.2880 -3.2281 -3.1197 -0.2237 -0.5367 -0.2933
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors ; adenylyl cyclase ; g-protein coupling
H-1406	-0.33923912048339844	▁receptor s ▁; ▁a den yl yl ▁cy cla se ▁; ▁g - prote in ▁coup ling
D-1406	-0.33923912048339844	receptors ; adenylyl cyclase ; g-protein coupling
P-1406	-0.1949 -0.5128 -0.3673 -0.1843 -0.3611 -0.1870 -0.2828 -0.1007 -0.0571 -0.7944 -0.3317 -0.6771 -0.2116 -0.0519 -0.5675 -0.0711 -0.7156 -0.4532 -0.3232
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients ; systolic hf ; etiology ; coronary angiography
H-1184	-0.5417273640632629	▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology ▁; ▁corona ry ▁ang i ography
D-1184	-0.5417273640632629	systolic HF ; unclear etiology ; coronary angiography
P-1184	-0.2728 -0.4125 -0.0887 -0.6311 -0.3274 -0.2968 -0.9686 -0.5786 -0.1167 -0.1746 -0.0842 -0.3714 -0.6091 -3.0879 -0.7040 -0.4975 -0.3511 -0.4113 -0.3083
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality ; patients ; implantable cardiac defibrillator ; meta-analysis
H-59	-0.5835088491439819	▁mortal iteit ▁; ▁implant able ▁cardiac ▁de fi br illa tor
D-59	-0.5835088491439819	mortaliteit ; implantable cardiac defibrillator
P-59	-1.4722 -2.2635 -0.3401 -0.4382 -0.2829 -0.0446 -0.3285 -0.1685 -1.0150 -0.2937 -0.2059 -0.3904 -0.3420
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular venous pressure ; peripheral oedema ; patient
H-1895	-0.45822903513908386	▁jugu lar ▁ve nous ▁pressure ▁; ▁per i pher al ▁oed ema ▁; ▁volume
D-1895	-0.45822903513908386	jugular venous pressure ; peripheral oedema ; volume
P-1895	-0.0407 -0.4055 -1.7376 -0.6633 -0.7038 -0.2335 -0.2594 -0.1378 -0.1261 -0.1811 -0.1922 -0.2675 -0.5109 -0.3000 -1.3076 -0.2645
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart failure ; hf ; condition ; morbidity ; mortality
H-1487	-0.7856264710426331	▁Heart ▁failure ▁; HF ▁; ▁condition ▁; ▁significant
D-1487	-0.7856264710426331	Heart failure ;HF ; condition ; significant
P-1487	-1.6199 -0.2781 -0.2448 -0.7440 -0.2935 -1.7964 -0.4706 -0.1328 -1.9457 -0.3304
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical ; rule ; cad ; systolic hf
H-1185	-0.37054014205932617	▁CAD ▁; ▁sy sto lic ▁ HF
D-1185	-0.37054014205932617	CAD ; systolic HF
P-1185	-0.9892 -0.3190 -0.0536 -0.1245 -0.1494 -0.5147 -0.3839 -0.4806 -0.3200
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo sternotomy ; cardiopulmonary bypass
H-775	-1.1086868047714233	▁pump - ex change ▁techniek ▁; ▁ster no to my ▁; ▁cardio pul mon ary
D-775	-1.1086868047714233	pump-exchange techniek ; sternotomy ; cardiopulmonary
P-775	-3.2568 -0.3053 -0.9690 -0.4481 -2.3415 -0.2907 -0.6993 -0.2183 -0.3412 -1.4902 -0.3620 -0.1280 -1.3482 -2.1192 -0.7868 -3.4058 -0.3373
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical ; revascularization ; revascularization
H-1603	-0.9389119148254395	▁chirurg ische ▁re vas cular ization ▁; ▁cat heter - based ▁re vas cular ization
D-1603	-0.9389119148254395	chirurgische revascularization ; catheter-based revascularization
P-1603	-6.2804 -2.1714 -0.1694 -0.5025 -0.2690 -1.8076 -0.5654 -0.4698 -0.0265 -0.2547 -0.0810 -0.1114 -0.4472 -0.2511 -1.6439 -0.5474 -0.3629
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline ; hgb ; exercise ; training ; kccq
H-841	-1.2705168724060059	▁Base ▁h gb ▁; ▁exercise ▁; ▁ nc w
D-841	-1.2705168724060059	Base hgb ; exercise ; ncw
P-841	-4.0426 -2.3914 -0.7504 -0.3403 -0.7742 -1.5142 -1.6745 -1.3775 -0.2160 -0.6051 -0.2893
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical treatment ; hf ; hf ; symptom ; mva
H-371	-1.2509948015213013	▁ HF ▁; ▁ HF ▁; ▁MS ▁; ▁m va
D-371	-1.2509948015213013	HF ; HF ; MS ; mva
P-371	-3.8177 -2.0081 -0.3353 -2.1531 -1.0604 -0.3922 -1.1435 -0.3864 -0.2075 -2.9000 -0.3407 -0.2670
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical treatment ; hf ; functional ms ; medical treatment
H-354	-0.9944388270378113	▁MS ▁; ▁medical ▁treatment ▁; HF ▁; ▁functional ▁; ▁MS ▁; ▁medical ▁treatment
D-354	-0.9944388270378113	MS ; medical treatment ;HF ; functional ; MS ; medical treatment
P-354	-1.1349 -0.3650 -1.4101 -1.3333 -0.3303 -3.4196 -0.4406 -0.4508 -1.7921 -0.9169 -0.4116 -1.1701 -1.1018 -0.3676 -0.2720
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic ; histological ; gastrointestinal
H-1359	-0.8597140908241272	
D-1359	-0.8597140908241272	
P-1359	-1.4156 -0.3039
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence ; parasympathetic ; therapeutic ; hf
H-1134	-0.6943684816360474	▁para sy mpa the tic ▁function ▁; ▁ therapeut ic ▁; ▁w h
D-1134	-0.6943684816360474	parasympathetic function ; therapeutic ; wh
P-1134	-0.1015 -0.4521 -0.6058 -1.0269 -1.2455 -0.1666 -0.2547 -0.1733 -0.5640 -0.6237 -0.3513 -3.8165 -0.4355 -0.3639 -0.2341
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes ; exercise ; training ; patients ; ambulatory ; hf
H-1631	-1.2238413095474243	▁race ▁; ▁exercise ▁; ▁ambula tory ▁ HF
D-1631	-1.2238413095474243	race ; exercise ; ambulatory HF
P-1631	-5.4157 -0.3202 -0.5699 -2.3224 -1.0990 -0.5699 -0.4938 -0.7604 -0.3594 -0.3278
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical cardiac support ; renal function ; end-stage heart failure
H-1384	-0.8808899521827698	▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function ▁; ▁children ▁; ▁end - s tage ▁heart ▁failure
D-1384	-0.8808899521827698	mechanical cardiac support ; renal function ; children ; end-stage heart failure
P-1384	-1.3617 -0.1554 -0.1650 -1.0077 -0.4083 -0.1210 -0.1587 -0.3642 -5.0390 -0.9193 -2.9774 -0.1456 -0.2301 -0.0677 -1.1823 -0.7434 -0.5203 -0.2888
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients ; systolic blood pressure ; renal impairment ; hypertension
H-1529	-0.6804081797599792	▁CH ▁; ▁eh ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁renal ▁im pair ment ▁; ▁hyper tension
D-1529	-0.6804081797599792	CH ; eh ; systolic blood pressure ; renal impairment ; hypertension
P-1529	-3.2187 -0.3720 -0.3983 -0.3127 -0.1587 -0.1694 -0.2848 -1.0996 -2.4148 -0.3693 -0.2052 -0.3779 -0.0672 -1.5244 -0.4012 -0.4318 -0.4138 -0.4033 -0.3047
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic myocardial ischemia ; heart failure ; therapeutic
H-503	-0.9781524538993835	▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure
D-503	-0.9781524538993835	chronic myocardial ischemia ; heart failure
P-503	-3.8382 -3.4145 -0.2416 -0.5894 -1.2532 -0.2382 -0.1276 -0.5967 -0.2696 -1.1295 -0.2064 -0.5059 -0.3051
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based ; nucleolin ; protein expression
H-96	-0.7184694409370422	▁Mor pho lino - based ▁knock down ▁; ▁nucleo lin ▁; ▁protein ▁expression
D-96	-0.7184694409370422	Morpholino-based knockdown ; nucleolin ; protein expression
P-96	-4.4050 -0.8159 -0.5943 -0.2529 -0.1022 -0.1002 -0.8844 -0.3816 -0.4502 -1.3174 -0.3464 -0.1845 -0.1462 -0.4798 -0.3160
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital ; rehospitalization
H-1719	-0.7093558311462402	▁re hospital ization
D-1719	-0.7093558311462402	rehospitalization
P-1719	-1.7081 -0.1159 -1.0836 -0.3667 -0.2726
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients ; hfpef ; adverse outcomes
H-237	-0.8139239549636841	▁ HF p EF
D-237	-0.8139239549636841	HFpEF
P-237	-2.0122 -1.2863 -0.0822 -0.7540 -0.4373 -0.3115
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule ; patients ; cad ; patients ; cad
H-1191	-0.952919065952301	▁CAD ▁; ▁CAD
D-1191	-0.952919065952301	CAD ; CAD
P-1191	-0.8847 -0.4327 -2.7988 -0.3684 -0.2800
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes mellitus ; cardiovascular disease ; baseline
H-630	-0.39545732736587524	▁diabetes ▁mell itus ▁; ▁cardiovascular ▁disease
D-630	-0.39545732736587524	diabetes mellitus ; cardiovascular disease
P-630	-0.3989 -0.0177 -0.1751 -0.2779 -0.2040 -1.4569 -0.3210 -0.3122
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia ; rv function
H-1159	-0.5934033393859863	▁cache xia ▁; ▁ rv ▁function ▁; ▁body ▁composition
D-1159	-0.5934033393859863	cachexia ; rv function ; body composition
P-1159	-1.1608 -0.3683 -0.3585 -0.6621 -1.0825 -0.2698 -0.3547 -1.5701 -0.0862 -0.3737 -0.2407
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic ; rule ; prospectively
H-1188	-1.4235881567001343	
D-1188	-1.4235881567001343	
P-1188	-2.5644 -0.2828
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo ; egfr ; egfr
H-1392	-1.3854488134384155	▁ec mo ▁group ▁; ▁e g FR ▁; ▁e g FR
D-1392	-1.3854488134384155	ecmo group ; egFR ; egFR
P-1392	-0.9115 -3.6125 -2.2001 -0.2766 -0.1631 -2.3938 -2.2031 -0.3245 -0.3599 -2.5324 -2.3748 -0.3806 -0.2779
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise ; haemodynamic ; pulmonary
H-1277	-0.5692601799964905	▁ha emo dynamic ▁; ▁pulmonar y ▁; ▁per i pher al ▁ab normal ities
D-1277	-0.5692601799964905	haemodynamic ; pulmonary ; peripheral abnormalities
P-1277	-0.6340 -0.1421 -0.0190 -0.2552 -0.1391 -1.0932 -0.3114 -0.3819 -0.3664 -0.1523 -0.2195 -0.0267 -0.4430 -4.2911 -0.3424 -0.2907
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital ; cardiac ; hospital ; south dakota
H-1577	-1.1319161653518677	▁hospital ▁; ▁cardiac ▁special ty ▁hospital ▁; ▁South ▁da kota
D-1577	-1.1319161653518677	hospital ; cardiac specialty hospital ; South dakota
P-1577	-7.5381 -0.2741 -0.0642 -0.5165 -0.1784 -0.8679 -0.2546 -2.4714 -0.6915 -0.0861 -0.3536 -0.2865
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality ; readmission
H-207	-0.8066176176071167	▁cognitive ▁im pair ment
D-207	-0.8066176176071167	cognitive impairment
P-207	-0.6767 -0.5225 -0.2325 -1.9303 -1.1636 -0.3141
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications ; acs ; patients ; patients ; vad
H-1286	-1.0046873092651367	▁ac s ▁; ▁MT ▁; ▁ VAD
D-1286	-1.0046873092651367	acs ; MT ; VAD
P-1286	-2.9534 -0.4357 -0.5511 -1.8229 -0.3974 -1.8031 -0.2846 -0.4918 -0.3023
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd ; psoriasis ; hazard ratio ; confidence interval
H-1563	-0.6772969365119934	▁CV d ▁; ▁psoriasis
D-1563	-0.6772969365119934	CVd ; psoriasis
P-1563	-1.8501 -0.9033 -0.3093 -0.0877 -0.6136 -0.2998
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy substrate metabolism ; hearts ; aac
H-1781	-0.6594743132591248	▁energy ▁substrat e ▁metabolism ▁; ▁isola ted ▁working ▁heart s ▁; ▁a ac
D-1781	-0.6594743132591248	energy substrate metabolism ; isolated working hearts ; aac
P-1781	-1.2299 -0.0639 -0.1469 -0.3991 -0.2955 -1.3186 -0.8016 -0.8292 -0.8887 -0.4031 -0.3095 -0.7958 -1.8260 -0.3371 -0.2473
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence ; schfi v.6.2 ; clinical
H-1509	-1.765902042388916	▁ sche i
D-1509	-1.765902042388916	schei
P-1509	-0.4201 -2.2724 -5.4577 -0.4303 -0.2490
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam study ; psoriasis ; cardiovascular ; outcomes
H-1556	-0.7795482277870178	▁Rotterdam ▁; ▁psoriasis ▁; ▁cardiovascular ▁outcome s
D-1556	-0.7795482277870178	Rotterdam ; psoriasis ; cardiovascular outcomes
P-1556	-1.6886 -2.0233 -0.5628 -0.2539 -0.2686 -1.2058 -0.3738 -0.3927 -0.2464
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf antagonists ; nbdmard
H-607	-0.7857092618942261	▁HR ▁; ▁ nc w ▁; ▁n b DM ARD
D-607	-0.7857092618942261	HR ; ncw ; nbDMARD
P-607	-1.2131 -0.2805 -1.1153 -1.2455 -1.3211 -0.4124 -0.1321 -0.0690 -1.7376 -1.2217 -0.3743 -0.3060
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone ; hyperkalemia ; acute kidney injury
H-445	-0.40534332394599915	▁Spir ono lac tone ▁; ▁hyper kal emia ▁; ▁ki dne y ▁injury
D-445	-0.40534332394599915	Spironolactone ; hyperkalemia ; kidney injury
P-445	-0.5144 -0.3289 -0.0718 -0.1320 -0.3202 -0.2694 -0.3915 -0.8979 -0.2955 -0.3860 -1.0123 -0.4730 -0.2747 -0.4367 -0.2759
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary ; congenital ; heart ; death
H-1906	-1.0606225728988647	▁heart ▁; ▁non trau matic ▁death
D-1906	-1.0606225728988647	heart ; nontraumatic death
P-1906	-4.8472 -0.2976 -0.4535 -0.1150 -1.0083 -0.8166 -0.6002 -0.3466
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan circulation ; skeletal muscle ; metabolic
H-1494	-0.5475483536720276	▁Font an ▁circulation ▁; ▁skelet al ▁muscle ▁mass ▁; ▁metabol ic ▁ab normal ities
D-1494	-0.5475483536720276	Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
P-1494	-0.6663 -0.6867 -0.1022 -0.2042 -0.2985 -0.2745 -1.1959 -0.2709 -0.3151 -0.1245 -0.3887 -0.0639 -0.3366 -3.1995 -0.3814 -0.2519
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based ; patient ; outcomes
H-85	-0.5560304522514343	
D-85	-0.5560304522514343	
P-85	-0.7887 -0.3234
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular ; conditions ; patients ; hf
H-694	-1.2967636585235596	▁cardiovascular ▁conditions ▁; HF
D-694	-1.2967636585235596	cardiovascular conditions ;HF
P-694	-1.9116 -2.8058 -0.3602 -2.0621 -0.3399 -0.3009
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients ; heartmate ii ; lvad
H-303	-0.6414979100227356	▁isola ted ▁Heart Mate ▁i ▁l VAD
D-303	-0.6414979100227356	isolated HeartMate i lVAD
P-303	-0.7390 -1.2310 -0.7557 -0.3765 -0.5638 -0.9179 -0.2591 -0.5393 -0.3912
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin ; lvad ; postoperative
H-536	-0.6275190711021423	▁album in ▁levels ▁; ▁l VAD
D-536	-0.6275190711021423	albumin levels ; lVAD
P-536	-0.8019 -0.6109 -0.6617 -0.3924 -0.2704 -0.2813 -1.6918 -0.3098
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid receptor antagonists
H-1709	-0.5240825414657593	▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁race
D-1709	-0.5240825414657593	mineralocorticoid receptor antagonists ; race
P-1709	-0.2061 -0.4762 -1.3719 -1.3486 -0.4233 -0.0206 -0.0963 -0.0257 -1.6496 -0.3474 -0.2684 -0.3280 -0.2509
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right heart circulation ; right heart failure
H-1459	-1.1225582361221313	▁right ▁heart ▁circulation ▁; ▁right ▁heart ▁failure
D-1459	-1.1225582361221313	right heart circulation ; right heart failure
P-1459	-2.7604 -1.5918 -0.4777 -0.2689 -2.4625 -1.1103 -0.6629 -0.4700 -0.2985
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi ; mi ; hf
H-1104	-1.4669201374053955	▁MI ▁; ▁MI ▁; ▁ HF
D-1104	-1.4669201374053955	MI ; MI ; HF
P-1104	-0.9356 -0.5648 -5.7988 -0.5940 -1.5287 -1.4434 -0.5087 -0.3613
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients ; fontan circulation ; svr ; cardiac index
H-232	-0.44882112741470337	▁Font an ▁circulation ▁; ▁s VR ▁index ▁; ▁cardiac ▁index
D-232	-0.44882112741470337	Fontan circulation ; sVR index ; cardiac index
P-232	-0.6352 -0.3520 -0.1422 -0.2515 -0.8743 -1.6692 -0.0469 -0.2556 -0.2222 -0.1044 -0.5367 -0.2958
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients ; lvad ; patients ; biventricular support
H-297	-0.8448557257652283	▁isola ted ▁l VAD ▁; ▁patients
D-297	-0.8448557257652283	isolated lVAD ; patients
P-297	-0.1557 -0.8015 -0.2285 -0.1898 -0.4196 -2.7860 -1.8059 -0.3718
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health ; health ; u.s. ; drug ; administration
H-1830	-1.0056239366531372	▁health ▁insurance ▁; ▁health ▁system ▁; ▁u . s . ▁Food ▁and ▁Drug ▁Administration
D-1830	-1.0056239366531372	health insurance ; health system ; u.s. Food and Drug Administration
P-1830	-2.3694 -0.8019 -0.2977 -1.1334 -0.2024 -0.5363 -4.5429 -0.4166 -0.3465 -0.2827 -1.2063 -2.4657 -0.3484 -0.2968 -0.4723 -0.3707
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp ; patients ; acute heart failure
H-262	-0.951470673084259	▁cut off ▁value ▁; ▁NT - pro b NP ▁testing ▁; ▁ED ▁; ▁a cute ▁heart ▁failure
D-262	-0.951470673084259	cutoff value ; NT-probNP testing ; ED ; acute heart failure
P-262	-1.6347 -0.9059 -1.7586 -0.3072 -4.0417 -0.1205 -0.0741 -1.2953 -1.1953 -1.2599 -0.3076 -0.6152 -0.6392 -1.1246 -0.3250 -1.1955 -0.4413 -0.4881 -0.3482
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension ; diabetes ; ischemic ; etiology
H-1635	-0.3373812139034271	▁black s ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁ ische mic ▁et i ology ▁; ▁socio economic ▁status ▁; ▁white s
D-1635	-0.3373812139034271	blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status ; whites
P-1635	-0.9682 -0.7152 -0.2804 -0.2482 -0.1145 -0.2356 -0.1045 -0.2335 -0.3811 -0.1006 -0.5460 -0.0169 -0.1426 -0.0942 -0.2945 -0.1162 -0.7243 -0.2373 -0.3065 -0.7625 -0.4560 -0.4072 -0.2739
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate ; heart failure
H-1544	-1.0691763162612915	▁bis phos phon ate ▁; ▁heart ▁failure
D-1544	-1.0691763162612915	bisphosphonate ; heart failure
P-1544	-1.3142 -0.1149 -0.4520 -3.4474 -0.4828 -2.4876 -0.5526 -0.4839 -0.2873
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape ; functional enrichment analysis ; david
H-1612	-0.5039533376693726	▁Cy to scape ▁; ▁functional ▁en rich ment ▁analysis ▁; ▁da VID
D-1612	-0.5039533376693726	Cytoscape ; functional enrichment analysis ; daVID
P-1612	-0.3336 -0.2448 -0.3184 -0.3213 -0.0968 -0.0959 -0.2527 -1.1939 -1.1414 -0.2841 -1.0481 -0.3339 -1.0903 -0.3002
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling pathway ; remodelling
H-994	-0.4713476896286011	▁Raf - MEK 1/2 - ER k 1/2
D-994	-0.4713476896286011	Raf-MEK1/2-ERk1/2
P-994	-0.0245 -0.3260 -0.0279 -0.3173 -0.2111 -1.4250 -0.3275 -1.0870 -0.6332 -0.3341
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs ; outcomes
H-2009	-0.5475161075592041	▁kosten
D-2009	-0.5475161075592041	kosten
P-2009	-0.9848 -0.3916 -0.2661
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary outcomes
H-620	-0.713924765586853	▁sustain ability
D-620	-0.713924765586853	sustainability
P-620	-0.9418 -1.2618 -0.4046 -0.2475
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-0.8216754198074341	
D-1473	-0.8216754198074341	
P-1473	-1.3774 -0.2659
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-0.9533922672271729	▁patient ▁safety
D-7	-0.9533922672271729	patient safety
P-7	-0.8641 -1.6482 -0.9946 -0.3067
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling ; emd
H-1151	-0.9488149285316467	▁EM d
D-1151	-0.9488149285316467	EMd
P-1151	-2.5331 -0.4532 -0.5706 -0.2383
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf ; transition ; compensated lv hypertrophy ; hf ; hhd
H-283	-0.8310093879699707	▁mouse ▁; HF ▁; ▁compensa ted ▁LV ▁hyper trop hy ▁; ▁ HF ▁; ▁h HD
D-283	-0.8310093879699707	mouse ;HF ; compensated LV hypertrophy ; HF ; hHD
P-283	-0.4134 -0.2815 -3.0474 -0.2460 -0.5817 -0.6281 -0.2326 -0.0777 -0.0466 -2.3575 -0.2627 -1.2328 -1.8415 -0.2138 -0.5398 -2.3603 -0.3584 -0.2363
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis ; heart failure with preserved ejection fraction ; clinical ; doppler echocardiography
H-21	-0.5567727088928223	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁do pp ler ▁e cho card i ography
D-21	-0.5567727088928223	heart failure ; preserved ejection fraction ; doppler echocardiography
P-21	-2.9683 -0.4665 -0.3808 -0.6080 -0.2859 -2.3057 -0.2034 -0.4876 -0.0871 -0.3010 -0.0257 -0.3350 -0.1232 -0.0656 -1.1673 -0.2268 -0.5264 -0.2739 -0.4772 -0.2054 -0.4539 -0.2743
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic peptide ; biomarkers ; point of care ; poc
H-1023	-0.8972564339637756	▁na tri ure tic ▁pe pti de ▁; ▁bio mark ers ▁; PO c
D-1023	-0.8972564339637756	natriuretic peptide ; biomarkers ;POc
P-1023	-1.0033 -2.8172 -1.4296 -1.4943 -0.8782 -0.1858 -0.5350 -1.4336 -0.0307 -0.1553 -0.3263 -0.3071 -1.7792 -1.3657 -0.3419 -0.2731
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
H-1352	-0.45368024706840515	▁antico a gul ants ▁; ▁anti plate let ▁drugs ▁; ▁heart ▁failure ▁; ▁at rial ▁fi bril lation
D-1352	-0.45368024706840515	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
P-1352	-0.3231 -0.4236 -0.6069 -0.5561 -0.3140 -0.0215 -0.1725 -0.2443 -0.3120 -0.2846 -1.9784 -0.4253 -0.2829 -1.3119 -0.4439 -0.3898 -0.1042 -0.2808 -0.3564 -0.2414
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic ; parasympathetic activity ; hf ; symptoms ; disease
H-1868	-0.7896388173103333	▁sympa the tic ▁; ▁para sy mpa the tic ▁activity ▁; ▁ HF
D-1868	-0.7896388173103333	sympathetic ; parasympathetic activity ; HF
P-1868	-0.2941 -0.9761 -0.8242 -0.2583 -0.1143 -0.5920 -0.5187 -1.8405 -1.5475 -1.4298 -0.2796 -1.4787 -1.0765 -0.3898 -0.2244
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global left ventricular longitudinal systolic strain ; cardiovascular events ; patients ; atrial fibrillation
H-808	-0.47048717737197876	▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation
D-808	-0.47048717737197876	left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
P-808	-1.1886 -0.5874 -2.1654 -0.4830 -0.2043 -0.4025 -0.0935 -0.0560 -0.1705 -0.0935 -0.0980 -0.2869 -0.1530 -0.7444 -0.2569 -1.3323 -0.4390 -0.4416 -0.0955 -0.3383 -0.4648 -0.2556
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up ; deaths ; heart transplantations ; lv assist device implantations ; heart failure ; admissions
H-434	-0.8345451354980469	▁follow - up ▁; ▁heart ▁transplant ations ▁; LV ▁assist ▁device ▁implant ations ▁; ▁heart ▁failure ▁ad missions
D-434	-0.8345451354980469	follow-up ; heart transplantations ;LV assist device implantations ; heart failure admissions
P-434	-0.6415 -0.2421 -0.0365 -0.3691 -3.1523 -0.3669 -0.5325 -0.4053 -1.4238 -1.5311 -0.1393 -0.3607 -0.1757 -0.2828 -2.1917 -0.9679 -2.9891 -0.1361 -0.4107 -0.3358
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported ; functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-333	-0.42031097412109375	▁functional ▁mit ral ▁sten osis ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation
D-333	-0.42031097412109375	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
P-333	-0.3413 -1.6674 -0.2892 -0.0186 -0.1811 -0.3898 -0.0385 -1.0226 -0.1529 -0.2736 -1.3866 -0.3163 -0.1967 -0.1024 -0.2685 -0.6434 -0.3813 -0.0702 -0.1424 -0.7793 -0.1588 -0.5383 -0.3079
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine oxidase inhibition ; left ventricular ; systolic ; diastolic function ; cardiac volume overload
H-469	-0.6563229560852051	▁Xan thi ne ▁oxid ase ▁inhibi tion ▁; ▁vent ri cular ▁sy sto lic ▁; ▁dia sto lic ▁function ▁; ▁cardiac ▁volume ▁over load
D-469	-0.6563229560852051	Xanthine oxidase inhibition ; ventricular systolic ; diastolic function ; cardiac volume overload
P-469	-0.0369 -0.9082 -1.9228 -0.2071 -3.2894 -0.0598 -2.7582 -0.3610 -0.1242 -2.3579 -0.6102 -0.1277 -0.2270 -0.1073 -0.3210 -0.0138 -0.1318 -0.1137 -0.1828 -0.3449 -0.1817 -0.5769 -1.0465 -0.1236 -0.6519 -0.2783
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence ; bnp ; patients ; pad ; bnp ; hf
H-1572	-1.1558877229690552	▁b NP ▁; PAD ▁; ▁b NP ▁; ▁ HF
D-1572	-1.1558877229690552	bNP ;PAD ; bNP ; HF
P-1572	-1.9791 -1.4402 -0.9242 -1.1732 -0.3219 -2.5378 -1.2910 -0.5277 -2.0669 -0.9627 -0.3646 -0.2815
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients ; heart failure ; hf ; heart failure adherence and retention trial ; hart
H-238	-0.9607011079788208	▁heart ▁failure ▁; HF ▁; ▁Heart ▁Fail ure ▁; ▁ad her ence ▁; ▁re tention ▁tri al ▁; HAR t
D-238	-0.9607011079788208	heart failure ;HF ; Heart Failure ; adherence ; retention trial ;HARt
P-238	-2.9864 -0.4355 -0.3237 -1.1449 -0.3526 -0.6742 -0.4308 -1.5966 -1.0127 -4.3235 -0.7840 -1.8468 -1.6470 -0.3576 -0.1344 -0.1877 -0.1901 -0.2835 -1.3928 -0.4163 -0.3263 -0.2880
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf with preserved ejection fraction ; hfpef ; hypertension
H-1076	-0.7657716870307922	HF ▁met ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁hyper tension
D-1076	-0.7657716870307922	HF met preserved ejection fraction ;HFpEF ; hypertension
P-1076	-1.7624 -2.3984 -0.4890 -0.2571 -3.6237 -0.2028 -0.5108 -0.1655 -0.3776 -0.0453 -0.2840 -1.2028 -0.0854 -1.1166 -0.2861 -0.8727 -0.1676 -0.4294 -0.2725
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end points ; nyha functional class ; quality-of-life ; 6-minute hall walk
H-1873	-0.5357478857040405	▁NY ha ▁; ▁functional ▁class ▁; ▁quality - of - life ▁score
D-1873	-0.5357478857040405	NYha ; functional class ; quality-of-life score
P-1873	-1.0068 -2.1319 -0.9656 -0.0481 -0.2290 -0.2903 -0.2307 -0.1701 -0.0401 -0.3826 -0.7245 -0.5815 -0.4095 -0.2897
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial infarction ; left anterior descending coronary artery occlusion
H-1338	-0.7589291334152222	▁My o card ial ▁in far ction ▁; ▁left ▁anterior ▁descend ing ▁; ▁corona ry ▁arter y ▁oc clusi on
D-1338	-0.7589291334152222	Myocardial infarction ; left anterior descending ; coronary artery occlusion
P-1338	-2.6049 -0.5706 -0.7073 -1.0731 -0.1501 -1.1670 -0.5790 -0.3917 -1.8056 -0.6426 -0.1445 -0.1683 -0.3956 -0.3498 -2.4860 -0.0405 -1.9710 -0.0233 -0.0065 -0.6328 -0.5221 -0.2640
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical ; symptoms ; hfpef ; symptoms ; breathlessness ; fluid retention
H-1891	-0.8140583634376526	▁ HF p EF ▁; ▁breath less heid ▁; ▁fatigue ▁; ▁fluid ▁re tention
D-1891	-0.8140583634376526	HFpEF ; breathlessheid ; fatigue ; fluid retention
P-1891	-2.1583 -1.3674 -0.0894 -1.3423 -0.5586 -1.3019 -0.5319 -3.0271 -0.3169 -0.3672 -0.2824 -0.0275 -0.2968 -0.7588 -0.3223 -0.2761
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection ; nt-probnp ; antibodies ; terminal
H-1521	-0.620616614818573	▁immun o det ection ▁; ▁NT - pro b NP ▁; ▁anti bo dies
D-1521	-0.620616614818573	immunodetection ; NT-probNP ; antibodies
P-1521	-0.2172 -0.5190 -0.5805 -1.3217 -0.2996 -0.8784 -0.1189 -0.1001 -1.4256 -1.7403 -0.3327 -0.0441 -0.0651 -1.6274 -0.3836 -0.2755
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; heart failure
H-574	-0.8500076532363892	▁Nordic ▁walking ▁; ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁heart ▁failure
D-574	-0.8500076532363892	Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
P-574	-1.5048 -1.8653 -0.3756 -0.3157 -0.1451 -1.1092 -0.4923 -0.7007 -1.1585 -0.3817 -2.3979 -0.6094 -0.5290 -0.3150
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
H-1132	-0.41603323817253113	▁para sy mpa the tic ▁tone ▁; ▁py rido stig mine ▁; ▁vent ri cular ▁dys function ▁; ▁heart ▁failure
D-1132	-0.41603323817253113	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
P-1132	-0.2112 -0.3881 -0.3187 -0.8502 -1.2431 -0.2252 -0.3069 -0.0076 -0.0255 -0.0073 -0.1567 -0.3450 -0.1467 -1.7429 -0.7954 -0.0801 -0.1289 -0.2548 -0.8390 -0.3746 -0.4502 -0.2547
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade ; cardiac angiogenesis ; heart failure ; vegf signaling pathway
H-459	-0.6356492638587952	▁β - Block ade ▁; ▁cardiac ▁ang io gene sis ▁; ▁heart ▁failure ▁; ▁VE GF ▁signal ing ▁path way
D-459	-0.6356492638587952	β-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
P-459	-0.4712 -0.1372 -0.5357 -1.3051 -0.5286 -0.2999 -0.5245 -1.2232 -0.5303 -1.7451 -0.4208 -0.9833 -0.4971 -0.3568 -2.0911 -0.4619 -0.3146 -0.5024 -0.0564 -0.2240 -0.4551 -0.3200
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes ; myocardial ischemic events ; patients ; cardiac resynchronization therapy
H-101	-0.6039606332778931	▁my o card ial ▁ ische mic ▁events ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-101	-0.6039606332778931	myocardial ischemic events ; cardiac resynchronization therapy
P-101	-3.4280 -0.4427 -0.6924 -1.1202 -0.3118 -0.1326 -0.8527 -0.5616 -0.2770 -0.2370 -0.1459 -0.0534 -0.0154 -1.5488 -0.2630 -0.0474 -0.4207 -0.3207
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report ; patients ; aortic valve ; surgery ; post-lvad ai
H-544	-0.6784513592720032	▁a or tic ▁val ve ▁surgery ▁; ▁new - ons et ▁post - ▁l VAD ▁; ▁AI
D-544	-0.6784513592720032	aortic valve surgery ; new-onset post- lVAD ; AI
P-544	-0.2728 -0.1227 -1.0577 -0.6017 -0.1675 -0.8722 -0.3221 -2.1378 -0.0663 -0.6872 -0.0385 -0.0431 -0.0358 -2.0958 -0.2077 -2.2409 -1.2404 -0.3842 -0.2962
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart ; hr reduction ; patients ; systolic heart failure
H-527	-0.5497605800628662	▁un load ing ▁; ▁heart ▁; ▁isola ted ▁HR ▁re duction ▁; ▁sy sto lic ▁heart ▁failure
D-527	-0.5497605800628662	unloading ; heart ; isolated HR reduction ; systolic heart failure
P-527	-0.1621 -0.2042 -0.1850 -0.7334 -3.6271 -0.3172 -0.1649 -0.4565 -0.8839 -0.4818 -0.1314 -0.3008 -0.0676 -0.1272 -0.3546 -1.1661 -0.3559 -0.4500 -0.2759
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone ; diagnosed ; systolic heart failure ; clinical
H-439	-0.4478687047958374	▁spi rono lac tone ▁; ▁adults ▁; ▁sy sto lic ▁heart ▁failure
D-439	-0.4478687047958374	spironolactone ; adults ; systolic heart failure
P-439	-0.1042 -0.1403 -0.2149 -0.2062 -0.4007 -1.7619 -0.3307 -0.1556 -0.2389 -0.3644 -1.0477 -0.5659 -0.4590 -0.2798
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart failure ; clinical ; medicine ; prevalence ; coronary disease
H-980	-0.8148054480552673	▁Heart ▁failure ▁; ▁medicine ▁; ▁a ther omat ous ▁corona ry ▁disease
D-980	-0.8148054480552673	Heart failure ; medicine ; atheromatous coronary disease
P-980	-2.3466 -0.4440 -0.2390 -1.9608 -0.2220 -0.1879 -0.5185 -0.0560 -1.3112 -0.3275 -2.6331 -0.4821 -0.3893 -0.2895
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart failure ; hf ; latin america ; health ; hf
H-1789	-1.180996298789978	▁Heart ▁failure ▁; HF ▁; ▁Latin ▁America ▁; ▁l issa bon ▁; ▁ HF
D-1789	-1.180996298789978	Heart failure ;HF ; Latin America ; lissabon ; HF
P-1789	-1.4439 -0.3095 -0.2207 -1.1341 -0.3389 -1.2367 -1.7579 -0.2741 -1.0599 -4.6127 -0.5908 -0.2967 -3.2631 -1.6833 -0.3870 -0.2868
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization ; medicare ; discharged ; nursing
H-1710	-0.3870677947998047	▁re hospital ization ▁; ▁medica re ▁; ▁dis charge d ▁; ▁skille d ▁nur sing ▁facilities
D-1710	-0.3870677947998047	rehospitalization ; medicare ; discharged ; skilled nursing facilities
P-1710	-1.0816 -0.1601 -0.9188 -0.3499 -0.0365 -0.2018 -0.3294 -1.1709 -0.0948 -0.1121 -0.3022 -0.3557 -0.0902 -0.8101 -0.2869 -0.0800 -0.3179 -0.2683
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death ; hf ; hospitalization ; crt ; hazard ratio
H-755	-1.0372236967086792	▁ HF ▁; ▁c RT ▁; haz ard ▁ratio
D-755	-1.0372236967086792	HF ; cRT ;hazard ratio
P-755	-1.6455 -1.7706 -0.5476 -1.8169 -4.0098 -0.5130 -0.0808 -0.1013 -0.1288 -0.4467 -0.3486
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative care ; patients ; terminal ; disease ; therapeutic
H-1820	-1.3192249536514282	▁palli ative ▁; ▁advanced ▁disease
D-1820	-1.3192249536514282	palliative ; advanced disease
P-1820	-0.4755 -1.4395 -1.3769 -4.1967 -0.9809 -0.4341 -0.3309
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic ; hfpef ; medical history ; physical examination
H-1892	-1.363513469696045	▁diagnostic ▁test ▁; ▁ HF p EF ▁; ▁medical ▁; ▁physical
D-1892	-1.363513469696045	diagnostic test ; HFpEF ; medical ; physical
P-1892	-1.4401 -1.7848 -0.3390 -2.5408 -1.6261 -0.0844 -1.1143 -0.7477 -2.8156 -2.6015 -0.8627 -1.4480 -0.3206
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative stress ; gtpase ; rac1 ; activity ; hearts
H-281	-1.034857988357544	▁o xi da tive ▁stress ▁; ▁GT Pas e ▁Rac 1 ▁; ▁heart s ▁; ▁ ANS ▁mi ce
D-281	-1.034857988357544	oxidative stress ; GTPase Rac1 ; hearts ; ANS mice
P-281	-2.8473 -1.4699 -0.0666 -1.1565 -0.3789 -0.2971 -1.6135 -2.3025 -0.0144 -0.1004 -2.5873 -0.2366 -1.9930 -0.2840 -0.2171 -1.4065 -2.7592 -0.8089 -0.6257 -0.3387 -0.2277
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin ; insulin resistance ; monocytes ; inflammatory
H-928	-0.24130436778068542	▁circula ting ▁media tor ▁; ▁insulin ▁resist ance ▁; ▁mono cy tes ▁; ▁infla mma tory ▁stimul i
D-928	-0.24130436778068542	circulating mediator ; insulin resistance ; monocytes ; inflammatory stimuli
P-928	-0.1840 -0.5056 -0.0913 -0.0613 -0.2934 -0.1016 -0.1062 -0.3335 -0.2763 -0.0261 -0.0872 -0.1327 -0.2952 -0.2746 -0.2546 -0.3009 -0.1165 -0.6858 -0.3680 -0.3311
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end point ; cardiovascular death ; cardiac transplant ; secondary end point ; death
H-1757	-0.808737576007843	▁cardiovascular ▁death ▁; ▁urgent ▁cardiac ▁transplant ▁; ▁death
D-1757	-0.808737576007843	cardiovascular death ; urgent cardiac transplant ; death
P-1757	-1.1025 -1.8324 -0.2781 -0.4255 -0.0703 -0.3583 -0.2486 -2.9929 -0.4898 -0.2891
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications ; outpatients ; heart failure ; ncdr pinnacle
H-658	-1.1428245306015015	▁medication s ▁; ▁out patient s ▁; ▁heart ▁failure ▁; ▁ nc w ▁PIN NA CLE ▁program
D-658	-1.1428245306015015	medications ; outpatients ; heart failure ; ncw PINNACLE program
P-658	-1.8178 -0.4702 -0.5061 -3.7424 -0.1052 -0.3270 -1.6589 -1.3980 -0.5005 -0.4435 -2.0831 -0.0115 -2.8801 -1.0503 -1.4287 -1.2700 -1.2700 -0.4240 -0.3264
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; patients ; heart failure
H-1110	-0.6842572689056396	▁beta - block ers ▁; ▁cardiac ▁sympa the tic ▁activity ▁; ▁hemos tas is ▁; ▁heart ▁failure
D-1110	-0.6842572689056396	beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
P-1110	-1.3157 -0.2405 -0.5142 -0.5152 -0.5061 -0.1790 -0.1527 -0.6663 -2.0288 -1.0224 -0.3455 -0.2183 -0.3083 -0.9546 -0.3793 -2.4328 -0.4315 -0.5005 -0.2893
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf ; patients ; emergency department ; intubated
H-210	-0.6307748556137085	▁CHF ▁; ▁emergency ▁department ▁; ▁d c ▁; ▁in tuba ted
D-210	-0.6307748556137085	CHF ; emergency department ; dc ; intubated
P-210	-0.4124 -0.3557 -0.3305 -0.0960 -0.2294 -1.1132 -3.6923 -0.3084 -0.1159 -0.2285 -0.7073 -0.3404 -0.2701
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality ; lcx ; lad ; disease
H-513	-0.8828099966049194	▁l c x ▁; ▁ LAD
D-513	-0.8828099966049194	lcx ; LAD
P-513	-0.1491 -2.4378 -1.4039 -0.3484 -1.7174 -0.3432 -0.3453 -0.3174
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv dysfunction ; prognosis ; hf
H-1160	-0.7433925867080688	RV ▁dys function ▁; ▁weight ▁loss ▁; ▁ab normal ▁body ▁composition ▁; HF
D-1160	-0.7433925867080688	RV dysfunction ; weight loss ; abnormal body composition ;HF
P-1160	-2.8276 -0.0790 -0.1632 -0.2580 -0.6439 -0.6153 -0.2694 -0.9170 -0.2687 -1.4545 -0.0546 -0.2649 -2.7602 -0.3009 -0.2736
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients ; diagnosis ; congestive heart failure
H-1578	-1.0764282941818237	▁con ges tive ▁heart ▁failure
D-1578	-1.0764282941818237	congestive heart failure
P-1578	-1.2046 -0.7952 -3.2099 -1.1021 -0.3896 -0.5181 -0.3155
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial structure ; sarcomeric microstructure
H-1250	-0.6048294305801392	▁mito cho ndri al ▁structure ▁; ▁sar come ric ▁micro structure
D-1250	-0.6048294305801392	mitochondrial structure ; sarcomeric microstructure
P-1250	-0.1153 -0.8657 -0.1553 -0.1844 -1.7683 -0.2918 -0.1104 -0.7868 -2.2453 -0.0628 -0.6636 -0.3671 -0.2460
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart failure ; emergency department ; patient ; outcomes
H-462	-1.0097415447235107	▁he art ▁failure ▁; ▁Emer gen cy ▁Department ▁; ED ▁; ▁ED
D-462	-1.0097415447235107	heart failure ; Emergency Department ;ED ; ED
P-462	-2.6993 -2.4367 -0.4487 -0.3138 -0.2932 -1.2126 -0.3025 -0.5638 -0.2426 -3.6747 -0.3934 -0.7792 -0.4847 -0.2914
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ; ischemic heart failure
H-1613	-0.6032535433769226	▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure
D-1613	-0.6032535433769226	non-ischemic ; ischemic heart failure
P-1613	-0.5829 -0.1163 -0.1713 -0.5512 -1.3686 -0.3781 -0.1226 -1.2912 -1.5133 -0.4171 -0.4166 -0.3098
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr ; acr ; cms ; correlated
H-141	-0.7757219672203064	▁p p ▁; ▁a cr ▁; ▁CMS
D-141	-0.7757219672203064	pp ; acr ; CMS
P-141	-0.9035 -2.9392 -0.4285 -0.7758 -0.3001 -0.3153 -0.3273 -0.6767 -0.3152
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut ; inflammation ; heart failure ; patients ; heart failure
H-1363	-0.9893041253089905	▁gut ▁; ▁ inflammation ▁; ▁dieta ry ▁intervention s ▁; ▁heart ▁failure ▁; ▁heart ▁failure
D-1363	-0.9893041253089905	gut ; inflammation ; dietary interventions ; heart failure ; heart failure
P-1363	-1.6841 -0.2473 -0.3613 -0.6379 -0.3426 -3.1811 -1.7358 -0.7574 -0.3249 -0.3802 -1.1679 -0.4125 -0.6328 -2.6575 -0.3575 -1.6579 -0.2795
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients ; heart failure and reduced ejection fraction
H-668	-0.6163673400878906	▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-668	-0.6163673400878906	heart failure ; ejection fraction
P-668	-3.6525 -0.4835 -0.3250 -0.1930 -0.3456 -0.0743 -0.2763 -0.0381 -0.4597 -0.3156
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous ; symptoms ; patients ; heart failure
H-51	-0.8704196810722351	▁Intra ven ous ▁ir on ▁; ▁heart ▁failure ▁; ▁ir on ▁de fici en cy
D-51	-0.8704196810722351	Intravenous iron ; heart failure ; iron deficiency
P-51	-1.2726 -0.2192 -3.9796 -0.4559 -0.7155 -0.4454 -2.4901 -0.4993 -0.3400 -0.8173 -0.6188 -0.7359 -0.1147 -1.0009 -0.2844 -0.5181 -0.2895
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait ; therapy ; lokomat ; heart failure ; patients
H-1912	-0.716911256313324	▁robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ▁; ▁system ▁; ▁heart ▁failure
D-1912	-0.716911256313324	robot-assisted gait therapy ; Lokomat ; system ; heart failure
P-1912	-3.7976 -0.2772 -0.0778 -0.4156 -0.6355 -0.4203 -0.3462 -0.0618 -0.3190 -0.3595 -0.0165 -1.7564 -0.2781 -0.3737 -0.9072 -0.3431 -2.2624 -0.2566
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions ; remodelling ; leading ; heart failure
H-991	-1.2788962125778198	▁stress ▁conditions ▁; ▁heart ▁failure
D-991	-1.2788962125778198	stress conditions ; heart failure
P-991	-3.1036 -0.9249 -0.3249 -3.3501 -0.5729 -0.3601 -0.3157
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.2311149686574936	▁significant
D-158	-0.2311149686574936	significant
P-158	-0.0168 -0.4286 -0.2480
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission ; patients
H-1581	-0.4758773148059845	▁significant
D-1581	-0.4758773148059845	significant
P-1581	-0.1401 -0.9699 -0.3176
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-1.0577290058135986	
D-609	-1.0577290058135986	
P-609	-1.8358 -0.2796
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.37231194972991943	
D-86	-0.37231194972991943	
P-86	-0.4832 -0.2615
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis ; systemic ; followed up
H-1559	-1.0348752737045288	▁psoriasis ▁; UV ▁treatment
D-1559	-1.0348752737045288	psoriasis ;UV treatment
P-1559	-0.1150 -0.4838 -2.8587 -2.0730 -0.3979 -0.2808
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp ; hf ; patient ; plasma ; immunoprecipitation ; mass spectrometric analysis
H-1515	-0.8367039561271667	▁NT - pro b NP ▁; HF ▁; ▁plasma ▁; ▁immun o preci pit ation ▁; ▁mass ▁spec tro metric ▁analysis
D-1515	-0.8367039561271667	NT-probNP ;HF ; plasma ; immunoprecipitation ; mass spectrometric analysis
P-1515	-0.5115 -0.1191 -0.0645 -1.6913 -2.9349 -0.4242 -2.3290 -0.8229 -1.8392 -0.3533 -0.0636 -0.3515 -0.7032 -1.7235 -2.4602 -0.4549 -0.1600 -0.1875 -0.1802 -0.4022 -0.6370 -0.4923 -0.3382
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated proteins ; chromatin structure ; changing ; dna ; gene expression profile
H-90	-0.6227083802223206	▁Chro mat in - as soci ated ▁protein s ▁; ▁chr omat in ▁structure ▁; ▁DNA ▁; ▁gene ▁expression ▁profile
D-90	-0.6227083802223206	Chromatin-associated proteins ; chromatin structure ; DNA ; gene expression profile
P-90	-1.7307 -0.7036 -1.7445 -0.3279 -0.1457 -0.0476 -1.0864 -0.9444 -0.7013 -0.3661 -0.1642 -0.2008 -0.7661 -1.1647 -0.2760 -1.5549 -0.4593 -0.3417 -0.2040 -0.0772 -0.3872 -0.3052
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis ; clinical ; prognostic ; diastolic dysfunction ; leading ; hfpef
H-26	-0.5948673486709595	▁dia sto lic ▁dys function ▁; ▁h FP EF
D-26	-0.5948673486709595	diastolic dysfunction ; hFPEF
P-26	-0.0296 -0.2221 -0.1734 -0.0258 -0.0912 -0.2902 -0.9270 -2.1122 -1.9750 -0.4333 -0.2638
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right ventricle ; leads ; stroke volume ; shortens ; left ventricular ejection time ; lvet
H-578	-0.6991159319877625	▁right ▁vent ric le ▁over load ▁; ▁stroke ▁volume ▁; ▁left ▁vent ri cular ▁e je ction ▁time ▁; ▁l VET
D-578	-0.6991159319877625	right ventricle overload ; stroke volume ; left ventricular ejection time ; lVET
P-578	-2.7297 -0.7950 -1.7812 -0.7917 -0.3052 -0.1196 -0.2638 -0.3345 -0.1259 -0.2642 -1.3034 -0.2925 -2.6642 -0.4619 -0.2428 -0.4819 -0.2618 -1.0809 -0.3037 -0.3379 -0.3914 -0.4850 -0.2615
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic receptor blockade ; mortality ; all-cause hospitalizations ; patients ; heart failure ; hf
H-1424	-0.8511170148849487	▁β - Ad r energi c ▁receptor ▁block ade ▁; ▁mortal iteit ▁; ▁heart ▁failure ▁; HF
D-1424	-0.8511170148849487	β-Adrenergic receptor blockade ; mortaliteit ; heart failure ;HF
P-1424	-0.1373 -0.1109 -2.4710 -0.6323 -1.3272 -0.3181 -0.0519 -0.3647 -0.5547 -0.4158 -2.0493 -1.6809 -0.4202 -2.2037 -0.5909 -0.3247 -1.7931 -0.4503 -0.2743
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd ; clinical ; hospitalizations ; complications ; therapy ; end-stage hf
H-895	-0.8216018676757812	▁PD ▁; ▁complica tions ▁; ▁ therapy ▁; ▁ HF
D-895	-0.8216018676757812	PD ; complications ; therapy ; HF
P-895	-1.0945 -0.2316 -0.0842 -1.8597 -0.2154 -0.1801 -0.1905 -0.2493 -3.8844 -1.2072 -0.3816 -0.2807
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal echocardiography ; shunts ; thrombosis
H-1957	-0.42259564995765686	▁trans o es op hage al ▁e cho card i ography ▁; ▁shu nts ▁; ▁patent ▁; ▁ thro mbo sis ▁; ▁migration
D-1957	-0.42259564995765686	transoesophageal echocardiography ; shunts ; patent ; thrombosis ; migration
P-1957	-0.1190 -0.5093 -0.4369 -0.1135 -1.1907 -0.2511 -0.3378 -0.1916 -0.3348 -0.5428 -0.4497 -0.3518 -0.8417 -0.5226 -0.2325 -0.1616 -0.2237 -0.3906 -0.4397 -0.5502 -1.2441 -0.3526 -0.0196 -0.4699 -0.2873
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 ; healthy ; heart muscle ; cells ; phenotype ; pathological ; hypertrophy
H-641	-0.6386584043502808	▁line ▁; ▁mu tant ▁mi ce ▁; ▁hand 2 ▁; ▁healthy ▁heart ▁muscle ▁cell s ▁; ▁path ological ▁hyper trop hy
D-641	-0.6386584043502808	line ; mutant mice ; hand2 ; healthy heart muscle cells ; pathological hypertrophy
P-641	-0.0960 -0.2702 -0.2914 -0.6186 -0.4710 -0.5990 -0.3460 -0.7332 -0.4918 -0.2987 -3.2164 -0.7984 -1.5608 -0.5347 -0.4251 -0.5381 -0.2152 -0.4139 -0.1697 -0.0232 -1.9653 -0.3392 -0.2734
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician ; follow-up ; discharge ; death ; readmission ; patients ; heart failure
H-1413	-1.0472956895828247	▁physician ▁follow - up ▁after ▁dis charge ▁; ▁death ▁; ▁read mission ▁; ▁heart ▁failure
D-1413	-1.0472956895828247	physician follow-up after discharge ; death ; readmission ; heart failure
P-1413	-2.8051 -0.4150 -0.2816 -0.0407 -2.6806 -0.7509 -0.3953 -0.3294 -3.6015 -0.2780 -1.6939 -1.1095 -0.2949 -1.8672 -0.5299 -0.4683 -0.2623
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis ; patients ; adverse events ; echocardiographic ; outcomes
H-914	-0.6226944923400879	▁di al ysis ▁; ▁e cho car dio graphic ▁outcome s
D-914	-0.6226944923400879	dialysis ; echocardiographic outcomes
P-914	-0.4764 -0.2043 -0.1290 -1.4222 -0.5047 -0.4418 -0.0804 -0.9048 -1.1981 -1.6866 -0.3672 -0.3992 -0.2804
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese ; zsf1 ; heart failure with preserved ejection fraction
H-770	-0.8291999697685242	▁z SF 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-770	-0.8291999697685242	zSF1 rats ; heart failure ; ejection fraction
P-770	-2.0760 -3.2430 -2.1484 -0.7557 -0.2312 -0.3298 -1.6816 -0.4976 -0.2793 -0.3830 -0.2744 -0.0988 -0.4094 -0.0413 -0.5126 -0.3052
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory ; hf ; patients ; left ventricular ejection fraction
H-122	-0.7646721601486206	▁ambula tory ▁ HF ▁; ▁vent ri cular ▁e je ction ▁ fraction
D-122	-0.7646721601486206	ambulatory HF ; ventricular ejection fraction
P-122	-0.7738 -0.8386 -0.3572 -0.3584 -0.6807 -3.5704 -1.6557 -0.4988 -0.3984 -0.6249 -0.3704 -0.4677 -0.0417 -0.4964 -0.3369
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt variability ; qtv ; repolarization ; qtv ; cardiac death
H-1435	-1.3551294803619385	▁ QT ▁variabil iteit ▁; Q t ▁; ▁Q t ▁; ▁cardiac ▁death
D-1435	-1.3551294803619385	QT variabiliteit ;Qt ; Qt ; cardiac death
P-1435	-0.5613 -1.6060 -0.0286 -3.2555 -0.2572 -3.3620 -1.8945 -0.3991 -2.9225 -2.1848 -0.2993 -1.6953 -1.1252 -0.4022 -0.3334
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk ; heart ; adipose tissue ; cachectic heart failure ; patients ; prospective study
H-8	-0.6211020350456238	▁Cross - talk ▁; ▁heart ▁; ▁adi pose ▁tissu e ▁; ▁cache ctic ▁heart ▁failure ▁; ▁body ▁composition
D-8	-0.6211020350456238	Cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
P-8	-0.3696 -0.1774 -0.2110 -0.8134 -3.1538 -0.3515 -0.1987 -0.2314 -0.1409 -0.1762 -0.3740 -0.0576 -0.5882 -1.1796 -0.3555 -0.4031 -2.8466 -0.1156 -0.3973 -0.2806
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial tonometry ; lvet ; prognostic ; patients ; precapillary ph ; heart failure
H-579	-0.8017761707305908	▁arterial ▁ton ometr y ▁; ▁l VET ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-579	-0.8017761707305908	arterial tonometry ; lVET ; precapillary PH ; heart failure
P-579	-0.9194 -0.7910 -0.1943 -1.1458 -1.2364 -0.6481 -0.4740 -0.2395 -2.0408 -0.3050 -0.5716 -2.4739 -0.5463 -0.3040 -1.3633 -0.3807 -0.4974 -0.3005
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart magnetic resonance imaging ; chelation ; compliance ; heart disease ; patients ; thalassaemia major
H-744	-0.8315390944480896	▁heart ▁; ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁heart ▁disease ▁; ▁tha lassa emia ▁major
D-744	-0.8315390944480896	heart ; magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia major
P-744	-4.0216 -1.1278 -0.3105 -0.9062 -1.0833 -0.5031 -0.2964 -0.5664 -0.3657 -0.1856 -0.2536 -0.5910 -0.3663 -0.3205 -3.3685 -0.8834 -0.2605 -0.0675 -0.5294 -1.8582 -0.5777 -0.3924 -0.2899
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf ; shift ; chronic heart failure ; chronic heart failure ; cardiology
H-1964	-0.8234250545501709	▁para DIG m - HF ▁; ▁paradigm ▁shift ▁; ▁chronic ▁heart ▁failure ▁; ▁Chro nic ▁heart ▁failure ▁; ▁card i ology
D-1964	-0.8234250545501709	paraDIGm-HF ; paradigm shift ; chronic heart failure ; Chronic heart failure ; cardiology
P-1964	-1.0021 -0.9802 -0.8852 -0.1173 -0.3032 -0.2681 -4.6880 -0.8348 -0.2976 -1.6187 -1.4836 -0.6484 -0.3831 -0.8380 -1.1253 -1.4800 -0.3445 -0.2626 -0.4940 -0.1528 -0.0765 -0.3731 -0.2816
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient ; implantable cardioverter-defibrillator
H-1859	-0.6479928493499756	▁ab m ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1859	-0.6479928493499756	abm ; implantable cardioverter-defibrillator deactivation
P-1859	-1.9722 -0.2465 -0.2831 -0.8607 -0.2681 -1.2430 -0.1956 -0.6945 -0.3152 -0.1313 -0.2895 -1.7378 -0.4032 -0.1447 -0.4885 -0.1057 -2.0867 -0.5594 -0.2860
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new zealand ; renal dnx ; pacing-induced chf
H-1373	-0.6252356767654419	▁New ▁Zealand ▁; ▁White ▁rabbi ts ▁; ▁renal ▁DN x ▁; ▁CHF
D-1373	-0.6252356767654419	New Zealand ; White rabbits ; renal DNx ; CHF
P-1373	-1.7986 -0.3536 -1.7213 -1.5768 -0.0834 -0.2777 -0.3137 -0.1150 -0.9399 -0.2394 -0.3158 -0.2505 -0.4879 -0.2794
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy ; hdl ; chf-nyha-iiib ; hdl
H-258	-1.180058479309082	▁ET ▁; ▁HD l ▁function ▁; ▁ET ▁; ▁CHF - NY ha - III b ▁; ▁HD l ▁function
D-258	-1.180058479309082	ET ; HDl function ; ET ; CHF-NYha-IIIb ; HDl function
P-258	-4.0229 -0.3913 -1.3305 -2.5810 -0.0846 -0.4817 -2.0485 -0.4669 -4.6042 -0.2137 -0.7317 -1.3399 -0.1456 -0.4842 -0.1265 -0.5377 -1.5971 -2.8045 -0.1820 -0.3287 -0.2777
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
H-1647	-0.3798026144504547	▁cat heter ▁ab lation ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁ rhythm ▁control ▁ therapy
D-1647	-0.3798026144504547	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
P-1647	-0.9242 -0.1560 -0.0969 -0.4775 -0.2675 -0.0270 -0.2795 -0.4648 -0.3409 -0.0812 -0.3215 -0.4217 -0.6775 -1.1836 -0.2701 -0.0494 -0.4744 -0.3228
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet ; sensitivity ; specificity ; death ; icu
H-584	-0.7194685935974121	▁l VET ▁; ▁death ▁; ICU
D-584	-0.7194685935974121	lVET ; death ;ICU
P-584	-0.9362 -1.0777 -0.3256 -1.9383 -0.2502 -0.4733 -0.4811 -0.2734
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient ; symptomatic ; therapeutic ; exercise ; hemodynamic
H-1179	-0.5870295166969299	▁ therapeut ic ▁; ▁exercise ▁; ▁hem o dynamic ▁status
D-1179	-0.5870295166969299	therapeutic ; exercise ; hemodynamic status
P-1179	-2.4075 -0.2101 -0.7089 -0.3663 -1.3457 -0.2600 -0.3862 -0.4123 -0.0597 -0.1704 -0.4256 -0.2916
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac failure ; death ; patients ; type 2 diabetes ; diabetes ; heart failure
H-652	-0.7985744476318359	▁Card iac ▁failure ▁; ▁diabetes ▁; ▁molecular ▁mechanism ▁; ▁diabetes ▁; ▁heart ▁failure
D-652	-0.7985744476318359	Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
P-652	-2.9798 -1.3739 -0.4504 -0.3254 -1.8598 -0.3401 -0.1591 -0.0139 -0.3692 -0.3598 -0.3130 -2.1874 -0.5876 -0.3699 -0.2894
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive ; patients ; pulmonary hypertension ; heart failure
H-577	-0.9748251438140869	▁pulmonar y ▁hyper tension ▁; PH ▁; ▁heart ▁failure
D-577	-0.9748251438140869	pulmonary hypertension ;PH ; heart failure
P-577	-4.1612 -1.2719 -0.1484 -0.1931 -0.3081 -1.6027 -0.3254 -1.5293 -0.3621 -0.4796 -0.3414
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker ; patients ; resting hr ; bpm ; p value
H-1941	-0.6167216897010803	▁Beta - block er ▁dose ▁; ▁rest ing ▁; ▁HR ▁; ▁bp m
D-1941	-0.6167216897010803	Beta-blocker dose ; resting ; HR ; bpm
P-1941	-0.4648 -0.1868 -0.2238 -0.4034 -1.6822 -0.4178 -0.7013 -0.3063 -0.7010 -1.6363 -1.3822 -0.2057 -0.3181 -0.4054 -0.2156
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis ; patients ; chf ; therapeutic ; neurohormonal systems
H-635	-0.3738367557525635	▁CHF ▁; ▁ therapeut ic ▁interrupt ion ▁; ▁activa ted ▁neuro hormon al ▁systems
D-635	-0.3738367557525635	CHF ; therapeutic interruption ; activated neurohormonal systems
P-635	-1.0528 -0.3758 -0.3727 -0.5321 -0.8296 -0.0573 -0.1757 -0.3322 -0.0103 -0.9247 -0.1677 -0.1967 -0.1166 -0.0971 -0.4518 -0.2884
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients ; uptitration ; heart rate ; renal function ; spironolactone
H-180	-0.8692802786827087	▁heart ▁rate ▁; ▁renal ▁function ▁; ▁spi rono lac tone
D-180	-0.8692802786827087	heart rate ; renal function ; spironolactone
P-180	-6.7253 -0.8501 -0.3403 -0.2660 -0.2716 -0.4372 -0.1709 -0.1510 -0.1967 -0.1888 -0.4419 -0.3916
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence ; micrornas ; mirnas ; pathogenesis ; heart failure
H-1481	-0.4121285676956177	▁micro RNA s ▁; mi RNA s ▁; ▁heart ▁failure
D-1481	-0.4121285676956177	microRNAs ;miRNAs ; heart failure
P-1481	-0.0820 -0.3860 -0.3862 -0.2723 -0.5675 -0.1722 -0.3031 -0.3234 -1.2971 -0.4402 -0.4475 -0.2680
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping ; mri ; tidal respiration ; myocardial t1 ; heart failure
H-1054	-0.5749890208244324	▁multi acquisition ▁; ▁t 1- ma pping ▁; ▁m RI ▁; ▁tid al ▁respira tion ▁; ▁my o card ial ▁t 1 ▁; ▁s win e ▁; ▁heart ▁failure
D-1054	-0.5749890208244324	multiacquisition ; t1-mapping ; mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
P-1054	-0.7408 -0.7123 -0.2258 -1.0272 -0.4989 -0.2508 -0.2593 -0.3364 -0.4718 -2.0884 -0.4205 -1.2732 -0.0655 -0.5085 -0.7802 -0.4364 -1.0145 -0.2856 -0.6286 -0.6205 -0.3916 -0.7497 -0.3123 -0.2075 -0.0627 -0.2502 -1.1819 -0.9083 -0.2154 -0.5583 -0.3415
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis ; medical ; hf
H-200	-1.5788626670837402	▁ HF
D-200	-1.5788626670837402	HF
P-200	-4.3838 -1.2485 -0.3728 -0.3103
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas ; cardiac remodeling ; heart failure
H-1483	-0.5006158351898193	▁mi RNA s ▁; ▁cardiac ▁remodel ing ▁; ▁heart ▁failure
D-1483	-0.5006158351898193	miRNAs ; cardiac remodeling ; heart failure
P-1483	-1.0440 -0.1334 -0.3428 -0.3546 -0.2171 -0.0742 -0.1982 -0.2718 -1.7114 -0.5575 -0.8521 -0.2504
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal ; likelihood ratio
H-487	-0.7444503903388977	
D-487	-0.7444503903388977	
P-487	-1.1654 -0.3235
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients ; cardiovascular disease ; drs
H-1838	-0.7227935194969177	▁cardiovascular ▁disease ▁; ▁d RS ▁; ▁deci les
D-1838	-0.7227935194969177	cardiovascular disease ; dRS ; deciles
P-1838	-0.5552 -0.8921 -0.2868 -0.0825 -1.5358 -1.3482 -0.1747 -1.7419 -0.3637 -0.2471
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy ; patients ; follow-up
H-861	-0.8560544848442078	▁follow - up
D-861	-0.8560544848442078	follow-up
P-861	-2.0299 -0.3028 -0.0774 -1.5893 -0.2809
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital compare ; ami ; mortality
H-1697	-1.5193227529525757	▁ AMI ▁mortal iteit ▁rates
D-1697	-1.5193227529525757	AMI mortaliteit rates
P-1697	-1.8942 -1.9458 -0.7907 -2.9417 -2.2113 -0.4841 -0.3675
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins ; subproteome
H-94	-1.1160322427749634	
D-94	-1.1160322427749634	
P-94	-1.9643 -0.2678
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty ; heart failure ; hf
H-622	-0.766986608505249	▁fra il ty ▁; ▁risk ▁; ▁heart ▁failure ▁; HF ▁; ▁older ▁adults
D-622	-0.766986608505249	frailty ; risk ; heart failure ;HF ; older adults
P-622	-0.1192 -0.3584 -1.1876 -0.3690 -2.0112 -0.4962 -0.9851 -0.3528 -0.2974 -1.6327 -1.3883 -0.5546 -1.1570 -0.3130 -0.2822
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart failure ; patients ; bisphosphonates
H-1535	-0.8715980052947998	▁heart ▁failure ▁; ▁bis phos phon ates
D-1535	-0.8715980052947998	heart failure ; bisphosphonates
P-1535	-3.5630 -0.4276 -0.2887 -0.4671 -0.1835 -0.8878 -1.2570 -0.4703 -0.2994
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients ; beta-blocker ; therapy
H-1939	-0.5831334590911865	▁beta - block er ▁ therapy
D-1939	-0.5831334590911865	beta-blocker therapy
P-1939	-2.9721 -0.1238 -0.2829 -0.1350 -0.2703 -0.0953 -0.4381 -0.3476
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis ; cardiovascular disease ; cvd
H-1555	-1.037619948387146	▁psoriasis ▁; ▁cardiovascular ▁disease ▁; CV d
D-1555	-1.037619948387146	psoriasis ; cardiovascular disease ;CVd
P-1555	-1.4516 -1.9583 -0.6644 -1.4260 -0.2322 -2.5676 -0.4096 -0.3679 -0.2610
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes ; hypertrophic
H-1217	-0.5599938035011292	▁p de 2- over express ing ▁; ▁cardio my o cy tes ▁; ▁no re pine ph rine - indu ced ▁hyper trop hic ▁response s
D-1217	-0.5599938035011292	pde2-overexpressing ; cardiomyocytes ; norepinephrine-induced hypertrophic responses
P-1217	-3.6704 -0.7661 -0.0660 -0.0636 -0.6941 -0.1992 -0.4935 -0.1585 -1.1027 -0.5197 -0.3487 -0.3645 -0.3871 -0.4003 -0.1845 -0.1301 -0.6369 -0.3675 -0.1839 -0.1872 -1.0874 -0.0836 -0.0139 -1.3495 -1.0422 -0.3768 -0.4868 -0.3149
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause readmissions
H-726	-0.667924702167511	▁read missions
D-726	-0.667924702167511	readmissions
P-726	-0.9790 -0.7937 -0.6001 -0.2989
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular disease ; baseline
H-1767	-0.7416455149650574	▁cardiovascular ▁disease
D-1767	-0.7416455149650574	cardiovascular disease
P-1767	-1.2033 -1.1220 -0.3344 -0.3068
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs ; clinical
H-2015	-0.8135245442390442	
D-2015	-0.8135245442390442	
P-2015	-1.3103 -0.3167
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage ; poc
H-1029	-0.9820828437805176	▁PO c ▁technology
D-1029	-0.9820828437805176	POc technology
P-1029	-2.3498 -1.1564 -0.5983 -0.4798 -0.3262
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm control therapy
H-1645	-0.8247202038764954	▁ Rhythm ▁control ▁ therapy ▁; ▁benefit ▁; ▁side ▁effects
D-1645	-0.8247202038764954	Rhythm control therapy ; benefit ; side effects
P-1645	-0.3842 -0.5690 -1.0032 -0.3769 -0.1130 -0.2877 -3.2140 -1.2063 -1.7321 -0.3122 -0.4679 -0.2301
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker ; uptitration ; clinical ; outcome ; patients ; hfref ; hfpef
H-185	-1.0050994157791138	RAS - block er ▁up tit ration ▁; ▁h Fr EF ▁; ▁ HF p EF
D-185	-1.0050994157791138	RAS-blocker uptitration ; hFrEF ; HFpEF
P-185	-0.6813 -0.1606 -0.6006 -0.4928 -2.2369 -1.5258 -2.0228 -0.4097 -0.8689 -1.6362 -1.9464 -0.3839 -0.8824 -1.3064 -0.1055 -2.1738 -0.3805 -0.2775
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv diastolic dysfunction ; filling pressures ; non-invasively ; doppler echocardiography
H-28	-0.3635096251964569	▁dia sto lic ▁dys function ▁; ▁fill ing ▁pressure s ▁; ▁do pp ler ▁e cho card i ography
D-28	-0.3635096251964569	diastolic dysfunction ; filling pressures ; doppler echocardiography
P-28	-0.3869 -0.4520 -0.0877 -0.0280 -0.1606 -0.2826 -0.3594 -0.2295 -0.4081 -0.3201 -0.3284 -0.3036 -0.0954 -1.5939 -0.2783 -0.1998 -0.4190 -0.5603 -0.2895 -0.5389 -0.3119
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin ; exercise ; training ; health ; patients ; chronic heart failure ; hf-action ; randomized
H-833	-1.0450679063796997	▁Hem o glob in ▁; ▁exercise ▁; ▁chronic ▁heart ▁failure ▁; ▁ HF - ac TION
D-833	-1.0450679063796997	Hemoglobin ; exercise ; chronic heart failure ; HF-acTION
P-833	-0.7227 -0.4078 -0.1708 -0.9241 -0.4149 -2.6111 -0.4105 -3.6858 -1.0962 -0.7841 -0.3916 -0.5875 -0.8655 -0.1576 -1.4429 -3.4597 -0.3479 -0.3305
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac dysfunction ; subcellular ; metoprolol ; heart failure ; myocardial infarction
H-1546	-0.5012226104736328	▁cardiac ▁dys function ▁; ▁sub cel lular ▁altera tions ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1546	-0.5012226104736328	cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
P-1546	-0.4209 -0.1101 -0.2276 -0.3487 -0.1342 -0.6233 -0.2273 -0.5831 -1.5774 -0.4217 -0.1236 -0.1631 -0.1387 -0.4413 -0.3778 -1.3788 -0.3851 -0.3451 -1.6689 -0.1655 -0.9181 -0.9195 -0.0977 -0.3191 -0.6487 -0.4698 -0.2979
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial collagen ; collagen cross-linking ; titin ; isoforms ; phosphorylation
H-764	-0.38629111647605896	▁My o card ial ▁collage n ▁; ▁collage n ▁cross - link ing ▁; ▁titi n ▁iso form s ▁; ▁ phos phor y lation
D-764	-0.38629111647605896	Myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
P-764	-1.6597 -0.3672 -0.6208 -1.2992 -0.1283 -0.3459 -0.3488 -0.1880 -0.2874 -0.1976 -0.1738 -0.0285 -0.2228 -0.3461 -0.1348 -0.2636 -0.0414 -0.1118 -0.4625 -0.2910 -0.1988 -0.0831 -0.8314 -0.9703 -0.1401 -0.3997 -0.2869
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac magnetic resonance postcontrast t1 time ; outcome ; patients ; heart failure ; preserved ejection fraction
H-733	-0.567781925201416	▁Card iac ▁magnetic ▁res on ance ▁post contra st ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-733	-0.567781925201416	Cardiac magnetic resonance postcontrast ; heart failure ; ejection fraction
P-733	-1.5157 -0.6041 -0.1287 -0.2273 -0.5895 -0.4525 -1.1171 -0.2880 -0.2382 -0.3080 -2.2827 -0.4845 -0.2145 -1.4473 -0.2929 -0.1329 -0.2592 -0.0658 -0.4737 -0.2329
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
H-88	-0.6145566701889038	▁systems ▁prote o mics ▁; ▁cardiac ▁chr omat in ▁; ▁nucleo lin ▁; ▁regulator ▁; ▁cel lular ▁plastic iteit ▁; ▁cardio my o cy tes
D-88	-0.6145566701889038	systems proteomics ; cardiac chromatin ; nucleolin ; regulator ; cellular plasticiteit ; cardiomyocytes
P-88	-2.9014 -0.3945 -0.6505 -0.0121 -0.2330 -0.1363 -0.1408 -0.1138 -0.6557 -0.3443 -0.3060 -1.0762 -0.2224 -1.3637 -2.0344 -1.7907 -0.0902 -0.2024 -1.8192 -0.2639 -0.0703 -0.4522 -0.3051 -0.0866 -0.2772 -0.3863 -0.2638
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity ; doxorubicin ; anti-neoplastic agent
H-955	-0.4533390700817108	▁cardio toxic iteit ▁; ▁do xor ubi cin ▁; ▁anti - neo plast ic ▁agent ▁; ▁cancer s
D-955	-0.4533390700817108	cardiotoxiciteit ; doxorubicin ; anti-neoplastic agent ; cancers
P-955	-0.2968 -0.7329 -2.5427 -0.3613 -0.2758 -0.1317 -0.1776 -0.7548 -0.2805 -0.0294 -0.1264 -0.0567 -0.4135 -0.1698 -0.0521 -0.2802 -1.0188 -0.7301 -0.3760 -0.2599
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients ; heart failure ; left ventricular ; ejection fraction
H-22	-0.7799623012542725	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁; ▁v n ▁; ▁e je ction ▁ fraction
D-22	-0.7799623012542725	heart failure ; left ventricular ; vn ; ejection fraction
P-22	-3.5173 -0.6156 -0.3329 -2.2274 -0.2621 -1.9109 -0.4474 -0.3107 -2.2880 -0.4115 -0.2766 -0.1046 -0.2443 -0.1042 -0.2088 -0.0239 -0.4444 -0.3087
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic adult fontan ; saf ; patients ; catheterization
H-226	-0.7241067886352539	▁Font an ▁; SAF
D-226	-0.7241067886352539	Fontan ;SAF
P-226	-1.3167 -0.1420 -0.3906 -0.3505 -1.7469 -0.3980
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic peptides ; point of care ; ambulatory
H-1019	-0.7776199579238892	▁na tri ure tic ▁pe pti des
D-1019	-0.7776199579238892	natriuretic peptides
P-1019	-0.0535 -1.7880 -1.0330 -1.7855 -0.7766 -0.2771 -0.2230 -0.7996 -0.2622
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa ; immunoassays ; nt-probnp
H-1516	-0.899644672870636	▁al pha LIS a ▁; ▁immun o assa ys
D-1516	-0.899644672870636	alphaLISa ; immunoassays
P-1516	-3.0701 -1.2014 -0.7633 -0.8536 -0.4202 -0.0395 -0.3825 -0.3215 -2.1337 -0.4673 -0.2429
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf ; patients ; rheumatoid arthritis ; ra
H-602	-0.8369726538658142	▁ HF ▁; ▁rhe um ato id ▁ar thri tis ▁; RA
D-602	-0.8369726538658142	HF ; rheumatoid arthritis ;RA
P-602	-3.0982 -1.2096 -0.3294 -1.0176 -0.1529 -0.4585 -0.2779 -0.0576 -0.5675 -1.5487 -0.3097 -1.9470 -0.4258 -0.3172
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal ; hospital ; hf ; patients ; cms ; conditions
H-139	-1.1772582530975342	▁hospital ▁rates ▁; HF ▁; ▁CMS
D-139	-1.1772582530975342	hospital rates ;HF ; CMS
P-139	-3.7170 -1.6655 -0.3591 -2.1811 -0.5379 -0.3464 -0.2873 -0.3237
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported ; patient ; implantable cardioverter-defibrillator
H-1858	-0.5459396839141846	▁implant able ▁; ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1858	-0.5459396839141846	implantable ; cardioverter-defibrillator deactivation
P-1858	-0.8899 -0.2882 -0.9049 -0.1001 -0.2361 -0.6908 -0.2540 -0.1036 -0.2001 -1.6800 -0.3051 -0.1904 -0.4403 -0.1196 -2.0984 -0.5034 -0.2761
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients ; sinus rhythm ; antiplatelet agents ; anticoagulants
H-1354	-0.36109110713005066	▁sinus ▁ rhythm ▁; ▁anti plate let ▁agents ▁; ▁antico a gul ants
D-1354	-0.36109110713005066	sinus rhythm ; antiplatelet agents ; anticoagulants
P-1354	-0.4184 -0.3182 -0.9579 -0.4120 -0.0229 -0.2155 -0.2938 -0.1471 -0.3470 -0.0618 -0.3596 -0.7894 -0.3598 -0.4321 -0.2809
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death ; c-statistics ; biological phenotype ; deficit index
H-1011	-0.4238746166229248	▁death ▁; ▁bi ological ▁ph eno type ▁; ▁deficit ▁index
D-1011	-0.4238746166229248	death ; biological phenotype ; deficit index
P-1011	-1.6000 -0.3528 -0.9770 -0.5077 -0.2730 -0.1713 -0.0141 -0.3391 -0.1190 -0.0733 -0.3726 -0.2865
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac angiogenesis ; therapy ; cardiac function ; remodeling
H-460	-0.6011583209037781	▁β - Block er - indu ced ▁enhance ment ▁; ▁cardiac ▁ang io gene sis ▁; ▁ therapy ▁; ▁cardiac ▁function
D-460	-0.6011583209037781	β-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
P-460	-0.2077 -0.0741 -0.5038 -0.0950 -0.1250 -0.4045 -2.1108 -2.3788 -1.0893 -0.9385 -0.1250 -0.5033 -0.8707 -0.4533 -1.2886 -0.3590 -0.4521 -0.1656 -0.3224 -0.2037 -0.2134 -0.7081 -0.2337
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician ; patient ; admission ; admission
H-1417	-0.6263551115989685	▁index ▁ad mission ▁; ▁index ▁ad mission
D-1417	-0.6263551115989685	index admission ; index admission
P-1417	-0.1086 -0.5871 -1.2489 -0.8215 -0.0466 -0.7961 -1.2879 -0.3478 -0.3927
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression ; bax ; bcl-2 ; proteins ; pacing
H-170	-0.4685966968536377	▁Bax ▁; ▁b cl -2 ▁protein s
D-170	-0.4685966968536377	Bax ; bcl-2 proteins
P-170	-0.1879 -0.2654 -0.6993 -0.1757 -0.2535 -0.2078 -0.6495 -1.4653 -0.3129
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt ; gdmt ; bat
H-1871	-1.0657743215560913	▁GD t ▁; control ▁group ▁; ▁GD t ▁; ▁BAT ▁; tre at ment ▁group
D-1871	-1.0657743215560913	GDt ;control group ; GDt ; BAT ;treatment group
P-1871	-1.5104 -2.9650 -0.6050 -1.8555 -1.1494 -0.3787 -1.5253 -2.5905 -0.4760 -0.1497 -1.6563 -0.5891 -0.0738 -0.5649 -1.3805 -0.3838 -0.2643
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported ; heart failure ; clcnka ; snp
H-1804	-1.3443892002105713	▁heart ▁failure ▁; ▁CL cn ka ▁s NP
D-1804	-1.3443892002105713	heart failure ; CLcnka sNP
P-1804	-3.5886 -0.8737 -0.3617 -1.5961 -1.6257 -2.6382 -0.8570 -1.1804 -0.4300 -0.2926
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate ; alendronate ; heart failure
H-1545	-0.7167234420776367	▁ale ndr onate ▁; ▁ale ndr onate ▁; ▁heart ▁failure
D-1545	-0.7167234420776367	alendronate ; alendronate ; heart failure
P-1545	-0.7950 -0.7611 -0.4841 -0.2942 -1.5432 -0.6960 -0.7096 -0.2779 -1.6976 -0.6306 -0.4168 -0.2945
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction pathways ; engage ; signalling proteins
H-993	-0.4765854477882385	▁trans duction ▁path ways ▁; ▁protein s
D-993	-0.4765854477882385	transduction pathways ; proteins
P-993	-0.0210 -0.7334 -0.1881 -0.2674 -0.2879 -1.4648 -0.6835 -0.3693 -0.2739
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline ; patients ; resting hr ; bpm
H-1940	-1.13019597530365	▁HR
D-1940	-1.13019597530365	HR
P-1940	-2.6676 -0.4281 -0.2949
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma ; collected ; hf ; patients
H-1514	-0.8677082061767578	▁Plas ma ▁sample s ▁; HF
D-1514	-0.8677082061767578	Plasma samples ;HF
P-1514	-0.3131 -1.6227 -0.2526 -0.3549 -0.4084 -2.5299 -1.1883 -0.2718
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation ; anti-inflammatory ; chf
H-1362	-0.5663506984710693	▁feed ing ▁; ▁nutrition al ▁; ▁anti - in flam ma tory ▁effects ▁; ▁CHF
D-1362	-0.5663506984710693	feeding ; nutritional ; anti-inflammatory effects ; CHF
P-1362	-1.1550 -0.2324 -0.3050 -0.4650 -0.2470 -0.3532 -0.0154 -0.1406 -0.3237 -0.1028 -2.8306 -0.6576 -1.0369 -0.3068 -0.8661 -0.3445 -0.2453
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical ; diastolic dysfunction ; mortality
H-25	-0.42190590500831604	▁dia sto lic ▁dys function ▁; ▁mortal iteit
D-25	-0.42190590500831604	diastolic dysfunction ; mortaliteit
P-25	-0.0192 -0.2147 -0.1775 -0.0525 -0.1042 -0.6753 -0.6068 -1.8331 -0.2875 -0.2482
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs ; patients ; oht ; transplant ; vad
H-1288	-0.9088350534439087	▁ac s ▁; ▁o HT ▁; ▁transplant ▁; ▁m t ▁; VAD
D-1288	-0.9088350534439087	acs ; oHT ; transplant ; mt ;VAD
P-1288	-2.6551 -0.2632 -0.3104 -0.2529 -3.8642 -0.3265 -0.3225 -0.3114 -1.8216 -0.6375 -0.3257 -1.0909 -0.3003 -0.2414
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients ; β-blocker ; patients ; uptitration
H-179	-1.1157772541046143	▁β - block er ▁dose
D-179	-1.1157772541046143	β-blocker dose
P-179	-3.9356 -0.1516 -0.5005 -0.3525 -1.0994 -1.4918 -0.2789
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs ; hf with reduced ejection fraction ; hfref
H-1077	-0.6004457473754883	▁drugs ▁; HF ▁; ▁e je ction ▁ fraction ▁; HF r EF
D-1077	-0.6004457473754883	drugs ;HF ; ejection fraction ;HFrEF
P-1077	-0.4052 -0.3064 -2.1874 -0.3870 -0.5208 -0.2953 -0.0612 -0.3535 -0.0264 -0.2658 -2.5810 -0.0416 -1.0242 -0.3398 -0.2111
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas city cardiomyopathy questionnaire ; patients ; heart failure ; reduced ejection fraction
H-779	-0.4983821511268616	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-779	-0.4983821511268616	Kansas City Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
P-779	-0.0934 -2.1884 -1.4322 -0.0709 -0.1619 -0.8691 -0.1497 -0.4292 -0.0223 -0.2741 -2.2703 -0.3273 -0.2822 -0.0899 -0.1770 -0.0723 -0.2656 -0.0243 -0.4455 -0.3218
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence ; heart failure with preserved ejection fraction ; hfpef ; prognosis
H-23	-0.7985988259315491	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h bf
D-23	-0.7985988259315491	heart failure ; preserved ejection fraction ; hbf
P-23	-1.9957 -0.4442 -0.6815 -0.5759 -0.2714 -3.0397 -0.1815 -0.3354 -0.0928 -0.3893 -0.0293 -0.2540 -0.4988 -1.9293 -1.8167 -0.2421
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic ; bnp ; nt-probnp ; patients ; coronary artery disease ; cad
H-1366	-1.002599835395813	▁b NP ▁; ▁NT - pro b NP ▁; ▁corona ry ▁arter y ▁disease ▁; CAD
D-1366	-1.002599835395813	bNP ; NT-probNP ; coronary artery disease ;CAD
P-1366	-1.8640 -3.0341 -0.3494 -0.1923 -0.1749 -0.0590 -1.1890 -1.9098 -0.3650 -0.7340 -2.9212 -0.1501 -1.9021 -0.6159 -0.2999 -1.6004 -0.3819 -0.3038
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-337	-0.5239256024360657	▁function al ▁mit ral ▁sten osis ▁; ▁m ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation ▁; MR
D-337	-0.5239256024360657	functional mitral stenosis ; m ; ring annuloplasty ; ischemic mitral regurgitation ;MR
P-337	-1.3679 -0.2122 -0.9467 -0.2088 -0.0144 -0.2803 -0.3181 -0.4198 -3.0174 -0.0527 -0.8371 -0.1052 -0.1994 -1.1027 -0.3427 -0.1488 -0.1192 -0.3320 -0.7762 -0.4141 -0.0547 -0.1655 -0.9165 -0.1272 -0.3486 -1.0123 -0.5365 -0.2933
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart ; hospitalization ; death ; patients ; preserved left ventricular ejection fraction
H-235	-0.7414501905441284	▁heart ▁failure - related ▁hospital ization ▁; ▁death ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-235	-0.7414501905441284	heart failure-related hospitalization ; death ; left ventricular ejection fraction
P-235	-2.6768 -1.2526 -0.3670 -0.2053 -0.3798 -0.9131 -0.2920 -1.3235 -0.2958 -1.3266 -0.3031 -2.4861 -0.8604 -0.2728 -0.4348 -0.2209 -0.3151 -0.0500 -0.4772 -0.3762
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations ; refractory congestive heart failure ; peritoneal dialysis
H-893	-0.5606043338775635	▁re frac tory ▁con ges tive ▁heart ▁failure ▁; ▁per ito ne al ▁di al ysis
D-893	-0.5606043338775635	refractory congestive heart failure ; peritoneal dialysis
P-893	-0.3492 -0.1335 -0.8772 -0.0400 -0.9442 -2.2478 -1.3423 -0.3269 -0.3543 -0.5279 -0.9482 -0.5458 -0.0797 -0.5508 -0.0260 -0.0924 -0.4180 -0.2867
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients ; heart failure ; elevated ; left atrial pressure ; symptoms ; hospital ; admission
H-1949	-1.2930476665496826	▁heart ▁failure ▁; ▁eleva ted ▁left ▁at rial ▁pressure
D-1949	-1.2930476665496826	heart failure ; elevated left atrial pressure
P-1949	-3.1928 -0.5120 -0.3419 -3.4141 -0.9973 -1.3697 -1.5986 -0.8065 -0.8531 -0.8672 -0.2704
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 ; hypertensive ; obese ; zsf1 ; hypertensive ; diabetic
H-766	-0.9877660274505615	▁lean ▁; ▁z SF 1 ▁group ▁; ▁hyper tensi ve ▁; ▁obes e ▁; ▁z SF 1 ▁groups ▁; ▁hyper tensi ve ▁; ▁diabet ic
D-766	-0.9877660274505615	lean ; zSF1 group ; hypertensive ; obese ; zSF1 groups ; hypertensive ; diabetic
P-766	-0.2580 -0.8985 -1.6222 -2.0533 -2.9041 -1.7938 -0.2608 -3.1179 -0.2044 -0.7504 -0.3307 -0.2145 -0.3465 -0.8058 -2.5018 -2.1465 -2.4671 -0.6820 -0.3240 -1.1020 -0.3904 -0.5058 -0.2820 -0.0579 -0.1242 -0.3152 -0.2099
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue doppler ; left ventricular filling pressure ; patients ; stable ; severe systolic heart failure
H-479	-0.6421030163764954	▁tissu e ▁; ▁do pp ler ▁imagin g ▁; ▁left ▁vent ri cular ▁fill ing ▁pressure ▁; ▁sy sto lic ▁heart ▁failure
D-479	-0.6421030163764954	tissue ; doppler imaging ; left ventricular filling pressure ; systolic heart failure
P-479	-1.5477 -0.1913 -0.2479 -0.2147 -0.1394 -1.7521 -0.1774 -0.2610 -0.3894 -1.1508 -0.2806 -1.9121 -0.3371 -1.2658 -0.2980 -1.9441 -0.3301 -0.2361 -0.1652 -0.3953 -0.9471 -0.3933 -0.5415 -0.2923
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart failure with preserved ejection fraction ; hfpef ; cardiovascular morbidity ; mortality
H-236	-0.7213412523269653	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁cardiovascular ▁morbi d iteit
D-236	-0.7213412523269653	Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbiditeit
P-236	-1.2286 -0.4097 -1.2863 -0.6851 -0.3520 -3.2223 -0.1287 -0.5073 -0.0841 -0.3976 -0.0324 -0.2547 -1.6584 -0.0654 -1.5349 -0.2689 -0.2138 -0.3757 -0.1513 -1.6232 -1.1348 -0.2541
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence ; vad ; acs ; consultations ; operations ; mortality ; morbidity
H-1289	-0.9793230295181274	▁MT ▁; ▁ VAD ▁groups ▁; ▁a CS
D-1289	-0.9793230295181274	MT ; VAD groups ; aCS
P-1289	-0.5233 -0.2831 -1.6435 -0.2323 -1.2195 -0.3454 -1.1290 -3.5805 -0.5730 -0.2636
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv diastolic dysfunction ; combination ; figure ; hfpef
H-24	-0.6250190734863281	▁dia sto lic ▁dys function ▁; ▁combinatie ▁; ▁figuur ▁; ▁h bf
D-24	-0.6250190734863281	diastolic dysfunction ; combinatie ; figuur ; hbf
P-24	-0.4045 -0.2181 -0.0883 -0.0371 -0.1856 -0.3070 -0.7942 -0.3415 -1.3484 -0.3015 -1.1803 -2.7690 -0.4951 -0.2798
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ; hf
H-1810	-0.5031245946884155	▁Mamma lian ▁enabled ▁; Men a ▁; ▁cy tos kelet al ▁act in ▁dynamic s ▁; ▁heart ▁failure ▁; HF
D-1810	-0.5031245946884155	Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure ;HF
P-1810	-0.5238 -0.5014 -0.2163 -0.1917 -1.4371 -0.0357 -0.3021 -0.8272 -1.0091 -0.1868 -0.1572 -0.5488 -0.5134 -0.1621 -0.1139 -0.2939 -0.9070 -0.4870 -0.2515 -1.8617 -0.3211 -0.2198
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal bleeding ; reported ; patients ; ventricular assist devices
H-1659	-0.8339071273803711	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices
D-1659	-0.8339071273803711	Gastrointestinal bleeding ; ventricular assist devices
P-1659	-0.7810 -1.9072 -3.3982 -0.2313 -0.2361 -1.4578 -0.2628 -0.3743 -0.0853 -1.8708 -0.4033 -0.4935 -0.2731 -0.4600 -0.2739
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni inhibitors ; angiotensin-receptor neprilysin inhibitors
H-1966	-0.5825639367103577	▁AR NI ▁inhibi tors ▁; angi oten sin - recept or ▁nepri ly sin ▁inhibi tors
D-1966	-0.5825639367103577	ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
P-1966	-1.5157 -1.4768 -0.1555 -0.3532 -0.4126 -0.0135 -0.4663 -2.1759 -0.5236 -0.0447 -0.0904 -0.2350 -0.4621 -0.9820 -0.1377 -0.6544 -0.4355 -0.3513
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes ; patients ; preserved ejection fraction ; hfpef
H-1328	-0.9256502389907837	▁f es ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1328	-0.9256502389907837	fes ; preserved ejection fraction ;HFpEF
P-1328	-3.5658 -2.0826 -0.3090 -1.0252 -0.3511 -2.2961 -0.1647 -0.5050 -0.1467 -0.3041 -0.0619 -0.3483 -2.7128 -0.0549 -1.1570 -0.3720 -0.2787
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas ; cardiac ; benign tumors ; left atrium ; right atrium
H-593	-0.6156046986579895	▁My xo mas ▁; ▁cardiac ▁benign ▁tumor s ▁; ▁left ▁at rium
D-593	-0.6156046986579895	Myxomas ; cardiac benign tumors ; left atrium
P-593	-1.4451 -0.0722 -1.2974 -0.3515 -0.1659 -0.1249 -0.1687 -0.7438 -0.4499 -0.5495 -1.5530 -0.0603 -1.3379 -0.2983
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil ; cytotoxic ; doxorubicin ; ehrlich carcinoma
H-966	-0.35436174273490906	▁nic oran dil ▁; ▁cy to toxic ▁effect ▁; ▁do xor ubi cin ▁; ▁eh r lich ▁car cino ma
D-966	-0.35436174273490906	nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
P-966	-0.2035 -0.2235 -0.7341 -0.3403 -0.5223 -0.2742 -0.1947 -0.0768 -0.2974 -0.2515 -0.1011 -0.1191 -0.6926 -0.3461 -0.4465 -0.0323 -0.0185 -0.0172 -0.2725 -1.8776 -0.4585 -0.2957
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory ; icd ; patients ; mortality ; multivariable regression
H-63	-1.2406151294708252	▁i CD ▁; ▁mortal iteit
D-63	-1.2406151294708252	iCD ; mortaliteit
P-63	-1.4914 -2.1283 -0.9184 -1.3426 -2.1767 -0.2838 -0.3431
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart failure with preserved ejection fraction ; hfpef ; cardiovascular reserve
H-916	-0.6568675637245178	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h bf ▁; ▁cardiovascular ▁reserve
D-916	-0.6568675637245178	Heart failure ; preserved ejection fraction ; hbf ; cardiovascular reserve
P-916	-2.0399 -0.8840 -0.7611 -0.5780 -0.3422 -2.3756 -0.1773 -0.4106 -0.0728 -0.3150 -0.0203 -0.3175 -0.4088 -2.0350 -0.5882 -0.3244 -0.1150 -0.4688 -0.2459
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal denervation ; dnx ; chf ; patients ; symptomatic
H-1371	-0.8152424693107605	▁Ren al ▁den er va tion ▁; ▁d n x ▁; ▁CHF
D-1371	-0.8152424693107605	Renal denervation ; dnx ; CHF
P-1371	-2.6975 -0.2498 -0.8207 -0.9362 -0.2721 -0.9110 -0.3585 -0.1252 -3.0109 -0.6304 -0.3388 -0.1615 -0.6329 -0.2679
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician ; follow-up ; discharge ; physician ; outcomes ; patients ; heart failure
H-1421	-0.9217293858528137	▁physician ▁follow - up ▁; ▁dis charge ▁; ▁physician ▁continu iteit ▁; ▁heart ▁failure
D-1421	-0.9217293858528137	physician follow-up ; discharge ; physician continuiteit ; heart failure
P-1421	-1.8800 -0.2100 -0.3138 -0.0472 -2.2861 -1.1499 -0.4400 -0.3188 -0.2768 -0.2280 -3.4245 -0.3874 -2.3234 -0.6605 -0.5129 -0.2885
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia ; acute kidney injury ; spironolactone ; clinical
H-444	-0.43285250663757324	▁hyper kal emia ▁; ▁ki dne y ▁injury ▁; ▁spi rono lac tone
D-444	-0.43285250663757324	hyperkalemia ; kidney injury ; spironolactone
P-444	-0.3633 -0.5620 -0.5955 -0.2913 -0.2727 -1.3257 -0.6438 -0.9916 -0.2655 -0.0405 -0.0934 -0.1000 -0.0546 -0.6180 -0.2746
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial ; pde2 ; intracellular ; antiadrenergic ; therapeutic ; hf
H-1220	-0.6946690082550049	▁activa ting ▁; ▁my o card ial ▁p de 2 ▁; ▁intra cel lular ▁anti ad r energi c ▁ therapeut ic ▁strategy ▁; HF
D-1220	-0.6946690082550049	activating ; myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ;HF
P-1220	-0.3933 -0.6838 -1.1381 -1.1016 -0.2785 -0.4748 -1.1434 -1.8284 -0.8446 -0.1308 -0.3295 -0.8215 -0.7063 -0.2252 -0.0305 -0.2310 -0.1444 -0.5336 -0.4633 -0.9943 -0.5337 -0.6923 -0.6105 -0.3048 -3.3945 -0.4111 -0.3122
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid intima-media thickness ; psoriasis
H-1561	-0.6161125302314758	▁caro tid ▁; ▁psoriasis
D-1561	-0.6161125302314758	carotid ; psoriasis
P-1561	-0.8571 -0.6357 -0.3468 -1.1213 -0.3999 -0.3358
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary occlusion ; collateral growth ; stent
H-510	-0.5765475034713745	▁corona ry ▁oc clusi on ▁; ▁significant ▁; ▁col lateral ▁growth ▁; ▁sten t ▁oc clusi on
D-510	-0.5765475034713745	coronary occlusion ; significant ; collateral growth ; stent occlusion
P-510	-1.1020 -3.0084 -0.0190 -0.1254 -1.3569 -0.3329 -0.0234 -0.9244 -0.6106 -0.0278 -0.8858 -0.4268 -0.1443 -0.1958 -0.0182 -0.1125 -1.0424 -0.3457 -0.2519
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up ; hf ; hospitalization
H-690	-0.6650963425636292	▁follow - up ▁; ▁ HF
D-690	-0.6650963425636292	follow-up ; HF
P-690	-0.0542 -0.3550 -0.0650 -0.3599 -1.5868 -1.4723 -1.1007 -0.3269
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination ; exercise ; peak vo2 ; joint
H-1985	-0.6832346320152283	▁combinatie ▁; ▁die t ▁; ▁VO 2 ▁; jo int ▁effect
D-1985	-0.6832346320152283	combinatie ; diet ; VO2 ;joint effect
P-1985	-2.5794 -0.2798 -1.0725 -0.2637 -0.3384 -1.6877 -0.1276 -0.2941 -1.2512 -0.2947 -0.0156 -0.4010 -0.2763
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone ; clinical ; medications
H-447	-0.5839148163795471	▁voordelen ▁; ▁spi rono lac tone ▁; ▁medication s
D-447	-0.5839148163795471	voordelen ; spironolactone ; medications
P-447	-2.6225 -0.3133 -0.1912 -0.2869 -0.3178 -0.2965 -0.6368 -0.5399 -0.4958 -0.4153 -0.3071
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv dysfunction ; cardiac cachexia
H-1168	-0.5144892930984497	RV ▁dys function ▁; ▁cardiac ▁cache xia
D-1168	-0.5144892930984497	RV dysfunction ; cardiac cachexia
P-1168	-2.9473 -0.1504 -0.1942 -0.2221 -0.0932 -0.0986 -0.2375 -0.4172 -0.2700
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg ; crt ; clinical
H-881	-1.4016202688217163	▁e CG ▁; ▁c RT
D-881	-1.4016202688217163	eCG ; cRT
P-881	-1.4664 -2.6142 -0.4374 -0.8574 -3.7668 -0.3797 -0.2895
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients ; narrow qrs complex ; crt ; patients
H-846	-0.7120989561080933	▁Mechanic al ▁dys syn chron y ▁; ▁QR s ▁complex ▁; ▁c RT
D-846	-0.7120989561080933	Mechanical dyssynchrony ; QRs complex ; cRT
P-846	-1.4006 -0.1090 -0.0305 -0.0797 -0.0158 -1.8866 -0.3585 -0.5067 -1.2477 -0.3747 -0.3573 -0.9742 -2.6903 -0.3782 -0.2717
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic ; clinical ; pharmacologic
H-1470	-0.6892402172088623	▁ pharma c ologic ▁treatment
D-1470	-0.6892402172088623	pharmacologic treatment
P-1470	-0.3579 -0.9033 -0.1711 -0.2083 -1.4123 -1.4498 -0.3220
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart failure ; hf ; death ; crt-d
H-105	-1.0600495338439941	▁IE ▁; ▁heart ▁failure ▁; HF ▁; ▁death
D-105	-1.0600495338439941	IE ; heart failure ;HF ; death
P-105	-4.8607 -0.3604 -1.1902 -0.3173 -0.3100 -1.4616 -0.3846 -1.0825 -0.3647 -0.2686
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence ; chronic heart failure ; hungary
H-646	-1.1839473247528076	▁chronic ▁heart ▁failure ▁; ▁Hungary
D-646	-1.1839473247528076	chronic heart failure ; Hungary
P-646	-2.2649 -2.1302 -0.6005 -0.3524 -2.0625 -0.6014 -0.2758
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast cancer ; patients ; chf ; reported ; clinical
H-681	-0.6856222152709961	▁breast ▁cancer ▁patients ▁; ▁tras tuz um b - related ▁CHF
D-681	-0.6856222152709961	breast cancer patients ; trastuzumb-related CHF
P-681	-2.4221 -0.3339 -1.8032 -0.2978 -0.3019 -0.2344 -0.6085 -0.7648 -0.7103 -0.4810 -0.3306 -0.3455 -0.2789
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote monitoring ; rm ; heart failure
H-148	-0.8828549385070801	▁remote ▁monitoring ▁; RM ▁; ▁heart ▁failure
D-148	-0.8828549385070801	remote monitoring ;RM ; heart failure
P-148	-0.8489 -0.0476 -0.2000 -2.1167 -0.3225 -2.3050 -0.3636 -1.4677 -0.2739
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-0.37340331077575684	
D-1851	-0.37340331077575684	
P-1851	-0.5024 -0.2444
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.7190451622009277	▁NT - pro b NP
D-1512	-0.7190451622009277	NT-probNP
P-1512	-0.5698 -0.1244 -0.1627 -1.7759 -1.7263 -0.3815 -0.2927
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf ; pb ; bp
H-1348	-0.9175136685371399	▁ pv f ▁; ▁p b ▁; ▁p b
D-1348	-0.9175136685371399	pvf ; pb ; pb
P-1348	-1.6192 -0.1647 -3.4951 -0.2174 -0.4146 -0.3612 -0.6735 -2.3793 -0.1419 -0.3449 -0.2809
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions ; patients ; heart disease
H-48	-0.7917467951774597	▁trans fusion s ▁; ▁heart ▁disease
D-48	-0.7917467951774597	transfusions ; heart disease
P-48	-0.0669 -0.4068 -0.4118 -0.3823 -3.5547 -0.7369 -0.5049 -0.2696
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant ; exercise
H-1883	-1.0597314834594727	▁control ▁group ▁; ▁exercise ▁group
D-1883	-1.0597314834594727	control group ; exercise group
P-1883	-3.9368 -0.9208 -0.4716 -0.3674 -1.0431 -0.4053 -0.2732
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients ; sst2 ; cardiovascular event
H-407	-0.8406099677085876	▁s st 2 ▁; ▁BB ▁; ▁cardiovascular ▁event ▁rate
D-407	-0.8406099677085876	sst2 ; BB ; cardiovascular event rate
P-407	-0.0555 -2.5814 -0.3152 -0.2968 -2.1941 -0.3410 -0.3341 -0.7536 -1.6804 -0.4356 -0.2591
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ; ecct
H-713	-0.8992111682891846	▁ec t
D-713	-0.8992111682891846	ect
P-713	-0.7366 -2.1505 -0.4193 -0.2905
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.6084490418434143	▁significant ▁; ▁aero bic ▁capacity ▁; ▁left - hand ▁grip ▁strength ▁; ▁body ▁weight ▁; ▁wa ist ▁circum ferenc e ▁; ▁anxiety
D-573	-0.6084490418434143	significant ; aerobic capacity ; left-hand grip strength ; body weight ; waist circumference ; anxiety
P-573	-0.9896 -1.5600 -0.2320 -0.5364 -0.4166 -0.4100 -1.3415 -0.2633 -0.0982 -0.4779 -2.9644 -0.3326 -2.1472 -0.3921 -0.3043 -0.0529 -0.5235 -0.0202 -0.2436 -0.1307 -0.3671 -0.2915 -0.2897 -0.2174
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial ; irs1 ; irs2 ; heart failure ; p38alpha ; mapk ; insulin resistance
H-651	-0.7479057312011719	▁My o card ial ▁loss ▁; ▁i RS 1 ▁; ▁i RS 2 ▁; ▁heart ▁failure ▁; ▁p 38 al pha ▁MA PK ▁; ▁insulin ▁resist ance
D-651	-0.7479057312011719	Myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
P-651	-1.7430 -0.4822 -0.8218 -1.7428 -0.7215 -0.3034 -1.2080 -1.9523 -3.0923 -0.4611 -1.2331 -1.6171 -0.1483 -0.3677 -1.4407 -0.4899 -0.3447 -0.5730 -0.9152 -0.0521 -0.0031 -0.3686 -0.3083 -0.3332 -0.0584 -0.0916 -0.0781 -0.4049 -0.3327
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart failure ; hypertensive heart disease ; angiotensin ii ; infusion ; nephrectomy ; salt loading
H-273	-0.60057133436203	▁heart ▁failure ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁ang io ten sin ▁II ▁in fusion ▁; ▁nep hr ecto my ▁; ▁salt ▁load ing
D-273	-0.60057133436203	heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
P-273	-3.0917 -0.2074 -0.2079 -0.2753 -0.1990 -0.2347 -1.6724 -1.0943 -0.2715 -0.8108 -1.0730 -0.1746 -1.6291 -1.9394 -0.0374 -0.0866 -0.2667 -0.1908 -0.7586 -0.1363 -0.6215 -0.2824 -0.0374 -0.0717 -0.1566 -0.4235 -0.2651
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened ; lvet ; icu ; admission ; prognostic ; patients ; precapillary ph ; heart failure
H-590	-0.9982380270957947	▁ ICU ▁ad mission ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-590	-0.9982380270957947	ICU admission ; precapillary PH ; heart failure
P-590	-1.7067 -0.8185 -1.5604 -0.5468 -0.2912 -2.1880 -0.3841 -0.6489 -3.2623 -0.4796 -0.3129 -1.5969 -0.3357 -0.5198 -0.3216
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal dysfunction ; all-cause mortality ; cardiovascular events ; postoperative ; cabg
H-978	-0.9868003129959106	▁renal ▁dys function ▁; ▁mortal iteit ▁; ▁cardiovascular ▁events ▁; ▁primary ▁isola ted ▁CA BG
D-978	-0.9868003129959106	renal dysfunction ; mortaliteit ; cardiovascular events ; primary isolated CABG
P-978	-3.3334 -0.1319 -0.1666 -0.3123 -0.8807 -2.4887 -0.3323 -0.0810 -0.4637 -0.3508 -3.5759 -0.0483 -0.5154 -1.4897 -1.9360 -0.3960 -0.2728
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline ; isoprenaline ; infusion ; sdqt ; hf ; patients
H-1443	-0.9974961876869202	▁iso pren a line ▁in fusion ▁; ▁SD QT ▁; ▁h Nor m ▁; ▁ HF
D-1443	-0.9974961876869202	isoprenaline infusion ; SDQT ; hNorm ; HF
P-1443	-0.2181 -0.2720 -0.5309 -0.1964 -0.2256 -0.5488 -0.3916 -1.3740 -4.0454 -0.3640 -0.7225 -5.0541 -0.2991 -0.3258 -1.6363 -1.0062 -0.4385 -0.3054
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart failure ; preserved ejection fraction ; myocardial infarction
H-1098	-0.6076737642288208	▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁my o card ial ▁in far ction
D-1098	-0.6076737642288208	heart failure ; ejection fraction ; myocardial infarction
P-1098	-2.3984 -0.5731 -0.2999 -0.1859 -0.2588 -0.0566 -0.3288 -0.0227 -0.3385 -1.4730 -0.3075 -0.8152 -1.9538 -0.0922 -0.4256 -0.7188 -0.4098 -0.2795
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical ; coronary artery disease ; patients ; systolic heart failure ; etiology
H-1181	-0.8816317915916443	▁corona ry ▁arter y ▁disease ▁; ▁sy sto lic ▁heart ▁failure
D-1181	-0.8816317915916443	coronary artery disease ; systolic heart failure
P-1181	-0.6222 -3.1364 -0.1104 -1.9983 -1.2874 -0.3111 -0.0796 -0.2204 -0.3832 -1.2662 -0.7082 -1.0210 -0.3168
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea ; total arterial compliance ; tac ; end-systolic elastance ; ees ; baseline
H-520	-0.8348291516304016	▁Ea ▁; ▁arterial ▁compliance ▁; TAC ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es
D-520	-0.8348291516304016	Ea ; arterial compliance ;TAC ; end-systolic elastance ; ees
P-520	-1.2656 -0.2829 -1.4460 -0.6546 -0.2932 -2.5474 -0.4066 -2.7987 -0.1985 -1.2057 -0.1497 -0.1357 -0.1265 -2.4015 -0.3304 -0.7243 -0.1528 -0.4795 -0.2622
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical ; clinical ; outcomes ; aldosterone antagonist ; heart failure
H-1734	-0.568184494972229	▁al do ster one ▁anta gon ist ▁; ▁heart ▁failure
D-1734	-0.568184494972229	aldosterone antagonist ; heart failure
P-1734	-0.1393 -0.0781 -0.2424 -0.9715 -0.1227 -0.0375 -1.5668 -0.3901 -1.9827 -0.4697 -0.5134 -0.3040
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic ; congestive heart failure ; haematopoietic cell transplantation
H-1448	-0.9078596234321594	▁Gene tic ▁; ▁an thra cycli ne - related ▁con ges tive ▁heart ▁failure ▁; ▁ha e mato po ie tic ▁cell ▁transplant ation
D-1448	-0.9078596234321594	Genetic ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
P-1448	-2.6494 -2.0396 -0.6764 -0.3061 -0.4055 -1.3464 -1.7307 -0.4388 -0.3356 -0.2245 -0.8858 -3.2459 -1.4677 -0.4439 -0.2810 -0.0366 -0.2412 -0.1859 -0.3235 -1.6724 -2.0111 -0.5562 -0.0476 -1.2061 -0.5304 -0.3161
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hfpef
H-1890	-0.6496474146842957	▁cardiovascular ▁risk ▁factors ▁; ▁diabetes ▁mell itus ▁; ▁at rial ▁fi bril lation ▁; ▁corona ry ▁arter y ▁disease ▁; ▁ HF p EF
D-1890	-0.6496474146842957	cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
P-1890	-0.5374 -1.9014 -0.6420 -0.2173 -0.1747 -0.0132 -0.1591 -0.2393 -0.9899 -0.1401 -0.5786 -0.0684 -0.2827 -0.2327 -0.1957 -2.8273 -0.0951 -2.2136 -0.8285 -0.2744 -1.8275 -0.9509 -0.0569 -0.8332 -0.3480 -0.2629
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal dysfunction ; mortality ; myocardial infarction ; coronary artery bypass grafting ; cabg
H-969	-0.9205551743507385	▁Ren al ▁dys function ▁; ▁my o card ial ▁in far ction ▁; ▁corona ry ▁arter y ▁by pass ▁graf ting ▁; ▁ca b
D-969	-0.9205551743507385	Renal dysfunction ; myocardial infarction ; coronary artery bypass grafting ; cab
P-969	-2.7425 -0.2814 -0.0392 -0.1716 -0.3385 -2.5655 -0.2133 -0.6291 -0.9911 -0.0784 -0.6203 -0.4748 -0.3174 -0.2355 -2.1895 -0.0580 -2.4464 -2.7744 -0.0451 -0.3707 -1.3134 -0.3464 -1.0124 -2.9446 -0.4300 -0.3048
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular support ; heartmate ii ; lvad ; centrimag ; rvad ; mortality ; hospital ; discharge
H-304	-0.974265992641449	▁Bi ven tri cular ▁support ▁; ▁Heart Mate ▁i i ▁l VAD ▁; ▁Centri Mag ▁r VAD
D-304	-0.974265992641449	Biventricular support ; HeartMate ii lVAD ; CentriMag rVAD
P-304	-5.8630 -0.2926 -2.2943 -0.6946 -1.1956 -0.3495 -1.3207 -0.0816 -0.5578 -0.3218 -0.4325 -0.1231 -0.3384 -0.1557 -1.1530 -0.9071 -0.9008 -1.1596 -0.3693
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis ; post-myocardial infarction ; heart ; heart failure
H-449	-0.7821068167686462	▁ang io gene sis ▁; ▁post - my o card ial ▁in far ction ▁heart ▁; ▁heart ▁failure
D-449	-0.7821068167686462	angiogenesis ; post-myocardial infarction heart ; heart failure
P-449	-1.3479 -1.8668 -0.6689 -1.8705 -0.3361 -0.1232 -0.0942 -0.6730 -0.2214 -1.2014 -1.4129 -0.1001 -0.5747 -0.5389 -1.8390 -0.2962 -1.4659 -0.2773 -0.4559 -0.2779
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 ; hearts ; acute ; β-ar
H-1218	-0.7965329885482788	▁p de 2 ▁; ▁heart s ▁; ▁β - AR ▁stimul ation
D-1218	-0.7965329885482788	pde2 ; hearts ; β-AR stimulation
P-1218	-1.7675 -0.8268 -0.1457 -0.3832 -1.5505 -0.2919 -0.5665 -1.3655 -0.0567 -1.1369 -0.2981 -2.0494 -0.3713 -0.3415
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery ; medical treatment ; hf ; hypertension ; vasodilators ; diuretics
H-355	-0.4768623411655426	▁surgery ▁; ▁medical ▁; HF ▁; ▁hyper tension ▁; ▁vaso dila tors ▁; ▁di ure tics
D-355	-0.4768623411655426	surgery ; medical ;HF ; hypertension ; vasodilators ; diuretics
P-355	-0.2842 -0.3280 -2.6200 -0.7231 -1.6152 -0.2883 -0.1117 -0.0683 -0.2860 -0.0569 -0.0219 -0.1435 -0.3671 -0.4802 -0.1728 -0.3289 -0.4653 -0.2220
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr ; diuretics ; hypertension ; patients ; esrd
H-397	-0.7313941121101379	▁e g FR ▁; ▁di ure tics ▁; ▁un control led ▁hyper tension ▁; ▁ES RD
D-397	-0.7313941121101379	egFR ; diuretics ; uncontrolled hypertension ; ESRD
P-397	-0.1891 -2.6531 -1.1142 -0.3182 -0.2646 -0.3996 -0.4693 -0.3890 -0.1051 -0.0259 -1.9990 -0.1655 -0.1973 -0.2925 -2.8046 -1.0471 -0.4370 -0.2941
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence ; prevalence ; heart failure ; leading ; death ; hospitalisation
H-1664	-1.0926384925842285	▁heart ▁failure ▁; ▁death
D-1664	-1.0926384925842285	heart failure ; death
P-1664	-1.9115 -0.5122 -0.7214 -2.6063 -0.4663 -0.3381
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care ; outpatient ; acute heart failure
H-1026	-0.7437235713005066	▁Point - of - care ▁systems ▁; NP ▁; ▁ED ▁; ▁community ▁out patient ▁setting s ▁; ▁a cute ▁heart ▁failure
D-1026	-0.7437235713005066	Point-of-care systems ;NP ; ED ; community outpatient settings ; acute heart failure
P-1026	-2.7325 -0.1747 -0.0115 -0.1252 -0.2173 -0.5679 -0.4186 -2.3115 -0.5536 -1.4659 -0.3129 -2.2225 -1.9283 -0.1062 -1.1013 -0.2129 -0.3010 -0.3838 -0.2457 -0.7678 -0.2211 -0.4238 -0.2997
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus ; mortality ; hazard ratio ; confidence interval
H-129	-0.7145729660987854	▁mortal iteit ▁; haz ard ▁ratio
D-129	-0.7145729660987854	mortaliteit ;hazard ratio
P-129	-2.2669 -1.9307 -0.5744 -0.0431 -0.0461 -0.1894 -0.3922 -0.2738
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab ; chf ; nontrastuzumab users
H-678	-0.8638649582862854	▁tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab
D-678	-0.8638649582862854	trastuzumab ; CHF ; nontrastuzumab
P-678	-0.7688 -0.5518 -0.5552 -1.2328 -0.7217 -0.4211 -0.4030 -1.4381 -0.9224 -0.9871 -0.9834 -1.7743 -1.0303 -0.3040
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians ; patient ; anemic ; patients ; heart disease
H-34	-1.212479591369629	▁a ne mic ▁; ▁ir on - d eficient ▁adult ▁; ▁heart ▁disease
D-34	-1.212479591369629	anemic ; iron-deficient adult ; heart disease
P-34	-7.3918 -1.1060 -0.3084 -0.4478 -0.5066 -0.1566 -0.1899 -0.1185 -1.0053 -1.3244 -1.2220 -3.2210 -0.4236 -0.4337 -0.3315
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration ; patients ; hr reduction ; beta-blocker ; therapy
H-1947	-0.6617588400840759	▁HR ▁; ▁beta - block er ▁ therapy
D-1947	-0.6617588400840759	HR ; beta-blocker therapy
P-1947	-3.3867 -1.0500 -0.3042 -0.1565 -0.3899 -0.2223 -0.2358 -0.1205 -0.3972 -0.3545
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute heart failure ; ahf ; symptoms ; heart failure ; hf
H-1466	-1.160435438156128	▁a cute ▁heart ▁failure ▁; ▁a HF ▁; ▁heart ▁failure ▁; HF
D-1466	-1.160435438156128	acute heart failure ; aHF ; heart failure ;HF
P-1466	-1.7362 -0.1516 -1.1796 -0.3173 -0.2545 -3.1481 -2.9890 -0.2712 -2.1849 -0.5488 -0.2204 -2.6448 -0.3350 -0.2647
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis ; patients ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
H-1565	-0.9585848450660706	▁psoriasis ▁; ▁disease ▁; ▁at hero sc ler osis ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
D-1565	-0.9585848450660706	psoriasis ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
P-1565	-1.1900 -1.7224 -5.6139 -0.2675 -1.6426 -0.1193 -0.0347 -1.5208 -0.0764 -0.2460 -0.1767 -1.4338 -0.2307 -0.3490 -0.4258 -0.2877
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf ; remodeling ; emd ; dyssynchronous failing heart
H-1150	-0.8887537717819214	▁ HF ▁; ▁EM d ▁; ▁dys syn chron ous ▁fail ing ▁heart
D-1150	-0.8887537717819214	HF ; EMd ; dyssynchronous failing heart
P-1150	-1.0922 -2.0219 -0.2399 -2.5329 -0.5016 -0.2142 -0.2273 -0.0438 -0.0285 -2.6015 -0.3095 -0.4106 -2.4123 -0.3909 -0.3042
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
H-1142	-0.49683550000190735	▁Pyr ido stig mine ▁; ▁vas cular ▁en dot heli al ▁growth ▁factor ▁; ▁protein ▁; ▁left ▁vent ric le ▁; ▁my o card ial ▁ang io gene sis
D-1142	-0.49683550000190735	Pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
P-1142	-0.0950 -0.0218 -0.0025 -0.4790 -0.3729 -0.6519 -0.4973 -0.0365 -0.3564 -0.1825 -0.0457 -0.6547 -0.7952 -0.4105 -0.5637 -0.5767 -0.6540 -0.0780 -1.2895 -0.6218 -0.3741 -1.6816 -0.2077 -1.1118 -1.0682 -0.3665 -0.5649 -0.2046 -0.6683 -0.4604 -0.3082
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis ; idiopathic dilated cardiomyopathy
H-1742	-0.42768594622612	▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁co hor t
D-1742	-0.42768594622612	idiopathic dilated cardiomyopathy cohort
P-1742	-0.7561 -0.3454 -0.1496 -0.7785 -0.1914 -0.1290 -0.0822 -1.0228 -0.3097 -0.0811 -0.0691 -1.7063 -0.1306 -0.3655 -0.2980
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests ; cardiac growth ; disease ; chromatin ; remodeling
H-92	-0.7943435907363892	▁cardiac ▁; ▁plastic iteit ▁; ▁disease ▁; ▁chr omat in ▁remodel ing
D-92	-0.7943435907363892	cardiac ; plasticiteit ; disease ; chromatin remodeling
P-92	-0.4588 -2.4126 -1.0376 -1.4028 -0.3044 -1.8969 -0.7671 -0.1892 -0.0898 -0.4238 -0.0602 -0.2624 -1.5198 -0.2954
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients ; chf ; international classification of diseases
H-213	-0.7016359567642212	▁CHF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁Nin th ▁re vision
D-213	-0.7016359567642212	CHF ; international Classification of Diseases ; Ninth revision
P-213	-2.8327 -0.3429 -0.2379 -0.0904 -1.0301 -0.6595 -0.3083 -0.2302 -0.8975 -0.1068 -0.2222 -1.1070 -0.8746 -1.2445 -0.3400
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline ; embase ; cochrane ; clinical
H-41	-0.6244785189628601	▁med line ▁; EMBA se ▁; ▁co ch rane ▁database s ▁; ▁clinic al ▁trial ▁registri es
D-41	-0.6244785189628601	medline ;EMBAse ; cochrane databases ; clinical trial registries
P-41	-1.0677 -2.0706 -0.2910 -1.8007 -1.2204 -0.2721 -0.0450 -0.3254 -0.1448 -1.8203 -0.2683 -0.4634 -0.7039 -0.1385 -0.3997 -0.0357 -0.0539 -0.4095 -0.3340
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr ; vad ; ecmo ; vad ; ecmo
H-1393	-1.601231575012207	▁e g FR ▁; ▁ VAD ▁group ▁; ▁ec mo ▁; VAD ▁group ▁; ▁ec mo
D-1393	-1.601231575012207	egFR ; VAD group ; ecmo ;VAD group ; ecmo
P-1393	-0.1562 -2.7223 -3.0651 -0.3015 -1.8295 -0.4766 -2.5377 -0.3026 -0.9617 -3.1735 -2.5275 -1.8042 -3.2666 -0.3395 -1.2853 -2.3853 -1.4164 -0.2706
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ; ea ; tac ; ees ; patients
H-522	-0.9318095445632935	▁Ea ▁; ▁ TAC ▁; ▁HR ▁; ▁e es
D-522	-0.9318095445632935	Ea ; TAC ; HR ; ees
P-522	-1.6225 -0.3569 -1.1060 -2.8158 -0.3975 -1.3742 -0.3945 -1.0274 -0.3717 -0.4559 -0.3275
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant ; erc ; epicatechin ; muscle
H-1256	-0.8763628602027893	▁ ERC ▁; ▁pure ▁epi cate chin ▁; ▁muscle ▁function
D-1256	-0.8763628602027893	ERC ; pure epicatechin ; muscle function
P-1256	-2.9134 -1.1748 -0.2689 -1.4271 -0.1302 -0.0325 -0.7520 -0.3578 -2.3990 -0.2452 -0.4794 -0.3362
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait ; therapy ; lokomat ; heart failure ; patients
H-1921	-0.5847224593162537	▁Robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ▁; ▁system ▁; ▁heart ▁failure
D-1921	-0.5847224593162537	Robot-assisted gait therapy ; Lokomat ; system ; heart failure
P-1921	-0.8986 -0.4346 -0.0938 -0.6360 -0.3669 -0.3870 -0.2581 -0.0637 -0.3233 -0.3743 -0.0246 -2.1011 -1.1439 -0.3463 -1.0127 -0.3005 -1.5195 -0.2401
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline ; crf ; hf ; mortality ; hf
H-1775	-1.0819696187973022	▁c RF ▁; ▁ HF ▁mortal iteit ▁risk ▁; ▁ HF ▁risk ▁factors
D-1775	-1.0819696187973022	cRF ; HF mortaliteit risk ; HF risk factors
P-1775	-0.5809 -3.2616 -0.2800 -0.7250 -0.7228 -0.4281 -2.5255 -1.7895 -0.2029 -1.6875 -1.3792 -1.8047 -0.2451 -0.3349 -0.2620
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv dysfunction ; body mass index ; fat mass ; cachexia
H-1163	-0.7308420538902283	▁ rv ▁dys function ▁; ▁lower ▁body ▁mass ▁index ▁; ▁fat ▁mass ▁index ▁; ▁cache xia
D-1163	-0.7308420538902283	rv dysfunction ; lower body mass index ; fat mass index ; cachexia
P-1163	-2.4618 -0.8249 -0.0902 -0.2004 -0.3003 -2.1615 -2.1077 -0.1065 -0.0372 -0.3594 -2.9233 -0.2398 -0.0334 -0.3441 -0.1498 -0.1758 -0.3902 -0.2490
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients ; severe hf ; prognostic ; hf
H-1764	-1.1848254203796387	▁ HF ▁; HF
D-1764	-1.1848254203796387	HF ;HF
P-1764	-1.9640 -1.3264 -0.3300 -2.7561 -0.4222 -0.3103
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium ; expression ; pka ; downstream signaling
H-1433	-0.7723067998886108	▁my o car dium ▁; ▁display s ▁; ▁p ka ▁; ▁down stream ▁signal ing
D-1433	-0.7723067998886108	myocardium ; displays ; pka ; downstream signaling
P-1433	-1.5299 -0.2358 -0.1021 -0.2163 -0.4328 -2.0939 -0.3220 -0.2688 -1.4726 -2.7824 -0.3514 -1.2775 -0.1305 -0.5181 -0.7048 -0.3774 -0.3127
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth ; health ; outcomes ; medicare
H-1628	-0.5063015818595886	▁Care ▁management ▁; ▁content - driv en ▁tele health ▁technology ▁; ▁health ▁outcome s ▁; ▁Medica re
D-1628	-0.5063015818595886	Care management ; content-driven telehealth technology ; health outcomes ; Medicare
P-1628	-2.0265 -0.2221 -0.2881 -1.3584 -0.1562 -0.0989 -0.3326 -0.2571 -0.3560 -0.4208 -0.3074 -1.7104 -0.4713 -0.2966 -0.2646 -0.1665 -0.1301 -0.4904 -0.2656
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients ; hfpef ; prospective
H-736	-1.6971133947372437	▁h FP EF
D-736	-1.6971133947372437	hFPEF
P-736	-1.6834 -3.2475 -2.5691 -0.7245 -0.2612
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise ; health ; cardiac disease ; heart failure
H-1904	-1.0092523097991943	▁exercise ▁; ▁health ▁benefits ▁; ▁cardiac ▁disease ▁; ▁heart ▁failure
D-1904	-1.0092523097991943	exercise ; health benefits ; cardiac disease ; heart failure
P-1904	-2.4801 -0.3692 -2.4624 -1.6001 -0.4351 -0.3086 -1.1920 -0.2991 -1.7869 -0.4811 -0.4217 -0.2747
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl ; chf ; vascular
H-260	-1.0036011934280396	▁HD l ▁function ▁; ▁CHF ▁; ▁et h ▁; ▁vas cular ▁effects
D-260	-1.0036011934280396	HDl function ; CHF ; eth ; vascular effects
P-260	-2.0433 -2.9392 -0.1385 -0.3285 -0.2797 -0.3269 -1.4223 -0.4000 -1.5236 -2.6366 -0.2347 -1.1355 -0.3757 -0.2660
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf ; hf ; mortality
H-1774	-0.9053806662559509	▁ HF ▁; ▁risk ▁factors ▁; ▁fit ▁; ▁ HF ▁mortal iteit
D-1774	-0.9053806662559509	HF ; risk factors ; fit ; HF mortaliteit
P-1774	-1.2742 -1.0039 -0.7542 -0.5710 -0.2006 -0.3398 -0.9031 -1.2479 -1.5944 -1.0436 -0.2741 -2.4716 -0.6524 -0.3446
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician ; hf ; cpgs
H-1853	-1.1597132682800293	▁ HF ▁c PG s
D-1853	-1.1597132682800293	HF cPGs
P-1853	-2.1811 -1.3604 -2.0044 -1.6640 -0.1983 -0.4067 -0.3031
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective ; lvas
H-1995	-0.952569305896759	▁l VAS
D-1995	-0.952569305896759	lVAS
P-1995	-2.1543 -0.9900 -0.4056 -0.2604
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical ; nonprescribing ; patients
H-1128	-0.4593624770641327	▁bio medic al ▁; ▁non pre scribi ng
D-1128	-0.4593624770641327	biomedical ; nonprescribing
P-1128	-0.0634 -0.3720 -0.0936 -1.3290 -0.5146 -0.2073 -0.4368 -0.6514 -0.6543 -0.2713
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf ; hospitalization ; cardiovascular mortality
H-1639	-0.8614917993545532	▁black ▁race ▁; HF ▁; ▁hospital ization ▁; HR ▁; ▁cardiovascular ▁mortal iteit
D-1639	-0.8614917993545532	black race ;HF ; hospitalization ;HR ; cardiovascular mortaliteit
P-1639	-0.1179 -0.4002 -0.3192 -2.2950 -0.3565 -0.5340 -0.7521 -0.2981 -3.6033 -0.3489 -0.2463 -0.2772 -2.7510 -0.3406 -0.2821
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine ; nesiritide ; placebo
H-78	-0.5363160371780396	▁dop amine ▁; ▁nesi riti de ▁; ▁poole d ▁place bo ▁group
D-78	-0.5363160371780396	dopamine ; nesiritide ; pooled placebo group
P-78	-0.0296 -0.2912 -0.3230 -0.3174 -0.1918 -0.2981 -0.4071 -1.7358 -0.1507 -1.0359 -0.0746 -1.9351 -0.4342 -0.2836
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician ; nonprescribing ; patient
H-1127	-0.7179264426231384	▁chart ▁review
D-1127	-0.7179264426231384	chart review
P-1127	-1.9804 -0.1691 -0.4029 -0.3193
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt ; implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
H-1953	-0.5018422603607178	▁Shu nt ▁implant s ▁; ▁trans sept al ▁cat heter isation ▁; ▁trans o es op hage al ▁e cho car dio graphic
D-1953	-0.5018422603607178	Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic
P-1953	-1.3783 -0.1872 -0.6422 -0.5906 -0.4620 -0.0200 -0.2117 -0.2940 -0.2917 -0.0544 -0.3743 -0.3989 -0.0153 -1.2151 -0.6272 -0.0798 -1.1140 -0.1982 -0.2668 -0.2320 -0.1964 -0.9418 -1.4234 -0.9796 -0.3512
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric focusing ; riα ; ser77 ; ser83 ; in vivo ; phosphorylation
H-1430	-0.7031404972076416	▁iso electric ▁focus ing ▁; ▁RI α ▁; ▁ser 77 ▁; ▁ser 83 ▁; ▁in ▁vivo ▁ phos phor y lation ▁sites
D-1430	-0.7031404972076416	isoelectric focusing ; RIα ; ser77 ; ser83 ; in vivo phosphorylation sites
P-1430	-0.8132 -1.1950 -0.3990 -0.3246 -0.2408 -1.1841 -1.6237 -0.3619 -0.6522 -0.6233 -0.3120 -0.6405 -2.0271 -0.3247 -1.3518 -0.0274 -0.2436 -0.1803 -1.2953 -1.8035 -0.1705 -0.5344 -0.3149 -0.2317
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated ; baseline ; nt-probnp ; mr-proanp ; mr-proadm
H-17	-0.7393831014633179	▁NT - pro b NP ▁; ▁MR - pro AN p ▁; ▁MR - pro ad m
D-17	-0.7393831014633179	NT-probNP ; MR-proANp ; MR-proadm
P-17	-1.4018 -0.1441 -0.1225 -2.7699 -2.1710 -0.4814 -0.3617 -0.1173 -0.1311 -1.4697 -0.3939 -0.4507 -0.3531 -0.0937 -0.2144 -2.4220 -0.2399 -0.4083 -0.3017
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf antagonists ; hf ; hospital ; admissions ; nbdmards ; ra
H-611	-0.5208603143692017	▁t NF ▁; ▁anta gon ists ▁; ▁ HF ▁; ▁hospital ▁ad missions ▁; ▁n b DM ARD s ▁; ▁RA
D-611	-0.5208603143692017	tNF ; antagonists ; HF ; hospital admissions ; nbDMARDs ; RA
P-611	-1.4124 -1.7325 -0.4580 -0.0227 -0.0200 -1.0405 -0.3386 -0.8448 -0.7437 -0.3945 -0.2435 -0.2568 -0.2254 -0.2823 -0.1451 -0.0401 -1.1593 -0.8280 -0.4884 -0.3143 -0.1657 -0.5289 -0.2943
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology ; myocardial infarction ; mi ; outcomes ; heart failure ; hf
H-1099	-0.9269083142280579	▁my o card ial ▁in far ction ▁; ▁m ▁; ▁heart ▁failure ▁; HF
D-1099	-0.9269083142280579	myocardial infarction ; m ; heart failure ;HF
P-1099	-2.3744 -0.3392 -0.6975 -1.4590 -0.1282 -0.7588 -0.6410 -0.2765 -1.2574 -2.6100 -1.4456 -0.4283 -0.2412 -1.4602 -0.3930 -0.3204
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart rate reduction ; exercise ; heart failure with reduced ejection fraction ; beta-blocker
H-1935	-0.5540098547935486	▁Heart ▁rate ▁re duction ▁; ▁exercise ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁beta - block er
D-1935	-0.5540098547935486	Heart rate reduction ; exercise ; heart failure ; ejection fraction ; beta-blocker
P-1935	-1.4621 -1.0069 -0.4654 -0.5570 -0.2516 -0.6665 -0.8810 -1.9032 -0.3621 -0.3035 -0.2057 -0.1074 -0.0433 -0.2785 -0.0184 -2.4791 -0.0973 -0.0637 -0.2542 -0.0882 -0.4061 -0.2871
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients ; heartmate ii ; biventricular support ; heartmate ii ; implantation
H-300	-1.045366883277893	▁Heart Mate ▁II ▁ insertion ▁; ▁Heart Mate ▁i ▁implant ation
D-300	-1.045366883277893	HeartMate II insertion ; HeartMate i implantation
P-300	-0.9885 -0.4068 -1.7374 -1.1662 -0.1947 -0.3067 -3.0052 -0.7176 -1.5749 -1.0018 -1.6483 -0.4766 -0.3650
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient ; st-segment-elevation mis ; killip class ; comorbid ; conditions
H-1105	-0.48391270637512207	▁MI s ▁; ▁lower ▁Kill ip ▁class
D-1105	-0.48391270637512207	MIs ; lower Killip class
P-1105	-1.9510 -0.4291 -0.2989 -0.4245 -0.2427 -0.3242 -0.0940 -0.3108 -0.2799
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-868	-0.5278498530387878	▁m ADI t - c RT ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy ▁; ▁ nc w
D-868	-0.5278498530387878	mADIt-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy ; ncw
P-868	-2.4405 -0.2865 -0.1286 -0.0742 -0.4484 -3.5335 -0.3127 -0.6258 -0.0541 -0.3304 -0.0840 -0.2927 -0.1533 -0.6238 -0.0857 -0.2893 -0.6651 -0.7331 -0.3744 -0.2904 -0.4381 -0.0917 -0.0071 -1.0851 -0.3478 -0.3784 -0.2119 -0.0155 -1.0762 -0.6199 -0.2651
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic ; admission ; brain natriuretic peptide ; bnp ; creatinine ; natremia
H-585	-0.7075436115264893	▁se rum ▁levels ▁; ▁brain ▁; ▁na tri ure tic ▁pe pti de ▁; ▁b p ▁; ▁creati nine ▁; ▁na trem ia
D-585	-0.7075436115264893	serum levels ; brain ; natriuretic peptide ; bp ; creatinine ; natremia
P-585	-0.5418 -1.1441 -1.2768 -0.2764 -0.8887 -0.4955 -0.0237 -1.0428 -0.2133 -1.7424 -0.5006 -0.2724 -0.8690 -0.3238 -0.3987 -2.9648 -0.2932 -0.0530 -1.5841 -0.2652 -0.0535 -0.2310 -1.5252 -0.4186 -0.2901
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ; ras ; asymptomatic ; clinically ; hypertension ; nephropathy ; congestive heart failure
H-1597	-0.50636225938797	RAS ▁; ▁hyper tension ▁; ▁nep hro pathy ▁; ▁con ges tive ▁heart ▁failure
D-1597	-0.50636225938797	RAS ; hypertension ; nephropathy ; congestive heart failure
P-1597	-0.2566 -0.2763 -0.2426 -0.0992 -0.2414 -0.1730 -0.0433 -0.2031 -0.2839 -0.3910 -0.6489 -3.3500 -0.9357 -0.2357 -0.4587 -0.2626
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-367	-0.6209009885787964	▁functional ▁; ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV ▁; ▁disease
D-367	-0.6209009885787964	functional ; MS ; valve plasty ; degenerative MR ; LV ; disease
P-367	-0.6882 -1.0874 -0.8663 -0.3342 -1.8044 -0.1031 -0.2251 -1.7467 -0.2919 -0.1070 -0.0201 -1.3876 -0.5637 -0.3427 -0.2193 -0.7157 -0.6666 -0.3421 -0.2850
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 ; n2bus ; s12884 ; pevk
H-769	-0.6635291576385498	▁n 2 bu s ▁segment ▁; ▁PE v k
D-769	-0.6635291576385498	n2bus segment ; PEvk
P-769	-0.6404 -0.1468 -1.1481 -0.6959 -0.2382 -0.3037 -0.3388 -1.2839 -1.1104 -1.0949 -0.2977
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end stage heart failure ; heart failure ; public ; health ; patient ; europe ; north america
H-1663	-1.2996033430099487	▁end ▁stage ▁heart ▁failure ▁; ▁Heart ▁failure ▁; ▁public ▁health ▁; ▁europa ▁; ▁north ▁America
D-1663	-1.2996033430099487	end stage heart failure ; Heart failure ; public health ; europa ; north America
P-1663	-5.1356 -0.2088 -2.1806 -0.8322 -0.3735 -2.3910 -0.5782 -0.2437 -1.1223 -1.6113 -1.2614 -3.0368 -0.3169 -0.5764 -1.4764 -0.4502 -0.2980
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil ; mitochondrial dysfunction ; heart failure ; cardioprotection
H-954	-0.4296341836452484	▁Nico rand il ▁; ▁mito cho ndri al ▁dys function ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s ▁; ▁cardio protec tion
D-954	-0.4296341836452484	Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; cardioprotection
P-954	-0.0334 -0.0444 -0.1672 -0.3607 -0.1281 -1.4406 -0.4164 -0.2391 -0.0644 -0.2078 -0.3080 -0.2584 -0.0665 -0.0664 -1.4368 -0.2989 -0.4225 -1.3369 -1.0309 -0.3774 -0.2298 -0.1934 -0.1971 -0.2447 -0.4784 -0.4207 -1.3680 -0.3917 -0.2308
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate ; left ventricular assist system ; lvas ; patients ; heart failure
H-1993	-1.016069769859314	▁Heart Mate ▁; ▁left ▁vent ri cular ▁assist ▁system ▁; ▁l VAS ▁; ▁heart ▁failure
D-1993	-1.016069769859314	HeartMate ; left ventricular assist system ; lVAS ; heart failure
P-1993	-1.3073 -0.5286 -0.2602 -2.1845 -0.2600 -2.0427 -0.4720 -1.3642 -0.2866 -0.3589 -0.0762 -1.0278 -0.3438 -5.3845 -0.6355 -0.4723 -0.2681
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 ; hno ; cxl-1051 ; t1
H-416	-0.944745659828186	▁c XL -10 20 ▁; ▁h no ▁; ▁in active ▁; ▁c XL -10 51
D-416	-0.944745659828186	cXL-1020 ; hno ; inactive ; cXL-1051
P-416	-0.5456 -1.7839 -0.4742 -2.4889 -0.3759 -2.5547 -1.3631 -0.3100 -0.1140 -0.4414 -0.7624 -0.7484 -1.7188 -0.8230 -0.7340 -0.5078 -0.3147
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
H-517	-0.6415246725082397	▁arterial ▁elastan ce ▁; ▁e a ▁; ▁pulsa tile ▁after load ▁; ▁heart ▁; ▁pressure ▁volume ▁relation
D-517	-0.6415246725082397	arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
P-517	-0.5913 -0.8343 -1.8893 -0.2907 -1.0127 -0.0316 -0.3587 -0.3159 -0.1554 -2.5017 -0.2499 -0.2284 -1.4452 -0.2631 -0.5818 -0.3091 -0.4566 -0.4334 -0.2399
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic ; acute hf ; adverse event ; chronic hf
H-1016	-0.576885461807251	▁ pharma c ologic ▁management ▁; ▁a cute ▁ HF ▁; ▁advers e ▁event ▁rates ▁; ▁chronic ▁ HF
D-1016	-0.576885461807251	pharmacologic management ; acute HF ; adverse event rates ; chronic HF
P-1016	-0.8824 -1.1947 -0.1320 -0.2130 -0.4551 -0.2501 -0.3025 -0.1193 -0.3928 -0.5443 -0.2972 -2.2298 -0.0654 -0.3835 -1.5220 -0.2789 -0.6720 -0.6645 -0.8995 -0.3483 -0.2673
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics ; chromatin-associated proteins ; disease
H-93	-0.5421372056007385	▁prote o mics ▁; ▁chr omat in - as soci ated ▁protein s ▁; ▁detergent
D-93	-0.5421372056007385	proteomics ; chromatin-associated proteins ; detergent
P-93	-0.4379 -1.2182 -0.0655 -0.4431 -0.2588 -0.1275 -0.8082 -0.3087 -0.1710 -0.0554 -1.0003 -0.4846 -0.5616 -0.5169 -1.0628 -1.4376 -0.2580
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart failure ; cardiology-cardiovascular surgery consensus report ; heart failure ; disease
H-1818	-0.716659665107727	▁heart ▁failure ▁; ▁mechanic al ▁support ▁devices ▁; ▁Card i ology - car dio vas cular ▁Sur ger y ▁Cons en sus ▁report ▁; ▁Heart ▁failure ▁; ▁progressive ▁disease
D-1818	-0.716659665107727	heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery Consensus report ; Heart failure ; progressive disease
P-1818	-3.5125 -0.6670 -0.1851 -0.7683 -0.0870 -0.5655 -0.3846 -0.2159 -2.5871 -0.1012 -0.2086 -0.0830 -0.1443 -1.0155 -1.1489 -0.2060 -1.1481 -2.1685 -0.4756 -0.0982 -0.0522 -0.5864 -1.1041 -0.4299 -1.0748 -0.4092 -0.4792 -1.2927 -0.4771 -0.2853 -0.2549
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect ; heart failure ; patients ; implantable cardioverter-defibrillator
H-1860	-0.5585924386978149	▁heart ▁failure ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
D-1860	-0.5585924386978149	heart failure ; implantable cardioverter-defibrillator
P-1860	-4.1817 -0.2420 -0.4317 -0.6148 -0.2276 -0.3466 -0.1220 -0.2965 -0.2799 -0.0664 -0.0613 -0.9095 -0.3562 -0.1071 -0.4406 -0.2536
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care of heart failure index version 6.2 ; schfi v.6.2 ; psychometric
H-1504	-0.8071532845497131	▁Self - car e ▁of ▁Heart ▁Fail ure ▁index ▁; ▁ schen fi ▁; ▁psycho metric ▁profile
D-1504	-0.8071532845497131	Self-care of Heart Failure index ; schenfi ; psychometric profile
P-1504	-0.2128 -0.0851 -1.6992 -0.5558 -1.2933 -1.0039 -0.5238 -1.0530 -0.7012 -0.3273 -0.6730 -2.0170 -4.0343 -0.2539 -0.1111 -0.1306 -0.0865 -0.3303 -0.2438
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-867	-0.5274642109870911	▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol
D-867	-0.5274642109870911	atrial fibrillation ; carvedilol ; metoprolol
P-867	-2.7073 -0.4602 -1.0233 -0.1980 -0.5279 -0.4308 -0.0395 -0.2819 -0.2658 -0.4369 -0.2503 -0.2641 -0.2217 -0.6081 -0.4363 -0.2872
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt ; sd of rr intervals ; sdrr ; qtv ; heart rate variability
H-1440	-1.2501599788665771	▁SD QT ▁; ▁SD r ▁interval s ▁; SD r ▁; ▁index ▁; ▁ nc w ▁; ▁heart ▁rate ▁variabil iteit
D-1440	-1.2501599788665771	SDQT ; SDr intervals ;SDr ; index ; ncw ; heart rate variabiliteit
P-1440	-1.0816 -3.9396 -0.3364 -0.9965 -2.5925 -2.3516 -0.2911 -0.2640 -3.5363 -1.9149 -0.3225 -0.0646 -0.3675 -1.2407 -1.9074 -0.3427 -0.3080 -1.4920 -0.8127 -0.2852 -3.6137 -0.3811 -0.3110
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health care ; clinically ; gastrointestinal bleeding
H-1658	-0.862216591835022	▁devices ▁; ▁significant ▁; ▁gastro inte stin al ▁ble ed ing
D-1658	-0.862216591835022	devices ; significant ; gastrointestinal bleeding
P-1658	-1.3518 -0.2957 -2.7451 -1.8527 -0.3357 -0.6664 -1.7226 -0.2047 -0.1382 -1.0893 -0.1982 -0.3739 -0.2345
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital ; readmission ; patients ; heart failure ; follow-up
H-731	-1.0923823118209839	▁heart ▁failure ▁; ▁follow - up ▁visit s
D-731	-1.0923823118209839	heart failure ; follow-up visits
P-731	-7.2177 -0.6365 -0.4223 -0.0228 -0.2589 -0.0454 -1.2786 -0.3558 -0.3735 -0.3123
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic regression ; primary outcome ; secondary outcome ; death
H-973	-0.8834373950958252	▁Log istic ▁re gression ▁; ▁death
D-973	-0.8834373950958252	Logistic regression ; death
P-973	-1.8877 -0.4840 -0.1355 -0.1969 -1.1834 -2.6105 -0.2995 -0.2700
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr ; vad ; ecmo ; vad ; renal function
H-1391	-1.2476606369018555	▁e g FR ▁; ▁ VAD ▁group ▁; ▁ec mo ▁; VAD ▁; ▁renal ▁function
D-1391	-1.2476606369018555	egFR ; VAD group ; ecmo ;VAD ; renal function
P-1391	-0.1624 -2.0309 -2.3502 -0.2923 -2.6209 -0.3941 -2.2899 -0.3075 -0.5971 -3.1720 -2.9243 -1.2755 -1.3489 -0.1395 -0.6786 -0.3635 -0.2625
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs ; septal ; qrs ; resynchronization
H-486	-1.4428380727767944	▁ac s ▁; ▁e sept al ▁; ▁QR s ▁ width
D-486	-1.4428380727767944	acs ; eseptal ; QRs width
P-486	-3.6430 -2.0132 -0.6959 -2.2793 -4.2159 -0.1285 -0.3674 -2.8155 -0.8678 -0.5326 -0.2999 -0.5782 -0.3196
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician ; mortality ; hf ; physicians
H-1731	-0.9219181537628174	▁ HF ▁; ▁non car dio logist ▁; ▁physician s
D-1731	-0.9219181537628174	HF ; noncardiologist ; physicians
P-1731	-4.1549 -1.4509 -0.3482 -0.3462 -0.0563 -0.6625 -0.6262 -2.2424 -0.2042 -0.3153 -0.3691 -0.2868
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv ejection fraction ; pcwp
H-483	-0.5087940692901611	▁LV ▁; ▁e je ction ▁ fraction ▁; ▁pc w
D-483	-0.5087940692901611	LV ; ejection fraction ; pcw
P-483	-0.3858 -0.4943 -0.1986 -0.6765 -0.2687 -0.4455 -0.0655 -0.4567 -0.1532 -1.8726 -0.7860 -0.3019
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective ; diuretics ; morbidity ; mortality
H-1200	-0.5674669742584229	▁di ure tics ▁; ▁morbi d iteit ▁; ▁mortal iteit
D-1200	-0.5674669742584229	diuretics ; morbiditeit ; mortaliteit
P-1200	-0.3903 -0.3046 -0.3901 -0.5328 -0.1908 -0.1590 -1.7841 -0.6213 -0.0628 -1.8509 -0.2928 -0.2303
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission ; hospital ; congestive heart failure ; united states
H-1574	-0.92802894115448	▁con ges tive ▁heart ▁failure ▁; ▁veren ig de ▁staten
D-1574	-0.92802894115448	congestive heart failure ; verenigde staten
P-1574	-0.9682 -0.7019 -2.3659 -0.9921 -0.6499 -0.3161 -2.6207 -0.0343 -0.1799 -1.5266 -0.4510 -0.3296
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc occlusion ; correlated ; rs ; rs synchrony
H-326	-0.4544163942337036	▁i cc ▁oc clusi on ▁; ▁co ▁; ▁twist ▁; ▁ap ical ▁ro tation ▁; ▁RS ▁; ▁RS ▁synchron y ▁; ▁CS
D-326	-0.4544163942337036	icc occlusion ; co ; twist ; apical rotation ; RS ; RS synchrony ; CS
P-326	-0.4446 -0.2137 -0.7874 -0.0564 -1.8415 -0.3270 -0.8372 -0.3526 -0.7300 -0.2738 -0.4341 -0.5411 -0.0305 -0.0628 -0.3508 -0.2682 -0.3508 -0.3204 -0.0093 -1.0291 -0.3277 -0.6960 -0.3709 -0.2501
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf ; chf ; patients ; intubated
H-214	-0.9044712781906128	▁CHF ▁; ▁ED ▁visit s ▁; ▁CHF ▁; ▁in tuba ted
D-214	-0.9044712781906128	CHF ; ED visits ; CHF ; intubated
P-214	-1.0284 -1.2870 -2.2764 -2.0760 -0.5606 -0.3295 -1.4057 -0.5783 -0.6503 -0.3692 -0.5964 -0.3276 -0.2728
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency department ; acute heart failure ; clinical ; patient ; collins
H-56	-0.4256807565689087	▁emergency ▁department ▁; ▁a cute ▁heart ▁failure ▁; ▁Collins
D-56	-0.4256807565689087	emergency department ; acute heart failure ; Collins
P-56	-1.1015 -0.0650 -0.2520 -0.2837 -0.1150 -1.0475 -0.2975 -0.3746 -0.4775 -0.4010 -0.2670
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin ; genomic reprogramming ; disease
H-100	-0.35308513045310974	▁zebra fish ▁; ▁nu cle olin ▁; ▁genom ic ▁re programm ing ▁events
D-100	-0.35308513045310974	zebrafish ; nucleolin ; genomic reprogramming events
P-100	-0.0754 -0.3285 -0.3428 -0.3801 -0.0090 -0.1742 -0.4095 -0.2169 -0.4196 -0.0914 -0.2490 -0.1133 -1.4690 -0.7892 -0.2284
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician ; evidence
H-1842	-1.1600691080093384	▁voordelen
D-1842	-1.1600691080093384	voordelen
P-1842	-2.8442 -0.3884 -0.2476
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate analysis ; gls
H-817	-1.0989038944244385	▁g s ▁; HR ▁; ▁CV
D-817	-1.0989038944244385	gs ;HR ; CV
P-817	-0.3992 -2.4387 -0.2980 -2.5789 -0.3373 -1.6630 -0.6877 -0.3885
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 ; sst2 ; outcomes
H-406	-0.8830592036247253	▁s st 2/ low - dos e ▁BB ▁; ▁s st 2/ high - dos e ▁BB
D-406	-0.8830592036247253	sst2/low-dose BB ; sst2/high-dose BB
P-406	-0.8313 -2.3900 -1.3053 -0.5615 -0.3113 -0.8642 -0.2714 -0.5093 -0.3692 -0.4530 -2.2850 -1.5185 -2.2624 -0.4847 -1.0456 -0.2212 -0.5029 -0.3352 -0.2562
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients ; t1 times ; cardiac events
H-740	-0.43957310914993286	▁cardiac ▁events
D-740	-0.43957310914993286	cardiac events
P-740	-0.3568 -0.7159 -0.4314 -0.2542
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ; ejection fraction
H-1236	-0.354574978351593	▁e je ction ▁ fraction
D-1236	-0.354574978351593	ejection fraction
P-1236	-0.2256 -0.7241 -0.2669 -0.3447 -0.1060 -0.4855 -0.3291
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence ; hf ; ami ; mortality
H-1314	-1.3546762466430664	HF ▁; AMI ▁; ▁mortal iteit
D-1314	-1.3546762466430664	HF ;AMI ; mortaliteit
P-1314	-2.8383 -0.3137 -2.7807 -1.4457 -0.5587 -2.3153 -0.3207 -0.2643
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized ; exercise ; exercise
H-1981	-0.7748235464096069	▁exercise ▁; ▁die t ▁; ▁exercise ▁; ▁die t
D-1981	-0.7748235464096069	exercise ; diet ; exercise ; diet
P-1981	-1.9448 -0.3407 -0.5261 -0.1952 -0.4727 -3.0416 -0.3036 -0.8502 -0.2214 -0.3488 -0.2778
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality ; hospitals
H-1695	-1.0529371500015259	▁mortal iteit
D-1695	-1.0529371500015259	mortaliteit
P-1695	-0.2632 -2.3209 -1.3240 -0.3036
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses ; magnet
H-87	-0.7343592643737793	▁nurse s ▁; ▁benefits ▁; ▁magnet
D-87	-0.7343592643737793	nurses ; benefits ; magnet
P-87	-0.8466 -0.2466 -0.3081 -1.1502 -0.3437 -0.3186 -2.4264 -0.2346
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed ; patients ; hf ; drug treatment ; paf ; biosynthetic enzymes ; lyso-paf-at
H-1271	-0.8104897141456604	▁ HF ▁; ▁drug ▁treatment ▁; ▁PA f ▁bio syn the tic ▁enzym es ▁; ▁lys o - pa f - AT
D-1271	-0.8104897141456604	HF ; drug treatment ; PAf biosynthetic enzymes ; lyso-paf-AT
P-1271	-2.6838 -1.5176 -0.3166 -1.1394 -0.5285 -0.3177 -1.7815 -2.9398 -0.2158 -0.0535 -0.7027 -1.4596 -0.1550 -0.3893 -0.3975 -0.0806 -0.1517 -0.0636 -0.6069 -2.0678 -0.1657 -0.9517 -0.4525 -0.3129
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic ; tests ; cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments ; baseline
H-737	-0.45567238330841064	▁cardiac ▁magnetic ▁res on ance ▁imagin g ▁; ▁t 1 ▁ma pping ▁; ▁invasi ve ▁hem o dynamic ▁assessment s
D-737	-0.45567238330841064	cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments
P-737	-0.6110 -0.9517 -0.8816 -0.7582 -0.3136 -0.5080 -0.6749 -0.3417 -0.4542 -0.8911 -0.0554 -0.1739 -0.3664 -0.3109 -0.6286 -0.1954 -0.5763 -0.0674 -0.0776 -0.4510 -0.4219 -0.3140
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf with preserved ejection fraction ; pef ; uptitration ; hospitalization
H-176	-1.01055109500885	HF ▁; ▁e je ction ▁ fraction ▁; ▁p EF
D-176	-1.01055109500885	HF ; ejection fraction ; pEF
P-176	-5.1983 -0.3918 -1.3709 -0.7293 -0.2009 -0.4737 -0.0427 -0.3624 -0.4477 -1.8288 -0.7602 -0.3198
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf ; hhd ; salt loading ; uninephrectomy ; ang ii infusion
H-275	-0.581727147102356	▁mouse ▁; ▁h h ▁; ▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion
D-275	-0.581727147102356	mouse ; hh ; salt loading ; uninephrectomy ; ANG II infusion
P-275	-0.5039 -0.2539 -1.6594 -2.3971 -0.2698 -0.2902 -0.1175 -0.2426 -0.3054 -0.0753 -1.2114 -0.9925 -0.0656 -0.0805 -1.1988 -0.3139 -0.1319 -1.8453 -0.0360 -0.1056 -0.4302 -0.2712
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras ; neprilysin inhibition ; change ; stable ; chronic heart failure ; systolic dysfunction
H-1971	-0.6020430326461792	▁Dual ▁ RAS ▁; ▁nepri ly sin ▁inhibi tion ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function ▁; ▁treatment
D-1971	-0.6020430326461792	Dual RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction ; treatment
P-1971	-1.0834 -0.6910 -0.1264 -0.3491 -0.2055 -0.5542 -1.1616 -0.1316 -1.6642 -0.3813 -2.7275 -1.5582 -0.3921 -0.3136 -0.1145 -0.1240 -0.4401 -0.0316 -0.0686 -0.3186 -0.5421 -0.5763 -0.2916
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping ; tidal respiration ; administration ; gadolinium-chelate contrast agent
H-1058	-0.6352860927581787	▁t 1- ma pping ▁se que nce ▁; ▁tid al ▁respira tion ▁; ▁ gado lini um - che late ▁contrast ▁agent
D-1058	-0.6352860927581787	t1-mapping sequence ; tidal respiration ; gadolinium-chelate contrast agent
P-1058	-1.2473 -0.3220 -0.7550 -0.7950 -1.4377 -2.0807 -1.7834 -0.4025 -0.3660 -0.1385 -0.5233 -0.9550 -0.3688 -0.2367 -0.2251 -0.3045 -0.3324 -0.2171 -0.0586 -1.0847 -0.7785 -0.0376 -0.4538 -0.3427
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare ; inpatient ; hf ; admissions ; acute ; hospitals ; united states
H-1723	-0.7248907089233398	▁Medica re ▁in patient ▁; ▁ HF ▁; ▁ad missions ▁; ▁a cute ▁care ▁hospital s ▁; ▁veren ig de ▁staten
D-1723	-0.7248907089233398	Medicare inpatient ; HF ; admissions ; acute care hospitals ; verenigde staten
P-1723	-0.1437 -0.1994 -0.4661 -0.0947 -1.9889 -1.6796 -1.4727 -0.6013 -0.2420 -0.4277 -0.3516 -0.1884 -0.1597 -2.0022 -0.6259 -0.5355 -0.2884 -2.2033 -0.0210 -0.1544 -2.2146 -0.3370 -0.2742
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients ; idiopathic dilated cardiomyopathy ; tuscany ; evidence-based
H-1739	-0.3509254455566406	▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁tu sca ny
D-1739	-0.3509254455566406	idiopathic dilated cardiomyopathy ; tuscany
P-1739	-0.5603 -0.2186 -0.2707 -0.6074 -0.1735 -0.1930 -0.0643 -0.7629 -0.2520 -0.0472 -0.2813 -0.1233 -0.1282 -1.1755 -0.4428 -0.3139
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity ; mortality ; hfpef ; patients ; hf ; reduced ef
H-1301	-0.8120867609977722	▁Morbi d iteit ▁; ▁mortal iteit ▁; HF p EF ▁; ▁ HF ▁; ▁EF
D-1301	-0.8120867609977722	Morbiditeit ; mortaliteit ;HFpEF ; HF ; EF
P-1301	-0.7900 -0.5526 -1.2213 -0.2575 -0.1359 -2.0941 -0.3386 -2.2850 -0.0578 -0.5701 -0.3891 -2.0146 -1.3209 -0.4254 -0.4557 -0.6664 -0.2304
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report ; dapc ; dystrophin-associated protein complex ; sarcomeric microstructure ; baseline
H-1253	-0.40166938304901123	▁DAP c ▁; dys trop hin - as soci ated ▁protein ▁complex ▁; ▁sar come ric ▁micro structure
D-1253	-0.40166938304901123	DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
P-1253	-0.0603 -1.0060 -0.2734 -0.0727 -0.0889 -1.0089 -0.2851 -0.1039 -0.0100 -1.1741 -0.2029 -0.2764 -0.2996 -0.0947 -0.3733 -1.4648 -0.0961 -0.5540 -0.3232 -0.2649
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; rose ; acute heart failure ; randomized
H-71	-0.48911529779434204	▁dop amine ▁; ▁low - dos e ▁nesi riti de ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁a cute ▁heart ▁failure
D-71	-0.48911529779434204	dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction ; acute heart failure
P-71	-0.8945 -0.3191 -0.3653 -1.1114 -0.1384 -0.4202 -0.2077 -0.2457 -0.1327 -0.4759 -0.4565 -0.2594 -0.0933 -1.4105 -0.3640 -0.5892 -0.1195 -0.0522 -0.0981 -0.3485 -1.4478 -0.2516 -1.9380 -0.3463 -0.3613 -0.2701
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes ; catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction
H-941	-0.4430837631225586	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-941	-0.4430837631225586	catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
P-941	-0.7388 -0.1764 -0.0772 -0.3667 -0.3788 -0.7742 -0.2803 -0.4582 -0.1739 -0.3360 -0.3287 -1.3082 -0.3804 -0.2241 -1.7772 -0.4027 -0.1114 -0.2060 -0.0128 -0.4909 -0.3018
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg ; congenital ; accessory ; ion channelopathies ; cardiomyopathy
H-1909	-0.4582821726799011	▁e CG ▁; ▁con geni tal ▁accesso ry ▁path ways ▁; ▁ion ▁channel o pathi es ▁; ▁cardio my o pathy
D-1909	-0.4582821726799011	eCG ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
P-1909	-1.1341 -2.9201 -0.2839 -1.0958 -0.0904 -0.0922 -0.0928 -1.5328 -0.2668 -0.1437 -0.3099 -0.0372 -0.0639 -0.5013 -0.0491 -0.2327 -0.2726 -0.1116 -0.4521 -0.0969 -0.0341 -0.4386 -0.2880
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart failure ; hf ; risk stratification ; inpatient ; outpatient
H-378	-0.8119350671768188	▁heart ▁failure ▁; HF ▁; ▁risk ▁strat ification ▁; ▁in patient ▁; ▁out patient
D-378	-0.8119350671768188	heart failure ;HF ; risk stratification ; inpatient ; outpatient
P-378	-2.1567 -0.5671 -0.2986 -1.1422 -0.3489 -1.5704 -0.6239 -1.3455 -0.3654 -0.0959 -0.0848 -0.9715 -2.5189 -0.1111 -0.4995 -0.2905
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf ; pyridostigmine ; basal heart rate ; sympathetic control of heart rate
H-1140	-0.607477605342865	▁ conscious ▁; HF ▁; ▁py rido stig mine ▁; ▁bas al ▁heart ▁rate ▁; ▁va gal ▁; ▁sympa the tic ▁control ▁; ▁heart ▁rate
D-1140	-0.607477605342865	conscious ;HF ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
P-1140	-0.7592 -1.9850 -0.3119 -1.4345 -0.5094 -0.0161 -0.0288 -0.0084 -0.3601 -0.3081 -1.5957 -0.1557 -1.1396 -0.7654 -0.3123 -0.0249 -0.0372 -0.2673 -0.1100 -0.8789 -1.0432 -0.8853 -0.2187 -1.6528 -0.9173 -0.3661 -0.3101
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence ; intravenous ; exercise tolerance ; quality of life ; patients ; heart failure
H-46	-1.0372505187988281	▁Moder e - streng th ▁; ▁intra ven ous ▁ir on ▁; ▁exercise ▁ tolerance ▁; ▁heart ▁failure
D-46	-1.0372505187988281	Modere-strength ; intravenous iron ; exercise tolerance ; heart failure
P-46	-3.2457 -3.5447 -0.2108 -0.0203 -2.1570 -0.4247 -1.1441 -0.0616 -3.1777 -0.6427 -0.2552 -0.3419 -1.1322 -0.1807 -0.0733 -0.3475 -2.6031 -0.4329 -0.4804 -0.2684
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating agents ; patients ; anemia ; heart disease
H-52	-1.0595604181289673	▁ thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁heart ▁disease
D-52	-1.0595604181289673	thropoiesis-stimulating agents ; anemia ; heart disease
P-52	-2.4326 -4.6984 -1.3686 -1.2565 -0.4508 -0.5903 -0.0678 -1.4382 -0.4479 -0.3177 -1.3471 -0.6168 -0.3098 -1.4011 -0.6949 -0.3218 -0.2524
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet ; bromodomain-containing protein 4 ; brd4 ; cardiac
H-1045	-0.7293769717216492	▁bet ▁; ▁bro modo main - conta ining ▁protein ▁; br d ▁; ▁cardiac ▁tissu es
D-1045	-0.7293769717216492	bet ; bromodomain-containing protein ;brd ; cardiac tissues
P-1045	-1.6008 -0.3521 -0.0078 -0.2937 -0.6541 -0.4273 -0.1907 -1.7545 -0.2068 -1.2947 -3.0361 -0.3037 -1.6823 -0.0830 -0.2522 -0.3822 -0.3338 -0.2731
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs ; québec health insurance board ; costs ; ontario case costing initiative
H-1235	-0.9131421446800232	▁kosten ▁; ▁Québec ▁Health ▁Insurance ▁Board ▁; ▁kosten ▁; ▁Ontario ▁Case ▁cost ing ▁Initiative
D-1235	-0.9131421446800232	kosten ; Québec Health Insurance Board ; kosten ; Ontario Case costing Initiative
P-1235	-1.8017 -0.3525 -1.0691 -1.8723 -1.0337 -0.8111 -0.3537 -1.5486 -0.2889 -2.5958 -0.7154 -0.7005 -0.1304 -0.6531 -0.4655 -0.2181
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report ; mitral valve plasty ; degenerative mitral regurgitation
H-335	-0.6248220205307007	▁mit ral ▁val ve ▁; ▁plast y ▁; ▁de genera tive ▁mit ral ▁re gur gi tation
D-335	-0.6248220205307007	mitral valve ; plasty ; degenerative mitral regurgitation
P-335	-0.9390 -0.4843 -0.2336 -0.2785 -1.3100 -0.1119 -1.8769 -0.2614 -0.3083 -0.0300 -1.7525 -1.2367 -0.8176 -0.0582 -0.3864 -0.8134 -0.2690 -0.4278 -0.2761
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol ; metoprolol ; therapy ; heart failure ; patients
H-857	-0.46898460388183594	▁car vedi lol ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁; ▁devices
D-857	-0.46898460388183594	carvedilol ; metoprolol ; heart failure ; devices
P-857	-0.0951 -0.2146 -0.2379 -0.3499 -0.0853 -0.2528 -0.2293 -0.4603 -0.3608 -2.6074 -0.4485 -0.4063 -0.6189 -0.3818 -0.2859
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf ; heart failure ; t2d ; type 2 diabetes ; skm ; skeletal muscle
H-1244	-0.5240572094917297	HF ▁; heart ▁failure ▁; ▁t 2 d ▁; Type ▁2 ▁diabetes ▁; ▁Sk m ▁; s kelet al ▁muscle
D-1244	-0.5240572094917297	HF ;heart failure ; t2d ;Type 2 diabetes ; Skm ;skeletal muscle
P-1244	-1.1973 -0.2663 -1.3836 -0.1582 -0.3068 -0.6184 -0.0204 -0.3577 -0.2386 -0.3544 -1.1812 -0.0478 -0.4044 -0.1363 -0.2675 -0.2848 -3.0749 -0.0833 -0.3364 -0.2578 -0.2995 -0.2535
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians ; public ; health ; air ; cardiovascular ; health ; lead ; hospitalisation ; death
H-1808	-1.0685499906539917	▁public ▁health ▁; ▁air ▁pollution ▁; ▁industrial ▁; ▁cardiovascular ▁health ▁; ▁hospital isation ▁; ▁death
D-1808	-1.0685499906539917	public health ; air pollution ; industrial ; cardiovascular health ; hospitalisation ; death
P-1808	-1.8708 -1.9218 -0.3470 -0.3277 -0.4661 -0.3019 -2.1360 -3.6764 -0.2729 -2.4609 -1.2609 -1.1496 -0.1305 -0.6193 -0.5708 -0.3543 -0.2985
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence ; biomarkers ; pathophysiology ; chronic hf ; therapeutic
H-1474	-0.4421526789665222	▁molecular ▁bio mark ers ▁; ▁pat ho phy si ology ▁; ▁chronic ▁ HF
D-1474	-0.4421526789665222	molecular biomarkers ; pathophysiology ; chronic HF
P-1474	-0.3319 -0.1611 -0.4187 -0.4357 -0.3583 -0.4610 -0.1030 -0.3552 -1.4700 -0.1305 -0.2783 -0.3290 -0.7000 -0.8338 -0.4231 -0.2848
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary exercise test ; quality of life ; muscular ; peak quadriceps force
H-1915	-1.0817604064941406	▁cardio pul mon ary ▁exercise ▁; ▁quality ▁of ▁life ▁score ▁; ▁muscular ▁strength ▁; ▁quadri cep s ▁force
D-1915	-1.0817604064941406	cardiopulmonary exercise ; quality of life score ; muscular strength ; quadriceps force
P-1915	-0.4309 -1.5279 -2.9644 -1.7439 -1.5940 -2.7194 -3.1957 -0.6937 -0.8626 -1.9858 -0.2084 -0.4166 -0.8329 -0.2511 -0.1557 -0.8508 -0.2040 -0.3586 -0.3707 -0.2679
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial ; titin hypophosphorylation ; heart failure with preserved ejection fraction ; metabolic
H-759	-0.5758886933326721	▁My o card ial ▁titi n ▁hypo phos phor y lation ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁rat ▁; ▁metabol ic ▁risk
D-759	-0.5758886933326721	Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat ; metabolic risk
P-759	-2.4157 -0.2861 -0.5321 -1.0093 -0.2460 -0.1252 -0.3536 -0.2093 -1.1483 -2.0767 -0.1640 -0.4014 -1.7798 -0.4116 -0.3106 -0.1375 -0.1529 -0.0979 -0.3416 -0.0425 -0.3693 -0.4489 -1.0077 -0.0148 -0.1179 -0.7449 -0.9204 -0.2591
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp ; antibodies ; nonterminal epitopes
H-1519	-0.9062418341636658	▁NT - pro b NP ▁; ▁anti bo dies ▁; ▁non gly cos yla ted ▁; ▁non termin al ▁e pito pes
D-1519	-0.9062418341636658	NT-probNP ; antibodies ; nonglycosylated ; nonterminal epitopes
P-1519	-1.4767 -0.1498 -0.0914 -1.5473 -2.4491 -0.7143 -0.0429 -0.0680 -2.3801 -0.3424 -0.5300 -0.4598 -1.2766 -1.0325 -0.8637 -1.2816 -0.6102 -4.1866 -0.1285 -0.1215 -0.1399 -1.1261 -0.4339 -0.2969
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university of connecticut heart failure center ; heart failure ; nurse practitioner
H-728	-0.6439417600631714	▁University ▁of ▁Connect i cut ▁Heart ▁Fail ure ▁Center ▁; ▁cardio logist ▁; ▁heart ▁failure
D-728	-0.6439417600631714	University of Connecticut Heart Failure Center ; cardiologist ; heart failure
P-728	-0.9032 -0.1215 -0.4820 -0.0399 -0.8064 -0.5565 -0.6314 -1.6252 -0.7451 -0.2934 -0.1558 -0.8060 -0.3111 -1.4291 -0.3130 -1.4314 -0.2958
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients ; baseline ; serum creatinine ; serum potassium
H-441	-0.7879706025123596	▁se rum ▁creati nine ▁level ▁; ▁se rum ▁po tas s ium ▁level
D-441	-0.7879706025123596	serum creatinine level ; serum potassium level
P-441	-1.7064 -1.2139 -0.5148 -1.8145 -0.3802 -0.2870 -1.4939 -0.9889 -0.9025 -0.9435 -0.3767 -0.2625 -0.1699 -0.4650 -0.2999
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd ; diuretic ; peripheral edema ; functional class
H-899	-0.5874461531639099	▁PD ▁; ▁weight ▁loss ▁; ▁di ure tic ▁response ▁; ▁per i pher al ▁ed ema ▁; ▁functional
D-899	-0.5874461531639099	PD ; weight loss ; diuretic response ; peripheral edema ; functional
P-899	-0.7588 -0.3500 -0.6786 -1.0258 -0.3436 -0.3744 -0.3084 -0.8886 -1.0781 -0.4718 -0.9522 -0.2811 -0.3053 -0.2945 -0.6265 -0.0782 -0.4571 -0.0807 -2.1465 -0.2488
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic ; cardiac resynchronization therapy ; crt
H-427	-0.6342089176177979	▁e cho car dio graphic ▁; ▁response ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-427	-0.6342089176177979	echocardiographic ; response ; cardiac resynchronization therapy ; cRT
P-427	-0.1853 -0.4073 -0.2147 -0.6669 -0.6964 -0.4666 -1.4430 -0.7108 -0.1473 -0.1660 -0.1174 -0.0217 -1.7402 -0.2591 -0.0858 -0.2661 -0.7592 -3.6409 -0.4092 -0.2805
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients ; heartmate ii ; lvad ; centrimag ; rvad
H-298	-0.526692807674408	▁Heart Mate ▁i i ▁l VAD ▁; ▁Centri Mag ▁r VAD
D-298	-0.526692807674408	HeartMate ii lVAD ; CentriMag rVAD
P-298	-0.7678 -0.1966 -0.6658 -0.6415 -0.3331 -0.1174 -0.2888 -0.2109 -1.4356 -0.9786 -0.5307 -0.4316 -0.2486
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf ; mi ; reduced ejection fraction ; ef
H-1100	-0.8072088360786438	HF ▁; ▁MI ▁; ▁e je ction ▁ fraction ▁; EF
D-1100	-0.8072088360786438	HF ; MI ; ejection fraction ;EF
P-1100	-2.7115 -0.2533 -2.9833 -0.2834 -0.4189 -0.3080 -0.0998 -0.4126 -0.0413 -0.3188 -2.0179 -0.3694 -0.2756
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia ; patients ; chronic heart failure ; hf ; prevalence ; outcomes
H-834	-0.9134576320648193	▁an emia ▁; ▁chronic ▁heart ▁failure ▁; HF
D-834	-0.9134576320648193	anemia ; chronic heart failure ;HF
P-834	-1.9710 -0.6259 -0.3643 -1.6124 -1.9713 -0.4815 -0.3400 -1.0699 -0.3916 -0.3067
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac mrna ; inflammatory ; cell adhesion genes ; retn
H-934	-0.4971625804901123	▁Hum - re t n ▁mi ce ▁; ▁cardiac ▁m RNA ▁; ▁infla mma tory ▁; ▁cell ▁a dhe sion ▁gene s ▁; ▁Ret n
D-934	-0.4971625804901123	Hum-retn mice ; cardiac mRNA ; inflammatory ; cell adhesion genes ; Retn
P-934	-0.2986 -0.1532 -2.5210 -0.6523 -0.1080 -0.9987 -1.0831 -0.3971 -0.2802 -0.0871 -0.5524 -0.4399 -0.4048 -0.1529 -0.3278 -0.2889 -0.5311 -0.2955 -0.0834 -0.7449 -0.9683 -0.5687 -0.3891 -0.1549 -0.0984 -0.4944 -0.3485
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin subproteomes ; heart failure ; proteins ; chromatin structure
H-91	-0.6930150389671326	▁chr omat in ▁sub prote om es ▁; ▁heart ▁failure ▁; ▁protein s ▁; ▁chr omat in ▁structure
D-91	-0.6930150389671326	chromatin subproteomes ; heart failure ; proteins ; chromatin structure
P-91	-0.4405 -0.2926 -1.0031 -0.6042 -0.2324 -0.8388 -0.7438 -0.3068 -1.1715 -0.5049 -0.2985 -3.1638 -0.8687 -0.2728 -0.3632 -0.4129 -0.7389 -0.9755 -0.3408 -0.2868
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients ; hfpef ; kccq ; health ; prognostic
H-791	-1.0695618391036987	▁ HF p EF ▁; ▁ nc w t
D-791	-1.0695618391036987	HFpEF ; ncwt
P-791	-1.2994 -1.3675 -0.0827 -1.0945 -0.3641 -2.5356 -1.7066 -0.1527 -2.4381 -0.4020 -0.3220
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard ; tnf antagonist ; baseline ; covariates
H-606	-0.6650529503822327	▁n b DM ARD ▁; ▁t NF ▁anta gon ist
D-606	-0.6650529503822327	nbDMARD ; tNF antagonist
P-606	-0.0235 -0.0661 -0.8459 -0.7769 -0.3456 -1.4761 -1.8592 -1.2125 -0.0185 -0.4720 -0.5193 -0.3651
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods study ; exercise ; patients ; heart failure
H-615	-1.1329139471054077	▁voordelen ▁; ▁structure d ▁exercise ▁programme ▁; ▁heart ▁failure
D-615	-1.1329139471054077	voordelen ; structured exercise programme ; heart failure
P-615	-2.6825 -0.3105 -2.9408 -0.0967 -1.2138 -0.1008 -0.3298 -3.6908 -0.3595 -0.4878 -0.2491
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized ; af ablation
H-953	-0.7996514439582825	▁AF ▁ab lation
D-953	-0.7996514439582825	AF ablation
P-953	-2.9449 -0.0272 -0.2732 -0.4171 -0.3359
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage heart failure ; mechanical cardiac support
H-1386	-1.1937791109085083	▁end - s tage ▁heart ▁failure ▁; ▁mechanic al ▁cardiac ▁support
D-1386	-1.1937791109085083	end-stage heart failure ; mechanical cardiac support
P-1386	-5.9823 -0.1716 -0.2358 -0.0904 -1.5138 -0.5973 -0.3764 -2.9666 -0.2836 -0.1220 -2.3362 -0.5649 -0.2783
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic heart failure ; yield ; atrial ; cells
H-1334	-0.7968082427978516	▁Chro nic ▁heart ▁failure ▁; ▁transform ing ▁growth ▁factor ▁; ▁beta - dependent ▁yi eld ▁; ▁functional ▁; ▁at rial
D-1334	-0.7968082427978516	Chronic heart failure ; transforming growth factor ; beta-dependent yield ; functional ; atrial
P-1334	-1.6906 -0.9536 -1.0085 -0.4492 -0.3094 -3.1964 -0.2761 -0.9248 -0.4622 -0.3394 -4.4868 -0.0561 -0.1091 -0.0604 -0.0096 -0.2557 -0.2727 -1.1346 -0.5984 -0.2082 -0.4579 -0.2700
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv failure ; diagnostic ; left ventricular dysfunction
H-1093	-0.6773978471755981	rv ▁; ▁intr in sic ▁left ▁vent ri cular ▁dys function
D-1093	-0.6773978471755981	rv ; intrinsic left ventricular dysfunction
P-1093	-2.6842 -0.3350 -1.5126 -0.1235 -0.3102 -0.5944 -0.1240 -1.6172 -0.5178 -0.0468 -0.1609 -0.4633 -0.3162
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change ; readmission ; follow-up ; follow-up
H-724	-0.3404987156391144	▁follow - up ▁visit s ▁; ▁follow - up ▁visit s
D-724	-0.3404987156391144	follow-up visits ; follow-up visits
P-724	-0.1029 -0.3502 -0.0954 -1.0285 -0.3366 -0.3297 -0.0432 -0.3699 -0.1082 -0.7717 -0.2984 -0.3071 -0.2847
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality ; inpatient ; admissions ; hospital ; emergency department
H-1623	-0.866927981376648	▁ corrupt ie ▁; ▁in patient ▁ad missions ▁; ▁hospital ▁days ▁; ▁emergency ▁department ▁; ▁d p
D-1623	-0.866927981376648	corruptie ; inpatient admissions ; hospital days ; emergency department ; dp
P-1623	-2.8452 -2.9686 -0.3735 -0.3759 -0.0588 -0.1789 -1.2912 -0.2178 -0.3016 -0.7188 -0.9205 -0.2997 -0.1878 -0.1188 -0.2439 -1.0159 -3.5405 -0.4973 -0.3167
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence ; economic ; lvad ; outcomes
H-317	-0.5873638987541199	▁economische ▁; ▁l VAD
D-317	-0.5873638987541199	economische ; lVAD
P-317	-1.3646 -0.2736 -0.9792 -0.2647 -0.3920 -0.2500
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic ; crt
H-428	-0.8986911177635193	▁multi para metric ▁e cho car dio graphic ▁score ▁; ▁c RT
D-428	-0.8986911177635193	multiparametric echocardiographic score ; cRT
P-428	-1.9098 -0.1400 -0.3753 -0.3370 -0.5771 -0.1178 -0.7414 -1.2692 -0.8652 -0.2248 -0.8003 -3.9441 -1.0028 -0.2769
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection fraction ; patients
H-909	-0.30409860610961914	▁e je ction ▁ fraction
D-909	-0.30409860610961914	ejection fraction
P-909	-0.2237 -0.5406 -0.1854 -0.3463 -0.0576 -0.4898 -0.2852
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel inhibition ; hemodynamic ; exercise tolerance ; heart failure with preserved ejection fraction ; randomized
H-1170	-0.5287368893623352	▁If - chan nel ▁inhibi tion ▁; ▁hem o dynamic ▁status ▁; ▁exercise ▁ tolerance ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1170	-0.5287368893623352	If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
P-1170	-2.9820 -0.1466 -0.0413 -0.1545 -0.1016 -2.6011 -0.3892 -0.2775 -0.5199 -0.0414 -0.1909 -0.3182 -0.5048 -0.1568 -0.0237 -0.3154 -0.8767 -0.3420 -0.2658 -0.9925 -0.2869 -2.3500 -0.0878 -0.2810 -0.1200 -0.2821 -0.0292 -0.4022 -0.2524
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
H-1777	-0.5021382570266724	▁Card iac ▁; ▁insulin - re si stance ▁; ▁mito cho ndri al ▁energy ▁production ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁pressure - over load ▁hyper trop hy
D-1777	-0.5021382570266724	Cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
P-1777	-1.2681 -0.6678 -0.2396 -1.6312 -0.1840 -0.2274 -1.7682 -0.0557 -0.2760 -0.0315 -0.9995 -0.2530 -0.1223 -0.8616 -0.9370 -0.2536 -0.0766 -0.1244 -0.1464 -0.9757 -1.1005 -0.2216 -0.4149 -0.2601 -0.0390 -0.1217 -0.1345 -0.0126 -1.5048 -0.4111 -0.2459
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf ; proteins
H-1361	-1.0800880193710327	▁CHF ▁; ▁fat
D-1361	-1.0800880193710327	CHF ; fat
P-1361	-1.0905 -0.9504 -1.7255 -1.3466 -0.2875
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior vena cava ; ivc
H-321	-0.8644228577613831	▁pig s ▁; ▁inferior ▁ve na ▁ca va ▁; ▁i cc ▁; ▁snar ed ▁; ▁co
D-321	-0.8644228577613831	pigs ; inferior vena cava ; icc ; snared ; co
P-321	-1.2220 -0.4478 -0.3170 -0.6994 -2.9731 -2.1271 -0.0390 -0.0797 -0.2952 -0.8022 -0.7155 -0.3713 -1.7369 -2.1622 -0.3849 -0.6028 -0.3272 -0.2564
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin ; resistin
H-932	-0.44433823227882385	▁do xor ubi cin ▁; ▁i p ▁; ▁se rum ▁resist in ▁; ▁Hum - re t n ▁mi ce
D-932	-0.44433823227882385	doxorubicin ; ip ; serum resistin ; Hum-retn mice
P-932	-0.1160 -0.2086 -0.0928 -0.6103 -0.3756 -0.1373 -0.0357 -0.4458 -0.5520 -0.4891 -0.0833 -0.5836 -1.0931 -0.2664 -0.1098 -1.9443 -0.7519 -0.0819 -0.5924 -0.4994 -0.4071 -0.2990
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs ; physicians ; hospital
H-1729	-0.8624252080917358	▁kosten
D-1729	-0.8624252080917358	kosten
P-1729	-1.4423 -0.8794 -0.2656
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery ; rheumatic ; surgery ; mva
H-359	-0.6629177331924438	▁rhe u matic ▁; ▁MS ▁; ▁m va
D-359	-0.6629177331924438	rheumatic ; MS ; mva
P-359	-0.9409 -0.1733 -0.1961 -0.3390 -1.0404 -0.3647 -0.2653 -2.6588 -0.3773 -0.2735
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.5426832437515259	▁de activa tion
D-1864	-0.5426832437515259	deactivation
P-1864	-0.2271 -0.2101 -1.5436 -0.4835 -0.2492
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.4246322214603424	
D-557	-0.4246322214603424	
P-557	-0.5912 -0.2580
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
H-1144	-0.40764036774635315	HF ▁; ▁py rido stig mine ▁; ▁stroke ▁; ▁e je ction ▁ fraction ▁; ▁cardiac ▁output ▁; ▁contract ility ▁; ▁left ▁vent ric le
D-1144	-0.40764036774635315	HF ; pyridostigmine ; stroke ; ejection fraction ; cardiac output ; contractility ; left ventricle
P-1144	-2.0243 -0.4632 -0.0803 -0.0227 -0.0065 -0.4238 -0.2780 -0.5875 -1.2334 -0.1902 -0.1525 -0.0581 -0.3025 -0.0304 -0.2444 -0.1577 -0.0301 -0.2547 -0.0301 -0.7812 -0.2224 -0.6297 -0.1533 -1.2356 -0.8541 -0.3197 -0.2398
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin ; protein-c ; phosphorylation ; troponin i ; phosphorylation ; hf
H-1427	-0.8943608403205872	▁my os in ▁ binding ▁; ▁protein - c ▁ phos phor y lation ▁; ▁ser 23 /24 ▁trop onin ▁I ▁ phos phor y lation ▁; HF
D-1427	-0.8943608403205872	myosin binding ; protein-c phosphorylation ; ser23/24 troponin I phosphorylation ;HF
P-1427	-1.5015 -0.1996 -0.4061 -0.9450 -0.0168 -0.2929 -0.2983 -0.2869 -0.7361 -0.2434 -0.2352 -2.4919 -3.1448 -0.4194 -0.2909 -0.5807 -1.3699 -0.7086 -0.0992 -0.1914 -3.0947 -0.1985 -0.2268 -3.1936 -2.8686 -0.2684 -0.3054 -1.5805 -0.3559 -0.2799
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone receptor antagonists ; randomized ; morbidity ; mortality ; symptomatic systolic heart failure
H-438	-0.5486423373222351	▁al do ster one ▁receptor ▁anta gon ists ▁; ▁morbi d iteit ▁; ▁mortal iteit ▁; ▁sy sto lic ▁heart ▁failure
D-438	-0.5486423373222351	aldosterone receptor antagonists ; morbiditeit ; mortaliteit ; systolic heart failure
P-438	-0.6251 -0.0786 -0.1943 -1.2424 -0.0180 -0.0443 -0.0254 -1.9383 -0.3456 -0.2235 -0.1155 -1.5232 -0.3049 -0.1028 -1.3004 -0.2805 -1.3597 -0.1314 -0.3928 -1.2157 -0.5061 -0.4147 -0.2359
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr ; protein kinase r-like er kinase ; perk ; calreticulin ; chop ; hf
H-1084	-0.6108349561691284	▁u PR ▁effect ors ▁; ▁protein ▁kina se ▁; ▁r - like ▁ER ▁kina se ▁; PER k ▁; ▁cal ret icul in ▁; ▁CHO p ▁; ▁ HF ▁tissu es
D-1084	-0.6108349561691284	uPR effectors ; protein kinase ; r-like ER kinase ;PERk ; calreticulin ; CHOp ; HF tissues
P-1084	-2.9624 -1.3599 -0.4790 -0.6412 -0.3528 -0.4511 -0.0448 -0.4495 -0.4583 -0.5888 -0.2366 -0.6657 -0.6496 -0.0278 -0.4119 -0.4803 -1.0144 -0.9506 -0.3283 -0.0319 -0.8883 -0.0456 -0.4909 -0.3913 -0.3637 -0.2997 -0.3255 -0.9580 -1.5342 -1.3353 -0.2314 -0.4376 -0.2713
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref ; exercise ; resting hr ; bpm ; beta-blocker ; therapy
H-1946	-0.6635100245475769	▁h Fr EF ▁; ▁exercise ▁performance ▁; ▁rest ing ▁; ▁HR ▁; ▁beta - block er ▁ therapy
D-1946	-0.6635100245475769	hFrEF ; exercise performance ; resting ; HR ; beta-blocker therapy
P-1946	-1.1091 -2.4785 -2.3946 -0.3033 -0.7916 -0.7274 -0.2492 -0.8071 -0.3192 -0.3873 -1.5914 -0.3614 -0.3315 -0.1145 -0.1974 -0.1195 -0.1860 -0.0537 -0.4793 -0.2682
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory
H-1324	-0.6957567930221558	▁e cho car dio graphic ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁marker s
D-1324	-0.6957567930221558	echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory markers
P-1324	-1.8639 -1.2169 -0.2818 -0.9706 -0.7606 -0.4135 -4.6033 -0.0667 -0.9734 -0.0711 -0.3327 -0.0943 -0.4819 -0.1986 -0.2566 -0.9112 -0.5711 -1.7237 -0.5462 -0.2249 -0.3973 -0.3291 -0.0847 -0.5341 -1.0513 -0.1206 -0.3191 -0.4119 -0.3660
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox hazard models ; esrd ; death ; composite end point ; esrd ; death ; esrd
H-391	-1.276018738746643	▁co x ▁hazard ▁models ▁; ▁ES RD ▁; ▁death ▁; ▁ES RD ▁; ▁death ▁; ▁ES RD
D-391	-1.276018738746643	cox hazard models ; ESRD ; death ; ESRD ; death ; ESRD
P-391	-0.0875 -0.1864 -0.1890 -1.1934 -0.2338 -3.5497 -1.9581 -0.2531 -2.7984 -0.2574 -3.5935 -1.7758 -0.2356 -1.5163 -0.2594 -3.7559 -1.8125 -0.3416 -0.2471
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled trials ; rcts ; observational cohort studies ; contemporaneous control group
H-152	-1.1848759651184082	▁r cr t
D-152	-1.1848759651184082	rcrt
P-152	-1.0915 -2.6603 -0.2412 -1.6551 -0.2763
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients ; heart failure ; heart failure ; nurses ; follow-up ; cardiology ; mortality
H-1896	-0.6616171002388	▁heart ▁failure ▁; ▁heart ▁failure ▁; ▁nurse s ▁; ▁follow - up ▁; ▁card i ology ▁; ▁mortal iteit
D-1896	-0.6616171002388	heart failure ; heart failure ; nurses ; follow-up ; cardiology ; mortaliteit
P-1896	-3.1665 -0.5691 -0.3649 -2.4228 -0.3033 -0.3371 -0.1555 -0.1616 -0.3600 -0.0581 -0.2852 -0.0380 -0.3302 -0.6369 -0.1506 -0.1406 -1.7739 -0.3700 -1.6662 -0.3389 -0.2646
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients ; heart failure ; hf ; cardiopulmonary exercise test ; anaerobic threshold
H-1753	-0.7512844204902649	▁heart ▁failure ▁; HF ▁; ▁cardio pul mon ary ▁exercise ▁test ▁; ▁ana ero bic ▁thre s hold ▁; AT
D-1753	-0.7512844204902649	heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold ;AT
P-1753	-2.5605 -0.4353 -0.2582 -0.8195 -0.2593 -0.1494 -0.9664 -2.0474 -1.3673 -1.0348 -1.1561 -0.2873 -0.3499 -0.6805 -0.9896 -0.0528 -0.2405 -1.1052 -0.3973 -0.6614 -0.4358 -0.2736
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative ; renal dysfunction ; stroke ; myocardial infarction ; heart failure ; cabg
H-970	-0.5975607633590698	▁renal ▁dys function ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁CA BG
D-970	-0.5975607633590698	renal dysfunction ; stroke ; myocardial infarction ; heart failure ; CABG
P-970	-0.3259 -0.0806 -0.1624 -0.2636 -0.4342 -0.2524 -1.7233 -0.2226 -0.7073 -1.2577 -0.0820 -0.3855 -0.8300 -0.2893 -1.2865 -0.2959 -0.2532 -1.5637 -1.5980 -0.2874 -0.2472
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo inhibition ; cardiomyocyte bioenergetics ; lv function ; chronic acf
H-472	-0.6134923696517944	▁ XO ▁inhibi tion ▁; ▁cardio my o cy te ▁bio ener ge tics ▁; ▁LV ▁; ▁chronic ▁a CF ▁; ▁rat
D-472	-0.6134923696517944	XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic aCF ; rat
P-472	-1.2179 -0.3071 -0.0679 -1.9700 -0.2336 -0.0785 -1.0045 -0.2830 -0.3504 -0.2154 -0.0473 -1.0093 -0.3780 -0.4828 -0.2838 -0.3742 -0.2154 -0.4997 -2.0189 -1.7462 -1.1708 -0.1355 -0.3615 -0.2720
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol ; thromboembolic events ; patients ; heart failure ; β2-receptor haplotype
H-1120	-0.40727880597114563	▁car vedi lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure ▁; ▁β 2- recept or ▁ha plo type ▁status
D-1120	-0.40727880597114563	carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype status
P-1120	-0.0237 -0.1678 -0.4517 -0.3740 -0.3188 -0.3655 -1.9680 -0.1614 -0.2290 -0.4572 -0.8827 -0.2999 -1.8112 -0.4332 -0.3230 -0.0852 -0.0844 -0.0630 -0.1172 -0.0146 -0.1670 -0.0696 -0.5707 -0.4809 -0.2624
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine ; administration ; methylatropine ; propranolol ; cardiac ; sympathovagal balance
H-1138	-0.34009048342704773	▁py rido stig mine ▁; ▁met hy la tropi ne ▁; ▁propra no lol ▁; ▁cardiac ▁sympa t hova gal ▁balance
D-1138	-0.34009048342704773	pyridostigmine ; methylatropine ; propranolol ; cardiac sympathovagal balance
P-1138	-0.0170 -0.0608 -0.0129 -0.3069 -0.5550 -0.3760 -0.2125 -0.4632 -0.0303 -1.3951 -0.3815 -0.0528 -0.0449 -0.6454 -0.3644 -0.1929 -0.1118 -0.3496 -0.1817 -0.4956 -0.8637 -0.4513 -0.2565
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline ; follow-up ; paf ; activity ; metabolic ; enzymes ; patients ; heart failure ; healthy
H-1266	-0.9225941896438599	▁PA f ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure
D-1266	-0.9225941896438599	PAf ; metabolic enzymes ; heart failure
P-1266	-3.2533 -3.1320 -0.3201 -0.1302 -0.0943 -0.1112 -0.3428 -0.3833 -1.9882 -0.4654 -0.5512 -0.2991
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab ; adjuvant ; outcomes ; cardiotoxicity ; congestive heart failure ; chf
H-670	-0.9470953941345215	▁tras tuz um ab ▁; ▁cardio toxic iteit ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ nc w
D-670	-0.9470953941345215	trastuzumab ; cardiotoxiciteit ; congestive heart failure ; ncw
P-670	-0.1626 -0.1575 -0.0887 -1.1571 -0.3775 -0.2457 -0.7208 -2.6165 -0.2885 -0.3202 -0.4611 -3.3433 -0.8323 -0.4175 -0.3153 -2.7134 -2.4466 -1.5794 -0.4484 -0.2497
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
H-1207	-0.5915275812149048	▁Pho s pho dies tera se -2 ▁; ▁heart s ▁; ▁beta - ad r energi c ▁response s ▁; ▁cardio my o cy tes
D-1207	-0.5915275812149048	Phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
P-1207	-0.4292 -0.2592 -0.2635 -3.0551 -0.1136 -0.2813 -0.0977 -0.4082 -3.2514 -0.2871 -0.3066 -0.8140 -0.1127 -0.4631 -0.4763 -1.7055 -0.6533 -0.7350 -0.2902 -0.2666 -0.0714 -0.3502 -0.1326 -0.0736 -0.3000 -0.4506 -0.3231
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis ; expenditure ; b natriuretic peptides ; nps
H-10	-0.7205891013145447	▁li poly sis ▁; ▁energie ▁ex pendi ture ▁; ▁na tri ure tic ▁pe pti des ▁; NP s ▁; ▁CC
D-10	-0.7205891013145447	lipolysis ; energie expenditure ; natriuretic peptides ;NPs ; CC
P-10	-0.3134 -0.2160 -1.0888 -0.2812 -1.7128 -0.1213 -0.4350 -2.8509 -0.3603 -0.1718 -1.4224 -0.5670 -2.1340 -0.3705 -0.2312 -0.3719 -0.3226 -1.1830 -0.1617 -0.3100 -1.3940 -0.2939 -0.2599
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox proportional hazards models ; health ; health ; hazard ratios ; confidence intervals
H-689	-0.9380108118057251	▁co x ▁proportion al ▁hazard s ▁; ▁health
D-689	-0.9380108118057251	cox proportional hazards ; health
P-689	-0.0422 -0.2543 -0.0347 -0.0840 -0.3553 -0.5845 -0.3159 -3.1287 -4.3324 -0.2482
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east ; rhythm control therapy ; diagnosis ; cardiovascular ; complications
H-1655	-0.6685613989830017	▁ec b ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁AF ▁; ▁cardiovascular ▁complica tions ▁; ▁AF
D-1655	-0.6685613989830017	ecb ; rhythm control therapy ; AF ; cardiovascular complications ; AF
P-1655	-3.2532 -1.1353 -0.2751 -0.1807 -0.4105 -0.7940 -0.3282 -0.0649 -0.3326 -0.6987 -0.2590 -0.2627 -0.0330 -2.0536 -0.3348 -0.9772 -0.3732 -0.2674
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts ; mena ; cardiac injury ; mena ; hf ; pathophysiology
H-1817	-0.7557570338249207	▁heart s ▁; ▁men a ▁; ▁cardiac ▁injury ▁; ▁men a ▁; ▁ HF ▁pat ho phy si ology
D-1817	-0.7557570338249207	hearts ; mena ; cardiac injury ; mena ; HF pathophysiology
P-1817	-2.6457 -0.3617 -0.3839 -1.7993 -0.3318 -0.2939 -0.3894 -0.4552 -0.2966 -2.3802 -0.3137 -0.2833 -1.2466 -1.0121 -0.9001 -0.1253 -0.4504 -1.4956 -0.1532 -0.3432 -0.2097
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a ; upr ; downregulation ; cardiac ; genes ; hf
H-1089	-0.9653298258781433	▁s cn 5 a ▁tran script ▁; ▁u PR ▁; ▁cardiac ▁gene s ▁; HF
D-1089	-0.9653298258781433	scn5a transcript ; uPR ; cardiac genes ;HF
P-1089	-1.1230 -0.0714 -0.6747 -0.4040 -1.4430 -0.1810 -0.2820 -3.6408 -1.7572 -0.2948 -0.8736 -0.8794 -0.5500 -0.2471 -3.3785 -0.3409 -0.2691
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome ; gls ; beat ; cox proportional hazards analyses
H-814	-0.6419623494148254	AIN ▁o UTC OME ▁; ▁g ls ▁; ▁index ▁beat ▁; ▁CV ▁events ▁; ▁co x ▁proportion al ▁hazard s ▁analyse s
D-814	-0.6419623494148254	AIN oUTCOME ; gls ; index beat ; CV events ; cox proportional hazards analyses
P-814	-2.1948 -0.6636 -0.4457 -0.3949 -0.6116 -0.2268 -2.4508 -0.3090 -0.0244 -0.0287 -0.9949 -2.7570 -1.3698 -0.3297 -0.0601 -0.4621 -0.0606 -0.0796 -0.1940 -0.4003 -0.5215 -0.2422 -0.3526 -0.2324
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients ; vad ; patients ; ecmo ; vad ; patients ; ecmo
H-1389	-1.8492165803909302	▁ VAD ▁group ▁; ▁ec mo + VAD ▁group ▁; ▁ec mo
D-1389	-1.8492165803909302	VAD group ; ecmo+VAD group ; ecmo
P-1389	-2.0252 -0.4763 -3.6537 -0.2886 -0.9158 -3.3333 -5.2247 -0.3246 -2.2977 -0.3378 -1.4478 -2.7692 -2.4896 -0.3048
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse ; pasp ; downward ; regression line ; shift ; pasp ; tapse
H-496	-1.3176178932189941	▁ pac se ▁; ▁PAS p ▁; ▁down ward ▁re gression ▁line ▁; ▁non sur viv ors ▁; ▁PAS p ▁; ▁ pv se
D-496	-1.3176178932189941	pacse ; PASp ; downward regression line ; nonsurvivors ; PASp ; pvse
P-496	-2.2776 -5.5324 -2.1005 -0.2248 -0.8162 -1.3280 -0.3138 -2.2952 -0.8477 -0.0950 -0.0893 -0.0644 -1.7842 -0.8276 -0.1785 -0.2676 -1.7198 -0.3550 -1.6340 -0.9650 -0.4680 -1.8749 -5.2972 -2.2831 -0.3596 -0.2588
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right ventricular ; rv ; left ventricular assist device ; lvad ; outcomes
H-294	-0.8953096866607666	▁Right ▁vent ri cular ▁; ▁v n ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD
D-294	-0.8953096866607666	Right ventricular ; vn ; left ventricular assist device ; lVAD
P-294	-2.2833 -0.2602 -2.0029 -0.3424 -0.3609 -1.6896 -0.9394 -0.3351 -2.7226 -0.3237 -2.6712 -0.3815 -0.8342 -0.5392 -0.3427 -0.0884 -0.1926 -0.4013 -0.2998
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin ; inflammation ; hepatic ; prognosis ; patients ; lvad ; implantation
H-540	-0.6159453392028809	▁album in ▁levels ▁; ▁ inflammation ▁; ▁he pati c ▁function ▁; ▁l VAD ▁implant ation
D-540	-0.6159453392028809	albumin levels ; inflammation ; hepatic function ; lVAD implantation
P-540	-0.6171 -0.4352 -2.3334 -0.3055 -1.0295 -0.6951 -0.4144 -0.2052 -0.2403 -0.8226 -0.0834 -0.3611 -0.4298 -0.2629 -1.1655 -1.0109 -0.3912 -0.2840
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 ; c statistic ; net reclassification improvement ; integrated discrimination improvement
H-705	-0.8475193381309509	▁ST 2 ▁; ▁c ▁; ▁net ▁re class ification ▁; ▁discrimina tion
D-705	-0.8475193381309509	ST2 ; c ; net reclassification ; discrimination
P-705	-0.9806 -0.1602 -0.2576 -1.5150 -2.1682 -0.2941 -0.4898 -0.3906 -1.4703 -0.2970 -0.1607 -2.4578 -0.8997 -0.3236
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf ; patients ; hct ; city of hope
H-1452	-1.0456409454345703	post - h CT ▁CHF ▁; ▁h CT ▁; ▁City ▁of ▁Hope
D-1452	-1.0456409454345703	post-hCT CHF ; hCT ; City of Hope
P-1452	-1.1615 -0.1129 -1.5970 -2.0637 -0.3610 -0.3181 -1.1353 -2.0988 -0.3883 -2.5409 -0.8079 -1.3770 -0.4182 -0.2582
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ; ischemic heart failure ; biomarkers ; heart failure
H-1615	-0.6677447557449341	▁ ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁bio mark ers ▁; ▁heart ▁failure
D-1615	-0.6677447557449341	ischemic ; ischemic heart failure ; biomarkers ; heart failure
P-1615	-3.3036 -0.1813 -0.5049 -0.4622 -0.4429 -0.0647 -0.6407 -1.6262 -0.4433 -0.2797 -0.2283 -0.2519 -0.5057 -0.3033 -1.7524 -0.3378 -0.4091 -0.2815
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted ; left ventricle end-diastolic pressure
H-1340	-0.6900115609169006	▁in far cted ▁animals ▁; ▁left ▁vent ric le ▁; ▁end - dia sto lic ▁pressure ▁; ▁h g
D-1340	-0.6900115609169006	infarcted animals ; left ventricle ; end-diastolic pressure ; hg
P-1340	-0.1897 -0.2828 -3.0492 -0.9097 -0.3611 -0.7987 -0.1381 -0.7512 -0.5369 -0.8883 -1.9845 -0.2452 -0.0192 -0.2611 -0.2396 -0.6677 -0.7445 -0.3069 -0.2073 -1.6798 -0.2288
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health ; followed up ; hf ; hospitalization ; death ; contact
H-687	-1.3620411157608032	▁Women ' s ▁Health ▁Initiative ▁; ▁ HF
D-687	-1.3620411157608032	Women's Health Initiative ; HF
P-687	-1.7923 -4.5854 -0.5068 -1.4570 -0.6009 -0.3633 -2.1843 -1.3006 -0.5504 -0.2795
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak oxygen consumption ; pulse ; patients
H-1918	-0.7693831324577332	▁oxygen ▁consum p tion ▁; ▁oxygen ▁puls e
D-1918	-0.7693831324577332	oxygen consumption ; oxygen pulse
P-1918	-1.3179 -1.3442 -0.3802 -1.7671 -0.3460 -1.0091 -0.4676 -0.3281 -0.4558 -0.2779
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients ; hf ; crt ; implantation ; complications
H-912	-0.8571040034294128	▁di al ysis - dependent ▁patients ▁; HF ▁; ▁c RT ▁implant ation
D-912	-0.8571040034294128	dialysis-dependent patients ;HF ; cRT implantation
P-912	-0.5010 -0.1166 -0.0575 -0.1770 -0.1031 -1.5187 -0.3266 -2.1424 -0.3075 -1.0530 -2.5091 -0.5638 -1.7177 -1.5136 -0.2490
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv ; pathophysiologic ; rv dysfunction
H-1094	-0.826079249382019	▁v n ▁; ▁pat ho phy si ologic ▁mechanism s ▁; ▁ RV ▁dys function
D-1094	-0.826079249382019	vn ; pathophysiologic mechanisms ; RV dysfunction
P-1094	-1.8941 -1.8790 -0.2351 -0.9515 -0.2888 -1.6165 -2.0256 -0.2422 -0.0930 -0.6593 -0.2601 -1.7063 -1.2171 -0.2286 -0.1399 -0.3278 -0.2784
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac deaths ; atherosclerotic cad
H-1907	-0.5631499290466309	▁cardiac ▁death s ▁; ▁a ther os cle ro tic ▁CAD
D-1907	-0.5631499290466309	cardiac deaths ; atherosclerotic CAD
P-1907	-2.2870 -1.2634 -0.5113 -0.2697 -0.2270 -0.3957 -0.5934 -0.2678 -0.1551 -0.5119 -0.2122 -0.3547 -0.2717
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air ; cardiovascular ; health ; acute myocardial infarction
H-1806	-0.6926719546318054	▁Ambient ▁air ▁pollution ▁; ▁cardiovascular ▁health ▁; ▁a cute ▁my o card ial ▁in far ction
D-1806	-0.6926719546318054	Ambient air pollution ; cardiovascular health ; acute myocardial infarction
P-1806	-0.2823 -0.2700 -0.4861 -0.2935 -0.7134 -2.5879 -0.2954 -1.0392 -0.1180 -2.0489 -0.2132 -0.5374 -1.1902 -0.0739 -0.4843 -1.1019 -0.4372 -0.2953
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic ; nhs ; chronic ; disease ; exercise ; acute ; hospital
H-613	-0.6664934158325195	▁economische ▁; ▁NH s ▁; ▁behaviour al - change ▁; ▁chronic ▁disease ▁; ▁exercise ▁; ▁hospital ▁facilities
D-613	-0.6664934158325195	economische ; NHs ; behavioural-change ; chronic disease ; exercise ; hospital facilities
P-613	-1.5453 -0.2818 -1.0226 -0.7634 -0.2820 -0.9755 -0.1614 -0.2818 -0.1749 -0.3064 -0.2452 -0.6062 -0.3736 -0.8400 -2.7777 -0.6144 -0.7952 -0.3240 -0.2919
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths ; stroke ; hospitalisations ; heart failure ; follow-up
H-816	-0.5275281667709351	▁non - fa tal ▁stroke ▁; ▁heart ▁failure ▁; ▁follow - up
D-816	-0.5275281667709351	non-fatal stroke ; heart failure ; follow-up
P-816	-0.5654 -0.0943 -0.6648 -0.2005 -0.4793 -0.3601 -2.9336 -0.3804 -0.6966 -0.0279 -0.3163 -0.0300 -0.3971 -0.2391
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic ; biomarkers ; molecular dysfunction ; chronic hf
H-1477	-0.39347589015960693	▁bio mark ers ▁; ▁molecular ▁dys function ▁; ▁chronic ▁ HF
D-1477	-0.39347589015960693	biomarkers ; molecular dysfunction ; chronic HF
P-1477	-0.8372 -0.4857 -0.4573 -0.3184 -0.2508 -0.0154 -0.0493 -0.2615 -0.1730 -0.7679 -0.8417 -0.3700 -0.2867
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq ; kaplan-meier curves ; death ; all-cause hospitalization
H-784	-0.901218831539154	▁ nc w ▁; ▁ka plan - me ier ▁cur ves ▁; ▁death ▁; ▁hospital ization
D-784	-0.901218831539154	ncw ; kaplan-meier curves ; death ; hospitalization
P-784	-1.6064 -1.3783 -0.1159 -0.7982 -1.6645 -0.0349 -0.1510 -0.5030 -0.3417 -0.2833 -3.6810 -0.3760 -1.5873 -0.9797 -1.1480 -0.8731 -0.3642 -0.3355
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d ; therapy
H-107	-0.7917237281799316	▁c RT - d ▁; ▁significant ▁; ▁IE ▁; ▁de fi br illa tor - on ly ▁ therapy ▁; HR
D-107	-0.7917237281799316	cRT-d ; significant ; IE ; defibrillator-only therapy ;HR
P-107	-0.8417 -3.9692 -0.1448 -0.8500 -0.3980 -0.0775 -1.1229 -2.0560 -0.4380 -0.2906 -0.2461 -1.6507 -0.3704 -0.1939 -0.3871 -1.2842 -1.3156 -0.1573 -0.2895 -0.5312 -0.9572 -0.3485 -0.2894
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr variability ; risk stratification
H-1587	-1.050028920173645	▁HR ▁; ▁HR ▁; ▁risk ▁strat ification
D-1587	-1.050028920173645	HR ; HR ; risk stratification
P-1587	-1.7622 -0.2206 -2.7863 -0.6389 -1.4950 -0.3523 -1.4417 -0.4214 -0.3320
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients ; terminal ; diagnostic ; follow-up
H-1819	-0.7123103141784668	▁diagnose ▁; ▁alternatieve ▁treatment s ▁; ▁follow - up
D-1819	-0.7123103141784668	diagnose ; alternatieve treatments ; follow-up
P-1819	-2.1865 -0.3799 -1.7349 -1.7534 -0.3422 -0.4115 -0.0630 -0.3268 -0.0436 -0.3122 -0.2815
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity ; diabetes mellitus ; metabolic ; comorbidities ; heart failure with preserved ejection fraction
H-760	-0.6425973176956177	▁figuur ▁; ▁diabetes ▁mell itus ▁; ▁metabol ic ▁risk ▁factors ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-760	-0.6425973176956177	figuur ; diabetes mellitus ; metabolic risk factors ; heart failure ; ejection fraction
P-760	-5.4987 -0.3096 -0.5332 -0.0180 -0.1073 -0.2944 -0.1070 -0.1374 -0.5523 -0.4287 -0.2425 -2.9785 -0.4478 -0.2490 -0.1815 -0.1898 -0.0673 -0.3194 -0.0299 -0.4974 -0.3046
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary endpoints ; therapy ; atrial fibrillation ; atrial tachyarrhythmias ; atp ; shock therapy
H-860	-0.6356696486473083	▁ therapy ▁; ▁at rial ▁fi bril lation ▁; ▁at rial ▁ta chy ar rhythm ias ▁; ▁ATP ▁; ▁shock ▁ therapy
D-860	-0.6356696486473083	therapy ; atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
P-860	-2.6428 -0.2199 -0.3882 -1.5565 -0.3264 -0.5520 -0.0631 -0.2214 -0.4141 -1.1294 -0.8867 -0.5560 -0.7191 -0.0844 -0.1653 -2.5182 -0.4044 -0.7894 -0.2852 -0.0840 -0.5012 -0.0488 -0.4225 -0.2773
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia ; postoperative ; mortality ; patients ; left ventricular assist device ; lvad ; implantation
H-530	-0.5881351232528687	▁hypo album in emia ▁; ▁post operativ e ▁mortal iteit ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD ▁; ▁implant ation
D-530	-0.5881351232528687	hypoalbuminemia ; postoperative mortaliteit ; left ventricular assist device ; lVAD ; implantation
P-530	-0.1209 -0.1843 -0.2441 -0.9849 -0.3341 -0.2971 -0.4651 -0.1312 -0.1405 -1.8319 -0.3689 -1.0843 -0.3505 -2.4878 -0.4331 -0.8411 -0.5898 -0.3471 -0.1636 -0.2505 -0.8238 -0.0783 -1.5514 -0.3274 -0.2717
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ; ami ; complications ; heart failure ; kidney infection ; uti ; complications ; rehospitalization
H-1718	-0.9243670105934143	AMI ▁; ▁heart ▁failure ▁; ▁ki dne y ▁infection ▁; UTI
D-1718	-0.9243670105934143	AMI ; heart failure ; kidney infection ;UTI
P-1718	-1.5222 -0.3714 -3.0644 -0.6440 -0.3409 -0.0807 -0.5281 -0.2944 -0.8455 -0.2872 -2.6233 -1.1288 -0.2859
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary exercise testing ; echocardiographic ; myocardial function ; left ventricular filling ; exercise
H-1174	-0.9639578461647034	▁cardio pul mon ary ▁exercise ▁; ▁e cho car dio graphic ▁assessment ▁; ▁my o card ial ▁function ▁; ▁left ▁vent ri cular ▁fill ing ▁; ▁exercise
D-1174	-0.9639578461647034	cardiopulmonary exercise ; echocardiographic assessment ; myocardial function ; left ventricular filling ; exercise
P-1174	-3.4291 -1.5163 -2.6496 -1.6695 -1.9070 -0.4165 -0.3820 -0.2434 -0.1605 -0.6623 -1.1244 -1.8870 -0.2980 -1.6217 -0.2769 -1.5802 -1.6409 -0.2392 -0.2774 -0.6030 -0.1266 -1.4731 -0.4893 -0.5790 -0.2208 -1.5083 -0.4244 -0.3358 -0.2124
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous ; coronary revascularization ; hemodynamically ; stable ; patient ; intensive care unit ; icu
H-1293	-0.7946944832801819	▁per cuta ne ous ▁corona ry ▁re vas cular ization ▁; ▁hem o dynamic ally ▁; ▁intensiv e ▁care ▁unit ▁; ICU
D-1293	-0.7946944832801819	percutaneous coronary revascularization ; hemodynamically ; intensive care unit ;ICU
P-1293	-1.1759 -0.0136 -1.4850 -1.7644 -0.3436 -2.2163 -0.1199 -0.3849 -0.2661 -1.7247 -0.3010 -0.4632 -0.2713 -0.0539 -1.2949 -0.7005 -3.4539 -0.0498 -2.1128 -0.0829 -0.1892 -0.0332 -0.3388 -0.2325
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle tracking echocardiography ; ste ; bivp ; acute ; right ventricular pressure overload ; rvpo
H-320	-0.8094537258148193	▁spec kle ▁track ing ▁; ▁e cho card i ography ▁; STE ▁; ▁Bi VP ▁; ▁right ▁vent ri cular ▁pressure ▁over load ▁; rv p
D-320	-0.8094537258148193	speckle tracking ; echocardiography ;STE ; BiVP ; right ventricular pressure overload ;rvp
P-320	-0.0917 -2.0111 -0.1732 -0.2723 -0.5071 -0.3550 -0.2559 -0.1763 -0.5429 -0.2842 -0.4015 -2.7140 -0.3804 -0.4408 -0.5882 -0.3187 -3.1084 -0.3461 -1.7037 -0.8301 -0.7856 -0.3250 -0.2120 -0.3635 -2.2042 -2.4444 -0.5252 -0.3033
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic ; renal underperfusion ; renin- angiotensin-aldosterone pathway
H-1596	-0.5187241435050964	▁pat ho phy si ologic ▁mechanism ▁; ▁renal ▁under per fusion ▁; ▁re nin - ▁ang io ten sin - al do ster one ▁path way
D-1596	-0.5187241435050964	pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
P-1596	-0.7027 -0.2592 -1.0686 -1.9854 -0.2332 -0.0518 -0.2992 -0.1627 -1.0803 -0.1510 -0.2566 -0.2741 -0.1064 -1.1958 -0.1521 -0.4956 -0.9855 -0.3033 -2.0189 -0.2939 -0.0450 -0.0895 -0.1299 -0.5887 -0.4319 -0.4121 -0.4126 -0.3382
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted county ; minnesota ; mi ; diagnosed ; hf ; followed-up
H-1102	-0.6766657829284668	▁o m sted ▁County ▁; ▁Minnesota ▁; ▁MI ▁diagnose d ▁; ▁ HF
D-1102	-0.6766657829284668	omsted County ; Minnesota ; MI diagnosed ; HF
P-1102	-0.7837 -3.0741 -0.2046 -0.6520 -0.1920 -0.4848 -0.2565 -0.6667 -0.7807 -0.1927 -0.2696 -1.0873 -0.9584 -0.3450 -0.2017
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
H-869	-0.504675030708313	▁prote o mics ▁; ▁path way ▁analysis ▁; ▁pressure - over load - indu ced ▁heart ▁failure ▁; ▁att en u ation ▁; ▁mito cho ndri al - tar get ed ▁pe pti des
D-869	-0.504675030708313	proteomics ; pathway analysis ; pressure-overload-induced heart failure ; attenuation ; mitochondrial-targeted peptides
P-869	-0.1790 -0.7461 -0.0323 -0.3265 -0.5134 -0.5531 -0.6839 -0.3653 -0.4654 -0.1713 -0.0327 -0.1791 -0.2886 -0.6147 -1.1483 -1.3826 -0.4916 -0.2906 -1.1491 -0.1841 -0.0945 -0.7352 -0.3825 -0.0328 -0.8539 -1.0725 -0.2848 -0.2518 -1.1566 -1.3292 -0.5753 -0.4303 -0.1624 -0.2960 -0.4256 -0.2870
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration ; neurohumoral blockers ; hf ; hospitalization ; patients ; co-morbidity
H-184	-0.8002688884735107	▁neuro hu moral ▁block ers ▁; ▁ HF
D-184	-0.8002688884735107	neurohumoral blockers ; HF
P-184	-0.2900 -0.1141 -1.6870 -0.5190 -0.7869 -0.3326 -2.2025 -0.5699 -1.1728 -0.3279
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence ; adjusted odds ratio ; hazard ratio ; death ; hf ; ami ; admission ; discharge
H-1308	-1.4780728816986084	▁odds ▁ratio ▁; haz ard ▁ratio ▁; ▁death ▁; HF ▁; AMI
D-1308	-1.4780728816986084	odds ratio ;hazard ratio ; death ;HF ;AMI
P-1308	-6.0093 -0.2543 -0.5326 -0.0504 -0.0823 -0.0310 -0.3286 -3.5377 -0.3387 -3.4569 -0.3579 -3.8426 -1.5499 -0.3209
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective ; patients ; rule ; sensitivity ; specificity ; cad ; sensitivity ; cad
H-1192	-0.5784778594970703	▁CAD ▁; ▁CAD
D-1192	-0.5784778594970703	CAD ; CAD
P-1192	-0.4994 -0.4184 -1.3889 -0.2981 -0.2875
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular endothelial growth factor ; vegf ; transition ; compensatory hypertrophy ; cardiac failure
H-450	-0.7097525596618652	▁vas cular ▁en dot heli al ▁growth ▁factor ▁; ▁veu ▁; ▁compensa tory ▁hyper trop hy ▁; ▁cardiac ▁failure
D-450	-0.7097525596618652	vascular endothelial growth factor ; veu ; compensatory hypertrophy ; cardiac failure
P-450	-2.4691 -0.7617 -0.0212 -0.7171 -0.2434 -0.0428 -0.4385 -0.5982 -0.3863 -3.3410 -1.1693 -0.3747 -0.2810 -0.1610 -0.0305 -2.6676 -0.3140 -0.0364 -0.3304 -0.3250 -0.1954
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left ventricular ejection fraction ; mortality ; patients ; heart failure ; heart failure survey ; israel
H-110	-0.9086218476295471	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁Survey ▁; ▁is ra el
D-110	-0.9086218476295471	left ventricular ejection fraction ; heart failure ; Heart Failure Survey ; israel
P-110	-2.2272 -0.6313 -2.0836 -1.1059 -0.4659 -0.3303 -0.2383 -0.4798 -0.0686 -0.3952 -5.2247 -0.8469 -0.2863 -0.5462 -0.6062 -2.4006 -1.1023 -0.3024 -0.3114 -0.3419 -0.0274 -0.5289 -0.3467
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected ; clinical ; death ; medical ; hospitalization ; hf ; clinic ; outpatients
H-379	-1.5394901037216187	▁death ▁; ▁medical ▁hospital ization ▁; ▁ HF
D-379	-1.5394901037216187	death ; medical hospitalization ; HF
P-379	-4.3350 -0.2827 -2.9959 -0.3966 -0.7725 -0.2591 -2.7503 -1.2588 -2.0501 -0.2938
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ; ic ; multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy
H-103	-0.3902757465839386	▁i cc ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁tri al - Card iac ▁re syn chron ization ▁Therapy
D-103	-0.3902757465839386	icc ; multicenter Automatic Defibrillator Implantation ; trial-Cardiac resynchronization Therapy
P-103	-0.2920 -0.2932 -0.2448 -0.6658 -0.0648 -0.4070 -0.0604 -0.3963 -0.1183 -1.1986 -0.1102 -0.2922 -1.5834 -0.2164 -0.0466 -0.2204 -0.1337 -0.4136 -0.4641 -0.5003 -0.0847 -0.0083 -1.2161 -0.3532 -0.4552 -0.3076
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone therapy ; exercise rehabilitation ; patients ; chronic heart failure ; testosterone ; double-blind ; randomized
H-1316	-1.0431230068206787	▁Test o ster one ▁ therapy ▁; ▁exercise ▁rehabilita tion ▁; ▁chronic ▁heart ▁failure ▁; ▁testosteron e ▁status
D-1316	-1.0431230068206787	Testosterone therapy ; exercise rehabilitation ; chronic heart failure ; testosterone status
P-1316	-4.0937 -0.4216 -0.0774 -1.3743 -1.4847 -0.1263 -0.4446 -1.1518 -0.1062 -1.9954 -0.4135 -4.6403 -1.3082 -0.3498 -0.3460 -1.5786 -0.0639 -0.1346 -0.4568 -0.2948
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health buddy program ; admissions ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
H-1627	-0.8357400298118591	▁Health ▁Budd y ▁Program ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁mortal iteit ▁; ▁con ges tive ▁heart ▁failure
D-1627	-0.8357400298118591	Health Buddy Program ; chronic obstructive pulmonary disease ; mortaliteit ; congestive heart failure
P-1627	-1.2779 -0.0747 -0.2638 -1.0753 -0.3056 -0.6519 -0.7896 -0.5684 -1.5941 -0.0432 -0.9221 -0.8570 -0.2511 -1.2185 -1.5749 -0.2657 -0.8925 -0.7123 -3.4955 -1.1813 -0.4446 -0.5033 -0.2587
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ; ras ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
H-1599	-0.47917166352272034	RAS ▁; ▁do pp ler ▁ultra son ography ▁; ▁com put ed ▁to mo graphic ▁ang i ography ▁; ▁magnetic ▁res on ance ▁ang i ography
D-1599	-0.47917166352272034	RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
P-1599	-0.3859 -0.3761 -0.2591 -0.1457 -1.8208 -0.1887 -0.2614 -1.0271 -0.4408 -0.3272 -0.0376 -0.3314 -0.2907 -0.5020 -0.8539 -0.8480 -0.7066 -0.6372 -0.4172 -0.2265 -0.2451 -0.2376 -0.3343 -0.4961 -0.6153 -0.5324 -0.5585 -0.3136
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil ; cardioprotection ; apoptotic signaling pathway ; dna fragmentation ; mitochondrial
H-965	-0.4812268316745758	▁nic oran dil ▁; ▁significant ▁; ▁cardio protec tion ▁; ▁apo pto tic ▁signal ing ▁path way ▁; ▁DNA ▁fragment ation ▁; ▁mito cho ndri al ▁ultra struct ural ▁changes
D-965	-0.4812268316745758	nicorandil ; significant ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
P-965	-0.1583 -0.1506 -0.9611 -0.2752 -1.1287 -0.2952 -0.0796 -0.5187 -1.4437 -0.2825 -0.1367 -0.2362 -1.3986 -0.1134 -0.6043 -0.0960 -0.3189 -0.3244 -0.3042 -0.0891 -1.4577 -0.3506 -0.0151 -0.7408 -0.3257 -0.1356 -0.4580 -0.7010 -0.1122 -1.5186 -0.4141 -0.2546
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients ; atrial fibrillation ; heart failure ; hf ; stroke ; anticoagulation ; patients
H-1353	-0.7386137843132019	▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; HF ▁; ▁stroke ▁; ▁antico ag ulation
D-1353	-0.7386137843132019	atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
P-1353	-2.2384 -0.2925 -0.4378 -0.1213 -0.4662 -0.4292 -3.9706 -0.5050 -1.1970 -0.4547 -0.3787 -1.1773 -0.3835 -0.3997 -0.3155 -0.1243 -0.3008 -0.6766 -0.5986 -0.3046
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination ; echocardiographic ; lv reverse remodeling ; sensitivity ; specificity
H-433	-0.45003676414489746	▁e cho car dio graphic ▁score ▁; ▁LV ▁; ▁rever se ▁remodel ing
D-433	-0.45003676414489746	echocardiographic score ; LV ; reverse remodeling
P-433	-0.1967 -0.5009 -0.1343 -0.5340 -1.0432 -1.0036 -0.3010 -0.1495 -1.7440 -0.1307 -0.1030 -0.0429 -0.2087 -0.3635 -0.2943
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk ; scn5a ; kv4.3 ; mrna ; mrna splice
H-1087	-0.7648026943206787	▁per k ▁inhibi tion ▁; ▁s cn 5 a ▁; ▁kv 4.3 ▁m RNA ▁levels ▁; ▁na + ▁channel ▁m RNA ▁sp lice
D-1087	-0.7648026943206787	perk inhibition ; scn5a ; kv4.3 mRNA levels ; na+ channel mRNA splice
P-1087	-2.1821 -0.9194 -0.1479 -2.1956 -0.3537 -0.4297 -0.1336 -1.5502 -0.4020 -0.3466 -0.1662 -0.5532 -0.1306 -0.6573 -1.4743 -0.4020 -0.1529 -2.8970 -0.1097 -0.1033 -0.7143 -0.0411 -1.4887 -1.2784 -0.2902
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck stent ; myocardial infarction ; antiplatelet medication
H-508	-0.47169697284698486	▁bottle ne ck ▁sten t ▁; ▁my o card ial ▁in far ction ▁; ▁anti plate let ▁medication
D-508	-0.47169697284698486	bottleneck stent ; myocardial infarction ; antiplatelet medication
P-508	-0.3447 -0.3288 -0.0892 -0.0354 -0.1387 -0.3451 -1.3132 -0.3002 -1.0034 -1.8472 -0.0943 -0.6591 -0.7298 -0.3325 -0.0170 -0.1226 -0.3172 -0.6599 -0.4610 -0.2945
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef ; bnp ; hf ; patients ; prognostic ; significance ; bnp ; ef
H-188	-1.1536821126937866	▁sex ▁; ▁EF ▁; ▁b NP ▁; ▁ HF ▁; ▁b NP ▁; ▁sex ▁; ▁EF
D-188	-1.1536821126937866	sex ; EF ; bNP ; HF ; bNP ; sex ; EF
P-188	-2.7639 -0.2482 -0.9406 -0.3693 -1.2065 -2.4744 -0.3270 -1.9160 -1.2186 -0.3285 -2.0558 -2.4550 -0.3456 -2.0969 -0.2721 -1.1071 -0.3610 -0.2797
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab ; chf ; nontrastuzumab users ; hazard ratio
H-679	-0.7538740634918213	▁Tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab ▁; haz ard ▁ratio ▁; HR
D-679	-0.7538740634918213	Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio ;HR
P-679	-0.5092 -0.8515 -0.7054 -0.9301 -0.6531 -0.5588 -0.3800 -0.7803 -0.4620 -0.9031 -0.9822 -2.1000 -1.0117 -1.6077 -0.0563 -0.1522 -0.2915 -1.3405 -0.4841 -0.3177
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction ; rad variant ; q66p ; congestive heart failure
H-1673	-0.8373428583145142	▁Rad ▁variant ▁; Q 66 p ▁; ▁con ges tive ▁heart ▁failure ▁; ▁humans
D-1673	-0.8373428583145142	Rad variant ;Q66p ; congestive heart failure ; humans
P-1673	-0.5050 -0.1327 -0.2472 -3.5973 -1.1045 -0.2987 -0.2885 -0.3114 -0.4935 -3.1966 -1.0011 -0.4259 -0.3593 -0.8420 -0.3488 -0.2451
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt loading ; uninephrectomy ; ang ii infusion ; cardiac function ; hf
H-282	-0.5560992360115051	▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion ▁; ▁mouse ▁; ▁cardiac ▁function ▁; ▁mi ce ▁; HF
D-282	-0.5560992360115051	salt loading ; uninephrectomy ; ANG II infusion ; mouse ; cardiac function ; mice ;HF
P-282	-0.2089 -0.1415 -0.1812 -0.2585 -0.0327 -1.4653 -0.7662 -0.0612 -0.0667 -1.4023 -0.3104 -0.1910 -1.6555 -0.0327 -0.0767 -0.3548 -0.7343 -0.2625 -0.1982 -0.3105 -0.3144 -2.3099 -0.5365 -0.2696 -2.3258 -0.2929 -0.2544
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated ; mena expression ; correlates ; hf ; mena ; cardiac ; pathophysiology
H-1812	-0.7261579632759094	▁Men a ▁expression ▁; HF ▁; ▁men a ▁; ▁cardiac ▁pat ho phy si ology
D-1812	-0.7261579632759094	Mena expression ;HF ; mena ; cardiac pathophysiology
P-1812	-1.8702 -0.2894 -0.2023 -0.2584 -3.3040 -0.2934 -1.8701 -0.3630 -0.2606 -0.1340 -0.2741 -0.2746 -0.4083 -1.7953 -0.1503 -0.3410 -0.2556
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential effect ; lvef ; mortality ; hospitalization ; acute ; decompensated hf
H-112	-0.8028117418289185	▁LV EF ▁; ▁mortal iteit ▁; ▁hospital ization ▁; ▁a cute ▁de com pensa ted ▁ HF
D-112	-0.8028117418289185	LVEF ; mortaliteit ; hospitalization ; acute decompensated HF
P-112	-0.8626 -2.4516 -0.3838 -1.1994 -1.8881 -0.3104 -2.8448 -0.8326 -0.2760 -0.4489 -0.2398 -0.1253 -0.1380 -0.1179 -0.9025 -0.5957 -0.9463 -0.3874 -0.3021
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan failure ; circulatory ; hemodynamic ; portal hypertension ; cardiac output
H-234	-0.43815818428993225	▁Font an ▁failure ▁; ▁circula tory ▁de rang ement ▁; ▁hem o dynamic ▁; ▁portal ▁hyper tension ▁; ▁cardiac ▁output
D-234	-0.43815818428993225	Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
P-234	-0.4125 -1.3211 -1.3467 -0.2587 -0.0206 -0.4869 -0.7239 -0.0126 -1.2732 -0.3876 -0.3253 -0.3263 -0.0409 -1.3817 -0.0424 -0.0424 -0.0823 -0.2825 -0.1728 -0.0388 -0.3994 -0.2608
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ; ami ; hazard ratio ; mortality
H-1313	-1.0679373741149902	HF ▁; ▁index ▁; AMI
D-1313	-1.0679373741149902	HF ; index ;AMI
P-1313	-3.4538 -0.3234 -0.0712 -1.1452 -1.5214 -0.6321 -0.3285
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic heart failure ; spironolactone ; hospitalization ; death
H-446	-0.3811851739883423	▁sy sto lic ▁heart ▁failure ▁; ▁spi rono lac tone
D-446	-0.3811851739883423	systolic heart failure ; spironolactone
P-446	-0.1384 -0.3939 -0.1834 -1.3686 -0.4792 -0.3556 -0.0514 -0.0733 -0.1206 -0.1767 -0.9426 -0.2905
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr ; mrna splice ; cardiac ; hf
H-1088	-0.9540927410125732	▁uc p ▁; ▁na + ▁channel ▁m RNA ▁sp lice ▁; ▁cardiac ▁; ▁na + ▁current ▁; ▁human ▁ HF
D-1088	-0.9540927410125732	ucp ; na+ channel mRNA splice ; cardiac ; na+ current ; human HF
P-1088	-3.7176 -3.4254 -0.2884 -0.2038 -3.4551 -0.0670 -0.1557 -0.2546 -0.0113 -1.0857 -0.3667 -0.2716 -0.6955 -0.1880 -2.7200 -0.0635 -0.1810 -1.7881 -0.6793 -0.6851 -0.4198 -0.2667
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic ; neurohormonal ; symptoms ; fluid overload
H-1201	-0.6172933578491211	▁di ure tic ▁ef fica cy ▁; ▁neuro hormon al ▁activa tion ▁; ▁fluid ▁over load
D-1201	-0.6172933578491211	diuretic efficacy ; neurohormonal activation ; fluid overload
P-1201	-1.8370 -1.4307 -1.7821 -0.2978 -1.2934 -0.6797 -0.3433 -0.1004 -0.0974 -0.1495 -0.0087 -1.2320 -0.3358 -0.6146 -0.0469 -0.3063 -0.3315 -0.2242
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets ; transcriptional pause release ; pathological
H-1052	-0.4297545850276947	BET s ▁; ▁tran scription al ▁pause ▁release ▁; ▁re - activa ting ▁tran scription ▁; ▁path ological ▁stress
D-1052	-0.4297545850276947	BETs ; transcriptional pause release ; re-activating transcription ; pathological stress
P-1052	-0.8236 -1.4148 -0.3198 -0.0831 -0.2457 -0.3226 -0.2930 -0.3115 -0.2846 -0.9102 -0.1483 -0.0226 -1.2550 -0.1821 -0.1690 -0.3686 -0.1832 -0.5330 -0.5171 -0.3505 -0.2865
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence ; lvad ; transplantation ; patients ; budget
H-316	-0.6561716198921204	▁l VAD ▁; ▁transplant ation ▁e ligi bility ▁status ▁; ▁patients ▁; ▁budget
D-316	-0.6561716198921204	lVAD ; transplantation eligibility status ; patients ; budget
P-316	-0.2300 -0.5468 -0.3174 -0.3607 -1.9162 -1.1020 -0.1204 -2.4203 -0.3469 -0.4147 -0.9848 -0.3847 -0.0951 -0.3789 -0.2235
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients ; preserved lvef ; lvef
H-114	-0.8616880774497986	▁LV EF ▁; ▁LV EF
D-114	-0.8616880774497986	LVEF ; LVEF
P-114	-0.5034 -1.9674 -0.3513 -0.5406 -1.9230 -0.4275 -0.3185
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis ; pathogenesis ; heart failure
H-173	-1.1769258975982666	▁apo pto sis ▁; ▁heart ▁failure
D-173	-1.1769258975982666	apoptosis ; heart failure
P-173	-2.7363 -0.7312 -2.0663 -0.3963 -2.3790 -0.3833 -0.4146 -0.3084
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional enrichment analysis ; regulation ; cell death ; degs
H-1614	-0.7006779313087463	▁functional ▁en rich ment ▁analysis ▁; ▁programme d ▁cell ▁death ▁; ▁de g s
D-1614	-0.7006779313087463	functional enrichment analysis ; programmed cell death ; degs
P-1614	-0.2220 -0.1074 -0.2870 -0.9978 -1.3064 -0.3195 -0.5787 -0.1783 -0.3922 -0.5125 -0.3260 -0.0923 -4.7020 -0.4699 -0.4333 -0.2857
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg ; atherosclerotic cad ; cardiac death
H-1910	-0.6626386642456055	▁e CG ▁; ▁bijdrage ▁; ▁a ther os cle ro tic ▁CAD ▁; ▁cardiac ▁death
D-1910	-0.6626386642456055	eCG ; bijdrage ; atherosclerotic CAD ; cardiac death
P-1910	-0.7104 -2.5485 -0.2746 -1.7813 -0.2154 -0.2736 -1.1217 -0.6628 -0.2807 -0.1922 -0.6501 -0.3394 -0.2286 -0.4571 -0.8638 -0.4046 -0.2600
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration ; hr reduction ; bpm ; p value
H-1942	-1.209344744682312	▁HR ▁re duction
D-1942	-1.209344744682312	HR reduction
P-1942	-3.2450 -1.4996 -0.4924 -0.4734 -0.3363
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv fractional shortening ; lung ; incidence
H-278	-1.0443931818008423	ANS ▁mi ce ▁; ▁LV ▁; ▁lung ▁weight
D-278	-1.0443931818008423	ANS mice ; LV ; lung weight
P-278	-3.0522 -2.3690 -0.9180 -0.3149 -1.4303 -0.2983 -0.8067 -0.5990 -0.3738 -0.2818
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes ; patients ; atrial fibrillation ; early treatment of atrial fibrillation for stroke prevention trial
H-1642	-0.8651441931724548	▁at rial ▁fi bril lation ▁; ▁At rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention
D-1642	-0.8651441931724548	atrial fibrillation ; Atrial fibrillation ; Stroke prevention
P-1642	-3.5372 -0.5894 -1.0663 -0.3430 -0.6881 -0.3596 -2.9206 -0.3656 -1.1045 -0.2640 -0.6340 -0.2250 -1.1456 -0.6794 -0.9598 -0.0465 -0.3857 -0.2585
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty ; prognostic ; heart failure ; hf ; biological phenotype
H-1001	-0.8146123290061951	▁fra il ty ▁; ▁heart ▁failure ▁; HF ▁; ▁bi ological ▁ph eno type
D-1001	-0.8146123290061951	frailty ; heart failure ;HF ; biological phenotype
P-1001	-2.4158 -0.7642 -1.0946 -0.4000 -1.8484 -0.4590 -0.3195 -1.6125 -1.4184 -0.9695 -0.5920 -0.3211 -0.1080 -0.0069 -0.4342 -0.2698
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional ms ; patients ; valve plasty ; degenerative mr ; dilated ; disease
H-340	-0.4865287244319916	▁functional ▁; ▁MS ▁; ▁val ve ▁plast y ▁; ▁ann ular ▁size ▁re duction ▁; ▁de genera tive ▁MR ▁; ▁LV ▁; ▁disease
D-340	-0.4865287244319916	functional ; MS ; valve plasty ; annular size reduction ; degenerative MR ; LV ; disease
P-340	-0.4450 -0.7997 -0.6643 -0.2643 -1.7881 -0.1166 -0.1365 -1.3799 -0.2801 -0.3597 -0.0402 -1.0245 -0.2762 -0.3228 -0.2683 -0.1753 -0.0157 -1.3512 -0.4474 -0.2957 -0.1582 -0.5244 -0.5272 -0.2764 -0.2254
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based ; prognosis ; idiopathic dilated cardiomyopathy
H-1750	-0.5041321516036987	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1750	-0.5041321516036987	idiopathic dilated cardiomyopathy
P-1750	-1.9573 -0.9752 -0.1718 -0.8989 -0.1879 -0.2013 -0.0937 -0.6599 -0.1679 -0.0721 -0.3892 -0.2743
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right ventricular ; rv ; prognosis ; patients ; heart failure ; hf
H-1158	-1.2755508422851562	▁right ▁vent ri cular ▁; ▁v n ▁; ▁body ▁composition ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1158	-1.2755508422851562	right ventricular ; vn ; body composition ; advanced heart failure ;HF
P-1158	-2.2910 -0.2001 -1.4645 -0.3291 -0.4289 -1.8562 -0.5545 -0.2554 -8.9141 -0.7367 -0.2254 -2.3940 -0.9933 -0.4003 -0.2460 -1.0244 -0.3636 -0.2823
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american college of cardiology ; american heart association ; patients ; ras ; patients ; ras
H-1604	-1.2532267570495605	▁American ▁college ▁of ▁Card i ology ▁; American ▁Heart ▁association ▁; ▁ RAS ▁; ▁treatment ▁plans ▁; RAS
D-1604	-1.2532267570495605	American college of Cardiology ;American Heart association ; RAS ; treatment plans ;RAS
P-1604	-2.5626 -1.6077 -0.7983 -1.6132 -0.2330 -0.0802 -0.2571 -0.9523 -2.0988 -0.5024 -0.3036 -4.3871 -1.0103 -0.3875 -2.3226 -1.2404 -0.2976 -3.8421 -0.3369 -0.2308
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni ; cardiovascular mortality ; hospitalization ; heart failure ; quality of life
H-1969	-0.9468105435371399	▁AR NI ▁; ▁cardiovascular ▁mortal iteit ▁; ▁hospital ization ▁; ▁heart ▁failure
D-1969	-0.9468105435371399	ARNI ; cardiovascular mortaliteit ; hospitalization ; heart failure
P-1969	-1.9149 -1.6183 -0.4278 -0.3489 -0.3417 -2.4748 -0.3925 -1.1303 -0.9030 -0.3962 -0.8038 -0.6480 -1.5397 -0.3153
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined training ; peak work rate ; peak quadriceps force
H-1917	-0.41307154297828674	▁quadri cep s ▁force
D-1917	-0.41307154297828674	quadriceps force
P-1917	-0.4380 -0.7847 -0.1990 -0.2427 -0.5137 -0.3003
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable cardioverter-defibrillator ; physicians ; heart failure ; patients
H-1857	-0.7426002621650696	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁heart ▁failure ▁patients
D-1857	-0.7426002621650696	implantable cardioverter-defibrillator deactivation ; heart failure patients
P-1857	-1.6378 -0.2449 -1.1141 -0.1997 -0.7023 -0.2185 -0.1044 -0.3266 -2.1637 -0.4300 -0.2298 -0.2341 -0.1498 -2.6409 -0.2732 -1.5895 -0.2138 -1.5969 -0.4862 -0.2957
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus ; cells ; functional capacity ; mortality ; nondiabetic ; patients
H-131	-1.1778806447982788	▁o - c FU s ▁; ▁cd 34 ▁; ve g FR 2 ▁; ▁cell s ▁; ▁mortal iteit ▁; ▁non dia be tic ▁patients
D-131	-1.1778806447982788	o-cFUs ; cd34 ;vegFR2 ; cells ; mortaliteit ; nondiabetic patients
P-131	-3.7408 -1.8344 -0.4931 -2.7103 -0.6092 -0.3119 -0.6769 -1.1390 -1.4555 -2.4098 -1.3086 -2.2661 -0.3709 -0.3859 -1.7725 -0.4970 -0.3168 -3.9236 -1.9567 -0.3299 -0.4342 -0.0190 -0.3694 -0.5728 -1.3259 -0.3154 -0.2573
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-375	-0.5522270202636719	▁functional ▁; ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV ▁; ▁disease
D-375	-0.5522270202636719	functional ; MS ; valve plasty ; degenerative MR ; LV ; disease
P-375	-0.4984 -1.4773 -0.7788 -0.2893 -1.5995 -0.0926 -0.1249 -1.3350 -0.2668 -0.0619 -0.0212 -1.2415 -0.5764 -0.3339 -0.1331 -0.4619 -0.6561 -0.3032 -0.2406
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients ; exercise ; anaerobic metabolism ; peak respiratory quotient
H-1756	-0.9051822423934937	▁ana ero bic ▁metabolism ▁; ▁respirator y ▁ quot ient
D-1756	-0.9051822423934937	anaerobic metabolism ; respiratory quotient
P-1756	-3.6174 -1.0818 -0.6691 -0.4490 -0.4078 -0.3715 -1.2671 -0.7307 -0.3757 -1.1513 -0.4733 -0.2675
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise ; training ; outcomes ; hf ; patients ; exercise ; training ; therapy ; clinical
H-1934	-1.1848046779632568	▁exercise ▁training ▁; HF ▁; ▁exercise ▁; ▁ therapy
D-1934	-1.1848046779632568	exercise training ;HF ; exercise ; therapy
P-1934	-2.0352 -1.4500 -0.3578 -1.7840 -0.5611 -4.9984 -0.9186 -0.1708 -0.0800 -0.3811 -0.2957
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial dd ; muscle ; titin hypophosphorylation
H-768	-0.804119348526001	▁my o card ial ▁ DD ▁; ▁high ▁muscle ▁strip ▁; ▁sti ff ness ▁; ▁titi n ▁hypo phos phor y lation
D-768	-0.804119348526001	myocardial DD ; high muscle strip ; stiffness ; titin hypophosphorylation
P-768	-1.7687 -0.2473 -0.5397 -0.8153 -0.5198 -0.8597 -0.2945 -4.2682 -0.9103 -0.2107 -0.4287 -0.4905 -0.0941 -3.2720 -0.2809 -0.2364 -0.2768 -0.1093 -0.2013 -1.2010 -1.5420 -0.1361 -0.3378 -0.2579
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc ; nps ; clinical
H-1024	-1.0404245853424072	▁ NP ▁measure ment ▁; ▁PO c ▁measure ment ▁; ▁ NP s
D-1024	-1.0404245853424072	NP measurement ; POc measurement ; NPs
P-1024	-1.2163 -1.2266 -1.6714 -0.8384 -0.2830 -2.3976 -1.6505 -1.5148 -0.7449 -0.3158 -1.2004 -1.4145 -0.5660 -0.2947 -0.2715
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology ; comorbidities ; patients ; outcomes
H-564	-0.5124194025993347	▁et i ology ▁; ▁como rbi di ties
D-564	-0.5124194025993347	etiology ; comorbidities
P-564	-0.1725 -0.3376 -0.1244 -0.4200 -0.7551 -0.0524 -0.5365 -0.0958 -2.3284 -0.3014
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients ; physicians ; readmission ; hospital
H-1728	-0.8623865842819214	▁high - volu me ▁physician s ▁; ▁read mission ▁rates
D-1728	-0.8623865842819214	high-volume physicians ; readmission rates
P-1728	-3.1992 -0.1409 -0.2965 -0.4564 -0.5678 -0.5005 -0.4803 -1.4603 -1.6037 -0.7570 -0.5905 -0.2953
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence ; intestinal ; patients ; chf
H-1358	-0.6963239312171936	▁financiële ▁; ▁intestinal ▁ morph ology ▁; ▁ab sor p tion ▁function ▁; ▁CHF
D-1358	-0.6963239312171936	financiële ; intestinal morphology ; absorption function ; CHF
P-1358	-4.2147 -0.1623 -0.6243 -0.2008 -0.0994 -0.4445 -0.3510 -0.0875 -0.3915 -0.8415 -1.5404 -0.0944 -0.3581 -1.1137 -0.3435 -0.2736
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins ; expression ; cardiac hypertrophy ; proteins ; nucleolin
H-95	-0.6109291911125183	▁protein s ▁; ▁cardiac ▁hyper trop hy ▁; ▁protein s ▁; ▁nu cle olin
D-95	-0.6109291911125183	proteins ; cardiac hypertrophy ; proteins ; nucleolin
P-95	-2.0314 -0.7591 -0.2848 -0.1755 -0.1088 -0.0443 -1.7772 -0.2288 -2.0811 -0.7976 -0.2099 -0.5308 -0.0185 -0.1620 -0.3013 -0.2637
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized ; follow-up
H-1751	-0.3932057321071625	▁benefits ▁; ▁follow - up
D-1751	-0.3932057321071625	benefits ; follow-up
P-1751	-1.3612 -0.3230 -0.0725 -0.2984 -0.0439 -0.3785 -0.2749
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic volume ; echocardiography
H-521	-0.44231051206588745	▁Blood ▁pressure ▁; ▁arm ▁cu ff ▁; ▁stroke ▁volume ▁; ▁v n ▁; ▁e je ction ▁ fraction ▁; ▁end - dia sto lic ▁volume ▁; ▁e cho card i ography
D-521	-0.44231051206588745	Blood pressure ; arm cuff ; stroke volume ; vn ; ejection fraction ; end-diastolic volume ; echocardiography
P-521	-0.5739 -0.8180 -0.3044 -1.8062 -1.3509 -0.1847 -0.2271 -0.1930 -0.2752 -0.3270 -0.6251 -0.9205 -0.2843 -0.4158 -0.2402 -0.0909 -0.2143 -0.0230 -0.3428 -1.4051 -0.1887 -0.0228 -0.4981 -0.3339 -0.4230 -0.3258 -0.2456 -0.3607 -0.1794 -0.3597 -0.3502 -0.4263 -0.2595
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas city cardiomyopathy questionnaire ; kccq ; hf with reduced ef ; patients ; hfpef
H-781	-0.8129348754882812	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁ nc w t ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-781	-0.8129348754882812	Kansas City Cardiomyopathy Questionnaire ; ncwt ; HF ; EF ; HFpEF
P-781	-0.0853 -2.4642 -1.5614 -0.1128 -0.1327 -0.9037 -0.1499 -0.4359 -0.0347 -0.2403 -1.9992 -2.6481 -0.2822 -2.1213 -0.2584 -1.1893 -1.3464 -0.2243 -0.4427 -0.3224 -1.3480 -1.2797 -0.0421 -0.8729 -0.3617 -0.2767
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients ; biventricular support ; heartmate ii ; lvad ; centrimag ; right ventricular assist device ; rvad
H-296	-0.6715474128723145	▁bi ven tri cular ▁support ▁; ▁hybrid ▁system ▁; ▁Heart Mate ▁i i ▁; ▁l VAD ▁; ▁Centri Mag ▁; ▁right ▁vent ri cular ▁assist ▁device ▁; ▁r VAD
D-296	-0.6715474128723145	biventricular support ; hybrid system ; HeartMate ii ; lVAD ; CentriMag ; right ventricular assist device ; rVAD
P-296	-1.0350 -0.2165 -2.2190 -0.7600 -2.6638 -0.3189 -0.0215 -0.3175 -0.2953 -1.1276 -0.0601 -0.5053 -0.1782 -0.3398 -0.1043 -0.1128 -0.3803 -0.1431 -1.1249 -1.1337 -0.5012 -0.3172 -2.2115 -0.6212 -0.8385 -0.5198 -0.2712 -1.2857 -0.5602 -0.3593 -0.2748
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; right ventricular contractile function ; prognosis
H-491	-0.4220418930053711	▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; ▁heart ▁failure ▁; ▁index ▁; ▁right ▁vent ri cular ▁contract ile ▁function
D-491	-0.4220418930053711	tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; index ; right ventricular contractile function
P-491	-0.0370 -0.3365 -0.0989 -0.9306 -0.0278 -0.2120 -0.1576 -0.2298 -0.1565 -0.1794 -0.1031 -0.2064 -0.0287 -0.8496 -0.0368 -0.0370 -0.1321 -0.2602 -1.8016 -0.1866 -1.2737 -0.5334 -0.2457 -0.0272 -1.7486 -0.2906 -0.3038 -1.8781 -0.4811 -0.1096 -0.0926 -0.7394 -0.3943 -0.2231
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis ; heart failure ; myocardial tissue ; left ventricular ; trichrome blue histologic analysis
H-1060	-0.6155275106430054	▁fibro sis ▁; ▁heart ▁failure ▁; ▁my o card ial ▁tissu e ▁; ▁left ▁vent ri cular ▁tissu e ▁; ▁tri ch rom e ▁blue ▁his t ologic ▁analysis
D-1060	-0.6155275106430054	fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue histologic analysis
P-1060	-0.1461 -1.6825 -0.3028 -1.5919 -0.3316 -0.2746 -2.5900 -0.5568 -1.0502 -1.3908 -0.3311 -0.2347 -0.2812 -1.5319 -0.1987 -1.7755 -0.3589 -0.2038 -0.1831 -0.2855 -0.0079 -0.0706 -0.0048 -0.0165 -0.1282 -1.6156 -0.2006 -0.2162 -0.8324 -0.4169 -0.2700
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt ; dt ; btt ; patients
H-314	-1.2001999616622925	▁b t ▁; ▁d t ▁; ▁b t
D-314	-1.2001999616622925	bt ; dt ; bt
P-314	-2.9574 -1.6328 -0.3465 -1.4782 -0.5546 -0.4676 -2.6313 -1.0835 -0.4861 -0.3640
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure ; health ; income ; hf
H-1800	-1.386567234992981	▁ex pendi ture ▁; ▁health ▁per ▁capita ▁; ▁gross ▁national ▁income ▁; ▁ HF ▁; ▁la
D-1800	-1.386567234992981	expenditure ; health per capita ; gross national income ; HF ; la
P-1800	-0.3780 -0.3463 -3.2411 -0.3631 -2.2387 -2.4713 -0.2087 -0.3126 -0.6022 -3.9038 -0.7959 -0.9291 -2.8878 -1.8797 -0.3893 -0.6705 -3.1045 -0.2356
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ; ef
H-192	-0.8628442287445068	▁border line ▁; ▁female ▁; ▁EF
D-192	-0.8628442287445068	borderline ; female ; EF
P-192	-0.4239 -0.1975 -0.4313 -2.0820 -0.5064 -2.5604 -0.3767 -0.3246
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood pressure ; therapy ; patients ; ras
H-1600	-0.7278544902801514	▁blood ▁pressure ▁control ▁; ▁lipid - lo wering ▁ therapy ▁; ▁smoking ▁ces s ation ▁; RAS
D-1600	-0.7278544902801514	blood pressure control ; lipid-lowering therapy ; smoking cessation ;RAS
P-1600	-1.8504 -1.1635 -2.3585 -0.2590 -0.8931 -0.1921 -0.1783 -0.1425 -0.9285 -0.1108 -0.2891 -0.1108 -0.3112 -0.2428 -1.0088 -0.3086 -2.8735 -0.3676 -0.2401
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt ; atrial pacing
H-1442	-1.3806297779083252	▁SD t ▁; HF VT ▁; ▁ HF VT ▁; ▁h Nor m ▁; ▁fixed - rate ▁at rial ▁pa cing
D-1442	-1.3806297779083252	SDt ;HFVT ; HFVT ; hNorm ; fixed-rate atrial pacing
P-1442	-0.8286 -3.9131 -0.3757 -2.4816 -2.7673 -0.3278 -1.5650 -1.2297 -3.2868 -0.3506 -1.1138 -5.0155 -0.2520 -0.9868 -1.2106 -0.3232 -0.4492 -2.1354 -0.9749 -0.0932 -1.3364 -0.4487 -0.2889
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-0.43278735876083374	
D-2014	-0.43278735876083374	
P-2014	-0.5998 -0.2658
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals ; patients ; hfpef
H-952	-0.8368037343025208	▁AF ▁; ▁ pharma ce u tical s ▁; ▁h FP EF
D-952	-0.8368037343025208	AF ; pharmaceuticals ; hFPEF
P-952	-0.7048 -0.3110 -0.5438 -0.9124 -0.7806 -0.1997 -0.1097 -0.6167 -0.3576 -1.8316 -2.4199 -2.2728 -0.3679 -0.2867
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies ; crt-d ; heart failure ; death
H-108	-1.1808271408081055	▁IE s ▁; ▁c RT - d ▁; ▁heart ▁failure ▁; ▁death
D-108	-1.1808271408081055	IEs ; cRT-d ; heart failure ; death
P-108	-5.1287 -0.5977 -0.2832 -1.2186 -2.6800 -0.1825 -0.6328 -0.5727 -2.4336 -0.6540 -0.3519 -1.2067 -0.3164 -0.2727
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical ; bnp ; inhospital ; mortality
H-196	-1.0588868856430054	▁b p ▁; ▁in hospital ▁mortal iteit
D-196	-1.0588868856430054	bp ; inhospital mortaliteit
P-196	-1.1396 -3.5073 -0.3996 -0.1756 -0.3600 -0.3243 -2.8579 -0.4396 -0.3261
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping ; myocardial ; heart failure
H-1063	-0.7805222868919373	▁t 1- ma pping ▁techniek ▁; ▁diffuse ▁my o card ial ▁changes ▁; ▁heart ▁failure ▁; ▁contrast ▁agent ▁; ▁breath - hold ing
D-1063	-0.7805222868919373	t1-mapping techniek ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
P-1063	-1.3367 -0.2865 -0.7436 -0.7157 -2.9596 -0.3311 -1.2255 -1.4512 -0.2514 -0.9506 -1.8492 -1.6124 -0.3173 -1.3570 -0.8246 -0.2597 -0.8537 -0.0163 -0.3287 -0.1615 -0.2306 -0.5257 -0.2263 -0.3941 -0.3041
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable cardioverter-defibrillators ; icds ; mortality ; cardiac resynchronization therapy ; crt ; symptoms ; mortality
H-1068	-0.6922923922538757	▁implant able ▁cardio ver ter - de fi br illa tors ▁; ▁i cc s ▁; ▁mortal iteit ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-1068	-0.6922923922538757	implantable cardioverter-defibrillators ; iccs ; mortaliteit ; cardiac resynchronization therapy ; cRT
P-1068	-1.0674 -0.2630 -0.0795 -0.2164 -0.7748 -0.3053 -0.0961 -0.2567 -1.4729 -0.6006 -0.4704 -0.3502 -0.1990 -0.5230 -1.4010 -0.3080 -1.9753 -2.1228 -0.3663 -0.1796 -0.1359 -0.0973 -0.0171 -1.8749 -0.3065 -0.0628 -0.3336 -0.8521 -3.7998 -0.6565 -0.2963
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular assist device ; vad ; extracorporeal membrane oxygenation ; ecmo ; renal function
H-1385	-0.523224413394928	▁vent ri cular ▁assist ▁device ▁; VAD ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁renal ▁function ▁; ▁children
D-1385	-0.523224413394928	ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function ; children
P-1385	-0.0900 -1.5638 -0.3100 -0.7890 -0.4329 -0.3312 -0.2469 -0.3037 -0.1585 -0.1663 -0.1857 -0.4997 -0.0844 -0.0972 -0.2097 -1.6291 -0.3654 -0.3243 -2.9731 -0.2350 -0.0711 -0.3377 -0.8966 -0.8206 -0.2639 -0.2182
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular endothelial growth factor blockade ; beta-blocker ; therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
H-448	-0.5181276798248291	▁Vas cular ▁en dot heli al ▁growth ▁factor ▁block ade ▁; ▁beta - block er ▁ therapy ▁; ▁cardiac ▁function ▁; ▁ang io gene sis ▁; ▁heart ▁failure
D-448	-0.5181276798248291	Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; heart failure
P-448	-3.7095 -0.7397 -0.0269 -0.5437 -0.3388 -0.0463 -0.5543 -0.6480 -0.6139 -0.5112 -0.3324 -0.2284 -0.0624 -0.1798 -0.1380 -0.2168 -0.0607 -0.3127 -0.1431 -0.1204 -0.2932 -0.4809 -0.7272 -0.1976 -0.8910 -0.3288 -2.1682 -0.3228 -0.3662 -0.2411
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp ; plasma ; patients ; dyspnea ; left ventricular dysfunction ; admission
H-265	-0.703287661075592	▁NT - pro b NP ▁; ▁plasma ▁; ▁dys pne a ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁ED
D-265	-0.703287661075592	NT-probNP ; plasma ; dyspnea ; left ventricular dysfunction ; ED
P-265	-2.5016 -0.1119 -0.0713 -1.2032 -2.0997 -1.6344 -0.2096 -0.3574 -0.1141 -0.0180 -0.5541 -0.3857 -0.7378 -0.2000 -2.0091 -0.8612 -0.0726 -0.3151 -0.3481 -0.9698 -0.4074 -0.2905
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile function ; lv dilatation ; lv end-diastolic pressure ; wall stress ; lung
H-476	-0.5577382445335388	▁contract ile ▁function ▁; ▁LV ▁di la tation ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight
D-476	-0.5577382445335388	contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
P-476	-0.0187 -0.1007 -0.3973 -0.2422 -0.5865 -1.3366 -0.3418 -0.2259 -0.3138 -1.5072 -2.2093 -1.7788 -0.1097 -0.0176 -0.3909 -0.2621 -0.4351 -0.2967 -1.8956 -0.2782 -0.2474 -0.1216 -0.2513 -0.3264 -0.2519
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating progenitor cells ; cpcs ; endothelial ; prognostic ; cardiovascular diseases
H-120	-0.4202863872051239	▁circula ting ▁pro gen itor ▁cell s ▁; ▁c ▁pc s ▁; ▁en dot heli al ▁repair ▁; ▁cardiovascular ▁disease s
D-120	-0.4202863872051239	circulating progenitor cells ; c pcs ; endothelial repair ; cardiovascular diseases
P-120	-0.2096 -0.5788 -0.2285 -0.1090 -0.5090 -0.3575 -0.4888 -0.2750 -0.1741 -2.9558 -0.2415 -0.2607 -0.0898 -0.2192 -0.3307 -0.0588 -0.1946 -0.2683 -0.1509 -1.1607 -0.2210 -0.3658 -0.2183
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action ; correlation ; baseline ; hgb ; baseline ; hrqol ; kccq
H-842	-1.049795150756836	▁ HF - ac TION ▁co hor t ▁; ▁h gb ▁; ▁base line ▁HR Qo L ▁; ▁ nc w t
D-842	-1.049795150756836	HF-acTION cohort ; hgb ; baseline HRQoL ; ncwt
P-842	-1.4825 -1.4711 -0.1112 -0.8972 -3.7178 -0.0371 -1.3082 -0.1353 -0.2707 -0.3394 -1.5143 -0.3344 -3.8410 -0.1122 -0.5610 -0.0415 -2.9107 -0.3079 -1.5465 -1.4033 -0.1963 -1.9115 -0.4290 -0.3147
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological ; remodelling ; heart ; cardiac hypertrophy ; hf ; death ; fibrosis ; inflammation
H-1035	-0.9099650382995605	▁heart ▁; ▁cardiac ▁hyper trop hy ▁; HF ▁; ▁fibro sis ▁; ▁ inflammation
D-1035	-0.9099650382995605	heart ; cardiac hypertrophy ;HF ; fibrosis ; inflammation
P-1035	-4.4360 -0.3477 -0.3855 -0.1248 -0.0400 -2.3041 -0.3355 -2.8389 -0.2153 -1.4483 -0.7573 -0.2598 -0.2384 -0.1847 -0.3386 -0.3046
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped ; snp ; rs10927887 ; ka renal chloride channel gene ; clcnka
H-1802	-0.7161635756492615	▁Cau ca sian ▁; ▁geno type d ▁; ▁s NP ▁; ▁ka ▁renal ▁chlor ide ▁channel ▁gene ▁; ▁c cn ka
D-1802	-0.7161635756492615	Caucasian ; genotyped ; sNP ; ka renal chloride channel gene ; ccnka
P-1802	-0.2636 -0.0450 -1.3079 -0.3155 -1.9222 -0.0931 -0.3717 -0.2004 -0.8100 -1.7169 -0.4974 -0.2169 -0.0300 -0.2493 -0.2115 -0.1097 -1.8546 -0.2882 -2.4244 -0.4651 -2.4890 -0.3372 -0.2522
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis ; hfpef ; clinical ; echo-doppler cardiography ; invasive haemodynamic assessment
H-1303	-0.500036895275116	▁ HF p EF ▁; ▁e cho - d opp ler ▁card i ography ▁; ▁invasi ve ▁ha emo dynamic ▁assessment
D-1303	-0.500036895275116	HFpEF ; echo-doppler cardiography ; invasive haemodynamic assessment
P-1303	-1.3865 -1.1575 -0.0777 -1.3237 -0.2730 -0.2093 -0.3322 -0.1044 -1.1381 -0.1519 -1.1066 -0.4849 -0.4494 -0.4563 -0.2934 -0.4996 -0.7756 -0.0327 -0.4491 -0.0313 -0.0800 -0.4147 -0.2732
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv remodeling ; diastolic ; xo inhibition ; symptoms ; hospitalizations ; patients ; severe heart failure
H-478	-0.5630484223365784	▁LV ▁; ▁dia sto lic ▁properties ▁; ▁ XO ▁inhibi tion ▁; ▁heart ▁failure
D-478	-0.5630484223365784	LV ; diastolic properties ; XO inhibition ; heart failure
P-478	-0.0948 -0.3336 -0.0300 -0.2193 -0.0623 -0.2798 -0.4805 -0.4154 -0.1193 -0.0504 -1.4671 -0.3074 -3.8948 -0.5882 -0.3755 -0.2903
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker ; uptitrations ; patients ; hfref ; hfpef ; hospital ; admission
H-177	-1.2164068222045898	▁ RAS - ▁; ▁β - block er ▁up ti tra tions ▁; ▁h Fr EF ▁; ▁ HF p EF
D-177	-1.2164068222045898	RAS- ; β-blocker uptitrations ; hFrEF ; HFpEF
P-177	-2.8660 -0.8360 -0.1518 -3.6501 -0.0879 -0.0979 -0.7701 -0.2170 -2.6205 -0.9865 -3.8286 -1.7092 -0.4139 -1.1856 -1.2771 -2.2310 -0.3764 -0.7052 -1.2065 -0.1020 -1.9668 -0.3687 -0.3226
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac magnetic resonance ; amyloidotic ; diagnosis ; multiple myeloma ; osteomedullary biopsy
H-999	-0.4347938001155853	▁cardiac ▁magnetic ▁res on ance ▁; ▁a my lo ido tic ▁pattern ▁; ▁multiple ▁mye loma ▁; ▁osteo me dulla ry ▁bio psy
D-999	-0.4347938001155853	cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
P-999	-0.2100 -0.1815 -0.1341 -0.6209 -0.3643 -0.3189 -0.1092 -0.7188 -0.1593 -0.1077 -1.4255 -0.6768 -0.2616 -0.3980 -0.0672 -0.5678 -0.2507 -0.1242 -0.1164 -0.2960 -2.9035 -0.0115 -0.1798 -0.4238 -0.2422
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure with preserved ejection fraction
H-915	-0.3728675842285156	▁Low - so dium ▁DAS h ▁; ▁die t ▁; ▁dia sto lic ▁function ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-915	-0.3728675842285156	Low-sodium DASh ; diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
P-915	-0.2126 -0.1532 -0.1599 -0.0607 -0.2104 -0.2665 -0.5147 -1.5126 -0.1843 -0.4322 -0.0268 -0.1408 -0.0703 -0.2502 -0.3840 -0.0371 -2.5953 -0.3767 -0.2812 -0.4219 -0.3258 -0.0610 -0.5615 -0.3971 -0.2289 -0.3321 -0.4529 -0.8777 -0.4404 -0.2832 -0.0910 -0.2168 -0.1414 -0.3309 -0.0139 -0.4931 -0.2571
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire ; implanted ; pacemakers ; ventricularly ; beats ; heart failure
H-1056	-0.5018399953842163	▁York shire ▁s win e ▁; ▁implant ed ▁; ▁pace makers ▁; ▁vent ri cular ly ▁pace d ▁; ▁heart ▁failure
D-1056	-0.5018399953842163	Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; heart failure
P-1056	-0.2699 -0.2295 -0.1237 -0.0750 -0.2858 -0.3517 -1.4147 -1.1443 -0.3747 -0.3619 -0.2101 -0.3109 -0.5277 -1.2209 -0.1964 -0.3271 -0.1777 -0.4805 -0.3328 -2.2272 -0.1905 -0.4703 -0.2390
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic ; patients ; reverse remodeling ; crt ; clinical ; outcomes
H-436	-0.6357012391090393	▁multi para metric ▁e cho car dio graphic ▁score ▁; ▁rever se ▁remodel ing ▁; ▁c RT
D-436	-0.6357012391090393	multiparametric echocardiographic score ; reverse remodeling ; cRT
P-436	-0.2378 -0.1509 -0.4758 -0.4368 -0.6793 -0.1407 -1.0422 -1.4728 -1.0636 -0.2999 -0.3282 -0.1245 -0.0840 -0.1581 -0.2795 -1.2129 -3.2100 -0.4263 -0.2552
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart rate ; ivabradine ; afterload ; patients ; systolic heart failure
H-516	-0.6333397030830383	▁isola ted ▁heart ▁rate ▁; HR ▁; ▁i va bra dine ▁; ▁sy sto lic ▁heart ▁failure
D-516	-0.6333397030830383	isolated heart rate ;HR ; ivabradine ; systolic heart failure
P-516	-0.1022 -1.1898 -1.5734 -0.4739 -0.3276 -1.8420 -0.3541 -0.2632 -0.0193 -0.4803 -0.7695 -0.3275 -1.3794 -0.2335 -0.2514 -1.1455 -0.5313 -0.4825 -0.2870
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis ; biomedical ; biomedical ; patients ; dcm ; heart failure
H-1264	-0.7773007154464722	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d c ▁; ▁heart ▁failure
D-1264	-0.7773007154464722	biomedical treatment ; CHm ; biomedical treatment ; dc ; heart failure
P-1264	-0.1033 -0.6102 -0.1714 -1.6979 -0.3695 -3.2028 -0.2152 -0.3961 -0.1751 -0.6129 -0.1915 -1.0894 -0.3886 -0.4388 -2.4198 -0.2978 -1.7425 -0.6504 -0.4592 -0.3134
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular outcomes in renal atherosclerotic lesions ; coral ; stenting ; ras
H-1602	-0.5784029364585876	▁Card io vas cular ▁Out com es ▁; ▁Ren al ▁Ath eros cle ro tic ▁Les ions ▁; ▁co RAL ▁; ▁sten ting ▁; RAS
D-1602	-0.5784029364585876	Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ; coRAL ; stenting ;RAS
P-1602	-1.0879 -2.1935 -0.5459 -0.3757 -2.5371 -0.1165 -0.2839 -0.3146 -0.2719 -0.1056 -0.2776 -0.7624 -0.1300 -0.1378 -1.1524 -0.5041 -0.5261 -0.2795 -0.6362 -0.9760 -0.3110 -0.1212 -0.5421 -0.2857 -0.5224 -0.3950 -0.2249
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal flow pump ; hemocompatibility ; blood-flow ; pulse
H-1994	-0.5548868179321289	▁centri fu gal ▁flow ▁pump ▁; ▁hem o com pati bility ▁; ▁magnet ically ▁le vita ted ▁ro tor ▁; ▁blood - flow ▁path s ▁; ▁artificial ▁puls e
D-1994	-0.5548868179321289	centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
P-1994	-0.2181 -1.8713 -0.3678 -0.9353 -0.8970 -0.2951 -0.3857 -0.5484 -0.3171 -0.1750 -2.1200 -0.3469 -0.0236 -0.9992 -0.1180 -0.0053 -1.1057 -0.0322 -0.0812 -0.3252 -2.8877 -0.1226 -0.1911 -0.1975 -0.2520 -0.2798 -0.4275 -0.5830 -0.4956 -0.3469 -0.2499
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial complex v activity ; phosphocreatine ; atp
H-1786	-0.6688029766082764	▁mito cho ndri al ▁complex ▁; ▁post - a ac ▁; ▁ phos pho creati ne ▁; ▁ATP
D-1786	-0.6688029766082764	mitochondrial complex ; post-aac ; phosphocreatine ; ATP
P-1786	-0.2655 -1.1850 -0.6082 -0.3267 -0.2642 -0.4100 -2.0399 -0.0617 -1.1398 -1.4662 -0.2703 -0.2487 -0.0891 -0.5222 -1.3163 -2.0011 -0.3211 -0.2722 -0.3504 -0.2175
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary approaches to stop hypertension ; dash ; mortality ; postmenopausal ; hf
H-686	-0.9988491535186768	▁Mediterrane an ▁; ▁Diet ary ▁ richt es ▁to ▁Stop ▁Hyper tension ▁; DAS h ▁; ▁mortal iteit ▁; ▁post meno paus al ▁women ▁; HF
D-686	-0.9988491535186768	Mediterranean ; Dietary richtes to Stop Hypertension ;DASh ; mortaliteit ; postmenopausal women ;HF
P-686	-0.5472 -1.1278 -4.1934 -0.7664 -0.6608 -1.1276 -3.7366 -0.8233 -0.7562 -1.0073 -0.9999 -0.1278 -0.3691 -0.3838 -0.2570 -0.2434 -2.3578 -1.6249 -0.2772 -0.3638 -0.0878 -0.1090 -0.1124 -2.6989 -0.3049 -2.2761 -0.3413 -0.2861
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic ; interatrial shunting ; patients ; heart failure with reduced ejection fraction
H-1950	-0.7148182392120361	▁left - to - right ▁inter at rial ▁sh unting ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1950	-0.7148182392120361	left-to-right interatrial shunting ; heart failure ; ejection fraction
P-1950	-5.2164 -0.1648 -0.5478 -0.2480 -1.3132 -0.0489 -0.1205 -0.7728 -0.3605 -1.7095 -0.3321 -2.0144 -0.4360 -0.2783 -0.1484 -0.1784 -0.1221 -0.3186 -0.0258 -0.3937 -0.2612
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality ; heart failure ; hf ; implantable cardioverter defibrillators ; icds
H-60	-0.7290293574333191	▁mortal iteit ▁; ▁heart ▁failure ▁; HF ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; ▁i cc s
D-60	-0.7290293574333191	mortaliteit ; heart failure ;HF ; implantable cardioverter defibrillators ; iccs
P-60	-2.6814 -2.4524 -0.2868 -1.3874 -0.3599 -0.2404 -1.0107 -0.2715 -0.6205 -0.2456 -0.0996 -0.0900 -0.4393 -1.2511 -0.0913 -0.7622 -0.3862 -0.3528 -0.2980 -0.5722 -0.5768 -2.3810 -0.3611 -0.2784
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician ; outcomes ; patients ; outcomes ; medically ; diseases ; hf
H-1722	-1.206404447555542	▁Physic ian ▁; ▁med ically ▁managed ▁disease s ▁; HF
D-1722	-1.206404447555542	Physician ; medically managed diseases ;HF
P-1722	-2.2953 -4.1318 -0.4848 -1.1224 -1.1484 -0.2514 -1.2962 -0.3076 -0.2956 -2.5421 -0.3302 -0.2710
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients ; frail ; frail ; biological phenotype
H-1007	-0.47019919753074646	▁fra il ▁; ▁fra il
D-1007	-0.47019919753074646	frail ; frail
P-1007	-0.0388 -0.2067 -0.3989 -0.6027 -0.4219 -1.3529 -0.2696
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone ; patients ; hf-ref ; hyperkalemia ; patients
H-1224	-0.7266104221343994	▁e pler en one ▁; ▁ HF - re f ▁; ▁hyper kal emia ▁; ▁w RF
D-1224	-0.7266104221343994	eplerenone ; HF-ref ; hyperkalemia ; wRF
P-1224	-0.1206 -0.1049 -0.1258 -1.0228 -0.3618 -0.8721 -0.8806 -0.1052 -1.1449 -3.4290 -0.3545 -0.1889 -0.3583 -0.7740 -0.3442 -0.1998 -2.7586 -0.3840 -0.2755
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient ; emergency department ; acute heart failure ; ahf ; clinical
H-57	-1.0079175233840942	▁emergency ▁department ▁; ▁a cute ▁heart ▁failure ▁; ▁a HF
D-57	-1.0079175233840942	emergency department ; acute heart failure ; aHF
P-57	-2.7311 -0.1282 -0.2941 -0.2007 -0.1302 -1.0191 -0.4665 -0.3332 -2.4519 -3.6502 -0.3936 -0.2961
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm ; outcomes ; discharged ; admission ; heart failure
H-149	-0.7335614562034607	▁RM ▁; ▁dis charge d ▁; ▁heart ▁failure
D-149	-0.7335614562034607	RM ; discharged ; heart failure
P-149	-1.0291 -0.3324 -1.5219 -0.1805 -0.1198 -0.4148 -2.7088 -0.2825 -0.4602 -0.2856
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients ; lbbb ; implantable ; primary outcome ; primary outcome
H-887	-0.6103453040122986	▁l b ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - c RT
D-887	-0.6103453040122986	lb ; implantable cardioverter defibrillator-cRT
P-887	-0.5989 -1.4675 -0.8377 -0.9789 -0.2016 -0.0593 -0.1110 -0.2006 -1.0523 -0.0921 -0.7650 -0.2588 -0.0974 -0.2416 -0.6856 -2.5901 -0.4427 -0.3050
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard error of measurement ; mdc ; clinical ; change
H-807	-0.6605631709098816	▁m d
D-807	-0.6605631709098816	md
P-807	-0.3820 -1.4823 -0.4848 -0.2932
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene ; pathological ; heart disease ; transcription factors ; driving ; gene
H-639	-0.6688617467880249	▁em bry o nic ▁gene ▁programs ▁; ▁path ological ▁heart ▁disease ▁; ▁tran scription ▁factors ▁; ▁gene ▁programs
D-639	-0.6688617467880249	embryonic gene programs ; pathological heart disease ; transcription factors ; gene programs
P-639	-4.1424 -0.6585 -0.2555 -1.2714 -1.1871 -0.4475 -0.3736 -0.2437 -0.5773 -0.7403 -0.4964 -0.3069 -0.0391 -0.0773 -0.2631 -0.3117 -0.7891 -0.4981 -0.3794 -0.3188
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients ; hfpef ; longitudinal ; cardiac event
H-738	-1.4401780366897583	▁h FP EF ▁; ▁cardiac ▁event
D-738	-1.4401780366897583	hFPEF ; cardiac event
P-738	-0.9558 -3.4802 -2.3500 -0.3122 -2.2124 -1.3616 -0.5610 -0.2882
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients ; sst2 ; sst2 ; odds ratios ; cardiovascular events
H-409	-0.7951943874359131	▁s st 2/ low - dos e ▁BB ▁; ▁s st 2/ high - dos e ▁BB ▁; ▁cardiovascular ▁events
D-409	-0.7951943874359131	sst2/low-dose BB ; sst2/high-dose BB ; cardiovascular events
P-409	-0.9633 -2.2014 -1.1541 -0.5209 -0.2863 -0.8050 -0.2820 -0.7424 -0.4034 -0.3503 -1.9644 -1.1656 -1.8379 -0.4346 -0.9954 -0.2337 -0.6606 -0.4280 -0.3821 -0.9617 -0.4484 -0.2728
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal muscle ; sarcomere ; patients ; heart failure ; type 2 diabetes
H-1243	-0.5056532621383667	▁skelet al ▁muscle ▁; ▁sar com ere ▁structure ▁; ▁heart ▁failure ▁; ▁type ▁2 ▁diabetes ▁; ▁e pica tech in - rich ▁coco a
D-1243	-0.5056532621383667	skeletal muscle ; sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
P-1243	-1.1987 -0.4182 -0.9356 -2.0794 -0.1354 -0.1897 -0.9240 -1.9923 -0.3160 -1.3265 -0.2636 -0.2762 -0.1484 -0.4831 -0.0525 -0.3556 -0.1247 -0.1443 -0.3988 -0.1088 -0.3019 -0.0321 -0.1718 -0.1017 -0.3810 -0.2868
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs morphology ; cardiac resynchronization therapy ; crt
H-880	-0.6427796483039856	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-880	-0.6427796483039856	QRs morphology ; cardiac resynchronization therapy ; cRT
P-880	-0.5207 -0.9305 -0.4598 -0.1287 -0.4535 -0.3137 -0.1751 -0.2422 -0.2260 -0.0338 -2.2505 -0.3857 -0.1121 -0.2959 -1.0607 -3.3598 -0.3560 -0.2652
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients ; exercise-induced pasp ; pasp ; patients ; pasp
H-827	-0.9807710647583008	▁PAS p ▁; ▁h g ▁; ▁pas p ▁; ▁PAS p
D-827	-0.9807710647583008	PASp ; hg ; pasp ; PASp
P-827	-1.7538 -1.0823 -0.3786 -0.4856 -0.3080 -0.3179 -3.5248 -0.5919 -0.4859 -2.4726 -0.8126 -0.2839 -0.2520
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical treatment ; heart failure
H-336	-0.7638858556747437	▁heart ▁failure ▁; ▁severe ▁hyper tension ▁; ▁mit ral ▁re gur gi tation ▁; ▁significant ▁mit ral ▁sten osis ▁; ▁aggressiv e ▁medical ▁treatment ▁; ▁heart ▁failure
D-336	-0.7638858556747437	heart failure ; severe hypertension ; mitral regurgitation ; significant mitral stenosis ; aggressive medical treatment ; heart failure
P-336	-3.1248 -0.5675 -0.3075 -2.3496 -0.2194 -0.1590 -0.2658 -1.5863 -0.1522 -0.0638 -0.1471 -0.3920 -0.2029 -0.3775 -0.0083 -0.5679 -0.2135 -0.0252 -0.0642 -0.2884 -6.2246 -0.0586 -0.6018 -0.9551 -0.3637 -1.5141 -0.6837 -0.4341 -0.2342
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc ; diagnostic
H-1025	-1.1536073684692383	▁PO c ▁systems ▁; ▁ NP
D-1025	-1.1536073684692383	POc systems ; NP
P-1025	-0.8349 -1.4067 -1.1841 -0.5379 -1.4454 -0.9563 -2.5356 -0.3280
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality ; readmissions ; costs ; patient ; physician ; hospital
H-1725	-0.688102126121521	▁mortal iteit ▁; ▁read missions ▁; ▁kosten
D-1725	-0.688102126121521	mortaliteit ; readmissions ; kosten
P-1725	-0.2576 -2.3165 -0.3432 -0.5433 -0.1889 -0.2834 -1.3905 -0.5879 -0.2816
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients ; lbbb ; qrs ; implantable
H-890	-0.8142566084861755	▁l bf ▁; ▁QR s ▁; ▁benefit ▁; ▁implant able ▁cardio ver ter ▁; ▁de fi br illa tor - c RT
D-890	-0.8142566084861755	lbf ; QRs ; benefit ; implantable cardioverter ; defibrillator-cRT
P-890	-0.3947 -2.7957 -0.3012 -1.5998 -1.2982 -0.2580 -3.6567 -0.2855 -2.3708 -0.3240 -0.0908 -0.0828 -0.2327 -0.4120 -0.1176 -0.0430 -0.4266 -0.1975 -0.0724 -0.1754 -0.8001 -3.0156 -0.3645 -0.2264
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography ; cardiac ; cardiac function
H-453	-0.32061997056007385	▁e cho card i ography ▁; ▁cardiac ▁diameter s ▁; ▁cardiac ▁function
D-453	-0.32061997056007385	echocardiography ; cardiac diameters ; cardiac function
P-453	-0.1914 -0.3166 -0.2583 -0.4470 -0.5211 -0.4080 -0.1997 -0.1328 -0.3938 -0.3327 -0.3351 -0.2451 -0.5034 -0.2038
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline ; embase ; psycinfo
H-151	-0.5090116262435913	▁med line ▁; EMBA se ▁; ▁Psy c INFO
D-151	-0.5090116262435913	medline ;EMBAse ; PsycINFO
P-151	-1.3920 -1.3078 -0.2819 -0.3986 -0.8027 -0.2695 -0.3047 -0.1978 -0.0219 -0.4319 -0.1905
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality of life ; functional capacity
H-618	-0.7228516936302185	▁significant ▁; ▁functional ▁capacity
D-618	-0.7228516936302185	significant ; functional capacity
P-618	-0.0243 -2.4114 -0.2458 -0.9342 -0.4562 -0.2653
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized ; medical
H-1977	-0.9725680947303772	▁urban ▁academic ▁medical ▁center
D-1977	-0.9725680947303772	urban academic medical center
P-1977	-2.9896 -0.9813 -0.8038 -0.3772 -0.4082 -0.2753
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ; hf
H-696	-0.5420942306518555	▁ST 2 ▁; ▁cardio protec tive ▁signal ing ▁; ▁my o car dium ▁; ▁bio mark er ▁; ▁heart ▁failure ▁; HF
D-696	-0.5420942306518555	ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
P-696	-1.2333 -0.1831 -0.2769 -0.2307 -0.8347 -2.1722 -0.4442 -0.6264 -0.2748 -1.1646 -0.1151 -0.0754 -0.2310 -0.3029 -0.0218 -0.2290 -0.3592 -0.3415 -1.0048 -0.3587 -0.2274 -1.6630 -0.4018 -0.2377
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients ; systolic hf ; cxl-1020 ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
H-423	-0.595238983631134	▁sy sto lic ▁ HF ▁; ▁c XL -10 20 ▁; ▁left ▁; ▁right ▁heart ▁; ▁fill ing ▁pressure s ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁cardiac ▁; ▁stroke ▁volume ▁index
D-423	-0.595238983631134	systolic HF ; cXL-1020 ; left ; right heart ; filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
P-423	-0.2720 -0.2961 -0.0556 -0.7555 -0.7763 -0.3292 -0.3599 -1.7667 -0.2162 -0.6195 -0.4436 -1.5139 -0.5926 -1.4085 -1.6965 -0.3030 -2.1972 -0.1952 -0.7947 -0.4864 -0.3265 -0.2152 -0.8375 -0.1627 -0.5323 -0.1589 -0.3618 -0.3832 -0.3907 -0.3312 -0.2551 -0.9131 -0.0839 -0.5037 -0.2993
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients ; followed up ; composite primary outcome ; cardiovascular death ; stroke ; heart failure ; myocardial infarction
H-1650	-0.8205573558807373	▁cardiovascular ▁death ▁; ▁stroke ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1650	-0.8205573558807373	cardiovascular death ; stroke ; heart failure ; myocardial infarction
P-1650	-1.1545 -2.3585 -0.2185 -0.9569 -0.2535 -1.5395 -0.3942 -0.2967 -2.2929 -0.2708 -0.5367 -1.3311 -0.2201 -0.3859 -1.0315 -0.4020 -0.3061
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization therapy ; crt ; morbidity ; mortality ; chronic systolic heart failure ; wide qrs complex
H-845	-0.722427487373352	▁Card iac - re syn chron ization ▁ therapy ▁; ▁cm t ▁; ▁morbi d iteit ▁; ▁mortal iteit ▁; ▁chronic ▁sy sto lic ▁heart ▁failure ▁; ▁QR s ▁complex
D-845	-0.722427487373352	Cardiac-resynchronization therapy ; cmt ; morbiditeit ; mortaliteit ; chronic systolic heart failure ; QRs complex
P-845	-2.0882 -1.0702 -0.1268 -0.4159 -0.2997 -0.0206 -2.9770 -0.4772 -0.1129 -0.2897 -4.2471 -0.2626 -0.3510 -1.4577 -0.0956 -1.3972 -0.2782 -0.2714 -1.3200 -0.2575 -0.6494 -0.0856 -0.1390 -0.3287 -0.9833 -0.7460 -0.3107 -0.1295 -0.5423 -0.7039 -0.4415 -0.2410
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk ; scn5a ; kv4.3 ; mrnas ; transient receptor potential cation channel m7 ; trpm7 ; mrna
H-1086	-0.571692705154419	▁per k ▁activa tion ▁; ▁s cn 5 a ▁; ▁kv 4.3 ▁channel ▁m RNA s ▁; ▁trans ient ▁receptor ▁potential ▁ cation ▁channel ▁; ▁m 7 ▁; TR m 7) ▁channel ▁m RNA
D-1086	-0.571692705154419	perk activation ; scn5a ; kv4.3 channel mRNAs ; transient receptor potential cation channel ; m7 ;TRm7) channel mRNA
P-1086	-2.1636 -1.4448 -0.0312 -1.5519 -0.4735 -0.5524 -0.0959 -1.4297 -0.2493 -0.3175 -0.4846 -0.0657 -0.1569 -0.2043 -0.3769 -0.4194 -0.3420 -0.0132 -0.2472 -0.0367 -1.2121 -0.1127 -0.0792 -0.2234 -0.9431 -0.0984 -0.1351 -0.2916 -1.7835 -2.8430 -0.8074 -0.1205 -0.2220 -0.3360 -0.4283 -0.2880
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients ; implantable cardioverter-defibrillator ; heart function clinic ; university health network ; toronto ; canada
H-1861	-0.5991877317428589	▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁Heart ▁Fun ction ▁Clinic ▁; ▁University ▁Health ▁Network ▁; Tor onto ▁; ▁Canada
D-1861	-0.5991877317428589	implantable cardioverter-defibrillator ; Heart Function Clinic ; University Health Network ;Toronto ; Canada
P-1861	-0.5139 -0.1806 -0.1435 -0.1674 -0.4469 -0.2293 -0.1747 -0.2464 -1.8602 -0.4494 -0.1329 -0.4499 -0.7362 -0.1115 -0.0074 -0.4691 -0.3604 -3.2540 -1.8982 -0.7321 -0.2388 -0.7750 -0.0150 -0.4732 -1.4215 -0.4473 -0.2430
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced pasp ; clinical ; prognostic ; pulmonary hypertension ; patients ; right ventricular contractile reserve
H-831	-0.6954511404037476	▁pas p ▁; ▁pulmonar y ▁hyper tension ▁; ▁vent ri cular ▁contract ile ▁reserve
D-831	-0.6954511404037476	pasp ; pulmonary hypertension ; ventricular contractile reserve
P-831	-3.8040 -0.4394 -0.2671 -0.1438 -1.9268 -0.1230 -0.1331 -0.2062 -0.6784 -1.7649 -0.6154 -0.0392 -0.1929 -0.1276 -0.4415 -0.2239
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi ; metoprolol ; elevated ; plasma norepinephrine ; dopamine ; elevated ; epinephrine
H-1550	-0.558866560459137	▁MI ▁; ▁met o pro lol ▁; ▁plasma ▁; ▁no re pine ph rine ▁; ▁dop amine ▁; ▁e pine ph rine
D-1550	-0.558866560459137	MI ; metoprolol ; plasma ; norepinephrine ; dopamine ; epinephrine
P-1550	-1.0196 -1.4759 -0.5173 -0.3101 -0.3202 -0.9329 -0.3029 -0.2131 -1.5716 -0.6672 -0.5230 -0.1425 -0.8697 -1.0066 -0.2894 -0.0078 -0.1932 -0.2902 -0.1823 -0.0871 -0.9948 -0.8894 -0.3480 -0.2582
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; clinical ; outcomes ; chf
H-636	-0.5157371163368225	▁anta gon ists ▁; ▁inhibi tors ▁; ▁re nin - angi oten sin - al do ster one ▁; ▁sympa the tic ▁ner vous ▁systems ▁; ▁CHF
D-636	-0.5157371163368225	antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
P-636	-0.1688 -0.0547 -1.5224 -0.3314 -0.0261 -0.2325 -0.3379 -0.0748 -0.8110 -0.2002 -0.0064 -0.2350 -1.7707 -0.3964 -0.0512 -0.1662 -0.0989 -1.2637 -0.3179 -0.0495 -0.8852 -1.4486 -0.6687 -2.2313 -0.2362 -0.3790 -0.4355 -0.2898 -0.2663
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient ; patients ; heart failure ; hospital ; discharge ; readmissions ; patient ; follow-up
H-722	-0.7727598547935486	▁heart ▁failure ▁; ▁hospital ▁dis charge ▁; ▁read missions ▁; ▁follow - up ▁visit s
D-722	-0.7727598547935486	heart failure ; hospital discharge ; readmissions ; follow-up visits
P-722	-4.0182 -0.7125 -0.3458 -2.3961 -1.2879 -0.2396 -0.3637 -0.6850 -0.3859 -0.4496 -0.0248 -0.2872 -0.0500 -0.9677 -0.3039 -0.3337 -0.2855
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk stratification ; antiplatelet agents ; combination ; anticoagulants ; vascular diseases
H-1355	-0.4403509497642517	▁anti plate let ▁agents ▁; ▁combinatie ▁; ▁antico a gul ants ▁; ▁vas cular ▁disease s
D-1355	-0.4403509497642517	antiplatelet agents ; combinatie ; anticoagulants ; vascular diseases
P-1355	-0.0462 -0.2297 -0.2772 -0.1977 -0.3945 -1.1921 -0.5770 -0.1907 -0.3958 -1.0684 -0.3858 -0.3368 -0.7815 -0.2745 -0.5732 -0.2778 -0.4377 -0.2898
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; svr ; cardiac index
H-225	-0.688413679599762	▁Font an ▁failure ▁; ▁hem o dynamic ally ▁; ▁heart ▁failure ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁v n ▁; ▁index ▁; ▁cardiac ▁index
D-225	-0.688413679599762	Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; vn ; index ; cardiac index
P-225	-0.3855 -3.2722 -0.6474 -0.2500 -0.6228 -0.4242 -0.0472 -1.1395 -0.4006 -1.8094 -0.4618 -0.2540 -0.2564 -0.4557 -0.2286 -0.6936 -0.2136 -0.4700 -0.2783 -2.5299 -1.4613 -0.2759 -0.8321 -0.2562 -0.9403 -0.0897 -0.3446 -0.2351
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous hf
H-1156	-0.5532495975494385	▁my o fi ber ▁dynamic s ▁; ▁my o fi ber ▁short en ing ▁; ▁EM d ▁; ▁dys syn chron ous ▁ HF
D-1156	-0.5532495975494385	myofiber dynamics ; myofiber shortening ; EMd ; dyssynchronous HF
P-1156	-2.1931 -0.4772 -0.2403 -0.3871 -0.4092 -0.1234 -0.3245 -1.3334 -0.3253 -0.3064 -0.3299 -1.0029 -0.1153 -0.5152 -0.3054 -1.1276 -0.5635 -0.2169 -0.0671 -0.0419 -0.0170 -2.1429 -0.4871 -0.5908 -0.4752 -0.2660
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial index ; pulse-wave ; coronary artery calcium scores
H-1562	-0.6007447242736816	▁an kle - bra chi al ▁index ▁; ▁puls e - wa ve ▁veloci ty ▁; ▁corona ry ▁arter y ▁; ▁calci um ▁score s
D-1562	-0.6007447242736816	ankle-brachial index ; pulse-wave velocity ; coronary artery ; calcium scores
P-1562	-1.5360 -1.5962 -0.3592 -0.4601 -1.1751 -0.2336 -0.1000 -0.3838 -0.6699 -0.2521 -0.1867 -0.5716 -0.4071 -0.0444 -0.4672 -0.4405 -0.2392 -2.6065 -0.0518 -2.2065 -0.7319 -0.0428 -0.1758 -0.2315 -0.4050 -0.3883 -0.2571
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate ; unfolded protein response ; upr ; scn5a ; remodeling ; hf
H-1081	-0.756722092628479	▁na + ▁channel s ▁; ▁un fold ed ▁protein ▁response ▁; ▁un fold ed ▁protein ▁response ▁; ▁uc p ▁; ▁s cn 5 a ▁; ▁electric ▁remodel ing ▁; HF
D-1081	-0.756722092628479	na+ channels ; unfolded protein response ; unfolded protein response ; ucp ; scn5a ; electric remodeling ;HF
P-1081	-0.3118 -3.5424 -0.0768 -0.5038 -0.3629 -0.0418 -0.0096 -0.2533 -0.1415 -0.3533 -0.2701 -4.0211 -0.0659 -0.1800 -0.2107 -0.2100 -0.2664 -1.5806 -2.2515 -0.2840 -2.8730 -0.1210 -0.5920 -0.7480 -0.4815 -0.1312 -0.0739 -0.2104 -0.2747 -3.0342 -0.4310 -0.3067
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary endpoint ; intermacs ; interagency registry for mechanically assisted circulatory support
H-1996	-1.239712119102478	▁inter ma cs ▁; ▁interne ▁Registr y ▁voor ▁Mechanic ally ▁Assist ed ▁circula tory ▁Support
D-1996	-1.239712119102478	intermacs ; interne Registry voor Mechanically Assisted circulatory Support
P-1996	-1.5764 -3.0830 -5.1984 -0.3420 -1.0491 -4.4915 -0.4222 -1.0797 -0.3024 -0.3912 -0.2933 -0.3644 -0.4302 -0.3191 -0.9608 -0.5195 -0.2519
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international right heart foundation working group ; step ; syndrome ; right heart failure
H-1458	-1.144995093345642	▁international ▁Right ▁Heart ▁foundation ▁Work ing ▁Group ▁; ▁right ▁heart ▁failure
D-1458	-1.144995093345642	international Right Heart foundation Working Group ; right heart failure
P-1458	-2.6621 -1.3456 -1.5498 -0.5768 -1.4499 -0.1584 -1.9162 -0.2724 -2.4478 -1.0537 -0.8215 -0.3521 -0.2786
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
H-1780	-0.5862057209014893	▁cardiac ▁hyper trop hy ▁; ▁pressure - over load ▁; ▁abdominal ▁a or tic ▁con stri ction ▁; ▁a ac
D-1780	-0.5862057209014893	cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
P-1780	-2.3737 -0.1063 -0.0570 -2.2026 -0.3123 -0.6126 -0.1799 -0.0303 -0.3046 -0.3605 -0.1343 -0.2581 -0.1314 -0.7758 -0.0525 -0.9898 -0.4555 -0.3219 -1.1602 -1.4579 -0.4064 -0.2129
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf ; hf ; epidemiology ; rheumatic fever
H-1799	-0.7369551062583923	▁ HF ▁; ▁risk ▁factors ▁; ▁ HF ▁epidemi ology ▁; ▁SH ▁; ▁ nc w ▁; ▁rhe u matic ▁fe ver
D-1799	-0.7369551062583923	HF ; risk factors ; HF epidemiology ; SH ; ncw ; rheumatic fever
P-1799	-1.3612 -0.7015 -0.2618 -1.3567 -0.2877 -0.2574 -1.5324 -0.6208 -0.7893 -0.5559 -0.2824 -1.0324 -0.2470 -2.7076 -1.7897 -1.8558 -0.2452 -0.1822 -0.2317 -0.5286 -0.0529 -0.1459 -0.3423 -0.3183
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise ; training ; exercise ; exercise capacity ; qol ; obese ; patients ; hfpef
H-1976	-0.819823145866394	▁calor ic ▁restriction ▁; diet ▁; ▁aero bic ▁exercise ▁training ▁; exe rci se ▁; ▁exercise ▁capacity ▁; ▁Q OL ▁; ▁obes e ▁older ▁patients ▁; ▁h FP EF
D-1976	-0.819823145866394	caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese older patients ; hFPEF
P-1976	-1.8955 -0.3992 -0.5773 -0.1597 -0.0267 -0.2768 -0.0217 -0.3139 -0.4815 -1.9591 -0.1818 -0.8496 -0.1194 -0.2931 -0.2922 -1.6060 -0.2927 -0.2666 -3.4629 -1.1070 -0.2925 -0.8681 -0.2514 -1.5971 -1.4265 -0.2664 -1.7594 -2.1614 -1.5451 -0.4207 -0.2435
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic heart failure ; hf ; hemodynamic ; syndrome ; dysfunction ; molecular pathways
H-1472	-0.5467082262039185	▁chronic ▁heart ▁failure ▁; HF ▁; ▁hem o dynamic ▁disorder ▁; ▁syndrome ▁; ▁dys function
D-1472	-0.5467082262039185	chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction
P-1472	-1.4617 -1.8319 -0.3603 -0.2665 -1.1418 -0.2452 -0.1969 -0.3175 -0.0390 -0.3895 -0.2263 -0.0369 -1.6277 -0.0920 -0.0677 -0.7183 -0.2749
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications ; patients ; heart failure and reduced ejection fraction ; outpatient
H-667	-0.7017701268196106	▁medication s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁out patient ▁setting
D-667	-0.7017701268196106	medications ; heart failure ; ejection fraction ; outpatient setting
P-667	-1.9222 -0.5837 -0.4061 -1.9985 -0.3613 -0.3339 -0.1860 -0.2377 -0.0761 -0.2930 -0.0265 -0.4375 -3.3069 -0.1283 -0.9577 -0.4069 -0.2678
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms ; hfpef ; diastolic filling time ; heart rate ; symptoms
H-1172	-0.6026942133903503	▁ HF p EF ▁; ▁dia sto lic ▁fill ing ▁time ▁; ▁heart ▁rate
D-1172	-0.6026942133903503	HFpEF ; diastolic filling time ; heart rate
P-1172	-0.6634 -1.3728 -0.1000 -1.4083 -0.2818 -0.0247 -0.1831 -0.1515 -0.2262 -0.1810 -2.1009 -0.2818 -1.4240 -0.6031 -0.3825 -0.2580
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac ; myocyte-specific mena overexpression ; cardiac ; pathology
H-1813	-0.4832126498222351	▁cardiac ▁my o cy te - specific ▁Men a ▁over expression ▁; TTA ▁; ▁ gt t et Men a ▁; ▁cardiac ▁path ology
D-1813	-0.4832126498222351	cardiac myocyte-specific Mena overexpression ;TTA ; gttetMena ; cardiac pathology
P-1813	-2.6719 -1.7489 -0.3344 -0.0908 -0.0829 -0.5453 -0.0641 -0.6905 -0.0634 -0.0688 -0.0975 -0.2436 -2.3107 -0.2873 -0.8197 -0.2545 -0.2146 -0.0256 -0.3158 -0.0290 -0.3549 -0.1570 -0.2708 -0.2346 -0.3283 -0.2586
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol ; lv contractile function ; xo-mediated ros ; myofilament ; sensitivity
H-477	-0.610691249370575	▁allo puri nol ▁; ▁LV ▁contract ile ▁function ▁; ▁efficiency ▁; ▁ XO - media ted ▁ ROS ▁; ▁my o fila ment ▁; ▁ sensitiv iteit
D-477	-0.610691249370575	allopurinol ; LV contractile function ; efficiency ; XO-mediated ROS ; myofilament ; sensitiviteit
P-477	-0.0563 -0.1077 -1.8664 -0.2657 -1.0257 -0.2941 -0.0990 -0.5645 -0.2590 -2.4819 -0.3133 -0.1740 -0.5995 -0.0388 -0.1143 -0.9818 -0.1714 -0.4695 -0.7778 -2.2172 -0.0930 -0.0395 -1.1872 -0.5749 -0.2735 -0.0128 -2.0365 -0.3373 -0.2776
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate ratio ; therapy ; patient ; comorbidities
H-663	-0.6716365814208984	▁ therapy
D-663	-0.6716365814208984	therapy
P-663	-1.0749 -0.2982 -0.9875 -0.3259
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic ; patients ; severe heart failure ; financial
H-1242	-0.9018934369087219	▁AF ▁; ▁heart ▁failure ▁; ▁financiële ▁burde n
D-1242	-0.9018934369087219	AF ; heart failure ; financiële burden
P-1242	-1.1752 -0.2998 -4.7339 -0.4070 -0.3383 -0.7205 -0.5421 -0.2375 -0.3283 -0.2362
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization ; medicare ; hospital ; medicare ; policy
H-1715	-0.48416274785995483	▁re hospital ization ▁; ▁Medica re ▁; ▁hospital ▁claims ▁; ▁Medica re ▁; ▁post - a cute ▁care ▁transfer ▁policy
D-1715	-0.48416274785995483	rehospitalization ; Medicare ; hospital claims ; Medicare ; post-acute care transfer policy
P-1715	-1.8607 -0.2167 -1.0647 -0.4456 -0.0577 -0.1056 -0.5095 -1.2817 -0.4306 -0.2904 -0.1252 -0.1354 -0.3309 -0.1033 -0.0549 -0.2564 -0.1219 -1.2322 -0.4886 -0.7678 -0.4434 -0.3282
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart failure ; compliance ; etidronate ; alendronate
H-1543	-0.4441065788269043	▁heart ▁failure ▁; ▁re fill ▁compliance ▁; ▁et id rona te ▁; ▁ale ndr onate
D-1543	-0.4441065788269043	heart failure ; refill compliance ; etidronate ; alendronate
P-1543	-2.0291 -0.6952 -0.3137 -0.3511 -0.5445 -1.0781 -0.2740 -0.0784 -0.0921 -0.0671 -0.0996 -0.3727 -0.5228 -0.1791 -0.1279 -0.4375 -0.2869
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis ; metabolic exercise ; cardiac ; kidney
H-1762	-0.5747568607330322	▁AT ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁score
D-1762	-0.5747568607330322	AT ; metabolic exercise ; cardiac ; kidney index score
P-1762	-2.9981 -0.5254 -0.1641 -0.2196 -0.8488 -0.3360 -0.1647 -0.8955 -0.1057 -1.0149 -0.3208 -0.0514 -0.1955 -0.5442 -0.2367
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical ; activity ; crf ; hf ; mortality
H-1776	-1.1623257398605347	▁physical ▁activity ▁; ▁c RF ▁; ▁ HF ▁mortal iteit
D-1776	-1.1623257398605347	physical activity ; cRF ; HF mortaliteit
P-1776	-1.8341 -1.9255 -0.2854 -0.7862 -2.6497 -0.2872 -1.4891 -1.0785 -0.3425 -2.6850 -0.3336 -0.2512
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular pathways ; patients ; chronic heart failure ; chf
H-249	-1.1280665397644043	▁et ▁; ▁HD l - media ted ▁protect ive ▁effects ▁; ▁molecular ▁path ways ▁; ▁chronic ▁heart ▁failure ▁; ▁chw
D-249	-1.1280665397644043	et ; HDl-mediated protective effects ; molecular pathways ; chronic heart failure ; chw
P-249	-2.1604 -0.5242 -4.7233 -1.9102 -0.1180 -0.1139 -0.5358 -1.1893 -1.1944 -0.8722 -0.2946 -0.6631 -0.1616 -0.3652 -0.4019 -2.3802 -1.4917 -0.5830 -0.2783 -4.1707 -0.4343 -0.2509
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians ; patients ; heart failure ; equitable ; therapeutic
H-1823	-1.1474368572235107	▁physician s ▁; ▁advanced ▁heart ▁failure ▁; ▁ therapeut ic
D-1823	-1.1474368572235107	physicians ; advanced heart failure ; therapeutic
P-1823	-2.1009 -0.5582 -0.4867 -2.5461 -1.1627 -0.5130 -1.3838 -1.3379 -0.4839 -1.0399 -1.8397 -0.3165
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients ; heart transplant ; prospectively ; ecct
H-710	-0.8234176635742188	▁isola ted ▁heart ▁transplant ▁; ▁ec t
D-710	-0.8234176635742188	isolated heart transplant ; ect
P-710	-0.3974 -1.2945 -1.8215 -0.2361 -0.3008 -0.3583 -2.2169 -0.4805 -0.3047
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow up ; ffm ; patients
H-16	-1.2383683919906616	▁follow ▁up ▁body ▁weight ▁; ▁FM ▁; ▁f m ▁; ▁CC
D-16	-1.2383683919906616	follow up body weight ; FM ; fm ; CC
P-16	-0.2239 -3.1607 -2.8345 -0.8807 -0.4449 -2.8949 -0.5006 -0.5644 -2.0408 -0.5196 -1.3160 -0.4073 -0.3106
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential analysis ; cluster analysis
H-1610	-0.397442489862442	▁r . ▁Clu ster ▁analysis
D-1610	-0.397442489862442	r. Cluster analysis
P-1610	-0.2217 -0.4452 -0.1915 -0.2249 -1.0675 -0.3733 -0.2579
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1260	-0.8119106292724609	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter
D-1260	-0.8119106292724609	left ventricular ejection fraction ; left ventricular diastolic end diameter
P-1260	-0.9589 -0.9357 -2.3134 -0.8321 -1.0201 -0.3982 -0.2781 -0.3787 -0.0498 -0.3024 -1.4461 -0.6159 -3.1101 -1.1243 -0.1253 -0.2646 -0.2507 -1.7353 -0.1694 -0.4628 -0.2782
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence ; clinical ; outcomes ; concentric left ventricular hypertrophy ; heart failure with preserved ejection fraction
H-1523	-0.49111807346343994	▁ecce n tric ▁; ▁concentr ic ▁left ▁vent ri cular ▁hyper trop hy ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1523	-0.49111807346343994	eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
P-1523	-0.0856 -0.0659 -0.2389 -0.3882 -0.3174 -0.2175 -0.8427 -0.2457 -1.9862 -0.7314 -0.0930 -0.0428 -2.7009 -0.2790 -1.2152 -0.4332 -0.2083 -0.1908 -0.2600 -0.1022 -0.3612 -0.0109 -0.5012 -0.2691
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients ; left ventricular ejection fraction ; heart failure with preserved ejection fraction ; hfpef
H-1887	-0.6484800577163696	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1887	-0.6484800577163696	left ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
P-1887	-0.7313 -0.5435 -1.7605 -0.4889 -0.5617 -0.5526 -0.3774 -0.4720 -0.0908 -0.2954 -1.5965 -0.4525 -0.4067 -0.3966 -0.3648 -2.1494 -0.2324 -0.9401 -0.3572 -0.3637 -0.0938 -0.3012 -2.1877 -0.0584 -1.0803 -0.3675 -0.2862
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
H-451	-0.5088619589805603	▁β - ad r energi c ▁receptor ▁block er ▁ therapy ▁; ▁my o card ial ▁per fusion ▁; ▁neo angi ogen es is ▁; ▁heart
D-451	-0.5088619589805603	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
P-451	-0.1307 -0.1072 -0.2611 -0.2025 -1.7414 -0.2957 -0.0349 -0.4614 -0.3163 -0.9261 -0.0940 -0.3687 -1.6464 -0.2306 -1.1965 -1.7883 -0.4529 -0.1132 -0.3325 -0.3320 -0.0712 -0.2600 -0.1618 -0.1973 -0.2705 -1.6031 -0.3828 -0.2691
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline ; hgb ; correlated ; baseline ; kccq ; hgb ; exercise ; training ; hrqol
H-839	-1.0452969074249268	▁h gb ▁; ▁ nc w ▁; ▁scale s ▁; ▁h gb ▁; ▁exercise ▁; ▁HR Qo l
D-839	-1.0452969074249268	hgb ; ncw ; scales ; hgb ; exercise ; HRQol
P-839	-1.1509 -1.4223 -0.2445 -1.8441 -0.9511 -0.1065 -1.2822 -2.2955 -0.4479 -0.2593 -0.9654 -1.5495 -0.2502 -1.9383 -1.2453 -2.1357 -0.0461 -2.1867 -0.3110 -0.2732
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone morphogenetic protein 4 ; expression ; rrna transcription ; shift ; heterochromatic chromatin
H-98	-0.520876944065094	▁bone ▁mor pho gene tic ▁protein ▁; ▁r RNA ▁tran scription ▁; ▁hetero ch ro matic ▁chr omat in
D-98	-0.520876944065094	bone morphogenetic protein ; rRNA transcription ; heterochromatic chromatin
P-98	-0.3652 -0.3670 -0.5795 -1.9583 -2.1940 -0.1987 -0.5953 -0.5089 -0.4437 -0.0293 -0.0695 -0.5215 -0.0795 -0.6080 -0.1235 -0.7654 -0.0380 -0.1258 -0.7081 -0.4044 -0.2548
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo ; dopamine ; nesiritide ; secondary end points ; renal function ; clinical ; outcomes
H-82	-0.3525630235671997	▁place bo ▁; ▁dop amine ▁; ▁nesi riti de ▁; ▁de con gestion ▁; ▁renal ▁function
D-82	-0.3525630235671997	placebo ; dopamine ; nesiritide ; decongestion ; renal function
P-82	-2.3443 -0.0688 -0.2980 -0.1404 -0.2899 -0.3087 -0.0976 -0.1805 -0.2983 -0.3304 -0.4203 -0.0408 -0.3212 -0.2779 -0.0774 -0.2042 -0.4112 -0.2363
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin cytoskeleton ; mitochondrial function ; metabolism ; glycolysis ; gluconeogenesis ; citrate cycle
H-873	-0.5128080248832703	▁act in ▁; ▁cy tos kelet on ▁; ▁mito cho ndri al ▁function ▁; ▁intermedi ate ▁metabolism ▁; ▁gly col ysis ▁; glu cone ogen es is ▁; ▁cit rate ▁cycle
D-873	-0.5128080248832703	actin ; cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
P-873	-1.5327 -0.6801 -0.6071 -0.3291 -1.8781 -0.1852 -0.6971 -0.2853 -0.0798 -1.1772 -0.3857 -0.1132 -0.2262 -0.2186 -0.9746 -2.6615 -0.5274 -0.2169 -0.0702 -0.2286 -0.6451 -0.2309 -0.0830 -0.1518 -0.9724 -0.1346 -0.2236 -0.2558 -0.1149 -0.2072 -0.2008 -0.3553 -0.2727
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated ; resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
H-939	-0.7508968114852905	▁eleva ted ▁resist in ▁; ▁bio mark er ▁; ▁an thra cycli ne - indu ced ▁cardio toxic iteit ▁; ▁heart ▁failure ▁; ▁macro pha ges
D-939	-0.7508968114852905	elevated resistin ; biomarker ; anthracycline-induced cardiotoxiciteit ; heart failure ; macrophages
P-939	-2.7787 -1.5797 -0.2770 -0.5150 -0.2643 -0.9370 -0.6355 -0.3197 -0.3202 -0.6941 -0.1201 -0.5500 -2.1740 -0.3824 -0.4603 -0.9013 -0.0660 -0.7354 -2.6959 -0.3361 -1.1171 -0.3754 -0.2922 -0.2031 -0.0736 -1.5282 -0.4030 -0.2900
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular matrix ; left ventricular ; biopsies ; tissuefaxs ; correlated ; t1 time
H-741	-0.6159109473228455	▁extra cel lular ▁matri x ▁; ▁left ▁vent ri cular ▁bio psi es ▁; ▁t issue FAX s ▁; ▁technology
D-741	-0.6159109473228455	extracellular matrix ; left ventricular biopsies ; tissueFAXs ; technology
P-741	-1.7180 -0.7032 -0.3843 -0.0282 -0.5441 -0.4266 -0.5839 -0.3402 -2.0413 -0.4078 -0.1186 -0.7476 -0.5966 -0.3742 -2.0796 -0.0258 -0.0985 -0.6189 -0.6910 -0.2747 -0.4777 -0.2691
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients ; systolic hf ; the danish heart failure database ; esrd ; danish registry on dialysis
H-389	-0.8335352540016174	▁sy sto lic ▁ HF ▁; ▁Danish ▁Heart ▁Fail ure ▁database ▁; ▁ES r ▁; ▁Danish ▁Registr y ▁on ▁Dia lys is
D-389	-0.8335352540016174	systolic HF ; Danish Heart Failure database ; ESr ; Danish Registry on Dialysis
P-389	-0.1794 -0.1909 -0.0536 -0.3606 -0.3536 -0.3311 -2.6187 -0.7618 -0.4259 -1.3096 -0.2387 -0.3426 -3.3436 -2.8543 -0.2989 -1.9799 -1.3223 -0.5781 -0.5472 -1.0369 -0.0245 -0.2318 -0.3966 -0.2244
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left ventricular assist devices ; lvads ; patients ; heart failure ; incidence ; pump dysfunction ; pump
H-773	-0.6533843874931335	▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁heart ▁failure ▁; ▁pump ▁dys function ▁; ▁pump ▁replace ment
D-773	-0.6533843874931335	left ventricular assist devices ; lVADs ; heart failure ; pump dysfunction ; pump replacement
P-773	-0.4765 -0.4399 -1.8106 -0.2410 -0.7208 -0.6380 -0.3409 -0.1118 -0.2693 -0.2794 -0.3363 -3.9894 -0.6909 -0.3286 -0.8955 -0.0372 -0.0684 -0.2826 -0.9136 -0.6687 -0.8280 -0.4114 -0.2493
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate logistic regression analysis ; bnp ; patients ; diastolic dysfunction
H-1571	-0.5937044024467468	▁b p ▁; ▁dia sto lic ▁dys function
D-1571	-0.5937044024467468	bp ; diastolic dysfunction
P-1571	-1.3991 -2.9421 -0.2401 -0.0343 -0.1191 -0.2613 -0.0564 -0.1914 -0.4006 -0.2926
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart ; patients ; hfpef ; hf with reduced ejection fraction ; hfref
H-240	-0.8905493021011353	▁h ART ▁; ▁ HF p EF ▁; HF ▁; ▁e je ction ▁ fraction ▁; HF r EF
D-240	-0.8905493021011353	hART ; HFpEF ;HF ; ejection fraction ;HFrEF
P-240	-3.0840 -0.7117 -0.2960 -1.1029 -0.8965 -0.0934 -0.7765 -0.3129 -2.0900 -1.1677 -2.9087 -0.3570 -0.1536 -0.3544 -0.0505 -0.2539 -2.2270 -0.1475 -1.1225 -0.3199 -0.2749
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic function ; hfpef ; patients ; long axis function ; exercise
H-1888	-0.5941720008850098	▁techniek ▁; ▁sy sto lic ▁function ▁; HF p EF ▁; ▁long ▁a xis ▁function ▁; ▁exercise
D-1888	-0.5941720008850098	techniek ; systolic function ;HFpEF ; long axis function ; exercise
P-1888	-3.2218 -0.3884 -0.2977 -0.2091 -0.1751 -0.1385 -0.3048 -2.1266 -0.0812 -0.7259 -0.2898 -1.1451 -0.1992 -0.2685 -0.1273 -0.3210 -0.5360 -0.4585 -0.2750
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf ; multivariate-adjusted odds ratio ; mortality ; hazard ratio ; mortality
H-1312	-1.0265921354293823	current ▁ HF ▁; ▁mortal iteit ▁; ▁hazard ▁ratio ▁; ▁mortal iteit
D-1312	-1.0265921354293823	current HF ; mortaliteit ; hazard ratio ; mortaliteit
P-1312	-1.9595 -1.5233 -0.7049 -0.3683 -0.2199 -2.9134 -0.6755 -0.8942 -0.1737 -0.4452 -0.1260 -3.5832 -0.4200 -0.3653
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas ; hf ; hyperkalemia ; hypokalemia ; spironolactone ; clinical
H-1708	-0.7813442349433899	▁AA s ▁; HF ▁; ▁hyper kal emia ▁; ▁hypo kal emia ▁; ▁spi rono lac tone
D-1708	-0.7813442349433899	AAs ;HF ; hyperkalemia ; hypokalemia ; spironolactone
P-1708	-2.9992 -0.6199 -0.2627 -2.2171 -0.3422 -0.3021 -0.8214 -1.1427 -0.3009 -0.1694 -1.3078 -1.6758 -0.2501 -0.0454 -0.0891 -0.0652 -0.1222 -1.8614 -0.2511
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors ; g-protein-coupled receptor ; kinase-2 ; downregulation
H-1407	-0.2854706943035126	▁receptor s ▁; ▁g - prote in - co up led ▁receptor ▁kina se -2
D-1407	-0.2854706943035126	receptors ; g-protein-coupled receptor kinase-2
P-1407	-0.1487 -0.6859 -0.3461 -0.2563 -0.2218 -0.0472 -0.2824 -0.2888 -0.1236 -0.3333 -1.1986 -0.0337 -0.0119 -0.1180 -0.0545 -0.4129 -0.2893
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp ; nonterminal epitopes ; central glycosylated region
H-1522	-0.9447131752967834	▁NT - pro b NP ▁as say ▁; ▁e pito pes ▁; ▁gly cos yla ted ▁region
D-1522	-0.9447131752967834	NT-probNP assay ; epitopes ; glycosylated region
P-1522	-0.3724 -0.1057 -0.0944 -1.3898 -2.0954 -0.2784 -0.6400 -0.3988 -4.0455 -0.3239 -1.2688 -1.4238 -0.2041 -0.7785 -1.0259 -0.6613 -1.7777 -0.7604 -0.3048
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a ; angii ; hypoxia ; expression ; upr ; downregulation
H-1085	-1.2041882276535034	▁s cn 5 a ▁; ▁Ang II ▁; ▁hypo xia ▁; ▁u PR
D-1085	-1.2041882276535034	scn5a ; AngII ; hypoxia ; uPR
P-1085	-2.3985 -0.0879 -1.3951 -0.3419 -0.2755 -1.5142 -2.1320 -0.2729 -0.2881 -0.0435 -0.3346 -4.6170 -2.4981 -1.5425 -0.3211
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable models ; st2 ; outcomes ; clinical ; amino-terminal pro-b-type natriuretic peptide
H-704	-0.7708425521850586	▁ST 2 ▁; ▁na tri ure tic ▁pe pti de
D-704	-0.7708425521850586	ST2 ; natriuretic peptide
P-704	-1.1142 -0.1966 -0.4391 -1.0680 -1.1604 -0.5144 -1.7454 -1.1990 -0.2943 -0.8459 -0.4070 -0.2658
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 ; sst2 ; odds ratio ; cardiovascular event
H-408	-0.9509079456329346	▁s st 2/ high - dos e ▁BB ▁; ▁s st 2 ▁; ▁low - dos e ▁BB ▁; ▁cardiovascular ▁event
D-408	-0.9509079456329346	sst2/high-dose BB ; sst2 ; low-dose BB ; cardiovascular event
P-408	-0.4283 -2.2417 -1.8786 -1.8266 -0.3798 -0.9236 -0.3136 -0.8886 -0.4420 -0.1264 -2.2760 -0.4180 -0.3318 -4.1397 -0.2260 -0.9209 -0.2461 -0.8896 -0.3751 -0.4440 -1.4907 -0.3967 -0.2672
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia ; medline ; cochrane library
H-31	-0.5749149918556213	▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁med line ▁; ▁co ch rane ▁Library
D-31	-0.5749149918556213	anemia ; iron deficiency ; medline ; cochrane Library
P-31	-3.0960 -0.6891 -0.3741 -0.1843 -0.2609 -0.3619 -0.0478 -0.7755 -0.3777 -0.4159 -1.2051 -1.4343 -0.3306 -0.0357 -0.3941 -0.1824 -0.1343 -0.3485 -0.2754
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones ; adipokines ; fat free mass ; ffm ; fat mass
H-11	-0.5071102976799011	▁neuro hormon es ▁; ▁adi pok ines ▁; ▁body ▁composition ▁; cc ▁; ▁fat ▁free ▁mass ▁; ▁f m ▁; ▁fat ▁mass ▁; FM
D-11	-0.5071102976799011	neurohormones ; adipokines ; body composition ;cc ; fat free mass ; fm ; fat mass ;FM
P-11	-0.1922 -0.1934 -0.3009 -0.3248 -0.0338 -0.1761 -0.1785 -0.3368 -2.4573 -0.2123 -0.2288 -0.9940 -0.2446 -0.5451 -0.5267 -0.2374 -0.2792 -0.9386 -0.6686 -0.3833 -0.6812 -0.1625 -0.2779 -1.9780 -0.3785 -0.2544
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac plasma membrane ; s1pr1 ; β1ar ; heart failure
H-1411	-0.940769612789154	▁cardiac ▁plasma ▁membran e ▁; ▁s 1 PR 1 ▁; ▁β 1 ar ▁over stimul ation ▁; ▁heart ▁failure
D-1411	-0.940769612789154	cardiac plasma membrane ; s1PR1 ; β1ar overstimulation ; heart failure
P-1411	-1.0828 -0.2290 -0.0221 -0.0720 -1.4368 -0.8301 -0.9191 -2.0748 -3.8809 -0.4215 -0.5720 -1.9865 -1.6202 -0.0930 -0.1888 -2.2878 -0.2674 -0.8514 -0.3251 -0.3636 -0.2312
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley ; randomized ; acf ; allopurinol
H-473	-0.9740836024284363	▁Spr a gue - Da w ley ▁; ▁sham ▁; ▁a CF ▁; ▁allo puri nol
D-473	-0.9740836024284363	Sprague-Dawley ; sham ; aCF ; allopurinol
P-473	-1.9146 -1.0796 -0.6325 -0.1533 -1.9333 -0.0181 -3.0491 -0.5443 -0.2762 -0.3747 -2.2098 -2.1740 -0.4300 -0.1555 -0.1471 -1.6876 -0.4391 -0.3146
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 ; myocardial collagen ; myocardial
H-1064	-0.7947502136230469	▁t 1 ▁; ▁my o card ial ▁collage n ▁; ▁my o card ial ▁de lay ed ▁enhance ment ▁imagin g
D-1064	-0.7947502136230469	t1 ; myocardial collagen ; myocardial delayed enhancement imaging
P-1064	-0.8730 -1.2196 -0.2946 -1.2832 -0.4038 -1.7960 -2.0202 -0.2156 -0.2505 -0.3032 -1.5947 -0.3640 -1.9178 -2.4220 -0.3582 -0.1080 -0.4398 -0.5309 -0.5281 -0.4547 -0.2806 -0.3606 -0.2601
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin ; sitagliptin ; follow-up
H-1833	-0.8741224408149719	▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁follow - up
D-1833	-0.8741224408149719	saxagliptin ; sitagliptin ; follow-up
P-1833	-0.5388 -0.0916 -0.8351 -3.4804 -0.5491 -1.7755 -0.1854 -0.4625 -3.2854 -0.4228 -0.0462 -0.3893 -0.0749 -0.6888 -0.2860
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully magnetically levitated lvas ; mortality ; seattle ; heart failure
H-2002	-0.8504557609558105	▁magnet ically ▁le vita ted ▁l VAS ▁; ▁mortal iteit ▁; ▁Seattle ▁Heart ▁Fail ure
D-2002	-0.8504557609558105	magnetically levitated lVAS ; mortaliteit ; Seattle Heart Failure
P-2002	-2.6181 -1.0228 -0.1078 -0.0192 -0.8378 -0.1587 -0.9491 -0.3401 -0.1644 -2.2268 -1.2392 -1.0953 -0.8082 -0.3776 -1.5119 -0.7099 -0.2709
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change ; correlation ; hospitals ; longitudinal
H-138	-0.6931647062301636	
D-138	-0.6931647062301636	
P-138	-1.1118 -0.2746
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq ; patients ; hfpef
H-790	-1.086990475654602	▁ nc w ▁; ▁internal ▁consiste ncy ▁; ▁ HF p EF ▁; ▁ krot bach
D-790	-1.086990475654602	ncw ; internal consistency ; HFpEF ; krotbach
P-790	-1.5589 -1.5398 -0.0889 -1.0373 -2.2301 -0.6713 -0.2326 -0.2520 -1.5246 -1.2823 -0.0701 -1.0409 -0.3264 -1.0685 -5.8372 -0.1462 -0.3922 -0.2666
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable ; patients ; qrs duration
H-891	-0.8068891763687134	▁implant able ▁cardio ver ter ▁; ▁de fi br illa tor - c RT ▁; ▁l bf
D-891	-0.8068891763687134	implantable cardioverter ; defibrillator-cRT ; lbf
P-891	-0.9050 -0.4115 -0.1414 -0.1275 -0.2216 -0.5319 -0.1074 -0.0792 -0.7416 -0.2012 -0.1058 -0.2767 -1.2875 -3.0315 -0.3352 -2.1738 -3.0889 -1.2624 -0.3008
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal ; diagnostic ; clinical
H-1304	-1.3218941688537598	
D-1304	-1.3218941688537598	
P-1304	-2.3726 -0.2712
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up ; patients
H-1538	-0.8387080430984497	▁follow - up ▁; ▁et id rona te ▁; ▁ra lo xi fen e - tre ated
D-1538	-0.8387080430984497	follow-up ; etidronate ; raloxifene-treated
P-1538	-0.0990 -0.3771 -0.1055 -3.4821 -4.7689 -0.3884 -0.1780 -0.1092 -1.7249 -1.2364 -0.1619 -0.3327 -0.0332 -0.1489 -0.1913 -0.0511 -1.0994 -1.1546 -0.2930
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy ; trastuzumab ; comorbidities ; chf ; international classification of diseases ; healthcare common procedure coding system codes
H-674	-0.42695891857147217	▁che mo therapy ▁; ▁tras tuz um ab ▁; ▁como rbi di ties ▁; ▁CHF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁health care ▁common ▁procedure ▁co ding ▁system ▁code s
D-674	-0.42695891857147217	chemotherapy ; trastuzumab ; comorbidities ; CHF ; international Classification of Diseases ; healthcare common procedure coding system codes
P-674	-2.0978 -0.3865 -0.0964 -0.2977 -0.1341 -0.1987 -0.1375 -0.9666 -0.6672 -0.8286 -0.0126 -0.4856 -0.1423 -0.3671 -0.2993 -0.2854 -0.1428 -0.2257 -0.5748 -0.4083 -0.3275 -0.1706 -0.2270 -1.3078 -0.0766 -1.0980 -0.2714 -0.8315 -0.1687 -0.5349 -0.0439 -0.1417 -0.3101 -0.2520
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart failure ; hf ; therapies ; outcomes ; patients ; hf ; preserved left ventricular ejection fraction ; lvef
H-111	-0.9923087358474731	▁heart ▁failure ▁; HF ▁; ▁ therapie s ▁; HF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁l EF
D-111	-0.9923087358474731	heart failure ;HF ; therapies ;HF ; left ventricular ejection fraction ; lEF
P-111	-4.8083 -0.3443 -0.3198 -1.1987 -0.3308 -0.7534 -0.5836 -0.2718 -0.3707 -3.2948 -0.3531 -1.8068 -0.2797 -2.4541 -0.8598 -0.3063 -0.4271 -0.2229 -0.5003 -0.0361 -0.3795 -1.5651 -2.6809 -0.3849 -0.2751
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced hf ; cxl-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
H-421	-0.7625585794448853	▁ conscious ▁; ▁dog s ▁; ▁ta chy pac ing - indu ced ▁ HF ▁; ▁c XL -10 20 ▁; ▁contract ility
D-421	-0.7625585794448853	conscious ; dogs ; tachypacing-induced HF ; cXL-1020 ; contractility
P-421	-0.9118 -0.5381 -0.6728 -1.5152 -0.5405 -0.3468 -0.8601 -0.9172 -0.0521 -0.2978 -0.2205 -0.2402 -1.0385 -0.8448 -0.8463 -0.2933 -0.4855 -1.9999 -0.3315 -0.4503 -0.2963 -0.0189 -0.6529 -4.3832 -0.3093
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths ; crt ; hazard ratio
H-853	-1.2669826745986938	▁c RT ▁; ▁hazard ▁ratio
D-853	-1.2669826745986938	cRT ; hazard ratio
P-853	-0.5581 -4.4177 -1.1024 -1.6374 -0.1630 -0.6588 -0.3314
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation ; consultation ; consultation ; operation
H-1283	-1.3151094913482666	▁m t
D-1283	-1.3151094913482666	mt
P-1283	-3.7067 -0.8381 -0.4701 -0.2454
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox proportional hazards models ; death ; transplantation ; lv assist device implantation ; heart failure ; hospitalization ; follow-up
H-431	-0.5844425559043884	▁co x ▁proportion al ▁hazard s ▁; ▁death ▁; ▁transplant ation ▁; ▁LV ▁assist ▁device ▁implant ation ▁; ▁heart ▁failure ▁; ▁hospital ization ▁; ▁follow - up
D-431	-0.5844425559043884	cox proportional hazards ; death ; transplantation ; LV assist device implantation ; heart failure ; hospitalization ; follow-up
P-431	-0.3449 -0.2387 -0.0329 -0.0493 -0.1922 -0.8103 -0.2468 -2.6834 -0.2808 -0.3333 -1.9605 -0.2844 -0.5512 -0.6114 -0.1397 -0.5578 -1.2469 -0.2668 -1.3987 -0.5848 -1.0363 -1.1914 -0.7367 -0.3370 -0.0091 -0.2412 -0.0485 -0.2973 -0.2364
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity
H-964	-0.5277296900749207	▁Nico rand il ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁kina se ▁activity
D-964	-0.5277296900749207	Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
P-964	-0.0484 -0.0485 -0.1512 -0.3680 -0.2281 -0.1950 -0.3179 -0.5560 -1.7167 -0.4298 -0.1067 -0.0826 -2.7854 -0.1696 -0.4378 -0.1145 -0.4939 -0.0294 -0.8214 -0.3289 -0.1767 -0.0906 -1.2207 -0.2979 -0.1861 -2.7394 -1.8308 -0.2409 -0.5817 -0.3788 -0.0209 -0.8614 -0.0033 -0.0819 -0.6383 -0.4773 -0.2692
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass correlation coefficient ; icc ; kappa coefficient ; standard error of measurement ; minimal detectable change ; mdc
H-801	-0.35199955105781555	▁intra class ▁corre lation ▁co e ffi cient ▁; ▁i cc ▁; ▁ka ppa ▁co e ffi cient ▁; ▁m d
D-801	-0.35199955105781555	intraclass correlation coefficient ; icc ; kappa coefficient ; md
P-801	-0.5023 -0.5709 -0.1085 -1.1937 -0.0939 -0.3451 -0.1675 -0.3947 -0.2887 -0.3496 -0.2126 -0.3175 -0.1523 -0.5735 -0.0497 -0.2001 -0.1542 -0.2404 -0.3295 -0.2104 -0.8308 -0.5397 -0.2704
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized ; heart failure ; saxagliptin ; sitagliptin ; antihyperglycemic drugs ; retrospective cohort study
H-1826	-0.7943792343139648	▁Hospital ized ▁Heart ▁Fail ure ▁; ▁Sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁Drug s ▁; ▁Retro spec tive ▁co hor t ▁Study
D-1826	-0.7943792343139648	Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs ; Retrospective cohort Study
P-1826	-4.8642 -0.2276 -0.7519 -0.2950 -1.3417 -0.3019 -0.2155 -0.0448 -0.2823 -2.6240 -0.3915 -2.4657 -0.2734 -0.1677 -2.2843 -0.2954 -0.1481 -0.3731 -0.0664 -0.4440 -0.9541 -0.6745 -0.6299 -0.2239 -1.4296 -0.3955 -0.1497 -2.0745 -0.0873 -1.0274 -0.0949 -0.8208 -0.3389 -0.2492
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise ; training ; outcomes ; chronic heart failure ; heart failure - a controlled trial investigating outcomes in exercise training ; hf-action
H-1629	-0.9522254467010498	▁race ▁; ▁exercise ▁training ▁; ▁chronic ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁; ▁controle led ▁tri al ▁Investiga ting ▁Out com es ▁; ▁Exerci se ▁Tra i N ing ▁; HF - ac TION
D-1629	-0.9522254467010498	race ; exercise training ; chronic heart failure ; Heart Failure ; controleled trial Investigating Outcomes ; Exercise TraiNing ;HF-acTION
P-1629	-2.0216 -0.2080 -2.3941 -1.4716 -0.2723 -1.9095 -0.8917 -0.3303 -0.2893 -0.8183 -0.8079 -1.4457 -0.2077 -3.0409 -1.5702 -0.0950 -0.0999 -1.0483 -0.6872 -0.3344 -0.1248 -0.1316 -1.2720 -0.5255 -0.1427 -0.8170 -0.4541 -4.0556 -0.2701 -0.2644 -2.3838 -0.0688 -1.0535 -2.2381 -0.3091 -0.2252
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical ; biomedical ; patients ; dcm ; heart failure ; pubmed
H-1259	-0.717400312423706	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure ▁; ▁Pub Med
D-1259	-0.717400312423706	biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure ; PubMed
P-1259	-0.1162 -0.4812 -0.1400 -1.1956 -0.3822 -3.5084 -0.3364 -0.4598 -0.0892 -0.4581 -0.1145 -0.8554 -0.4679 -0.3587 -2.5818 -0.3735 -1.8903 -0.6228 -0.4784 -0.3369 -0.5460 -0.4336 -0.2734
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient ; primary end point ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; cabg
H-972	-0.6355361938476562	▁Swedish ▁national ▁in patient ▁Registr y ▁; ▁re hospital ization ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁ca BG
D-972	-0.6355361938476562	Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
P-972	-1.0287 -0.8759 -0.0771 -0.2419 -0.8159 -0.4126 -0.2783 -0.3952 -0.0521 -0.7486 -0.2518 -0.5847 -0.2508 -1.3947 -0.2277 -0.5486 -1.6385 -0.0544 -0.6822 -1.1134 -0.2870 -1.5807 -0.3252 -0.2871 -0.8554 -2.2043 -0.3425 -0.2394
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular pacing ; bivp ; cardiac output ; cardiac ; surgery ; patients
H-319	-0.9610191583633423	▁Bi ven tri cular ▁pa cing ▁; Bi VP ▁; ▁cardiac ▁output ▁; ▁co ▁; ▁cardiac ▁surgery
D-319	-0.9610191583633423	Biventricular pacing ;BiVP ; cardiac output ; co ; cardiac surgery
P-319	-4.3875 -0.4240 -2.9603 -0.7681 -0.0805 -0.7566 -0.3622 -2.0444 -1.3414 -0.3886 -0.3855 -0.0352 -0.2682 -1.9016 -0.3483 -0.2487 -0.2179 -1.0418 -0.2984
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients ; new york heart association ; nyha ; chronic heart failure ; reduced ejection fraction
H-1952	-0.7943284511566162	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁chronic ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁special ▁access ▁programme
D-1952	-0.7943284511566162	New York Heart association ;NYha ; chronic heart failure ; ejection fraction ; special access programme
P-1952	-1.0854 -1.4497 -1.6206 -0.2852 -0.3200 -2.6308 -2.1628 -0.4247 -1.7911 -1.1948 -0.5042 -0.3220 -0.4376 -0.1690 -0.0860 -0.2648 -0.0249 -0.5012 -1.0156 -1.1371 -0.1689 -0.4058 -0.2674
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa ; immunoassays ; antibodies ; c termini ; nt-probnp
H-1518	-0.7121050953865051	▁Alpha LIS a ▁immun o assa ys ▁; ▁anti bo dies
D-1518	-0.7121050953865051	AlphaLISa immunoassays ; antibodies
P-1518	-0.4980 -0.6904 -0.9264 -0.3672 -0.5138 -0.4520 -2.4872 -0.2437 -0.0410 -0.0607 -1.6562 -1.0767 -0.2439
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine ; bnp ; furosemide ; dobutamine ; norepinephrine ; outcome
H-587	-0.6969126462936401	▁creati nine ▁; ▁b NP ▁; ▁fur os em ide ▁; ▁oxygen ▁flow ▁; ▁dobu tamine ▁; ▁no re pine ph rine
D-587	-0.6969126462936401	creatinine ; bNP ; furosemide ; oxygen flow ; dobutamine ; norepinephrine
P-587	-2.4007 -2.0757 -0.3606 -1.2768 -2.2986 -0.2981 -0.7255 -0.3604 -0.2088 -0.1844 -0.6881 -0.7846 -0.5830 -0.2724 -0.2104 -0.3489 -0.3170 -0.2948 -0.1046 -0.0378 -0.7461 -0.2156 -1.6718 -0.2614
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule ; expression ; regulation ; rad ; q66p ; rgk protein ; in vivo
H-1678	-0.8724305033683777	▁expression ▁; ▁mis tar ge ting ▁; ▁alter ed ▁regula tion ▁; ▁Rad ▁Q 66 p ▁; ▁r GK ▁protein ▁; ▁ef fica cy ▁in ▁vivo
D-1678	-0.8724305033683777	expression ; mistargeting ; altered regulation ; Rad Q66p ; rGK protein ; efficacy in vivo
P-1678	-4.0937 -0.2245 -0.0406 -0.7736 -0.1630 -0.4289 -0.2853 -1.3021 -0.1798 -0.3691 -1.0086 -0.2361 -2.5247 -3.0294 -0.9977 -0.2827 -0.2623 -0.5937 -1.5705 -0.9861 -0.8777 -0.5092 -1.0381 -0.5247 -1.3370 -0.0744 -0.4823 -0.2321
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte hypertrophy ; heart failure ; global gene expression ; dna ; genomic
H-89	-0.7462911605834961	▁My o cy te ▁hyper trop hy ▁; ▁heart ▁failure ▁; ▁gene ▁expression ▁; ▁DNA
D-89	-0.7462911605834961	Myocyte hypertrophy ; heart failure ; gene expression ; DNA
P-89	-1.7463 -0.1669 -0.0952 -0.0422 -0.0853 -0.0237 -1.4874 -0.1640 -2.7517 -0.4588 -0.3105 -1.9593 -0.2257 -0.3574 -1.0754 -1.4485 -0.2886
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter ablation ; patients ; compensated hfpef ; left ventricular ; ejection fraction
H-944	-0.7081577181816101	▁Cat heter ▁ab lation ▁; ▁AF ▁; ▁compensa ted ▁h FP EF ▁; ▁le ft ▁vent ri cular ▁; ▁v n ▁; ▁e je ction ▁ fraction
D-944	-0.7081577181816101	Catheter ablation ; AF ; compensated hFPEF ; left ventricular ; vn ; ejection fraction
P-944	-1.6399 -0.0938 -0.0582 -0.3704 -0.2979 -0.4689 -0.3788 -0.1676 -0.4543 -1.2513 -2.4784 -1.3786 -0.3767 -3.7950 -0.4665 -0.1619 -1.6998 -0.2048 -0.3044 -1.8389 -0.8448 -0.2770 -0.1201 -0.2871 -0.0982 -0.3854 -0.0136 -0.3808 -0.2435
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology ; national cardiovascular disease registry practice innovation and clinical excellence registry
H-660	-0.8025234937667847	▁Card i ology ▁; ▁Card io vas cular ▁Disease ▁Registr y ▁; ▁practice ▁innovation ▁; ▁Clinic al ▁Excellence ▁registr y
D-660	-0.8025234937667847	Cardiology ; Cardiovascular Disease Registry ; practice innovation ; Clinical Excellence registry
P-660	-2.2781 -0.8054 -0.2559 -0.2361 -4.0177 -1.3807 -0.7020 -0.6039 -0.4297 -0.6616 -0.2581 -0.3046 -1.2236 -1.8226 -0.7566 -0.5728 -0.0396 -0.2843 -0.2469 -0.1910 -0.3679 -0.2166
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions ; readmission ; patients ; congestive heart failure ; south dakota
H-1583	-0.81479412317276	▁con ges tive ▁heart ▁failure ▁; ▁Mid we stern ▁state ▁; ▁South ▁da kota
D-1583	-0.81479412317276	congestive heart failure ; Midwestern state ; South dakota
P-1583	-0.5748 -1.0658 -2.8339 -0.9830 -0.3757 -0.3007 -0.9621 -0.2394 -1.6969 -0.9469 -0.2488 -1.4270 -0.5132 -0.0781 -0.5021 -0.2885
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts ; hh ; medical ; all-cause mortality ; discharged ; patients ; heart failure
H-162	-1.2677817344665527	▁s ts ▁ HH ▁; ▁TM ▁; ▁mortal iteit ▁; ▁dis charge d ▁; ▁patients ▁; ▁heart ▁failure
D-162	-1.2677817344665527	sts HH ; TM ; mortaliteit ; discharged ; patients ; heart failure
P-162	-1.2826 -2.0791 -2.5946 -0.7049 -0.3545 -1.7910 -0.4826 -1.9789 -2.2150 -0.3650 -3.5138 -0.3506 -0.1934 -1.0940 -1.8595 -1.9963 -1.3250 -0.3995 -0.4727 -0.3028
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically ; myocardial infarction ; heart failure ; randomized ; bisoprolol
H-452	-0.9055642485618591	▁induc ed ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁bis o pro lol ▁; ▁vehicle
D-452	-0.9055642485618591	induced myocardial infarction ; heart failure ; bisoprolol ; vehicle
P-452	-5.8515 -1.3890 -2.3850 -0.2272 -0.7395 -1.5315 -0.0667 -0.4774 -0.8326 -0.3411 -1.3463 -0.2661 -0.2691 -0.3913 -0.2396 -0.3046 -0.5968 -0.7822 -0.4120 -0.3198 -0.2475
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions ; training ; patients ; out-patient ; follow-up ; patient ; health care
H-1579	-1.1475754976272583	▁in - patient ▁follow - up ▁; ▁health ▁care ▁system
D-1579	-1.1475754976272583	in-patient follow-up ; health care system
P-1579	-7.1922 -0.5109 -0.4367 -0.0509 -0.3269 -0.1254 -0.2981 -1.5141 -2.4509 -0.2696 -0.3127 -0.2823
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf ; phenotype ; cardiac ; explant ; progenitors ; regulation
H-1337	-0.3931204676628113	▁CHF ▁; ▁cardiac ▁ex plant
D-1337	-0.3931204676628113	CHF ; cardiac explant
P-1337	-1.2285 -0.2738 -0.5119 -0.1349 -0.0767 -0.2824 -0.2435
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia ; intravenous ; atropine ; cardiac ; vagal tone
H-1380	-0.6697732210159302	▁ta chy car dia ▁; ▁intra ven ous ▁a tropi ne ▁; ▁cardiac ▁va gal ▁tone ▁; ▁CHF - DN x ▁; ▁animals
D-1380	-0.6697732210159302	tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; animals
P-1380	-0.7513 -0.6098 -0.1559 -0.1487 -0.4443 -0.8843 -0.0866 -3.5672 -0.1177 -0.0625 -1.1032 -0.3640 -0.1451 -0.0585 -0.1808 -0.0970 -0.9856 -0.4898 -0.1082 -2.9364 -0.5045 -0.7042 -1.6690 -0.3076 -0.2622
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes ; myocardium ; conditions
H-990	-0.4340800642967224	▁cardio my o cy tes ▁; ▁mechanic al ▁; ▁humor al ▁stimul i ▁; ▁my o car dium
D-990	-0.4340800642967224	cardiomyocytes ; mechanical ; humoral stimuli ; myocardium
P-990	-0.3106 -0.8748 -0.1882 -0.2085 -0.2212 -0.2854 -1.6751 -0.0781 -0.3229 -0.0922 -0.1003 -0.7790 -0.7469 -0.2632 -1.1711 -0.0790 -0.0821 -0.2617 -0.7145 -0.2266
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological phenotype ; clinically ; deficit index ; medical ; frailty
H-1013	-0.530262291431427	▁bi ological ▁ph eno type ▁; ▁deficit ▁index ▁; ▁medical ▁records
D-1013	-0.530262291431427	biological phenotype ; deficit index ; medical records
P-1013	-1.3362 -0.7185 -0.7115 -0.2825 -0.0091 -0.4095 -0.2272 -0.0653 -0.5375 -0.9498 -0.7967 -0.5773 -0.2725
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy ; sst2 ; patients ; chronic heart failure
H-411	-0.8590899705886841	▁BB ▁ therapy ▁; ▁s st 2 ▁measure ment ▁; ▁chronic ▁heart ▁failure ▁; ▁BB
D-411	-0.8590899705886841	BB therapy ; sst2 measurement ; chronic heart failure ; BB
P-411	-1.0233 -0.4667 -0.1579 -0.3900 -1.1949 -1.4984 -0.1067 -1.5317 -1.2800 -0.4382 -1.2391 -1.2148 -0.5631 -0.4597 -2.2525 -0.4727 -0.3148
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd ; outpatients ; systolic hf ; patients ; egfr
H-396	-1.3194326162338257	▁eh r ▁; ▁sy sto lic ▁ HF ▁; ▁e g FR
D-396	-1.3194326162338257	ehr ; systolic HF ; egFR
P-396	-6.5676 -1.2744 -0.3081 -2.4406 -0.0967 -0.0866 -0.3769 -0.3762 -0.3989 -0.2845 -2.6006 -2.8695 -0.4638 -0.3277
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse ; pasp ; step ; rv function ; lv dysfunction
H-501	-0.6149209141731262	▁ pv se ▁; ▁PAS p ▁; ▁length - force ▁relationship ▁; ▁ rv ▁function ▁evaluation ▁; ▁LV ▁dys function
D-501	-0.6149209141731262	pvse ; PASp ; length-force relationship ; rv function evaluation ; LV dysfunction
P-501	-0.8506 -1.6295 -1.4316 -0.2731 -1.1204 -0.4674 -0.3880 -0.2991 -0.1560 -0.4175 -0.6452 -0.3042 -0.7470 -1.0222 -0.1312 -1.6277 -0.2764 -0.2121 -0.8696 -0.0829 -0.3247 -0.2516
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel ; apoptotic cells ; tunel-positive cells
H-172	-0.8941397070884705	▁tu nel ▁as say ▁; ▁apo pto tic ▁cell s ▁; ▁tu nel - posi tive ▁cell s
D-172	-0.8941397070884705	tunel assay ; apoptotic cells ; tunel-positive cells
P-172	-2.3221 -2.9451 -0.3222 -0.7737 -0.2415 -0.5504 -0.5058 -0.7812 -0.4568 -0.4782 -0.2927 -2.0133 -3.3192 -0.2043 -0.0037 -1.3794 -0.3169 -0.3862 -0.3317 -0.2583
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno donor ; myocardial function ; evidence ; hf
H-425	-1.0197447538375854	▁functional ▁ef fica cy ▁; ▁h no ▁; ▁donor ▁; ▁my o card ial ▁function ▁; HF
D-425	-1.0197447538375854	functional efficacy ; hno ; donor ; myocardial function ;HF
P-425	-3.9547 -0.9954 -1.2296 -0.7099 -0.2328 -0.4885 -1.6044 -0.3241 -0.9467 -0.2770 -1.3345 -0.1888 -0.6993 -2.0380 -0.1748 -0.2741 -3.3149 -0.3207 -0.2671
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular support ; rvads ; explanted
H-301	-0.9089730381965637	▁bi ven tri cular ▁support ▁; ▁r VAD s ▁; ▁ex plant ed
D-301	-0.9089730381965637	biventricular support ; rVADs ; explanted
P-301	-1.0048 -0.1735 -1.6645 -0.5330 -2.0250 -0.3651 -1.2394 -2.9164 -0.5109 -0.2763 -0.3029 -0.1139 -1.7960 -0.4312 -0.2815
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal dialysis ; pd ; diuretic ; volume overload ; heart failure ; hf
H-894	-0.5728901624679565	▁Peri tone al ▁di al ysis ▁; PD ▁; ▁di ure tic ▁resist ant ▁volume ▁over load ▁; ▁heart ▁failure ▁; HF ▁; ▁benefit
D-894	-0.5728901624679565	Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF ; benefit
P-894	-0.7215 -0.7563 -0.0883 -0.3951 -0.0459 -0.1812 -0.3061 -1.3489 -0.3562 -0.7714 -0.6785 -1.1849 -0.3606 -0.2574 -0.5948 -0.0224 -0.2995 -0.3127 -1.3616 -0.5279 -0.2931 -2.0293 -0.5000 -0.7901 -0.4838 -0.2275
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial shunting ; patients ; heart failure with reduced ejection fraction ; proof-of-principle cohort study
H-1948	-0.7671961188316345	▁left - to - right ▁inter at rial ▁sh unting ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1948	-0.7671961188316345	left-to-right interatrial shunting ; heart failure ; ejection fraction
P-1948	-3.0333 -0.1588 -0.4667 -0.2190 -1.1805 -0.0717 -0.0799 -0.5320 -0.8758 -1.3506 -0.4444 -5.0017 -0.4370 -0.4062 -0.2634 -0.2509 -0.1819 -0.3602 -0.0540 -0.4655 -0.2775
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report ; stable ; hno donor ; cxl-1020 ; myoctyes ; hearts ; patients ; heart failure ; hf
H-415	-0.7188716530799866	▁h no ▁; ▁donor ▁; ▁c XL -10 20) ▁; ▁isola ted ▁my oc ty es ▁; ▁intact ▁heart s ▁; ▁heart ▁failure ▁; HF
D-415	-0.7188716530799866	hno ; donor ; cXL-1020) ; isolated myoctyes ; intact hearts ; heart failure ;HF
P-415	-1.1285 -1.6526 -1.2967 -0.3342 -0.2588 -0.4132 -2.1006 -0.3177 -0.8111 -0.6536 -0.7037 -0.3742 -1.3992 -0.2112 -0.2474 -0.3756 -0.3971 -0.3141 -1.2693 -0.3673 -0.2904 -1.8643 -0.2698 -0.2319 -1.4787 -0.3495 -0.2991
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical examination ; patient ; bmi ; heart rate ; rhythm ; blood pressure ; auscultation ; rule ; valvular disease ; pulmonary congestion
H-1894	-0.7519783973693848	▁Physic al ▁examina tion ▁; ▁b mi ▁; ▁weight ▁; ▁heart ▁rate ▁; ▁ rhythm ▁; ▁ly ing ▁; ▁standing ▁; ▁blood ▁pressure ▁; ▁uit cul tation ▁; ▁val vu lar ▁disease ▁; ▁pulmonar y ▁con gestion
D-1894	-0.7519783973693848	Physical examination ; bmi ; weight ; heart rate ; rhythm ; lying ; standing ; blood pressure ; uitcultation ; valvular disease ; pulmonary congestion
P-1894	-3.1598 -0.3268 -1.1971 -2.1303 -0.3660 -1.4109 -2.0842 -0.3318 -0.6259 -0.3269 -1.5225 -0.6144 -0.2944 -0.1862 -0.7950 -0.3037 -0.0594 -0.2984 -0.2312 -0.2387 -0.4077 -1.1089 -0.9435 -0.3192 -3.8386 -0.2007 -0.3461 -0.3745 -1.3109 -0.1073 -0.2333 -0.8114 -0.2674 -0.0336 -1.2929 -0.0769 -0.3546 -0.5003 -0.2959
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial extracellular matrix ; cardiac magnetic resonance ; t1 mapping ; pathobiology ; pathophysiology ; prognosis
H-735	-0.520408034324646	▁my o card ial ▁extra cel lular ▁matri x ▁; ▁cardiac ▁magnetic ▁res on ance ▁t 1 ▁ma pping ▁; ▁path obi ology ▁; pat ho phy si ology
D-735	-0.520408034324646	myocardial extracellular matrix ; cardiac magnetic resonance t1 mapping ; pathobiology ;pathophysiology
P-735	-2.3725 -0.4305 -1.2413 -1.1182 -1.0460 -0.7166 -0.2254 -0.0240 -0.6743 -0.2867 -0.1127 -0.2365 -0.5199 -0.2602 -0.4046 -0.7055 -0.6131 -0.1449 -0.2854 -1.2271 -0.3293 -0.1109 -0.1831 -0.4687 -0.2467 -0.0426 -0.3951 -1.0752 -0.0889 -0.2925 -0.2542
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone antagonist ; therapy ; chronic advanced heart failure ; patients ; post-myocardial infarction ; heart failure ; patients
H-1738	-0.6560711860656738	▁al do ster one ▁anta gon ist ▁ therapy ▁; ▁chronic ▁advanced ▁heart ▁failure ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁e je ction
D-1738	-0.6560711860656738	aldosterone antagonist therapy ; chronic advanced heart failure ; post-myocardial infarction ; heart failure ; ejection
P-1738	-0.1109 -0.0772 -0.2159 -1.1466 -0.1150 -0.0160 -0.8332 -0.8050 -0.0664 -0.2428 -2.3532 -2.1403 -1.4619 -0.5956 -0.6741 -0.6245 -0.0899 -0.5561 -0.2088 -0.6380 -1.6327 -0.1021 -0.6402 -0.8760 -1.6394 -1.7077 -0.5494 -0.4146 -0.1526 -0.1617 -0.1413 -0.3969 -0.2643
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil ; heart rate ; aortic ; blood flow ; mitochondrial ; oxidative stress ; doxorubicin ; cardiotoxicity
H-963	-0.5207377076148987	▁Nico rand il ▁; ▁heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁mito cho ndri al ▁oxid ative ▁stress ▁; ▁do xor ubi cin ▁; ▁cardio toxic iteit
D-963	-0.5207377076148987	Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin ; cardiotoxiciteit
P-963	-0.0431 -0.0390 -0.1134 -0.3066 -2.7187 -0.6946 -0.2697 -0.1441 -0.0776 -1.0058 -0.7274 -0.3855 -0.2868 -0.0372 -0.6942 -0.3934 -0.1804 -0.1125 -1.0335 -0.4682 -0.2621 -0.1076 -0.0581 -0.1130 -0.7189 -1.2567 -0.0484 -0.6455 -2.5959 -0.3750 -0.2300
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed ; heart failure ; left ventricular ejection fraction ; spironolactone ; kaiser permanente ; northern california
H-440	-0.4854566752910614	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁spi rono lac tone ▁; ▁Kaiser ▁Permanent e ▁Northern ▁California
D-440	-0.4854566752910614	heart failure ; left ventricular ejection fraction ; spironolactone ; Kaiser Permanente Northern California
P-440	-2.6364 -0.3545 -0.2630 -0.7772 -0.1872 -1.6602 -0.3939 -0.2415 -0.2671 -0.2270 -0.9917 -0.0390 -0.2676 -0.0320 -0.0568 -0.1170 -0.0539 -0.6817 -0.1799 -0.4936 -0.0492 -0.8674 -0.5167 -0.4969 -0.2852
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt ; elevated ; acute ; β-adrenoceptor blockade ; esmolol
H-1444	-1.0232410430908203	▁SD t ▁; ▁h w t ▁; ▁h Nor m ▁; ▁β - ad re no cept or ▁block ade ▁; ▁es mol ol
D-1444	-1.0232410430908203	SDt ; hwt ; hNorm ; β-adrenoceptor blockade ; esmolol
P-1444	-0.6197 -3.5568 -0.3933 -1.7866 -5.3045 -0.0538 -0.3116 -1.1218 -4.9214 -0.2939 -0.9500 -0.6266 -0.0921 -0.1975 -0.2867 -0.2619 -0.4434 -0.2684 -0.3530 -1.3977 -0.4279 -1.6439 -0.0191 -0.5428 -0.4537 -0.2764
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical ; outcomes ; heart failure ; charm ; candesartan in heart failure assessment of reduction in mortality and morbidity
H-554	-0.7556001543998718	▁heart ▁failure ▁; ▁CHA r ▁programme ▁; Can des ar tan ▁in ▁Heart ▁Fail ure ▁assessment ▁of ▁re duction ▁in ▁Mor t ality ▁; ▁Morbi d iteit
D-554	-0.7556001543998718	heart failure ; CHAr programme ;Candesartan in Heart Failure assessment of reduction in Mortality ; Morbiditeit
P-554	-3.0817 -0.4799 -0.3382 -1.4715 -1.1493 -0.2028 -0.3646 -2.0281 -0.0446 -0.0414 -0.0344 -1.5585 -1.4433 -0.8532 -2.0982 -0.0750 -1.1411 -1.7943 -0.0139 -0.2917 -0.5435 -0.0682 -0.0375 -0.8802 -0.0121 -0.2053 -1.1162 -0.3125 -0.2314
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients ; heart failure with preserved ejection fraction ; hfpef ; heart failure ; obese
H-1974	-0.6576968431472778	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h bf ▁; ▁heart ▁failure ▁; ▁over weight ▁; ▁obes e
D-1974	-0.6576968431472778	heart failure ; preserved ejection fraction ; hbf ; heart failure ; overweight ; obese
P-1974	-3.0885 -0.5958 -0.3763 -0.5009 -0.2470 -2.2349 -0.2233 -0.3835 -0.0874 -0.3922 -0.0328 -0.3190 -0.5481 -2.0536 -0.9023 -1.6727 -0.7637 -0.2389 -0.2949 -0.3504 -0.3268 -0.0337 -0.1520 -0.3524 -0.2713
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal dysfunction ; prognostic ; heart failure ; hf ; dysfunction ; end-stage renal disease ; esrd
H-387	-1.0080313682556152	▁renal ▁dys function ▁; ▁heart ▁failure ▁; HF ▁; ▁renal ▁disease ▁; ▁e RD
D-387	-1.0080313682556152	renal dysfunction ; heart failure ;HF ; renal disease ; eRD
P-387	-3.1839 -0.4857 -0.5425 -0.3306 -1.8929 -0.4247 -0.3127 -1.3964 -0.2933 -0.3710 -0.7628 -0.2238 -2.8303 -2.4225 -0.4035 -0.2520
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression analysis ; echocardiographic ; lv reverse remodeling ; lv end-systolic volume
H-430	-0.4888065755367279	▁e cho car dio graphic ▁score ▁; ▁LV ▁; ▁rever se ▁remodel ing ▁; ▁LV ▁; ▁end - sy sto lic ▁volume
D-430	-0.4888065755367279	echocardiographic score ; LV ; reverse remodeling ; LV ; end-systolic volume
P-430	-2.1615 -0.6103 -0.1407 -0.7686 -0.8422 -1.0234 -0.2521 -0.1372 -0.3948 -0.0991 -0.1042 -0.0649 -0.2115 -0.3390 -0.5876 -0.7346 -0.9620 -0.1342 -0.9288 -0.0893 -0.1570 -0.4541 -0.3250 -0.2091
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral artery disease ; pad ; heart failure ; hf ; prevalence ; hf ; patients ; pad
H-1567	-0.8223452568054199	▁Peri pher al ▁arter y ▁disease ▁; PAD ▁; ▁heart ▁failure ▁; HF ▁; HF ▁; HF ▁; PAD
D-1567	-0.8223452568054199	Peripheral artery disease ;PAD ; heart failure ;HF ;HF ;HF ;PAD
P-1567	-0.1246 -0.2444 -0.5113 -0.0872 -1.9722 -0.8937 -0.2677 -1.2722 -0.2890 -1.4830 -0.5692 -0.2715 -0.9880 -0.3149 -1.9242 -0.3352 -2.9123 -0.3501 -1.7671 -0.3800 -0.3115
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission ; disease ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia
H-137	-0.9673306941986084	▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia
D-137	-0.9673306941986084	heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
P-137	-4.2694 -0.6190 -0.3194 -1.2854 -0.3306 -0.9326 -0.1243 -2.6199 -0.3039 -0.5538 -2.0096 -0.0834 -1.3209 -0.9079 -0.3747 -1.4912 -0.3949 -0.2474 -1.3587 -0.4556 -0.3113
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; fontan circulation
H-1492	-0.4853779077529907	▁per i pher al ▁muscle ▁pump ▁; ▁cardiac ▁fill ing ▁; ▁exercise ▁; ▁sub pul mon ary ▁vent ric le ▁; ▁Font ▁circulation
D-1492	-0.4853779077529907	peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; Font circulation
P-1492	-0.4891 -0.2737 -0.4208 -0.3171 -1.1158 -0.5537 -0.2942 -0.2573 -0.2119 -0.1522 -0.2830 -1.0355 -0.3069 -0.1908 -0.7889 -2.2575 -0.7070 -0.0917 -0.6971 -0.4820 -0.2805 -0.1422 -0.0990 -0.4577 -0.2287
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative ; renal dysfunction ; cardiovascular events ; stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
H-968	-0.7305562496185303	▁renal ▁dys function ▁; ▁cardiovascular ▁events ▁; stro ke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁death ▁; ▁isola ted ▁corona ry ▁arter y ▁by pass ▁graf ting
D-968	-0.7305562496185303	renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
P-968	-0.3782 -0.0388 -0.1306 -0.2765 -0.2427 -0.5466 -0.2545 -0.6694 -0.6378 -0.3632 -1.2358 -0.2074 -0.5537 -1.1206 -0.0712 -0.2800 -0.4555 -0.3108 -1.2226 -0.2334 -0.2265 -4.4911 -0.3060 -0.1404 -1.1300 -0.3594 -2.5276 -0.0506 -2.0659 -3.1271 -0.0184 -0.3259 -0.8899 -0.4151 -0.2663
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic ; pediatric fontan ; patients ; catheterization
H-227	-0.545644998550415	▁as ym pto matic ▁pediatr ic ▁Font an ▁; PF ▁; ▁cat heter ization
D-227	-0.545644998550415	asymptomatic pediatric Fontan ;PF ; catheterization
P-227	-1.0804 -0.1748 -0.2757 -0.9272 -0.2394 -0.4318 -0.1080 -0.0572 -0.2226 -1.0751 -0.3099 -1.0126 -0.0525 -1.9655 -0.5274 -0.2703
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet ; patient ; subvalvular ; annular ms
H-374	-1.0578218698501587	▁MS ▁; ▁MS ▁; ▁fixed ▁ring
D-374	-1.0578218698501587	MS ; MS ; fixed ring
P-374	-0.7411 -0.2924 -2.8272 -0.3767 -2.2640 -0.0730 -1.6082 -0.2801
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ; ventricular assist devices ; cardiac ; nurses ; gastrointestinal bleeding
H-1660	-0.6333771347999573	▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse s ▁; ▁gastro inte stin al ▁ble ed ing
D-1660	-0.6333771347999573	ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
P-1660	-0.0903 -2.6668 -0.4988 -0.5749 -0.5721 -0.3764 -1.5676 -0.2620 -0.1839 -0.3638 -0.4536 -0.3279 -1.3090 -0.2716 -0.2004 -1.2476 -0.3514 -0.4386 -0.2773
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the lancet ; anoop shah ; air ; heart failure ; morbidity ; mortality
H-1807	-0.5310261845588684	▁Lance t ▁; ▁Ano op ▁Shah ▁; ▁air ▁pollution ▁; ▁heart ▁failure ▁; ▁morbi d iteit ▁; ▁mortal iteit ▁; ▁el der ly
D-1807	-0.5310261845588684	Lancet ; Anoop Shah ; air pollution ; heart failure ; morbiditeit ; mortaliteit ; elderly
P-1807	-0.4462 -0.0671 -0.2791 -0.6987 -0.2394 -0.6776 -0.3735 -0.1332 -0.3120 -0.2932 -0.8820 -0.4582 -0.4394 -0.3636 -0.1395 -1.4597 -0.2941 -0.0575 -1.3519 -0.3802 -1.4810 -0.0664 -0.7880 -1.3306 -0.2635
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia ; hf ; health-related quality of life ; hrqol ; hf
H-835	-1.1939165592193604	▁an emia ▁; HF ▁; ▁health - related ▁quality ▁of ▁life ▁; ▁h Qo l ▁; HF
D-835	-1.1939165592193604	anemia ;HF ; health-related quality of life ; hQol ;HF
P-835	-1.9232 -0.8296 -0.2799 -2.2497 -0.3448 -3.8111 -0.1432 -0.1622 -1.1122 -0.8101 -1.6488 -0.2737 -1.8679 -0.2911 -3.0052 -0.3327 -3.0435 -0.3180 -0.2374
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell therapy ; chronic heart failure ; chf ; disease ; progenitor cells
H-1336	-0.7154881954193115	▁cell ▁ therapy ▁; ▁chronic ▁heart ▁failure ▁; ▁chw ▁; ▁disease ▁; ▁ex plant - der i ved ▁pro gen itor ▁cell s
D-1336	-0.7154881954193115	cell therapy ; chronic heart failure ; chw ; disease ; explant-derived progenitor cells
P-1336	-0.6713 -0.5397 -0.0794 -0.3286 -0.7709 -1.1111 -0.4312 -0.3079 -3.4745 -0.9577 -2.0247 -0.4566 -0.7826 -0.0323 -0.2219 -0.1705 -0.6752 -1.7377 -0.5739 -0.0361 -0.5716 -0.8314 -0.3951 -0.4118 -0.2936
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous nonfailing ; hf ; combinations ; remodeling
H-1152	-0.6420076489448547	▁dys syn chron ous ▁non fail ing ▁; HF ▁; ▁can ine ▁electro me chan ics
D-1152	-0.6420076489448547	dyssynchronous nonfailing ;HF ; canine electromechanics
P-1152	-0.2067 -0.1390 -0.0595 -1.8322 -0.3010 -0.2286 -0.3696 -0.3238 -2.1354 -0.3348 -1.4511 -1.3371 -0.0283 -0.1608 -0.0768 -1.8558 -0.4566 -0.2592
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american college of physicians ; acp ; evidence ; clinical ; anemia ; patients ; heart disease
H-30	-0.9246935248374939	▁ amerika anse ▁college ▁of ▁Physic ians ▁; ▁a CP ▁; ▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁heart ▁disease
D-30	-0.9246935248374939	amerikaanse college of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
P-30	-1.8833 -0.6454 -2.7942 -1.6941 -0.8545 -0.3480 -1.2000 -0.2335 -2.3859 -1.8674 -0.2839 -1.5879 -0.7047 -0.2822 -0.1876 -0.2317 -0.1930 -0.0770 -0.9723 -0.2522 -0.2826 -2.9854 -0.5933 -0.3010 -0.2761
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence ; exercise ; cell senescence ; active ; osteoporosis
H-1901	-0.5282191038131714	▁exercise ▁; ▁cell ▁se nesc ence ▁; ▁active ▁; ▁malign a ncies ▁; ▁cancer ▁; ▁prostat e ▁; ▁colon ▁; ▁osteo por osis ▁; ▁depression ▁; ▁dem entia
D-1901	-0.5282191038131714	exercise ; cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
P-1901	-1.9475 -0.2704 -1.2356 -0.6273 -0.3469 -1.7928 -0.3487 -1.5692 -0.4539 -0.7788 -0.5450 -0.1136 -0.2629 -0.9523 -0.3446 -0.2231 -0.0845 -0.2281 -0.4330 -0.3563 -0.1405 -0.6711 -0.2253 -0.2598 -0.3321 -0.2276 -0.4511 -0.1071 -0.2858 -0.2318
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-0.5398072600364685	▁follow - up
D-947	-0.5398072600364685	follow-up
P-947	-0.0677 -0.3172 -0.1421 -1.8945 -0.2777
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes ; chronic heart failure ; hf ; exercise ; training
H-1630	-0.7108956575393677	▁race ▁; ▁chronic ▁heart ▁failure ▁; HF ▁; ▁exercise ▁training ▁response
D-1630	-0.7108956575393677	race ; chronic heart failure ;HF ; exercise training response
P-1630	-0.6150 -0.2855 -0.7411 -0.9527 -0.2961 -0.3248 -1.4694 -0.3433 -1.2669 -1.2135 -1.1245 -0.3595 -0.2493
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological ; capillary ; coronary perfusion
H-457	-1.0011123418807983	▁his t ological ▁analysis ▁; ▁cap illa ry ▁; ▁corona ry ▁per fusion ▁; ▁ad - f lk ▁rat s ▁; ▁ad - c
D-457	-1.0011123418807983	histological analysis ; capillary ; coronary perfusion ; ad-flk rats ; ad-c
P-457	-2.8806 -0.5793 -0.6357 -1.9398 -0.5082 -0.5008 -0.2033 -3.4134 -0.4677 -0.3321 -2.5464 -0.6272 -0.1298 -0.7198 -1.2154 -0.2134 -1.7523 -0.5016 -0.3769 -0.2266 -0.7210 -1.4387 -0.1767 -1.7487 -1.8820 -0.2916
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician ; mortality ; internists ; cardiologists
H-1730	-0.7413497567176819	▁intern ists ▁; ▁cardio logist s
D-1730	-0.7413497567176819	internists ; cardiologists
P-1730	-0.5019 -2.6112 -0.4546 -0.3451 -0.6753 -0.6170 -0.4298 -0.2959
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle walk test ; hand ; baseline
H-1322	-0.6860176920890808	▁shu ttle ▁walk ▁test ▁; ▁body ▁mass ▁; ▁hand ▁grip ▁strength ▁; ▁base line
D-1322	-0.6860176920890808	shuttle walk test ; body mass ; hand grip strength ; baseline
P-1322	-0.3242 -0.0317 -0.7666 -1.1805 -0.4808 -2.5672 -0.1743 -0.5657 -0.4065 -0.4313 -0.9757 -1.2585 -0.8779 -0.0958 -0.4381 -0.4015
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc ; frame ; patient ; consultation ; patients
H-1027	-0.9499691128730774	▁PO c ▁testing ▁; ▁ NP ▁; ▁ED
D-1027	-0.9499691128730774	POc testing ; NP ; ED
P-1027	-0.7597 -1.5864 -0.7142 -0.3222 -2.0275 -0.6265 -0.3809 -1.9922 -0.7199 -0.3701
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis risk in communities
H-284	-0.5955549478530884	▁tro ponin ▁t ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁bio mark er ▁; ▁heart ▁failure ▁; ▁at hero sc ler osis ▁risk
D-284	-0.5955549478530884	troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis risk
P-284	-0.2953 -0.3434 -1.3116 -0.6189 -0.8595 -0.0740 -0.3767 -0.0435 -0.1537 -0.0605 -1.1910 -0.2007 -0.0232 -0.0671 -0.9297 -0.6008 -1.7867 -0.9772 -0.4371 -0.9004 -0.4238 -0.0728 -0.1515 -0.1281 -0.8397 -1.2925 -0.3209 -1.0206 -1.9433 -0.0855 -0.0438 -1.4786 -0.1698 -1.4619 -0.3979 -0.3583
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic ; methylatropine ; vagal tone ; bradycardic ; propranolol ; sympathetic tone
H-1139	-0.7065832614898682	▁ta chy car dic ▁response ▁; ▁met hy la tropi ne ▁; ▁va gal ▁tone ▁; ▁bra dy car dic ▁response ▁; ▁propra no lol ▁; ▁sympa the tic ▁tone
D-1139	-0.7065832614898682	tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol ; sympathetic tone
P-1139	-0.9933 -2.1384 -0.3731 -1.1629 -1.7470 -0.2669 -0.1816 -0.2949 -0.5841 -0.0477 -1.6665 -0.3086 -0.1317 -0.1569 -0.2956 -0.3064 -0.2420 -2.6094 -0.2667 -1.6896 -2.6243 -0.2605 -0.1571 -0.0792 -1.0226 -0.3690 -0.0714 -0.5587 -1.1814 -0.3293 -0.2477 -0.2464
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients ; acute rv failure ; chronic pulmonary arterial hypertension ; pah ; acute ; pulmonary embolism
H-1095	-0.8445616364479065	▁a cute ▁ rv ▁failure ▁; ▁chronic ▁pulmonar y ▁arterial ▁hyper tension ▁; ▁p b ▁; ▁a cute ▁pulmonar y ▁e mbol ism
D-1095	-0.8445616364479065	acute rv failure ; chronic pulmonary arterial hypertension ; pb ; acute pulmonary embolism
P-1095	-1.8439 -0.2017 -0.3465 -0.9381 -0.7499 -0.3300 -0.9658 -0.1756 -1.2241 -0.0601 -0.4304 -0.2429 -0.3323 -2.7443 -3.0094 -0.3643 -1.5217 -0.2814 -0.1120 -1.3969 -0.5148 -0.1921 -2.4545 -0.4052 -0.2762
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac resynchronization therapy ; crt ; mild heart failure ; hf ; patients ; qrs prolongation ; ejection fraction ; ef
H-751	-0.6110660433769226	▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁mild ▁heart ▁failure ▁; HF ▁; ▁QR s ▁; ▁e je ction ▁ fraction ▁; EF
D-751	-0.6110660433769226	cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs ; ejection fraction ;EF
P-751	-0.5737 -0.3383 -0.2423 -0.0318 -2.1884 -0.6901 -0.1164 -0.3741 -0.6800 -3.7971 -0.3858 -0.6182 -0.5690 -0.3410 -0.2826 -1.3514 -0.3517 -0.5799 -0.7544 -0.3011 -0.1904 -0.4992 -0.1596 -0.4046 -0.0293 -0.3809 -0.7609 -0.4397 -0.2890
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ; lad
H-509	-0.5223994851112366	▁fra ction al ▁flow ▁reserve ▁; ▁posi tron ▁e mission ▁tom ography ▁imagin g ▁; ▁ ische mia ▁; ▁bottle ne ck ▁sten ting ▁; ▁left ▁vent ric le ▁; LAD
D-509	-0.5223994851112366	fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ;LAD
P-509	-1.6351 -0.2145 -0.1398 -0.2666 -0.2188 -0.2863 -0.3235 -0.4116 -0.4533 -0.4037 -0.7785 -0.7303 -2.6920 -0.5844 -0.3369 -0.3535 -0.1385 -0.3301 -0.3558 -0.1639 -0.0953 -0.0323 -0.0232 -0.4386 -0.8510 -0.7584 -0.1864 -1.4086 -0.6944 -0.3178 -0.9945 -0.3764 -0.2452
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity ; oxidative stress ; dna fragmentation
H-962	-0.5628261566162109	▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁kina se ▁activity ▁; ▁oxid ative ▁stress ▁marker s ▁; ▁DNA ▁fragment ation
D-962	-0.5628261566162109	mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
P-962	-0.2255 -1.1625 -0.4345 -0.2455 -0.3535 -1.3890 -0.2757 -0.2001 -1.6702 -2.1655 -0.3370 -0.5417 -0.3056 -0.0922 -0.5704 -0.0052 -0.0806 -0.7821 -0.2363 -0.0891 -1.3110 -0.3395 -0.1480 -0.3021 -0.2828 -0.3965 -0.1990 -1.8308 -0.6712 -0.2417
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox regression ; covariates ; spironolactone ; death ; hospitalization ; hyperkalemia ; acute kidney injury
H-442	-0.4525565207004547	▁co x ▁re gression ▁; ▁spi rono lac tone ▁; ▁death ▁; ▁hyper kal emia ▁; ▁ki dne y ▁injury
D-442	-0.4525565207004547	cox regression ; spironolactone ; death ; hyperkalemia ; kidney injury
P-442	-0.0735 -0.5165 -0.0674 -0.1634 -0.3598 -0.1136 -0.0917 -0.1802 -0.2065 -0.6346 -2.2952 -0.2627 -0.5326 -0.5456 -0.5751 -0.3135 -0.1992 -1.2500 -0.4435 -0.3475 -0.4519 -0.3323
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes ; mortality ; hospitalization ; mortality ; cardiovascular mortality ; hf ; hospitalization ; cox models ; exercise ; training
H-1633	-0.9663075804710388	▁mortal iteit ▁; ▁mortal iteit ▁; ▁cardiovascular ▁mortal iteit ▁; HF ▁hospital ization ▁; ▁race ▁; ▁co x ▁; ▁exercise ▁training
D-1633	-0.9663075804710388	mortaliteit ; mortaliteit ; cardiovascular mortaliteit ;HF hospitalization ; race ; cox ; exercise training
P-1633	-2.3668 -2.7581 -0.3330 -0.9226 -2.5982 -0.3332 -0.0607 -0.2015 -2.5336 -0.2960 -1.6964 -1.4596 -0.9509 -0.2744 -0.9990 -0.2948 -0.7853 -0.2414 -0.9324 -0.3103 -1.2848 -0.3395 -0.2524
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended criteria cardiac transplant ; ecct ; transplant ; donors ; transplant ; comorbidity
H-708	-0.820203423500061	▁cardiac ▁transplant ▁; ▁ec t ▁; ▁transplant ▁pool ▁; ▁transplant
D-708	-0.820203423500061	cardiac transplant ; ect ; transplant pool ; transplant
P-708	-0.3931 -0.4082 -0.2788 -0.1165 -2.1073 -0.2584 -1.0922 -0.9223 -0.3193 -1.2250 -2.4575 -0.2639
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use of exercise and medical therapies to improve cardiac function among patients with exertional shortness of breath due to lung congestion
H-1180	-0.6337817907333374	▁Exerci se ▁; ▁Medical ▁Therapie s ▁; ▁Card iac ▁Fun ction ▁; ▁Breath ▁; ▁Lung ▁con gestion ▁; ACT RN
D-1180	-0.6337817907333374	Exercise ; Medical Therapies ; Cardiac Function ; Breath ; Lung congestion ;ACTRN
P-1180	-2.5799 -0.3204 -0.2499 -0.9235 -1.0749 -0.2192 -0.3874 -1.0609 -0.4450 -0.1292 -0.0235 -0.3387 -1.1521 -0.2985 -0.1804 -0.6984 -0.5829 -0.5951 -0.3371 -1.6913 -0.4547 -0.2004
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum ; systolic ; lv posterior wall ; lv internal diameter ; metoprolol
H-1549	-0.8971349596977234	▁sept um ▁; sy sto lic ▁; ▁thi ck ness ▁; ▁LV ▁; ▁posterior ▁wall ▁; ▁interne ▁diameter ▁; ▁met o pro lol
D-1549	-0.8971349596977234	septum ;systolic ; thickness ; LV ; posterior wall ; interne diameter ; metoprolol
P-1549	-0.3629 -0.0298 -0.2808 -0.7347 -0.5011 -0.0507 -1.1745 -4.7850 -0.0638 -3.3529 -0.3269 -0.8558 -0.8511 -0.6581 -1.3702 -0.3910 -4.1529 -0.1309 -0.3477 -0.1376 -0.1065 -0.1822 -1.0281 -0.3146 -0.2384
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese ; patients ; clinically ; stable ; hfpef ; exercise ; training ; peak vo2
H-1990	-0.8781014680862427	▁obes e ▁; ▁older ▁; ▁h FP EF ▁; ▁calor ic ▁restriction ▁; ▁aero bic ▁exercise ▁training ▁; ▁VO 2
D-1990	-0.8781014680862427	obese ; older ; hFPEF ; caloric restriction ; aerobic exercise training ; VO2
P-1990	-0.7363 -0.2478 -0.4892 -1.5478 -1.2915 -0.8661 -3.0148 -1.6892 -0.3066 -1.4009 -0.7117 -1.0106 -0.2378 -0.0745 -1.0928 -0.5869 -2.1701 -0.2326 -0.9477 -0.0695 -0.3196 -0.2743
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2007	-1.179431438446045	▁economische ▁; ▁Patient ▁management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁; ▁heart ▁failure
D-2007	-1.179431438446045	economische ; Patient management Interventions ; Heart Failure ; heart failure
P-2007	-2.3002 -0.2077 -1.8680 -0.3575 -1.8251 -1.0409 -0.4543 -0.8750 -1.0350 -1.7071 -0.2817 -4.2954 -0.7566 -0.4025 -0.2847
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective ; hf ; patients ; hf with reduced ef ; ef ; hfpef ; ef
H-782	-1.050871729850769	▁ HF ▁registr y ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF ▁; EF
D-782	-1.050871729850769	HF registry ; HF ; EF ; HFpEF ;EF
P-782	-1.1764 -1.7261 -0.2207 -0.5057 -0.3616 -1.9100 -2.1141 -0.3391 -1.3254 -0.3650 -2.4429 -2.5275 -0.1407 -1.4099 -0.4384 -1.0916 -0.5235 -0.2972
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat ; n-terminal pro-brain natriuretic peptide ; hospitalized ; hf
H-1877	-0.797917366027832	▁BAT ▁; ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁ HF
D-1877	-0.797917366027832	BAT ; pro-brain natriuretic peptide ; HF
P-1877	-0.1457 -0.3902 -1.5831 -0.2048 -0.7579 -0.3273 -0.1601 -0.9390 -0.5355 -1.8102 -0.7066 -0.2647 -0.8627 -0.4189 -2.6478 -1.9079 -0.4260 -0.2739
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients ; hr variability ; mortality ; ami ; diagnosis ; chf ; lv dysfunction
H-1586	-0.8662393093109131	▁HR ▁variabil iteit ▁; ▁mortal iteit ▁; ▁ AMI ▁; ▁CHF ▁; LV ▁dys function
D-1586	-0.8662393093109131	HR variabiliteit ; mortaliteit ; AMI ; CHF ;LV dysfunction
P-1586	-1.5852 -0.1027 -2.6468 -0.2901 -0.1793 -1.5119 -0.3115 -2.4130 -1.6912 -0.3439 -0.8196 -0.4403 -1.5283 -0.1513 -0.1232 -0.3427 -0.2451
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin inhibitors ; natriuretic peptide ; atrial natriuretic peptide ; b-type natriuretic peptide
H-1462	-1.1033111810684204	▁ne pri ly sin ▁inhibi tors ▁; ▁na tri ure tic ▁pe pti de ▁; ▁at rial ▁; ▁na tri ure tic ▁pe pti de ▁; ▁na tri ure tic ▁pe pti de
D-1462	-1.1033111810684204	neprilysin inhibitors ; natriuretic peptide ; atrial ; natriuretic peptide ; natriuretic peptide
P-1462	-0.9197 -0.7062 -1.5825 -0.9823 -0.1136 -0.3193 -0.2818 -0.0972 -2.4348 -1.4890 -2.5452 -2.3078 -0.6658 -0.8426 -0.8908 -0.7772 -0.3519 -1.4981 -0.0497 -2.5174 -2.0290 -2.4807 -1.7460 -0.3674 -0.8696 -0.3731 -0.8702 -1.8097 -1.4042 -2.0559 -1.4413 -0.3764 -0.8242 -0.3279 -0.2673
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative ; patients ; preoperative ; hypoalbuminemia ; albumin
H-533	-0.7470757961273193	▁hypo album in emia ▁; ▁album in ▁concentration
D-533	-0.7470757961273193	hypoalbuminemia ; albumin concentration
P-533	-1.4985 -0.5331 -0.3680 -1.5138 -0.4773 -1.3302 -0.4031 -0.6081 -0.4435 -0.2952
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute rv failure ; pulmonary embolism ; mortality ; diagnostic
H-1097	-0.893261194229126	▁a cute ▁ rv ▁; ▁pulmonar y ▁e mbol ism ▁; ▁mortal iteit
D-1097	-0.893261194229126	acute rv ; pulmonary embolism ; mortaliteit
P-1097	-2.1136 -0.3096 -0.2967 -1.1991 -0.8265 -0.1447 -1.0892 -0.4907 -0.2654 -2.9761 -0.4206 -0.3646 -2.2043 -0.4070 -0.2907
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left bundle branch block ; remodeling ; dyssynchronous heart failure ; hf ; heart
H-1147	-0.7520691752433777	▁electric al ▁activa tion ▁; ▁dys syn chron ous ▁heart ▁failure ▁; HF ▁; ▁electro me chan ical ▁behavior ▁; ▁heart
D-1147	-0.7520691752433777	electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
P-1147	-1.8911 -0.3698 -0.0395 -1.2885 -0.3043 -0.0575 -0.0443 -0.0314 -2.3208 -1.6582 -0.4958 -0.2819 -1.5031 -0.2586 -0.0532 -0.0665 -0.0199 -0.9255 -2.1729 -0.2302 -2.6891 -0.3275 -0.2680
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients ; heart failure ; heart ; cardiologists ; cardiovascular ; surgeons ; medical ; patient
H-1822	-1.020134449005127	▁heart ▁failure ▁; heart ▁team ▁; ▁cardio logist s ▁; ▁cardiovascular ▁surge ons ▁; ▁medical ▁staff
D-1822	-1.020134449005127	heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
P-1822	-5.5356 -0.7100 -0.3729 -1.7896 -0.4882 -0.3312 -0.3730 -1.0515 -0.5848 -0.3929 -0.4847 -0.3128 -2.5334 -0.3943 -1.3345 -0.9769 -0.4143 -0.2820
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex sensitivity ; heart rate variability ; hrv ; renal dnx
H-1376	-0.688464343547821	▁Baro re flex ▁ sensitiv iteit ▁; ▁time ▁domain ▁; ▁heart ▁rate ▁variabil iteit ▁; ▁h v ▁; ▁CHF - in v ▁; ▁sham - in v ▁; ▁sham ▁levels ▁; ▁renal ▁DN x
D-1376	-0.688464343547821	Baroreflex sensitiviteit ; time domain ; heart rate variabiliteit ; hv ; CHF-inv ; sham-inv ; sham levels ; renal DNx
P-1376	-0.2415 -0.5899 -0.2773 -0.5299 -0.0266 -2.4605 -0.3416 -0.7730 -0.1387 -0.8515 -1.2200 -0.6363 -0.1114 -3.5816 -0.3213 -2.0734 -1.7675 -0.3889 -2.3389 -0.1704 -0.2573 -0.3529 -0.5695 -0.0908 -0.1734 -0.4043 -0.4426 -0.2792 -0.3297 -1.1595 -0.3431 -0.0846 -0.7397 -0.1561 -0.3356 -0.2265
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
H-1542	-0.39225471019744873	▁bis phos phon ates ▁; ▁ale ndr onate ▁; ▁et id rona te ▁; ▁significant ▁; ▁heart ▁failure ▁; ▁re fill ▁compliance
D-1542	-0.39225471019744873	bisphosphonates ; alendronate ; etidronate ; significant ; heart failure ; refill compliance
P-1542	-0.1169 -0.1185 -0.2266 -1.1467 -0.3676 -0.4007 -0.1225 -0.0724 -0.2976 -0.0254 -0.0733 -0.0888 -0.0526 -0.3230 -1.2978 -0.4920 -0.9831 -0.4535 -0.3118 -0.1032 -0.1752 -0.3225 -1.5918 -0.2507
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse ; hospitalization ; physician ; discharge ; patients ; hospitalized ; heart failure
H-206	-0.9112813472747803	▁cognitive ▁im pair ment ▁; ▁hospital ization ▁; ▁dis charge ▁; ▁heart ▁failure
D-206	-0.9112813472747803	cognitive impairment ; hospitalization ; discharge ; heart failure
P-206	-0.9409 -0.5961 -0.2277 -1.5884 -0.3404 -1.1641 -0.9601 -0.3152 -1.8593 -0.2549 -0.3789 -4.0087 -0.4279 -0.3424 -0.2643
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action ; randomized ; patients ; hf ; ejection fraction ; exercise ; training
H-1632	-0.7437815070152283	▁ HF - ac TION ▁; HF ▁; ▁e je ction ▁ fraction ▁; ▁exercise ▁training
D-1632	-0.7437815070152283	HF-acTION ;HF ; ejection fraction ; exercise training
P-1632	-1.2267 -0.9174 -0.1237 -1.0395 -3.4294 -0.3559 -2.4266 -0.3071 -0.5943 -0.4094 -0.0870 -0.3367 -0.0441 -0.5081 -0.2799 -0.6488 -0.3688 -0.2845
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine ; patients ; dilated cardiomyopathy ; dcm ; heart failure
H-1258	-0.6766664981842041	▁Chinese ▁herbal ▁medicine ▁; CH m ▁; ▁dil ated ▁cardio my o pathy ▁; ▁d c m ▁; ▁heart ▁failure
D-1258	-0.6766664981842041	Chinese herbal medicine ;CHm ; dilated cardiomyopathy ; dcm ; heart failure
P-1258	-1.3365 -0.0771 -0.2668 -0.2716 -4.0741 -0.8042 -0.3016 -0.9448 -0.4337 -0.0607 -0.6062 -0.2492 -0.0541 -0.3078 -0.4137 -0.9931 -1.3781 -0.2554 -1.0404 -0.3245 -0.4089 -0.2842
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin ; chemotherapy ; elevated ; cardiotoxicity
H-937	-0.8534753322601318	▁se rum ▁resist in ▁; ▁women ▁; ▁an thra cycli ne - conta ining ▁che mo therapy ▁; ▁cardio toxic iteit
D-937	-0.8534753322601318	serum resistin ; women ; anthracycline-containing chemotherapy ; cardiotoxiciteit
P-937	-0.3909 -1.2024 -0.4991 -0.8507 -0.7954 -2.8888 -0.3288 -0.8317 -0.3813 -0.8180 -1.9811 -0.4335 -0.3903 -2.1929 -0.2993 -0.7780 -0.2986 -0.3450 -0.0597 -0.5053 -2.6873 -0.4092 -0.2627
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients ; sst2 ; titrated ; cardiovascular event
H-405	-0.8080253005027771	▁s st 2 ▁; ▁BB ▁; ▁cardiovascular ▁event ▁rate
D-405	-0.8080253005027771	sst2 ; BB ; cardiovascular event rate
P-405	-0.0778 -2.4233 -0.2638 -0.3440 -2.4690 -0.3695 -0.3347 -0.8071 -1.0633 -0.4689 -0.2667
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad ; q66p ; cardiomyopathy
H-1677	-0.7133435010910034	▁Rad ▁Q 66 p ▁; ▁cardio my o pathy ▁; ▁l - type
D-1677	-0.7133435010910034	Rad Q66p ; cardiomyopathy ; l-type
P-1677	-1.2531 -2.9720 -0.9980 -0.2688 -0.2721 -0.1627 -0.8409 -0.1978 -0.0755 -1.0239 -0.6131 -0.1567 -0.0355 -1.5298 -0.3003
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular ; wall stiffness
H-1148	-0.7068597078323364	▁vent ri cular ▁structure ▁; ▁ge ometr y ▁; ▁fiber ▁; she et ▁ orientation
D-1148	-0.7068597078323364	ventricular structure ; geometry ; fiber ;sheet orientation
P-1148	-0.1663 -1.5613 -0.3971 -1.9844 -0.2906 -0.1798 -0.0360 -1.0956 -0.3465 -0.0597 -0.4804 -0.3158 -0.0929 -0.6528 -0.1159 -3.8930 -0.3485
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-1.5779714584350586	▁ nc w t - to - SD r ▁ratio ▁; ▁ HF VT ▁; ▁h w t ▁; ▁h Nor m
D-1441	-1.5779714584350586	ncwt-to-SDr ratio ; HFVT ; hwt ; hNorm
P-1441	-1.4198 -4.0423 -0.3357 -0.4096 -0.8270 -0.3966 -0.1564 -1.3167 -3.3746 -1.4806 -0.3344 -1.9755 -1.5073 -2.9765 -0.4165 -2.1075 -5.4452 -0.2835 -0.3513 -2.1094 -4.6001 -0.4157 -1.2768 -0.3123
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration ; renin-angiotensin system blocker ; beta-blocker ; therapy ; patients ; hospitalized ; heart failure ; preserved left ventricular ejection fractions
H-174	-0.567054033279419	▁re nin - angi oten sin ▁system ▁block er ▁; ▁beta - block er ▁ therapy ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction s
D-174	-0.567054033279419	renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection fractions
P-174	-0.2358 -1.7593 -0.1771 -0.0502 -1.3404 -1.7958 -0.2535 -0.5270 -0.3956 -0.3895 -0.2131 -0.0827 -0.2916 -0.1867 -0.3948 -0.0431 -0.3572 -1.4190 -0.5015 -0.3508 -1.2797 -0.3270 -2.0898 -0.8051 -0.4661 -0.3537 -0.3344 -0.4069 -0.0117 -0.4980 -0.4948 -0.3139
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional electrical stimulation ; peripheral muscles ; endothelial function ; clinical ; heart failure ; patients ; preserved left ventricular ejection fraction
H-1326	-0.6367859840393066	▁function al ▁electric al ▁stimul ation ▁; ▁per i pher al ▁muscle s ▁; ▁en dot heli al ▁function ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-1326	-0.6367859840393066	functional electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; left ventricular ejection fraction
P-1326	-3.1002 -0.1493 -0.4387 -0.1334 -0.1530 -1.5442 -0.3132 -0.3724 -0.3173 -0.3645 -0.2445 -1.4399 -0.2536 -0.3342 -0.3535 -0.6228 -0.2946 -0.0244 -0.3443 -0.2738 -2.8446 -0.3864 -0.2033 -1.8607 -0.2860 -2.0765 -0.7197 -0.4457 -0.3561 -0.3519 -0.2848 -0.0129 -0.4764 -0.2738
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline ; cardiac transplant ; ecct
H-716	-0.8461433053016663	▁cardiac ▁transplant ▁; ▁ec t
D-716	-0.8461433053016663	cardiac transplant ; ect
P-716	-0.4051 -0.2489 -1.6705 -0.4292 -2.4529 -0.4070 -0.3094
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic dysfunction ; pathophysiology ; hfpef ; cardiovascular function
H-1302	-0.5777960419654846	▁dia sto lic ▁dys function ▁; ▁pat ho phy si ology ▁; ▁ HF p EF ▁; ▁non - dia sto lic ▁ab normal ities ▁; ▁cardiovascular ▁function
D-1302	-0.5777960419654846	diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular function
P-1302	-0.0685 -0.3593 -0.2077 -0.1559 -0.2856 -0.2841 -0.3086 -0.1474 -0.3821 -1.9204 -0.2744 -0.3293 -2.2139 -1.2438 -0.0796 -1.1797 -0.3338 -0.3515 -0.2407 -0.3868 -0.4921 -0.2239 -0.0935 -0.6472 -3.6420 -0.3118 -0.2071 -0.3640 -0.3497 -0.2495
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd ; dyssynchronous hf ; remodeling ; insignificantly
H-1154	-0.6920956969261169	▁EM d ▁; ▁dys syn chron ous ▁ HF
D-1154	-0.6920956969261169	EMd ; dyssynchronous HF
P-1154	-1.5368 -0.4624 -0.2347 -0.0552 -0.0640 -0.0362 -2.8227 -0.3850 -1.2827 -0.4302 -0.3032
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients ; hypertension ; compensated hfpef ; dash ; sodium
H-919	-0.8224425315856934	▁hyper tension ▁; ▁compensa ted ▁H FP EF ▁; ▁DAS h ▁; ▁s RD ▁; ▁so dium ▁; ▁kcal
D-919	-0.8224425315856934	hypertension ; compensated HFPEF ; DASh ; sRD ; sodium ; kcal
P-919	-1.0002 -0.2502 -0.3142 -0.6142 -0.7209 -1.8034 -1.7239 -1.4604 -0.3338 -1.1689 -0.2382 -0.3227 -2.3180 -2.3081 -0.4045 -0.2239 -0.1018 -0.4293 -0.4231 -0.8518 -0.2598
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced cardiotoxicity ; resistin ; retn
H-933	-0.6624665856361389	▁do xor ubi cin - indu ced ▁cardio toxic iteit ▁; ▁Hum - re t n ▁; ▁litt er mate ▁; ▁resist in ▁; ▁re t n
D-933	-0.6624665856361389	doxorubicin-induced cardiotoxiciteit ; Hum-retn ; littermate ; resistin ; retn
P-933	-0.1579 -0.2166 -0.0754 -1.1036 -0.3516 -0.3668 -0.8122 -0.2043 -0.9045 -2.4225 -0.3446 -0.4684 -0.1113 -2.4954 -0.5933 -0.1289 -0.5168 -0.1827 -0.0833 -0.4055 -0.2731 -1.6895 -0.3121 -0.1802 -2.7677 -1.3031 -0.1533 -0.3486 -0.2384
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling ; arrhythmia ; ami ; hr variability ; arrhythmia
H-1590	-0.956537127494812	▁ar rhythm ia ▁substrat e ▁; AMI ▁; ▁HR ▁; ▁fatal ▁; ▁ar rhythm ia ▁events
D-1590	-0.956537127494812	arrhythmia substrate ;AMI ; HR ; fatal ; arrhythmia events
P-1590	-0.3630 -0.7615 -1.9944 -0.0440 -0.1280 -0.2907 -2.5224 -0.3585 -1.7535 -0.3821 -2.4450 -2.2841 -0.2984 -1.0060 -1.5846 -0.3664 -0.3798 -0.2553
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients ; heart failure ; hf ; evidence ; outcomes ; hf
H-685	-1.1396386623382568	▁heart ▁failure ▁; HF ▁; ▁ HF
D-685	-1.1396386623382568	heart failure ;HF ; HF
P-685	-4.7829 -0.5738 -0.3437 -0.8792 -0.3636 -1.6825 -0.9748 -0.3472 -0.3091
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ; ami ; pna ; mortality
H-1700	-1.2874442338943481	HF ▁; AMI ▁; ▁p NA ▁; ▁mortal iteit
D-1700	-1.2874442338943481	HF ;AMI ; pNA ; mortaliteit
P-1700	-2.1446 -0.2981 -3.3983 -0.3203 -1.0510 -3.0432 -0.7217 -0.2130 -2.3159 -0.3709 -0.2849
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension ; diabetes mellitus ; grade ; systolic ; diastolic murmurs ; apex
H-347	-0.25374090671539307	▁hyper tension ▁; ▁h g ▁; ▁diabetes ▁mell itus ▁; ▁sy sto lic ▁; ▁dia sto lic ▁mur mur s
D-347	-0.25374090671539307	hypertension ; hg ; diabetes mellitus ; systolic ; diastolic murmurs
P-347	-0.4529 -0.1905 -0.2444 -0.4002 -0.3585 -0.2807 -0.1377 -0.0084 -0.1131 -0.2852 -0.0998 -0.1183 -0.1397 -0.2767 -0.0322 -0.0979 -0.1366 -0.4055 -0.1582 -0.9533 -0.4309 -0.2616
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse ; pasp ; downward ; hfref ; hfpef ; prognostic ; resolution
H-500	-1.0393991470336914	▁ pac se ▁; ▁PAS p ▁; ▁non sur viv ors ▁; ▁h Fr EF ▁; ▁ HF p EF
D-500	-1.0393991470336914	pacse ; PASp ; nonsurvivors ; hFrEF ; HFpEF
P-500	-2.3489 -3.3611 -0.8142 -0.4278 -1.0270 -0.6541 -0.4561 -0.3800 -0.3914 -0.3072 -1.6405 -0.3517 -1.1486 -2.1530 -2.1136 -0.3352 -0.5885 -1.6466 -0.1287 -1.7126 -0.6107 -0.2693
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic ; proteins ; histone acetyltransferases ; epigenetic ; histone deacetylases ; cardiac ; disease
H-1041	-0.5234623551368713	▁epi gene tic ▁; writer ▁; ▁protein s ▁; hi stone ▁a ce tyl transfer as es ▁; ▁epi gene tic ▁; eras ers ▁; hi stone ▁de ace ty las es ▁; ▁cardiac
D-1041	-0.5234623551368713	epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac
P-1041	-0.3349 -1.1149 -1.4988 -0.6444 -1.3775 -0.5167 -0.8385 -0.6155 -0.3489 -0.2640 -0.1690 -0.1315 -0.7953 -0.8947 -0.0216 -0.1295 -0.3158 -0.3787 -0.1160 -0.7196 -2.2494 -0.8181 -0.0714 -0.2993 -0.4033 -0.1110 -0.3185 -0.1249 -0.3130 -0.6307 -0.0213 -0.2000 -0.4108 -0.0627 -1.2911 -0.2933
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated ; nt-probnp ; admission ; all-cause mortality ; patients ; acute hf ; admission
H-270	-0.7754217982292175	▁NT - pro b NP ▁; ▁mortal iteit ▁; ▁a cute ▁ HF
D-270	-0.7754217982292175	NT-probNP ; mortaliteit ; acute HF
P-270	-0.6001 -0.0796 -0.1502 -1.2655 -1.7327 -0.3978 -0.1645 -2.3349 -0.3065 -2.5099 -0.1514 -0.3752 -0.7976 -0.4154 -0.3501
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic cell transplantation ; hct ; congestive heart failure ; chf ; anthracyclines
H-1449	-1.2032818794250488	▁ha e mato po ie tic ▁cell ▁transplant ation ▁; ▁h t ▁; ▁con ges tive ▁heart ▁failure ▁; ▁chw ▁; ▁h t ▁; ▁exposure ▁; ▁an thra cycli nes
D-1449	-1.2032818794250488	haematopoietic cell transplantation ; ht ; congestive heart failure ; chw ; ht ; exposure ; anthracyclines
P-1449	-0.0865 -0.5644 -0.2691 -0.2546 -1.9345 -1.8309 -0.8059 -0.0674 -1.3722 -0.3266 -1.3622 -3.1386 -0.3861 -0.9297 -1.2303 -3.8167 -1.0645 -0.4872 -0.3446 -4.5175 -0.6195 -2.9704 -1.8834 -0.3363 -2.1031 -0.4264 -0.5064 -0.1127 -0.2556 -3.6641 -0.4802 -0.3571
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective ; nicorandil ; hemodynamic ; mitochondrial dysfunction ; administration ; doxorubicin
H-956	-0.4640384316444397	▁cardio protec tive ▁effect ▁; ▁nic oran dil ▁; ▁hem o dynamic ▁altera tions ▁; ▁mito cho ndri al ▁dys function ▁; ▁do xor ubi cin
D-956	-0.4640384316444397	cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; doxorubicin
P-956	-0.3402 -1.2115 -1.9694 -0.1788 -0.2540 -0.2359 -0.1936 -1.1295 -0.2353 -0.7848 -0.4015 -0.0588 -0.2768 -1.4752 -0.2540 -0.0382 -0.8028 -0.2668 -0.2073 -0.0191 -0.1251 -0.2773 -0.1571 -0.0853 -0.1401 -1.1978 -0.4253 -0.2515
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in vivo ; mir-25 ; antagomir ; cardiac dysfunction ; murine ; myocardium ; heart failure
H-643	-0.6503092646598816	▁in ▁vivo ▁inhibi tion ▁; ▁mi r -25 ▁; ▁anta go mir ▁; ▁cardiac ▁dys function ▁; ▁mur ine ▁my o car dium ▁; ▁heart ▁failure ▁; ▁hand 2- dependent
D-643	-0.6503092646598816	in vivo inhibition ; mir-25 ; antagomir ; cardiac dysfunction ; murine myocardium ; heart failure ; hand2-dependent
P-643	-1.0107 -0.1513 -0.2523 -2.7927 -0.3087 -0.2588 -1.8099 -0.2038 -0.3735 -0.2671 -0.0584 -0.2514 -0.3317 -0.7308 -0.0262 -0.0909 -0.3802 -1.2593 -3.3381 -1.1082 -0.1469 -0.0523 -0.3723 -0.3738 -1.2077 -0.2561 -1.1475 -0.5932 -0.0864 -0.0603 -1.2129 -0.2965
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol ; nonselective β-blocker ; selective β-blocker ; metoprolol ; thromboembolic events ; heart failure
H-1111	-0.5225226283073425	▁car vedi lol ▁; ▁β - block er ▁; ▁β - block er ▁; ▁met o pro lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure
D-1111	-0.5225226283073425	carvedilol ; β-blocker ; β-blocker ; metoprolol ; thromboembolic events ; heart failure
P-1111	-0.0633 -0.1587 -0.3879 -0.3640 -1.4555 -0.2368 -0.8831 -0.5287 -0.4005 -0.8592 -0.1579 -0.8938 -0.4675 -0.8449 -0.1931 -0.2090 -0.3651 -0.7659 -0.3930 -0.3437 -0.5990 -1.8768 -0.1581 -0.1604 -0.5298 -0.4035 -0.2667 -1.0417 -0.5133 -0.4100 -0.2672
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox regression models ; propensity score ; oral ; glucocorticoid ; hf ; hospitalisations ; loop diuretics
H-605	-0.6930371522903442	▁co x ▁re gression ▁models ▁; ▁pro pens ity ▁score ▁; ▁oral ▁gluco cor tico id ▁dos age ▁; ▁ HF ▁; ▁loop ▁di ure tics
D-605	-0.6930371522903442	cox regression models ; propensity score ; oral glucocorticoid dosage ; HF ; loop diuretics
P-605	-0.0439 -0.5709 -0.0613 -0.2510 -1.1763 -0.2822 -0.1256 -0.3265 -3.9317 -0.3381 -0.3133 -0.2697 -0.1351 -1.2433 -1.1008 -0.5140 -2.3963 -0.2030 -0.3356 -1.9423 -1.3727 -0.3009 -0.0187 -0.7758 -0.2689 -0.3895 -0.4412 -0.2760
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate analysis ; preoperative ; albumin ; mortality ; lvad ; implantation ; hazard ratio ; confidence interval
H-535	-0.6565598249435425	▁album in ▁; ▁mortal iteit ▁; ▁l VAD ▁implant ation ▁; haz ard ▁ratio
D-535	-0.6565598249435425	albumin ; mortaliteit ; lVAD implantation ;hazard ratio
P-535	-2.4328 -0.4965 -0.4655 -0.4370 -1.8898 -0.3883 -0.3834 -0.0956 -0.3561 -1.3261 -0.9847 -0.1950 -0.0892 -0.2123 -0.4342 -0.3185
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous hf ; electromechanical delay ; emd ; myocyte depolarization ; myofiber shortening
H-1149	-0.5769525170326233	▁dys syn chron ous ▁ HF ▁; ▁electro me chan ical ▁de lay ▁; ▁ec d ▁; ▁my o cy te ▁de po lar ization ▁; ▁my o fi ber
D-1149	-0.5769525170326233	dyssynchronous HF ; electromechanical delay ; ecd ; myocyte depolarization ; myofiber
P-1149	-0.3106 -0.0635 -0.0326 -2.1079 -1.1492 -0.8589 -0.2567 -0.0705 -0.1229 -0.0450 -1.4996 -0.2081 -0.2311 -0.2704 -4.0121 -0.4453 -0.2830 -0.9253 -0.1798 -0.2898 -0.1294 -0.3147 -0.0432 -0.1022 -1.0537 -0.3867 -1.3998 -0.1388 -0.2072 -0.4483 -0.5472 -0.3290
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta blockers ; all-cause mortality ; readmissions ; heart failure with reduced ejection fraction ; hfref ; heart rate
H-1936	-0.7319645881652832	▁Beta ▁block ers ▁; ▁mortal iteit ▁; ▁read missions ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁heart ▁rate ▁; HR
D-1936	-0.7319645881652832	Beta blockers ; mortaliteit ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
P-1936	-0.7956 -0.4939 -0.5124 -0.4732 -2.2758 -2.0397 -0.4028 -0.7880 -0.0912 -0.3421 -1.2305 -0.4276 -0.2994 -0.2551 -0.2120 -0.0563 -0.3214 -0.0232 -0.3691 -2.7087 -0.1536 -1.7864 -0.3654 -1.4064 -0.3184 -0.3488 -2.0135 -0.4840 -0.2324
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse events ; reoperation ; bleeding ; driveline ; infection ; gastrointestinal bleeding ; stroke ; rankin score
H-2003	-0.5299884080886841	▁ble ed ing ▁; ▁drive line ▁infection ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁de bilitat ing ▁stroke ▁; ▁Rank in ▁Score
D-2003	-0.5299884080886841	bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke ; Rankin Score
P-2003	-0.4642 -1.2168 -0.3460 -0.4714 -0.4020 -0.1228 -0.5398 -0.3757 -0.1337 -0.6253 -1.2178 -0.3355 -0.2034 -1.8228 -0.4325 -0.3899 -0.1641 -0.0699 -0.5184 -0.3382 -0.2772 -0.9055 -1.3802 -0.3067 -0.4351 -0.2849
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis ; patients ; hf ; hospitalization ; all-cause hospitalization ; mortality ; hf ; hospitalization ; death
H-910	-0.9214469790458679	▁dia lys is ▁; HF ▁; ▁hospital ization ▁; ▁mortal iteit ▁; ▁ HF ▁; ▁hospital ization ▁; ▁death
D-910	-0.9214469790458679	dialysis ;HF ; hospitalization ; mortaliteit ; HF ; hospitalization ; death
P-910	-0.8875 -0.1630 -0.3179 -0.6671 -1.1609 -0.8371 -1.3189 -1.1872 -0.4159 -1.1549 -2.1099 -0.4042 -1.7760 -1.0998 -1.3932 -1.4034 -1.0390 -0.3698 -0.9334 -0.3890 -0.3224
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional electrical stimulation ; fes ; exercise capacity ; quality of life ; endothelial function ; chronic heart failure ; systolic function
H-1327	-0.4602512717247009	▁function al ▁electric al ▁stimul ation ▁; ▁f es ▁; ▁exercise ▁capacity ▁; ▁emotional ▁stress ▁; ▁en dot heli al ▁function ▁; ▁heart ▁failure ▁; ▁sy sto lic ▁function
D-1327	-0.4602512717247009	functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; heart failure ; systolic function
P-1327	-1.4070 -0.1999 -0.2385 -0.0954 -0.1241 -1.3308 -0.2881 -0.6194 -0.8844 -0.2295 -0.7600 -0.2121 -0.2775 -0.6546 -0.4710 -0.2864 -0.0881 -0.2664 -0.2514 -0.0533 -0.1322 -0.3068 -3.2848 -0.3256 -0.2585 -0.1187 -0.0762 -0.1935 -0.1451 -0.4542 -0.2342
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ; ejection fraction ; cardiac index ; inotropes ; medical ; transplant
H-1997	-0.5474583506584167	▁e je ction ▁ fraction ▁; ▁cardiac ▁index ▁; ▁in o trop es ▁; ▁in ot rope - dependent ▁; ▁medical ▁; ▁transplant
D-1997	-0.5474583506584167	ejection fraction ; cardiac index ; inotropes ; inotrope-dependent ; medical ; transplant
P-1997	-0.1964 -0.4851 -0.1227 -0.4110 -0.0426 -0.4198 -0.2750 -0.0541 -0.4076 -0.1599 -0.5448 -0.0804 -0.6081 -0.3663 -1.2059 -0.7545 -0.5280 -0.3769 -0.0745 -0.3673 -1.4401 -3.8946 -0.1982 -0.4289 -0.2438
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients ; systolic heart failure ; qrs duration ; crt ; death ; hospitalization ; heart failure ; mortality
H-854	-0.994719922542572	▁sy sto lic ▁heart ▁failure ▁; ▁QR s ▁; ▁cm t ▁; ▁heart ▁failure ▁; ▁mortal iteit
D-854	-0.994719922542572	systolic heart failure ; QRs ; cmt ; heart failure ; mortaliteit
P-854	-0.1876 -0.3377 -0.2208 -1.7010 -0.7383 -0.3160 -0.3538 -1.2634 -0.3252 -3.6968 -0.4407 -0.3151 -5.0599 -0.8070 -0.3729 -0.2341 -1.9004 -0.3680 -0.2609
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density lipoprotein ; hdl ; endothelial cell ; nitric oxide
H-246	-0.7570546269416809	▁lipo prote in ▁; HD l ▁; ▁en dot heli al - protec tive ▁effects ▁; ▁en dot heli al ▁cell ▁; ▁ec ▁; ▁ni tric ▁oxid e ▁; NO
D-246	-0.7570546269416809	lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ; ec ; nitric oxide ;NO
P-246	-4.6830 -0.1891 -0.8849 -0.3344 -2.2834 -1.6322 -0.3969 -0.1254 -0.2719 -0.4167 -0.0656 -1.5607 -0.2386 -2.8562 -1.9524 -0.3416 -0.0830 -0.2893 -0.4789 -0.0642 -0.3436 -0.3286 -0.4066 -0.5445 -0.0750 -0.1660 -0.0246 -0.1617 -0.3682 -1.9301 -0.4583 -0.2703
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp ; phosphomimic ; ser77 ; ser83 ; riα ; proteins ; riα
H-1432	-0.6790381073951721	▁8- flu o - c AMP ▁ binding ▁; ▁ phos pho mi mic ▁; ▁ser 77 ▁; ▁ser 83 ▁mu tant ▁; ▁RI α ▁protein s ▁; ▁double ▁mu tant ▁; ▁w t ▁; ▁RI α
D-1432	-0.6790381073951721	8-fluo-cAMP binding ; phosphomimic ; ser77 ; ser83 mutant ; RIα proteins ; double mutant ; wt ; RIα
P-1432	-0.2933 -0.0906 -0.1577 -0.0861 -0.0417 -0.5600 -0.5863 -0.0589 -0.2552 -0.5992 -0.0819 -0.0997 -0.2318 -0.7106 -1.6749 -0.7628 -0.8611 -0.1978 -0.6005 -2.8347 -0.7208 -1.0996 -0.1926 -0.9863 -1.7709 -1.5670 -0.6860 -0.2754 -1.3445 -0.9434 -0.8012 -0.2453 -0.1539 -0.0709 -1.8331 -1.1867 -1.3032 -0.2872 -0.2298
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome ; admission ; discharge ; hospitalized ; heart failure ; hf ; nursing outcomes classification ; noc
H-1398	-1.070932149887085	▁significant ▁; ▁ad mission ▁to ▁dis charge ▁; ▁older ▁adults ▁; ▁heart ▁failure ▁; HF ▁; ▁Nur sing ▁Out com es ▁Classifica tion ▁; no c
D-1398	-1.070932149887085	significant ; admission to discharge ; older adults ; heart failure ;HF ; Nursing Outcomes Classification ;noc
P-1398	-0.0612 -1.1000 -4.7525 -0.7761 -1.2204 -0.6250 -0.1778 -0.3855 -1.6826 -0.7721 -1.2387 -1.5031 -0.3975 -0.3340 -2.2311 -0.2750 -0.8312 -0.5225 -2.9211 -0.2533 -0.2250 -0.1841 -0.6968 -0.3224 -4.4616 -1.5139 -0.2865 -0.2352
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin resistance ; type 2 diabetes ; insulin receptor substrates 1 ; irs1 ; irs2 ; cellular metabolism
H-653	-0.5865419507026672	▁in s ulin ▁resist ance ▁; ▁type ▁2 ▁diabetes ▁; ▁insulin ▁receptor ▁substrat es ▁; IR s 1 ▁; ▁i RS 2 ▁; ▁insulin - signal ing ▁; ▁cel lular ▁metabolism
D-653	-0.5865419507026672	insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling ; cellular metabolism
P-653	-1.8953 -0.4362 -0.3246 -0.2733 -0.4431 -0.2668 -0.1344 -0.5495 -0.0538 -0.2500 -0.0749 -0.0268 -0.0541 -0.3477 -0.2972 -2.5665 -0.0811 -1.7298 -0.3197 -1.2151 -1.6587 -1.8739 -0.4242 -0.3921 -0.1604 -0.0882 -0.2748 -0.6506 -1.5996 -0.1039 -0.0686 -0.4229 -0.2979
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially expressed genes ; degs ; ischemic heart failure ; healthy ; diagnosis ; heart failure
H-1608	-1.0596474409103394	▁gene s ▁; ▁de g s ▁; ▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁heart ▁failure
D-1608	-1.0596474409103394	genes ; degs ; non-ischemic ; ischemic heart failure ; heart failure
P-1608	-3.3484 -0.8756 -0.2386 -0.2738 -4.3182 -0.4970 -0.3090 -1.5454 -0.0896 -0.1292 -0.4487 -2.5957 -0.3718 -0.1127 -0.9133 -1.9995 -0.6911 -0.5670 -2.6462 -0.6379 -0.3962 -0.3072
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort study ; saxagliptin ; sitagliptin ; antihyperglycemic agents
H-1840	-0.6912599802017212	▁h HF ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁agents
D-1840	-0.6912599802017212	hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
P-1840	-0.0245 -2.2912 -0.3181 -0.3148 -0.0374 -0.7594 -3.1608 -0.3375 -1.8084 -0.2459 -0.1086 -2.3639 -0.3118 -0.0147 -0.4556 -0.1793 -0.1609 -0.6550 -0.8020 -0.2839 -0.3173 -0.2566
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs morphology ; outcomes ; cardiac resynchronization therapy ; resynchronization-defibrillation for ambulatory heart failure trial ; raft
H-879	-0.4219837784767151	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁re syn chron ization - Def i bril lation ▁; ▁amb ulator y ▁Heart ▁Fail ure ▁tri al ▁; RAF t
D-879	-0.4219837784767151	QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; ambulatory Heart Failure trial ;RAFt
P-879	-0.3800 -0.6682 -1.0963 -0.0690 -0.2031 -0.3315 -0.1913 -0.1935 -0.1149 -0.0283 -1.1053 -1.3806 -0.0891 -0.3703 -0.1581 -0.1343 -0.1087 -1.4087 -0.3334 -0.3242 -0.2883 -0.1374 -0.2033 -0.3532 -0.1800 -0.8621 -0.4623 -0.5787 -0.3651 -0.6730 -0.1267 -0.0572 -0.3024 -1.5604 -0.2733 -0.2721 -0.2296
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart magnetic resonance imaging ; chelation ; patient ; compliance ; heart failure ; arrhythmias
H-745	-0.8016906380653381	▁heart ▁; ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
D-745	-0.8016906380653381	heart ; magnetic resonance imaging ; chelation choices ; heart failure ; arrhythmias
P-745	-3.6093 -1.9154 -0.1932 -0.4533 -0.5247 -0.4051 -0.2642 -0.5171 -0.3176 -0.1578 -0.3064 -1.6143 -0.4146 -0.2861 -3.0408 -0.5338 -0.2656 -0.0433 -0.5159 -1.5873 -0.4221 -0.2494
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds ; discharge ; patients ; heart failure ; outcomes ; driven ; readmissions
H-467	-1.0373806953430176	▁hoog - volu me ▁ED s ▁; ▁dis charge ▁; ▁heart ▁failure ▁; ▁home ▁; ▁low - volu me ▁ED ▁; ▁read missions ▁; ▁repeat ▁ED ▁visit s
D-467	-1.0373806953430176	hoog-volume EDs ; discharge ; heart failure ; home ; low-volume ED ; readmissions ; repeat ED visits
P-467	-7.4206 -0.3093 -0.2358 -0.8763 -1.1567 -0.3154 -0.3550 -1.4831 -0.3127 -0.4527 -2.2639 -0.2246 -0.4384 -4.6302 -0.4959 -2.0440 -0.1494 -0.1908 -0.4975 -0.7944 -1.4292 -2.1046 -0.1431 -0.2571 -0.5140 -0.5522 -0.7275 -0.1702 -0.3339 -0.2430
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy ; anticoagulation ; rate control ; cardiovascular ; complications ; stroke ; cardiovascular death ; acute heart failure ; patients ; atrial fibrillation
H-1643	-0.6447794437408447	▁antico ag ulation ▁; ▁rate ▁control ▁; ▁cardiovascular ▁complica tions ▁; stro ke ▁; ▁cardiovascular ▁death ▁; ▁a cute ▁heart ▁failure ▁; ▁at rial ▁fi bril lation ▁; AF
D-1643	-0.6447794437408447	anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
P-1643	-0.3346 -0.3633 -0.3315 -0.3216 -0.8004 -0.8671 -0.3405 -0.4950 -0.0469 -1.7374 -0.3239 -0.8792 -1.0740 -0.3726 -0.1400 -1.4809 -0.2708 -0.3784 -0.2249 -0.6511 -0.2570 -0.3520 -2.1684 -0.3458 -0.5323 -0.1079 -0.4609 -0.2953 -3.3553 -0.3989 -0.2804
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl ; hno ; inotropic ; lusitropic ; vasodilator ; in vivo ; camp
H-413	-0.41466328501701355	▁ni tro x yl ▁; ▁h no ▁; ▁Angeli ▁; ▁salt ▁; ▁in o tropi c ▁; ▁ lusi tropi c ▁; ▁vaso dila tor ▁effects ▁; ▁vivo ▁; ▁c AMP
D-413	-0.41466328501701355	nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; vivo ; cAMP
P-413	-0.0418 -0.0532 -0.2793 -0.1451 -0.3459 -1.0378 -1.2554 -0.3034 -0.6820 -1.0048 -0.0905 -0.3125 -0.4019 -0.5021 -0.0275 -0.4255 -0.3171 -0.3264 -0.0148 -0.0631 -0.4050 -0.3388 -0.0610 -0.0098 -0.0713 -0.6802 -0.2643 -2.7074 -0.3048 -0.1052 -0.2882 -0.5577 -0.2600
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene expression ; bax ; pacing ; bcl-2 ; mrna ; expression ; heart failure ; bcl-2 ; bax
H-168	-0.7822431921958923	▁Gene ▁expression ▁; ▁Bax ▁; ▁b cl -2 ▁m RNA ▁expression ▁; ▁heart ▁failure ▁; ▁b cl - 2/ Ba x
D-168	-0.7822431921958923	Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
P-168	-5.3963 -0.3596 -0.2011 -0.3096 -0.2713 -0.3576 -0.7430 -0.1907 -0.0435 -0.3514 -0.8481 -0.2808 -1.8716 -0.4438 -0.2898 -1.2971 -1.0687 -0.1205 -0.0469 -2.3626 -0.4044 -0.4549 -0.2783
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs ; early-outgrowth colony-forming units ; eo-cfus ; cells
H-124	-1.0620468854904175	▁c ▁pc s ▁; ▁o - c FU s ▁; ▁circula ting ▁; ▁cd 34 ▁; ▁v EG FR 2 ▁; ▁cd 133
D-124	-1.0620468854904175	c pcs ; o-cFUs ; circulating ; cd34 ; vEGFR2 ; cd133
P-124	-0.3664 -4.0394 -0.2086 -0.3577 -3.2988 -1.8762 -1.0006 -2.5105 -0.6281 -0.3531 -0.0129 -0.9445 -0.4499 -0.7596 -1.6820 -1.0185 -0.2359 -2.2835 -1.5771 -0.1451 -0.5772 -0.4688 -0.5946 -0.8927 -0.2694
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection fraction ; ef ; patients ; nyha class iiib ; symptoms ; right ventricular dysfunction
H-897	-0.7315928339958191	▁e je ction ▁ fraction ▁; EF ▁; ▁pre - PD ▁; ▁NY ha ▁class ▁III b ▁; ▁right ▁vent ri cular ▁dys function
D-897	-0.7315928339958191	ejection fraction ;EF ; pre-PD ; NYha class IIIb ; right ventricular dysfunction
P-897	-0.1029 -0.6779 -0.1544 -0.4703 -0.0606 -0.2947 -1.1949 -0.3302 -2.6296 -0.0751 -0.3353 -0.3849 -2.2907 -1.8371 -1.3879 -0.4712 -0.5439 -0.3210 -1.5855 -0.2897 -1.7464 -0.8759 -0.0560 -0.2943 -0.3342 -0.2767
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence ; clinical ; continuous-flow lvads ; heartmate ii ; hm ii ; heartware ; btt ; dt ; patients
H-309	-0.5787001848220825	▁continuo us - flow ▁l VAD s ▁; ▁he art Mate ▁i i ▁; HM ▁i i ▁; ▁Heart War e ▁; ▁b t ▁; ▁d t
D-309	-0.5787001848220825	continuous-flow lVADs ; heartMate ii ;HM ii ; HeartWare ; bt ; dt
P-309	-0.3121 -0.4780 -0.2347 -0.1460 -1.0249 -0.4463 -0.5332 -0.3453 -0.1447 -2.0432 -0.1162 -0.3282 -0.2350 -0.1850 -1.7400 -0.7311 -0.1990 -0.2293 -0.6789 -0.1835 -0.0706 -0.3610 -1.9043 -1.0281 -0.3077 -1.0900 -1.0164 -0.3691 -0.3005
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency room ; undiagnosed ; heart disease ; symptoms ; hf ; surgical palliation
H-201	-0.9328259825706482	▁un diagnos ed ▁heart ▁disease ▁; HF ▁; ▁sur g ical ▁palli ation
D-201	-0.9328259825706482	undiagnosed heart disease ;HF ; surgical palliation
P-201	-4.1077 -0.0731 -0.3450 -0.9701 -0.6593 -0.2591 -2.7105 -0.2935 -1.3493 -0.2005 -0.9221 -0.0518 -1.3989 -0.3903 -0.2612
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d ; patients ; ic ; crt-d ; ies
H-109	-0.9779582619667053	▁c RT - d ▁; ▁IE ▁; ▁IC ▁; ▁benefit ▁; ▁c RT - d ▁; ▁IE s
D-109	-0.9779582619667053	cRT-d ; IE ; IC ; benefit ; cRT-d ; IEs
P-109	-1.7205 -2.7978 -0.1994 -1.1146 -0.3632 -1.8133 -0.3163 -1.6753 -0.3528 -1.1721 -0.2693 -0.8542 -3.3631 -0.2539 -0.7835 -0.3624 -0.7997 -0.6802 -0.3876 -0.2799
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty ; biological phenotype ; physical ; activity
H-1004	-0.6764697432518005	▁fra il ty ▁; ▁bi ological ▁ph eno type ▁; ▁we ak ▁grip ▁strength ▁; ▁physical ▁exhaust ion ▁; ▁weight ▁loss
D-1004	-0.6764697432518005	frailty ; biological phenotype ; weak grip strength ; physical exhaustion ; weight loss
P-1004	-1.9367 -0.6158 -1.2004 -0.3525 -1.0566 -0.6167 -0.2653 -0.2589 -0.0090 -0.3997 -0.0219 -0.0962 -0.1314 -1.3022 -0.2980 -1.5816 -0.2679 -0.1509 -0.2919 -2.8057 -1.2975 -0.3438 -0.2582
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant ; patients ; pd ; hf ; clinical
H-896	-0.9298412799835205	▁transplant ▁; ▁PD ▁; ▁ HF ▁volume ▁management ▁; ▁p b
D-896	-0.9298412799835205	transplant ; PD ; HF volume management ; pb
P-896	-0.3053 -0.6776 -3.0416 -0.3645 -1.4642 -1.2538 -0.6454 -0.2827 -0.3419 -1.6317 -1.3816 -0.4138 -0.2838
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf ; incidence ; liver ; nodularity
H-231	-0.7893890738487244	▁ab normal ▁ liver ▁texture ▁changes ▁; ▁no du lar iteit
D-231	-0.7893890738487244	abnormal liver texture changes ; nodulariteit
P-231	-0.5147 -0.5007 -0.2726 -1.0590 -0.6256 -1.9884 -0.4428 -0.3334 -0.0269 -0.2521 -3.5162 -0.4136 -0.3161
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker ; clinical ; therapeutic
H-1478	-0.670621931552887	▁bio mark er ▁studies ▁; ▁ therapeut ic ▁potential
D-1478	-0.670621931552887	biomarker studies ; therapeutic potential
P-1478	-0.0940 -0.5247 -0.2673 -1.0760 -0.4681 -0.5368 -0.4735 -0.9162 -2.0775 -0.6321 -0.3106
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report ; patient ; right atrial myxoma ; massive embolism ; pulmonary arteries ; surgically ; right atrial ; pulmonary embolectomy
H-595	-0.6656864881515503	▁right ▁at rial ▁my xo ma ▁; ▁massive ▁e mbol ism ▁; ▁pulmonar y ▁arteri es ▁; ▁right ▁at rial ▁mass ▁remo val ▁; ▁pulmonar y ▁e mbol ecto my
D-595	-0.6656864881515503	right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
P-595	-1.8996 -1.1825 -0.4402 -1.4196 -0.1534 -0.6065 -0.3261 -1.3934 -0.1100 -0.1184 -2.6388 -0.3050 -0.0745 -1.2260 -0.0481 -0.5240 -0.3275 -1.6073 -1.4049 -0.7190 -0.0946 -0.1985 -0.3051 -0.2901 -0.0408 -1.0632 -0.2916 -0.1797 -0.2019 -1.4911 -0.3881 -0.2327
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute right heart failure ; therapy ; refractory cardiogenic shock ; heart ; extra corporeal membrane oxygenation ; ecmo ; cpr ; icu
H-1295	-0.8977524638175964	▁right ▁heart ▁failure ▁; ▁ therapy ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁heart ▁; ▁corpore al ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁c PR ▁; ICU
D-1295	-0.8977524638175964	right heart failure ; therapy refractory cardiogenic shock ; heart ; corporeal membrane oxygenation ; ecmo ; cPR ;ICU
P-1295	-4.8283 -1.9527 -2.0650 -0.2984 -1.4501 -0.0971 -0.2428 -0.0489 -0.2840 -0.0728 -0.0869 -1.3366 -0.1455 -0.3396 -2.9616 -1.1666 -0.4722 -0.5895 -0.1352 -0.1154 -0.2749 -1.2266 -0.3583 -0.2971 -3.0363 -0.3684 -0.4321 -3.0001 -0.3239 -0.1094 -0.3940 -0.2179
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac vegf expression ; endothelial no synthase activation ; hearts
H-455	-0.7738072276115417	▁cardiac ▁; ▁VE GF ▁expression ▁; ▁Akt ▁; ▁en dot heli al ▁NO ▁synth ase ▁activa tion ▁; ▁heart s
D-455	-0.7738072276115417	cardiac ; VEGF expression ; Akt ; endothelial NO synthase activation ; hearts
P-455	-1.6634 -1.2675 -1.2962 -0.6347 -0.0907 -0.3028 -0.1148 -0.2976 -0.2215 -0.3682 -0.3539 -0.0456 -1.2517 -0.1272 -2.4446 -0.0065 -2.0859 -0.3438 -2.9705 -0.4096 -0.4376 -0.2894
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart failure ; left ventricular systolic dysfunction ; post hoc analysis
H-402	-0.7424167394638062	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁sy sto lic ▁dys function ▁; ▁BB
D-402	-0.7424167394638062	heart failure ; left ventricular systolic dysfunction ; BB
P-402	-2.4236 -0.4213 -0.2603 -1.3358 -0.5459 -3.1215 -0.5028 -0.1176 -0.1717 -0.4470 -0.0259 -0.3056 -0.3502 -1.2370 -0.3763 -0.2363
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic ; invasively
H-920	-0.758141815662384	▁post - DAS h ▁; ▁s RD ▁; ▁bra chi al ▁; ▁central ▁blood ▁pressure ▁; ▁radi al ▁arterial ▁ton ometr y ▁; ▁cardiovascular ▁function ▁; ▁e cho car dio graphic
D-920	-0.758141815662384	post-DASh ; sRD ; brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic
P-920	-2.0905 -0.1058 -0.0488 -0.3041 -0.3460 -1.5598 -1.9285 -0.5450 -0.1567 -0.4077 -0.1334 -0.5269 -1.7245 -1.3198 -1.0420 -0.3929 -0.6535 -0.1408 -0.1741 -1.2850 -0.1449 -1.4122 -0.3894 -0.4958 -0.6529 -0.3424 -0.5341 -0.1985 -0.0998 -0.7998 -1.3105 -3.4390 -0.3135
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac ; insulin-resistance ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose
H-1784	-0.3825925588607788	▁cardiac ▁; ▁insulin - re si stance ▁; ▁a ac ▁; ▁insulin - stimul ated ▁rates ▁; ▁gly col ysis ▁; ▁gluco se ▁oxid ation ▁; ▁plasma ▁membran e ▁trans location ▁; ▁gluco se ▁transporter
D-1784	-0.3825925588607788	cardiac ; insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
P-1784	-0.2441 -0.7078 -0.1156 -0.1195 -0.2230 -1.4506 -0.0963 -0.3059 -1.0359 -2.1841 -0.2753 -1.3226 -0.1360 -0.0319 -0.6444 -0.4770 -0.2658 -0.0214 -0.1534 -0.4093 -0.2612 -0.2098 -0.2417 -0.0603 -0.9672 -0.3155 -0.0695 -0.0369 -0.0477 -0.0252 -0.3680 -0.2478 -0.0990 -0.1585 -0.2708 -0.3278 -0.2289
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene expression profile ; gse9128 ; gene expression omnibus ; non-ischemic heart failure ; ischemic
H-1609	-0.4737373888492584	▁Gene ▁expression ▁profile ▁; ▁g se 91 28 ▁; ▁Gene ▁Express ion ▁Omni bus ▁; ▁non - ische mic ▁heart ▁failure ▁; ▁ ische mic ▁sample s
D-1609	-0.4737373888492584	Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic samples
P-1609	-1.0167 -0.3493 -0.1470 -0.4624 -0.2291 -1.5392 -0.3117 -0.8383 -0.2147 -0.3383 -0.1030 -0.0104 -0.0756 -0.3865 -0.2839 -1.1777 -0.0834 -0.0716 -0.6704 -1.3723 -0.3679 -1.3477 -0.3782 -0.0438 -0.5980 -0.4198 -0.2367 -0.3969 -0.2679
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced pasp ; right ventricular contractile reserve ; patients ; exercise-induced pasp
H-824	-0.856749951839447	▁pas p ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pas p
D-824	-0.856749951839447	pasp ; right ventricular contractile reserve ; pasp
P-824	-2.1048 -0.8906 -0.3083 -2.0619 -0.2803 -1.8539 -0.6162 -0.0421 -0.4955 -0.0611 -0.3239 -2.4648 -0.7814 -0.3190 -0.2476
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene expression ; cardiomyocytes ; jq1 ; drug ; genes
H-1046	-0.5705283880233765	▁Gene ▁expression ▁profil ing ▁; ▁cardio my o cy tes ▁; ▁j q 1 ▁; ▁drug ▁; ▁ phen yle ph rine - indu ced ▁gene s
D-1046	-0.5705283880233765	Gene expression profiling ; cardiomyocytes ; jq1 ; drug ; phenylephrine-induced genes
P-1046	-1.3068 -0.5348 -0.1053 -0.1273 -0.1851 -0.3709 -0.9927 -0.3178 -0.3209 -0.2216 -0.2982 -0.4996 -2.6632 -2.3681 -0.2357 -1.0666 -0.3366 -0.1366 -0.4552 -1.0241 -0.3476 -0.2655 -0.2135 -0.0622 -0.4238 -0.7693 -0.3697 -0.3030 -0.2236
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial ; exercise ; outcomes ; heart failure ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-1924	-1.011400818824768	▁Psycho social ▁Factor s ▁; ▁Exerci se ▁ad her ence ▁; ▁Heart ▁Fail ure ▁; ▁Patient s ▁; ▁Heart ▁Fail ure ▁; ▁Exerci se ▁Training ▁; HF - ac tion
D-1924	-1.011400818824768	Psychosocial Factors ; Exercise adherence ; Heart Failure ; Patients ; Heart Failure ; Exercise Training ;HF-action
P-1924	-1.3329 -1.6079 -1.3145 -0.3688 -0.2701 -0.9190 -0.2595 -3.0730 -2.0374 -1.7043 -0.3190 -1.2083 -0.2968 -1.4012 -1.0515 -2.1703 -0.3628 -0.3410 -0.7079 -0.2662 -2.0230 -0.2280 -0.5854 -0.2585 -0.7932 -0.2271 -2.8848 -0.0964 -0.8517 -2.7850 -0.3843 -0.2350
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 ; functional capacity ; outcomes ; ambulatory ; patients ; hf
H-706	-0.6451355218887329	▁ST 2 ▁; ▁functional ▁capacity ▁; ▁ambula tory ▁patients ▁; ▁ HF
D-706	-0.6451355218887329	ST2 ; functional capacity ; ambulatory patients ; HF
P-706	-1.4506 -0.1750 -0.3050 -0.3624 -0.5039 -0.3004 -0.1294 -0.9933 -0.9130 -0.2768 -1.9457 -1.0217 -0.3711 -0.2836
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients ; baseline ; ef ; ef ; core
H-753	-0.7971500754356384	▁EF ▁; ▁EF
D-753	-0.7971500754356384	EF ; EF
P-753	-0.9678 -0.4802 -0.8472 -1.3800 -0.3105
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular diseases ; heart failure ; hf ; incidence ; hf
H-285	-0.7752361297607422	▁cardiovascular ▁disease s ▁; ▁heart ▁failure ▁; HF ▁; ▁ HF
D-285	-0.7752361297607422	cardiovascular diseases ; heart failure ;HF ; HF
P-285	-0.7769 -1.6999 -0.3132 -0.2710 -1.2036 -0.4338 -0.2182 -1.1047 -0.2793 -2.0159 -1.1059 -0.4045 -0.2511
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef ; bnp ; bnp ; inhospital ; mortality
H-197	-1.4250074625015259	▁b NP ▁; ▁significant ▁; ▁b NP ▁; ▁in hospital ▁mortal iteit
D-197	-1.4250074625015259	bNP ; significant ; bNP ; inhospital mortaliteit
P-197	-3.7248 -3.3587 -0.4228 -2.1449 -0.9070 -2.3582 -2.8559 -0.3050 -0.2621 -0.3486 -0.1497 -2.4780 -0.3624 -0.2718
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality of life ; all-cause mortality ; mortality
H-561	-1.2332452535629272	▁mortal iteit ▁; ▁mortal iteit
D-561	-1.2332452535629272	mortaliteit ; mortaliteit
P-561	-1.6334 -2.4761 -0.5406 -0.2931 -2.9211 -0.4856 -0.2828
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash ; mortality ; hf ; nonsignificant
H-693	-0.7214023470878601	▁DAS h ▁; ▁die t ▁score s ▁; ▁mortal iteit ▁; ▁ HF ▁; ▁Mediterrane an ▁die t ▁score s
D-693	-0.7214023470878601	DASh ; diet scores ; mortaliteit ; HF ; Mediterranean diet scores
P-693	-0.2795 -0.2923 -0.3562 -2.3291 -0.3581 -0.2173 -0.2077 -0.2983 -0.2366 -1.6305 -0.2711 -2.9418 -1.0633 -0.2644 -0.6288 -1.5540 -1.6869 -0.3999 -0.1244 -0.1999 -0.3048 -0.2261
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal muscle ; lean mass ; z-score
H-1499	-0.7066543698310852	kelet al ▁muscle ▁mass ▁; ▁appen di cular ▁lean ▁mass ▁index ▁; ▁z - s core
D-1499	-0.7066543698310852	keletal muscle mass ; appendicular lean mass index ; z-score
P-1499	-4.1568 -0.6882 -1.6965 -0.3326 -0.3718 -1.7883 -0.3861 -0.3648 -0.4806 -0.2322 -0.0722 -0.4636 -0.1090 -0.2636 -0.3172 -0.3018 -0.3916 -0.3029
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka ; polymorphism ; rs10927887 ; p.arg83gly ; heart failure ; estimated glomerular filtration rate ; renastur
H-1801	-0.9433098435401917	▁CL cn ka ▁poly morph ism ▁; ▁heart ▁failure ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁RE NAS tur ▁co hor t
D-1801	-0.9433098435401917	CLcnka polymorphism ; heart failure ; glomerular filtration rate ; RENAStur cohort
P-1801	-2.6752 -1.4283 -2.0675 -0.2589 -0.0557 -3.6285 -0.2941 -2.1018 -0.7814 -0.3078 -0.2960 -0.3353 -0.1203 -0.0502 -1.4978 -0.7586 -0.3274 -1.5823 -0.7530 -0.7233 -0.9287 -1.8257 -0.1128 -0.3992 -0.2731
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-1.0997923612594604	▁in tub ation
D-220	-1.0997923612594604	intubation
P-220	-0.2856 -0.1645 -3.0009 -1.7190 -0.3290
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients ; chronic hf ; prevalence ; exercise ; hf ; hospitalization ; mortality ; exercise ; training
H-1641	-0.6955078840255737	▁black ▁race ▁; ▁ HF ▁; ▁modifi able ▁risk ▁factors ▁; ▁exercise ▁performance ▁; ▁ HF ▁; ▁mortal iteit ▁; ▁exercise ▁training
D-1641	-0.6955078840255737	black race ; HF ; modifiable risk factors ; exercise performance ; HF ; mortaliteit ; exercise training
P-1641	-0.7970 -0.3440 -0.2674 -2.0834 -0.6785 -0.2529 -1.6911 -0.7490 -0.4120 -0.2641 -0.2602 -0.9053 -0.1451 -0.2565 -1.1145 -1.1562 -0.3697 -0.6120 -2.2502 -0.3006 -0.6203 -0.5616 -0.3382 -0.2624
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
H-97	-0.5907283425331116	▁heart s ▁; ▁nu cle olin ▁; ▁cha mber ▁pattern ing ▁; ▁functional ▁; ▁cardiac ▁loop ing ▁; ▁my o cy te ▁differenti ation
D-97	-0.5907283425331116	hearts ; nucleolin ; chamber patterning ; functional ; cardiac looping ; myocyte differentiation
P-97	-3.9999 -0.3782 -0.2964 -2.3691 -0.0233 -0.2348 -0.3115 -0.0276 -0.0264 -0.3190 -0.6936 -0.2959 -1.5737 -0.9117 -0.2496 -0.0180 -0.2206 -0.3194 -1.2384 -0.1020 -0.0888 -0.0645 -0.1232 -0.8366 -0.3792 -0.2576
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean mass ; adverse outcome ; adipose tissue ; cardioprotective ; hf
H-1169	-0.7170494198799133	▁fat ▁; ▁lean ▁mass ▁; ▁fat ▁loss ▁; ▁enhance d ▁cata bol ism ▁; ▁adi pose ▁tissu e ▁; ▁cardio protec tive ▁; HF
D-1169	-0.7170494198799133	fat ; lean mass ; fat loss ; enhanced catabolism ; adipose tissue ; cardioprotective ;HF
P-1169	-4.1665 -0.2630 -0.4425 -0.1898 -0.3110 -1.2385 -1.1061 -0.2549 -1.6232 -0.2522 -0.0820 -0.4065 -1.4985 -0.3534 -0.0894 -0.0756 -0.0719 -0.1698 -0.2585 -0.1441 -0.6370 -1.4454 -0.2789 -2.7560 -0.2874 -0.2412
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients ; drugs ; heart failure ; biomedical ; nonprescribing ; patients
H-1126	-0.5732458233833313	▁drugs ▁; ▁heart ▁failure ▁; ▁chart ▁review ▁; ▁bio medic al ▁reasons ▁; ▁non pre scribi ng
D-1126	-0.5732458233833313	drugs ; heart failure ; chart review ; biomedical reasons ; nonprescribing
P-1126	-1.4255 -0.5237 -1.3155 -0.3622 -0.3589 -0.7182 -0.1875 -0.4281 -0.1175 -0.5414 -0.1312 -1.1142 -0.3087 -0.8192 -0.1631 -0.6387 -0.8864 -0.5509 -0.3008
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients ; hfref ; exercise ; respiratory gas analysis ; baseline
H-1938	-0.7990354895591736	▁h Fr EF ▁; ▁exercise ▁protocol ▁; ▁respirator y ▁gas ▁analysis ▁; ▁base line
D-1938	-0.7990354895591736	hFrEF ; exercise protocol ; respiratory gas analysis ; baseline
P-1938	-1.1039 -2.2028 -1.9772 -0.3685 -2.1076 -0.9254 -0.3686 -0.2625 -0.7492 -0.0722 -0.6241 -0.9687 -0.1999 -0.1022 -0.4485 -0.3033
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts ; heart mass ; transgenic
H-1814	-0.7322689294815063	▁heart s ▁; ▁ TTA ▁; ▁ gt t et Men a ▁mi ce ▁; ▁wild - type ▁litt er mates ▁; ▁heart ▁mass ▁; ▁trans ge nic ▁mi ce
D-1814	-0.7322689294815063	hearts ; TTA ; gttetMena mice ; wild-type littermates ; heart mass ; transgenic mice
P-1814	-2.5876 -0.3861 -0.2581 -2.1672 -1.0630 -0.4600 -1.9818 -0.5727 -0.0904 -0.0556 -0.3660 -0.0462 -2.4179 -0.7747 -0.2423 -2.5048 -0.1809 -0.0334 -0.0619 -0.1262 -0.3863 -0.2912 -2.3242 -0.2763 -0.2531 -0.0231 -0.0390 -1.1471 -1.3268 -0.5257 -0.2654 -0.1976
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene ; heart failure
H-1541	-0.9245820641517639	▁ra lo xi fen e ▁; ▁heart ▁failure ▁; ▁HR
D-1541	-0.9245820641517639	raloxifene ; heart failure ; HR
P-1541	-1.5617 -0.0735 -0.3651 -0.0237 -0.2431 -0.3290 -3.7552 -0.9856 -0.9485 -2.1707 -0.3734 -0.2655
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients ; coronary angiography ; diagnosis ; systolic hf ; etiology ; ejection fraction
H-1186	-0.4637857675552368	▁deriva tion ▁co hor t ▁; ▁corona ry ▁ang i ography ▁; ▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology ▁; ej ection ▁ fraction
D-1186	-0.4637857675552368	derivation cohort ; coronary angiography ; systolic HF ; unclear etiology ;ejection fraction
P-1186	-1.1240 -1.7336 -0.0622 -0.9296 -0.0938 -0.3091 -0.4317 -2.5334 -0.5757 -0.5541 -0.4245 -0.3938 -0.0851 -0.0743 -0.1236 -0.3545 -0.5228 -0.2675 -0.8248 -0.1649 -0.0443 -0.1062 -0.0721 -0.3677 -0.2029 -0.3629 -0.4153 -0.0264 -0.4532 -0.2797
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees ; ea
H-922	-0.8533957004547119	▁arterial ▁elastan ce ▁; ▁e a ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁e es
D-922	-0.8533957004547119	arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees
P-922	-0.6981 -1.5380 -3.6989 -0.2802 -0.9797 -0.4573 -0.3958 -3.4081 -0.2139 -1.2815 -0.2116 -0.0981 -0.6170 -3.5189 -0.2827 -0.6251 -0.2918 -0.2785 -0.1162 -1.6182 -0.3453 -0.2730 -0.1420 -0.2484 -0.2366 -1.0013 -0.3766 -0.1781 -0.5950 -2.1586 -0.2907
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart failure ; reduced left ventricular ejection fraction ; fes ; exercise capacity ; quality of life ; endothelial function ; hfpef
H-1332	-0.6737463474273682	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁f es ▁; ▁exercise ▁capacity ▁; ▁emotional ▁status ▁; ▁en dot heli al ▁function ▁; HF p EF
D-1332	-0.6737463474273682	heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ;HFpEF
P-1332	-2.4848 -0.5499 -0.2135 -0.8533 -0.2742 -1.8822 -0.5544 -0.3504 -0.3238 -0.1454 -0.3378 -0.0185 -0.2962 -2.0283 -1.1651 -0.2468 -1.1809 -0.1760 -0.2623 -0.7962 -1.0998 -0.2860 -0.3358 -0.2346 -0.0764 -0.0277 -0.0380 -0.2652 -3.4177 -0.1220 -1.6134 -0.3398 -0.2373
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal life support ; therapy ; patients ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion ; therapy
H-1298	-0.41433703899383545	▁extra corp o real ▁life ▁support ▁; ▁ brid ging ▁ therapy ▁; ▁a cute ▁ ische mic ▁right ▁heart ▁failure ▁; ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁reper fusion ▁ therapy
D-1298	-0.41433703899383545	extracorporeal life support ; bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
P-1298	-1.4035 -0.0568 -0.1741 -0.1868 -0.5829 -1.3253 -0.3186 -0.1797 -0.0979 -0.0814 -0.7171 -0.0464 -0.3757 -0.9635 -0.2096 -0.2547 -0.0858 -0.3442 -1.4145 -1.5209 -0.7003 -0.2978 -0.1710 -0.0885 -0.5466 -0.0524 -0.0546 -1.1058 -0.1215 -0.2865 -0.0192 -0.0461 -0.4174 -0.0322 -0.3910 -0.2457
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence ; hf with reduced ejection fraction ; hfref ; hf with preserved ejection fraction ; hfpef
H-1488	-0.958613395690918	▁ HF ▁met ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁treatment ▁; ▁ HF ▁met ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1488	-0.958613395690918	HF met reduced ejection fraction ;HFrEF ; treatment ; HF met preserved ejection fraction ;HFpEF
P-1488	-2.6189 -1.2163 -3.1904 -1.6456 -0.1897 -0.2784 -0.6166 -0.2760 -0.5735 -0.0838 -0.3027 -1.2262 -0.1494 -0.8091 -0.2724 -2.2843 -0.3069 -2.5854 -1.7313 -2.6807 -0.4312 -0.2121 -2.7617 -0.2793 -0.9213 -0.3686 -0.4835 -0.1011 -0.2756 -1.7415 -0.1871 -1.1685 -0.3745 -0.2491
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells ; angiotensin ii ; angii ; hypoxia ; scn5a ; mrna splicing ; scn5a
H-1083	-0.7282006144523621	▁Cell s ▁; ▁ang io ten sin ▁i i ▁; Ang II ▁; ▁hypo xia ▁; ▁activa tors ▁; ▁s cn 5 a ▁m RNA ▁; ▁s plic ing ▁; ▁over express ▁; ▁s cn 5 a ▁variant s
D-1083	-0.7282006144523621	Cells ; angiotensin ii ;AngII ; hypoxia ; activators ; scn5a mRNA ; splicing ; overexpress ; scn5a variants
P-1083	-2.3478 -0.7425 -0.3352 -0.7499 -1.6120 -0.1220 -2.0607 -0.8544 -0.4044 -0.1733 -0.2413 -1.5441 -0.2362 -0.1130 -0.0133 -0.2931 -0.0081 -0.4549 -0.2847 -1.4102 -0.1173 -1.6621 -0.8158 -0.1073 -0.2720 -1.4120 -0.0611 -2.6701 -0.3772 -0.3858 -1.8618 -0.0169 -1.0122 -1.3514 -0.1358 -1.3240 -0.7170 -0.1281 -0.6793 -0.4747 -0.2732
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic ; rhythm
H-1653	-0.48268964886665344	▁ rhythm ▁control ▁ therapy ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁cat heter ▁ab lation ▁; ▁electro car dio graphic ▁device ▁; ▁ rhythm
D-1653	-0.48268964886665344	rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
P-1653	-0.2961 -1.1258 -2.0588 -0.7617 -0.0967 -0.2508 -0.4953 -0.9718 -1.3762 -0.5039 -0.0768 -0.2818 -0.0170 -0.1579 -0.3334 -0.3505 -0.0525 -0.3047 -0.4625 -0.0408 -0.0392 -0.1536 -0.3154 -0.0139 -0.0659 -0.4844 -0.5934 -0.2634 -0.3168 -1.6080 -1.3826 -0.3770 -0.3002
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures ; hospitalizations ; noncardiovascular ; diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular ; drugs ; rate-control
H-1240	-0.5445262789726257	▁ex pendi tures ▁; ▁non car dio vas cular ▁diagnose s ▁; ▁implant able ▁cardiac ▁ar rhythm ia ▁devices ▁; ▁non car dio vas cular ▁drugs ▁; ▁rate - control ▁group
D-1240	-0.5445262789726257	expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs ; rate-control group
P-1240	-0.5274 -0.2200 -0.4640 -0.3108 -0.3715 -0.2216 -0.8726 -1.5448 -0.8766 -0.3631 -0.2957 -0.3524 -0.4466 -0.2937 -0.0763 -0.0497 -0.2474 -1.2298 -0.4609 -0.3360 -0.5146 -0.2905 -0.8973 -1.7539 -0.9488 -0.1842 -1.4273 -0.3462 -0.2071 -0.0255 -1.0568 -0.4583 -0.2978
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change ; follow-up ; readmissions ; hospital ; follow-up
H-721	-0.6272040605545044	▁follow - up ▁visit s ▁; ▁hospital ▁quality ▁improvement ▁; ▁follow - up ▁visit s
D-721	-0.6272040605545044	follow-up visits ; hospital quality improvement ; follow-up visits
P-721	-0.0806 -0.3426 -0.1359 -1.0384 -0.2594 -0.2918 -3.3176 -1.7506 -0.3765 -0.6648 -0.1076 -0.3161 -0.1258 -0.9588 -0.3550 -0.2915 -0.2495
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ; ventricular-arterial coupling ; patients
H-524	-0.7330643534660339	▁contract ility ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁SV ▁; ▁i va bra dine - tre ated ▁patients
D-524	-0.7330643534660339	contractility ; ventricular-arterial coupling ; SV ; ivabradine-treated patients
P-524	-0.0606 -1.9934 -0.4493 -0.1568 -2.8055 -0.9248 -0.3887 -0.0989 -0.3337 -0.1560 -1.3168 -0.4972 -0.9870 -0.9178 -0.3129 -0.0406 -0.9089 -1.7356 -0.1862 -0.0923 -1.2832 -1.3246 -0.3453 -0.2773
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power spectral analysis ; hf ; dnx
H-1377	-0.6172534227371216	▁power ▁spec tral ▁analysis ▁; ▁low - fre que ncy ▁; high - fre que ncy ▁; LF ▁; HF ▁; ▁CHF - in v ▁; ▁sham - in v ▁; ▁sham ▁levels ▁; ▁DN x
D-1377	-0.6172534227371216	power spectral analysis ; low-frequency ;high-frequency ;LF ;HF ; CHF-inv ; sham-inv ; sham levels ; DNx
P-1377	-0.1793 -0.4977 -0.0663 -1.4577 -0.3101 -0.3975 -0.2322 -0.1091 -3.5203 -0.1435 -0.6752 -1.0735 -0.4225 -0.1453 -3.0965 -0.1593 -0.2877 -0.7580 -0.5802 -0.6180 -0.3646 -1.1183 -0.1513 -0.3513 -0.6246 -0.2699 -0.0570 -0.2303 -0.5383 -0.7883 -0.3010 -0.0978 -0.7190 -0.2981 -1.9339 -0.3123 -0.3183 -0.2513
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence interval
H-803	-0.4293944239616394	
D-803	-0.4293944239616394	
P-803	-0.5914 -0.2674
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac magnetic resonance postcontrast t1 time ; prognosis ; hfpef ; postcontrast t1 ; biomarker ; hfpef
H-743	-0.8442398905754089	▁cardiac ▁magnetic ▁res on ance ▁; ▁h bf ▁; ▁bio mark er ▁; ▁h bf
D-743	-0.8442398905754089	cardiac magnetic resonance ; hbf ; biomarker ; hbf
P-743	-0.3166 -0.2424 -0.2745 -0.4757 -0.4796 -0.3094 -0.9807 -3.1876 -0.8106 -0.3192 -0.3133 -0.5015 -0.2389 -1.2457 -3.5271 -0.8719 -0.2573
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial dd ; collagen deposition ; titin ; obese ; diabetic ; zsf1 ; heart failure with preserved ejection fraction
H-762	-0.5134850740432739	▁my o card ial ▁ DD ▁; ▁collage n ▁de position ▁; ▁titi n ▁modification ▁; ▁obes e ▁; ▁diabet ic ▁; ▁z SF 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-762	-0.5134850740432739	myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic ; zSF1 rats ; heart failure ; ejection fraction
P-762	-1.1195 -0.2949 -0.6784 -1.2910 -0.8865 -0.5335 -0.2616 -0.0709 -0.3141 -0.1380 -0.3479 -0.2717 -0.1375 -0.1892 -0.2129 -0.3126 -0.1774 -0.1371 -0.3217 -0.0311 -0.1190 -2.0513 -0.7108 -1.8878 -2.0789 -0.8159 -0.2199 -0.2918 -1.1433 -0.2966 -0.2662 -0.1761 -0.1511 -0.0861 -0.4706 -0.0196 -0.7814 -0.2187
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action ; randomized ; patients ; left ventricular ejection fraction ; new york heart association class ii ; hf ; exercise ; training
H-698	-1.1547482013702393	▁ HF - ac tie ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁New ▁York ▁Heart ▁association ▁; ▁w h ▁; ▁exercise ▁training
D-698	-1.1547482013702393	HF-actie ; left ventricular ejection fraction ; New York Heart association ; wh ; exercise training
P-698	-2.9175 -1.3423 -0.1971 -2.2037 -3.5231 -0.3263 -1.0496 -0.3698 -2.2634 -0.4776 -0.4567 -0.4872 -0.3107 -0.6078 -0.0538 -0.3321 -2.0786 -1.7848 -1.3802 -0.4697 -0.3461 -4.3607 -0.9259 -1.0785 -0.4455 -1.7725 -0.4728 -0.2992
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse event ; acute myocardial infarction ; congestive heart failure ; adverse events
H-4	-0.6145753264427185	▁significant e ▁event ▁rates ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁advers e ▁events
D-4	-0.6145753264427185	significante event rates ; acute myocardial infarction ; congestive heart failure ; adverse events
P-4	-0.2066 -0.0701 -0.8146 -1.3434 -0.2557 -0.9306 -0.4220 -1.6772 -0.2026 -0.4298 -0.8776 -0.0600 -0.4808 -0.7455 -0.2498 -0.2359 -0.5560 -2.9340 -0.8442 -0.3776 -0.2943 -0.6717 -0.1540 -0.5800 -0.3314 -0.2335
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal pro-b-type natriuretic peptide ; nt-probnp ; misdiagnosis ; heart failure ; hf
H-1511	-0.8680262565612793	▁na tri ure tic ▁pe pti de ▁; ▁n - pro b NP ▁; ▁mis diagnos is ▁; ▁heart ▁failure ▁; HF
D-1511	-0.8680262565612793	natriuretic peptide ; n-probNP ; misdiagnosis ; heart failure ;HF
P-1511	-0.3081 -1.4123 -0.6292 -1.8716 -1.0876 -0.2765 -0.8257 -0.4088 -1.6872 -0.1435 -0.2967 -1.7263 -2.2201 -0.3967 -1.1926 -0.4409 -1.0512 -0.6703 -0.8255 -0.3434 -0.3157 -2.0123 -0.3789 -0.3114
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages ; cardiomyocytes ; doxorubicin ; in vitro ; resistin ; mrna ; protein expression
H-935	-0.44575172662734985	▁Mac rop hage s ▁; ▁cardio my o cy tes ▁; ▁Hum - Re t n ▁mi ce ▁; ▁do xor ubi cin ▁; ▁h Re t n ▁; human ▁resist in ▁; ▁m RNA ▁; ▁protein ▁expression
D-935	-0.44575172662734985	Macrophages ; cardiomyocytes ; Hum-Retn mice ; doxorubicin ; hRetn ;human resistin ; mRNA ; protein expression
P-935	-0.8172 -0.4309 -0.1798 -0.2997 -0.2899 -0.0443 -0.4284 -0.1583 -0.1228 -0.2252 -0.4032 -0.2958 -0.1518 -2.7748 -0.3945 -0.1366 -1.4936 -0.8280 -0.3169 -0.5338 -0.1055 -0.0844 -0.4591 -0.3658 -0.0571 -3.7162 -0.1641 -0.0856 -0.2272 -0.4693 -0.0666 -0.1303 -0.2747 -0.0162 -0.1046 -0.3451 -0.1166 -0.1088 -0.3632 -0.2443
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma ; collected ; hf ; patients ; immunoreactive ; nt-probnp ; c-terminally ; nt-probnp
H-1520	-0.9572134017944336	▁plasma ▁; HF ▁; ▁immun ore active ▁; ▁NT - pro b NP ▁; ▁NT - pro b NP
D-1520	-0.9572134017944336	plasma ;HF ; immunoreactive ; NT-probNP ; NT-probNP
P-1520	-0.4918 -0.7807 -2.5718 -0.4356 -0.0198 -1.2199 -0.3842 -0.5999 -0.3373 -0.1209 -0.4513 -1.9511 -1.8104 -0.7526 -1.5194 -0.0889 -0.4276 -2.2572 -2.4699 -1.1268 -0.2844
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef ; pathophysiologically ; hf with reduced ef ; hfref ; hfref ; therapy
H-1533	-1.0622249841690063	▁eh ▁; HF p EF ▁; ▁ HF ▁; ▁EF ▁; HF r EF ▁; ▁h Fr EF ▁; ▁ therapy
D-1533	-1.0622249841690063	eh ;HFpEF ; HF ; EF ;HFrEF ; hFrEF ; therapy
P-1533	-0.2241 -0.2563 -3.3881 -0.1362 -1.3308 -0.2791 -2.2377 -2.1351 -0.3976 -1.6129 -0.2371 -3.4015 -0.0633 -1.0883 -0.3241 -0.7755 -1.8621 -2.0554 -1.8242 -0.1542 -0.0949 -0.3094 -0.2432
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic tone ; parasympathetic tone ; heart rate ; intravenous bolus ; metoprolol ; atropine
H-1378	-0.5610003471374512	▁sympa the tic ▁tone ▁; ▁para sy mpa the tic ▁tone ▁; ▁heart ▁rate ▁; ▁met o pro lol ▁; ▁a tropi ne
D-1378	-0.5610003471374512	sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
P-1378	-0.1053 -1.0172 -0.9770 -0.3525 -0.2719 -0.1386 -0.5351 -0.4810 -1.1267 -1.2917 -0.3480 -0.2926 -1.6194 -0.5420 -1.5130 -0.4510 -0.2539 -0.2887 -0.5019 -0.2997 -0.1414 -0.0154 -0.8624 -0.3683 -0.2302
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma nps ; adiponectin ; baseline ; ffm ; correlate ; nps ; adiponectin ; follow up
H-19	-0.9470111727714539	▁FM ▁; ▁plasma ▁ NP s ▁; ▁adi pon ect in ▁; ▁f m ▁; ▁ NP s ▁; ▁adi pon ect in ▁; ▁follow up
D-19	-0.9470111727714539	FM ; plasma NPs ; adiponectin ; fm ; NPs ; adiponectin ; followup
P-19	-2.4370 -0.2622 -0.7555 -1.6984 -0.5764 -0.1893 -0.2992 -1.1834 -0.1086 -1.3899 -1.2067 -0.2989 -2.6601 -2.0062 -0.2812 -2.8500 -2.5137 -0.2876 -0.2210 -0.1614 -0.1059 -1.2411 -0.6981 -0.3945 -0.0311 -2.1680 -0.2673 -0.2235
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads ; heartmate ii ; thoratec corp ; pleasanton ; calif ; hvad ; heartware ; framingham
H-546	-0.4509000778198242	▁l VAD s ▁; ▁CF ▁devices ▁; ▁Heart Mate ▁i ▁devices ▁; ▁tho r a tec ▁Corp ▁; ▁Ple asan ton ▁; ▁cali f ▁; ▁h VAD ▁; ▁devices ▁; ▁Heart War e ▁in t l ▁; ▁Inc ▁; ▁Fram ing ham ▁; ▁Mass
D-546	-0.4509000778198242	lVADs ; CF devices ; HeartMate i devices ; thoratec Corp ; Pleasanton ; calif ; hVAD ; devices ; HeartWare intl ; Inc ; Framingham ; Mass
P-546	-0.1915 -0.3158 -0.4567 -0.2932 -1.8292 -0.7101 -0.2373 -1.3327 -0.2317 -0.7126 -1.3374 -0.2515 -0.1247 -0.1149 -1.7282 -0.0422 -0.2475 -0.2549 -0.6015 -0.0968 -0.0173 -0.8737 -0.2192 -0.1840 -0.2273 -1.3172 -0.9578 -0.4186 -0.6438 -0.2226 -1.0488 -0.2944 -0.0455 -0.1376 -0.1807 -0.0383 -0.5690 -0.4391 -0.2440 -0.4643 -0.0583 -0.0560 -0.2958 -0.0544 -0.3709 -0.2525
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt interval ; ecgs ; baseline ; atrial pacing ; esmolol ; isoprenaline ; atropine ; infusion
H-1438	-0.5990339517593384	▁beat - to - beat ▁ QT ▁interval ▁; ▁e CG s ▁; ▁horizontal ▁pa cing ▁; ▁es mol ol ▁; ▁iso pren a line ▁; ▁a tropi ne ▁in fusion
D-1438	-0.5990339517593384	beat-to-beat QT interval ; eCGs ; horizontal pacing ; esmolol ; isoprenaline ; atropine infusion
P-1438	-0.0494 -0.1975 -0.4117 -0.2230 -0.4447 -0.4143 -1.2301 -0.0959 -0.3297 -1.9227 -1.9558 -0.3045 -0.3517 -5.3367 -0.0774 -0.7676 -0.3162 -1.5623 -0.0495 -0.2852 -0.3216 -0.0372 -0.0963 -0.2051 -0.1098 -0.3311 -0.1198 -0.0265 -1.2477 -0.0861 -0.1590 -0.4337 -0.2684
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical ; rule ; patients ; cad ; angiography ; patients ; systolic hf ; cost
H-1193	-0.5286818146705627	▁CAD ▁; ▁ang i ography ▁; ▁sy sto lic ▁ HF ▁; ▁significant
D-1193	-0.5286818146705627	CAD ; angiography ; systolic HF ; significant
P-1193	-0.8008 -0.3468 -1.5992 -0.3254 -0.4891 -0.4831 -0.1887 -0.1413 -0.2016 -0.3346 -0.4222 -1.4949 -0.0075 -0.7208 -0.3743
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty ; health abc short physical performance battery ; habc battery ; gill index ; hf
H-625	-0.5819156765937805	▁fra il ty ▁; ▁Health ▁ABC ▁Short ▁Physic al ▁performance ▁Bat tery ▁; ▁h b ▁Bat tery ▁; ▁Gill ▁index ▁; HF
D-625	-0.5819156765937805	frailty ; Health ABC Short Physical performance Battery ; hb Battery ; Gill index ;HF
P-625	-0.0586 -0.2194 -1.1366 -0.3771 -1.9651 -0.6412 -0.6277 -0.5273 -0.0557 -0.1688 -0.2296 -0.1190 -0.2227 -0.9284 -2.4396 -0.6295 -0.1080 -0.2833 -0.2239 -0.0410 -0.2939 -2.0684 -0.3409 -0.2602
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild hf ; qrs prolongation ; lvef ; crt ; reverse remodeling ; clinical ; systolic dysfunction
H-758	-0.9119684100151062	▁ HF ▁; ▁QR s ▁prolong ation ▁; ▁LV EF ▁; ▁ nc w ▁; ▁rever se ▁remodel ing ▁; ▁benefit ▁; ▁LV ▁sy sto lic ▁dys function
D-758	-0.9119684100151062	HF ; QRs prolongation ; LVEF ; ncw ; reverse remodeling ; benefit ; LV systolic dysfunction
P-758	-1.7386 -1.6412 -0.3052 -0.7589 -0.9761 -0.8839 -2.8185 -0.2883 -1.6698 -1.2753 -0.3245 -2.8252 -1.3813 -0.9633 -0.3539 -0.7886 -0.1013 -0.0526 -0.2336 -0.3165 -4.5204 -0.4267 -1.2635 -0.4584 -0.0813 -0.1401 -0.0420 -0.1061 -0.3993 -0.2243
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients ; hf ; t2d ; erc ; vo2max ; maximum oxygen consumption ; skm ; biopsies
H-1251	-0.687463641166687	HF ▁; ▁t 2 d ▁; ERC ▁; ▁tre ad m ill ▁; VO 2 max ▁; ▁oxygen ▁consum p tion ▁; ▁Sk m ▁bio psi es
D-1251	-0.687463641166687	HF ; t2d ;ERC ; treadmill ;VO2max ; oxygen consumption ; Skm biopsies
P-1251	-2.7497 -0.3349 -0.5427 -0.0298 -0.2703 -0.3025 -3.1222 -0.3596 -0.8760 -0.0247 -0.7350 -0.7323 -2.0856 -1.3655 -0.2908 -0.2025 -0.3441 -0.6884 -0.6023 -0.3867 -1.2803 -0.5058 -0.1460 -0.2592 -0.2826 -0.3879 -0.3350 -0.4053 -0.2888
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous ; revascularization ; angioplasty ; stenting ; clinical ; patients ; randomized ; clinical
H-1601	-1.001167893409729	▁per cuta ne ous ▁re vas cular ization ▁; ▁ang io plast y ▁; ▁sten ting
D-1601	-1.001167893409729	percutaneous revascularization ; angioplasty ; stenting
P-1601	-3.9792 -0.0215 -1.4449 -2.5189 -0.1283 -0.2505 -0.2913 -2.0947 -0.4270 -0.9649 -1.7264 -0.2255 -1.7623 -0.3504 -0.0315 -0.5492 -0.9687 -0.2857
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient ; hospital ; gastrointestinal bleeding ; patient ; ventricular tachycardia ; terminal heart failure
H-1961	-0.7044222950935364	▁hospital ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁ince ssant ▁vent ri cular ▁ta chy car dia ▁storm ▁; ▁terminal ▁heart ▁failure
D-1961	-0.7044222950935364	hospital ; gastrointestinal bleeding ; incessant ventricular tachycardia storm ; terminal heart failure
P-1961	-2.5028 -0.4055 -0.1360 -0.2596 -1.4805 -0.2141 -0.0900 -0.8728 -0.2888 -0.3791 -3.4305 -0.0972 -0.1894 -2.0963 -0.5745 -0.2589 -0.3516 -0.1041 -0.0962 -0.0111 -0.3308 -2.3365 -0.9187 -0.2116 -0.4164 -0.2619
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic response ; heart rate ; exercise ; baseline ; follow-up ; tests ; heart rate ; exercise
H-1176	-0.960242748260498	▁chr ono tropi c ▁response ▁; ▁heart ▁rate ▁; ▁exercise ▁; ▁base line ▁; ▁follow - up ▁tests ▁; ▁heart ▁rate ▁; ▁exercise
D-1176	-0.960242748260498	chronotropic response ; heart rate ; exercise ; baseline ; follow-up tests ; heart rate ; exercise
P-1176	-2.4740 -0.2077 -0.2298 -0.3558 -1.1098 -0.3930 -2.4645 -1.2597 -0.3923 -4.1863 -2.2714 -1.5412 -0.0775 -0.3553 -0.0150 -0.2756 -0.0463 -0.4327 -0.3802 -2.5290 -1.2904 -0.4306 -0.6642 -0.3783 -0.2455
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac ; jq1 ; bet ; pathological ; cardiac ; gene expression
H-1049	-0.669225811958313	▁cardiac ▁tissu e ▁; ▁mi ce ▁; ▁sham - opera ted ▁; ▁j q 1 ▁; ▁vehicle ▁; ▁ BET ▁inhibi tion ▁; ▁path ological ▁cardiac ▁gene ▁expression ▁programme
D-1049	-0.669225811958313	cardiac tissue ; mice ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
P-1049	-0.8624 -1.3491 -0.2802 -0.3472 -0.6701 -0.9510 -0.3329 -1.4834 -0.2664 -0.0670 -1.0890 -0.3829 -0.1465 -3.0976 -1.3600 -0.3500 -0.2105 -0.4681 -1.4637 -0.2561 -0.1006 -1.8238 -0.3682 -0.8053 -0.6224 -0.2207 -0.4793 -0.1873 -0.0320 -0.4056 -0.2668
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic ; cardiac ; cardiac ; gene ; signal transduction ; pathological ; gene expression ; hf
H-1053	-0.47169578075408936	▁epi gene tic ▁readers ▁; ▁cardiac ▁bi ology ▁; ▁cardiac ▁gene ▁control ▁; ▁chr omat in - dependent ▁signal ▁trans duction ▁; ▁path ological ▁gene ▁expression ▁; ▁ HF ▁progression
D-1053	-0.47169578075408936	epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
P-1053	-0.1780 -0.6103 -0.9622 -0.1544 -0.3063 -0.1681 -1.0092 -0.3037 -0.2779 -0.6311 -1.1520 -0.7344 -0.2672 -0.0639 -0.0504 -0.3488 -0.3225 -0.0567 -0.4782 -0.0531 -1.2589 -0.3010 -0.1621 -0.6354 -0.5733 -0.2054 -0.2538 -1.9371 -0.4884 -0.4124 -0.4637 -0.2742
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional hazard models ; negative binomial regression models ; health
H-1624	-0.526710033416748	▁co x - propor tional ▁hazard ▁; ▁negative ▁bi nom ial ▁re gression ▁models
D-1624	-0.526710033416748	cox-proportional hazard ; negative binomial regression models
P-1624	-0.2721 -0.8790 -0.0644 -0.1914 -0.4396 -0.3347 -1.4827 -0.4646 -0.4871 -1.1813 -0.5577 -0.0945 -0.0731 -1.0663 -0.6075 -0.2312
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up ; patients ; combined end point ; death ; heart failure ; death ; cardiac transplant
H-1747	-0.49059683084487915	▁follow - up ▁; ▁death ▁; heart ▁failure ▁; ▁sud den ▁death ▁; ▁non card iac ▁; ▁cardiac ▁transplant
D-1747	-0.49059683084487915	follow-up ; death ;heart failure ; sudden death ; noncardiac ; cardiac transplant
P-1747	-0.0639 -0.3091 -0.0591 -0.3414 -2.3052 -0.2956 -1.2889 -0.2949 -0.9483 -0.3351 -0.1620 -1.2575 -0.2904 -0.5590 -0.1124 -0.2102 -0.3874 -0.1425 -0.2348 -0.3967 -0.3082
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak oxygen consumption ; vo2max ; resting hr ; bpm ; p value
H-1943	-0.9387590885162354	▁oxygen ▁consum p tion ▁; ▁v 2 max ▁; ▁rest ing ▁; ▁HR
D-1943	-0.9387590885162354	oxygen consumption ; v2max ; resting ; HR
P-1943	-1.5044 -1.5034 -0.4448 -1.5095 -0.4259 -1.7250 -0.9637 -0.1923 -0.4201 -0.9505 -0.4680 -0.4263 -1.8369 -1.4199 -0.2907
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission ; nt-probnp ; patients ; acute hf ; diagnosis
H-264	-0.9696377515792847	▁ad mission ▁; ▁NT - pro b NP ▁; ▁ED ▁; ▁a cute ▁ HF ▁ diagnos is
D-264	-0.9696377515792847	admission ; NT-probNP ; ED ; acute HF diagnosis
P-264	-4.0344 -1.0344 -0.2823 -1.2072 -0.0977 -0.0928 -1.5463 -1.8159 -0.3573 -3.1307 -0.3856 -0.3587 -0.1387 -0.2542 -1.1154 -1.5620 -0.4603 -0.8158 -0.3629 -0.3402
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 ; hypertrophy ; fibrosis ; ventricular dysfunction ; gene
H-642	-0.4025784134864807	▁hand 2 ▁; ▁pressure - over load - indu ced ▁hyper trop hy ▁; ▁fibro sis ▁; ▁vent ri cular ▁dys function ▁; ▁fet al ▁gene ▁program
D-642	-0.4025784134864807	hand2 ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
P-642	-0.3335 -0.3638 -0.2705 -1.2645 -0.1845 -0.0359 -0.1638 -0.3674 -0.3518 -0.6340 -0.0416 -0.0195 -2.0727 -0.2839 -0.0055 -0.9592 -0.2781 -0.0550 -1.1175 -0.5260 -0.0353 -0.0679 -0.3101 -0.1481 -0.0638 -0.3979 -0.6674 -0.3984 -0.2571
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic blood pressure ; elevated ; left ventricular ; hypertrophy
H-277	-1.0465649366378784	▁sy sto lic ▁blood ▁pressure ▁; ▁left ▁vent ri cular ▁; ▁v n ▁; ▁hyper trop hy ▁; ▁AT ▁; ▁AN ▁; ▁AS ▁; ▁ ANS
D-277	-1.0465649366378784	systolic blood pressure ; left ventricular ; vn ; hypertrophy ; AT ; AN ; AS ; ANS
P-277	-2.6997 -0.6175 -0.1621 -1.0386 -1.2751 -0.3918 -1.5601 -0.2398 -1.4951 -0.3195 -0.3339 -2.5578 -0.4318 -0.2754 -0.2319 -0.0626 -3.1933 -0.5036 -1.7121 -0.4368 -1.4886 -0.4486 -1.2337 -0.2311 -1.5508 -3.8846 -0.6290 -0.2986
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients ; rv support ; lvad ; patients ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
H-295	-0.734591543674469	▁ rv ▁; ▁l VAD ▁ insertion ▁; ▁cardio ge nic ▁shock ▁; ▁my o card ial ▁in far ction ▁; ▁chronic ▁de com pensa ted ▁heart ▁failure
D-295	-0.734591543674469	rv ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
P-295	-2.9851 -0.6265 -0.4154 -0.4758 -0.2367 -2.0791 -0.0430 -0.3613 -0.1741 -0.0437 -1.6191 -0.1719 -0.3526 -1.9807 -0.3260 -0.8355 -1.6125 -0.1048 -0.5350 -0.7253 -0.3640 -1.2838 -0.6073 -0.0829 -0.1915 -1.4857 -1.1380 -0.3792 -0.4776 -0.3239
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic ; new york heart association classes ; saf
H-229	-0.8776376247406006	▁ PF ▁co hor t ▁; New ▁York ▁Heart ▁association ▁; SAF ▁; PF
D-229	-0.8776376247406006	PF cohort ;New York Heart association ;SAF ;PF
P-229	-1.5702 -1.1998 -0.4887 -0.9208 -0.1379 -0.2652 -2.0889 -1.4756 -1.2300 -0.5395 -0.3756 -0.3897 -0.4729 -2.2907 -0.2888 -0.3079
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence ; hf ; ami ; adjusted odds ratio
H-1310	-1.335817813873291	HF ▁; AMI ▁; ▁odds ▁ratio ▁; ▁CI
D-1310	-1.335817813873291	HF ;AMI ; odds ratio ; CI
P-1310	-3.1640 -0.2894 -2.8792 -0.5497 -1.5177 -0.0501 -0.4085 -3.9228 -0.2947 -0.2821
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective cohort ; eds ; diagnosis ; heart failure
H-463	-1.3341875076293945	▁ED s ▁; ▁heart ▁failure ▁; ▁ED
D-463	-1.3341875076293945	EDs ; heart failure ; ED
P-463	-3.8658 -0.5102 -0.3610 -3.1149 -0.6951 -0.4457 -1.3029 -1.3638 -0.3482
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report ; connection ; patients ; disease ; healthcare ; conditions ; turkey
H-1825	-1.0462650060653687	▁Turkey
D-1825	-1.0462650060653687	Turkey
P-1825	-2.4293 -0.4182 -0.2913
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western ; administrative ; health ; patients ; hf ; hospitalized ; ami
H-1307	-1.4141020774841309	▁Western ▁Australian ▁; ▁administrative ▁health ▁; ▁ HF ▁; ▁index ▁; AMI
D-1307	-1.4141020774841309	Western Australian ; administrative health ; HF ; index ;AMI
P-1307	-0.8712 -2.0843 -0.8064 -2.7602 -2.9829 -0.4352 -2.5360 -2.8541 -0.3310 -0.1034 -0.3524 -2.9502 -0.4432 -0.2869
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients ; physicians ; mortality ; physicians ; hospitals
H-1727	-0.7123362421989441	▁high - volu me ▁physician s ▁; ▁mortal iteit ▁; ▁low - volu me ▁physician s ▁; ▁low - volu me ▁hospital s
D-1727	-0.7123362421989441	high-volume physicians ; mortaliteit ; low-volume physicians ; low-volume hospitals
P-1727	-4.9090 -0.1826 -0.3884 -0.4155 -0.5222 -0.4659 -0.3623 -0.3180 -2.1709 -0.3535 -1.1571 -0.2063 -0.4026 -0.1975 -0.9733 -0.4607 -0.3245 -1.0562 -0.2148 -0.5601 -0.2683 -0.7975 -0.5550 -0.2982 -0.2480
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians ; patients ; patient ; clinician ; medication ; patient
H-1129	-1.1096103191375732	
D-1129	-1.1096103191375732	
P-1129	-1.8539 -0.3653
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome ; prospective ; hospitalized ; hf ; nursing ; outcomes
H-1403	-1.2446115016937256	▁science ▁; ▁treatment ▁; ▁older ▁adults ▁; HF
D-1403	-1.2446115016937256	science ; treatment ; older adults ;HF
P-1403	-1.5105 -0.2555 -4.4390 -0.4497 -0.4275 -0.7403 -0.4289 -3.0230 -0.8239 -0.3478
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse ; myocardial t1 ; heart failure
H-1055	-0.6546705365180969	▁free - bre a thing ▁puls e ▁se que nce ▁; ▁my o card ial ▁t 1 ▁; ▁s win e ▁model ▁; ▁ta chy car dia - indu ced ▁heart ▁failure
D-1055	-0.6546705365180969	free-breathing pulse sequence ; myocardial t1 ; swine model ; tachycardia-induced heart failure
P-1055	-0.9735 -0.1639 -0.0414 -0.2084 -2.3626 -0.6168 -0.2450 -0.8799 -1.9988 -1.6453 -0.3204 -0.8326 -0.2261 -0.8763 -1.0608 -0.3758 -0.8294 -0.2067 -1.6660 -0.0851 -0.1178 -1.8077 -0.2618 -0.6831 -0.3054 -0.1267 -0.1362 -0.1388 -0.2234 -0.8953 -1.0760 -0.2237 -0.3777 -0.2706
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty ; gill index ; hf
H-628	-0.887576162815094	▁non - fra il ▁; HR ▁; ▁fra il ty ▁; HR ▁; ▁Gill ▁index ▁; HF
D-628	-0.887576162815094	non-frail ;HR ; frailty ;HR ; Gill index ;HF
P-628	-0.8031 -0.0758 -0.0579 -0.1724 -2.8761 -2.1520 -0.5479 -0.0823 -0.1753 -1.2360 -0.4530 -3.9865 -0.5063 -0.4317 -0.0312 -0.3911 -2.2101 -0.3684 -0.3067
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up ; patients
H-268	-1.311300277709961	▁die d ▁; ▁non - sur viv ors
D-268	-1.311300277709961	died ; non-survivors
P-268	-4.9892 -1.3753 -0.4959 -2.7693 -0.2155 -0.5052 -0.1867 -1.9321 -0.3755 -0.2684
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic ; β-ar ; catecholamine ; infusions ; pde2 ; expression ; camp ; activity ; correlated ; cardiac ; β-ar responsiveness
H-1214	-0.7038288116455078	▁β - AR ▁stimul ation ▁; ▁cate chol amine ▁in fusion s ▁; ▁rat s ▁; ▁p de 2 ▁expression ▁; ▁c AMP ▁hydro ly tic ▁activity ▁; ▁blu n ted ▁cardiac ▁β - AR ▁responsive ness
D-1214	-0.7038288116455078	β-AR stimulation ; catecholamine infusions ; rats ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
P-1214	-3.4650 -0.1244 -1.1567 -0.4433 -2.9206 -0.4063 -0.0356 -0.2331 -0.2987 -0.0915 -0.1003 -0.4639 -0.3603 -0.3988 -0.2560 -0.4399 -0.7047 -1.8545 -0.1932 -0.0782 -0.4011 -0.4283 -0.5728 -0.0542 -0.5866 -2.0013 -0.7729 -0.3983 -0.7058 -0.8183 -1.0973 -0.0492 -0.7762 -0.0786 -0.9496 -0.0842 -2.9088 -0.4406 -0.3004
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine oxidase ; xo ; left ventricular ; myocytes ; volume overload ; vo ; mitral regurgitation ; aortocaval fistula ; acf
H-470	-0.6137697696685791	▁Xan thi ne ▁oxid ase ▁; XO ▁; ▁left ▁vent ri cular ▁; ▁v n ▁; ▁my o cy tes ▁; ▁volume ▁over load ▁; ▁v n ▁; ▁mit ral ▁re gur gi tation ▁; ▁a orto ca val ▁fi stu la ▁; ▁ac f
D-470	-0.6137697696685791	Xanthine oxidase ;XO ; left ventricular ; vn ; myocytes ; volume overload ; vn ; mitral regurgitation ; aortocaval fistula ; acf
P-470	-0.0499 -0.3956 -1.3436 -0.0542 -1.6257 -0.3685 -0.8077 -0.3039 -3.6393 -0.1259 -1.3427 -0.3881 -0.3487 -2.1338 -0.8010 -0.3814 -1.0416 -0.1243 -0.0780 -0.2254 -0.3888 -0.1588 -0.0122 -0.1268 -0.3802 -0.9106 -1.0625 -0.3408 -1.0464 -0.2982 -0.0918 -0.1105 -0.4570 -0.2246 -0.2973 -0.1059 -0.0956 -0.2047 -0.0825 -0.2398 -0.0260 -1.1851 -0.3457 -1.0134 -3.4881 -0.3209 -0.2536
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese ; zsf1 ; heart failure with preserved ejection fraction ; lung ; preserved left ventricular ejection fraction ; left ventricular dd
H-767	-0.9693655967712402	▁obes e ▁; ▁z SF 1 ▁groups ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁lung ▁weight ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁ DD
D-767	-0.9693655967712402	obese ; zSF1 groups ; heart failure ; preserved ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular DD
P-767	-3.0453 -0.1758 -0.8424 -1.0991 -2.5887 -1.8811 -0.9545 -0.3297 -2.1931 -0.4976 -0.2229 -2.4143 -0.3513 -2.4098 -0.3754 -0.5989 -0.3692 -0.4551 -0.0967 -0.2752 -0.5251 -0.5147 -0.2414 -2.6012 -0.5099 -2.5855 -1.0764 -0.8991 -1.0376 -0.6887 -0.4614 -0.0674 -0.2519 -1.0587 -0.3631 -2.6327 -1.0213 -0.4266 -1.0264 -0.3030 -0.2754
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic pah ; clinical ; hospitalized ; patients ; acute ; rv decompensation ; pharmacologic ; therapies ; rv failure ; pah
H-1096	-0.9591821432113647	▁chronic ▁P AH ▁; ▁hospital ized ▁; ▁ rv ▁; ▁de com pensa tion ▁; ▁ rv ▁failure ▁management ▁; ▁p AH
D-1096	-0.9591821432113647	chronic PAH ; hospitalized ; rv ; decompensation ; rv failure management ; pAH
P-1096	-0.4332 -3.9508 -0.7818 -0.3012 -2.1107 -0.2035 -0.5256 -1.1084 -1.5174 -1.7456 -0.2043 -0.2992 -0.4938 -1.3117 -0.4266 -0.4025 -2.3464 -0.4649 -0.2416 -0.2835 -2.0194 -1.1008 -0.4071 -0.3403
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic heart failure ; chf ; multisystem disease ; comorbidities ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
H-1357	-0.7701832056045532	▁Chro nic ▁heart ▁failure ▁; ▁chw ▁; ▁aan emia ▁; ▁insulin ▁resist ance ▁; ▁autonomi c ▁dys balance ▁; ▁cardiac ▁cache xia
D-1357	-0.7701832056045532	Chronic heart failure ; chw ; aanemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
P-1357	-1.9575 -1.6288 -1.4809 -0.3799 -0.2542 -2.5434 -0.5473 -5.0375 -1.2298 -0.2762 -0.0635 -0.1998 -0.1785 -0.2764 -0.0180 -0.8952 -0.0792 -0.1855 -0.2511 -0.2178 -0.0611 -0.0845 -0.3871 -0.2511
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic ; heart failure with preserved ejection fraction ; hfpef ; patients ; health ; symptoms ; quality of life
H-780	-0.8746911883354187	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-780	-0.8746911883354187	heart failure ; preserved ejection fraction ;HFpEF
P-780	-2.5580 -0.4589 -0.2793 -1.3467 -0.2134 -2.7302 -0.1655 -0.3029 -0.0672 -0.3665 -0.0379 -0.2936 -2.0467 -0.0843 -1.6664 -1.9781 -0.2741
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 ; bets ; chromatin ; downstream signalling ; rna ; polymerase ii ; pol ii
H-1043	-0.6176524758338928	▁inhibi tor ▁; ▁j q 1 ▁; ▁ BET s ▁; ▁chr omat in ▁; ▁ RNA ▁poly mera se ▁i i ▁; Pol ▁II
D-1043	-0.6176524758338928	inhibitor ; jq1 ; BETs ; chromatin ; RNA polymerase ii ;Pol II
P-1043	-0.9202 -0.1071 -1.0105 -0.2979 -2.3887 -1.4139 -0.3391 -1.5109 -0.2841 -0.9652 -0.3326 -0.0972 -0.0695 -0.3416 -0.3542 -1.3700 -0.1229 -0.0479 -0.1523 -0.1172 -1.2044 -0.1687 -0.1925 -1.2970 -0.9667 -0.3335 -0.2707
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report ; patient ; diagnosis ; ischemic-hypertensive cardiomyiopathy ; angina ; myocardial ischemia ; coronary arteries
H-998	-0.6037266254425049	▁ ische mic - hy per tensi ve ▁cardio my io pathy ▁; ▁ang ina ▁; ▁induc ible ▁my o card ial ▁ ische mia ▁; ▁corona ry ▁arteri es
D-998	-0.6037266254425049	ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
P-998	-0.2950 -0.4145 -0.4925 -0.1755 -0.5055 -0.0517 -0.1426 -0.1871 -0.1502 -0.6968 -1.4818 -0.1977 -0.3449 -1.3581 -1.0464 -0.3204 -0.0256 -2.1308 -2.2192 -0.2055 -0.8307 -1.0609 -0.3822 -0.3648 -0.3491 -0.2786 -0.1809 -2.0279 -0.0861 -0.6855 -0.3941 -0.2365
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal dysfunction ; intestinal ; lead ; chronic ; inflammatory ; catabolic ; anabolic ; cardiac cachexia ; terminal ; chf ; prognosis
H-1360	-0.331852525472641	▁intestinal ▁dys function ▁; ▁intestinal ▁barrier ▁; ▁infla mma tory ▁state ▁; ▁cata bo lic ▁; ana bo lic ▁im balance ▁; ▁cardiac ▁cache xia ▁; ▁CHF
D-1360	-0.331852525472641	intestinal dysfunction ; intestinal barrier ; inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
P-1360	-0.6486 -0.1746 -0.2773 -0.1789 -1.6524 -0.3972 -0.2891 -0.8437 -0.4305 -0.3282 -0.6014 -0.2467 -0.1546 -0.0393 -0.0858 -0.5763 -0.2574 -0.0505 -0.1817 -0.5378 -0.2246 -0.2376 -0.1062 -0.0396 -0.0450 -0.2727 -0.2942 -0.2206 -0.2310
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra ; methotrexate ; tnf antagonist ; non-biological disease modifying antirheumatic drug ; nbdmard
H-604	-0.6091158390045166	▁RA ▁; ▁met ho tre xa te ▁; ▁t NF ▁anta gon ist ▁; ▁non - bi ological ▁disease ▁; ▁anti r heu matic ▁drug ▁; ▁n b DM ARD
D-604	-0.6091158390045166	RA ; methotrexate ; tNF antagonist ; non-biological disease ; antirheumatic drug ; nbDMARD
P-604	-0.9241 -0.3404 -0.2637 -0.2303 -0.2226 -0.7638 -0.1465 -0.3438 -2.0722 -2.2863 -0.0661 -0.0075 -0.3451 -0.3223 -0.9125 -0.1195 -2.7498 -0.7630 -0.4163 -0.3432 -0.0535 -0.4421 -0.3300 -0.3881 -0.5911 -0.3015 -0.6592 -0.0340 -1.8624 -0.5964 -0.3323 -0.2622
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic adenosine monophosphate ; camp ; cyclic guanosine monophosphate ; cgmp ; hearts
H-1209	-0.8052332401275635	▁ cycli c ▁ad enos ine ▁mono phos pha te ▁; ▁c AMP ▁; ▁aug mente d ▁ cycli c ▁gua no sine ▁mono phos pha te ▁; ▁c g m ▁; ▁heart s
D-1209	-0.8052332401275635	cyclic adenosine monophosphate ; cAMP ; augmented cyclic guanosine monophosphate ; cgm ; hearts
P-1209	-1.3576 -1.4000 -1.5835 -0.7493 -0.2315 -3.3209 -0.0089 -0.2280 -0.3044 -0.4190 -0.3204 -0.7007 -1.1801 -0.3626 -2.8950 -0.1879 -0.0943 -0.1901 -0.2018 -1.3674 -0.2203 -0.1093 -2.2829 -0.0139 -0.4240 -0.4124 -0.3500 -0.2487 -0.4269 -2.8411 -1.4934 -0.2598 -1.5835 -0.4067 -0.5045 -0.3076
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate cox proportional hazards regression modeling ; hospitalization ; acute coronary syndromes ; coronary interventions ; patients
H-104	-0.6921597123146057	▁co x ▁proportion al ▁hazard s ▁re gression ▁; ▁IE ▁; ▁a cute ▁corona ry ▁syndrome s ▁; ▁corona ry ▁intervention s
D-104	-0.6921597123146057	cox proportional hazards regression ; IE ; acute coronary syndromes ; coronary interventions
P-104	-0.0597 -0.5459 -0.0629 -0.1097 -0.2838 -0.5930 -0.3556 -0.0473 -1.7013 -4.1515 -0.2894 -0.8632 -0.2045 -0.2739 -2.3887 -0.0147 -0.3102 -0.3437 -0.1892 -2.6723 -0.1210 -0.2455 -0.4651 -0.3198
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas ; rnas ; expression ; genes ; messenger rna ; repression
H-1482	-0.5455225110054016	▁mi RNA s ▁; ▁non co ding ▁ RNA s ▁; ▁ binding ▁; ▁messenger ▁ RNA
D-1482	-0.5455225110054016	miRNAs ; noncoding RNAs ; binding ; messenger RNA
P-1482	-1.2343 -0.7585 -0.4508 -0.4020 -0.8374 -0.0375 -0.7132 -0.3459 -0.3260 -0.3774 -0.3017 -2.6092 -0.1182 -0.3369 -0.0625 -0.3335 -0.4431 -0.4322 -0.2448
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction ; hfpef
H-942	-0.6390835642814636	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h bf
D-942	-0.6390835642814636	catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hbf
P-942	-0.6977 -0.2851 -0.1205 -0.5971 -0.3122 -0.7000 -0.4841 -0.4532 -0.1531 -0.3312 -0.2903 -3.4999 -0.3014 -1.2820 -0.3386 -0.2695 -0.9238 -0.2971 -1.9676 -0.1212 -0.3051 -0.0972 -0.2526 -0.0206 -0.3124 -0.8050 -2.4217 -0.6328 -0.2606
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients ; hfpef ; ivabradine ; placebo ; double-blind
H-1173	-0.9247154593467712	▁ HF p EF ▁; ▁i va bra dine ▁; ▁place bo
D-1173	-0.9247154593467712	HFpEF ; ivabradine ; placebo
P-1173	-0.9956 -1.6198 -0.1301 -1.8628 -0.3849 -0.2678 -0.0501 -0.9210 -1.2194 -1.1435 -3.5356 -0.0640 -0.4497 -0.3017
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
H-1618	-0.7720965147018433	▁mortal iteit ▁; ▁health care ▁utiliza tion ▁; ▁care ▁management ▁; ▁tele health ▁; ▁con ges tive ▁heart ▁failure ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁mell itus
D-1618	-0.7720965147018433	mortaliteit ; healthcare utilization ; care management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
P-1618	-0.4611 -2.3820 -0.2287 -1.0700 -0.1209 -0.7214 -1.3789 -1.1214 -5.6355 -0.2597 -0.2313 -0.3585 -0.6411 -0.2955 -0.4912 -0.6702 -3.1827 -1.2796 -0.2989 -0.2660 -0.0933 -0.4461 -0.3236 -0.9965 -0.0427 -1.0090 -0.4285 -0.2417 -0.0967 -0.0170 -0.0672 -0.3657 -0.2565
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia ; pna
H-1691	-0.9394079446792603	▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia ▁; ▁p NA
D-1691	-0.9394079446792603	heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pNA
P-1691	-3.4150 -0.4374 -0.2546 -1.8039 -0.2838 -2.2730 -0.1536 -1.9798 -0.2263 -0.3934 -1.4950 -0.0680 -0.8125 -0.7479 -0.3225 -1.2490 -0.3222 -0.1746 -1.0400 -0.3076 -0.7426 -3.2829 -0.4517 -0.3084
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses ; pathophysiology ; hf ; nursing ; medical ; symptoms ; pathophysiologic
H-2022	-0.9965406656265259	▁pat ho phy si ology ▁; HF ▁; ▁medical ▁management ▁; ▁pat ho phy si ologic ▁state
D-2022	-0.9965406656265259	pathophysiology ;HF ; medical management ; pathophysiologic state
P-2022	-1.3675 -0.7753 -1.1880 -3.2373 -0.2793 -0.2651 -2.1206 -0.2087 -1.3593 -0.1488 -0.1766 -0.5207 -0.5360 -1.2691 -2.5988 -0.2624 -2.0374 -0.3429 -0.2404
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps ; adverse outcomes ; patients ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
H-1022	-0.7485897541046143	NP s ▁; ▁heart ▁failure ▁; ▁pulmonar y ▁e mbol ism ▁; ▁diabetes ▁; ▁che mo therapy
D-1022	-0.7485897541046143	NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
P-1022	-2.1124 -0.3237 -0.3305 -3.8308 -0.7617 -0.3369 -0.0778 -1.2059 -0.5772 -0.1122 -2.5381 -0.3429 -0.0810 -0.3141 -0.4005 -0.2117 -0.0826 -0.3255 -0.2577
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac ; cells ; cardiac ; cells ; cardiac functions ; myocardial infarction
H-1335	-0.7174976468086243	▁cardiac ▁c - K it ▁; ▁cell s ▁; ▁cardiac ▁; ▁ex plant - der i ved ▁cell s ▁; ▁cardiac ▁function s ▁; ▁my o card ial ▁in far ction
D-1335	-0.7174976468086243	cardiac c-Kit ; cells ; cardiac ; explant-derived cells ; cardiac functions ; myocardial infarction
P-1335	-3.3194 -1.2874 -0.2195 -1.3843 -0.1204 -0.8010 -0.6213 -0.4278 -0.3848 -0.6143 -1.4287 -0.2285 -0.0256 -0.3095 -0.1173 -0.4423 -0.6173 -1.0663 -0.4479 -0.3821 -0.9079 -0.3543 -0.3060 -0.3454 -2.2894 -0.2213 -1.1252 -1.5945 -0.0958 -0.5496 -0.9823 -0.3851 -0.2747
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate receptor 1 ; s1pr1 ; β1-adrenergic receptor ; β1ar ; g-protein-coupled receptors ; heart
H-1405	-0.756105363368988	▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁β 1- ad r energi c ▁receptor ▁; β 1 AR ▁; ▁g - prote in - co up led ▁receptor s ▁; ▁heart
D-1405	-0.756105363368988	sphingosine-1-phosphate receptor ; s1PR ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors ; heart
P-1405	-0.0161 -2.3679 -1.4056 -4.2727 -0.9744 -0.7906 -0.0493 -0.1194 -0.3021 -0.0781 -0.5374 -0.6333 -0.9484 -2.1257 -1.4611 -0.1067 -0.3271 -0.5195 -0.3104 -1.3581 -0.7240 -0.0927 -0.3188 -0.4717 -2.2170 -1.9483 -0.3176 -1.9051 -0.1972 -0.0226 -0.2345 -0.2297 -0.0790 -0.1126 -1.0538 -0.0679 -0.2928 -0.2783 -1.1004 -0.3853 -0.2470
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef ; lcx ; lad ; stenting ; infarcted ; left ventricle ; lcx ; lad
H-512	-0.930925726890564	▁EF ▁; ▁l c x ▁; LAD ▁; ▁sten ting ▁; ▁left ▁vent ric le ▁; ▁l c x ▁; LAD
D-512	-0.930925726890564	EF ; lcx ;LAD ; stenting ; left ventricle ; lcx ;LAD
P-512	-0.2146 -0.3094 -0.3653 -3.5193 -1.9235 -0.3507 -1.9488 -0.3600 -0.0871 -0.5795 -0.3832 -0.4815 -0.0687 -0.8661 -0.4935 -0.3659 -0.7380 -4.3344 -1.8692 -0.2999 -1.2302 -0.3397 -0.2827
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas ; expression ; bhlh ; transcription factor ; hand2 ; myocardium ; gene ; heart failure
H-644	-0.5008280277252197	▁signal ling ▁casca des ▁; ▁micro RNA s ▁; ▁b HL h ▁tran scription ▁factor ▁; ▁hand 2 ▁; ▁post na tal ▁mamma lian ▁my o car dium ▁; ▁em bry o nic ▁gene ▁programs ▁; ▁heart ▁failure
D-644	-0.5008280277252197	signalling cascades ; microRNAs ; bHLh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
P-644	-0.8126 -0.6873 -0.0401 -0.0371 -0.3428 -0.0236 -0.2754 -0.4742 -0.3820 -0.0894 -1.1141 -0.2470 -0.1039 -0.0531 -0.3154 -0.2571 -0.2156 -0.1716 -0.2766 -0.7931 -2.4420 -0.0408 -0.1565 -1.6712 -2.3697 -0.1215 -0.0619 -0.1695 -0.3497 -1.4931 -0.2647 -0.1430 -1.1629 -0.3527 -0.2390 -0.3182 -0.8840 -0.4526 -0.3775 -0.2504
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; hf ; pathogenesis ; hf
H-1038	-0.7640732526779175	BET ▁; ▁bro modo main ▁protein s ▁; BET s ▁; ▁a ce tyl - ly sine ▁reader ▁protein s ▁; ▁ HF ▁; ▁ HF
D-1038	-0.7640732526779175	BET ; bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF ; HF
P-1038	-2.5494 -0.5762 -0.0157 -0.1751 -0.5770 -0.8131 -0.6476 -0.2731 -0.7859 -0.5576 -0.2060 -0.1073 -0.6006 -0.6113 -0.1319 -1.0144 -1.4657 -0.2044 -2.2445 -0.5926 -0.2931 -1.3802 -1.3755 -0.3433 -1.7793 -1.4942 -0.2652 -0.3139
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in vivo ; cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
H-1783	-0.3962246775627136	▁cardiac ▁function ▁; ▁e cho card i ography ▁; ▁dia sto lic ▁dys function ▁; ▁sy sto lic ▁dys function ▁; ▁e je ction ▁ fraction
D-1783	-0.3962246775627136	cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
P-1783	-2.4728 -0.5173 -0.2841 -0.2943 -0.5782 -0.2508 -0.3591 -0.4578 -0.4010 -0.0776 -0.2458 -0.3843 -0.0847 -0.2651 -0.2878 -0.3411 -0.4821 -0.5422 -0.0876 -0.2684 -0.2866 -0.1493 -0.6514 -0.1988 -0.4276 -0.0377 -0.3805 -0.2805
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart ; patients ; new york heart association ; nyha ; hospitalized ; hf ; primary outcome ; death ; hf ; hospitalization
H-239	-1.0014798641204834	▁h ART ▁; ▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁ HF ▁; ▁self - management ▁counsel ing ▁; ▁death ▁; ▁ HF
D-239	-1.0014798641204834	hART ; New York Heart association ;NYha ; HF ; self-management counseling ; death ; HF
P-239	-2.8531 -0.9269 -0.3328 -1.5119 -1.5363 -1.4278 -0.3220 -0.2761 -2.2669 -2.2291 -0.3504 -2.2336 -2.1605 -0.3113 -0.2422 -0.0657 -0.0244 -0.1138 -0.2221 -0.3396 -2.0467 -0.2779 -1.6504 -1.4202 -0.5966 -0.3000
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva ; surgical ; implantation ; leaflet ; leaflet ; edge-to-edge anastomosis
H-360	-0.5569667816162109	▁m va ▁; ▁sur g ical ▁ring ▁implant ation ▁; ▁le a flet ▁motion ▁; ▁le a flet ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is
D-360	-0.5569667816162109	mva ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
P-360	-0.3079 -2.9444 -0.2383 -2.1676 -0.2539 -1.5074 -0.0509 -0.9256 -1.1903 -0.2570 -0.2903 -0.0912 -0.2195 -0.9869 -0.2614 -0.6122 -0.1011 -0.5687 -0.4810 -0.2125 -0.2727 -0.2834 -0.1027 -0.3187 -0.3499 -0.2380 -0.0537 -0.9087 -0.0158 -0.6912 -0.8158 -0.3833 -0.2779
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv compliance ; lv end-diastolic volume ; lv end-diastolic pressure ; β coefficient
H-1531	-0.7843462228775024	▁eh ▁; ▁LV ▁compliance ▁; ▁v n ▁; ▁end - dia sto lic ▁volume ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; ▁h g ▁; ▁β ▁co e ffi cient
D-1531	-0.7843462228775024	eh ; LV compliance ; vn ; end-diastolic volume ; LV ; end-diastolic pressure ; hg ; β coefficient
P-1531	-0.2900 -0.2289 -1.2758 -1.7584 -0.3170 -4.9630 -0.6702 -0.6846 -3.4889 -0.2652 -0.0461 -0.4531 -0.3073 -0.5147 -0.3841 -1.9388 -0.7248 -2.1925 -0.2615 -0.0945 -0.4015 -0.4517 -1.0737 -0.4546 -0.5600 -0.1571 -0.9527 -0.0525 -0.0422 -0.2719 -0.0779 -0.6046 -0.4188 -0.2891
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal ; correlated ; pcwp ; p values
H-484	-1.4584301710128784	▁e - sept al ▁; ▁pc WP
D-484	-1.4584301710128784	e-septal ; pcWP
P-484	-1.0848 -4.8784 -0.5505 -0.3020 -0.4215 -0.1439 -3.1685 -2.2315 -0.3448
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad ; q66p ; rad ; cav1.2 ; cav1.3 ; l-type channel ; isoforms ; heart
H-1674	-0.6737398505210876	▁Rad ▁Q 66 p ▁; ▁inhibi tory ▁actions ▁; ▁Rad ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁; ▁l - type ▁channel ▁iso form s ▁; ▁heart
D-1674	-0.6737398505210876	Rad Q66p ; inhibitory actions ; Rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
P-1674	-1.0081 -2.4241 -1.4925 -0.2300 -0.2454 -0.2322 -0.6752 -1.3584 -0.2785 -1.5019 -0.4532 -0.2408 -1.1787 -0.6086 -0.3461 -1.9319 -1.1902 -0.4171 -0.3581 -0.7797 -0.1227 -0.0184 -0.0491 -0.0215 -0.0779 -0.5180 -0.2884 -1.5422 -0.3432 -0.2800
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-864	-0.6122297048568726	▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol ▁; HR
D-864	-0.6122297048568726	atrial fibrillation ; carvedilol ; metoprolol ;HR
P-864	-2.3962 -0.4339 -0.8193 -0.1845 -0.7044 -0.4369 -0.0391 -0.2798 -0.5034 -0.4233 -0.5440 -0.3628 -0.2670 -0.8550 -0.7912 -1.3183 -0.3777 -0.2832
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc ; dapc protein ; sarcomeric microstructure ; skm ; myofibre regeneration
H-1254	-0.6923476457595825	ERC ▁; ▁DAP c ▁; ▁protein ▁levels ▁; ▁sar come ric ▁micro structure ▁; ▁Sk m ▁; ▁my o fi bre ▁regenera tion
D-1254	-0.6923476457595825	ERC ; DAPc ; protein levels ; sarcomeric microstructure ; Skm ; myofibre regeneration
P-1254	-2.0865 -0.5704 -0.3139 -1.0225 -0.9518 -0.9365 -1.7054 -0.2817 -0.0447 -0.3919 -1.2008 -0.0534 -0.4196 -0.3531 -0.1213 -0.3945 -0.2764 -2.7401 -0.1136 -0.0953 -0.1390 -0.1982 -2.2136 -0.4081 -0.2765
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls ; lvef ; prognostic ; clinical ; echocardiographic ; systolic
H-820	-0.7214959263801575	▁g s ▁; ▁LV EF ▁; ▁sa ▁; ▁CV ▁; ▁benefit ▁; ▁e cho car dio graphic ▁sy sto lic ▁parameter s ▁; ▁AF
D-820	-0.7214959263801575	gs ; LVEF ; sa ; CV ; benefit ; echocardiographic systolic parameters ; AF
P-820	-0.3462 -1.7102 -0.2962 -1.0521 -2.7457 -0.2351 -0.5208 -0.5091 -1.3001 -0.4842 -2.7689 -0.2805 -0.4773 -0.3084 -0.2424 -0.6701 -1.1958 -0.0813 -0.0502 -0.2580 -0.4766 -0.4175 -0.2626 -1.5051 -0.3202 -0.2442
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes ; patients ; prescribed ; pharmacological ; discharge ; left ventricular function
H-1849	-0.8075376749038696	▁ pharma c ological ▁treatment ▁; ▁device ▁consideration ▁; ▁left ▁vent ri cular ▁function ▁assessment
D-1849	-0.8075376749038696	pharmacological treatment ; device consideration ; left ventricular function assessment
P-1849	-2.8892 -1.2871 -0.1207 -1.3115 -1.7788 -0.3096 -0.2240 -1.1566 -0.3424 -0.7698 -0.1367 -1.8117 -0.6469 -0.1710 -0.1119 -0.3602 -0.3000
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized ; walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; severe heart failure
H-569	-0.8878077268600464	▁Nordic ▁walking ▁; ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁heart ▁failure
D-569	-0.8878077268600464	Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
P-569	-0.9356 -1.2524 -0.2406 -2.2721 -0.0944 -1.5727 -0.2456 -0.2659 -0.5005 -0.3166 -3.4718 -0.5969 -0.3902 -0.2740
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia ; intravenous ; metoprolol ; cardiac ; sympathetic tone
H-1379	-0.5955005884170532	▁Brad y car dia ▁; ▁intra ven ous ▁met o pro lol ▁; ▁cardiac ▁sympa the tic ▁tone ▁; ▁rabbi ts ▁; ▁sham - in v ▁; ▁CHF - DN x
D-1379	-0.5955005884170532	Bradycardia ; intravenous metoprolol ; cardiac sympathetic tone ; rabbits ; sham-inv ; CHF-DNx
P-1379	-0.7861 -0.7610 -0.0895 -0.2279 -0.3802 -1.8396 -0.0818 -3.9703 -0.1048 -0.2005 -0.2209 -0.7520 -0.2490 -0.0855 -0.0538 -0.3918 -1.0961 -0.0567 -0.4116 -0.2424 -0.5349 -0.3039 -0.1276 -0.2718 -0.4925 -0.5481 -0.4544 -0.7921 -0.0892 -2.9437 -0.4926 -0.3263 -0.2730
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood transfusions ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
H-42	-0.6862215399742126	▁blood ▁trans fusion s ▁; ▁ir on ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁adults ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease ▁; ▁trans fusion
D-42	-0.6862215399742126	blood transfusions ; iron ; erythropoiesis-stimulating agents ; adults ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
P-42	-1.0421 -0.0783 -0.2709 -0.3151 -0.3836 -0.2895 -0.1363 -0.3374 -0.3361 -0.6082 -0.6572 -0.4233 -1.8119 -0.4349 -0.7204 -0.0423 -1.2374 -0.6875 -0.3261 -2.3132 -0.4911 -1.1836 -0.4118 -0.3048 -0.2024 -0.8337 -4.0066 -0.9733 -0.4927 -0.2838 -0.0618 -2.1729 -0.7523 -0.6627 -0.3200 -0.0651 -0.5252 -0.3292 -0.2378
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence ; erythropoiesis-stimulating agent ; therapy ; venous thromboembolism
H-47	-0.8678596019744873	▁er y thro po ies is - stimul ating ▁agent ▁ therapy ▁; ▁benefits ▁; ▁ve nous ▁ thro mbo e mbol ism
D-47	-0.8678596019744873	erythropoiesis-stimulating agent therapy ; benefits ; venous thromboembolism
P-47	-1.2059 -1.3207 -1.2487 -0.8165 -1.6792 -0.6131 -0.5384 -0.0470 -1.6234 -0.0119 -0.3164 -0.1312 -0.2896 -1.1957 -0.3162 -4.0312 -1.0377 -0.2807 -0.3625 -1.7184 -0.1108 -0.2747 -1.9475 -0.3483 -0.2309
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular action potentials ; excitation-contraction ; myocardium
H-1671	-0.5633666515350342	▁l - type ▁volta ge - ga ted ▁; ▁vent ri cular ▁action ▁; ▁excita tion - con traction ▁; ▁ec ▁; ▁coup ling ▁; ▁my o car dium
D-1671	-0.5633666515350342	l-type voltage-gated ; ventricular action ; excitation-contraction ; ec ; coupling ; myocardium
P-1671	-0.5126 -0.2234 -0.0227 -0.0139 -0.1997 -0.2045 -0.1428 -1.3939 -0.6759 -0.3265 -2.4728 -0.8824 -0.2426 -0.9088 -0.2662 -2.0479 -0.2587 -0.2454 -0.7040 -0.3117 -0.7007 -0.4644 -1.0513 -0.5084 -0.3789 -1.2417 -0.0883 -0.0294 -0.1958 -0.4366 -0.3123
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart failure ; hf ; tumor necrosis factor ; tnf ; tnf antagonists ; disease ; severe hf
H-601	-0.9021828174591064	▁heart ▁failure ▁; HF ▁; ▁tumor ▁nec rosi s ▁factor ▁; ▁t bf ▁; ▁t n ▁; ▁anta gon ists ▁; ▁benefit ▁; ▁ HF
D-601	-0.9021828174591064	heart failure ;HF ; tumor necrosis factor ; tbf ; tn ; antagonists ; benefit ; HF
P-601	-2.2282 -0.5634 -0.2490 -1.0486 -0.2881 -0.1370 -0.2045 -0.0443 -0.2731 -0.3026 -0.2789 -2.7676 -1.4304 -0.3404 -1.0590 -2.8995 -0.5317 -0.5242 -0.0186 -1.0030 -0.2856 -3.4360 -0.2677 -1.7531 -1.8964 -0.3099 -0.2181
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable logistic analysis ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney ; prognostic ; hf index
H-1760	-0.6733972430229187	▁oxygen ▁up take ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁score ▁; ▁ HF ▁index
D-1760	-0.6733972430229187	oxygen uptake ; metabolic exercise ; cardiac ; kidney index score ; HF index
P-1760	-1.8056 -2.6878 -0.7834 -0.3465 -0.2777 -0.1715 -0.7794 -0.3859 -0.1708 -0.6440 -0.0632 -1.1529 -0.2520 -0.1170 -0.4542 -0.7376 -1.4447 -1.1532 -0.1093 -0.3516 -0.2529
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical ; genetic ; chf ; area under the curve ; auc ; genetic ; auc ; clinical ; auc
H-1456	-1.330634355545044	▁genetic ▁; ▁CHF ▁; ▁predict ive ▁; ▁cur ve ▁; AU c ▁; ▁genetic ▁; ▁ab c ▁; ▁clinic al ▁; AU c
D-1456	-1.330634355545044	genetic ; CHF ; predictive ; curve ;AUc ; genetic ; abc ; clinical ;AUc
P-1456	-2.7993 -1.6809 -0.3989 -0.3221 -1.8165 -0.9506 -0.9277 -1.9236 -0.2574 -0.3503 -3.4934 -2.5435 -0.3218 -0.6164 -0.3336 -4.5226 -1.6335 -1.1773 -0.5144 -0.3623 -0.4021 -3.0562 -2.2838 -0.3109 -0.2667
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous ; chronic myocardial ischemia ; stent ; polytetrafluoroethylene
H-504	-0.5941385626792908	▁chronic ▁my o card ial ▁ ische mia ▁; ▁sten t ▁; ▁poly te tra flu oro e thy lene ▁tube
D-504	-0.5941385626792908	chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
P-504	-2.0420 -2.8807 -0.3207 -0.8669 -1.4718 -0.2794 -0.4576 -0.6341 -0.3491 -0.0379 -0.1117 -0.4060 -0.1936 -0.3170 -1.6936 -0.0279 -0.0403 -0.1417 -0.0445 -0.5514 -0.1444 -0.3787 -0.2743
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable adjustment ; mortality ; hospitalization ; hazard ratio ; cardiovascular mortality ; hf ; hospitalization
H-1638	-0.8457844257354736	▁black ▁race ▁; ▁mortal iteit ▁; ▁hospital ization ▁; haz ard ▁ratio ▁; HR ▁; ▁cardiovascular ▁mortal iteit ▁; HF ▁; ▁hospital ization ▁; HR
D-1638	-0.8457844257354736	black race ; mortaliteit ; hospitalization ;hazard ratio ;HR ; cardiovascular mortaliteit ;HF ; hospitalization ;HR
P-1638	-0.0846 -0.5182 -0.3060 -0.8887 -2.3803 -0.3331 -1.4390 -1.2452 -0.3235 -0.0662 -0.0913 -0.1357 -0.2425 -2.0416 -0.3379 -0.2005 -0.6265 -2.7407 -0.3152 -1.4806 -1.1523 -0.3636 -1.2811 -0.5013 -3.0435 -0.3847 -0.3125
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers for medicare and medicaid services ; cms ; hospital ; outcomes ; reported ; mortality ; readmission ; penalties
H-1031	-0.7688837647438049	▁Center s ▁voor ▁Medica re ▁and ▁Medica id ▁Services ▁; ▁c ms ▁; ▁hospital ▁; ▁mortal iteit ▁; ▁read mission ▁rates ▁; ▁penal ties
D-1031	-0.7688837647438049	Centers voor Medicare and Medicaid Services ; cms ; hospital ; mortaliteit ; readmission rates ; penalties
P-1031	-0.9356 -0.4450 -1.2227 -0.1116 -0.2268 -1.9724 -0.0413 -0.0484 -0.7007 -0.2811 -0.7946 -0.8949 -0.4064 -2.0435 -1.3233 -0.9247 -2.2947 -0.3602 -1.6322 -1.0592 -0.3681 -0.4117 -0.5670 -0.2108 -0.4096 -0.3045
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade ; halt ; disease ; protein kinase ; pka ; β-adrenergic receptor
H-1425	-0.5570476651191711	▁β - block ade ▁; ▁disease ▁progression ▁; ▁c AMP - dependent ▁protein ▁kina se ▁; ▁p ka ▁; ▁β - ad r energi c ▁receptor ▁activa tion
D-1425	-0.5570476651191711	β-blockade ; disease progression ; cAMP-dependent protein kinase ; pka ; β-adrenergic receptor activation
P-1425	-0.4579 -0.1736 -1.0154 -1.2246 -0.3885 -1.2881 -0.1752 -0.3773 -0.0992 -0.5797 -0.1703 -0.0637 -0.1630 -0.0111 -0.2104 -0.5531 -1.0364 -2.3108 -0.4208 -0.7181 -0.1020 -0.2675 -0.2731 -1.5442 -0.4060 -0.0665 -0.0340 -1.8549 -0.4644 -0.2614
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right heart circulatory failure ; disease ; right heart
H-1460	-1.1298656463623047	▁right ▁heart ▁; ▁circula tory ▁failure ▁; ▁right ▁heart
D-1460	-1.1298656463623047	right heart ; circulatory failure ; right heart
P-1460	-2.6229 -1.6167 -0.3642 -0.0145 -0.5962 -0.1905 -0.3310 -4.7438 -1.3491 -0.3164 -0.2831
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf ; hospitalization
H-563	-1.1982694864273071	▁ HF
D-563	-1.1982694864273071	HF
P-563	-2.1534 -1.8176 -0.4306 -0.3915
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade ; clinical
H-202	-0.8491703271865845	▁Grad ing ▁of ▁re com mend ations ▁assessment ▁; ▁development ▁and ▁evaluat ion ▁; GRAD e
D-202	-0.8491703271865845	Grading of recommendations assessment ; development and evaluation ;GRADe
P-202	-1.3635 -1.2194 -1.9181 -0.6473 -0.4811 -0.5986 -0.0333 -0.5239 -1.1385 -0.9465 -2.3049 -0.1942 -1.9498 -0.2167 -0.7686 -0.3843 -0.3692 -0.2273
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; patients ; systolic dysfunction
H-1733	-0.6481644511222839	▁al do ster one ▁anta gon ism ▁; ▁heart ▁failure ▁; ▁al do ster one ▁; ▁neuro hormon e ▁; ▁electro ly tes ▁; ▁heart ▁failure ▁; ▁sy sto lic ▁dys function
D-1733	-0.6481644511222839	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
P-1733	-0.5198 -0.1134 -0.3563 -2.0184 -0.4199 -0.0510 -3.1909 -0.3140 -2.7376 -0.9516 -0.2882 -1.7712 -0.2479 -0.2873 -1.3470 -0.3388 -0.1221 -0.0892 -0.1478 -0.3543 -0.0130 -0.6821 -0.1323 -0.3454 -2.8490 -0.6616 -0.3038 -0.1599 -0.1302 -0.2385 -0.0299 -0.1024 -0.4342 -0.2886
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1 receptors ; neprilysin ; renin-angiotensin-aldosteron ; ras ; vasodilatory ; diuretic ; natriuretic peptides
H-1967	-0.4453809857368469	▁AT 1 ▁receptor s ▁; ▁nepri ly sin ▁block s ▁; ▁re nin - angi oten sin - al do ster on ▁; RAS ▁; ▁vaso dila tory ▁; ▁di ure tic ▁effect ▁; ▁na tri ure tic ▁pe pti des
D-1967	-0.4453809857368469	AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; vasodilatory ; diuretic effect ; natriuretic peptides
P-1967	-0.9344 -0.8506 -0.0108 -0.4341 -0.3532 -0.0919 -0.2312 -1.4186 -0.2954 -0.3117 -0.3990 -0.0183 -0.3573 -0.1552 -0.0017 -0.3527 -2.3908 -0.1821 -0.0299 -0.1367 -0.1761 -0.2438 -0.3285 -0.3668 -0.3133 -0.4579 -0.0257 -0.5290 -0.3080 -0.4513 -0.1893 -1.6403 -0.0947 -0.3062 -0.0155 -0.5025 -0.7781 -1.4171 -1.0541 -0.1944 -0.1837 -0.3278 -0.2917
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate analysis ; bnp ; estimated glomerular filtration rate ; hypertension ; transmitral ; e-wave ; diastolic mitral annular velocity
H-1570	-0.6463941335678101	▁b p ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁hyper tension ▁; ▁transmit ral ▁e - wa ve ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1570	-0.6463941335678101	bp ; glomerular filtration rate ; hypertension ; transmitral e-wave ; diastolic mitral annular velocity
P-1570	-1.3054 -2.5514 -0.3546 -0.5084 -0.3591 -0.0934 -0.0697 -1.8108 -1.2694 -0.3474 -0.1013 -0.0455 -0.3565 -0.3812 -1.3997 -2.8321 -0.1575 -0.8288 -0.2153 -0.3207 -0.1135 -0.2202 -0.0847 -0.4690 -0.2435 -1.5991 -0.0747 -0.3690 -0.7366 -0.4935 -0.3259
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine ; exercise capacity ; left ventricular filling ; patients ; heart failure with preserved ejection fraction ; hfpef
H-1171	-0.5848317742347717	▁i va bra dine ▁; ▁exercise ▁capacity ▁; ▁left ▁vent ri cular ▁fill ing ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1171	-0.5848317742347717	ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
P-1171	-0.0928 -0.0302 -0.4037 -0.9601 -0.2781 -1.2627 -0.3009 -0.2816 -0.6794 -0.1577 -1.7059 -0.3911 -0.6634 -0.2145 -0.2947 -1.8782 -0.4057 -0.2258 -0.9417 -0.2377 -1.5224 -0.0875 -0.2679 -0.0700 -0.2449 -0.0162 -0.3195 -2.6510 -0.0914 -1.4210 -0.3559 -0.2612
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-1.2277789115905762	▁medication ▁; no nadh er ence ▁; ▁salt ▁in take
D-559	-1.2277789115905762	medication ;nonadherence ; salt intake
P-559	-0.5965 -0.5106 -2.6550 -2.3699 -0.0503 -3.5020 -0.6875 -0.3603 -0.1355 -1.0030 -2.5327 -0.3301
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized ; hr variability ; hr variability ; clinical ; risk stratification ; cardiac ; patients
H-1591	-1.5289292335510254	▁HR ▁variabil iteit ▁; tur bul ence ▁; ▁HR ▁variabil iteit ▁; tur bul ence ▁; ▁cardiac ▁patients
D-1591	-1.5289292335510254	HR variabiliteit ;turbulence ; HR variabiliteit ;turbulence ; cardiac patients
P-1591	-2.1345 -0.4824 -2.8614 -0.9762 -1.2369 -2.0366 -4.5403 -0.3078 -2.0768 -0.1326 -3.2998 -0.7133 -1.2946 -1.8478 -4.0067 -0.3012 -0.4688 -1.2778 -0.3123 -0.2708
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine ; nesiritide ; renal function ; patients ; acute heart failure ; renal dysfunction
H-72	-0.434552937746048	▁dop amine ▁; ▁low - dos e ▁nesi riti de ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
D-72	-0.434552937746048	dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
P-72	-0.3882 -0.2366 -0.3493 -2.3447 -0.1314 -0.4887 -0.1903 -0.3815 -0.2782 -0.4006 -0.3824 -0.4963 -0.2673 -0.2835 -1.0761 -0.1728 -1.0415 -0.3313 -0.2478 -0.0893 -0.1130 -0.1061 -0.3888 -0.2435
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical ; hm ii ; heartware ; patients ; economic ; hm ii
H-310	-0.8631651997566223	▁h m ▁i i ▁; ▁Heart War e ▁; ▁economische ▁; HM ▁i i
D-310	-0.8631651997566223	hm ii ; HeartWare ; economische ;HM ii
P-310	-2.0049 -1.1084 -1.3052 -0.9083 -0.2189 -0.7235 -0.1297 -0.0364 -0.8308 -0.9550 -0.5318 -2.5295 -1.5895 -0.2675 -0.3280 -0.3433
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death ; patients ; estimated glomerular filtration rate ; odds ratio ; confidence interval
H-977	-0.7983893752098083	▁death ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; odd s ▁ratio
D-977	-0.7983893752098083	death ; glomerular filtration rate ;odds ratio
P-977	-4.3367 -0.4734 -0.2589 -0.4485 -0.0971 -0.0754 -2.1603 -1.5808 -0.5161 -0.0291 -0.1546 -0.1579 -0.5660 -0.3226
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate model ; creatinine ; hazard ratio ; confidence interval ; mortality
H-717	-0.4565245509147644	▁creati nine ▁; haz ard ▁ratio ▁; ▁significant ▁; ▁post - trans plant ▁mortal iteit
D-717	-0.4565245509147644	creatinine ;hazard ratio ; significant ; post-transplant mortaliteit
P-717	-0.1192 -1.5413 -0.3561 -0.1251 -0.0484 -0.0343 -0.3858 -0.3684 -0.5924 -0.1444 -0.1168 -0.1062 -0.1073 -0.2036 -2.8281 -0.3573 -0.3260
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad ; surgery ; patients ; albumin ; hypoalbuminemia ; surgery
H-534	-0.7727349996566772	▁l VAD ▁; ▁surgery ▁; ▁album in ▁levels ▁; ▁hypo album in emia ▁; ▁surgery
D-534	-0.7727349996566772	lVAD ; surgery ; albumin levels ; hypoalbuminemia ; surgery
P-534	-0.1460 -0.4284 -0.3640 -3.3184 -0.3898 -1.3394 -0.2703 -3.1923 -0.4384 -0.2654 -0.2139 -0.1748 -1.1268 -0.5256 -0.2525 -0.3815 -0.3088
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological ; diagnostic ; prognostic
H-1278	-1.0933887958526611	▁pat ho phy si ological
D-1278	-1.0933887958526611	pathophysiological
P-1278	-0.5845 -0.4753 -0.9829 -2.1325 -0.7975 -2.4232 -0.2578
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox proportional hazard models ; covariates ; follow-up ; physician ; discharge ; primary outcome ; death ; all-cause readmission
H-1416	-0.6381905674934387	▁co x ▁proportion al ▁hazard ▁; ▁follow - up ▁; ▁physician ▁; ▁dis charge ▁; ▁death ▁; ▁urgent ▁all - ca use ▁read mission
D-1416	-0.6381905674934387	cox proportional hazard ; follow-up ; physician ; discharge ; death ; urgent all-cause readmission
P-1416	-0.0619 -0.4673 -0.0296 -0.0694 -0.1185 -0.7308 -0.0667 -0.2551 -0.0453 -0.3277 -2.6274 -0.3452 -1.2761 -0.4083 -0.3625 -1.8794 -0.2909 -0.8916 -1.3153 -0.0988 -0.0997 -2.0002 -0.9401 -1.2445 -0.3495 -0.2911
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate logistic regression analysis ; rule ; cad ; stenosis ; 3-vessel cad ; 2-vessel cad ; left anterior descending artery
H-1187	-1.0248961448669434	▁CAD ▁; ▁diameter ▁sten osis ▁; ▁left ▁main ▁; ▁CAD ▁; ▁CAD ▁; ▁proxima l ▁left ▁anterior ▁descend ing ▁arter y
D-1187	-1.0248961448669434	CAD ; diameter stenosis ; left main ; CAD ; CAD ; proximal left anterior descending artery
P-1187	-5.0789 -0.3137 -0.9040 -0.0175 -0.1257 -0.3856 -1.0860 -0.1558 -0.3963 -0.9678 -0.3423 -5.9283 -0.3205 -0.6768 -0.2927 -1.8238 -1.9034 -0.1931 -0.2824 -0.0644 -1.6764 -0.3720 -0.2649
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence ; mortality ; outcomes ; heart failure ; acute myocardial infarction ; patients ; acute myocardial infarction ; western australia
H-1305	-1.108283281326294	▁heart ▁failure ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁Western ▁Australia
D-1305	-1.108283281326294	heart failure ; acute myocardial infarction ; acute myocardial infarction ; Western Australia
P-1305	-2.5055 -0.6337 -0.2309 -0.8380 -0.3328 -3.2712 -0.6366 -1.6467 -2.2922 -0.2030 -0.8963 -1.1856 -0.2704 -1.3133 -0.3697 -2.5504 -0.5046 -1.4268 -2.0453 -0.1567 -0.8623 -0.9993 -0.2620 -1.9653 -1.8420 -0.4075 -0.2757
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized aldactone evaluation study ; symptomatic chronic advanced heart failure ; patients ; aldosterone antagonist ; spironolactone ; mortality ; placebo
H-1735	-0.8461742401123047	▁Rand om ized ▁al da cto ne ▁evaluat ion ▁Study ▁; ▁chronic ▁advanced ▁heart ▁failure ▁; ▁al do ster one ▁anta gon ist ▁; ▁spi rono lac tone ▁; ▁mortal iteit
D-1735	-0.8461742401123047	Randomized aldactone evaluation Study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone ; mortaliteit
P-1735	-1.1231 -4.2203 -0.1926 -0.2579 -0.5160 -0.7990 -0.8343 -0.3469 -1.8684 -0.5407 -0.2603 -3.4403 -2.6285 -1.6341 -0.2344 -0.3823 -0.2706 -0.0915 -0.3708 -1.2939 -1.1780 -0.0110 -1.3058 -0.2746 -0.0736 -0.0562 -0.1134 -0.1201 -0.3013 -0.1830 -1.9940 -0.6918 -0.3150
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular dilatation
H-334	-0.38133665919303894	▁mechanism ▁; ▁ann ular ▁size ▁re duction ▁; ▁surgery ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁di la tation
D-334	-0.38133665919303894	mechanism ; annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular dilatation
P-334	-0.0555 -0.2623 -2.0361 -0.0175 -0.6623 -0.1871 -0.1245 -0.2598 -0.1114 -0.2700 -0.0057 -0.1134 -0.0645 -0.3161 -0.1456 -0.4355 -0.8654 -0.0247 -1.0652 -0.1627 -0.3488 -0.2353 -0.2595 -0.0304 -0.0615 -0.2421 -0.3021 -0.6571 -0.2546 -1.1692 -0.3735 -0.1993 -0.3614 -0.5168 -0.0929 -1.5298 -0.3637 -0.6782 -0.2943 -0.2245 -0.3712 -0.2645
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients ; hypertensive hfpef ; dash ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
H-926	-0.6723285913467407	▁hyper tensi ve ▁H FP EF ▁; ▁so dium - re strict ed ▁DAS h ▁; ▁die t ▁; ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling
D-926	-0.6723285913467407	hypertensive HFPEF ; sodium-restricted DASh ; diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
P-926	-0.7945 -0.6093 -0.2600 -2.0749 -2.5888 -1.9108 -0.2716 -0.1159 -0.0678 -0.0808 -0.1046 -0.2993 -0.5870 -0.2499 -0.2533 -0.2399 -3.8659 -0.1230 -0.2959 -0.2386 -2.8874 -0.4594 -0.0406 -0.1622 -0.1141 -0.1954 -0.3324 -0.0976 -0.3223 -0.6885 -0.3236 -0.2412 -2.9555 -0.7921 -0.3658 -0.3620 -0.5613 -0.1685 -0.7948 -0.4330 -0.2366
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate ; signal transduction ; transcription factors ; pathological ; cardiomyocytes ; transcription factors ; epigenetic ; chromatin structure
H-1040	-0.4470127820968628	▁signal ▁trans duction ▁casca de ▁; ▁tran scription ▁factors ▁; ▁cardio my o cy tes ▁; ▁tran scription ▁factors ▁; ▁epi gene tic ▁changes ▁; ▁chr omat in ▁structure
D-1040	-0.4470127820968628	signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
P-1040	-0.5778 -0.0327 -0.8300 -0.0396 -0.0986 -0.2874 -0.1833 -0.1208 -0.3657 -0.2772 -0.7365 -0.7746 -0.2182 -0.1432 -0.1553 -0.3145 -0.3697 -0.2868 -0.5769 -0.2328 -0.8205 -0.8435 -1.9424 -1.3407 -0.3640 -0.0575 -0.0689 -0.3381 -0.8449 -0.3377 -0.2778
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf ; hct ; polymorphisms ; genes ; anthracycline ; metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
H-1450	-0.7432494759559631	▁CHF ▁; ▁h t ▁; ▁poly morph ism s ▁; ▁an thra cycli ne ▁metabolism ▁; ▁home osta sis ▁; ▁anti - oxid ant ▁de fen ce ▁; ▁my o card ial ▁remodel ling
D-1450	-0.7432494759559631	CHF ; ht ; polymorphisms ; anthracycline metabolism ; homeostasis ; anti-oxidant defence ; myocardial remodelling
P-1450	-0.9046 -0.2329 -1.0190 -2.2387 -0.3175 -0.1559 -0.0146 -2.4955 -0.4851 -0.3373 -0.4264 -0.1918 -0.5769 -1.9509 -0.2192 -0.3231 -2.9012 -0.1883 -1.4062 -0.3192 -0.0207 -0.1096 -0.0263 -0.4549 -0.9408 -0.0116 -2.5889 -0.4016 -1.4822 -0.1554 -0.9355 -1.3761 -0.0497 -0.7165 -0.4750 -0.3082
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs ; hdl ; phosphorylation
H-251	-0.8736907839775085	▁ec s ▁; ▁HD l ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁e NOS - Th r ▁; ▁PK c - β i - Ser
D-251	-0.8736907839775085	ecs ; HDl ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βi-Ser
P-251	-1.5432 -1.2665 -0.4196 -1.7822 -2.5503 -0.4680 -0.1795 -0.2162 -0.8374 -1.7732 -0.4568 -0.4279 -0.3046 -0.4840 -0.1728 -0.4207 -0.4424 -0.7456 -0.4055 -0.0850 -3.4919 -0.0068 -0.5584 -1.0351 -2.3246 -0.1610 -0.8917 -2.9283 -0.2071 -0.2071 -0.8465 -0.3182
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates ; crt ; death ; hf ; hospitalization ; hazard ratio ; lvef
H-757	-1.248013973236084	▁c t ▁; ▁sterf ▁; ▁ HF ▁; ▁hospital ization ▁; haz ard ▁ratio ▁; ▁LV EF
D-757	-1.248013973236084	ct ; sterf ; HF ; hospitalization ;hazard ratio ; LVEF
P-757	-0.6574 -3.9279 -1.0411 -4.5086 -1.7439 -1.2671 -2.3231 -1.1591 -0.3926 -1.0176 -0.4151 -0.6248 -0.1530 -0.0949 -0.4673 -1.1373 -2.1592 -0.3287 -0.2936
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart failure ; histologically ; myocardial collagen ; healthy ; heart failure
H-1062	-1.0555893182754517	▁heart ▁failure ▁; ▁my o card ial ▁collage n ▁; ▁heart ▁failure
D-1062	-1.0555893182754517	heart failure ; myocardial collagen ; heart failure
P-1062	-3.4835 -0.7456 -0.3024 -1.7800 -0.4926 -0.6091 -0.8809 -0.0252 -0.2156 -0.3274 -4.5305 -0.7515 -0.3571 -0.2770
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative ; alberta ; discharged ; hospital ; diagnosis ; heart failure
H-1415	-1.0038063526153564	▁administratie ▁; ▁Albert a ▁; ▁dis charge d ▁ali ve ▁; ▁hospital ▁; ▁heart ▁failure
D-1415	-1.0038063526153564	administratie ; Alberta ; discharged alive ; hospital ; heart failure
P-1415	-4.2097 -1.5388 -0.4566 -1.6522 -0.3236 -1.8804 -0.3708 -0.1026 -2.0896 -0.1156 -1.4557 -0.4738 -0.3237 -1.1916 -0.2883 -0.3627 -0.2292
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular myocytes ; sarcomere ; shortening
H-417	-0.5952033996582031	▁mouse ▁; ▁vent ri cular ▁my o cy tes ▁; ▁sar com ere ▁; ▁μ mol ▁; ▁ca (2 +) ▁trans ient
D-417	-0.5952033996582031	mouse ; ventricular myocytes ; sarcomere ; μmol ; ca(2+) transient
P-417	-0.5808 -0.3215 -0.0734 -1.6646 -0.3655 -1.4010 -0.2401 -0.1553 -0.2591 -0.3269 -0.3361 -0.3226 -1.1784 -0.4307 -3.0994 -0.1344 -0.4311 -0.3930 -1.3002 -0.0252 -0.0194 -0.6033 -0.3746 -0.2482
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts ; patients ; sts ; hh ; sts
H-155	-1.3633456230163574	▁s ts ▁; HH ▁; ▁h m ▁; ▁TM ▁; ▁s ts ▁; ▁TM
D-155	-1.3633456230163574	sts ;HH ; hm ; TM ; sts ; TM
P-155	-3.0823 -2.1061 -0.3482 -3.1451 -0.4646 -2.0109 -1.0212 -0.4391 -1.4989 -0.7716 -1.2547 -2.5940 -0.4038 -1.9985 -0.3343 -0.3402
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp ; 6-minute walking distance ; peak o2
H-829	-0.8874278664588928	▁PAS p
D-829	-0.8874278664588928	PASp
P-829	-1.4838 -1.1953 -0.5413 -0.3293
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications ; implantation ; lvad therapy ; transplantation ; btt ; dt ; medical therapy
H-313	-0.6746343374252319	▁complica tions ▁; ▁implant ation ▁; ▁l VAD ▁ therapy ▁; ▁transplant ation ▁e ligi bility ▁status ▁; ▁device ▁; ▁b t ▁; ▁d t ▁; ▁medical ▁ therapy
D-313	-0.6746343374252319	complications ; implantation ; lVAD therapy ; transplantation eligibility status ; device ; bt ; dt ; medical therapy
P-313	-0.3002 -2.4124 -0.3431 -0.6188 -1.7058 -0.4365 -0.2218 -0.1454 -1.1998 -0.0477 -0.3426 -0.4496 -2.1250 -0.4245 -0.0931 -1.8194 -0.2922 -0.3461 -0.5093 -0.4134 -2.0249 -0.6655 -0.3274 -0.9264 -0.3981 -0.3793 -0.8562 -0.4072 -0.0693 -0.3354 -0.2772
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor 1 ; s1pr1 ; downregulation ; cardiac ; hypertrophic ; heart failure ; s1pr1 ; cardiac ; gene ; therapy
H-1404	-0.7028040885925293	▁beta 1- ad r energi c ▁receptor ▁; ▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁reciproc al ▁down regul ation ▁; ▁cardiac ▁hyper trop hic ▁response ▁; ▁heart ▁failure ▁; ▁s 1 PR 1 ▁; ▁cardiac ▁gene ▁ therapy
D-1404	-0.7028040885925293	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 ; cardiac gene therapy
P-1404	-0.6650 -0.3151 -0.3350 -0.1267 -1.1549 -0.3670 -0.0285 -0.3176 -0.0096 -2.1057 -0.6088 -3.0542 -1.0833 -0.8774 -0.0093 -0.0288 -0.2297 -0.0394 -0.4177 -0.8261 -1.3115 -2.7665 -1.1246 -0.1751 -0.0764 -0.3491 -0.2020 -1.7742 -0.3549 -0.1072 -0.0796 -0.0267 -2.1737 -0.3989 -0.2746 -0.6119 -0.2415 -0.3130 -1.1020 -0.8729 -2.1189 -2.4052 -1.3435 -0.1235 -0.4931 -0.4700 -0.0230 -0.3339 -0.1901
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical ; artery tonometry ; prospectively ; admission ; patients ; icu ; clinical
H-580	-0.8552983403205872	▁radi al ▁arter y ▁ton ometr y ▁; ▁PH ▁; ICU
D-580	-0.8552983403205872	radial artery tonometry ; PH ;ICU
P-580	-0.5532 -0.1722 -0.1050 -2.3357 -0.2124 -0.0987 -1.3525 -0.3730 -3.5932 -0.3891 -1.2453 -0.3855 -0.3031
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased ; cardiomyocytes ; pde2 ; activity ; cgmp synthesis ; nitric oxide ; donors ; pde2 inhibition ; β-ar responsiveness
H-1215	-0.7577439546585083	▁cardio my o cy tes ▁; ▁p de 2 ▁activity ▁; ▁c g MP ▁; ▁ni tric ▁oxid e ▁donor s ▁; ▁p de 2 ▁inhibi tion ▁; ▁β - AR ▁responsive ness
D-1215	-0.7577439546585083	cardiomyocytes ; pde2 activity ; cgMP ; nitric oxide donors ; pde2 inhibition ; β-AR responsiveness
P-1215	-0.1589 -0.9514 -0.2817 -0.1433 -0.2431 -0.3990 -2.2193 -1.6465 -0.2599 -1.5687 -0.3761 -0.1311 -1.5214 -1.6714 -0.4411 -0.1450 -0.1643 -0.0433 -0.1203 -0.4413 -0.6253 -0.3419 -2.1303 -1.5817 -0.4437 -0.3219 -2.0728 -0.4749 -0.0612 -0.0646 -0.9137 -0.1113 -3.7827 -0.3895 -0.2785
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection fraction ; b-type natriuretic peptide ; patients ; hospitalized ; heart failure ; inhospital ; outcomes ; get with the guideline-heart failure registry
H-186	-0.7770493626594543	▁e je ction ▁ fraction ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁heart ▁failure ▁; ▁in hospital ▁outcome s ▁; ▁get ▁With ▁the ▁Guide line - He art ▁Fail ure ▁Registr y
D-186	-0.7770493626594543	ejection fraction ; b-type natriuretic peptide ; heart failure ; inhospital outcomes ; get With the Guideline-Heart Failure Registry
P-186	-0.2821 -0.6740 -0.0884 -0.2517 -0.0377 -0.3235 -1.1200 -0.1295 -0.0307 -0.0626 -1.4031 -0.7715 -1.7273 -0.5727 -0.1098 -0.4056 -0.5567 -2.2029 -0.5240 -0.3325 -2.6535 -0.3428 -0.7952 -0.2801 -0.3346 -0.4033 -2.1507 -0.9520 -1.8284 -0.1419 -0.2353 -1.9030 -2.3959 -0.7095 -1.9564 -0.5688 -0.3539 -0.3934 -0.2997
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast cancer ; patients ; medicare ; diagnosed ; breast cancer ; chemotherapy ; seer-medicare ; texas ; medicare
H-672	-0.8141640424728394	▁Breast ▁cancer ▁; ▁Medica re ▁coverage ▁; ▁breast ▁cancer ▁; ▁che mo therapy ▁; ▁ EER - Medic are ▁; ▁Texas ▁Cancer ▁Registr y - Medic are
D-672	-0.8141640424728394	Breast cancer ; Medicare coverage ; breast cancer ; chemotherapy ; EER-Medicare ; Texas Cancer Registry-Medicare
P-672	-1.4601 -0.7480 -1.4875 -0.6367 -0.0998 -0.3703 -0.3427 -2.2358 -0.5699 -0.3329 -0.4137 -0.2557 -0.1460 -0.4193 -2.4595 -1.6526 -0.1422 -0.1726 -1.2763 -0.3036 -1.1171 -2.1630 -0.4552 -0.2615 -1.4050 -0.5355 -1.4127 -0.4527 -0.2830
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome complex ; scaffold protein ; drives ; kinases ; phosphorylation ; effector molecules
H-995	-0.5694378018379211	▁e RK 1/2 ▁; ▁signal o some ▁complex ▁; ▁sc af fold ▁protein ▁; ▁kina ses ▁; ▁sequenti al ▁ phos phor y lation
D-995	-0.5694378018379211	eRK1/2 ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
P-995	-0.6314 -0.5250 -0.2333 -0.3255 -0.3862 -0.8388 -1.5262 -0.3931 -0.2320 -0.4093 -0.5939 -0.1548 -0.4135 -0.2801 -0.0919 -2.5997 -0.2533 -0.2890 -0.4995 -0.1751 -0.2186 -1.1400 -1.2493 -0.0888 -0.9605 -0.2969
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully magnetically levitated centrifugal-flow chronic lvas ; adverse event ; quality of life ; functional status
H-2006	-0.5867294073104858	▁magnet ically ▁le vita ted ▁centri fu gal - flow ▁chronic ▁l VAS
D-2006	-0.5867294073104858	magnetically levitated centrifugal-flow chronic lVAS
P-2006	-1.6239 -0.9073 -0.0904 -0.0098 -1.2214 -0.1509 -1.3017 -0.2136 -0.6610 -0.1369 -0.4889 -0.5379 -0.6720 -0.5342 -0.2510
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko ; cardiac ; irs1 ; irs2 ; proteins ; heart failure ; cardiac energy metabolism gene expression ; p38α ; mitogen-activated protein kinase ; p38
H-656	-0.6974413990974426	▁l - d ko ▁; ▁cardiac ▁; ▁i RS 1 ▁; ▁i RS 2 ▁protein s ▁; ▁heart ▁failure ▁; ▁cardiac ▁energy ▁metabolism ▁; ▁p 38 α ▁; ▁mit ogen - activa ted ▁protein ▁kina se
D-656	-0.6974413990974426	l-dko ; cardiac ; iRS1 ; iRS2 proteins ; heart failure ; cardiac energy metabolism ; p38α ; mitogen-activated protein kinase
P-656	-0.1389 -0.2788 -0.2376 -0.7524 -1.2201 -0.9543 -0.4885 -1.0508 -1.3198 -2.0312 -0.4099 -2.0159 -1.0873 -0.1046 -1.6811 -0.5141 -0.3410 -1.1903 -0.4195 -0.3294 -0.6918 -1.0505 -0.0479 -0.2567 -0.7569 -0.7749 -0.9481 -1.3258 -0.4583 -0.0946 -0.3342 -0.0492 -1.8307 -0.1915 -0.0154 -0.3417 -0.4601 -0.3091
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients ; heart failure
H-1744	-1.2490684986114502	▁heart ▁failure ▁; ▁treatment
D-1744	-1.2490684986114502	heart failure ; treatment
P-1744	-2.9737 -0.4824 -2.3157 -0.8585 -0.4984 -0.3658
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals ; patients ; hospitalized ; heart failure ; hf ; conditions ; acute myocardial infarction ; pneumonia ; conditions
H-1032	-0.9211305379867554	▁hospital s ▁; ▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁pneu monia
D-1032	-0.9211305379867554	hospitals ; heart failure ;HF ; acute myocardial infarction ; pneumonia
P-1032	-3.2157 -1.1210 -0.3245 -1.9947 -0.3122 -0.2728 -1.3387 -0.2950 -3.4931 -0.0986 -2.2804 -0.1960 -0.3671 -1.6841 -0.0679 -0.5229 -0.7651 -0.3272 -0.2151 -0.7249 -0.3543 -0.2933
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol ; metoprolol ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-855	-0.47474977374076843	▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁; ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD - c RT ▁trial ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy
D-855	-0.47474977374076843	carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-cRT trial ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
P-855	-0.0820 -0.2095 -0.1948 -0.2865 -0.0851 -0.1548 -0.0942 -0.3080 -0.3141 -0.6003 -0.1145 -0.4230 -0.1952 -0.1161 -0.6691 -0.2535 -0.2336 -0.2942 -1.4246 -0.6129 -0.2441 -0.3023 -0.0564 -0.3760 -1.1100 -1.0209 -0.6829 -3.1843 -0.7710 -0.2589 -0.9726 -0.0385 -0.2935 -0.1039 -0.3190 -0.0987 -0.6585 -0.1158 -0.3042 -1.0581 -1.8911 -0.4051 -0.5782 -0.3430 -0.0300 -0.0038 -0.8739 -0.3700 -0.3682 -0.2385
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise ; training ; peak oxygen consumption ; quality of life ; obese ; patients ; heart failure with preserved ejection fraction ; randomized ; clinical
H-1973	-0.6426454782485962	▁Cal o ric ▁re stri ction ▁; ▁aero bic ▁Exerci se ▁Training ▁; ▁Peak ▁o xy gen ▁Consum p tion ▁; ▁Old er ▁; ▁Patient s ▁; ▁Heart ▁Fail ure ▁; ▁e je ction ▁Fra ction
D-1973	-0.6426454782485962	Caloric restriction ; aerobic Exercise Training ; Peak oxygen Consumption ; Older ; Patients ; Heart Failure ; ejection Fraction
P-1973	-0.5740 -0.6050 -0.4634 -0.6708 -0.4534 -0.4259 -0.2954 -0.7551 -0.4780 -0.5505 -0.3496 -0.7318 -0.2844 -0.2171 -0.3362 -0.4129 -0.0793 -0.1681 -0.3024 -0.3313 -0.3037 -4.6825 -0.0831 -0.6300 -2.9673 -0.3189 -0.6935 -0.8434 -0.1796 -1.6462 -0.2959 -2.0858 -0.1228 -0.0494 -0.4360 -0.0703 -0.3293 -0.1984
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left ventricular assist devices ; lvads ; chronic end-stage heart failure ; bridge to transplantation ; btt ; patients ; destination therapy ; dt
H-308	-0.6435874700546265	▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁chronic ▁end - s tage ▁heart ▁failure ▁; ▁ bridge ▁to ▁transplant ation ▁; ▁b t ▁; ▁transplant - ine ligi ble ▁patients ▁; ▁de stin ation ▁ therapy ▁; ▁d t
D-308	-0.6435874700546265	ventricular assist devices ; lVADs ; chronic end-stage heart failure ; bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy ; dt
P-308	-1.2964 -1.6990 -0.2621 -0.4608 -0.4928 -0.3516 -0.1069 -0.2120 -0.3109 -0.3579 -2.6695 -1.2435 -0.1406 -0.3060 -0.0885 -1.2469 -0.4859 -0.2838 -1.0999 -0.0105 -0.4611 -0.4257 -1.8291 -0.3574 -1.0774 -0.4170 -0.2910 -1.8721 -0.1895 -1.5392 -0.3166 -1.7043 -0.7827 -0.2575 -0.3339 -0.2179 -0.6558 -0.1809 -0.0393 -0.4448 -0.1090 -1.0710 -0.3715 -0.2476
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1 time ; correlated ; right ventricular-pulmonary arterial coupling ; pulmonary vascular resistance ; right ventricular ejection fraction
H-742	-0.9679954648017883	▁right ▁vent ri cular - pul mon ary ▁arterial ▁coup ling ▁; ▁pul mon ary ▁vas cular ▁resist ance ▁; ▁right ▁vent ri cular ▁e je ction ▁ fraction
D-742	-0.9679954648017883	right ventricular-pulmonary arterial coupling ; pulmonary vascular resistance ; right ventricular ejection fraction
P-742	-1.2797 -0.6563 -2.5280 -0.7165 -0.4510 -2.1925 -1.8917 -0.9633 -0.1281 -0.1774 -0.5685 -0.2871 -3.8682 -2.5664 -0.6611 -0.1023 -0.4874 -0.2246 -0.6656 -0.3573 -2.1514 -0.4688 -2.6943 -1.1385 -0.6402 -0.4285 -0.3035 -0.4399 -0.0569 -0.5719 -0.3408
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted ; interatrial shunt ; clinical ; haemodynamic ; outcomes ; patients ; heart failure with reduced ejection fraction
H-1962	-0.5587044358253479	▁implant ed ▁left - to - right ▁inter at rial ▁shu nt ▁; ▁ha emo dynamic ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1962	-0.5587044358253479	implanted left-to-right interatrial shunt ; haemodynamic ; heart failure ; ejection fraction
P-1962	-2.6570 -0.4814 -1.6503 -0.1110 -0.5628 -0.2345 -1.1372 -0.0554 -0.1298 -0.8818 -0.2539 -0.3351 -0.3962 -0.0419 -0.1835 -0.0157 -0.8731 -2.7972 -0.4119 -0.2780 -0.1688 -0.2415 -0.1783 -0.2777 -0.0285 -0.4327 -0.2697
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative risk ; rr ; heart failure ; bisphophonates ; rr ; confidence interval ; hazard ratio
H-1540	-1.1314207315444946	▁r ▁; ▁heart ▁failure ▁; ▁bis pho phon ates ▁; ▁cru de ▁ RR ▁; ▁ nc ▁; ▁hazard ▁ratio ▁; HR
D-1540	-1.1314207315444946	r ; heart failure ; bisphophonates ; crude RR ; nc ; hazard ratio ;HR
P-1540	-1.4348 -2.3423 -2.2244 -0.6001 -0.3623 -0.0938 -0.3222 -0.3484 -2.4652 -0.3650 -0.1616 -0.1992 -0.6763 -1.8694 -0.3825 -4.1187 -3.2812 -1.5329 -0.7853 -0.1185 -0.3650 -2.3699 -0.4069 -0.3283
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp ; red blood cell transfusion ; hemoglobin ; hemoglobin ; hospitalized ; patients ; coronary heart disease
H-36	-1.0036344528198242	▁ab c ▁; ▁red ▁blood ▁cell ▁trans fusion ▁; ▁hem o glob in ▁thre s hold ▁; ▁hem o glob in ▁levels ▁; ▁corona ry ▁heart ▁disease
D-36	-1.0036344528198242	abc ; red blood cell transfusion ; hemoglobin threshold ; hemoglobin levels ; coronary heart disease
P-36	-3.0968 -3.3196 -0.4110 -1.5122 -0.7693 -1.1155 -0.0611 -0.0967 -0.6243 -1.9147 -0.9590 -1.0034 -1.3374 -0.1166 -0.3864 -1.8219 -0.2876 -0.7306 -0.8504 -0.7724 -0.9178 -0.7350 -0.2724 -0.4946 -3.1690 -0.8959 -0.7605 -0.3696 -0.3037
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare ; centers for medicare and medicaid services ; clinics ; propensity-score
H-1621	-0.6659973859786987	▁Medica re ▁; ▁Center s ▁voor ▁Medica re ▁; ▁Medica id ▁Services
D-1621	-0.6659973859786987	Medicare ; Centers voor Medicare ; Medicaid Services
P-1621	-1.6326 -0.4768 -0.4446 -3.0649 -0.5276 -1.0653 -0.1013 -0.2911 -0.3870 -0.0408 -0.0945 -0.5087 -0.3434 -0.3452
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic ; therapy
H-83	-0.4327470362186432	▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁dop amine ▁; ▁low - dos e ▁nesi riti de ▁; ▁de con gestion ▁; ▁renal ▁function ▁; ▁di ure tic ▁ therapy
D-83	-0.4327470362186432	acute heart failure ; renal dysfunction ; dopamine ; low-dose nesiritide ; decongestion ; renal function ; diuretic therapy
P-83	-0.7432 -0.0976 -1.0084 -0.1909 -0.2274 -0.1092 -0.1249 -0.1435 -0.3309 -0.0721 -0.3322 -0.3455 -3.3853 -0.1889 -0.3561 -0.1388 -0.2752 -0.4648 -0.3689 -0.2833 -1.0604 -0.0543 -0.4281 -0.2931 -0.0900 -0.2770 -0.3143 -0.4132 -0.3027 -1.3879 -0.2263 -0.0737 -0.3846 -0.2206
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm control therapy ; diagnosis ; atrial ; sinus rhythm ; rhythm control ; symptoms ; rate control
H-1646	-0.6964404582977295	▁ Rhythm ▁control ▁ therapy ▁; ▁AF ▁; ▁at rial ▁structure ▁; ▁function ▁; ▁sinus ▁ rhythm ▁; ▁de lay ed ▁ rhythm ▁control ▁; ▁rate ▁control
D-1646	-0.6964404582977295	Rhythm control therapy ; AF ; atrial structure ; function ; sinus rhythm ; delayed rhythm control ; rate control
P-1646	-0.5057 -1.4268 -1.6541 -0.6602 -0.0775 -0.3657 -0.9872 -0.2883 -1.4596 -0.4691 -0.2957 -0.2617 -1.8708 -0.2820 -0.6494 -0.6143 -1.2873 -0.2738 -0.6920 -0.1275 -0.3236 -0.2454 -1.6857 -1.1784 -0.2747 -0.9492 -0.6578 -0.3922 -0.2412
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq ; new york heart association class ; patients ; hfpef ; hf with reduced ef
H-788	-1.0503878593444824	▁ nc w t ▁; ▁New ▁York ▁Heart ▁association ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁EF
D-788	-1.0503878593444824	ncwt ; New York Heart association ; HFpEF ; HF ; EF
P-788	-1.6588 -0.9335 -0.0787 -3.1258 -0.2900 -1.6346 -1.6829 -1.7005 -0.5007 -0.3869 -0.9206 -1.6176 -0.0770 -0.6636 -0.3234 -1.7821 -3.0074 -0.3353 -0.6061 -0.4231 -0.3095
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil ; heart failure ; hemodynamic ; mitochondrial dysfunction ; antitumor ; activity
H-967	-0.42653241753578186	▁nic oran dil ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s ▁; ▁hem o dynamic ▁perturba tions ▁; ▁mito cho ndri al ▁dys function ▁; ▁anti tum or ▁activity
D-967	-0.42653241753578186	nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; antitumor activity
P-967	-0.1062 -0.1375 -1.0678 -0.2700 -0.2963 -0.0812 -0.0395 -1.8430 -0.2728 -0.4607 -0.9667 -1.3495 -0.5304 -0.2482 -0.6990 -0.3321 -0.3571 -0.5725 -0.2646 -0.1097 -0.0164 -1.3071 -0.3352 -0.0450 -0.6172 -0.2262 -0.1880 -0.0327 -0.0372 -0.2631 -0.1276 -0.4101 -0.0303 -1.1172 -0.3372 -0.2598
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician ; heart failure ; clinical practice guideline ; cpg ; outcomes ; heart failure ; hf
H-1841	-1.0781242847442627	▁guide line ▁; ▁heart ▁failure ▁; ▁Clinic al ▁practice ▁Guide line ▁; ▁p g ▁; ▁heart ▁failure ▁; HF
D-1841	-1.0781242847442627	guideline ; heart failure ; Clinical practice Guideline ; pg ; heart failure ;HF
P-1841	-3.7754 -0.1334 -1.2509 -1.8059 -0.4386 -0.3946 -1.1489 -0.1124 -0.3753 -1.4066 -0.3084 -0.3302 -2.2258 -2.1706 -0.4415 -2.3793 -0.3560 -0.3167 -2.4944 -0.4875 -0.2881
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf ; prospective ; dual-energy x-ray absorptiometry ; echocardiography ; blood
H-1161	-0.9013587236404419	▁ HF ▁; ▁body ▁composition ▁; s kin fold ▁thi ck ness ▁; ▁dual - ener gy ▁X - ray ▁ab sor pti ometr y ▁; ▁e cho card i ography ▁; ▁blood ▁testing
D-1161	-0.9013587236404419	HF ; body composition ;skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
P-1161	-2.4657 -1.2740 -0.3171 -2.7585 -0.4417 -0.3147 -4.0227 -3.6352 -0.1295 -0.3462 -0.0391 -1.5306 -0.4348 -0.3597 -0.2368 -1.7466 -1.3754 -2.1440 -0.2132 -1.1141 -0.0320 -0.5129 -0.6539 -0.6255 -1.5310 -0.4005 -0.1644 -0.2873 -0.3990 -0.3700 -0.4245 -0.3204 -0.4758 -0.5592 -0.4772 -0.3159
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; hypertrophy ; heart failure
H-1787	-0.5922180414199829	▁cardiac ▁; ▁insulin - re si stance ▁; ▁mito cho ndri al ▁oxid ative ▁metabolism ▁; ▁metabol ic ▁; ▁cardiac ▁hyper trop hy ▁; ▁energy ▁deficit ▁; ▁hyper trop hy ▁; ▁heart ▁failure
D-1787	-0.5922180414199829	cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
P-1787	-0.4092 -0.8810 -0.0501 -0.1286 -0.2337 -2.1933 -0.0650 -0.2657 -0.0497 -0.9413 -0.2095 -0.0916 -0.0739 -1.0490 -0.2433 -0.2837 -1.0856 -0.1274 -0.5535 -0.4059 -0.2851 -0.1886 -2.6510 -0.2902 -0.6771 -0.0443 -0.2972 -0.4059 -0.4380 -3.8115 -0.2357 -1.1076 -0.3584 -0.3515 -0.2444
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2017	-1.0855382680892944	▁Tools ▁voor ▁economische ▁analysis ▁; ▁Patient ▁management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁; ▁kosten - ef ective ness ▁; ▁disease ▁management ▁programs ▁; ▁heart ▁failure
D-2017	-1.0855382680892944	Tools voor economische analysis ; Patient management Interventions ; Heart Failure ; kosten-efectiveness ; disease management programs ; heart failure
P-2017	-2.7618 -1.3888 -0.8395 -0.9496 -1.8127 -0.4639 -0.5317 -0.6013 -0.7265 -0.7416 -0.6988 -0.9222 -2.1629 -0.2266 -2.7961 -0.2236 -2.0511 -0.9217 -2.2749 -1.4088 -1.9186 -0.2244 -0.4503 -0.3452 -1.6907 -0.6661 -0.3512 -0.2444
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad ; rgk ; rem ; rem2 ; rad ; monomeric g proteins ; ventricular action potential ; gain ; cardiac ; l-type channel ; activity
H-1672	-0.5750983953475952	▁Rad ▁; ▁r GK ▁; ▁re m ▁; ▁rem 2 ▁; ▁Rad ▁; ▁Gem ▁; Kir ▁; ▁mono me ric ▁g ▁protein s ▁; ▁vent ri cular ▁action ▁; ▁ec ▁coup ling ▁; ▁cardiac ▁l - type ▁channel ▁activity
D-1672	-0.5750983953475952	Rad ; rGK ; rem ; rem2 ; Rad ; Gem ;Kir ; monomeric g proteins ; ventricular action ; ec coupling ; cardiac l-type channel activity
P-1672	-1.1761 -0.2826 -0.2972 -2.3295 -0.2268 -2.3879 -0.5726 -0.4147 -0.8022 -0.0876 -0.2140 -1.2451 -0.2230 -0.7893 -0.3074 -0.1294 -0.2956 -0.0042 -0.0610 -0.3334 -0.1696 -0.3097 -0.4148 -0.3294 -0.2249 -1.7749 -1.0073 -0.4397 -0.5238 -1.0424 -0.2440 -0.5253 -0.2697 -1.3538 -1.0739 -0.0761 -0.0160 -0.0903 -0.9069 -0.3674 -0.2398
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ; pvf ; implanted ; cardioverter-defibrillator device
H-1346	-0.6673741340637207	▁breath ing ▁control ▁; ▁cardiac ▁arrest ▁; ▁humans ▁; ▁puls e less ▁vent ri cular ▁fi bril lation ▁; ▁p bf ▁; ▁cardio ver ter - de fi br illa tor ▁device
D-1346	-0.6673741340637207	breathing control ; cardiac arrest ; humans ; pulseless ventricular fibrillation ; pbf ; cardioverter-defibrillator device
P-1346	-0.9560 -0.4345 -1.5733 -0.2547 -0.1998 -0.1795 -0.2270 -0.9806 -0.3048 -0.5578 -0.1950 -0.8336 -0.1436 -1.7808 -0.4334 -0.6948 -0.1619 -0.4152 -0.3311 -2.9880 -2.7102 -0.3167 -2.2618 -0.0928 -0.4981 -0.1895 -0.0622 -0.0921 -1.0515 -0.5673 -0.1424 -0.4407 -0.3804 -0.2397
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular ; dilatation
H-338	-0.4175053834915161	▁mechanism ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁; ▁v n
D-338	-0.4175053834915161	mechanism ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ; vn
P-338	-0.0515 -0.2719 -0.2738 -0.2082 -0.0618 -0.3156 -0.1872 -0.4644 -0.8182 -0.0232 -1.0643 -0.1626 -0.3550 -0.2197 -0.2858 -0.0289 -0.0605 -0.2377 -0.3287 -0.5133 -0.2430 -1.1391 -0.4222 -0.2070 -0.4172 -0.4975 -0.0881 -1.3962 -0.2014 -0.3618 -1.7658 -0.5905 -0.6507 -0.2822
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology ; heart failure with preserved ejection fraction ; hfpef ; myocardial extracellular matrix
H-734	-0.7445884943008423	▁pat ho phy si ology ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h bf ▁; ▁my o card ial ▁extra cel lular ▁matri x ▁accumula tion
D-734	-0.7445884943008423	pathophysiology ; heart failure ; preserved ejection fraction ; hbf ; myocardial extracellular matrix accumulation
P-734	-0.7909 -0.2732 -0.6164 -2.2275 -0.2347 -0.3214 -1.7056 -0.3165 -0.4642 -0.4931 -0.1802 -2.7216 -0.1118 -0.2837 -0.1327 -0.4651 -0.0391 -0.3020 -0.5560 -2.1569 -0.6293 -1.5795 -0.1629 -0.9998 -0.7930 -0.9025 -0.7097 -0.2537 -0.0424 -0.8162 -0.1152 -3.2023 -0.4582 -0.2585
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate cox model ; pasp ; exercise ; peak o2 ; prognostic ; hazard ratio ; peak o2 ; pasp
H-830	-0.9696839451789856	▁co x ▁model ▁analysis ▁; ▁PAS p ▁; ▁exercise ▁; haz ard ▁ratio ▁; ▁pas p
D-830	-0.9696839451789856	cox model analysis ; PASp ; exercise ;hazard ratio ; pasp
P-830	-0.0781 -0.6529 -0.5176 -1.4020 -0.4408 -1.6020 -0.9617 -0.5805 -2.5316 -0.3978 -2.4135 -0.2155 -0.1975 -0.4621 -2.8952 -0.8761 -0.9085 -0.3208
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral ; glucocorticoids ; hf
H-610	-1.0384972095489502	▁Oral ▁gluco cor tico ids ▁; ▁ HF ▁; ▁HR
D-610	-1.0384972095489502	Oral glucocorticoids ; HF ; HR
P-610	-1.6469 -0.2512 -0.9174 -1.3825 -1.8226 -0.4567 -1.1531 -0.9445 -0.7215 -2.5024 -0.3764 -0.2867
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi ; death ; medical ; hospitalization ; hf ; clinic ; outpatients ; hf ; health
H-385	-1.2538164854049683	▁ HF PSI ▁; ▁death ▁; ▁medical ▁hospital ization ▁; HF ▁; ▁clinic ▁out patient s ▁; ▁ HF ▁; ▁health ▁systems
D-385	-1.2538164854049683	HFPSI ; death ; medical hospitalization ;HF ; clinic outpatients ; HF ; health systems
P-385	-1.9047 -1.7211 -1.7247 -0.3188 -3.8705 -0.2903 -1.1047 -0.9192 -0.8001 -0.2894 -4.2851 -0.6446 -0.7420 -2.7443 -0.1151 -0.2298 -0.3288 -2.0554 -2.0454 -1.4309 -1.5831 -0.3430 -0.3262 -0.2745
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ; ea ; tac ; placebo
H-523	-0.7882660627365112	▁HR ▁; ▁i va bra dine ▁group ▁; ▁Ea ▁; ▁ TAC ▁; ▁place bo
D-523	-0.7882660627365112	HR ; ivabradine group ; Ea ; TAC ; placebo
P-523	-2.0951 -0.3699 -0.2575 -0.0252 -0.7531 -0.8305 -2.1117 -0.3515 -1.7600 -0.3402 -1.2327 -1.0551 -0.9111 -0.6344 -0.0277 -0.3667 -0.2783
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals ; get with the guidelines-heart failure ; hf ; patients ; ef ; ef ; ef ; ef
H-189	-0.9685631990432739	▁get ▁With ▁the ▁Guide lines - He art ▁Fail ure ▁; ▁ HF ▁; EF ▁; ▁border line ▁; EF ▁; ▁EF
D-189	-0.9685631990432739	get With the Guidelines-Heart Failure ; HF ;EF ; borderline ;EF ; EF
P-189	-0.5178 -2.7505 -1.0244 -0.9378 -0.1772 -0.1438 -2.2590 -1.0678 -0.2315 -1.4196 -0.3510 -2.4646 -1.7722 -0.3345 -1.6031 -0.3683 -0.2760 -0.0999 -0.3592 -1.2613 -0.5047 -2.5844 -0.3980 -0.3388
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change ; peak vo2 ; correlated ; change ; lean body mass ; change ; thigh ; muscle
H-1987	-0.6703152060508728	▁VO 2 ▁; ▁lean ▁body ▁mass ▁; ▁th igh ▁muscle ▁; inter mus cular ▁fat ▁ratio
D-1987	-0.6703152060508728	VO2 ; lean body mass ; thigh muscle ;intermuscular fat ratio
P-1987	-1.1547 -0.1063 -0.3004 -0.1941 -1.7173 -0.2352 -0.3529 -1.9754 -2.1904 -0.8447 -0.3512 -0.4227 -0.6130 -0.5046 -0.2760 -0.1433 -0.3806 -0.3029
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone supplementation ; exercise rehabilitation ; health ; outcomes ; patients ; chf ; testosterone
H-1325	-0.996822714805603	▁testosteron e ▁supplement ation ▁; ▁exercise ▁rehabilita tion ▁; ▁health ▁outcome s ▁; ▁CHF ▁; ▁low ▁testosteron e ▁status
D-1325	-0.996822714805603	testosterone supplementation ; exercise rehabilitation ; health outcomes ; CHF ; low testosterone status
P-1325	-0.4001 -0.0984 -1.8538 -2.5648 -0.3267 -0.9912 -0.2355 -1.2328 -0.3443 -3.3272 -0.8195 -0.6207 -0.3972 -4.3441 -0.2653 -2.0799 -0.2084 -0.0705 -0.1249 -0.3860 -0.2421
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up ; systemic ; adverse events ; patients ; dcm ; heart failure
H-1265	-1.1180076599121094	▁follow - up ▁; ▁et h nic ▁groups ▁; ▁CH m ▁; ▁ad ju nc tive ▁treatment ▁; ▁d c ▁; ▁heart ▁failure
D-1265	-1.1180076599121094	follow-up ; ethnic groups ; CHm ; adjunctive treatment ; dc ; heart failure
P-1265	-6.5219 -0.2021 -0.0373 -0.2944 -0.9099 -0.0514 -1.9091 -0.8193 -0.3889 -3.3642 -0.3263 -0.2653 -4.4113 -0.5800 -0.0739 -0.9776 -0.7006 -0.3009 -0.4779 -2.7398 -0.2481 -1.3581 -0.3356 -0.4082 -0.2480
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol ; therapy ; metoprolol ; hazard ratio ; confidence interval
H-862	-0.6557172536849976	▁car vedi lol ▁; ▁met o pro lol ▁; haz ard ▁ratio ▁; HR ▁; CI
D-862	-0.6557172536849976	carvedilol ; metoprolol ;hazard ratio ;HR ;CI
P-862	-0.0717 -0.3159 -0.4887 -0.3858 -0.8160 -0.3257 -0.2414 -0.5252 -0.4038 -0.1531 -0.0537 -0.0243 -0.3032 -1.9516 -0.5664 -4.5863 -0.2939 -0.2961
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase inhibitor ; pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; hf ; myocardial infarction
H-1136	-0.5416195392608643	▁a ce tyl cho line ster ase ▁inhibi tor ▁; ▁py rido stig mine ▁; ▁sympa t hova gal ▁balance ▁; ▁cardiac ▁remodel ing ▁; ▁cardiac ▁function ▁; HF ▁; ▁my o card ial ▁in far ction
D-1136	-0.5416195392608643	acetylcholinesterase inhibitor ; pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ;HF ; myocardial infarction
P-1136	-0.4336 -1.0763 -0.8136 -0.5535 -0.0868 -0.4752 -1.2070 -0.2145 -0.1456 -0.5950 -0.0044 -0.0168 -0.0036 -0.7079 -0.3317 -0.1500 -0.2445 -0.4834 -0.5274 -0.9939 -0.3260 -0.0904 -0.3258 -0.1973 -0.3563 -0.2056 -0.2091 -0.3705 -2.4736 -0.3148 -1.7653 -0.3696 -0.8045 -1.7511 -0.1752 -0.3500 -1.2491 -0.4480 -0.2764
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization ; admissions ; patient
H-900	-0.5195596218109131	▁re - hospital ization ▁; ▁ad missions
D-900	-0.5195596218109131	re-hospitalization ; admissions
P-900	-0.3166 -0.2082 -0.1052 -1.4267 -0.6029 -1.0424 -0.2933 -0.4269 -0.2539
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical ; cardiac arrest ; cardiopulmonary resuscitation ; cpr ; diagnosis ; posterior wall infarction ; hospitalized ; cardiac
H-1291	-0.831558883190155	▁cardiac ▁arrest ▁; ▁cardio pul mon ary ▁res uscita tion ▁; ▁c p ▁; ▁posterior ▁wall ▁in far ction ▁; ▁cardiac ▁centre
D-1291	-0.831558883190155	cardiac arrest ; cardiopulmonary resuscitation ; cp ; posterior wall infarction ; cardiac centre
P-1291	-3.2809 -0.3689 -0.2840 -0.1635 -1.5448 -2.9544 -1.5511 -0.1466 -0.1664 -1.6158 -0.3493 -0.4460 -2.7139 -0.3354 -0.1198 -0.8587 -0.0736 -0.4435 -0.5642 -0.3421 -0.2429 -0.6756 -0.4406 -0.2754
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory ; patients ; heart failure ; hf ; reduced ejection fraction ; renin-angiotensin system ; ras ; β-blockers ; all-cause mortality ; readmissions
H-175	-0.8088352680206299	▁heart ▁failure ▁; HF ▁; ▁e je ction ▁ fraction ▁; ▁r EF ▁; ▁re nin - angi oten sin ▁system ▁; RAS ▁; ▁β - block ers ▁; ▁doel ▁dose ▁; ▁mortal iteit ▁; ▁read missions
D-175	-0.8088352680206299	heart failure ;HF ; ejection fraction ; rEF ; renin-angiotensin system ;RAS ; β-blockers ; doel dose ; mortaliteit ; readmissions
P-175	-5.5407 -0.4255 -0.3398 -0.7445 -0.3322 -0.2459 -0.2265 -0.0868 -0.4364 -0.0176 -0.4039 -1.1623 -1.6391 -0.4029 -0.0329 -1.2810 -0.2075 -0.0061 -0.5946 -2.4820 -0.1346 -0.3806 -1.7779 -0.4754 -0.0997 -0.0956 -0.2723 -0.2547 -0.6923 -3.7112 -0.3872 -1.1156 -0.7880 -1.9183 -1.4971 -0.4067 -0.1905 -0.4359 -0.3027
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr ; scn5a ; ventricular systolic hf ; human induced pluripotent stem cell-derived cardiomyocytes ; hipsc-cms
H-1082	-0.5643755793571472	▁uc p ▁; ▁s cn 5 a ▁; ▁vent ri cular ▁sy sto lic ▁ HF ▁; ▁tissu e ▁sample s ▁; ▁induc ed ▁pluri potent ▁stem ▁cell - der i ved ▁cardio my o cy tes ▁; hi PS c - CM s
D-1082	-0.5643755793571472	ucp ; scn5a ; ventricular systolic HF ; tissue samples ; induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
P-1082	-2.9479 -3.1925 -0.2296 -0.4321 -0.0791 -0.6819 -0.2715 -0.3330 -0.2571 -1.9863 -0.3970 -0.0455 -0.0582 -0.1284 -0.2836 -0.8598 -0.3203 -1.4855 -0.1067 -0.0790 -0.2055 -0.3117 -1.0335 -0.8287 -0.0397 -0.0148 -0.0051 -0.6849 -0.2726 -0.2285 -0.3455 -1.2802 -0.0661 -0.8189 -0.1709 -0.1264 -0.2950 -0.3396 -0.8945 -1.4722 -1.2352 -0.0828 -0.2976 -0.0837 -0.4074 -0.2452
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients ; patients ; type 2 diabetes ; therapy ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; insulin
H-1831	-0.6063114404678345	▁type ▁2 ▁diabetes ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁sul fon yl ure as ▁; ▁insulin ▁products
D-1831	-0.6063114404678345	type 2 diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; insulin products
P-1831	-0.6035 -0.9442 -0.1043 -0.2931 -0.2803 -0.0249 -0.6115 -2.9231 -0.4586 -1.8623 -0.0693 -0.1263 -2.9696 -0.4118 -0.1612 -0.0261 -0.0497 -0.3119 -0.4400 -1.0899 -0.0995 -0.4377 -0.4361 -0.0796 -0.3416 -0.5803 -1.1593 -0.4079 -0.2795
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade ; evidence ; acp ; erythropoiesis-stimulating agents ; patients ; anemia ; congestive heart failure ; coronary heart disease
H-37	-0.9959099888801575	▁a CP ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease
D-37	-0.9959099888801575	aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
P-37	-2.5588 -2.3446 -0.3947 -0.7614 -0.7973 -1.2975 -0.6068 -1.7195 -0.3115 -0.9507 -0.0636 -1.7943 -0.6485 -0.3642 -1.0394 -0.3613 -0.2998 -0.2728 -1.0428 -3.6464 -0.9526 -0.4376 -0.2423 -0.1576 -3.2798 -1.1995 -0.6247 -0.4190 -0.2923
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence ; hyperkalemia ; mineralocorticoid receptor antagonists ; mineralocorticoid receptor antagonists ; heart failure ; hf
H-1702	-0.9665807485580444	▁hyper kal emia ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁race ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁heart ▁failure ▁; HF
D-1702	-0.9665807485580444	hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
P-1702	-0.3603 -0.7383 -1.2656 -0.3289 -0.4521 -1.0307 -2.4772 -2.3741 -1.0179 -0.0655 -0.1876 -0.1324 -2.6141 -0.3132 -0.1550 -0.3180 -1.5260 -1.0424 -2.7448 -3.2642 -0.8553 -0.0532 -0.2096 -0.1688 -2.6024 -0.2910 -0.8455 -0.3302 -0.2381 -2.3400 -0.3473 -0.2410
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde ; pde2 ; cgmp ; leading ; camp hydrolysis ; cross talk ; cgmp ; camp signaling
H-1210	-0.8716341853141785	▁p de ▁super family ▁; ▁p de 2 ▁; ▁c g MP ▁; ▁c AMP ▁hydro lys is ▁; ▁negative ▁cross ▁talk ▁; ▁c g MP ▁; ▁c AMP ▁signal ing
D-1210	-0.8716341853141785	pde superfamily ; pde2 ; cgMP ; cAMP hydrolysis ; negative cross talk ; cgMP ; cAMP signaling
P-1210	-1.0581 -1.6733 -0.8735 -0.2051 -0.3525 -0.5909 -1.5629 -0.0641 -0.4760 -0.1604 -2.9248 -1.8683 -0.4040 -0.2854 -3.4359 -0.0911 -0.0609 -0.3309 -0.4115 -1.8814 -0.1730 -0.2921 -0.3623 -0.1837 -3.5085 -1.8550 -0.3321 -0.1404 -1.7379 -0.3531 -0.4747 -0.3318 -0.3084
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides ; szeto-schiller ; ss ; ss20 ; cardiac function ; proteomic remodeling ; signaling pathways
H-870	-0.559395968914032	▁mito cho ndri al - tar get ed ▁antioxidant ▁; ▁Sze to - sch iller ▁; ▁s s ▁; ▁cardiac ▁function ▁; ▁prote om ic ▁remodel ing
D-870	-0.559395968914032	mitochondrial-targeted antioxidant ; Szeto-schiller ; ss ; cardiac function ; proteomic remodeling
P-870	-0.4114 -0.9630 -0.3404 -0.1691 -0.2143 -1.1955 -1.4770 -0.1712 -0.3141 -0.3234 -0.8710 -0.2318 -0.1558 -1.1289 -0.5631 -0.3108 -1.8396 -0.6029 -1.2325 -0.1617 -0.0945 -0.3429 -0.1606 -1.0469 -0.9683 -0.0456 -0.1299 -0.4949 -0.2612
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac sympathetic activity ; β-blocker
H-1112	-0.6671552658081055	▁cardiac ▁sympa the tic ▁activity ▁; ▁i - meta - i odob enz yl guan i dine ▁; ▁i - mi BG ▁; ▁β - block er
D-1112	-0.6671552658081055	cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
P-1112	-0.4835 -0.3668 -0.7630 -1.0693 -1.1864 -0.4163 -0.7663 -0.3420 -0.0276 -0.1191 -0.2520 -0.5581 -0.8159 -3.4378 -0.0091 -0.3480 -0.4164 -0.3691 -1.8292 -0.3822 -0.5365 -2.7260 -0.3975 -0.1255 -0.0784 -0.5420 -0.3487 -0.3544 -0.2802
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse ; longitudinal rv fiber shortening ; pasp ; rv ; in vivo ; rv ; prognosis
H-493	-0.7998776435852051	▁ pv se ▁; long itud in al ▁ RV ▁fiber ▁short en ing ▁; ▁pas p ▁; force ▁; ▁ RV ▁; ▁in ▁vivo ▁ RV ▁; ▁length - force ▁relationship
D-493	-0.7998776435852051	pvse ;longitudinal RV fiber shortening ; pasp ;force ; RV ; in vivo RV ; length-force relationship
P-493	-2.1336 -3.4562 -0.5574 -0.2744 -1.1958 -0.3123 -1.0699 -0.2211 -0.5461 -1.6362 -0.2531 -0.6733 -0.2993 -0.4306 -0.3283 -1.6152 -0.2781 -0.3589 -0.2698 -0.2378 -1.3424 -1.9430 -0.3273 -0.6114 -0.1230 -1.6488 -1.6511 -0.4924 -0.1322 -0.1929 -0.5146 -1.4466 -0.3494 -0.2731
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes ; coprimary end points ; end point ; change ; serum cystatin c ; renal function ; end point
H-79	-0.6666445732116699	▁co prima ry ▁end ▁points ▁; ▁urin e ▁volume ▁; ▁de con gestion ▁end ▁point ▁; ▁se rum ▁cyst atin ▁c ▁; ▁en roll ment ▁; ren al ▁function ▁end ▁point
D-79	-0.6666445732116699	coprimary end points ; urine volume ; decongestion end point ; serum cystatin c ; enrollment ;renal function end point
P-79	-0.0235 -0.4120 -2.1523 -1.8909 -0.6460 -0.3069 -1.1254 -0.1639 -0.5862 -0.2844 -0.1810 -0.0702 -0.5592 -1.8267 -1.0202 -0.3824 -0.6298 -0.6092 -0.0158 -0.3638 -0.7913 -0.2630 -0.1180 -0.5136 -1.3293 -0.3128 -1.6380 -0.2836 -0.1209 -1.9826 -0.6654 -0.4738 -0.2574
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients ; brain natriuretic peptide ; bnp ; bnp ; patients ; bnp ; bnp
H-1569	-1.3458633422851562	▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁b NP ▁; ▁b NP
D-1569	-1.3458633422851562	brain natriuretic peptide ; bNP ; bNP ; bNP
P-1569	-1.1985 -0.1460 -1.3099 -0.6997 -2.0706 -0.7050 -0.6442 -0.9830 -0.4315 -1.1138 -3.1567 -0.4431 -1.7303 -3.1607 -1.2375 -2.4367 -2.7414 -1.0131 -0.3496
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef ; clinical ; reverse remodeling ; death ; hf ; hospitalization ; hazard ratio
H-756	-0.9612516760826111	▁LV EF ▁; ▁sterf ▁; ▁ HF ▁; ▁hospital ization ▁; haz ard ▁ratio
D-756	-0.9612516760826111	LVEF ; sterf ; HF ; hospitalization ;hazard ratio
P-756	-0.6097 -1.7020 -0.3709 -3.7431 -1.0809 -1.8406 -1.3385 -1.9607 -0.4172 -0.7767 -0.4014 -0.0609 -0.1256 -0.2232 -0.4075 -0.3211
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based ; heart disease ; therapies ; patients ; cabg ; sweden
H-971	-0.9728736877441406	▁Swedish ▁web - systeem ▁for ▁en han ce ment ▁and ▁development ▁of ▁e viden ce - based ▁care ▁; ▁Heart ▁disease ▁; ▁Reco mmende d ▁Therapie s ▁registr y ▁; ▁primary ▁isola ted ▁CA BG ▁; ▁stockholm
D-971	-0.9728736877441406	Swedish web-systeem for enhancement and development of evidence-based care ; Heart disease ; Recommended Therapies registry ; primary isolated CABG ; stockholm
P-971	-3.0067 -1.3171 -0.0782 -0.9267 -1.2366 -0.2656 -1.8826 -2.9017 -0.1690 -1.7835 -1.1263 -0.8385 -1.9038 -0.2846 -1.4945 -0.1042 -0.0443 -1.7835 -0.7608 -0.5522 -0.3354 -2.0266 -2.6000 -0.0466 -0.2020 -0.3736 -0.2366 -0.0514 -0.2447 -0.3977 -1.3731 -0.0112 -0.2631 -1.8076 -1.7059 -0.3780 -2.7324 -0.4553 -0.2403
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal probnp ; nt-probnp ; midregional proanp ; mr-proanp ; adiponectin ; elevated ; chf ; correlated ; bmi
H-14	-1.0158326625823975	▁ bb p ▁; ▁n - pro b NP ▁; ▁mid region al ▁pro AN p ▁; ▁m - pro AN p ▁; ▁adi pon ect in ▁; ▁CHF ▁; ▁b mi ▁; ▁FM
D-14	-1.0158326625823975	bbp ; n-probNP ; midregional proANp ; m-proANp ; adiponectin ; CHF ; bmi ; FM
P-14	-3.6408 -3.8544 -1.2502 -0.4467 -1.4640 -0.3833 -0.1098 -2.6409 -2.7353 -0.4442 -0.9887 -1.2346 -0.1276 -0.2433 -1.3929 -0.3508 -0.4248 -0.6260 -1.1989 -0.0742 -2.1773 -0.2285 -0.4274 -0.6337 -0.0522 -0.7662 -0.6868 -0.4330 -0.5223 -0.4816 -2.7022 -0.7728 -0.3555 -1.8911 -0.4856 -0.3225
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient ; mi ; hazard ratios ; hf
H-1108	-1.3682360649108887	▁MI ▁; ▁ HF
D-1108	-1.3682360649108887	MI ; HF
P-1108	-2.5440 -0.5402 -2.1111 -2.2736 -0.3496 -0.3910
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol ; von willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
H-1118	-0.5145990252494812	▁car vedi lol ▁; ▁von ▁Will e brand ▁factor ▁; ▁met o pro lol ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1118	-0.5145990252494812	carvedilol ; von Willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
P-1118	-0.0532 -0.3814 -0.8263 -0.4502 -2.5616 -0.9643 -0.2083 -0.1798 -0.4516 -0.4307 -0.7701 -0.2828 -0.2802 -1.0328 -0.4449 -0.1981 -0.1414 -0.5096 -0.2198 -1.1460 -0.5538 -0.0357 -0.5750 -0.4037 -0.0419 -0.4420 -0.3088
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl ; nyha-iiib ; phosphorylation ; phosphorylation ; hdl ; healthy
H-255	-0.9017199873924255	▁ec ▁; ▁HD l ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁ phos phor y lation ▁; ▁e NOS - Th r ▁; ▁HD l
D-255	-0.9017199873924255	ec ; HDl ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
P-255	-1.5980 -0.3372 -2.2613 -2.0835 -0.3614 -0.0870 -0.5007 -2.2146 -2.4316 -0.5953 -0.4335 -0.6752 -0.5894 -0.1869 -0.4606 -0.3990 -0.3513 -0.7611 -2.4459 -2.3340 -0.4658 -0.3667 -0.5616 -0.6656 -0.0925 -1.5657 -0.0071 -0.3326 -1.0480 -1.7291 -0.6344 -0.2788
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf ; hf with reduced ef ; hf with preserved ef ; change ; hf ; mi
H-1109	-1.3279063701629639	▁ HF ▁; HF ▁; ▁EF ▁; ▁ HF ▁; ▁EF ▁; ▁ HF ▁; ▁mix ▁; ▁ HF ▁; ▁MI
D-1109	-1.3279063701629639	HF ;HF ; EF ; HF ; EF ; HF ; mix ; HF ; MI
P-1109	-1.9537 -1.4363 -0.3677 -3.2361 -0.3705 -0.7193 -0.4130 -2.2441 -2.4189 -0.3524 -1.3090 -0.4443 -1.5697 -2.4066 -0.4225 -3.8686 -0.4048 -2.0202 -2.2453 -0.3716 -1.2635 -0.4025 -0.3015
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt ; nt-probnp ; aric ; hf ; aucs ; nris
H-289	-0.7005159258842468	▁c t n t ▁; ▁NT - pro b NP ▁; ▁a RIC ▁ HF ▁; ▁ab c s ▁; ▁NR Is
D-289	-0.7005159258842468	ctnt ; NT-probNP ; aRIC HF ; abcs ; NRIs
P-289	-0.1383 -0.2137 -0.0432 -0.4810 -0.2306 -0.1927 -0.0937 -0.0525 -1.5718 -1.2171 -0.2614 -0.4415 -2.4912 -0.1920 -0.8449 -0.3876 -2.5021 -0.8744 -0.6125 -0.2726 -0.4616 -2.5766 -0.3562 -0.3032
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular events ; baseline ; sst2 ; metoprolol succinate
H-404	-0.6506653428077698	▁cardio vas cular ▁events ▁; ▁s st 2 ▁status ▁; ▁BB ▁dose ▁; ▁met o pro lol ▁suc cina te
D-404	-0.6506653428077698	cardiovascular events ; sst2 status ; BB dose ; metoprolol succinate
P-404	-1.7993 -1.3152 -0.7826 -1.4800 -0.4419 -0.0267 -2.0151 -0.2111 -0.8600 -0.4265 -1.0803 -0.6868 -0.3616 -0.3165 -0.2484 -0.3164 -0.9874 -0.1205 -0.1101 -0.1776 -0.3363 -0.2144
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare ; patients ; acute ; hospital ; hf ; ami ; pna
H-1693	-1.179099202156067	▁RES e ARCH ▁DESIGN ▁; ▁Medica re ▁; ▁older ▁patients ▁; ▁a cute ▁care ▁hospital ▁; HF ▁; AMI ▁; ▁p NA
D-1693	-1.179099202156067	RESeARCH DESIGN ; Medicare ; older patients ; acute care hospital ;HF ;AMI ; pNA
P-1693	-5.3097 -0.4296 -0.9777 -1.6110 -0.4396 -0.3410 -0.1368 -0.4353 -0.8478 -0.9900 -0.4022 -0.3577 -0.2166 -1.8252 -0.7277 -0.4034 -4.0169 -0.5065 -2.4024 -0.5262 -0.7455 -3.8703 -0.4258 -0.3536
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial ; cochrane effective practice and organisation of care taxonomy
H-1847	-0.599457859992981	▁co ch rane ▁Effective ▁practice ▁; ▁Organisation ▁of ▁Care ▁Tax ono my
D-1847	-0.599457859992981	cochrane Effective practice ; Organisation of Care Taxonomy
P-1847	-0.1111 -0.7710 -0.2107 -0.2270 -0.3637 -0.3764 -1.2483 -0.6552 -0.6408 -0.9786 -0.0404 -1.2758 -1.1874 -0.3061
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart failure ; hf ; hypertensive heart disease ; hhd ; pathophysiology ; therapeutic ; hhd ; stable ; phenotypes
H-274	-0.7755585312843323	▁mouse ▁; ▁heart ▁failure ▁; HF ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁h h ▁; ▁pat ho phy si ology ▁; ▁h h
D-274	-0.7755585312843323	mouse ; heart failure ;HF ; hypertensive heart disease ; hh ; pathophysiology ; hh
P-274	-0.2465 -0.9653 -1.9620 -0.3376 -0.2551 -1.2474 -0.2336 -0.1891 -0.1439 -0.2143 -1.5096 -0.9184 -0.2242 -0.6560 -3.1506 -0.2626 -0.5713 -0.0925 -0.5611 -1.2161 -0.1155 -0.2739 -1.1345 -3.0376 -0.3945 -0.2516
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd ; chf ; crf ; icc ; kappa coefficients
H-802	-1.015977144241333	▁co PD ▁; ▁CHF ▁; ▁c RF ▁; ▁i cc ▁; ▁ka ppa ▁co ef fici ents
D-802	-1.015977144241333	coPD ; CHF ; cRF ; icc ; kappa coefficients
P-802	-1.1178 -3.0744 -0.4501 -0.4613 -0.4012 -1.0115 -3.9211 -0.4130 -0.6628 -0.0333 -1.2337 -0.1368 -0.5352 -0.1293 -0.0988 -0.0941 -4.8412 -0.3882 -0.2996
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global left ventricular longitudinal systolic strain ; gls ; left ventricular ; cardiovascular ; atrial fibrillation
H-809	-0.8115705251693726	▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁g ls ▁; ▁left ▁vent ri cular ▁mechanic s ▁; ▁cardiovascular ▁; CV ▁; ▁at rial ▁fi bril lation ▁; ▁f
D-809	-0.8115705251693726	left ventricular longitudinal systolic strain ; gls ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ; f
P-809	-2.1327 -0.6069 -2.2729 -0.6341 -0.1202 -0.4179 -0.1353 -0.0603 -0.1142 -0.1210 -0.0286 -0.3599 -0.3390 -2.1647 -0.2685 -2.3270 -0.3988 -2.4914 -0.7504 -0.9559 -0.2335 -0.3337 -0.1687 -0.6109 -1.0383 -0.4075 -2.6078 -0.1648 -0.5837 -0.1456 -0.5797 -0.3014 -3.2835 -0.9619 -0.2843
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients ; implantable cardioverter-defibrillator ; patients ; implantable cardioverter-defibrillator
H-1866	-0.7293654084205627	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁shock s
D-1866	-0.7293654084205627	implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator shocks
P-1866	-0.7620 -0.4139 -0.2331 -0.3052 -0.9673 -0.3277 -0.1899 -0.5543 -2.8384 -0.8533 -0.3412 -0.3908 -0.2067 -2.8446 -0.3428 -1.3437 -0.4292 -0.2444 -0.2185 -1.0831 -0.2813 -0.1391 -0.4997 -1.9291 -0.8776 -0.2369 -0.9591 -0.3137 -1.4476 -0.3064
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients ; heart failure ; myocardial function ; dilated ; contracting ; ventricles ; aetiologies
H-987	-1.0485533475875854	▁heart ▁failure ▁; ▁my o card ial ▁function ▁; ▁vent ric les
D-987	-1.0485533475875854	heart failure ; myocardial function ; ventricles
P-987	-3.6740 -0.4211 -0.3148 -1.1673 -0.3137 -1.2060 -2.4839 -0.1503 -0.3681 -0.6170 -1.0398 -2.1450 -0.4763 -0.3023
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient ; implantable cardioverter-defibrillator ; implant ; change ; clinical
H-1865	-0.6031126379966736	▁implant able ▁; ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant ▁; ▁end - of - life
D-1865	-0.6031126379966736	implantable ; cardioverter-defibrillator deactivation ; implant ; end-of-life
P-1865	-1.1423 -0.2947 -0.5007 -0.0756 -0.1840 -0.7158 -0.2368 -0.1052 -0.1929 -1.6944 -0.2740 -0.1750 -0.2361 -0.1607 -2.3024 -0.2874 -0.6655 -0.3927 -1.7699 -0.1336 -0.0752 -0.1755 -0.5830 -2.4323 -0.2720
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients ; stable heart failure ; left ventricular ejection fraction ; training ; training
H-1913	-0.7877935171127319	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁aero bic ▁; ▁dynamic ▁resist ance ▁training ▁; ▁lower ▁lim bs
D-1913	-0.7877935171127319	heart failure ; left ventricular ejection fraction ; aerobic ; dynamic resistance training ; lower limbs
P-1913	-4.1389 -0.3935 -0.2954 -1.2934 -0.3827 -2.0097 -0.5604 -0.2798 -0.4574 -0.2510 -1.1075 -0.0830 -0.3294 -0.0307 -0.4385 -1.1479 -0.3768 -0.2308 -0.4004 -2.4555 -0.2442 -0.4184 -0.0163 -2.4906 -0.3981 -0.2522
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad ; q65p ; murine ; rad ; q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type rad
H-1675	-0.8461872935295105	▁mouse ▁Rad ▁; ▁mur ine ▁; ▁human ▁Rad ▁; ▁Q 66 p ▁; ▁l - type ▁current s ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁; ▁wild - type ▁Rad
D-1675	-0.8461872935295105	mouse Rad ; murine ; human Rad ; Q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type Rad
P-1675	-0.4664 -2.1043 -0.5686 -0.5227 -2.5528 -0.3498 -1.5007 -0.9258 -0.7424 -3.3966 -2.3378 -0.3199 -0.2744 -0.9938 -0.1248 -0.0469 -0.1241 -0.3631 -0.3643 -0.4511 -0.8515 -0.5430 -0.3727 -3.2204 -1.1323 -0.3320 -1.0975 -0.3729 -0.1488 -0.0556 -0.6517 -0.3339 -0.2814
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary outcome ; patients ; crt ; hazard ratio ; confidence interval
H-852	-0.858756422996521	▁c RT ▁; ▁hazard ▁ratio ▁; ▁95% ▁confidence ▁interval ▁; CI
D-852	-0.858756422996521	cRT ; hazard ratio ; 95% confidence interval ;CI
P-852	-0.4331 -3.4873 -0.5669 -0.7997 -0.0939 -0.4133 -0.5598 -0.2463 -0.1872 -0.3481 -3.4526 -0.2762 -0.2996
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf ; hazard ratios ; body mass index ; obese
H-1773	-0.5783412456512451	▁fit ▁; ▁un fit ▁; ▁c RF ▁; ▁fit ▁; ▁un fit ▁; ▁over weight ▁; ▁body ▁mass ▁index ▁; ▁obes e ▁men
D-1773	-0.5783412456512451	fit ; unfit ; cRF ; fit ; unfit ; overweight ; body mass index ; obese men
P-1773	-0.3043 -0.3981 -0.0380 -0.6190 -0.3436 -0.6632 -1.9813 -0.3364 -2.1549 -0.2969 -0.1257 -0.5629 -0.3942 -0.1043 -0.2717 -0.7238 -0.6898 -0.0989 -0.0271 -0.4387 -0.3012 -0.2163 -2.7458 -0.3539 -0.2684
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left ventricular ejection fraction ; egfr
H-393	-1.1582053899765015	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁e g FR
D-393	-1.1582053899765015	left ventricular ejection fraction ; egFR
P-393	-4.1974 -0.3409 -1.7192 -0.6202 -0.5595 -0.7697 -0.5942 -0.7809 -0.1083 -0.4105 -0.4616 -3.2593 -2.6737 -0.4768 -0.4010
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost ; patient ; rhythm-control ; rate-control
H-1241	-0.7729852199554443	▁kosten ▁; ▁ rhythm - control ▁; ▁rate - control
D-1241	-0.7729852199554443	kosten ; rhythm-control ; rate-control
P-1241	-1.6588 -0.4193 -0.3966 -2.1706 -0.6848 -0.1228 -0.3851 -1.8520 -0.4931 -0.1539 -0.5539 -0.3850
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient ; prescribing ; medications ; medical
H-1122	-1.1042284965515137	▁medication s ▁; ▁medical ▁records ▁; ▁performance ▁measure ment ▁systems
D-1122	-1.1042284965515137	medications ; medical records ; performance measurement systems
P-1122	-6.5849 -0.7867 -0.3980 -2.1926 -0.4908 -0.3664 -0.0182 -0.3131 -1.0711 -0.4552 -0.3276 -0.2462
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically ; legal ; decisions
H-1680	-0.9113860726356506	▁et h ically ▁; ▁pediatr ics ▁; ▁religious ▁belief s ▁; ▁legale ▁majority
D-1680	-0.9113860726356506	ethically ; pediatrics ; religious beliefs ; legale majority
P-1680	-0.2852 -0.2658 -1.5594 -1.0684 -0.1726 -0.5632 -0.3018 -1.0012 -0.8052 -0.3284 -0.2667 -4.7148 -1.3289 -0.7514 -0.2577
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare patient safety monitoring system ; mpsms ; adverse event ; patients ; hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
H-2	-0.7177737355232239	▁Medica re ▁Patient ▁Safety ▁monitoring ▁system ▁; ▁m ms ▁; ▁advers e ▁event ▁rates ▁; ▁patients ▁; ▁hospital ized ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁pneu monia ▁; ▁surgery
D-2	-0.7177737355232239	Medicare Patient Safety monitoring system ; mms ; adverse event rates ; patients ; hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
P-2	-0.2399 -0.1677 -0.8049 -0.9878 -0.1766 -0.7698 -0.2469 -0.3191 -2.3792 -0.3145 -0.6518 -0.0539 -0.6876 -1.6177 -0.3019 -2.8652 -0.7485 -2.8849 -0.4837 -0.4452 -0.9794 -0.1294 -1.6925 -0.1977 -0.4090 -1.3083 -0.0596 -0.5242 -0.5479 -0.2914 -0.1256 -0.5260 -2.8930 -0.7613 -0.3199 -0.2650 -0.2527 -0.6525 -0.3174 -0.1671 -0.3533 -0.2267
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic reticular ; protein ; phospholamban ; infarcted ; hearts ; metoprolol
H-1551	-0.7174819707870483	▁sar co plas mic ▁reti cular ▁; SR ▁; ▁ca (2 +) - up take ▁; ▁protein ▁; ▁SR ▁; ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁in far cted ▁heart s ▁; ▁met o pro lol
D-1551	-0.7174819707870483	sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
P-1551	-0.2996 -0.2276 -1.4904 -2.5015 -0.0244 -0.5774 -0.3014 -2.0902 -0.3593 -0.1400 -1.7088 -0.1036 -0.3473 -0.3129 -1.3124 -0.3059 -0.5581 -2.9640 -1.1901 -0.5510 -0.2493 -2.0610 -0.2286 -0.2844 -0.6248 -0.2919 -0.2578 -0.1695 -0.3003 -0.9068 -0.7075 -0.3169 -0.3401 -0.8162 -2.8284 -0.9911 -0.2996 -0.3101 -0.2283 -0.1649 -0.2223 -1.0537 -0.3144 -0.2354
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi ; blood urea nitrogen ; b-type natriuretic peptide ; new york heart association class ; diabetes ; atrial fibrillation ; all-cause hospitalization
H-382	-0.739518404006958	▁ HF PSI ▁; ▁blood ▁u rea ▁nit rogen ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁New ▁York ▁Heart ▁association ▁; ▁diabetes ▁status ▁; ▁at rial ▁fi bril lation ▁; flu tter
D-382	-0.739518404006958	HFPSI ; blood urea nitrogen ; b-type natriuretic peptide ; New York Heart association ; diabetes status ; atrial fibrillation ;flutter
P-382	-2.8333 -1.5555 -2.8225 -0.2732 -0.9113 -1.1313 -1.4468 -0.5118 -0.0786 -0.3060 -1.0498 -0.1507 -0.0176 -0.0496 -0.8250 -0.4337 -1.7975 -0.5333 -0.2250 -0.9239 -0.3074 -0.9848 -1.0429 -1.8226 -0.5442 -0.2153 -0.3792 -1.4163 -0.2536 -1.5118 -0.3564 -0.2906 -0.1162 -0.2665 -0.3274 -0.0686 -0.1370 -0.6197 -0.3042
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug ; patients ; chronic obstructive pulmonary disease ; copd ; chronic heart failure ; chf ; chronic renal failure ; crf
H-794	-1.315481424331665	▁Time up ▁; ▁go ▁; ▁tu g ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁co PD ▁; ▁chronic ▁heart ▁failure ▁; ▁ nc w ▁; ▁chronic ▁renal ▁failure ▁; ▁r bf
D-794	-1.315481424331665	Timeup ; go ; tug ; chronic obstructive pulmonary disease ; coPD ; chronic heart failure ; ncw ; chronic renal failure ; rbf
P-794	-1.1540 -3.0974 -2.0321 -3.4034 -0.2177 -1.0115 -3.7232 -0.3104 -2.5981 -1.1694 -0.5888 -1.9938 -0.0359 -0.8997 -0.4498 -0.2878 -1.7298 -3.3638 -0.3054 -0.3190 -1.4837 -0.4748 -0.2585 -3.3031 -2.0817 -0.9314 -0.3346 -0.2523 -0.2441 -1.0300 -0.2397 -2.8781 -3.1705 -0.3753 -0.2932
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm ; telemonitoring ; implanted ; medical ; structured telephone support ; sts ; human-to-human contact ; hh ; human-to-machine interface
H-153	-0.738288938999176	▁RM ▁; ▁home ▁tele monitor ing ▁; ▁m t ▁; ▁implant ed ▁monitoring ▁devices ▁; ▁medical ▁; ▁telephone ▁support ▁; ▁sp s ▁; ▁human - to - human ▁contact ▁; HH ▁; ▁human - to - machine ▁interface ▁; ▁h m
D-153	-0.738288938999176	RM ; home telemonitoring ; mt ; implanted monitoring devices ; medical ; telephone support ; sps ; human-to-human contact ;HH ; human-to-machine interface ; hm
P-153	-0.7314 -0.3303 -2.1057 -0.4840 -0.4662 -0.2050 -0.4138 -1.8683 -1.7186 -0.3503 -0.1528 -0.2367 -0.0285 -0.6146 -0.3870 -1.2792 -2.0045 -2.4683 -1.4915 -0.3990 -4.8879 -0.2058 -0.6089 -0.7430 -0.1162 -0.4579 -0.3576 -0.2134 -0.0157 -0.3123 -2.5423 -0.3152 -0.2185 -0.0626 -0.4158 -0.1299 -0.3256 -0.0056 -0.3520 -0.8011 -0.2692 -0.4076 -0.2467
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart failure ; hf ; plasma b-type natriuretic peptide ; bnp ; preserved ejection fraction ; ef ; hf
H-187	-0.7936474680900574	▁heart ▁failure ▁; HF ▁; ▁plasma ▁; ▁na tri ure tic ▁pe pti de ▁; ▁b p ▁; ▁e je ction ▁ fraction ▁; EF ▁; ▁ HF ▁; ▁sex
D-187	-0.7936474680900574	heart failure ;HF ; plasma ; natriuretic peptide ; bp ; ejection fraction ;EF ; HF ; sex
P-187	-2.3710 -0.4240 -0.3115 -1.3440 -0.3413 -0.1258 -0.8207 -0.6529 -1.0023 -0.6836 -2.2410 -0.5834 -0.1564 -0.8934 -0.4184 -0.6167 -2.6208 -0.3833 -0.3923 -0.3310 -0.0629 -0.2760 -0.0156 -0.3696 -1.0897 -0.4524 -2.0011 -2.1271 -0.4552 -0.5429 -1.0266 -0.2637
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls ; left ventricular ejection fraction ; lvef ; systolic mitral annulus velocity ; multivariate models
H-818	-0.8168787956237793	▁g s ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁l bf ▁; ▁sy sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁sa ▁; ▁CV ▁events
D-818	-0.8168787956237793	gs ; left ventricular ejection fraction ; lbf ; systolic mitral annulus velocity ; sa ; CV events
P-818	-0.3339 -1.8250 -0.2764 -1.7280 -0.4207 -1.8944 -0.8576 -0.7942 -0.4775 -0.3702 -0.7406 -0.0485 -0.3669 -1.1631 -3.0223 -0.3694 -0.1725 -0.1356 -0.3016 -1.2775 -0.7063 -1.8961 -1.0684 -0.3136 -0.7602 -0.3923 -0.1607 -0.5940 -0.8111 -2.0576 -0.5156 -0.2882
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients ; hospitalized ; hf ; preserved lvef ; mortality ; patients ; lvef ; lvef ; mortality
H-117	-1.2528576850891113	HF ▁; ▁LV EF ▁; ▁long - term ▁mortal iteit ▁; ▁LV EF ▁; ▁LV EF ▁; ▁long - term ▁mortal iteit
D-117	-1.2528576850891113	HF ; LVEF ; long-term mortaliteit ; LVEF ; LVEF ; long-term mortaliteit
P-117	-3.2789 -0.3557 -1.4714 -1.6353 -0.3511 -4.8938 -0.2338 -0.3501 -0.2358 -2.7335 -0.4002 -1.5619 -1.6337 -0.4164 -1.1552 -1.8718 -1.0221 -2.3305 -0.2201 -0.3478 -0.2132 -2.7649 -0.3107 -0.2810
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise ; intramuscular testosterone supplementation ; patients ; chronic heart failure ; chf ; testosterone ; collected ; health ; outcomes
H-1317	-1.1839418411254883	▁exercise ▁; ▁intra mus cular ▁testosteron e ▁supplement ation ▁; ▁chronic ▁heart ▁failure ▁; ▁chw ▁; ▁low ▁testosteron e ▁status
D-1317	-1.1839418411254883	exercise ; intramuscular testosterone supplementation ; chronic heart failure ; chw ; low testosterone status
P-1317	-3.7721 -0.2915 -0.9324 -0.1874 -0.3233 -0.2558 -0.0755 -0.6170 -1.8442 -0.3054 -8.3983 -1.5386 -0.3455 -0.3127 -3.4246 -1.0590 -0.9466 -0.1984 -0.1168 -0.1162 -0.7437 -0.2418
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox regression analysis ; patients ; beta-blockers ; beta-blockers ; primary endpoint ; therapy ; antitachycardia pacing ; atp ; shock therapy
H-859	-0.5632138252258301	▁co x ▁re gression ▁analysis ▁; ▁beta - block ers ▁; ▁beta - block ers ▁; ▁anti ta chy car dia ▁pa cing ▁; ▁a TP ▁; ▁shock ▁ therapy
D-859	-0.5632138252258301	cox regression analysis ; beta-blockers ; beta-blockers ; antitachycardia pacing ; aTP ; shock therapy
P-859	-0.2588 -0.5108 -0.0931 -0.0867 -0.8867 -0.3941 -0.6646 -0.1548 -0.9845 -0.3543 -0.3547 -0.3105 -0.1921 -1.3492 -0.3696 -0.3645 -0.0699 -2.0582 -0.3604 -0.0816 -0.1269 -0.0248 -0.5415 -0.3570 -2.1319 -3.2608 -0.3638 -0.1372 -0.4357 -0.1119 -0.3296 -0.3024
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise ; rehabilitation ; walking ; minnesota quality of life ; exercise
H-1882	-1.5339001417160034	▁walking ▁; ▁Minnesota ▁; ▁quality ▁of ▁life
D-1882	-1.5339001417160034	walking ; Minnesota ; quality of life
P-1882	-4.8631 -0.3805 -1.1155 -0.4662 -0.9510 -1.9278 -2.1803 -1.6653 -0.2555
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive heart failure ; correlation coefficient
H-218	-1.6884313821792603	▁con ges tive ▁heart ▁failure ▁visit s ▁; ▁ED
D-218	-1.6884313821792603	congestive heart failure visits ; ED
P-218	-4.6039 -1.4701 -2.9697 -1.1012 -0.4871 -3.1161 -0.4636 -0.3869 -1.7704 -1.8930 -0.3108
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; β-blockers ; patients ; heart failure and reduced ejection fraction
H-661	-0.6916466951370239	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-661	-0.6916466951370239	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
P-661	-5.3790 -2.4815 -0.3562 -3.0170 -0.8947 -0.0811 -0.1859 -0.6592 -0.2226 -0.1282 -0.0526 -0.7350 -0.3171 -0.0540 -0.3027 -1.7407 -0.0245 -0.4216 -0.3987 -0.3025 -0.0944 -0.1249 -0.3673 -0.2602 -0.3295 -2.8401 -0.5133 -0.3001 -0.1114 -0.2223 -0.1682 -0.4103 -0.0339 -0.4154 -0.2614
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; bax ; caspase 3 ; expression
H-961	-0.42789849638938904	▁Rat s ▁; ▁heart s ▁; ▁cas pas e -3 ▁activity ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁cy to ch rom e ▁c ▁; ▁b cl 2 ▁; ▁Bax ▁; ▁cas pas e ▁3 ▁expression
D-961	-0.42789849638938904	Rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
P-961	-0.8594 -0.4169 -0.2786 -2.1783 -0.3251 -0.3236 -0.3375 -0.1017 -0.1463 -0.1984 -1.7794 -0.2661 -0.2354 -0.0968 -0.4781 -0.2760 -1.2670 -0.3623 -0.1052 -0.0529 -1.9054 -0.1273 -0.4826 -0.0914 -0.3400 -0.3169 -0.1396 -0.3160 -0.0062 -0.0421 -0.8989 -0.6508 -0.1723 -0.3583 -0.1166 -0.2241 -0.1219 -0.2312 -0.3198 -0.2083 -0.1048 -0.9847 -0.3956 -0.3647 -0.2508
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right ventricular pacing ; gene expressions ; bax ; bcl-2 ; caspase-3 ; rtq-pcr ; interventricular septum ; biopsies ; heart failure
H-166	-0.6002786755561829	▁right ▁vent ri cular ▁pa cing ▁; ▁gene ▁expression s ▁; ▁Bax ▁; ▁b cl -2 ▁; ▁Cas pas e -3 ▁; ▁ nc w - ▁pc r ▁; ▁interven tri cular ▁sept um ▁bio psi es ▁; ▁beag le ▁dog s ▁; ▁heart ▁failure
D-166	-0.6002786755561829	right ventricular pacing ; gene expressions ; Bax ; bcl-2 ; Caspase-3 ; ncw- pcr ; interventricular septum biopsies ; beagle dogs ; heart failure
P-166	-5.2495 -0.4508 -1.8079 -0.5137 -0.0559 -0.5033 -0.3413 -0.8952 -0.1705 -0.2481 -0.2771 -0.1254 -0.2398 -0.2390 -0.7945 -0.2039 -0.3147 -0.0861 -0.0592 -0.0810 -0.1066 -0.3315 -3.0806 -2.5558 -1.0156 -0.3687 -0.8787 -0.0216 -0.2902 -0.0703 -1.3546 -0.4993 -0.0774 -0.0221 -0.0325 -0.2981 -0.2839 -0.3196 -0.0810 -0.1856 -1.1418 -0.2862 -0.3214 -0.9040 -0.4227 -0.3718 -0.2344
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary approaches to stop hypertension ; dash ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hfpef
H-918	-0.6451417207717896	▁so dium - re strict ed ▁dieta ry ▁; ▁hyper tension ▁; ▁die t ▁; DAS h ▁; ▁s RD ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁h bf
D-918	-0.6451417207717896	sodium-restricted dietary ; hypertension ; diet ;DASh ; sRD ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hbf
P-918	-1.0394 -0.0402 -0.0672 -0.0731 -0.2966 -0.3419 -1.6012 -1.7078 -0.4985 -0.2117 -0.0535 -1.0454 -1.0090 -0.1300 -0.2630 -0.1951 -0.2415 -0.2588 -2.2546 -1.5198 -0.3370 -1.1915 -0.6102 -2.9401 -0.4519 -0.0843 -0.1197 -0.1087 -0.1622 -0.3439 -0.1106 -0.2076 -0.6447 -0.3259 -0.2061 -2.7397 -0.6862 -0.3542 -0.2588 -0.2619 -0.0768 -0.9058 -0.2871 -0.4209 -0.2870 -0.5961 -1.0182 -2.8041 -0.6218 -0.2458
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies ; medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; risk stratification ; patient ; heart failure ; therapies ; disease
H-1205	-0.5703579783439636	▁medication ▁; ▁physical ▁ therapy ▁; ▁implant able ▁de fi br illa tors ▁; ▁circula tory ▁support ▁; ▁transplant ation ▁; ▁heart ▁failure ▁; ▁ therapie s
D-1205	-0.5703579783439636	medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; heart failure ; therapies
P-1205	-3.8338 -0.3373 -0.3353 -0.5428 -0.0496 -0.3641 -0.3782 -0.1224 -0.1463 -0.0968 -0.9552 -0.1874 -0.3189 -0.3943 -0.0063 -0.3779 -0.3642 -0.3622 -0.3828 -1.2546 -0.3293 -1.8352 -0.2677 -0.5758 -0.2974 -0.4024 -0.3496 -1.3754 -0.2972
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells ; functional capacity ; cells ; peak vo2
H-127	-1.2093850374221802	▁cd 34 ▁; ve g FR 2 ▁; ▁cell s ▁; ▁functional ▁capacity ▁; ▁10- cell ▁; ▁cd 34 ▁; ve g FR 2 ▁; ▁cell s ▁; ▁VO 2
D-127	-1.2093850374221802	cd34 ;vegFR2 ; cells ; functional capacity ; 10-cell ; cd34 ;vegFR2 ; cells ; VO2
P-127	-1.0715 -1.9170 -1.3644 -2.1623 -2.1743 -2.3654 -0.6583 -0.7553 -3.3393 -0.4751 -0.2631 -0.6449 -0.5362 -0.2880 -1.2646 -0.4480 -0.3332 -1.5694 -2.6597 -1.2842 -2.8162 -2.2765 -2.8771 -0.5657 -0.6661 -0.6124 -0.4984 -0.3020 -1.7689 -0.1693 -0.3110 -0.2624
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine vasopressin ; avp ; physiologic ; chf ; avp ; vasopressin receptor antagonist ; therapy ; therapeutic ; chf
H-637	-0.728428304195404	▁argi nine ▁vaso press in ▁; ▁a VP ▁; ▁physio logic ▁; ▁CHF ▁; ▁a VP ▁; ▁vaso press in ▁receptor ▁anta gon ist ▁ therapy ▁; ▁CHF
D-637	-0.728428304195404	arginine vasopressin ; aVP ; physiologic ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
P-637	-0.1143 -1.6531 -0.3490 -0.2839 -1.1848 -0.3993 -1.1558 -1.3493 -0.3915 -0.6479 -0.6666 -2.7035 -0.8086 -0.3995 -1.9949 -2.7504 -0.3229 -0.1959 -0.2396 -0.6389 -0.0396 -0.5253 -0.0088 -0.5673 -0.5295 -0.1132 -0.3705 -0.8094 -0.3568 -0.2825
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients ; heart failure and reduced ejection fraction ; patient
H-659	-0.9423719644546509	▁treatment ▁; ▁out patient s ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-659	-0.9423719644546509	treatment ; outpatients ; heart failure ; ejection fraction
P-659	-6.2719 -0.3176 -3.0836 -0.2156 -0.3279 -0.6822 -1.6855 -0.4222 -0.2717 -0.4956 -0.1917 -0.0644 -0.2879 -0.0261 -0.4701 -0.2638
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training ; exercise capacity ; muscle ; quality of life ; cardiac ; nt-probnp ; inflammatory ; il6 ; hscrp ; biomarkers
H-1922	-0.7480902075767517	▁aero bic ▁; ▁resist ance ▁; ▁voordelen ▁; ▁exercise ▁capacity ▁; ▁muscle ▁strength ▁; ▁cardiac ▁; ▁n - pro b NP ▁; ▁infla mma tory ▁; ▁i 6 ▁; ▁h s cr p
D-1922	-0.7480902075767517	aerobic ; resistance ; voordelen ; exercise capacity ; muscle strength ; cardiac ; n-probNP ; inflammatory ; i6 ; hscrp
P-1922	-0.1688 -0.7188 -0.3053 -0.1707 -0.2429 -1.2395 -3.2500 -0.2866 -1.4026 -0.2004 -0.2956 -0.7673 -0.3210 -0.3400 -0.1474 -0.4106 -1.6486 -0.4404 -1.3998 -1.8518 -2.4213 -0.4242 -0.2526 -0.3276 -0.3855 -0.3514 -1.8046 -2.1058 -0.2664 -0.0205 -0.0565 -0.0799 -0.7478 -1.0144 -0.3165
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart failure ; myocardial infarction ; mi ; β-adrenoceptor blockade ; infarcted ; metoprolol
H-1547	-0.7349965572357178	▁heart ▁failure ▁; ▁my o card ial ▁in far ction ▁; ▁m ▁; ▁β - ad re no cept or ▁block ade ▁; ▁in far cted ▁rat s ▁; ▁met o pro lol
D-1547	-0.7349965572357178	heart failure ; myocardial infarction ; m ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
P-1547	-3.0519 -0.6654 -0.2953 -1.7862 -0.3943 -0.8086 -1.5418 -0.1299 -0.5220 -0.8020 -0.2834 -1.0392 -1.8524 -0.1844 -0.0650 -0.1237 -0.1493 -0.4599 -0.3599 -0.2075 -0.1357 -0.8356 -0.3695 -0.1924 -0.8130 -3.7689 -2.1628 -0.3005 -0.3307 -0.2009 -0.1898 -0.3120 -0.7811 -0.3524 -0.2574
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting tension ; fpassive ; muscle ; kcl-ki ; titin ; titin ; extracellular matrix ; fpassive
H-765	-0.6716148853302002	▁rest ing ▁tension ▁; ▁f pass ive ▁; sar com ere ▁length ▁; ▁muscle ▁strip s ▁; ▁k c l - KI ▁treatment ▁; ▁titi n ▁; ▁extra cel lular ▁matri x ▁; ▁f pass ive
D-765	-0.6716148853302002	resting tension ; fpassive ;sarcomere length ; muscle strips ; kcl-KI treatment ; titin ; extracellular matrix ; fpassive
P-765	-2.1710 -0.1914 -0.2568 -0.2020 -1.6734 -0.1192 -1.1424 -0.4405 -4.9038 -0.1879 -0.9689 -0.2537 -0.3405 -1.8166 -0.3432 -0.4174 -0.3849 -3.1675 -0.9462 -0.2260 -0.1038 -0.0812 -0.7694 -0.3579 -0.0676 -0.1018 -0.2629 -0.1958 -0.3788 -0.1547 -0.0089 -0.2484 -0.3230 -0.9186 -0.0404 -0.8289 -0.2954 -0.2305
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame ; chf ; anthracycline ; stem cell ; allogeneic ; autologous ; follow-up
H-1453	-0.36425262689590454	▁CHF ▁; ▁an thra cycli ne ▁exposure ▁; ▁stem ▁cell ▁source ▁; allo gene ic ▁; ▁follow - up
D-1453	-0.36425262689590454	CHF ; anthracycline exposure ; stem cell source ;allogeneic ; follow-up
P-1453	-0.4236 -0.3675 -0.5945 -0.3574 -0.4615 -1.4843 -0.1558 -0.3360 -0.0292 -0.3862 -0.3932 -0.3847 -0.0130 -0.3504 -0.3754 -0.5443 -0.0943 -0.2866 -0.0349 -0.3165 -0.2600
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality rate ; patients ; hf ; hf ; case-fatality rate
H-1311	-0.9686842560768127	▁case - fat ality ▁rate ▁; ▁concurrent ▁ HF ▁; ▁concurrent ▁ HF
D-1311	-0.9686842560768127	case-fatality rate ; concurrent HF ; concurrent HF
P-1311	-4.6889 -0.3321 -0.2734 -0.8458 -1.4569 -0.3447 -0.0240 -0.5452 -1.1745 -0.3466 -0.1057 -0.5807 -1.8687 -1.5837 -0.3595
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital ; readmission ; all-cause readmission ; acr ; potential preventable readmission ; ppr ; medicare ; medicaid ; readmission ; cms
H-135	-0.8556804060935974	▁read mission ▁; ▁all - ca use ▁read mission ▁; ▁a cr ▁; ▁Potential ▁Prev en table ▁Read mission ▁; ▁p b ▁; ▁Center s ▁voor ▁Medica re ▁; ▁Medica id ▁; ▁30- day ▁read mission ▁; ▁c ms
D-135	-0.8556804060935974	readmission ; all-cause readmission ; acr ; Potential Preventable Readmission ; pb ; Centers voor Medicare ; Medicaid ; 30-day readmission ; cms
P-135	-3.5527 -2.3526 -1.1663 -1.1130 -0.0620 -0.0773 -1.3732 -1.4457 -1.4623 -0.3280 -1.1161 -0.2777 -0.3275 -0.1862 -0.9801 -0.4656 -0.7945 -1.5321 -1.0504 -0.2695 -0.1116 -3.0569 -0.4042 -0.8087 -0.4581 -1.1980 -0.0335 -0.0721 -1.2089 -0.0310 -0.1056 -0.3505 -0.3778 -0.8576 -2.0274 -1.7756 -0.2810 -0.5590 -0.8093 -0.3675 -0.2560
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol ; carvedilol ; sympathetic activity ; von willebrand factor
H-1119	-0.6283013820648193	▁met o pro lol ▁; ▁car vedi lol ▁; ▁sympa the tic ▁activity ▁; ▁von ▁Will e brand ▁factor
D-1119	-0.6283013820648193	metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor
P-1119	-0.2853 -0.4140 -0.1405 -0.8262 -0.4330 -0.0153 -0.6250 -0.8018 -0.3701 -0.1414 -0.5797 -1.0003 -1.3814 -0.3753 -1.1827 -1.3494 -0.1039 -0.3232 -0.3055 -2.2640 -0.2764
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute hf ; relax-ahf ; astronaut ; pronto ; patient ; patients ; end points
H-1017	-0.9263770580291748	▁a cute ▁ HF ▁; ▁RELA x - a HF ▁; AST RON AUT ▁; ▁PR ONTO ▁; ▁patient ▁en roll ment
D-1017	-0.9263770580291748	acute HF ; RELAx-aHF ;ASTRONAUT ; PRONTO ; patient enrollment
P-1017	-0.4076 -0.2587 -0.5285 -0.9322 -0.3054 -0.1337 -2.5257 -0.1364 -0.5751 -2.3999 -0.2725 -4.4510 -0.5097 -0.2415 -0.3163 -1.4503 -0.0501 -0.9866 -1.4442 -0.0520 -0.7158 -1.6690 -1.5530 -0.3178
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized ; hf ; international classification of diseases ; clinical ; principal ; discharge ; diagnosis
H-1832	-0.6109398603439331	HF ▁; ▁international ▁Classifica tion ▁of ▁Disease s ▁; ▁Nin th ▁re vision ▁; ▁Clinic al ▁Modifica tion ▁code s ▁; ▁dis charge ▁ diagnos is
D-1832	-0.6109398603439331	HF ; international Classification of Diseases ; Ninth revision ; Clinical Modification codes ; discharge diagnosis
P-1832	-4.7683 -0.3419 -0.1537 -0.2701 -0.3076 -0.3386 -0.3701 -0.1867 -0.4427 -0.2211 -0.1285 -0.6418 -0.5615 -0.2621 -0.8091 -0.0456 -0.4699 -1.2681 -0.0393 -0.2080 -0.5060 -1.2360 -0.2742 -1.4909 -0.6291 -0.4881 -0.3530 -0.2940
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary capillary wedge pressure ; baseline ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
H-1959	-1.0210926532745361	▁pulmonar e ▁cap illa ry ▁we dge ▁pressure ▁; ▁h g ▁; ▁s d ▁; ▁h g ▁; ▁right ▁at rial ▁pressure ▁; ▁pulmonar y ▁arterial ▁pressure ▁; ▁pulmonar y ▁resist ance
D-1959	-1.0210926532745361	pulmonare capillary wedge pressure ; hg ; sd ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
P-1959	-3.9776 -5.6012 -0.9236 -0.8858 -1.8741 -0.1317 -0.3149 -1.3146 -0.3461 -0.4915 -0.3668 -0.3390 -2.8301 -0.5766 -0.3786 -1.2760 -0.2393 -0.3122 -0.9632 -2.1398 -0.5668 -1.8264 -0.3511 -0.1831 -1.1913 -0.2114 -2.6809 -0.3096 -0.0701 -0.9640 -0.1830 -0.2939 -0.3505 -0.2524
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad ; q65p ; movement ; wild-type rad ; q65p ; l-type channel ; rgk proteins
H-1676	-1.052250623703003	▁Rad ▁; ▁ nc w p ▁; ▁ga ting ▁movement ▁; ▁wild - type ▁Rad ▁; ▁ nc w p ▁; ▁l - type ▁channel ▁inhibi tion ▁; ▁r GK ▁protein s
D-1676	-1.052250623703003	Rad ; ncwp ; gating movement ; wild-type Rad ; ncwp ; l-type channel inhibition ; rGK proteins
P-1676	-1.7793 -0.2522 -2.4292 -2.9716 -0.3444 -0.9996 -0.2472 -4.3930 -0.1243 -1.5901 -0.2583 -0.8008 -0.1383 -0.0296 -1.0219 -0.2471 -1.4603 -3.5218 -0.2338 -1.3622 -0.3602 -2.3329 -0.3327 -0.0842 -0.2723 -0.5397 -3.1023 -0.2204 -0.7927 -1.8719 -0.3986 -0.6175 -0.3729 -0.2733
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 ; heart failure ; proteomics ; actin cytoskeleton ; ss20 ; mitochondrial ; metabolic pathways
H-876	-0.6551600694656372	▁SS 20 ▁; ▁heart ▁failure ▁; ▁prote o mics ▁; ▁cy tos kelet on ▁path ways ▁; ▁SS 20 ▁; ▁mito cho ndri al ▁; ▁metabol ic ▁path ways
D-876	-0.6551600694656372	SS20 ; heart failure ; proteomics ; cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
P-876	-1.8217 -1.9934 -0.3355 -2.5356 -0.5360 -0.2804 -0.2195 -0.6101 -0.0376 -0.4088 -1.5365 -1.1334 -0.1099 -0.4966 -0.7297 -0.3603 -0.3747 -0.9910 -1.2355 -0.3286 -0.1366 -0.9661 -0.4057 -0.2396 -0.4011 -0.1472 -0.4703 -0.3070 -0.5184 -0.3926 -0.2507
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic insufficiency ; mechanical circulatory support ; continuous flow ; left ventricular assist devices ; lvads ; pulsatile devices
H-542	-0.6179762482643127	▁a or tic ▁insu ffi cie ncy ▁; AI ▁; ▁mechanic al ▁circula tory ▁support ▁; ▁continuo us ▁flow ▁; cf ▁; ▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁pulsa tile ▁devices
D-542	-0.6179762482643127	aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;cf ; left ventricular assist devices ; lVADs ; pulsatile devices
P-542	-0.3149 -0.1939 -1.2783 -0.0626 -0.0757 -2.3602 -0.2389 -0.2987 -4.3521 -0.3694 -0.7524 -0.1232 -0.0084 -0.5551 -0.5901 -0.3462 -0.1885 -0.8893 -0.4873 -0.2802 -2.0631 -0.3641 -0.5620 -0.1934 -1.7475 -0.2852 -0.9389 -0.7809 -0.2951 -0.1767 -0.1100 -0.3546 -0.3336 -0.2387 -0.2019 -0.3841 -0.4326 -0.2553
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration ; pyridostigmine ; coronary artery ligation ; cardiac ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; hf
H-1145	-0.5438625812530518	▁py rido stig mine ▁; ▁corona ry ▁arter y ▁liga tion ▁; ▁cardiac ▁va gal ▁; ▁sympa the tic ▁tone ▁; ▁cardiac ▁remodel ing ▁; ▁left ▁vent ri cular ▁dys function ▁; HF
D-1145	-0.5438625812530518	pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ;HF
P-1145	-0.0323 -0.0436 -0.0082 -0.3169 -0.3113 -0.4753 -2.0855 -0.1021 -2.0152 -0.4306 -1.3030 -0.3147 -0.5784 -0.0262 -0.1007 -0.2489 -0.1093 -0.6673 -1.0068 -0.0719 -0.3369 -0.1808 -0.0321 -0.2948 -0.3262 -0.4650 -0.1588 -1.5390 -0.6638 -0.0350 -0.1383 -0.3223 -3.2870 -0.7757 -0.2315
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge ; patients ; follow-up ; physician ; physician
H-1418	-0.6263695359230042	▁dis charge ▁; ▁follow - up ▁visit s
D-1418	-0.6263695359230042	discharge ; follow-up visits
P-1418	-3.0132 -0.6441 -0.4644 -0.0617 -0.3257 -0.0547 -0.6274 -0.3332 -0.4232 -0.3162
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life expectancy ; heart failure ; patients ; disease ; terminal heart failure
H-1665	-1.0922045707702637	▁heart ▁failure ▁; ▁end ▁stage ▁; ▁re frac tory ▁; ▁terminal ▁heart ▁failure
D-1665	-1.0922045707702637	heart failure ; end stage ; refractory ; terminal heart failure
P-1665	-5.7533 -0.8343 -0.2395 -4.0500 -0.4505 -0.2267 -0.1511 -0.0998 -0.4549 -0.4380 -0.2891 -2.1454 -0.5915 -0.3478 -0.3111
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart failure ; discharges ; university of connecticut health center ; patients ; follow-up
H-723	-0.9029728770256042	▁heart ▁failure ▁dis charge s ▁; ▁University ▁of ▁Connect i cut ▁health ▁Center ▁; ▁patients ▁; ▁follow - up
D-723	-0.9029728770256042	heart failure discharges ; University of Connecticut health Center ; patients ; follow-up
P-723	-2.2086 -0.3394 -1.6551 -0.3057 -0.3753 -0.2393 -2.5870 -0.3997 -0.7700 -0.0751 -0.8189 -1.6988 -0.9320 -0.3995 -1.8781 -1.1264 -0.0428 -0.2927 -0.0480 -2.5014 -0.2688
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes ; patients ; new york heart association ; nyha ; heart failure ; eplerenone ; placebo ; heart failure ; medicines ; emphasis-hf
H-1229	-0.9595407843589783	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁Class ▁II ▁Heart ▁Fail ure ▁; ▁e pler en one ▁; ▁Place bo ▁; ▁Heart ▁Fail ure ▁Medicine s ▁; EMP s - HF ▁Study
D-1229	-0.9595407843589783	New York Heart association ;NYha ; Class II Heart Failure ; eplerenone ; Placebo ; Heart Failure Medicines ;EMPs-HF Study
P-1229	-1.3890 -1.9400 -2.4958 -0.3674 -0.2145 -2.4738 -2.5270 -0.2784 -1.0765 -0.8978 -1.2186 -0.4606 -1.9883 -0.2075 -0.7028 -0.1354 -0.1446 -0.8146 -0.2295 -0.3624 -0.0258 -0.2411 -2.0551 -0.4114 -1.6777 -0.6054 -0.3204 -0.2312 -1.4021 -4.2895 -0.1285 -0.4404 -0.9686 -0.5693 -0.2927
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; ivc occlusion ; bivp ; ste ; rs
H-324	-0.6750510931015015	▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁base ▁; ▁mid pap illa ry ▁; ▁ap ex ▁; ▁base line ▁; ▁i cc ▁oc clusi on ▁; ▁Bi VP ▁; ▁ STE ▁analysis ▁; ▁twist ▁; ▁ap ical ▁; ▁bas al ▁rota tions ▁; ▁CS ▁; ▁RS
D-324	-0.6750510931015015	echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; icc occlusion ; BiVP ; STE analysis ; twist ; apical ; basal rotations ; CS ; RS
P-324	-0.9040 -0.2687 -0.1438 -0.4035 -0.0265 -0.9374 -0.3955 -1.3038 -0.2175 -1.4474 -0.2367 -1.1350 -0.3704 -0.3106 -0.1004 -0.3448 -1.4516 -0.3285 -0.6493 -0.5094 -0.3166 -1.4632 -0.1304 -0.3632 -1.2712 -0.1851 -0.0802 -0.0112 -0.6334 -0.3913 -0.8160 -1.6914 -0.3390 -3.4372 -1.7299 -1.3550 -0.3043 -0.4344 -0.3032 -2.0798 -0.3953 -1.1025 -0.0992 -0.0436 -0.0226 -0.6317 -0.3801 -2.1190 -0.3443 -0.4837 -0.4176 -0.2425
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence ; drugs ; drugs ; raas ; renin inhibitors ; endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
H-1490	-0.513667643070221	▁drugs ▁; ▁RA as ▁; ▁direct ▁re nin ▁inhibi tors ▁; ▁en dop ep tida se ▁inhibi tors ▁; ▁vaso pe pti das e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers
D-1490	-0.513667643070221	drugs ; RAas ; direct renin inhibitors ; endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
P-1490	-0.1971 -0.2794 -0.6031 -1.0823 -0.2828 -0.0354 -0.0810 -2.4618 -0.2000 -0.3365 -0.3613 -1.8009 -0.2542 -0.8894 -0.1158 -0.0917 -0.0809 -0.4382 -0.3270 -0.0758 -0.2062 -0.2729 -2.3972 -0.0718 -0.0895 -0.5753 -0.3232 -0.7555 -0.7212 -0.1140 -1.5051 -0.0246 -0.5068 -0.1816 -0.4361 -0.3163
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute heart failure ; hf ; pharmacologic ; therapeutics ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
H-1015	-0.5420179963111877	▁a cute ▁heart ▁failure ▁; HF ▁; ▁ pharma c ologic ▁; ▁ therapeut ics ▁; ▁calci um - sensi t izing ▁agents ▁; ▁anta gon ists ▁; ▁en do the lin ▁; ▁vaso press in ▁; ▁ad enos ine
D-1015	-0.5420179963111877	acute heart failure ;HF ; pharmacologic ; therapeutics ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
P-1015	-0.5835 -0.2661 -1.3109 -0.3433 -0.2914 -1.1557 -0.2352 -0.5416 -3.0621 -0.1726 -0.3732 -1.1559 -0.6249 -0.4029 -2.2235 -0.3253 -0.6091 -0.0658 -0.1270 -0.1815 -1.3117 -0.0714 -0.2714 -0.3181 -1.0269 -0.0194 -1.2781 -0.5858 -0.1071 -0.0446 -0.1647 -0.6979 -0.3462 -0.0174 -0.0329 -0.2320 -0.3308 -0.2072 -0.0178 -0.9246 -0.4327 -0.2745
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in vivo ; hf ; phenylephrine ; haemodynamic ; surgical ; transverse aortic constriction ; tac ; jq1 ; pathological ; cardiac hypertrophy
H-1047	-0.7121989727020264	▁ HF ▁; ▁ phen yle ph rine ▁; ▁ha emo dynamic ▁stress ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC ▁; ▁j q 1 ▁; ▁cardiac ▁hyper trop hy
D-1047	-0.7121989727020264	HF ; phenylephrine ; haemodynamic stress ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
P-1047	-3.8459 -1.3635 -0.2363 -1.0476 -0.3631 -0.5313 -0.1096 -0.3092 -0.3029 -0.0096 -0.2197 -0.0128 -0.3841 -0.2630 -0.3044 -0.9197 -0.1049 -0.0948 -1.1084 -0.0971 -0.7285 -0.5324 -0.3112 -1.3053 -0.3845 -0.9799 -2.7696 -1.6477 -0.3490 -1.0513 -0.2109 -0.0327 -2.4331 -0.3190 -0.2439
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; fontan
H-1502	-0.5720093846321106	▁Mus cle ▁aero bic ▁capacity ▁; ▁poste xer ci se ▁ phos pho creati ne ▁re syn the sis ▁; ▁Font an
D-1502	-0.5720093846321106	Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
P-1502	-2.4840 -0.8269 -0.4144 -0.7549 -0.4349 -0.2970 -0.1854 -0.0553 -0.1931 -0.4033 -0.2091 -0.0611 -0.6434 -0.7197 -1.7901 -0.0615 -0.1126 -0.4810 -1.6291 -0.3219 -0.2335 -0.0824 -1.0683 -0.2654
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
H-1117	-0.7876632213592529	▁i - mi BG ▁; ▁cardiac ▁was hout ▁; ▁car vedi lol ▁; ▁met o pro lol ▁treatment ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1117	-0.7876632213592529	i-miBG ; cardiac washout ; carvedilol ; metoprolol treatment ; β2-adrenergic receptor haplotype
P-1117	-0.1834 -0.8766 -0.2500 -4.4817 -0.9493 -0.4192 -3.2188 -1.8638 -0.4321 -0.0677 -0.6216 -0.5732 -0.3960 -0.5221 -0.3403 -0.3451 -0.8235 -2.8436 -0.4592 -0.2326 -0.1587 -0.5075 -0.2456 -1.3316 -0.6242 -0.0825 -0.2799 -0.4592 -0.0385 -0.4850 -0.3052
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute myocardial infarction ; ami ; incidence ; deaths ; heart failure ; hf ; ami
H-1306	-1.0733411312103271	▁treatment ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁heart ▁failure ▁; HF ▁; AMI
D-1306	-1.0733411312103271	treatment ; acute myocardial infarction ;AMI ; heart failure ;HF ;AMI
P-1306	-3.5404 -0.4063 -0.8781 -0.4249 -1.9051 -0.2757 -0.3892 -1.4115 -0.0690 -0.3833 -0.6725 -0.3008 -2.4775 -0.3122 -2.6559 -0.3570 -0.3300 -2.2150 -0.3698 -3.6557 -0.3235 -0.2600
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; cardiac metabolic gene expression ; atp
H-655	-0.4693167805671692	▁h - d ko ▁; ▁vent ri cular ▁mass ▁; ▁cardiac ▁apo pto sis ▁; ▁fibro sis ▁; ▁Akt ▁; ▁voor k head ▁box ▁; ▁o -1 ▁; ▁cardiac ▁metabol ic ▁gene ▁expression ▁; ▁ATP ▁content
D-655	-0.4693167805671692	h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ; voorkhead box ; o-1 ; cardiac metabolic gene expression ; ATP content
P-655	-0.6355 -0.1923 -0.1152 -0.8228 -0.2277 -0.3109 -1.4670 -0.5746 -0.2176 -0.2294 -0.2700 -0.1000 -0.4385 -1.2996 -0.2411 -0.0042 -0.3595 -0.3153 -0.1724 -0.7502 -0.6036 -0.0856 -0.8531 -0.1502 -0.3720 -0.1411 -1.0622 -0.4097 -0.2773 -0.0312 -0.3001 -0.6851 -0.2249 -0.2401 -0.9986 -1.8694 -0.5257 -0.2607
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck stent ; implanted ; lad ; circumflex artery ; lcx ; lcx ; lad
H-505	-0.7793968319892883	▁bottle ne ck ▁sten t ▁; ▁proxima l ▁left ▁anterior ▁descend ing ▁; LAD ▁; ▁proxima l ▁circum flex ▁arter y ▁; ▁l x ▁; ▁proxima l ▁ LC x ▁; ▁mid ▁ LAD
D-505	-0.7793968319892883	bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ; lx ; proximal LCx ; mid LAD
P-505	-0.2457 -0.1915 -0.0532 -0.0185 -0.1423 -0.4677 -3.1633 -0.5102 -1.3224 -0.3685 -0.1413 -0.1366 -0.3460 -0.6360 -0.4686 -0.3857 -0.5898 -0.0388 -0.1249 -0.1059 -1.8352 -0.3696 -0.3652 -3.8517 -1.2161 -1.0146 -0.3887 -0.3163 -2.0036 -2.5735 -0.4063 -1.9317 -0.5287 -0.5666 -0.9383 -0.2952
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized ; heart failure ; dipeptidyl peptidase-4 ; dpp-4 ; antihyperglycemic agents
H-1827	-0.6994310021400452	▁hospital ized ▁heart ▁failure ▁; ▁h HF ▁; ▁di pe pti dy l ▁pep tida se -4 ▁; ▁d p -4 ▁; ▁inhibi tors ▁; ▁anti hy per gly ce mic ▁agents
D-1827	-0.6994310021400452	hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dp-4 ; inhibitors ; antihyperglycemic agents
P-1827	-4.2955 -0.3724 -0.9743 -0.4782 -0.2879 -0.3974 -3.1971 -0.3133 -0.2715 -0.0498 -0.2453 -4.5462 -1.3916 -0.0099 -0.1046 -0.5640 -0.1695 -0.3662 -0.0688 -0.9693 -0.3054 -0.5004 -0.0813 -0.4343 -0.3222 -0.0141 -0.5064 -0.1137 -0.1601 -0.6682 -0.6261 -0.3507 -0.3577 -0.2674
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox modeling ; heart failure patient severity index ; hfpsi ; university of michigan ; hf ; clinic ; primary outcome
H-380	-1.1163973808288574	▁multi vari able ▁co x ▁model ing ▁; ▁Heart ▁Fail ure ▁Patient ▁Sever ity ▁index ▁; HF PSI ▁; ▁University ▁of ▁Michigan ▁; HF ▁clinic ▁; UM ▁co hor t
D-380	-1.1163973808288574	multivariable cox modeling ; Heart Failure Patient Severity index ;HFPSI ; University of Michigan ;HF clinic ;UM cohort
P-380	-4.3494 -0.1935 -0.3374 -0.0494 -0.2992 -0.9556 -0.3733 -0.3332 -0.8889 -0.4327 -1.0546 -0.3678 -0.6033 -3.8342 -0.3470 -0.2808 -1.7033 -2.0732 -0.3450 -2.0494 -0.2532 -0.3337 -0.2896 -3.4583 -0.9434 -0.2768 -5.3110 -1.0424 -2.1702 -0.0907 -0.4112 -0.2727
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 ; healthy ; cardiomyocytes ; camp ; inotropic effect ; acute ; β-ar ; contractility
H-1216	-0.4233747124671936	▁p de 2 ▁over expression ▁; ▁cardio my o cy tes ▁; ▁c AMP ▁; ▁l - type ▁ca 2 ▁; ▁in o tropi c ▁effect ▁; ▁β - AR ▁stimul ation ▁; ▁bas al ▁contract ility
D-1216	-0.4233747124671936	pde2 overexpression ; cardiomyocytes ; cAMP ; l-type ca2 ; inotropic effect ; β-AR stimulation ; basal contractility
P-1216	-1.7869 -0.9946 -0.1464 -0.3429 -0.1371 -0.2228 -0.1905 -0.8385 -0.2458 -0.2318 -0.3491 -0.3378 -0.0832 -0.3418 -0.6697 -0.1908 -0.0804 -0.0139 -0.3728 -0.2480 -0.2455 -0.3577 -0.2611 -0.0615 -0.4225 -0.0529 -0.3014 -0.5237 -0.0433 -1.1875 -0.4078 -2.4535 -0.3152 -0.1275 -0.1307 -0.0220 -1.0686 -0.4119 -0.2926
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp ; shock therapy
H-863	-1.0851020812988281	▁ATP ▁; HR ▁; ▁shock ▁ therapy ▁; HR
D-863	-1.0851020812988281	ATP ;HR ; shock therapy ;HR
P-863	-1.9549 -0.3420 -3.1786 -0.4217 -1.0497 -0.3101 -0.0666 -0.4593 -3.4666 -0.3589 -0.3277
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac resynchronization therapy ; crt ; patients ; heart failure ; hf ; outcomes ; crt ; dialysis ; reported
H-904	-0.9975111484527588	▁Card iac ▁re syn chron ization ▁ therapy ▁; ▁c t ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure ▁; HF ▁; ▁benefit ▁; ▁c t ▁; ▁di al ysis
D-904	-0.9975111484527588	Cardiac resynchronization therapy ; ct ; dialysis-dependent patients ; heart failure ;HF ; benefit ; ct ; dialysis
P-904	-2.0364 -1.9306 -0.0893 -0.1567 -0.0193 -2.1426 -0.4428 -0.1004 -0.2882 -0.8365 -4.2788 -0.3092 -1.6998 -0.2129 -0.2873 -0.2435 -0.2080 -3.0067 -0.6716 -1.3299 -0.4185 -0.2937 -1.8555 -0.3199 -2.0840 -0.3370 -0.9585 -4.2643 -0.2238 -1.6005 -0.2925 -0.4009 -0.2972 -0.2788
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint ; cardiorespiratory fitness ; crf ; body mass index ; heart failure ; hf ; mortality ; cardiovascular ; hf ; mortality
H-1766	-0.8695945739746094	▁cardio re spira tory ▁fitness ▁; ▁r bf ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁; HF ▁; ▁mortal iteit ▁; ▁cardiovascular ▁risk ▁factors ▁; HF ▁; ▁mortal iteit ▁; ▁fit ▁; ▁un fit ▁men
D-1766	-0.8695945739746094	cardiorespiratory fitness ; rbf ; body mass index ; heart failure ;HF ; mortaliteit ; cardiovascular risk factors ;HF ; mortaliteit ; fit ; unfit men
P-1766	-0.5037 -0.3027 -0.3370 -0.3242 -1.3689 -0.2950 -2.3932 -2.2784 -0.2964 -1.6691 -0.1150 -0.0191 -0.3290 -1.3002 -0.6905 -0.2536 -1.8675 -0.2965 -0.3785 -2.8583 -0.3304 -0.1908 -0.7986 -0.6494 -0.2741 -3.2884 -0.5563 -0.4682 -2.9567 -0.2532 -0.6085 -0.5586 -0.0330 -0.0887 -2.5730 -0.4216 -0.2486
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; eplerenone ; patients ; hospitalization ; heart failure
H-1221	-0.627712070941925	▁e pler en one ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁EM PHA SIS - HF ▁; ▁e pler en one ▁; ▁Mil d ▁Patient s ▁Hospital ization ▁; ▁Sur v I val ▁Study ▁in ▁Heart ▁Fail ure
D-1221	-0.627712070941925	eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone ; Mild Patients Hospitalization ; SurvIval Study in Heart Failure
P-1221	-0.1189 -0.3398 -0.2178 -1.9051 -0.2939 -0.2126 -0.4795 -0.5107 -0.2719 -0.1571 -0.2606 -0.3216 -1.9149 -0.5450 -1.8364 -0.1185 -0.5533 -1.0041 -0.3685 -0.4775 -0.2626 -1.3690 -0.2785 -0.8166 -0.0334 -0.2326 -0.1814 -1.2358 -0.5905 -0.2910 -0.7375 -0.1271 -3.3354 -0.0386 -0.7368 -1.2234 -0.6946 -0.1568 -0.9353 -0.3065 -0.2449
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart rate ; cardiac ; patients ; patients ; acute myocardial infarction ; ami ; patients ; congestive heart failure ; chf ; left ventricular ; dysfunction
H-1585	-1.0063556432724	▁Heart ▁rate ▁; HR ▁; ▁cardiac ▁patients ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ec b ▁; ▁left ▁vent ri cular ▁; LV
D-1585	-1.0063556432724	Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ; ecb ; left ventricular ;LV
P-1585	-1.9363 -0.8665 -0.2719 -2.0259 -0.3501 -0.2458 -1.0533 -0.3250 -0.8387 -0.2091 -2.1459 -0.2876 -0.6297 -2.6462 -0.0849 -0.4110 -0.8560 -0.3697 -2.2476 -0.3789 -0.4437 -0.6163 -3.3465 -0.9292 -0.2896 -0.3106 -5.5602 -0.8501 -0.3796 -0.6169 -0.2028 -1.7959 -0.5276 -0.3345 -2.0361 -0.5156 -0.2998
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular cardiomyocytes ; chronic ; insulin ; irs1 ; irs2 ; proteins ; insulin ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
H-657	-0.495563268661499	▁ne ona tal ▁rat ▁; ▁vent ri cular ▁cardio my o cy tes ▁; ▁chronic ▁insulin ▁exposure ▁; ▁i RS 1 ▁; ▁i RS 2 ▁protein s ▁; ▁insulin ▁action ▁; ▁mechanism ▁; ▁cardiac ▁dys function ▁; ▁insulin ▁resist ance ▁; ▁type ▁2 ▁diabetes
D-657	-0.495563268661499	neonatal rat ; ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; mechanism ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
P-657	-0.1003 -0.3702 -0.1631 -0.2587 -0.3940 -0.1732 -1.3304 -0.4002 -0.0589 -1.2812 -0.2195 -0.1772 -0.2813 -0.3708 -1.5828 -0.6012 -0.0810 -0.3337 -1.4460 -0.7113 -1.7003 -0.3652 -1.5154 -1.2507 -0.0473 -0.4548 -0.4701 -0.3516 -0.5243 -0.1734 -0.2432 -0.3452 -2.5300 -0.1123 -0.0363 -0.0257 -0.2988 -0.2086 -0.1761 -0.1160 -0.2513 -0.0982 -0.4206 -0.0399 -0.4408 -0.2647
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms ; left ventricular ; midpapillary ; atrioventricular delay ; avd ; interventricular delay ; vvd ; ste ; circumferential strain ; radial strain ; rs
H-323	-0.7799680829048157	▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁mid pap illa ry ▁level ▁; ▁at rio ven tri cular ▁de lay ▁; ▁v d ▁; ▁interven tri cular ▁de lay ▁; ▁v d ▁; ▁ste ▁analysis ▁; ▁circum fer ential ▁strain ▁; CS ▁; ▁radi al ▁strain ▁; ▁r ms
D-323	-0.7799680829048157	echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ; vd ; interventricular delay ; vd ; ste analysis ; circumferential strain ;CS ; radial strain ; rms
P-323	-1.2902 -0.3809 -0.2376 -0.4721 -0.0467 -1.0169 -0.3708 -1.4094 -0.2806 -1.8025 -0.3475 -0.4437 -0.1454 -0.3917 -1.7585 -0.2195 -0.3305 -1.3133 -0.4810 -0.1460 -3.0879 -1.0971 -0.2548 -0.3127 -0.3569 -1.2448 -1.4775 -0.3591 -0.0738 -2.7770 -0.5001 -0.2277 -0.3447 -0.3529 -0.1189 -0.9938 -0.3394 -2.3525 -1.0275 -0.6068 -0.6663 -0.7479 -1.8992 -0.0553 -0.3345 -3.6366 -0.3266 -0.0653 -0.3862 -0.0949 -0.3025 -0.4116 -2.6096 -0.3577 -0.2130
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients ; new york heart association ; nyha ; functional class ; hf ; ejection fractions ; chronic ; stable ; guideline-directed medical therapy ; gdmt ; united states ; canada ; europe
H-1870	-0.8190074563026428	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁functional ▁class ▁III ▁ HF ▁; ▁e je ction ▁ fraction s ▁; ▁chronic ▁stable ▁; ▁guide line - direct ed ▁medical ▁ therapy ▁; GD t ▁; ▁veren ig de ▁staten ▁; ▁Canada ▁; ▁europa
D-1870	-0.8190074563026428	New York Heart association ;NYha ; functional class III HF ; ejection fractions ; chronic stable ; guideline-directed medical therapy ;GDt ; verenigde staten ; Canada ; europa
P-1870	-0.9514 -1.7959 -2.1665 -0.2722 -0.2549 -2.5665 -2.4264 -0.2907 -0.1076 -0.1064 -1.0606 -0.8844 -1.3406 -0.2558 -0.1836 -0.3656 -0.1021 -0.3078 -0.0181 -0.4895 -0.3013 -0.3472 -1.1237 -1.1031 -1.4355 -0.1273 -0.1894 -0.0221 -0.3906 -0.4440 -0.1452 -0.0435 -0.2408 -1.8416 -1.8615 -0.3304 -2.8467 -0.0089 -0.2744 -0.7591 -0.2094 -3.7617 -0.2998 -2.9120 -0.5013 -0.2075
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients ; qrs ; hazard ratio ; primary outcome ; patients ; qrs ; hazard ratio
H-889	-0.9280621409416199	▁non - LB bb ▁; ▁QR s ▁; ▁QR s
D-889	-0.9280621409416199	non-LBbb ; QRs ; QRs
P-889	-0.6446 -0.1171 -0.9077 -3.0026 -0.3379 -0.3108 -1.9356 -0.4899 -1.1158 -1.6537 -0.3114 -0.3095
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous hf ; myofiber shortening ; septum ; myofiber shortening ; stretch ; wall
H-1155	-0.7472184896469116	▁dys syn chron ous ▁ HF ▁; ▁my o fi ber ▁short en ing ▁; ▁sept um ▁; ▁my o fi ber ▁; ▁stretch ▁rate ▁; ▁late - activa ted ▁lateral ▁wall
D-1155	-0.7472184896469116	dyssynchronous HF ; myofiber shortening ; septum ; myofiber ; stretch rate ; late-activated lateral wall
P-1155	-0.7728 -0.0537 -0.0366 -1.9353 -0.4400 -0.5453 -0.3311 -2.2917 -0.3908 -0.5015 -0.8978 -3.1419 -0.2438 -0.9059 -0.5177 -1.4931 -0.0494 -0.3113 -2.0845 -0.2940 -0.5263 -0.7368 -0.8362 -0.2983 -1.1796 -0.4333 -0.6614 -0.0865 -0.0901 -1.0133 -0.3373 -1.2286 -0.4365 -0.3032
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics ; proteomics ; transverse aortic constriction ; tac ; heart failure ; signaling pathway ; ingenuity pathway analysis
H-871	-0.5501924753189087	▁label - free ▁shot gun ▁; ▁prote o mics ▁; ▁prote o mics ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC ▁; ▁heart ▁failure ▁; ▁signal ing ▁path way ▁; ▁ingen u ity ▁path way ▁analysis
D-871	-0.5501924753189087	label-free shotgun ; proteomics ; proteomics ; transverse aortic constriction ;TAC ; heart failure ; signaling pathway ; ingenuity pathway analysis
P-871	-0.5963 -0.1583 -0.2509 -0.1903 -0.1888 -0.5096 -0.1944 -1.1448 -0.0636 -0.2629 -0.7751 -0.9079 -0.0776 -0.2571 -0.0142 -0.8218 -0.1301 -0.1502 -0.8812 -0.1238 -1.4658 -0.3643 -0.2674 -1.4099 -0.3097 -0.9112 -0.3105 -0.7263 -0.7766 -0.6794 -0.2415 -0.2817 -1.6884 -0.2809 -0.2121 -2.9075 -0.2912 -0.2604 -0.9261 -0.3293 -0.2189
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells ; transforming growth factor-β ; tgf-β ; epithelial ; mesenchymal ; transition ; expression ; pluripotency markers
H-1342	-0.5851461291313171	▁c - K it + ▁cell s ▁; ▁growth ▁factor - β ▁; ▁t bf - β ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker s ▁; ▁sham s
D-1342	-0.5851461291313171	c-Kit+ cells ; growth factor-β ; tbf-β ; mesenchymal transition markers ; pluripotency markers ; shams
P-1342	-0.3424 -0.2534 -2.0808 -0.1410 -2.7791 -0.3296 -0.4117 -0.3834 -1.8767 -0.8404 -0.3180 -0.5519 -0.3484 -1.2789 -2.2849 -0.2108 -0.5031 -0.3744 -0.2782 -0.4525 -0.6144 -0.9199 -0.1594 -0.2989 -0.2100 -0.3458 -0.1398 -0.1863 -0.0828 -0.1033 -0.1923 -0.3352 -0.1007 -0.6192 -0.4233 -0.2943
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka ; change ; riiα ; cα ; expression ; riiα ; ser96 ; cα ; thr197 ; phosphorylation ; hf
H-1428	-0.9703038930892944	▁p ka ▁; ▁sub un its ▁; ▁type ▁II ▁regulator y ▁; RI i α ▁; ▁cata ly tic ▁; ▁c α ▁; ▁sub un it ▁expression ▁; ▁r II α ▁; ▁ser 96) ▁; ▁c α ▁; ▁ phos phor y lation ▁; HF
D-1428	-0.9703038930892944	pka ; subunits ; type II regulatory ;RIiα ; catalytic ; cα ; subunit expression ; rIIα ; ser96) ; cα ; phosphorylation ;HF
P-1428	-1.6027 -2.2177 -0.7285 -4.1821 -0.5459 -0.5808 -0.3386 -0.4809 -0.6026 -0.5871 -0.6803 -0.3248 -2.8755 -0.6291 -0.8854 -0.3823 -0.1568 -0.1448 -0.4722 -0.7225 -1.4157 -2.5058 -0.3127 -4.0052 -0.4640 -0.4940 -0.2032 -0.3439 -0.5768 -3.9844 -1.3860 -0.3390 -0.7414 -0.7923 -0.5590 -0.6113 -1.6815 -0.2659 -0.0993 -0.1983 -1.2884 -1.2462 -0.2734 -0.3224 -1.7937 -0.3442 -0.2156
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients ; hfref ; left ventricular ejection fraction ; hfpef ; left ventricular ejection fraction ; β-blocker ; hf ; hospitalization
H-178	-1.0899001359939575	▁h Fr EF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF p EF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁β - block er ▁; ▁index ▁ HF
D-178	-1.0899001359939575	hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; β-blocker ; index HF
P-178	-0.7883 -2.0876 -2.3724 -0.4477 -1.3199 -0.9708 -3.1220 -2.1277 -1.6376 -1.1687 -1.2078 -0.7914 -0.2244 -0.3579 -1.0694 -1.5495 -0.1325 -1.7808 -0.4442 -1.7258 -1.3607 -3.6140 -2.3489 -1.5806 -1.6722 -1.2619 -0.6172 -0.2930 -0.4241 -0.8823 -0.1625 -0.2019 -0.1815 -0.4530 -0.2907 -0.3458 -0.7014 -0.4923 -0.2959
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross talk ; g-protein-coupled receptors ; physiological ; significance ; regulation ; hearts ; chronic ; β-adrenergic receptor ; postischemic heart failure
H-1410	-0.6030371785163879	▁cross ▁talk ▁; ▁g - prote in - co up led ▁receptor s ▁; ▁mouse ▁heart s ▁; ▁β - ad r energi c ▁receptor ▁; ▁rat ▁; ▁post ische mic ▁heart ▁failure
D-1410	-0.6030371785163879	cross talk ; g-protein-coupled receptors ; mouse hearts ; β-adrenergic receptor ; rat ; postischemic heart failure
P-1410	-0.5162 -0.6770 -0.2398 -0.2143 -0.2093 -0.0638 -0.3910 -0.2937 -0.0715 -0.2373 -1.0443 -0.1459 -0.5030 -0.2904 -4.0908 -1.2959 -0.3591 -0.2887 -2.1637 -0.1133 -0.5946 -0.2227 -1.3216 -0.3117 -0.0694 -1.2798 -1.5957 -0.1610 -0.1890 -0.0396 -0.2454 -1.1158 -0.1890 -0.3434 -0.2188
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric remodeling ; concentric hypertrophy ; left ventricular ; remodeling ; heart failure with preserved ejection fraction ; hfpef ; eccentric hypertrophy ; patients
H-1524	-0.7853392362594604	▁concentr ic ▁remodel ing ▁; cr ▁; ▁concentr ic ▁hyper trop hy ▁; CH ▁; ▁left ▁vent ri cular ▁; ▁v n ▁; ▁remodel ing ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁ecce n tric ▁hyper trop hy ▁; ▁eh
D-1524	-0.7853392362594604	concentric remodeling ;cr ; concentric hypertrophy ;CH ; left ventricular ; vn ; remodeling ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ; eh
P-1524	-0.1395 -0.3330 -0.5930 -0.3844 -0.3359 -0.9070 -0.4175 -0.1669 -0.4164 -0.2861 -0.4221 -2.9511 -0.3957 -2.6051 -0.3827 -0.9013 -0.1013 -1.4588 -0.4497 -0.3846 -2.0878 -1.0045 -0.3775 -3.9809 -0.3643 -0.3438 -1.3511 -0.2776 -0.4363 -0.9364 -0.2019 -2.4661 -0.1226 -0.2247 -0.1244 -0.3093 -0.0253 -0.4015 -1.9023 -0.0900 -1.5159 -0.3480 -0.0735 -0.2173 -0.8083 -0.3077 -0.2939 -3.8837 -0.2826 -1.4221 -0.3266 -0.2976
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise ; exercise
H-1989	-1.083580732345581	▁weight ▁; SD ▁; ▁die t ▁group ▁; SD ▁; ▁exercise ▁group ▁; SD ▁; ▁exercise ▁; ▁die t ▁group ▁; SD
D-1989	-1.083580732345581	weight ;SD ; diet group ;SD ; exercise group ;SD ; exercise ; diet group ;SD
P-1989	-3.5291 -0.4623 -1.1053 -0.4490 -1.8983 -0.2581 -1.6755 -0.4653 -1.7060 -0.4188 -0.9326 -2.0438 -0.4429 -1.7113 -0.4416 -1.8419 -0.3663 -1.8426 -0.2938 -1.4912 -0.4742 -1.6142 -0.2429 -0.2990
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv dysfunction ; hazard ratio ; confidence interval ; cachexia ; hazard ratio ; multivariate analyses
H-1166	-0.6368752717971802	RV ▁dys function ▁; haz ard ▁ratio ▁; ▁cache xia ▁; haz ard ▁ratio
D-1166	-0.6368752717971802	RV dysfunction ;hazard ratio ; cachexia ;hazard ratio
P-1166	-3.1735 -0.0727 -0.0797 -0.2928 -0.2323 -0.2290 -0.8064 -0.3785 -1.4204 -0.2589 -0.3673 -0.9765 -0.5338 -0.4490 -0.5906 -0.3285
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients ; resting hr ; follow-up ; baseline ; vo2max ; patients ; resting hr ; p value
H-1945	-1.1019630432128906	▁rest ing ▁; ▁HR ▁; ▁follow - up ▁; ▁VO 2 max ▁; ▁rest ing ▁; ▁HR
D-1945	-1.1019630432128906	resting ; HR ; follow-up ; VO2max ; resting ; HR
P-1945	-1.9505 -0.2822 -0.6873 -2.1999 -0.4045 -0.3594 -0.3228 -0.0567 -0.4296 -4.9991 -0.2530 -0.3462 -0.4065 -2.8637 -0.4394 -1.4105 -2.8520 -0.3781 -0.2960
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β ; cell ; phenotype ; in vitro ; cardiac progenitor function ; cell ; clinical
H-1344	-0.6907085180282593	▁t bf - β ▁inhibi tion ▁; ▁c - K it ▁; ▁cell ▁ph eno type ▁; ▁function ▁; ▁vi tro ▁; ▁cardiac ▁pro gen itor ▁function ▁; ▁cell ▁exp an sion
D-1344	-0.6907085180282593	tbf-β inhibition ; c-Kit ; cell phenotype ; function ; vitro ; cardiac progenitor function ; cell expansion
P-1344	-1.2172 -2.5811 -0.1145 -0.7476 -0.2638 -2.1198 -0.2526 -0.0410 -0.1963 -1.8042 -0.0628 -2.6749 -0.4221 -0.1826 -0.1643 -0.0177 -0.3610 -0.5500 -0.9859 -0.5879 -0.1224 -0.4763 -0.5434 -0.4827 -0.0670 -1.0425 -0.1514 -0.3036 -0.7871 -0.0806 -0.2911 -2.6785 -0.8550 -0.2549
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp ; inflammatory ; biomarkers ; hscrp ; il6 ; patients ; hscrp
H-1920	-0.6954802870750427	▁NT - pro b NP ▁; ▁infla mma tory ▁bio mark ers ▁; ▁h s cr p ▁; ▁IL ▁6 ▁; ▁h s cr p
D-1920	-0.6954802870750427	NT-probNP ; inflammatory biomarkers ; hscrp ; IL 6 ; hscrp
P-1920	-0.2221 -0.1938 -1.2674 -1.5665 -1.9266 -0.4311 -0.1783 -0.6154 -0.9377 -0.0668 -0.4056 -0.7490 -0.4690 -0.3330 -0.1388 -0.2717 -1.1756 -0.4155 -1.7626 -1.2408 -0.5565 -1.7615 -0.1291 -0.3314 -0.7628 -0.4873 -0.3818
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets ; in vitro ; neurohormonally ; heart disease ; nanomolar ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological ; gene induction
H-1044	-0.5098845362663269	BET s ▁; ▁neuro hormon ally ▁induc ed ▁heart ▁disease ▁; ▁na nomo lar ▁dos es ▁; ▁j w t ▁; ▁ phen yle ph rine - media ted ▁hyper trop hy ▁; ▁cardio my o cy tes ▁; ▁path ological ▁gene ▁in duction
D-1044	-0.5098845362663269	BETs ; neurohormonally induced heart disease ; nanomolar doses ; jwt ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
P-1044	-1.0316 -0.7737 -0.2454 -0.1295 -0.1031 -0.8971 -0.0152 -0.4959 -1.4612 -1.1498 -0.2644 -0.1071 -0.1942 -0.1834 -2.1317 -0.1152 -0.2841 -0.3501 -4.4198 -0.9194 -0.6836 -0.1354 -0.1978 -0.5828 -0.2143 -0.2223 -0.1449 -0.0849 -0.5023 -0.0288 -0.0136 -2.4100 -0.2275 -0.0710 -0.4682 -0.1163 -0.1023 -0.2164 -0.2436 -0.0736 -0.4504 -0.2475 -0.0705 -0.0479 -0.3861 -0.2409
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat ; functional status ; quality of life ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; heart failure ; hospitalizations ; patients ; nyha functional class iii ; hf
H-1878	-0.7671782970428467	▁BAT ▁; ▁functional ▁status ▁; ▁exercise ▁capacity ▁; ▁n - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁heart ▁failure ▁; ▁hospital ization s ▁; ▁ gt m - tre ated ▁w ha ▁; ▁functional ▁class ▁III ▁ HF
D-1878	-0.7671782970428467	BAT ; functional status ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; heart failure ; hospitalizations ; gtm-treated wha ; functional class III HF
P-1878	-0.1024 -0.2613 -1.9101 -1.3317 -0.2459 -1.1674 -0.3296 -0.2879 -3.5022 -0.0729 -1.2736 -0.1184 -0.6682 -0.0995 -0.1556 -0.1509 -0.0392 -0.4759 -0.4483 -1.2578 -0.5223 -0.1230 -0.4018 -0.3348 -1.4918 -0.2238 -0.3821 -1.3835 -0.8801 -0.2407 -0.2766 -1.7076 -0.9721 -1.2842 -0.4223 -0.0280 -2.0884 -3.1661 -0.9365 -0.1522 -0.1184 -0.1982 -1.3323 -2.0985 -0.7294 -0.4162 -0.2473
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated ; p70s6k ; pkc-βii ; hdl ; nyha-iiib ; malondialdehyde ; bound ; hdl ; nyha-iiib ; hdl ; healthy
H-257	-1.0349465608596802	▁activa tion ▁; ▁PK c - β II ▁; ▁HD l ▁; ▁malo ndi alde hy de ▁; ▁HD l ▁; ▁ny ha - III b ▁; ▁HD l ▁; health y
D-257	-1.0349465608596802	activation ; PKc-βII ; HDl ; malondialdehyde ; HDl ; nyha-IIIb ; HDl ;healthy
P-257	-0.1490 -2.0931 -0.3532 -3.1126 -1.5560 -0.1583 -0.3172 -1.8830 -0.3673 -2.0870 -2.7481 -0.3615 -0.7890 -0.1656 -0.2007 -1.2983 -0.3938 -0.4220 -1.4504 -1.9777 -0.3839 -2.5961 -2.3794 -0.1990 -1.6640 -0.2359 -0.4878 -0.8235 -2.0143 -0.5266 -1.0704 -0.4116 -0.2434 -0.2681
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change ; exercise ; exercise
H-1986	-1.2413420677185059	ML HF ▁; ▁exercise ▁; ▁die t ▁; ▁exercise ▁; ▁die t
D-1986	-1.2413420677185059	MLHF ; exercise ; diet ; exercise ; diet
P-1986	-3.3436 -3.2718 -0.4154 -2.8053 -0.3213 -1.0533 -0.3140 -0.3879 -2.3643 -0.3492 -1.6595 -0.4054 -0.3819 -0.3059
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx ; dnx
H-1374	-1.054636836051941	▁non pa ce ▁; ▁non - DN x ▁; ▁stam - i nner vat ed ▁; ▁stam - in v ▁; ▁non pa ce ▁; ▁DN x ▁; ▁s ham - DN x ▁; ▁pace ▁; ▁non - DN x ▁; ▁ nc w - in v ▁; ▁pace ▁; ▁DN x ▁; ▁ nc w - DN x
D-1374	-1.054636836051941	nonpace ; non-DNx ; stam-innervated ; stam-inv ; nonpace ; DNx ; sham-DNx ; pace ; non-DNx ; ncw-inv ; pace ; DNx ; ncw-DNx
P-1374	-0.3941 -0.3060 -0.7658 -0.7272 -0.2787 -0.1572 -1.5288 -0.8124 -0.5843 -2.5334 -0.2434 -3.5659 -0.0346 -0.3474 -0.7499 -0.3682 -2.3437 -0.2419 -0.2181 -0.3999 -0.5933 -1.2619 -0.1316 -0.6963 -0.7088 -2.4698 -0.4657 -0.5452 -4.7275 -0.8878 -0.2181 -3.2290 -0.7656 -0.5101 -0.2890 -0.9437 -2.3674 -0.1566 -2.8241 -1.0762 -0.4809 -1.6827 -2.7545 -1.2918 -0.2564 -0.1925 -0.3289 -0.5360 -1.3334 -0.7417 -2.1656 -0.4325 -0.4880 -1.9277 -2.0435 -0.9389 -0.3545 -3.4628 -0.8170 -0.3693 -0.2654
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc battery ; hf ; health abc hf model ; death
H-629	-1.2073794603347778	▁h bc ▁Bat tery ▁score ▁; ▁ HF ▁risk ▁; ▁Health ▁ABC ▁; ▁ HF ▁model ▁; ▁h b ▁; ▁SD ▁; ▁significant ▁; ▁death ▁; ▁h b
D-629	-1.2073794603347778	hbc Battery score ; HF risk ; Health ABC ; HF model ; hb ; SD ; significant ; death ; hb
P-629	-1.9234 -2.1522 -0.6396 -0.1691 -0.9793 -0.2726 -1.3460 -0.7404 -2.7144 -0.2668 -1.4711 -0.3531 -0.7160 -2.4407 -1.3279 -1.9631 -0.2987 -1.5043 -3.1824 -0.2642 -1.8492 -0.3889 -0.0970 -0.3669 -2.7659 -0.3100 -2.7890 -2.3835 -0.2751 -0.2705
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection fraction ; patients ; frail ; biological phenotype ; death ; frailty ; deficit index ; death
H-1010	-0.6994715332984924	▁e je ction ▁ fraction ▁; ▁fra il ▁; ▁bi ological ▁ph eno type ▁; ▁death ▁; ▁fra il ty ▁; ▁deficit ▁index ▁; ▁death
D-1010	-0.6994715332984924	ejection fraction ; frail ; biological phenotype ; death ; frailty ; deficit index ; death
P-1010	-0.1595 -0.5093 -0.0730 -0.4608 -0.0331 -0.3466 -0.1492 -0.1238 -0.3071 -0.8659 -0.6493 -0.2767 -0.1230 -0.0192 -0.3779 -6.1499 -0.3451 -0.1318 -0.2275 -1.4067 -0.3662 -0.1149 -0.0537 -0.3053 -4.6607 -0.3963 -0.2534
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin ; hgb ; hrqol ; hrqol ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-836	-0.9552164673805237	▁hem o glob in ▁; ▁h gb ▁; ▁HR Qo l ▁; ▁HR Qo l ▁; ▁Heart ▁Fail ure ▁; ▁Exerci se ▁Training ▁; HF - ac TION
D-836	-0.9552164673805237	hemoglobin ; hgb ; HRQol ; HRQol ; Heart Failure ; Exercise Training ;HF-acTION
P-836	-0.6190 -0.4273 -0.2275 -0.8836 -0.3322 -0.5503 -1.3215 -0.3656 -1.7366 -0.1051 -3.3166 -0.3170 -2.4043 -0.1653 -2.9381 -0.3382 -0.9986 -0.1972 -1.5018 -0.2583 -1.8043 -0.1629 -0.8539 -0.2193 -2.6308 -0.0862 -1.0712 -2.2859 -0.2957 -0.2424
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial fibrillation ; congestive heart failure ; health care ; expenditures ; patients ; québec ; randomized ; rhythm ; rate-control
H-1234	-0.9057589769363403	▁At rial ▁Fi bril lation ▁; ▁con ges tive ▁Heart ▁Fail ure ▁; ▁health ▁; ▁ex pendi tures ▁; ▁Québec ▁; ▁ rhythm ▁; ▁rate - control ▁; ▁treatment
D-1234	-0.9057589769363403	Atrial Fibrillation ; congestive Heart Failure ; health ; expenditures ; Québec ; rhythm ; rate-control ; treatment
P-1234	-1.8455 -0.0796 -0.4627 -0.1175 -0.2535 -0.3093 -0.3218 -0.6507 -3.5102 -0.6787 -0.5373 -1.5041 -1.2418 -2.9390 -2.6302 -0.0401 -0.2025 -1.1081 -0.2886 -3.5037 -0.3567 -0.1641 -0.8171 -0.4235 -0.2287 -0.1732 -0.0338 -1.3386 -1.3009 -0.7470 -0.2704
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart failure ; patient ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
H-1668	-0.5510169863700867	▁heart ▁failure ▁; ▁my o card ial ▁is cha emia ▁; ▁bra dy ar rhythm ias ▁; ▁val vu lar ▁re gur gi tation ▁; ▁pulmonar y ▁e mbol ism ▁; ▁infection ▁; ▁renal ▁dys function
D-1668	-0.5510169863700867	heart failure ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
P-1668	-2.6279 -0.4018 -0.2930 -1.5345 -0.2309 -0.8083 -1.7235 -0.2458 -0.0446 -1.7494 -0.3429 -0.1053 -1.3437 -0.0772 -0.2017 -0.9367 -0.3446 -0.8691 -0.2116 -0.1376 -0.1273 -0.1875 -0.4915 -0.1910 -0.3073 -0.0337 -1.1973 -0.4129 -0.1064 -2.3732 -0.2521 -0.0954 -0.2375 -0.0164 -0.0420 -0.0382 -0.3654 -0.2335
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report ; calcineurin ; nfat ; mir-25 ; expression ; basic helix-loop-helix ; bhlh ; transcription factor ; dhand ; hand2 ; diseased ; myocardium
H-640	-0.5076248049736023	▁calci ne uri n ▁; ▁n fat ▁signal ling ▁; ▁mi r -25 ▁expression ▁; ▁heli x - loop - heli x ▁; ▁b HL h ▁; ▁tran scription ▁factor ▁; ▁hand ▁; ▁mouse ▁; ▁my o car dium
D-640	-0.5076248049736023	calcineurin ; nfat signalling ; mir-25 expression ; helix-loop-helix ; bHLh ; transcription factor ; hand ; mouse ; myocardium
P-640	-0.1854 -0.7375 -0.0421 -0.2346 -0.3669 -1.4283 -0.6906 -1.3371 -0.5943 -0.3494 -0.5541 -1.8265 -0.1732 -0.1800 -0.3369 -0.1239 -0.5032 -0.1317 -0.0506 -0.3270 -0.0312 -0.8097 -0.6885 -0.6219 -1.9345 -1.1649 -0.3547 -0.0228 -0.0347 -0.2179 -0.2921 -0.3510 -0.3194 -1.4777 -0.2844 -1.1040 -0.0915 -0.0262 -0.1195 -0.4139 -0.2790
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise ; correlated ; psss ; btes ; exercise ; psss ; btes
H-1929	-1.1556000709533691	▁ps s ▁; ▁b tes ▁; ▁exercise ▁time ▁; ▁ps s ▁; ▁b tes
D-1929	-1.1556000709533691	pss ; btes ; exercise time ; pss ; btes
P-1929	-1.4747 -0.6960 -0.6053 -1.8186 -1.0832 -0.4174 -1.3300 -2.2078 -0.4064 -2.4960 -0.6117 -1.0794 -2.1846 -1.3043 -0.4506 -0.3236
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp ; admission ; sensitivity ; specificity ; confidence interval ; area under the curve
H-269	-0.9412313103675842	▁NT - pro b p ▁; ▁cut off ▁point
D-269	-0.9412313103675842	NT-probp ; cutoff point
P-269	-0.7494 -0.1624 -0.1430 -1.5376 -2.9073 -1.3775 -0.3751 -0.8370 -0.7995 -1.1840 -0.2807
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic ; r-r interval ; hr variability ; short-term fractal scaling exponent ; prognostic
H-1588	-0.612334132194519	▁fra c tal ▁scal ing ▁ex ponent
D-1588	-0.612334132194519	fractal scaling exponent
P-1588	-1.9021 -0.1497 -0.1742 -0.9324 -0.2745 -1.0665 -0.2858 -0.4356 -0.2901
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic function ; diastolic filling formalism ; relaxation ; doppler mitral inflow velocity ; e-wave
H-921	-0.44892212748527527	▁dia sto lic ▁function ▁; ▁dia sto lic ▁fill ing ▁; ▁relax ation ▁; vis co ela stic ▁; ▁passiv e ▁; sti ff ness ▁; ▁do pp ler ▁mit ral ▁in flow ▁veloci ty ▁; ▁e - wa ve
D-921	-0.44892212748527527	diastolic function ; diastolic filling ; relaxation ;viscoelastic ; passive ;stiffness ; doppler mitral inflow velocity ; e-wave
P-921	-0.1601 -0.2708 -0.0532 -0.2414 -0.3603 -0.0403 -0.2191 -0.1550 -0.3315 -0.2398 -0.4080 -0.2569 -0.9209 -0.4156 -0.1187 -0.0307 -0.0334 -0.2565 -0.4665 -0.3511 -0.0672 -0.3484 -3.1037 -0.1073 -2.0926 -0.4192 -0.4742 -0.1730 -1.6030 -0.3746 -0.2103 -0.1967 -0.4517 -0.4207 -1.0583 -0.3255 -0.5944 -0.0745 -0.5076 -0.2917 -0.3524 -0.2776
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart failure ; hf ; patients ; spontaneous ventricular tachycardia ; hf ; patients ; spontaneous vt ; hearts
H-1437	-1.2682791948318481	▁heart ▁failure ▁; HF ▁; ▁vent ri cular ▁ta chy car dia ▁; HF VT ▁; ▁ HF ▁; ▁ VT ▁; HF VT ▁; ▁structura lly ▁normal ▁heart s ▁; ▁h Nor m
D-1437	-1.2682791948318481	heart failure ;HF ; ventricular tachycardia ;HFVT ; HF ; VT ;HFVT ; structurally normal hearts ; hNorm
P-1437	-2.8398 -0.5541 -0.2517 -0.7378 -0.2957 -0.4229 -2.2394 -0.5663 -0.9555 -0.3318 -0.2083 -0.2550 -0.2879 -1.5860 -3.6699 -0.2993 -2.5180 -1.9310 -0.7672 -3.7370 -2.7461 -0.2028 -3.0400 -3.4069 -0.2137 -0.7493 -1.9564 -0.7550 -1.2443 -0.2526 -0.2074 -2.5354 -3.1576 -0.1315 -0.3510 -0.2536
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; stroke ; estimated glomerular filtration rate ; lvef
H-819	-0.7521023750305176	▁g s ▁; ▁co x ▁model ▁; ▁chronic ▁heart ▁failure ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁prior ▁stroke ▁score ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁LV EF ▁; ▁sa ▁; ▁CV ▁events
D-819	-0.7521023750305176	gs ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; sa ; CV events
P-819	-0.2791 -1.9594 -0.3336 -0.0281 -0.3860 -0.8560 -0.4282 -1.3363 -1.2937 -0.3596 -0.3214 -0.1003 -0.0659 -0.3330 -0.3373 -0.2983 -1.0752 -0.4698 -0.4353 -0.3715 -0.2554 -0.2759 -0.1771 -0.0541 -1.5814 -0.6937 -0.4665 -1.7098 -2.5289 -0.3217 -1.9706 -0.5882 -2.7176 -1.9988 -0.4205 -0.2473
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient ; vad ; patients ; ventricular assist device ; ecmo ; patients ; extracorporeal membrane oxygenation ; ecmo ; vad ; patients ; ecmo ; vad
H-1387	-1.0989453792572021	▁ VAD ▁; ▁vent ri cular ▁assist ▁device ▁; ▁ec mo ▁; ▁extra corp o real ▁membran e ▁; ▁oxygen ation ▁membran e ▁; ▁ec mo ▁; ▁ec mo ▁; ▁ VAD
D-1387	-1.0989453792572021	VAD ; ventricular assist device ; ecmo ; extracorporeal membrane ; oxygenation membrane ; ecmo ; ecmo ; VAD
P-1387	-2.5372 -1.1182 -0.4504 -0.0759 -1.7665 -0.3835 -0.7744 -0.1991 -2.1007 -1.0692 -3.8121 -0.3877 -0.4316 -0.1841 -0.2165 -0.8591 -0.2022 -0.0784 -1.3164 -0.4354 -1.8422 -0.1609 -0.0915 -1.1957 -0.8290 -3.4302 -0.7283 -1.6029 -3.5879 -0.4763 -3.0725 -1.1151 -0.5094 -0.3237
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic events ; ies ; patients ; ischemic cardiomyopathy ; ic ; cardiac resynchronization therapy ; defibrillator ; crt-d
H-102	-0.5497676134109497	▁ ische mic ▁events ▁; ▁i i ▁; ▁ ische mic ▁cardio my o pathy ▁; ▁i cc ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁c RT - d
D-102	-0.5497676134109497	ischemic events ; ii ; ischemic cardiomyopathy ; icc ; cardiac resynchronization therapy ; defibrillator ; cRT-d
P-102	-0.4527 -0.4122 -0.6448 -0.4680 -0.2916 -0.8420 -3.5927 -0.6840 -0.4084 -0.3359 -0.7358 -0.0597 -0.5752 -0.2266 -0.0592 -0.3048 -0.1683 -1.2423 -0.3075 -0.1765 -0.1630 -0.0976 -0.0271 -1.4648 -0.7840 -0.0527 -0.3293 -0.1684 -0.0653 -0.5441 -0.1980 -0.1503 -0.2862 -0.3445 -3.4847 -0.1047 -0.4400 -0.4327 -0.3156
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart failure ; disease ; evidence-based ; health care
H-2016	-1.1860047578811646	▁heart ▁failure ▁disease ▁management ▁; ▁treatment s ▁; ▁health ▁care ▁system
D-2016	-1.1860047578811646	heart failure disease management ; treatments ; health care system
P-2016	-2.8284 -0.4068 -1.4644 -0.5372 -0.6537 -3.2191 -0.4599 -1.0992 -1.4789 -2.4931 -0.2141 -0.3254 -0.2378
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin ; heart failure ; murine ; resistin ; transgenic ; retn ; gene ; resistin
H-930	-0.7922999262809753	▁resist in ▁; ▁heart ▁failure ▁; ▁mouse ▁; ▁mur ine ▁resist in ▁; ▁trans ge nic ▁; ▁Ret n ▁gene ▁; ▁h um - re t n ▁mi ce ▁; ▁ inflammation - stimul ated ▁resist in ▁; ▁humans
D-930	-0.7922999262809753	resistin ; heart failure ; mouse ; murine resistin ; transgenic ; Retn gene ; hum-retn mice ; inflammation-stimulated resistin ; humans
P-930	-3.8882 -0.8785 -0.3981 -1.6194 -0.3024 -0.3018 -4.1083 -0.2739 -0.1817 -2.4783 -0.9360 -1.2374 -0.2910 -0.0126 -0.0650 -0.3889 -0.2919 -0.1380 -0.0589 -0.3958 -0.2803 -1.3727 -0.6268 -0.1070 -1.8137 -0.7899 -0.0641 -0.6125 -0.4520 -0.5696 -2.5934 -0.1884 -0.0870 -0.0403 -0.8250 -0.4229 -0.6857 -1.3715 -0.7755 -0.2917 -0.2679
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients ; angiotensin-converting enzyme inhibitors ; angiotensin receptors blockers ; β-blockers
H-1745	-0.6100406646728516	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor s ▁block ers ▁; ▁β - block ers ▁; ▁devices
D-1745	-0.6100406646728516	angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers ; devices
P-1745	-2.3739 -2.1224 -0.3877 -3.0958 -0.9438 -0.0720 -0.2120 -0.7890 -0.2192 -0.1112 -0.0278 -0.6176 -0.3598 -0.0362 -0.2111 -1.5717 -0.0277 -0.3508 -0.5909 -0.4633 -0.3287 -0.0900 -0.1537 -0.4443 -0.3421 -0.6408 -0.3570 -0.3910 -0.3600
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ; tac
H-1815	-0.4748169183731079	TTA ▁; ▁t g t et Men a ▁; ▁cardiac ▁injury ▁; ▁e je ction ▁ fraction ▁; ▁heart ▁di la tation ▁; ▁hyper trop hy ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC
D-1815	-0.4748169183731079	TTA ; tgtetMena ; cardiac injury ; ejection fraction ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
P-1815	-1.7706 -0.3458 -1.8578 -0.3284 -0.0740 -0.0511 -0.4840 -0.0717 -0.3098 -0.3301 -0.3021 -0.2977 -0.1832 -0.1367 -0.1127 -0.2896 -0.0233 -0.3338 -1.7138 -1.1382 -0.2759 -0.1265 -0.2973 -0.0536 -0.0357 -2.1646 -0.2825 -0.0029 -0.5643 -0.1404 -0.1297 -0.8800 -0.0479 -0.5835 -0.5572 -0.3559 -1.3666 -0.3013 -0.1976
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation for ambulatory heart failure trial ; implantable ; primary end point ; all-cause mortality ; heart failure ; hospitalization
H-882	-0.6259639859199524	▁re syn chron ization - Def i bril lation ▁; ▁amb ulator y ▁Heart ▁Fail ure ▁tri al ▁; ▁implant able ▁cardio ver ter ▁; ▁de fi br illa tor - c RT ▁; ▁significant ▁; ▁mortal iteit ▁; ▁heart ▁failure ▁hospital ization
D-882	-0.6259639859199524	resynchronization-Defibrillation ; ambulatory Heart Failure trial ; implantable cardioverter ; defibrillator-cRT ; significant ; mortaliteit ; heart failure hospitalization
P-882	-0.1238 -0.1828 -0.0522 -1.0732 -0.1466 -0.4006 -0.2508 -0.2369 -0.1894 -0.2948 -0.0849 -0.6253 -0.7110 -0.6561 -0.8560 -1.9901 -0.2637 -0.1159 -0.2745 -0.6756 -0.2463 -0.1089 -0.1211 -0.3179 -0.6537 -0.0472 -0.0994 -0.3942 -0.0929 -0.0754 -0.1610 -0.5766 -3.3029 -0.2564 -0.2267 -0.3786 -5.0510 -1.9343 -0.2398 -1.7524 -0.9136 -0.9840 -0.4818 -0.3233 -0.2245
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart failure ; patients ; italy ; confirmatory factor analysis ; cfa ; schfi v.6.2 ; self-care maintenance ; self-care management ; self-care confidence
H-1505	-0.8646387457847595	▁heart ▁failure ▁; ▁itali ë ▁; ▁confirma tory ▁factor ▁analysis ▁; ▁c fa ▁; ▁ sch fi ▁; ▁Self - car e ▁Main ten ance ▁; ▁Self - car e ▁management ▁; ▁Self - car e ▁Confi den ce
D-1505	-0.8646387457847595	heart failure ; italië ; confirmatory factor analysis ; cfa ; schfi ; Self-care Maintenance ; Self-care management ; Self-care Confidence
P-1505	-2.3756 -0.5548 -0.6409 -2.0113 -1.4079 -0.3601 -0.1019 -0.1612 -0.3216 -0.6670 -0.3062 -0.8477 -3.3920 -0.3413 -0.2930 -2.7197 -3.3889 -0.2853 -1.4394 -0.1025 -1.9699 -0.2408 -3.0582 -1.0975 -0.6182 -0.2869 -0.1100 -0.0625 -1.2982 -0.1717 -0.3859 -0.2362 -0.0907 -0.0517 -0.9815 -0.1966 -0.6452 -0.1457 -1.4828 -0.3432 -0.2583
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional status ; 6-mwt ; nyha class ; patients ; hfpef ; hfref ; prescribed ; therapy ; patients ; hfpef ; death ; hf ; hospitalization
H-244	-1.0654221773147583	▁mw t ▁; ▁NY ha ▁class ▁; ▁ HF p EF ▁; ▁h Fr EF ▁; ▁ therapy ▁; ▁ HF p EF ▁; ▁death ▁; ▁ HF ▁hospital ization
D-244	-1.0654221773147583	mwt ; NYha class ; HFpEF ; hFrEF ; therapy ; HFpEF ; death ; HF hospitalization
P-244	-2.3785 -0.0257 -0.3185 -1.7893 -1.7553 -1.3593 -0.3293 -0.6277 -2.3608 -0.1558 -0.9072 -0.3704 -1.2695 -2.0014 -2.0348 -0.3817 -0.6985 -0.6084 -0.3751 -1.5148 -2.5378 -0.1628 -1.1065 -0.3322 -2.2087 -0.2427 -1.3514 -1.7804 -1.9356 -0.5357 -0.3646 -0.2729
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; follow-up ; mortality ; ischemic cardiomyopathy
H-69	-0.4081645607948303	▁renal ▁dys function ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁i CD ▁shock s ▁; ▁follow - up ▁; ▁ ische mic ▁cardio my o pathy ▁; ▁male ▁sex
D-69	-0.4081645607948303	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; follow-up ; ischemic cardiomyopathy ; male sex
P-69	-0.3153 -0.0524 -0.1996 -0.2026 -0.1575 -0.4493 -0.5886 -1.8904 -0.0254 -1.0139 -0.6025 -0.2184 -0.0799 -0.1877 -0.1692 -0.2776 -0.3380 -0.2204 -0.1437 -0.2193 -0.5864 -0.2345 -0.5199 -0.3716 -2.0750 -0.7834 -0.1827 -0.3166 -0.2885 -0.4062 -0.0420 -0.3247 -0.8677 -0.6580 -0.3953 -0.1735 -0.2268 -0.1304 -0.2705 -0.0686 -0.2707 -1.5347 -0.0913 -0.6150 -0.0399 -0.6706 -0.1395 -0.0530 -0.4072 -0.1800 -0.7202 -0.3860 -0.2505
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold proteins ; cardiac remodelling ; field ; therapeutic
H-996	-0.495816171169281	▁Raf - MEK 1/2 - ER k 1/2 ▁sc af fold ▁protein s ▁; ▁cardiac ▁remodel ling
D-996	-0.495816171169281	Raf-MEK1/2-ERk1/2 scaffold proteins ; cardiac remodelling
P-996	-0.0513 -0.3593 -0.0276 -0.1436 -0.1285 -0.9984 -0.2570 -0.4521 -1.5756 -1.7202 -0.4566 -0.8952 -0.6761 -0.2847 -0.2880 -0.0319 -0.3735 -0.4435 -0.2575
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients ; chf ; testosterone ; exercise ; testosterone ; placebo
H-1318	-0.529155433177948	▁CHF ▁; ▁SD ▁testosteron e ▁; ▁n mol ▁; ▁exercise ▁; ▁testosteron e ▁; ▁place bo ▁groups
D-1318	-0.529155433177948	CHF ; SD testosterone ; nmol ; exercise ; testosterone ; placebo groups
P-1318	-0.3928 -0.4306 -0.7987 -0.4994 -0.1004 -0.9823 -0.2854 -0.0995 -0.7608 -1.4406 -0.6384 -0.4974 -0.1648 -0.4109 -0.7753 -0.0419 -1.0550 -0.4144 -0.2654
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional ms ; lv dilatation ; heart failure ; hf ; functional ms ; hf ; prolapse ; degenerative mitral valve
H-341	-0.8947863578796387	▁functional ▁MS ▁; ▁LV ▁; ▁di la tation ▁; ▁treatment ▁; ▁heart ▁failure ▁; HF ▁; ▁LV ▁; ▁functional ▁MS ▁; ▁ HF ▁; ▁MR ▁; ▁de genera tive ▁mit ral ▁val ve
D-341	-0.8947863578796387	functional MS ; LV ; dilatation ; treatment ; heart failure ;HF ; LV ; functional MS ; HF ; MR ; degenerative mitral valve
P-341	-0.6988 -2.5593 -0.2920 -1.1610 -0.9779 -1.5682 -0.3139 -0.2001 -0.4184 -1.8122 -1.4945 -1.1728 -0.2782 -0.2973 -2.7503 -0.2850 -3.0090 -0.2983 -0.3733 -1.6075 -0.3722 -1.7218 -2.5598 -0.2837 -0.4372 -0.2607 -0.5035 -0.0162 -1.7296 -0.2020 -0.1008 -0.1876 -0.6077 -0.5037 -0.2627
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new york heart association class ; kccq ; symptom ; spearman correlations ; 2-way anova ; patients ; hf with reduced ef ; hfpef
H-783	-0.8232572078704834	▁New ▁York ▁Heart ▁association ▁; ▁ nc w t ▁; ▁ nc w t ▁; ▁symptom ▁domain s ▁; ▁Spe ar man ▁corre lation s ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-783	-0.8232572078704834	New York Heart association ; ncwt ; ncwt ; symptom domains ; Spearman correlations ; HF ; EF ; HFpEF
P-783	-1.4248 -2.0543 -1.8907 -0.2418 -0.3852 -2.8028 -0.6855 -0.1140 -1.3614 -0.2826 -2.2714 -1.6052 -0.0903 -0.9888 -0.2191 -2.3676 -0.3167 -0.5453 -0.3579 -0.1413 -0.0200 -0.0912 -0.7009 -0.2146 -0.2424 -0.3824 -0.8948 -2.3687 -0.3429 -0.7330 -0.3764 -0.7839 -1.7037 -0.0542 -0.6819 -0.4494 -0.2734
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; patients ; heart failure ; medications ; medical
H-1130	-1.0271482467651367	▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure
D-1130	-1.0271482467651367	angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure
P-1130	-4.2428 -3.7515 -0.3678 -2.5039 -0.5910 -0.3851 -0.0685 -0.1150 -0.1204 -0.2517 -0.3009 -1.5130 -3.5007 -0.9572 -4.3943 -0.6906 -0.1467 -0.2499 -0.3751 -0.7384 -0.3689 -0.1454 -0.1614 -0.5157 -0.4571 -0.3915 -1.9974 -0.4321 -0.7451 -0.3353
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang ii infusion ; ang ii infusion ; uninephrectomy ; ang ii infusion ; salt loading ; ang ii infusion ; uninephrectomy ; salt loading
H-276	-0.9363322854042053	▁c 57 b ▁; ▁ANG ▁II ▁in fusion ▁; ▁as ▁; ▁ANG ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion ▁; ▁salt ▁load ing ▁; ▁as ▁; ▁ANG ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁salt ▁load ing
D-276	-0.9363322854042053	c57b ; ANG II infusion ; as ; ANG II infusion ; uninephrectomy ; ANG II infusion ; salt loading ; as ; ANG II infusion ; uninephrectomy ; salt loading
P-276	-1.4182 -2.7262 -2.6192 -0.3709 -0.6758 -1.8824 -0.1123 -0.2040 -0.3477 -4.9178 -0.3024 -0.6251 -2.5368 -0.0939 -0.3828 -0.3433 -0.0563 -2.1556 -1.3982 -0.1823 -0.2809 -1.2746 -0.4370 -2.0180 -3.1549 -0.1142 -0.5421 -0.2801 -0.0438 -0.2843 -0.4495 -0.3525 -0.9711 -0.3615 -0.8040 -2.1834 -0.1240 -0.3725 -0.2920 -0.1182 -1.7391 -1.2074 -0.1346 -0.6833 -1.4663 -0.3798 -0.1950 -0.4819 -0.3456 -3.0392 -0.2707
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral blood flow velocity ; tissue doppler ; diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcwp ; patients ; decompensated systolic heart failure ; hf
H-480	-0.6998159885406494	▁early ▁transmit ral ▁blood ▁flow ▁veloci ty ▁; ▁tissu e ▁; ▁do pp ler ▁; ▁early ▁dia sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁pulmonar y ▁cap illa ry ▁we dge ▁pressure ▁; ▁pc p ▁; ▁de com pensa ted ▁sy sto lic ▁heart ▁failure ▁; HF
D-480	-0.6998159885406494	early transmitral blood flow velocity ; tissue ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcp ; decompensated systolic heart failure ;HF
P-480	-0.5628 -0.3803 -1.3453 -1.8953 -0.3530 -2.1537 -0.3645 -0.2865 -2.0502 -0.1121 -0.9184 -0.1216 -0.0600 -0.8548 -0.3157 -0.7672 -0.0620 -0.2521 -0.1968 -1.0492 -0.4412 -2.0967 -0.6429 -1.0834 -0.4593 -0.3676 -0.0631 -0.8664 -0.1476 -0.2483 -2.0271 -0.0695 -0.1581 -0.5498 -0.3744 -0.4934 -1.8036 -0.7673 -1.7255 -0.1431 -0.4200 -1.8082 -0.0905 -0.2263 -0.4425 -1.4779 -0.5342 -0.2627 -1.1897 -0.3733 -0.2356
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic ; lv ejection fraction ; lv strain ; strain ; systole ; diastolic ; lv strain rate ; diastole ; transmitral flow ; patients ; sinus rhythm ; follow-up
H-951	-0.6654876470565796	▁sy sto lic ▁indice s ▁; LV ▁; ▁e je ction ▁ fraction ▁; ▁LV ▁strain ▁; stra in ▁rate ▁; ▁sy stol e ▁; ▁dia sto lic ▁indice s ▁; ▁strain ▁rate ▁; ▁dia stol e ▁; ▁early ▁transmit ral ▁flow ▁; ▁sinus ▁ rhythm ▁; ▁follow - up
D-951	-0.6654876470565796	systolic indices ;LV ; ejection fraction ; LV strain ;strain rate ; systole ; diastolic indices ; strain rate ; diastole ; early transmitral flow ; sinus rhythm ; follow-up
P-951	-3.6316 -0.8287 -0.1146 -0.3630 -0.1941 -0.3244 -1.5098 -1.8746 -0.2394 -0.5225 -0.0833 -0.2530 -0.0258 -0.3909 -1.1529 -0.6764 -0.5605 -2.3065 -0.3616 -0.8633 -0.3636 -0.5782 -1.4289 -0.4944 -0.3109 -0.2210 -0.8705 -0.3104 -0.6615 -0.3221 -0.3327 -4.2049 -0.7220 -0.2739 -0.1462 -0.6914 -0.3558 -0.6144 -1.2515 -0.3174 -0.4826 -0.5877 -0.3789 -0.2807 -0.3426 -0.6521 -0.2700 -0.0057 -0.2611 -0.0229 -0.3293 -0.2433
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak vo2 ; exercise
H-1984	-1.308750033378601	▁VO 2 ▁; ▁exercise ▁; ▁body ▁mass ▁; ▁die t ▁; ▁body ▁mass
D-1984	-1.308750033378601	VO2 ; exercise ; body mass ; diet ; body mass
P-1984	-5.3530 -0.2000 -0.3955 -2.0608 -0.4238 -3.0210 -0.3066 -0.4949 -2.2216 -0.3418 -0.4604 -3.1605 -0.3739 -0.4809 -0.3364
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard ratios ; confidence interval ; hf ; hf
H-1107	-1.4783673286437988	▁ HF ▁; ▁confidence ▁interval ▁; ▁i cc ▁; ▁early - ons et ▁ HF ▁; ▁ HF
D-1107	-1.4783673286437988	HF ; confidence interval ; icc ; early-onset HF ; HF
P-1107	-2.6303 -1.3589 -0.4182 -4.3448 -0.2082 -0.3085 -5.6028 -1.5432 -0.4353 -1.9843 -0.2384 -1.3396 -0.3094 -0.7114 -1.2653 -0.6112 -3.0791 -2.5720 -0.2798 -0.3264
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami ; patient ; hospital ; hospital compare ; p-value
H-1698	-0.7827101349830627	AMI ▁; ▁hospital ▁; ▁hospital ▁Compar e ▁; ▁dy ing
D-1698	-0.7827101349830627	AMI ; hospital ; hospital Compare ; dying
P-1698	-1.9303 -0.6301 -0.7074 -0.5794 -1.4729 -0.3248 -0.0845 -0.5882 -2.2968 -0.2005 -0.2611 -0.3167
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass spectrometry ; c-terminally ; nt-probnp ; physiological ; proteolysis
H-1517	-0.8264873623847961	▁Mass ▁spec tro met ry ▁; ▁circula ting ▁; ▁NT - pro b NP ▁; ▁physio logic al ▁prote ol ysis ▁; ▁pro 2- le u 3 ▁; ▁le u 3- g ly ▁; ▁pro 6 - g ly 7
D-1517	-0.8264873623847961	Mass spectrometry ; circulating ; NT-probNP ; physiological proteolysis ; pro2-leu3 ; leu3-gly ; pro6-gly7
P-1517	-0.4871 -0.1625 -0.1408 -0.1272 -5.1213 -0.3544 -0.0033 -0.3152 -0.4928 -0.6610 -0.0718 -0.3001 -2.1488 -2.1071 -0.3301 -0.1520 -0.9887 -0.1251 -0.0396 -0.3637 -0.4744 -0.3459 -1.0288 -0.2286 -1.4071 -0.0208 -0.4779 -0.2783 -0.2226 -0.0269 -0.3018 -2.6624 -0.4186 -1.8705 -0.5540 -3.5915 -0.0793 -4.4397 -0.6278 -0.3146 -0.6127 -0.2359
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt ; nt-probnp ; report ; ctnt ; nt-probnp ; clinical ; hf
H-292	-0.6597598791122437	▁c t n t ▁; ▁NT - pro b NP ▁; ▁c t n t ▁; ▁NT - pro b NP ▁; ▁ HF
D-292	-0.6597598791122437	ctnt ; NT-probNP ; ctnt ; NT-probNP ; HF
P-292	-0.0890 -0.4113 -0.2903 -0.8749 -0.3100 -0.3309 -0.1686 -0.3158 -2.0477 -1.5466 -0.3334 -0.1958 -0.3688 -0.1624 -0.5629 -0.2995 -0.3517 -0.1389 -0.3417 -2.0464 -1.7951 -0.3419 -1.0293 -1.9528 -0.5330 -0.3150
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef ; patients ; new york heart association class ii ; ejection fraction ; fes ; placebo
H-1329	-0.9381934404373169	▁ HF p EF ▁; ▁New ▁York ▁Heart ▁association ▁; ▁e je ction ▁ fraction ▁; ▁f es
D-1329	-0.9381934404373169	HFpEF ; New York Heart association ; ejection fraction ; fes
P-1329	-0.5406 -1.9813 -0.1322 -0.8274 -0.4059 -2.1577 -2.0668 -1.7917 -0.4082 -0.3156 -1.9091 -0.3691 -0.0711 -0.3567 -0.0282 -0.4071 -1.8510 -2.1279 -0.7435 -0.2725
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left ventricular ; systolic pressure ; ejection fraction ; fractional shortening ; cardiac output ; lv end-diastolic pressure ; mi ; metoprolol
H-1548	-0.5610285401344299	▁de press ed ▁left ▁vent ri cular ▁; ▁v n ▁; ▁sy sto lic ▁pressure ▁; ▁pressure ▁; ▁e je ction ▁ fraction ▁; ▁cardiac ▁output ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; ▁met o pro lol
D-1548	-0.5610285401344299	depressed left ventricular ; vn ; systolic pressure ; pressure ; ejection fraction ; cardiac output ; LV ; end-diastolic pressure ; metoprolol
P-1548	-0.2717 -0.0411 -0.4913 -0.4252 -0.1883 -1.3207 -0.2566 -0.3076 -2.1075 -0.5817 -0.3398 -0.1558 -0.2639 -0.2530 -1.6223 -0.2563 -1.3128 -0.2088 -0.1742 -0.1851 -0.1664 -0.3190 -0.0226 -0.2894 -0.2439 -0.0321 -0.3261 -1.9125 -0.5934 -2.0931 -0.1905 -0.0260 -0.4215 -0.2436 -1.0453 -0.2924 -2.8119 -0.1307 -0.1879 -0.8960 -0.3350 -0.2201
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction ; clinical ; carotid ; baroreflex activation therapy ; bat ; heart failure ; hf
H-1867	-0.8801785707473755	▁bar ore flex ▁Activ ation ▁Therapy ▁; ▁Heart ▁Fail ure ▁; ▁Red u ced ▁e je ction ▁Fra ction ▁; ▁caro tid ▁; ▁baro re flex ▁activa tion ▁ therapy ▁; BAT ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1867	-0.8801785707473755	baroreflex Activation Therapy ; Heart Failure ; Reduced ejection Fraction ; carotid ; baroreflex activation therapy ;BAT ; advanced heart failure ;HF
P-1867	-4.1479 -3.2527 -0.4184 -2.6725 -0.7561 -0.2717 -0.2642 -1.0642 -0.6544 -1.4740 -0.5703 -2.1009 -0.0214 -2.2403 -0.2982 -0.0440 -0.0413 -0.4892 -0.0714 -0.2750 -0.1476 -0.7575 -0.8642 -0.7351 -1.7547 -0.6715 -0.0874 -2.0240 -0.5042 -0.1076 -0.2025 -0.6459 -0.2285 -2.1036 -1.0991 -0.4790 -0.1789 -0.9723 -0.3084 -0.2071
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome ; hazard ratio
H-1748	-0.9781202077865601	haz ard ▁ratio ▁; HR ▁; HR
D-1748	-0.9781202077865601	hazard ratio ;HR ;HR
P-1748	-3.0811 -0.1005 -0.0617 -0.3104 -1.5628 -0.5169 -2.2682 -0.5323 -0.3693
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf ; blood glucose ; obesity ; systemic hypertension ; rheumatic fever ; disease
H-1793	-0.7762466669082642	▁ HF ▁; ▁raised ▁blood ▁gluco se ▁levels ▁; ▁obes iteit ▁; ▁to ba cco ▁; ▁system ic ▁hyper tension ▁; SH ▁; ▁rhe u matic ▁fe ver ▁; ▁cha gas ▁; ▁disease ▁; ▁la
D-1793	-0.7762466669082642	HF ; raised blood glucose levels ; obesiteit ; tobacco ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; la
P-1793	-2.1937 -0.7385 -0.2169 -2.7362 -0.7648 -0.0413 -0.1683 -0.5521 -0.2922 -0.3753 -3.7523 -0.2775 -0.1206 -1.5741 -0.2416 -0.3345 -0.3227 -0.2474 -0.1177 -0.1220 -0.2668 -2.2580 -0.2291 -0.1786 -0.1602 -0.6487 -0.0585 -0.2655 -0.3064 -0.6487 -0.1708 -2.3867 -0.2570 -0.2903 -2.5862 -2.5316 -0.2881
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard ratios ; crf ; obese ; body mass index
H-1772	-0.5631936192512512	▁c RF ▁; ▁over weight ▁; ▁obes e ▁body ▁mass ▁index
D-1772	-0.5631936192512512	cRF ; overweight ; obese body mass index
P-1772	-0.4412 -2.9418 -0.3067 -0.0517 -0.3893 -0.3485 -0.2987 -0.2306 -1.2744 -0.1897 -0.0482 -0.4648 -0.3359
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq ; patients ; hfpef ; log rank ; ef
H-789	-0.9844480156898499	▁ nc w t ▁; ▁ HF p EF ▁; log ▁rank ▁; ▁EF
D-789	-0.9844480156898499	ncwt ; HFpEF ;log rank ; EF
P-789	-1.2631 -1.5054 -0.1785 -3.2002 -0.4272 -1.1353 -1.8174 -0.1085 -1.3467 -0.4116 -1.1741 -0.9237 -0.3785 -1.0643 -0.4648 -0.3519
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline ; egfr ; egfr ; egfr ; hypertension ; diuretics ; esrd
H-395	-1.3569468259811401	▁e g FR ▁; ▁e g FR ▁; ▁e g FR ▁; ▁un control led ▁hyper tension ▁; ▁di ure tics ▁; ▁ES RD
D-395	-1.3569468259811401	egFR ; egFR ; egFR ; uncontrolled hypertension ; diuretics ; ESRD
P-395	-1.2544 -3.7782 -1.9709 -0.7634 -1.0562 -3.1883 -2.5124 -1.6571 -0.8860 -2.8148 -2.3457 -1.6217 -0.2357 -0.0453 -2.6355 -0.2674 -0.2859 -0.3582 -0.4976 -0.7908 -0.5068 -0.4282 -3.3108 -1.2224 -0.4863 -0.3605
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial ; phosphodiesterase-2 ; pde2 ; heart failure ; hf ; beta-adrenergic receptor ; β-ar ; healthy ; diseased ; cardiomyocytes
H-1208	-0.7434409260749817	▁my o card ial ▁ phos pho dies tera se -2 ▁; ▁p de 2 ▁; ▁heart ▁failure ▁; HF ▁; ▁p de 2- media ted ▁effects ▁; ▁beta - ad r energi c ▁receptor ▁; β - AR ▁; ▁cardio my o cy tes
D-1208	-0.7434409260749817	myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2-mediated effects ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
P-1208	-1.8779 -0.4381 -1.3837 -1.8022 -0.1808 -0.0777 -0.6008 -4.3415 -0.1060 -0.5034 -0.3456 -0.3497 -0.3519 -1.2399 -1.7947 -0.3591 -1.3660 -0.3173 -0.2687 -2.6185 -0.3300 -0.8485 -1.1870 -0.1433 -1.0238 -0.9672 -0.9434 -0.3720 -0.3812 -0.1019 -0.2160 -0.2586 -2.0907 -0.6502 -0.0573 -0.3563 -0.7814 -0.0807 -1.1194 -0.4063 -0.1176 -0.8426 -0.2073 -0.1609 -0.3054 -0.4281 -0.2411
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart failure ; patients ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator ; carvedilol ; atp ; shock therapy ; metoprolol
H-866	-0.4857913553714752	▁heart ▁failure ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁device ▁; ▁car vedi lol ▁; ▁ATP ▁; ▁shock ▁ therapy ▁; ▁met o pro lol
D-866	-0.4857913553714752	heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
P-866	-2.8300 -0.4839 -0.3214 -0.1874 -0.1554 -0.0908 -0.0137 -1.5401 -0.9291 -0.0996 -0.3167 -0.0913 -0.2789 -1.7677 -0.9833 -0.3900 -0.3343 -0.6213 -0.2337 -0.1660 -0.1193 -0.5536 -0.2051 -0.1530 -0.2930 -2.4843 -0.9203 -0.3015 -0.2997 -0.4257 -0.0129 -0.1816 -0.2093 -0.3781 -0.7640 -0.2795 -0.1961 -0.5998 -0.1057 -0.3324 -0.1453 -0.1393 -0.2540 -0.4669 -0.4398 -0.2518
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich cocoa ; skm ; mitochondrial structure ; taub ; ramirez-sanchez ; ciaraldi ; perkins ; murphy ; naviaux ; hogan ; ceballos ; maisel ; henry
H-1245	-0.421550452709198	ERC ▁; ▁e pica tech in - rich ▁coco a ▁; ▁Sk m ▁; ▁mito cho ndri al ▁structure ▁; ▁ta ub ▁; ▁Ram i rez - s anche z ▁; ▁ci ar aldi ▁; ▁per kin s ▁; ▁Murphy ▁; ▁na vi aux ▁; ▁Hoga n ▁; ▁ce ball os ▁; ▁Mais el ▁; ▁Henry
D-1245	-0.421550452709198	ERC ; epicatechin-rich cocoa ; Skm ; mitochondrial structure ; taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
P-1245	-2.9014 -0.3058 -1.1700 -0.1824 -0.2181 -0.1750 -0.2381 -0.0195 -0.2548 -0.0659 -0.4195 -0.2802 -0.3684 -0.9853 -0.0418 -0.8274 -0.4300 -0.1224 -1.0584 -0.3076 -0.4792 -1.0376 -0.4303 -1.6006 -0.0451 -0.0420 -0.1496 -1.4751 -0.0220 -0.0965 -0.3469 -0.0585 -0.0479 -0.0326 -0.3657 -0.9191 -0.8733 -0.1437 -0.3055 -0.8549 -0.3179 -0.0261 -0.0486 -0.0857 -0.3142 -0.0162 -0.0407 -0.3977 -0.0595 -0.9400 -0.2602 -0.3330 -0.8228 -0.0057 -0.2708 -0.0660 -0.4920 -0.2544
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up ; death ; readmission ; patients ; physician ; physicians
H-1420	-0.9698835015296936	▁follow - up ▁visit s ▁; ▁death ▁; ▁urgent ▁read mission
D-1420	-0.9698835015296936	follow-up visits ; death ; urgent readmission
P-1420	-0.0822 -0.2766 -0.0638 -2.4151 -0.3461 -0.4017 -3.9463 -0.3229 -0.3592 -1.4003 -1.1328 -1.5895 -0.2720
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena overexpression ; tac ; surgery ; mena ; cardiac hypertrophy ; cardiac
H-1816	-0.8753184080123901	▁men a ▁over expression ▁; ▁ TTA ▁; ▁t g t et Men a ▁; ▁ TAC ▁surgery ▁; ▁cardiac ▁hyper trop hy ▁; ▁ TTA ▁; ▁t g t et Men a ▁; ▁cardiac ▁functional
D-1816	-0.8753184080123901	mena overexpression ; TTA ; tgtetMena ; TAC surgery ; cardiac hypertrophy ; TTA ; tgtetMena ; cardiac functional
P-1816	-6.4433 -0.6864 -0.6275 -0.0696 -0.2462 -0.7437 -0.9065 -0.5366 -2.2056 -0.8243 -0.1687 -0.2876 -0.5155 -0.1367 -0.3544 -1.0417 -1.0917 -0.6319 -0.2443 -2.2354 -0.1524 -0.0597 -2.3644 -0.3130 -0.6369 -1.2409 -0.4436 -1.7446 -0.6561 -0.1088 -0.3331 -0.9477 -0.1138 -0.2438 -1.1775 -0.6261 -1.8364 -0.2661
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography ; lv end-diastolic volume ; mitral valve opening ; mva
H-357	-0.6225855350494385	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁; ▁m 2 ▁; ▁MR ▁; ▁mit ral ▁val ve ▁; ▁m va ▁; ▁mean ▁pressure ▁gradi ent
D-357	-0.6225855350494385	echocardiography ; LV ; end-diastolic volume ; m2 ; MR ; mitral valve ; mva ; mean pressure gradient
P-357	-0.1316 -0.4009 -0.2166 -0.4212 -0.5046 -0.4333 -1.0354 -1.0136 -1.8327 -0.1464 -0.0079 -0.1125 -0.0680 -0.2807 -0.4361 -0.0306 -2.8351 -0.4242 -0.7205 -0.4431 -0.4212 -0.1167 -0.1926 -0.4042 -0.3961 -0.2012 -4.1043 -0.3279 -1.0685 -0.4108 -0.0261 -0.7452 -0.9908 -0.2674
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd ; diuretic ; hf ; outcomes ; clinical ; hospitalizations ; pdrelated ; complications
H-901	-0.5810462832450867	▁PD ▁; ▁di ure tic ▁re frac tory ▁; ▁severe - end - s tage ▁ HF ▁; ▁PD related ▁complica tions
D-901	-0.5810462832450867	PD ; diuretic refractory ; severe-end-stage HF ; PDrelated complications
P-901	-1.2727 -0.2289 -0.4020 -0.3352 -0.8672 -0.0668 -0.1274 -0.4534 -0.3611 -1.5219 -0.3598 -0.6411 -0.2366 -0.4712 -0.0481 -0.4296 -0.9711 -0.2898 -1.6709 -0.7703 -0.0184 -1.8085 -0.3507 -0.2426
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial ; glycolysis
H-1785	-0.5766549706459045	▁ATP ▁; ▁mito cho ndri al ▁oxid ation ▁; ▁gluco se ▁; ▁lac tate ▁; ▁fa tty ▁acid s ▁; ▁my o card ial ▁gly col ysis
D-1785	-0.5766549706459045	ATP ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
P-1785	-0.9604 -0.4058 -0.3271 -1.2083 -0.3670 -0.1673 -0.1278 -1.5890 -0.3116 -0.1367 -0.2413 -0.3595 -0.0233 -0.4342 -0.3878 -0.1989 -0.2676 -0.0474 -0.4948 -0.3798 -1.2876 -0.3481 -1.8647 -2.3365 -0.0277 -0.2118 -0.3418 -1.5321 -0.3369
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients ; eplerenone ; potassium ; potassium ; hospitalization ; hyperkalemia ; medication ; adverse events
H-1226	-0.6848832964897156	▁e pler en one ▁; ▁po tas s ium ▁; ▁po tas s ium ▁; ▁hyper kal emia ▁; ▁medication
D-1226	-0.6848832964897156	eplerenone ; potassium ; potassium ; hyperkalemia ; medication
P-1226	-0.0916 -0.2731 -0.1417 -1.6037 -0.3490 -1.3115 -1.3759 -0.6288 -0.6374 -0.3766 -1.8770 -1.7365 -0.4559 -0.7413 -0.3406 -0.2915 -0.4408 -0.8208 -0.3394 -0.5221 -0.4490 -0.2632
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient ; new york heart association class iii ; heart failure ; hf ; left ventricular ejection fraction ; periodic breathing ; pb ; report
H-1347	-0.7413400411605835	▁New ▁York ▁Heart ▁association ▁; ▁heart ▁failure ▁; HF ▁; ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁permanent ▁periodic ▁breath ing ▁; ▁p b
D-1347	-0.7413400411605835	New York Heart association ; heart failure ;HF ; ventricular ejection fraction ; permanent periodic breathing ; pb
P-1347	-1.7411 -2.0685 -1.9304 -0.3905 -0.3597 -2.5177 -0.5984 -0.3110 -2.0212 -0.3028 -0.8632 -2.1239 -0.6046 -0.2328 -0.3008 -0.1598 -0.4215 -0.0330 -0.3560 -0.4034 -0.7025 -0.6984 -0.4326 -0.2987 -0.0861 -0.1532 -0.3659 -0.2798
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation ; bottleneck stent ; lad ; lcx ; myocardial ischemia ; stent ; ischemic heart failure ; stent ; therapeutic
H-514	-0.5596635937690735	▁bottle ne ck ▁sten t ▁; ▁proxima l ▁ LAD ▁; ▁l x ▁; ▁por cine ▁; ▁rever sible ▁my o card ial ▁ ische mia ▁; ▁open ▁sten t ▁; ▁ ische mic ▁heart ▁failure ▁; ▁sten t
D-514	-0.5596635937690735	bottleneck stent ; proximal LAD ; lx ; porcine ; reversible myocardial ischemia ; open stent ; ischemic heart failure ; stent
P-514	-1.1824 -0.2405 -0.0341 -0.0543 -0.1519 -0.4003 -0.1151 -0.1660 -0.3993 -0.5563 -0.4240 -0.2317 -3.2981 -1.0652 -2.2998 -0.5421 -1.0894 -0.1707 -0.1244 -1.3487 -0.1357 -0.5128 -0.9747 -0.4168 -0.2083 -0.4628 -0.3552 -1.6459 -0.0545 -0.1651 -0.3334 -0.3046 -0.0780 -0.3294 -0.5486 -0.1419 -0.2297 -1.1961 -0.1891 -0.4703 -0.2994
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium ; spironolactone ; aas
H-1705	-0.8534436225891113	▁Po tas s ium ▁; ▁spi rono lac tone ▁; ▁AA s ▁; ▁AA s
D-1705	-0.8534436225891113	Potassium ; spironolactone ; AAs ; AAs
P-1705	-3.3873 -0.4532 -0.2239 -0.4307 -0.5301 -0.1077 -0.1074 -0.2262 -0.2411 -0.4791 -2.2687 -0.8698 -0.5299 -1.8805 -0.7366 -1.7238 -0.3126
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese ; body mass index ; chronic ; stable ; hfpef
H-1978	-0.9810457825660706	▁obes e ▁; SD ▁; ▁body ▁mass ▁index ▁; ▁h FP EF
D-1978	-0.9810457825660706	obese ;SD ; body mass index ; hFPEF
P-1978	-0.7039 -0.2571 -0.5936 -1.8768 -0.3614 -1.8059 -0.1701 -0.0199 -0.3792 -1.8835 -2.7249 -2.2505 -0.4124 -0.2954
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic ; vegf pathway ; intravenously ; injected ; adenoviral ; vegf receptor ; adenovirus
H-456	-0.6157428622245789	▁pro angi ogen ic ▁effects ▁; ▁b ▁; ▁VE GF ▁path way ▁; ▁a den ovi ral ▁ve ctor ▁; ▁de co y ▁; ▁VE GF ▁receptor ▁; ▁ad - f lk ▁; ▁ade no virus ▁; ▁ad - c
D-456	-0.6157428622245789	proangiogenic effects ; b ; VEGF pathway ; adenoviral vector ; decoy ; VEGF receptor ; ad-flk ; adenovirus ; ad-c
P-456	-0.5188 -0.2981 -0.4763 -0.2658 -0.5679 -0.2538 -0.8092 -0.4093 -4.0855 -0.7487 -0.1830 -0.2373 -0.3125 -0.4400 -0.0997 -0.2409 -1.1183 -2.3688 -0.0275 -0.3129 -0.5183 -0.0083 -0.5789 -1.2710 -1.9518 -0.9878 -0.0256 -0.2892 -1.1929 -0.2162 -0.5876 -0.1700 -0.3394 -0.0454 -0.0850 -0.1265 -0.2290 -1.5238 -0.1172 -0.4073 -1.1627 -0.2531
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical ; post-lvad ai ; aortic valve ; leaflet ; bioprosthetic aortic valve replacement ; functional capacity ; lvad ; patients ; symptomatic
H-552	-0.9265967011451721	▁surgery ▁; ▁post - ▁l VAD ▁; ▁AI ▁; ▁a or tic ▁val ve ▁; ▁le a flet ▁repair ▁; ▁bio pro sthetic ▁; ▁a or tic ▁val ve ▁replace ment ▁; ▁functional ▁capacity ▁; ▁ cf ▁l VAD ▁; ▁AI
D-552	-0.9265967011451721	surgery ; post- lVAD ; AI ; aortic valve ; leaflet repair ; bioprosthetic ; aortic valve replacement ; functional capacity ; cf lVAD ; AI
P-552	-4.3109 -0.3878 -0.8118 -0.0402 -2.4873 -0.9366 -1.1357 -2.3280 -0.4697 -0.2136 -0.1636 -1.5464 -1.6656 -0.6724 -0.3671 -0.8794 -0.0341 -0.3077 -1.4091 -0.3065 -0.0205 -0.2809 -0.2534 -0.3809 -0.3252 -0.1901 -2.0118 -1.5813 -0.6894 -0.5909 -1.0335 -0.3597 -0.3446 -0.2870 -0.2757 -3.5066 -0.4701 -1.2422 -0.3414 -0.2775 -4.1565 -0.4740 -0.2769
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced pulmonary artery systolic pressure ; pasp ; stress doppler echocardiography ; right ventricular contractile reserve ; patients ; pulmonary hypertension ; right heart failure
H-822	-0.6854639053344727	▁exercise - indu ced ▁pulmonar y ▁arter y ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁do pp ler ▁e cho card i ography ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension ▁; ▁right ▁heart ▁failure
D-822	-0.6854639053344727	exercise-induced pulmonary artery systolic pressure ;PASp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
P-822	-5.0261 -0.1357 -0.4859 -0.7594 -0.0963 -1.3252 -0.1088 -1.5644 -0.7037 -0.1827 -0.2770 -0.6790 -0.3136 -1.1400 -0.5468 -0.3063 -0.6798 -0.1097 -1.0037 -0.1822 -0.3273 -0.5123 -0.2982 -0.3386 -0.3717 -1.0305 -0.3077 -2.6202 -0.4269 -0.0821 -0.3592 -0.4299 -0.3066 -0.6589 -1.2448 -0.3574 -0.2767 -0.2587 -1.6478 -0.8987 -0.4232 -0.4420 -0.2294
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline ; embase ; healthstar ; cinahl ; cochrane library ; campbell collaboration ; joanna briggs institute evidence based practice ; centre for reviews and dissemination ; evidence based practice centres
H-1844	-0.9238782525062561	▁med line ▁; EMBA se ▁; ▁he al star ▁; ▁c INA HL ▁; ▁co ch rane ▁Library ▁; ▁Campbell ▁Col labora tion ▁; ▁Joan na ▁Brig gs ▁institut e ▁et viden ce ▁based ▁practice ▁; ▁Centre ▁for ▁Review s ▁and ▁Disse mination ▁; ▁e viden ce ▁Base d ▁practice ▁Centre s
D-1844	-0.9238782525062561	medline ;EMBAse ; healstar ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institute etvidence based practice ; Centre for Reviews and Dissemination ; evidence Based practice Centres
P-1844	-1.3431 -1.2253 -0.2743 -0.0744 -2.2843 -0.3046 -0.2672 -0.2979 -3.3309 -0.3517 -4.5938 -3.2551 -1.4348 -0.3627 -0.0216 -0.1607 -0.1281 -0.1431 -0.3908 -0.0753 -0.4689 -0.6476 -0.2099 -0.3920 -0.2694 -2.8560 -0.3682 -0.6375 -0.4036 -0.0373 -4.0981 -0.8012 -0.9819 -1.7060 -0.8159 -0.4872 -0.5960 -1.1483 -1.0153 -0.1360 -0.9333 -0.0486 -0.0890 -1.1195 -1.9050 -0.0863 -1.5953 -2.2089 -0.0694 -1.2376 -1.5164 -0.2336 -0.2412 -0.2092
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods study ; health care ; systolic heart failure ; prescribed ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
H-1123	-0.7317231297492981	▁sy sto lic ▁heart ▁failure ▁; ▁β - block er ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block er
D-1123	-0.7317231297492981	systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
P-1123	-2.3525 -0.4679 -0.1907 -1.1591 -0.5978 -0.3164 -0.3262 -0.1472 -0.9817 -0.3819 -0.3835 -1.5746 -2.0125 -0.3863 -2.2690 -0.1713 -0.3982 -0.0707 -0.1200 -0.1071 -0.1619 -0.3044 -0.8162 -2.0366 -0.5563 -3.2293 -0.5279 -0.1577 -0.0898 -0.5914 -0.5655 -0.4362 -0.2591
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ; angiotensin receptor blockers ; angiotensin converting enzyme inhibitors ; beta receptor blockers ; mineralocorticoid receptor antagonists
H-647	-0.72516268491745	▁heart ▁failure ▁; ▁neuro - hormon al ▁system ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁in tolerance ▁; ▁beta ▁receptor ▁block ers ▁; ▁mineral o cor tico id ▁receptor
D-647	-0.72516268491745	heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor
P-647	-2.5389 -0.5130 -0.2687 -0.0609 -0.1214 -0.0490 -0.0923 -0.1400 -0.3048 -0.7502 -1.9344 -0.3597 -3.1497 -0.2004 -0.5893 -0.0884 -0.1955 -0.1256 -0.6896 -0.2444 -0.1346 -0.8151 -2.5089 -0.0363 -0.5332 -0.4204 -0.2587 -1.3223 -2.4074 -0.4658 -3.1971 -0.4068 -0.9521 -0.1309 -0.2652 -0.1082 -0.8678 -1.9889 -0.1224 -0.3067 -0.2652 -0.0568 -1.4051 -0.5471 -0.3198 -0.0824 -0.2120 -1.4120 -1.8790 -0.3210 -0.0116 -1.9360 -0.3204
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest ; rs ; rs synchrony ; ste ; noninvasive ; rvpo ; rs synchrony ; strain ; bivp
H-330	-0.8502078056335449	▁open ▁che st ▁model ▁; ▁twist ▁; ▁RS ▁; ▁RS ▁synchron y ▁; ▁CS ▁; ▁ ste ▁; ▁co ▁; rv po ▁; ▁RS ▁synchron y ▁; ▁CS ▁; ▁Bi VP ▁; ▁co
D-330	-0.8502078056335449	open chest model ; twist ; RS ; RS synchrony ; CS ; ste ; co ;rvpo ; RS synchrony ; CS ; BiVP ; co
P-330	-0.0584 -0.5649 -0.0646 -1.1899 -0.3082 -0.0935 -0.3311 -0.6001 -0.3480 -0.3385 -0.0108 -1.4649 -0.2933 -2.0550 -0.3652 -0.6494 -4.3275 -0.5553 -1.3977 -0.9895 -1.8605 -2.2398 -0.3142 -1.0889 -0.0097 -1.4586 -0.3340 -1.7034 -0.3366 -0.8438 -1.6545 -0.3645 -0.9882 -0.2939 -0.2609
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse ; pasp ; tapse ; pasp ; cox regression ; kaplan-meier analyses ; tapse ; pasp
H-498	-1.2172044515609741	▁ pac se ▁; ▁pas p ▁; ▁ fft - to - PAS p ▁ratio ▁; TA PS e ▁; ▁pas p ▁; ▁co x ▁re gression ▁; ▁ka plan - me ier ▁analyse s ▁; ▁ pv se ▁; ▁pas p
D-498	-1.2172044515609741	pacse ; pasp ; fft-to-PASp ratio ;TAPSe ; pasp ; cox regression ; kaplan-meier analyses ; pvse ; pasp
P-498	-2.2454 -5.5204 -1.3474 -0.3266 -1.8261 -0.9564 -0.4132 -2.9317 -4.3857 -0.5010 -0.8145 -0.2006 -1.5563 -1.2173 -0.3816 -0.3111 -2.3258 -3.0314 -0.2668 -0.5950 -2.2552 -0.4377 -0.4013 -0.0453 -0.6862 -0.1049 -0.1262 -0.4083 -0.2784 -0.0563 -0.2219 -0.3747 -0.1602 -0.9399 -0.5170 -0.4202 -2.6382 -5.6764 -3.0779 -0.4624 -1.8099 -0.5675 -0.4074 -0.3291
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom ; cpet ; patients ; chf ; patients ; exercise ; exercise ; patients ; exercise ; rehabilitation
H-1880	-0.9311040639877319	▁c PET ▁; ▁CHF ▁; ▁exercise ▁; ▁exercise ▁; ▁exercise
D-1880	-0.9311040639877319	cPET ; CHF ; exercise ; exercise ; exercise
P-1880	-0.6791 -2.2803 -0.4236 -0.4113 -0.4324 -1.5201 -0.4340 -1.0159 -0.5852 -1.3612 -1.7325 -0.2977
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart failure ; hf ; mrna splicing ; cardiac ; scn5a ; endoplasmic reticulum
H-1080	-0.5477943420410156	▁heart ▁failure ▁; HF ▁; ▁m RNA ▁; ▁volta ge - ga ted ▁cardiac ▁; ▁na + ▁channel ▁; ▁α - sub un it ▁; ▁s cn 5 a ▁; ▁en co ding ▁; ▁en do plas mic ▁reti culum
D-1080	-0.5477943420410156	heart failure ;HF ; mRNA ; voltage-gated cardiac ; na+ channel ; α-subunit ; scn5a ; encoding ; endoplasmic reticulum
P-1080	-4.6142 -0.3753 -0.2525 -1.0546 -0.2986 -0.0658 -0.3807 -0.4847 -0.4251 -0.1082 -0.2477 -0.0844 -1.3255 -0.1646 -0.9692 -0.0710 -2.8132 -0.2492 -0.7577 -0.1017 -0.0858 -0.0935 -0.1199 -0.1720 -0.2359 -1.5096 -0.2395 -0.7719 -0.5377 -0.3595 -0.1750 -0.2509 -0.6986 -0.2835 -0.3538 -0.1547 -0.2112 -1.1627 -0.0101 -0.0085 -0.4483 -0.2808
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart failure ; diagnosis ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; disease
H-988	-0.6802219152450562	▁pa e dia tric ▁heart ▁failure ▁; ▁my o card itis ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure ▁; ▁cel lular ▁response s ▁; ▁heart ▁failure ▁; ▁an thra cycli ne ▁; ▁malign ant ▁disease
D-988	-0.6802219152450562	paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; cellular responses ; heart failure ; anthracycline ; malignant disease
P-988	-0.3238 -0.2071 -0.0754 -1.2899 -2.7809 -0.8982 -0.3033 -1.6977 -0.2525 -0.6940 -1.2717 -0.3114 -0.5540 -0.2606 -0.0549 -0.5129 -0.1479 -0.0706 -0.3715 -2.0599 -0.5880 -0.2546 -0.2794 -0.1307 -1.0833 -0.2342 -0.3360 -1.9055 -0.9362 -0.2892 -0.3730 -0.2545 -0.6846 -1.1531 -0.2430 -1.7998 -0.6225 -0.6773 -0.9524 -0.2737
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; clinical ; evidence-based ; medications ; costs ; outcomes
H-2010	-0.7243601083755493	▁Tools ▁for ▁economische ▁analysis ▁of ▁Patient ▁management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁; ▁kosten
D-2010	-0.7243601083755493	Tools for economische analysis of Patient management Interventions ; Heart Failure ; kosten
P-2010	-1.1188 -1.2064 -1.2171 -0.5866 -1.3111 -0.3879 -0.3270 -0.3399 -0.5857 -1.0425 -0.7365 -0.4018 -1.1993 -0.2688 -0.9875 -0.3745 -0.2228
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic peptides ; nps ; b-type np ; n-terminal pro-b-type np ; diagnosis ; acute heart failure ; patients ; emergency department ; acute dyspnea
H-1020	-0.5003147125244141	▁na tri ure tic ▁pe pti des ▁; NP s ▁; ▁b - type ▁ NP ▁; ▁n - termin al ▁pro - b - type ▁ NP ▁; ▁a cute ▁heart ▁failure ▁; ▁Emer gen cy ▁Department ▁; ▁d p ▁; ▁a cute ▁dys pne a
D-1020	-0.5003147125244141	natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-b-type NP ; acute heart failure ; Emergency Department ; dp ; acute dyspnea
P-1020	-0.0259 -0.9879 -0.9805 -1.4574 -0.6600 -0.3934 -0.3440 -0.3671 -0.5917 -0.4268 -0.2632 -0.9492 -0.1338 -0.0324 -0.1959 -0.4270 -0.3805 -1.1145 -0.0612 -0.2732 -0.1251 -0.1079 -0.0660 -1.5092 -0.1298 -0.0110 -0.1584 -0.4216 -0.3350 -0.3198 -0.2148 -0.8501 -0.2661 -0.3045 -0.1919 -0.9915 -0.5511 -0.6506 -0.2791 -1.8142 -2.8393 -0.4044 -0.6559 -0.1920 -0.1046 -0.0059 -0.3009 -0.3415 -0.3078
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak oxygen consumption ; peak vo2 ; exercise ; exercise oscillatory ventilation ; eov ; partial pressure of end-tidal co2 ; petco2 ; gain ; cardiopulmonary exercise testing
H-1275	-0.9458367228507996	▁oxygen ▁consum p tion ▁; ▁VO 2 ▁; ▁v co 2 ▁s lope ▁; ▁exercise ▁; ▁os cilla tory ▁ventilation ▁; ▁e OV ▁; ▁end - ti dal ▁co 2 ▁; PET co 2 ▁; ▁cardio pul mon ary ▁exercise ▁testing
D-1275	-0.9458367228507996	oxygen consumption ; VO2 ; vco2 slope ; exercise ; oscillatory ventilation ; eOV ; end-tidal co2 ;PETco2 ; cardiopulmonary exercise testing
P-1275	-1.5441 -1.5010 -0.5578 -1.4255 -0.2997 -2.0736 -1.1773 -0.2575 -0.4881 -2.0004 -0.3923 -0.3067 -0.4954 -0.2978 -1.2201 -0.3038 -0.5708 -0.1245 -0.4803 -0.0321 -0.2834 -1.2866 -2.4841 -0.3123 -7.0814 -0.1375 -0.3584 -1.0883 -1.6344 -0.3641 -0.2795 -0.3535 -0.9118 -1.8279 -0.2278 -0.5413 -0.6998 -1.6394 -1.5520 -0.9256 -0.4117 -0.4569 -0.2642
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective cohort study ; denmark ; bisphosphonates ; raloxifene
H-1536	-0.6506019234657288	▁Denmark ▁; ▁bis phos phon ates ▁; ▁ra lo xi fen e
D-1536	-0.6506019234657288	Denmark ; bisphosphonates ; raloxifene
P-1536	-2.8390 -0.3167 -0.1686 -0.1123 -0.2807 -2.3073 -0.4124 -1.0695 -0.1169 -0.3741 -0.0533 -0.3058 -0.4843 -0.2676
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension ; lv dilatation ; lv dysfunction ; mitral valve ; organic ; lesion ; systolic ; diastolic tethering ; etiology
H-365	-0.45588698983192444	▁hyper tension ▁; ▁LV ▁di la tation ▁; ▁LV ▁dys function ▁; ▁MR ▁; ▁significant ▁MS ▁; ▁mit ral ▁val ve ▁; ▁sy sto lic ▁; ▁dia sto lic ▁te ther ing ▁; ▁functional ▁et i ology ▁; ▁MS
D-365	-0.45588698983192444	hypertension ; LV dilatation ; LV dysfunction ; MR ; significant MS ; mitral valve ; systolic ; diastolic tethering ; functional etiology ; MS
P-365	-0.5648 -0.1898 -0.2433 -0.5676 -1.1330 -0.3751 -0.1950 -0.2862 -0.1704 -0.0355 -0.0601 -0.2351 -1.2719 -0.2290 -0.0119 -0.7476 -0.2997 -0.8000 -0.1469 -0.2833 -0.3764 -0.2954 -2.1284 -0.1824 -0.0615 -0.5002 -0.0132 -0.1623 -0.1511 -0.0187 -1.4892 -0.2333 -0.3174 -0.3361 -0.2353 -0.0734 -0.0741 -0.2615 -3.2549 -0.4385 -0.2419
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; patients ; diuretic ; therapy ; serum sodium ; systolic function
H-1196	-0.6901116967201233	▁to lv ap tan ▁; ▁hypo na trem ia ▁; ▁veren ig de ▁staten ▁; ▁japan ▁; ▁con ges tive ▁heart ▁failure ▁; ▁di ure tic ▁ therapy ▁; ▁so dium ▁levels ▁; ▁sy sto lic ▁function
D-1196	-0.6901116967201233	tolvaptan ; hyponatremia ; verenigde staten ; japan ; congestive heart failure ; diuretic therapy ; sodium levels ; systolic function
P-1196	-0.1023 -0.6720 -0.6730 -0.1726 -0.3871 -0.1624 -1.2051 -0.1520 -1.9085 -0.4022 -3.5881 -0.0145 -0.4322 -1.4638 -0.2649 -1.2574 -0.2803 -0.2505 -0.9365 -3.3224 -0.8134 -0.2777 -0.3881 -0.3825 -1.1527 -1.1913 -0.6258 -0.1854 -0.3401 -1.8118 -0.0559 -0.3894 -0.3031 -0.0603 -0.1446 -0.2096 -0.2920 -0.4124 -0.2307
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal ; strain ; left ventricle ; echocardiographic ; patients ; baseline ; echocardiography ; crt ; follow-up ; echocardiograms
H-429	-0.7642289996147156	▁left ▁vent ric le ▁; ▁e cho car dio graphic ▁measure ments ▁; ▁base line ▁e cho card i ography ▁; ▁c t ▁; ▁follow - up ▁e cho card i ogram s
D-429	-0.7642289996147156	left ventricle ; echocardiographic measurements ; baseline echocardiography ; ct ; follow-up echocardiograms
P-429	-2.3591 -0.2956 -1.0958 -0.9895 -0.3095 -0.2090 -0.3163 -0.4009 -1.1172 -0.9868 -1.6402 -2.5620 -0.3226 -1.1827 -0.0903 -0.2290 -0.4375 -1.2370 -0.9177 -0.4830 -0.3401 -0.8457 -3.7636 -0.2883 -0.0128 -0.2109 -0.0573 -0.9459 -0.4662 -0.8876 -0.6180 -0.0568 -0.4741 -0.3792 -0.2200
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating factor ; paf ; metabolic ; enzymes ; follow-up ; patients ; diagnosed ; heart failure ; hf ; healthy
H-1267	-0.7366935014724731	▁plate let - activa ting ▁factor ▁; ▁p bf ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure ▁; HF
D-1267	-0.7366935014724731	platelet-activating factor ; pbf ; metabolic enzymes ; heart failure ;HF
P-1267	-0.3994 -1.1456 -0.2766 -0.1370 -0.7885 -0.3488 -0.3419 -2.2693 -2.3913 -0.3012 -0.0560 -0.1801 -0.1026 -0.2769 -0.3511 -2.2287 -0.6109 -0.3202 -2.3784 -0.3057 -0.2603
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute care surgery ; acs ; consultations ; oht ; transplantation ; medical therapy ; intravenous ; inotropes ; ventricular assist devices ; vads
H-1281	-0.591697633266449	▁a cute ▁care ▁surgery ▁; ▁ac s ▁; ▁o w t ▁; ▁transplant ation ▁; ▁medical ▁ therapy ▁; ▁m t ▁; ▁intra ven ous ▁in o trop es ▁; ▁vent ri cular ▁assist ▁devices ▁; VAD s
D-1281	-0.591697633266449	acute care surgery ; acs ; owt ; transplantation ; medical therapy ; mt ; intravenous inotropes ; ventricular assist devices ;VADs
P-1281	-0.0663 -0.0736 -1.8312 -0.4126 -0.2582 -0.8295 -0.2204 -0.3476 -0.6285 -5.4224 -0.0175 -0.2840 -0.1909 -1.6881 -0.3263 -0.3640 -0.1975 -0.0347 -0.3533 -0.6168 -0.1452 -0.3310 -0.4188 -0.0389 -3.0755 -0.1017 -0.3388 -0.0412 -0.3727 -0.3736 -0.0598 -1.3611 -0.4146 -0.4235 -0.2205 -0.3185 -0.2873 -0.5968 -0.3361 -0.2491
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients ; hfpef ; ivabradine ; exercise capacity ; left ventricular filling pressure ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1178	-0.7499776482582092	▁ HF p EF ▁; ▁i va bra dine ▁; ▁exercise ▁capacity ▁; ▁left ▁vent ri cular ▁; ▁fill ing ▁pressure ▁; ▁exercise ▁; ▁dia sto lic ▁mit ral ▁flow ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1178	-0.7499776482582092	HFpEF ; ivabradine ; exercise capacity ; left ventricular ; filling pressure ; exercise ; diastolic mitral flow ; diastolic mitral annular velocity
P-1178	-1.7174 -1.4292 -0.1133 -1.4392 -0.3525 -0.8978 -0.0379 -0.7488 -1.1617 -0.2976 -2.3990 -0.3585 -0.3263 -1.1205 -0.3100 -2.0155 -0.3078 -1.2931 -0.3799 -0.2273 -0.7342 -0.3692 -0.7246 -0.3339 -0.0879 -0.2179 -0.1232 -0.9125 -0.2538 -1.7803 -2.3326 -0.7774 -0.2761 -0.3971 -1.2598 -0.5085 -1.4010 -0.0371 -0.2726 -1.1065 -0.3910 -0.2687
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone system ; raas ; hfref ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; evidence ; hfpef
H-1489	-0.9691290855407715	▁re nin - angi oten sin - al do ster one ▁system ▁; RA as ▁; ▁h Fr EF ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁al do ster one ▁block ade ▁; ▁ HF p EF
D-1489	-0.9691290855407715	renin-angiotensin-aldosterone system ;RAas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
P-1489	-0.0569 -1.9812 -0.2626 -0.0468 -1.1878 -3.6449 -0.3058 -0.2019 -0.3849 -0.5367 -2.3774 -0.2128 -0.3192 -2.7834 -0.6281 -0.3191 -0.9386 -2.9193 -2.7386 -0.2633 -0.6958 -2.5808 -0.5467 -3.7946 -0.6867 -0.1252 -0.2415 -0.6974 -0.1021 -0.0902 -0.0441 -0.4520 -0.2955 -0.7332 -2.3469 -0.3496 -2.7748 -0.2117 -0.2935 -0.3481 -0.2967 -0.1238 -0.1804 -0.9121 -2.6669 -0.5090 -0.9948 -0.3935 -2.0126 -1.4559 -0.1127 -2.5337 -0.3643 -0.2567
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission ; lvet ; patients ; outcome ; tonometric
H-583	-0.7839537262916565	▁l VET ▁; ▁to no metric ▁indice s
D-583	-0.7839537262916565	lVET ; tonometric indices
P-583	-0.2660 -2.7050 -0.3277 -0.5322 -0.2686 -0.2873 -2.3584 -0.3270 -0.4571 -0.3103
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart rate ; blood pressure ; renal function ; spironolactone ; ras blockers ; β-blockers
H-182	-0.8842942118644714	▁heart ▁rate ▁; ▁blood ▁pressure ▁; ▁renal ▁function ▁; ▁spi rono lac tone ▁; ▁significant ▁; ▁ RAS ▁block ers ▁; HR ▁; ▁β - block ers
D-182	-0.8842942118644714	heart rate ; blood pressure ; renal function ; spironolactone ; significant ; RAS blockers ;HR ; β-blockers
P-182	-3.6104 -2.0671 -0.3183 -1.5809 -1.4249 -0.3866 -0.0900 -0.4686 -0.4153 -0.0855 -0.0867 -0.2201 -0.1329 -0.4218 -0.2995 -0.3785 -2.1640 -0.8132 -0.8117 -0.5512 -0.3579 -4.1459 -1.5407 -0.7678 -0.1899 -0.6111 -0.8624 -0.5407 -0.3009
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac ; β-adrenoceptor blockade ; heart failure ; reverse ; cardiac remodeling ; elevated ; plasma catecholamines
H-1553	-0.4623706340789795	▁cardiac ▁performance ▁; ▁β - ad re no cept or ▁block ade ▁; ▁heart ▁failure ▁; ▁SR ▁ca (2 +) - pump ▁function ▁; ▁cardiac ▁remodel ing ▁; ▁plasma ▁cate chol amine s
D-1553	-0.4623706340789795	cardiac performance ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; cardiac remodeling ; plasma catecholamines
P-1553	-0.9373 -0.5004 -0.2482 -0.1218 -0.0880 -0.3162 -0.1767 -0.5318 -0.5887 -0.2429 -0.2078 -1.2475 -0.3129 -1.5840 -0.5847 -0.3328 -1.0747 -0.9740 -1.1611 -0.0564 -0.1874 -0.2218 -0.3145 -0.3032 -1.5576 -0.0435 -0.2442 -0.3657 -0.2870 -0.0787 -0.1452 -0.3485 -0.2334 -0.3417 -0.2227
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate ratio ; confidence interval ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; therapy ; confidence interval ; β-blockers ; therapy
H-666	-0.5751257538795471	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁β - block ers ▁ therapy
D-666	-0.5751257538795471	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers therapy
P-666	-1.7680 -2.5112 -0.2638 -1.9836 -0.7148 -0.0314 -0.1510 -0.2982 -0.0952 -0.0925 -0.0367 -0.5982 -0.3493 -0.0405 -0.4183 -1.3900 -0.0515 -0.3242 -0.3355 -0.5902 -1.4641 -0.1327 -0.4802 -0.2819 -0.4663 -0.1944 -0.6877 -0.3518
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 ; congestive heart failure ; phenotypes ; mitochondrial ; tac ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein
H-874	-0.7901383638381958	▁SS 31 ▁; ▁con ges tive ▁heart ▁failure ▁; ▁ph eno type s ▁; ▁mito cho ndri al ▁damage ▁; ▁ TAC ▁; ▁mito cho ndri al ▁prote ome ▁; ▁mito cho ndri al ▁; ▁non mi to cho ndri al ▁protein ▁changes
D-874	-0.7901383638381958	SS31 ; congestive heart failure ; phenotypes ; mitochondrial damage ; TAC ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein changes
P-874	-0.3784 -0.8881 -0.3555 -0.1933 -1.0380 -3.0871 -1.4848 -0.2914 -1.0489 -0.1030 -0.0731 -0.0207 -0.2827 -0.3505 -0.2597 -2.0152 -1.0788 -0.4104 -1.2684 -0.3176 -2.3070 -0.5628 -0.3431 -0.1757 -1.9907 -1.3310 -0.3318 -0.1388 -0.1196 -1.2949 -0.3036 -2.0151 -1.5454 -0.3481 -0.5647 -0.6666 -0.2881 -0.2193 -2.0375 -1.2372 -0.3226 -0.5046 -1.3021 -0.4139 -0.2463
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar ; atpase ; activity ; mrna ; phospholamban ; α-myosin heavy chain ; mrna ; β-myosin heavy chain ; metoprolol
H-1552	-0.6011436581611633	▁my o fi bril lar ▁ca (2 +) - stimul ated ▁ATP ase ▁activity ▁; ▁m RNA ▁levels ▁; ▁SR ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁α - my os in ▁heavy ▁chain ▁; ▁m RNA ▁; ▁β - my os in ▁heavy ▁chain ▁; ▁met o pro lol
D-1552	-0.6011436581611633	myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA ; β-myosin heavy chain ; metoprolol
P-1552	-2.5253 -0.8328 -0.2515 -0.2733 -0.4307 -0.6790 -1.5251 -0.0912 -0.0947 -0.0560 -1.5035 -0.9550 -1.9954 -0.7761 -0.3608 -0.0601 -0.7594 -1.9400 -0.3568 -1.3815 -0.7079 -1.6938 -0.1468 -0.2447 -0.4101 -0.3495 -0.2344 -0.1734 -0.3154 -0.7520 -0.8884 -0.4161 -0.2376 -0.0847 -0.9911 -0.4266 -0.4395 -0.7768 -0.1052 -0.3662 -0.1230 -0.8886 -0.9754 -0.5477 -0.0713 -0.8405 -0.3853 -0.4458 -0.7632 -0.0793 -0.3685 -0.2142 -0.1929 -0.2433 -0.8774 -0.3973 -0.2428
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl ; healthy ; hdl ; healthy ; patients ; chf-nyha-iii ; hdl ; nyha-iiib ; patients ; chf-nyha-ii ; hdl ; nyha-ii
H-250	-1.4480061531066895	▁HD l ▁; ▁healthy ▁; HD l ▁; health y ▁; ▁CHF - NY ha - III ▁; HD l ▁; ▁ny ha - III b ▁; ▁ET ▁; ▁CHF - NY ha - II ▁; HD l ▁; NY ha - II
D-250	-1.4480061531066895	HDl ; healthy ;HDl ;healthy ; CHF-NYha-III ;HDl ; nyha-IIIb ; ET ; CHF-NYha-II ;HDl ;NYha-II
P-250	-3.0536 -3.6845 -0.3761 -2.7051 -0.3228 -3.6543 -2.5700 -0.4141 -1.8107 -0.2041 -0.5245 -1.7798 -0.2303 -0.8558 -2.1575 -0.1661 -0.4312 -0.4811 -2.9005 -2.4446 -0.4778 -3.7792 -1.7370 -0.1135 -0.8292 -0.3364 -0.5004 -3.2281 -0.6422 -3.2183 -0.1607 -1.0790 -2.2276 -0.1164 -1.5303 -0.4722 -3.0576 -1.8650 -0.6391 -3.4771 -2.2549 -0.1156 -1.8977 -0.4102 -0.2281
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized ; coronary microembolization-induced hf ; cxl-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; maximal ventricular power index
H-420	-0.759722113609314	▁an est het ized ▁dog s ▁; ▁corona ry ▁micro e mbol ization - indu ced ▁ HF ▁; ▁c XL -10 20 ▁; ▁left ▁vent ri cular ▁; ▁end - dia sto lic ▁pressure ▁; ▁my o card ial ▁oxygen ▁consum p tion ▁; ▁e je ction ▁ fraction ▁; ▁vent ri cular ▁power ▁index
D-420	-0.759722113609314	anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular ; end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
P-420	-1.5544 -0.4542 -3.3892 -0.8326 -0.6737 -0.4843 -0.3767 -0.7299 -1.5884 -0.0655 -0.6103 -0.0910 -1.0168 -0.3191 -0.1163 -0.7866 -0.4737 -0.5804 -0.3300 -1.1596 -1.8143 -0.4207 -0.7307 -0.3523 -0.9168 -0.5109 -2.4393 -0.7624 -1.8326 -2.5808 -0.2714 -0.0244 -0.3590 -0.1653 -0.7295 -0.4179 -1.2202 -0.1714 -0.9635 -1.5417 -0.2714 -0.6187 -0.1940 -1.9509 -0.3197 -0.1768 -0.2919 -0.2004 -0.5296 -0.0306 -0.3089 -0.1562 -2.6879 -1.4906 -0.1756 -0.0541 -0.4812 -0.2677
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard error of measurement ; mdc ; mdc
H-805	-0.6967858672142029	▁m d ▁; ▁95% ▁confidence ▁level ▁; ▁m d ▁; ▁m d ▁; ▁95% ▁confidence ▁level ▁; ▁m d
D-805	-0.6967858672142029	md ; 95% confidence level ; md ; md ; 95% confidence level ; md
P-805	-0.6451 -1.7442 -0.2613 -1.3387 -0.2103 -0.2315 -0.2069 -0.3335 -1.4688 -0.9852 -0.9399 -1.1158 -0.3991 -1.2001 -0.1987 -0.2767 -0.2513 -0.4757 -1.3909 -0.6821 -0.2765
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline ; heart failure ; t1-mapping ; administration ; administration
H-1061	-0.8639248013496399	▁heart ▁failure ▁; ▁t 1- ma pping ▁; ▁contrast ▁agent ▁; ▁contrast ▁agent
D-1061	-0.8639248013496399	heart failure ; t1-mapping ; contrast agent ; contrast agent
P-1061	-4.5119 -0.7881 -0.4098 -0.6879 -0.5179 -0.5079 -0.2278 -0.8034 -0.8545 -0.0444 -0.4409 -1.1122 -0.0648 -1.6687 -0.3186
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies ; hf ; idiopathic dilated cardiomyopathy ; ischemic ; valvular
H-1794	-0.7746356725692749	HF ▁; ▁la ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁c ' d ▁; ▁ ische mic ▁; ▁SH ▁; ▁val vu lar ▁; ▁alcohol
D-1794	-0.7746356725692749	HF ; la ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
P-1794	-3.4573 -0.2799 -1.1042 -5.6592 -0.6018 -0.3417 -0.1318 -0.8465 -0.2913 -0.1028 -0.0386 -0.4814 -0.1855 -0.0337 -0.4755 -0.2381 -4.3894 -0.1636 -0.3207 -0.2171 -0.1010 -0.4228 -0.4295 -0.8123 -0.3703 -0.3564 -0.0209 -0.2235 -0.4177 -0.3078 -1.6306 -0.3354
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 ; functional capacity ; clinical ; outcomes ; ambulatory ; patients ; hf ; heart failure ; outcomes ; exercise ; training ; hf-action ; randomized ; exercise ; training ; hf
H-697	-0.859422504901886	▁ST 2 ▁; ▁functional ▁capacity ▁; ▁ambula tory ▁patients ▁; ▁ HF ▁; ▁Heart ▁Fail ure ▁; ▁Exerci se ▁Training ▁; ▁ HF
D-697	-0.859422504901886	ST2 ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; Exercise Training ; HF
P-697	-1.2199 -0.1348 -0.6660 -0.2207 -0.4268 -0.3526 -0.0966 -0.6842 -1.0416 -0.3030 -1.2559 -1.6002 -0.3121 -1.4745 -0.2982 -1.2617 -0.2682 -1.8912 -0.6388 -1.0081 -0.2012 -3.1499 -1.0905 -1.6217 -0.2671
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report ; cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ; exercise rehabilitation ; patient ; chronic heart failure ; chf ; clinical ; cardiopulmonary exercise testing ; cpet ; exercise rehabilitation ; china
H-1879	-1.6686584949493408	▁cardio pul mon ary ▁exercise ▁testing ▁; ▁exercise ▁rehabilita tion ▁; ▁patients ▁met ▁chronic ▁heart ▁failure ▁; ▁heart ▁failure ▁; ▁ nc w ▁; ▁Card io p ul mon ary ▁Exerci se ▁test ing ▁; ▁cm t ▁; ▁exercise ▁rehabilita tion ▁; ▁ europe se
D-1879	-1.6686584949493408	cardiopulmonary exercise testing ; exercise rehabilitation ; patients met chronic heart failure ; heart failure ; ncw ; Cardiopulmonary Exercise testing ; cmt ; exercise rehabilitation ; europese
P-1879	-0.6614 -1.8678 -3.1350 -1.9046 -1.3263 -0.9692 -0.3264 -2.0920 -0.7447 -1.5271 -0.3372 -2.9768 -3.2524 -2.0203 -1.2345 -1.0615 -0.3066 -6.3015 -0.8884 -0.2873 -3.2897 -2.3430 -0.9513 -0.3905 -1.9269 -2.0776 -3.5068 -1.9192 -3.7106 -0.8591 -2.1520 -1.2386 -3.0065 -0.7229 -0.2565 -3.2427 -1.2204 -0.3177 -1.9293 -0.3346 -1.6464 -0.2953 -3.4777 -2.1004 -0.2319 -1.7909 -0.2675
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ; ischemic hf ; pathogenesis ; nyha functional class iv ; estimated glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
H-1704	-0.6200271248817444	▁AA ▁; ▁ ische mic ▁ HF ▁; ▁w ha ▁; ▁functional ▁class ▁IV ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁heart ▁rate ▁; ▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁my o card ial ▁in far ction
D-1704	-0.6200271248817444	AA ; ischemic HF ; wha ; functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
P-1704	-0.6612 -0.3288 -0.2343 -0.3756 -0.2399 -0.3559 -0.5208 -0.4310 -3.9522 -1.1096 -0.2177 -0.0708 -0.0712 -1.1110 -0.4183 -0.1917 -0.2054 -0.1091 -0.0339 -1.3507 -1.0694 -0.3379 -1.7673 -1.2662 -0.3150 -0.1667 -0.0938 -0.2490 -0.1076 -0.0103 -0.1106 -0.3283 -1.6874 -0.2464 -0.6651 -1.6092 -0.1550 -0.5466 -1.0309 -1.3650 -0.3044
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action ; randomized ; exercise ; training ; patients ; hf ; left ventricular ejection fractions ; hrqol ; kansas city cardiomyopathy questionnaire ; kccq ; baseline
H-837	-0.8382663130760193	HF - ac TION ▁; ▁exercise ▁training ▁; ▁ HF ▁; ▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction s ▁; ▁HR Qo l ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁ nc w t
D-837	-0.8382663130760193	HF-acTION ; exercise training ; HF ; low left ventricular ejection fractions ; HRQol ; Kansas City Cardiomyopathy Questionnaire ; ncwt
P-837	-2.4265 -0.1064 -0.8571 -3.2047 -0.3178 -0.6698 -1.5043 -0.2698 -2.3839 -0.9386 -0.3332 -1.9264 -1.9252 -0.5069 -2.2677 -1.0480 -0.2900 -0.4851 -0.3691 -0.5369 -0.0385 -0.5043 -0.3517 -1.8268 -0.1089 -2.4013 -0.3116 -0.2014 -1.2885 -1.0403 -0.0731 -0.1155 -0.4856 -0.1852 -0.3049 -0.0557 -0.2728 -0.8161 -1.2975 -0.1935 -1.2171 -0.3225 -0.2653
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt ; systolic dysfunction ; outcomes ; resynchronization reverses remodeling in systolic left ventricular dysfunction ; reverse ; patients ; left ventricular ; ejection fraction ; lvef
H-752	-0.8254765272140503	▁c t ▁; ▁sy sto lic ▁dys function ▁; ▁re syn chron ization ▁re ve rse s ▁re model ing ▁; ▁sy sto lic ▁left ▁v ▁en tri cular ▁dys function ▁; ▁re versi e ▁; ▁left ▁vent ri cular ▁; ▁v n ▁; ▁e je ction ▁ fraction ▁; ▁l EF
D-752	-0.8254765272140503	ct ; systolic dysfunction ; resynchronization reverses remodeling ; systolic left v entricular dysfunction ; reversie ; left ventricular ; vn ; ejection fraction ; lEF
P-752	-0.3472 -3.6320 -0.2676 -0.2345 -0.2864 -0.3076 -0.1683 -0.3096 -0.3039 -0.4718 -0.1733 -0.0298 -1.6485 -0.0697 -0.8425 -0.5668 -0.3088 -0.3495 -1.2319 -0.1642 -0.3389 -1.0478 -0.1754 -0.3350 -1.2894 -0.2446 -4.1414 -2.7738 -0.6724 -0.0553 -0.2721 -0.2417 -2.5220 -4.6715 -0.0475 -0.2712 -0.9275 -0.2564 -1.7114 -0.5153 -0.2650 -1.6409 -1.1373 -0.3375 -0.0820 -0.5448 -0.1586 -0.3792 -0.0383 -0.2697 -1.8225 -3.0596 -0.3612 -0.2548
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated glomerular filtration rate ; egfr ; type 2 diabetes ; cholesterol ; ldl-cholesterol ; clcnka ; genotype
H-1803	-0.8573930859565735	▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR ▁; ▁diabetes ▁; ▁total ▁cholesterol ▁; ▁l DL - ch olesterol ▁; ▁CL cn ka ▁ gg ▁geno type
D-1803	-0.8573930859565735	glomerular filtration rate ; egFR ; diabetes ; total cholesterol ; lDL-cholesterol ; CLcnka gg genotype
P-1803	-0.2339 -0.6839 -0.1498 -0.1460 -2.0654 -0.9258 -0.3599 -1.2081 -2.6692 -2.9569 -0.3780 -0.3282 -0.3100 -1.5998 -0.3902 -0.3037 -0.3033 -1.5716 -0.3113 -0.5985 -0.0270 -0.3366 -0.8583 -2.5645 -2.7774 -0.3332 -1.1889 -0.2221 -0.0192 -0.4281 -0.3302
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography ; lv end-diastolic dimension ; lv end-diastolic pressure ; wall stress ; lung ; acf
H-474	-0.8635535836219788	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁ dimension ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight ▁; ▁a CF ▁; ▁sham ▁group
D-474	-0.8635535836219788	echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; aCF ; sham group
P-474	-0.8573 -0.3682 -0.2270 -0.4549 -0.4729 -0.3675 -1.2445 -1.5411 -2.1751 -0.3208 -0.1014 -0.5942 -0.4012 -0.4234 -0.3728 -0.3612 -1.4663 -1.2138 -2.2255 -0.3042 -0.1457 -0.6676 -0.6332 -0.6546 -0.4230 -1.0403 -0.3998 -0.3665 -0.5166 -0.8336 -0.3411 -4.6230 -2.8320 -1.3382 -0.0777 -1.7304 -0.4024 -0.2961
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic ; patients ; auc ; auc
H-488	-1.6540125608444214	▁s ' lateral ▁; ▁a UC ▁; ▁s ' lateral ▁; ▁a UC
D-488	-1.6540125608444214	s'lateral ; aUC ; s'lateral ; aUC
P-488	-3.2544 -4.6487 -0.4174 -0.3336 -1.0375 -2.8489 -0.7182 -0.2479 -4.8227 -0.7356 -0.3755 -1.5152 -3.1708 -0.3758 -0.3083
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients ; follow-up ; patients ; spironolactone ; hospitalization ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval
H-443	-0.9956285953521729	▁spi rono lac tone ▁; ▁hospital ization ▁; ▁significant e ▁hazard ▁ratio ▁; ▁death
D-443	-0.9956285953521729	spironolactone ; hospitalization ; significante hazard ratio ; death
P-443	-0.3385 -0.1141 -0.1582 -0.1988 -0.4276 -1.6553 -0.9234 -0.3315 -7.3365 -0.4726 -0.4676 -0.2215 -0.3844 -2.2170 -0.3556 -0.3274
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control ; patients ; cardiac ; driven ; cardioversions ; costs ; antiarrhythmic drugs ; cad ; patient ; confidence interval ; patient
H-1239	-0.7038809657096863	▁Rate - control ▁; ▁cardiac ▁procedure s ▁; ▁cardio version s ▁; ▁kosten ▁; ▁anti ar rhythm ic ▁drugs ▁; CAD ▁; ▁confidence ▁interval ▁; ▁CI
D-1239	-0.7038809657096863	Rate-control ; cardiac procedures ; cardioversions ; kosten ; antiarrhythmic drugs ;CAD ; confidence interval ; CI
P-1239	-2.6104 -0.2889 -0.0284 -0.8067 -0.4072 -0.6894 -0.2577 -0.4315 -0.1526 -0.3332 -0.5577 -0.4485 -1.1997 -0.3871 -0.0365 -0.2073 -0.4074 -0.2674 -0.1493 -0.4676 -1.6346 -0.5669 -1.2598 -0.0878 -0.3776 -4.6379 -0.6623 -0.3473
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients ; bundle branch morphology ; diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin ii receptor blocker
H-906	-0.676215648651123	▁diabetes ▁mell itus ▁; ▁cardio my o pathy ▁origin ▁; ▁β - block er ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin ▁II ▁receptor ▁block er
D-906	-0.676215648651123	diabetes mellitus ; cardiomyopathy origin ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
P-906	-2.1906 -0.0265 -0.1540 -0.2406 -0.0311 -0.6843 -0.2242 -0.0318 -0.6871 -0.2890 -0.1314 -0.1005 -0.6980 -0.2869 -0.3536 -1.6267 -1.5887 -0.6633 -3.3581 -0.8778 -0.0907 -0.2069 -0.3789 -0.1691 -0.1337 -0.0863 -0.2000 -0.3128 -0.7687 -1.5220 -0.5157 -2.6199 -2.5821 -0.0502 -0.6140 -0.3955 -0.5207 -0.2849
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone post myocardial infarction heart failure efficacy and survival study ; ephesus ; post-myocardial infarction ; patients ; heart failure ; mortality ; hospitalizations ; patients ; randomized ; aldosterone antagonist ; eplerenone
H-1737	-0.8825696110725403	▁e pler en one ▁; ▁post ▁my o card ial ▁in far ction ▁; ▁Heart ▁failure ▁Ef fica cy ▁; ▁su rvi val ▁Study ▁; ▁e we SUS ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁mortal iteit ▁; ▁al do ster one ▁anta gon ist ▁; ▁e pler en one
D-1737	-0.8825696110725403	eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival Study ; eweSUS ; post-myocardial infarction ; heart failure ; mortaliteit ; aldosterone antagonist ; eplerenone
P-1737	-0.1374 -0.0994 -0.1369 -1.2939 -0.2535 -0.5145 -3.3063 -0.6509 -1.7468 -2.7328 -0.2376 -0.8495 -0.8234 -0.7127 -1.1274 -0.3577 -1.7774 -0.7593 -0.8226 -0.2003 -0.3114 -0.1037 -0.0390 -0.8175 -0.2259 -0.1928 -3.3477 -3.4150 -0.2610 -0.2460 -0.2527 -2.1455 -0.5411 -1.9711 -2.3628 -0.1708 -0.8940 -0.8507 -0.3663 -2.3650 -0.4586 -0.2583 -2.8975 -1.1652 -0.2806 -0.8958 -0.0589 -0.1750 -1.1721 -1.1121 -0.0104 -1.0460 -0.4727 -0.0578 -0.1413 -0.1679 -1.6390 -0.3552 -0.2866
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol ; metoprolol ; endpoint ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-856	-0.5774617791175842	▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁; ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD - cr t ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁With ▁Card iac ▁re syn chron ization ▁Therapy
D-856	-0.5774617791175842	carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-crt ; multicenter Automatic Defibrillator Implantation With Cardiac resynchronization Therapy
P-856	-0.2982 -0.3680 -0.3074 -0.2497 -0.1344 -0.1210 -0.1431 -0.6525 -0.2796 -0.9492 -0.2003 -0.3640 -0.1314 -0.1288 -0.7990 -0.2074 -0.2193 -0.1731 -1.2648 -0.4791 -0.2014 -0.2103 -0.0717 -0.3006 -1.3298 -0.4882 -3.8300 -1.4142 -0.2841 -0.6699 -0.0819 -0.4203 -0.2067 -0.6914 -0.2555 -1.6189 -0.1486 -0.4384 -1.6609 -2.4847 -0.3161 -0.8996 -0.4590 -0.0793 -0.0102 -1.3520 -0.3115 -0.3622 -0.2277
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence interval ; heart ; mortality ; death
H-1749	-1.1653777360916138	HR ▁; ▁heart ▁failure - related ▁mortal iteit ▁; ▁sud den ▁death ▁; ▁HR
D-1749	-1.1653777360916138	HR ; heart failure-related mortaliteit ; sudden death ; HR
P-1749	-2.5546 -0.3963 -2.9725 -1.3144 -0.4043 -0.2766 -0.2310 -2.0057 -0.3590 -2.0345 -0.1928 -1.1634 -0.4095 -3.5674 -0.4826 -0.2814
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash ; clinic ; brachial systolic pressure ; central end-systolic pressure
H-924	-0.9308049082756042	▁DAS h ▁; ▁s rd ▁; ▁bra chi al ▁sy sto lic ▁pressure ▁; ▁h g ▁; ▁centrale ▁end - sy sto lic ▁pressure ▁; ▁h g
D-924	-0.9308049082756042	DASh ; srd ; brachial systolic pressure ; hg ; centrale end-systolic pressure ; hg
P-924	-0.1723 -0.2276 -0.3778 -1.4496 -2.3355 -0.4211 -0.1940 -0.7627 -0.5212 -0.1256 -0.3069 -0.3622 -1.4685 -0.3901 -2.7872 -0.6923 -0.4481 -2.3882 -2.9187 -0.4432 -2.7231 -0.6543 -0.3705 -1.4698 -0.5834 -1.0277 -0.6789 -0.4370 -0.2558
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients ; hf ; obese ; body mass index ; idiopathic-dilated cardiomyopathy
H-558	-0.6735067367553711	HF ▁; ▁obes e ▁; ▁body ▁mass ▁index ▁; ▁black ▁et hni city ▁; ▁cardio my o pathy
D-558	-0.6735067367553711	HF ; obese ; body mass index ; black ethnicity ; cardiomyopathy
P-558	-2.8679 -0.5026 -0.7870 -0.2613 -0.4004 -1.9768 -0.1822 -0.0225 -0.4674 -0.4317 -0.1984 -0.6686 -1.4415 -0.4119 -0.9554 -0.9078 -0.1967 -0.0765 -0.4319 -0.2819
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause mortality ; hospitalization ; hf ; lvef ; patients ; heart failure survey ; israel
H-113	-1.088553547859192	▁mortal iteit ▁; HF ▁; ▁LV EF ▁; ▁Heart ▁Fail ure ▁Survey ▁; ▁is ra el
D-113	-1.088553547859192	mortaliteit ;HF ; LVEF ; Heart Failure Survey ; israel
P-113	-3.4250 -2.3864 -0.3724 -2.4115 -0.3916 -1.3856 -1.8428 -0.3525 -1.4635 -0.3250 -1.7044 -0.9243 -0.3735 -0.5817 -0.7023 -0.0673 -0.5652 -0.3188
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients ; left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; coronary angiography ; followed up
H-1743	-0.6482203602790833	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁world ▁Health ▁Organization ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁negative ▁corona ry ▁ang i ography
D-1743	-0.6482203602790833	left ventricular ejection fraction ; world Health Organization ; idiopathic dilated cardiomyopathy ; negative coronary angiography
P-1743	-1.4585 -0.3738 -2.0356 -0.5851 -0.3182 -0.3062 -0.1844 -0.4802 -0.0536 -0.3492 -1.1311 -2.8760 -1.8698 -0.2494 -0.4593 -0.1057 -0.1311 -0.8221 -0.0905 -0.1188 -0.0991 -0.9165 -0.2028 -0.0730 -0.3342 -0.3408 -0.8029 -2.6728 -0.4279 -0.3135 -0.4249 -0.5115 -0.2726
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european society of cardiology ; hfpef ; symptoms ; heart failure ; preserved lv ejection fraction ; non-dilated left ventricle ; evidence ; diastolic dysfunction ; lv relaxation ; lv diastolic stiffness ; elevated ; lv filling pressures
H-27	-0.6850070953369141	▁ europe se ▁Society ▁of ▁Card i ology ▁; ▁h FP EF ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁non - dila ted ▁left ▁vent ric le ▁; ▁dia sto lic ▁dys function ▁; impa i red ▁LV ▁relax ation ▁; ▁LV ▁dia sto lic ▁sti ff ness ▁; ▁LV ▁fill ing ▁pressure s
D-27	-0.6850070953369141	europese Society of Cardiology ; hFPEF ; heart failure ; ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
P-27	-0.6220 -0.0293 -0.0861 -3.3995 -0.9052 -1.0695 -0.3309 -0.2252 -0.4120 -1.0187 -3.4494 -2.1492 -0.2439 -1.6579 -0.2803 -0.2403 -0.9541 -0.1616 -0.0929 -0.4275 -0.0234 -0.2987 -4.0553 -0.0516 -0.0428 -0.4095 -0.6179 -0.1659 -1.9020 -0.4877 -0.3089 -0.0509 -0.3875 -0.1877 -0.0612 -0.0519 -0.3131 -0.5273 -0.6199 -0.3210 -0.2120 -0.2879 -1.4227 -0.3316 -1.3551 -0.4225 -0.6548 -0.4807 -0.0791 -0.6567 -3.0540 -0.3107 -0.9251 -0.3404 -0.1435 -0.1934 -0.2873 -0.3769 -0.2412
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars ; s1pr1s ; myocyte ; camp ; report ; receptors ; g-protein-coupled receptor ; kinase-2
H-1408	-0.5804030299186707	▁β 1 AR s ▁; ▁s 1 PR 1 s ▁; ▁my o cy te ▁; ▁c AMP ▁production ▁; ▁receptor s ▁; ▁regulator y ▁; ▁g - prote in - co up led ▁receptor ▁kina se -2
D-1408	-0.5804030299186707	β1ARs ; s1PR1s ; myocyte ; cAMP production ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
P-1408	-1.6521 -1.8837 -1.1106 -0.5954 -0.3085 -1.0180 -0.8950 -1.1377 -2.7840 -0.6971 -0.3016 -1.2835 -0.1333 -0.2018 -0.0703 -0.3965 -0.1237 -0.4490 -0.4348 -0.2908 -0.4524 -0.6152 -0.2960 -0.6564 -1.6178 -0.2876 -0.4103 -0.1472 -0.0893 -0.2359 -0.2046 -0.2137 -0.2412 -1.1183 -0.0412 -0.0170 -0.0976 -0.0409 -0.4346 -0.2313
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up ; paf-cpt ; paf ; lyso-paf-at ; downregulated ; paf-ah ; lp-pla2 ; elevated
H-1270	-1.0164834260940552	▁follow - up ▁; ▁PA f - c p ▁; ▁PA f ▁; ▁lys o - pa f - at ▁; ▁PA f - AH ▁; ▁l p - PLA 2
D-1270	-1.0164834260940552	follow-up ; PAf-cp ; PAf ; lyso-paf-at ; PAf-AH ; lp-PLA2
P-1270	-0.1607 -0.2243 -0.0579 -0.3886 -2.3112 -2.2657 -0.2437 -1.4016 -2.8974 -0.6688 -1.7845 -2.9797 -0.7685 -0.8125 -0.4354 -0.1581 -1.2646 -2.1918 -0.6401 -1.5640 -0.3927 -2.4989 -2.3829 -0.2570 -2.9044 -0.4524 -0.0517 -0.0372 -0.1780 -0.2155 -0.0969 -0.5314 -0.3261
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients ; heart failure ; ejection fraction ; cardiac rehabilitation ; walking ; exercise
H-570	-0.7865524888038635	▁heart ▁failure ▁; ▁me an ▁e je ction ▁ fraction ▁; ▁cardiac ▁rehabilita tion ▁; ▁Nordic ▁walking ▁; ▁exercise
D-570	-0.7865524888038635	heart failure ; mean ejection fraction ; cardiac rehabilitation ; Nordic walking ; exercise
P-570	-3.0119 -0.5487 -0.3366 -1.8071 -0.2628 -0.1820 -0.1216 -0.0516 -0.2746 -0.0264 -0.4149 -1.1576 -0.1283 -1.4180 -1.4329 -1.4287 -1.0291 -0.7673 -1.3850 -0.4617 -0.2705
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
H-1836	-1.3111754655838013	▁ nc w - stra t ified ▁hazard ▁ratio s ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁si tag lip tin ▁; ▁sul fon yl ure as ▁; ▁si tag lip tin ▁; ▁insulin
D-1836	-1.3111754655838013	ncw-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
P-1836	-5.3209 -2.6832 -1.0681 -0.4699 -0.2099 -0.2893 -0.8499 -0.6433 -0.4263 -0.6747 -0.4129 -4.6546 -0.6086 -0.7337 -3.4693 -0.5000 -0.4432 -0.0890 -0.1212 -0.6287 -0.4237 -5.9092 -0.7934 -0.8792 -3.5146 -0.4281 -0.2166 -0.2195 -0.4112 -1.9241 -0.3252 -0.3567 -5.7255 -0.9507 -0.8522 -4.0103 -0.4058 -0.0566 -0.4195 -0.3284
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal muscle ; t-score ; fontan ; sarcopenic range muscle wasting ; t-score ; clinically ; t-score
H-1501	-0.8162064552307129	▁skelet al ▁muscle ▁mass ▁; ▁t - s core ▁; ▁sar co pen ic ▁range ▁; ▁muscle ▁was ting ▁; ▁t - s core ▁; ▁significant ▁; ▁t - s core
D-1501	-0.8162064552307129	skeletal muscle mass ; t-score ; sarcopenic range ; muscle wasting ; t-score ; significant ; t-score
P-1501	-1.1161 -0.3084 -1.9484 -0.5199 -0.3622 -0.5565 -0.1793 -0.3666 -0.9026 -0.3193 -3.0519 -0.0744 -0.0758 -0.5019 -0.0295 -0.4622 -1.6503 -3.5888 -0.1879 -0.2458 -1.2077 -0.1125 -0.3166 -1.0944 -0.3118 -0.1885 -0.9708 -4.2435 -0.1098 -0.2607 -1.0997 -0.3329 -0.2383
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise ; testosterone ; baseline ; peak oxygen uptake ; beck depression inventory ; leg ; medical outcomes study short-form ; quality of life ; exercise ; placebo
H-1323	-0.7754868865013123	▁testosteron e ▁group ▁; ▁oxygen ▁up take ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁leg ▁strength ▁; ▁Medical ▁Out com es ▁Study ▁Short - form ▁quality ▁of ▁life ▁domain s ▁; ▁exercise ▁; ▁place bo ▁group
D-1323	-0.7754868865013123	testosterone group ; oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes Study Short-form quality of life domains ; exercise ; placebo group
P-1323	-3.6533 -0.1170 -1.5002 -0.2921 -1.2235 -2.1586 -0.8660 -0.2959 -0.2430 -0.3551 -0.0892 -0.2832 -0.8363 -0.2962 -0.3461 -1.3190 -1.2334 -0.3152 -0.8035 -1.7915 -0.3700 -0.1479 -0.3681 -0.1960 -0.1096 -1.0982 -0.3733 -0.5132 -1.0081 -0.3848 -0.4589 -0.2873 -1.6863 -2.0804 -0.9169 -0.0511 -1.4979 -0.4183 -0.2592
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker ; uptitrations ; composite end-point ; all-cause mortality ; hf ; readmissions ; hfref ; hazard ratio ; confidence interval
H-181	-1.2160511016845703	▁significant e ▁; ▁all - ca use ▁mortal iteit ▁; ▁ HF ▁; ▁read missions ▁; ▁h bf ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁cm
D-181	-1.2160511016845703	significante ; all-cause mortaliteit ; HF ; readmissions ; hbf ;hazard ratio ;HR ; confidence interval ; cm
P-181	-5.2212 -0.1002 -0.3712 -1.8204 -0.0455 -0.0900 -0.6869 -0.1319 -2.0690 -0.4414 -1.6478 -1.4630 -2.0705 -0.7597 -0.5177 -0.3440 -0.8068 -3.5490 -0.4910 -0.1819 -0.1565 -0.0556 -0.2797 -2.6458 -0.5363 -3.8105 -0.1012 -0.2974 -5.8810 -0.8519 -0.2724
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients ; heart failure ; outcomes ; exercise ; training ; hf-action ; exercise ; perceived social support score ; psss ; barriers to exercise score ; btes
H-1927	-0.9216620922088623	▁Heart ▁Fail ure ▁; ▁control led ▁tri al ▁Investiga ting ▁Out com es ▁of ▁Exerci se ▁Training ▁; HF - ac tion ▁; ▁social ▁support ▁; ▁barrier s ▁to ▁exercise ▁; ▁social ▁support ▁score ▁; ▁p s s ▁; ▁barrier s ▁to ▁exercise ▁score ▁; ▁b tes
D-1927	-0.9216620922088623	Heart Failure ; controlled trial Investigating Outcomes of Exercise Training ;HF-action ; social support ; barriers to exercise ; social support score ; pss ; barriers to exercise score ; btes
P-1927	-2.6656 -0.3781 -1.3127 -0.2749 -4.5607 -0.5830 -0.1310 -0.1252 -1.3203 -1.0447 -0.8967 -0.3685 -0.1958 -0.7584 -0.7484 -0.8418 -0.7049 -0.3389 -2.9646 -0.1614 -0.8886 -2.7939 -0.3888 -1.8653 -0.6975 -0.2726 -1.3784 -0.2690 -1.6687 -1.4578 -0.4086 -1.5294 -1.0397 -0.2308 -0.2805 -1.0659 -0.8148 -0.1625 -0.3022 -1.0384 -0.2548 -1.1311 -1.5779 -0.4179 -0.2954 -1.4087 -0.5615 -0.3609 -0.2245
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable analysis ; st2 ; death ; hospitalization ; hazard ratio ; cardiovascular death ; hf ; hospitalization ; hazard ratio ; all-cause mortality ; hazard ratio ; hazard ratios
H-703	-1.1231790781021118	▁ST 2 ▁; ▁death ▁; ▁hospital ization ▁; haz ard ▁ratio ▁; ▁cardiovascular ▁death ▁; ▁ HF ▁; ▁hospital ization ▁; haz ard ▁ratio ▁; ▁mortal iteit ▁; haz ard ▁ratio
D-703	-1.1231790781021118	ST2 ; death ; hospitalization ;hazard ratio ; cardiovascular death ; HF ; hospitalization ;hazard ratio ; mortaliteit ;hazard ratio
P-703	-1.6728 -0.3525 -0.3409 -5.2237 -0.3224 -0.4714 -1.9389 -0.3027 -1.7384 -0.6127 -0.4060 -0.3908 -0.4666 -1.5320 -0.2860 -1.3963 -1.7432 -1.4875 -0.4451 -1.9259 -0.2895 -2.5030 -0.9778 -0.3394 -0.3784 -0.3934 -2.3291 -0.3505 -2.1972 -1.1781 -0.3248 -2.3681 -0.3798
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients ; new york heart association class i ; fontan ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dxa ; calf ; muscle ; magnetic resonance spectroscopy ; healthy
H-1495	-0.7099983096122742	▁New ▁York ▁Heart ▁association ▁; ▁Font an ▁; ▁cardio pul mon ary ▁exercise ▁; ▁lean ▁mass ▁quant ification ▁; ▁dual ▁x - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁cal f ▁muscle ▁; ▁magnetic ▁res on ance ▁spec tros copy
D-1495	-0.7099983096122742	New York Heart association ; Fontan ; cardiopulmonary exercise ; lean mass quantification ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
P-1495	-1.5861 -2.3791 -3.0984 -0.3394 -0.2802 -0.3181 -0.0767 -0.4825 -0.1427 -1.0844 -2.0328 -1.6193 -0.7333 -1.8800 -0.1516 -0.2912 -0.5983 -0.7453 -0.3080 -0.1907 -0.5129 -0.2015 -0.5496 -0.0236 -0.6246 -0.9375 -0.7673 -1.5157 -0.2934 -0.2485 -1.8960 -0.3103 -0.1957 -0.0650 -0.5401 -0.2723 -0.3770 -0.5891 -0.7061 -0.2655 -0.2372 -0.0944 -1.5628 -0.5394 -0.2863
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo ; dopamine ; nesiritide ; bolus ; diuretic ; therapy ; renal function ; patients ; acute heart failure ; renal dysfunction
H-73	-0.4300624430179596	▁place bo ▁; ▁dop amine ▁; ▁nesi riti de ▁; ▁di ure tic ▁ therapy ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
D-73	-0.4300624430179596	placebo ; dopamine ; nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
P-73	-1.9745 -0.0919 -0.3133 -0.0417 -0.2515 -0.3997 -0.9978 -0.1640 -0.3074 -0.4329 -0.8421 -0.6048 -0.9323 -0.3889 -0.1669 -0.3317 -0.1504 -0.4922 -0.3422 -0.6621 -0.1326 -0.6941 -0.2588 -0.2844 -0.1088 -0.1874 -0.2782 -0.3965 -0.2426
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized ; crt ; patients ; new york heart association class iii ; heart failure ; left ventricular ejection fraction ; qrs duration ; echocardiographic ; evidence ; left ventricular dyssynchrony
H-847	-0.869888424873352	▁c RT ▁; ▁New ▁York ▁Heart ▁association ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁QR s ▁; ▁e cho car dio graphic ▁; ▁left ▁vent ri cular ▁dys syn chron y
D-847	-0.869888424873352	cRT ; New York Heart association ; heart failure ; left ventricular ejection fraction ; QRs ; echocardiographic ; left ventricular dyssynchrony
P-847	-0.5303 -3.3594 -0.2888 -1.8905 -1.8867 -2.2454 -0.3593 -0.3192 -2.7207 -0.8985 -0.3007 -0.9113 -0.9523 -2.7127 -0.6715 -0.3942 -0.3830 -0.1737 -0.8334 -0.0394 -0.3244 -0.2345 -0.8277 -0.2606 -0.5731 -0.2512 -0.1023 -0.5036 -1.0231 -0.4309 -1.1466 -0.6616 -3.0434 -0.9197 -0.0434 -0.1353 -0.0073 -1.7085 -0.4442 -0.2832
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients ; left ventricular ; ejection fraction ; stable hf ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
H-482	-0.4934495985507965	▁left ▁vent ri cular ▁; ▁v n ▁; ▁e je ction ▁ fraction ▁; HF ▁; ▁right - side d ▁cardiac ▁cat heter ization ▁; ▁trans t hora cic ▁e cho card i ography ▁; ▁transmit ral ▁flow ▁veloci ties ▁; ▁mit ral ▁ann ulus ▁veloci ties ▁; ▁sy stol e ▁; ▁dia stol e
D-482	-0.4934495985507965	left ventricular ; vn ; ejection fraction ;HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
P-482	-0.3561 -0.2378 -1.4489 -0.3514 -0.3300 -1.6516 -0.6308 -0.2826 -0.2638 -0.3058 -0.1238 -0.3278 -0.0262 -0.3224 -3.7912 -0.3088 -1.5696 -0.2036 -0.7674 -0.2410 -0.0924 -0.5034 -0.0538 -1.7689 -0.3916 -0.0107 -0.2423 -0.2384 -0.3560 -0.3143 -0.6181 -0.4140 -0.3169 -0.3724 -0.3150 -0.1234 -0.8274 -0.4113 -0.7318 -0.2342 -0.3037 -0.4698 -0.2804 -0.5885 -0.2885 -1.1240 -0.2051 -0.2740 -0.7421 -0.5234 -0.2259 -0.2511 -0.0143 -0.1360 -0.1844 -0.3800 -0.2584
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients ; acute coronary syndromes ; patients ; stable ; cad ; bnp ; nt-probnp ; cad ; prognostic ; clinical ; outcome
H-1367	-0.8330675959587097	▁a cute ▁corona ry ▁syndrome s ▁; ▁CAD ▁; ▁b NP ▁; ▁NT - pro b NP ▁; ▁CAD
D-1367	-0.8330675959587097	acute coronary syndromes ; CAD ; bNP ; NT-probNP ; CAD
P-1367	-0.2458 -0.2207 -0.2207 -2.7933 -0.0144 -0.4031 -0.4235 -1.1532 -0.4801 -1.2253 -2.6341 -0.3888 -0.4149 -0.2401 -0.0633 -1.5400 -2.2951 -0.6846 -1.4091 -0.3367 -0.3074
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline ; patients ; hf ; lyso-paf-at ; paf-cpt ; paf ; paf-ah ; lp-pla2
H-1269	-1.145838737487793	HF ▁; ▁lys o - pa f - at ▁; ▁PA f - c p ▁; ▁PA f ▁; ▁PA f - AH ▁; ▁l p - PLA 2
D-1269	-1.145838737487793	HF ; lyso-paf-at ; PAf-cp ; PAf ; PAf-AH ; lp-PLA2
P-1269	-3.9157 -0.4609 -0.5418 -0.3177 -0.1429 -0.7660 -2.2665 -0.3317 -1.5159 -0.3597 -1.8827 -2.5330 -0.1881 -1.4704 -2.5088 -0.3970 -2.0511 -2.5481 -1.1663 -2.1405 -2.1467 -0.4109 -3.8591 -0.3895 -0.0478 -0.0510 -0.1900 -0.0875 -0.0837 -0.4380 -0.3122
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical therapy ; patients ; redo sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; patients ; transcatheter aortic valve procedure ; surgery ; aortic valve
H-549	-0.8264628648757935	▁ster no to my ▁; ▁a or tic ▁val ve ▁; ▁bio pro sthetic ▁val ve ▁replace ment ▁; ▁da cro n ▁patch ▁ closure ▁; ▁a or tic ▁val ve ▁; ▁trans cat heter ▁; ▁a or tic ▁val ve ▁; ▁open ▁surgery ▁; ▁a or tic ▁val ve ▁replace ment
D-549	-0.8264628648757935	sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; transcatheter ; aortic valve ; open surgery ; aortic valve replacement
P-549	-1.8219 -0.1930 -0.2373 -0.8703 -0.3008 -0.2899 -0.1936 -2.7322 -1.9846 -0.8530 -0.6215 -0.0276 -0.4106 -0.2877 -1.3246 -0.5594 -2.3491 -1.7730 -0.3358 -0.1913 -0.0338 -0.0868 -0.0569 -0.1470 -0.0201 -0.3712 -0.3126 -0.2210 -2.6404 -1.7151 -1.2289 -1.4328 -0.0359 -0.5056 -0.1166 -0.5062 -0.2842 -0.1655 -3.0226 -2.0039 -1.1709 -1.0111 -0.2517 -0.3520 -0.2945 -0.4308 -0.1654 -2.5849 -1.4839 -1.1219 -0.9559 -1.7754 -0.4794 -0.2866
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma n-terminal pro-b-type natriuretic peptide ; nt-probnp ; patients ; acute heart failure ; hf ; admission ; emergency department
H-263	-0.7857533693313599	▁plasma ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁n - pro b NP ▁; ▁a cute ▁heart ▁failure ▁; HF ▁; ▁emergency ▁department ▁; ▁d c
D-263	-0.7857533693313599	plasma ; n-terminal pro-b-type natriuretic peptide ; n-probNP ; acute heart failure ;HF ; emergency department ; dc
P-263	-2.3292 -0.3538 -2.8153 -0.1011 -0.6787 -0.0862 -0.3571 -0.0621 -1.1869 -0.2057 -0.0094 -0.0161 -0.9703 -0.7643 -1.2734 -0.5707 -0.1987 -0.3926 -0.2934 -1.6488 -0.0617 -0.0973 -1.6796 -2.1255 -0.3229 -1.4248 -0.3093 -1.0968 -0.3447 -0.2664 -1.7859 -0.2868 -0.3654 -0.1584 -0.2213 -0.9997 -4.1327 -0.3682 -0.2830
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac troponin t ; ctnt ; n-terminal pro-b-type natriuretic peptide ; nt-probnp ; biomarkers ; hf ; hf ; atherosclerosis risk in communities ; aric
H-286	-0.7161322832107544	▁cardiac ▁trop onin ▁t ▁; ▁c t n t ▁; ▁high - sensitiv iteit ▁as say ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁n - pro b NP ▁; ▁bio mark ers ▁; ▁ HF ▁; ▁ HF ▁; ▁Ath eros cle rosi s ▁Risk ▁in ▁Communi ties ▁; ARI c
D-286	-0.7161322832107544	cardiac troponin t ; ctnt ; high-sensitiviteit assay ; n-terminal pro-b-type natriuretic peptide ; n-probNP ; biomarkers ; HF ; HF ; Atherosclerosis Risk in Communities ;ARIc
P-286	-0.2873 -0.0981 -0.3250 -0.5758 -0.3898 -0.2632 -0.0447 -0.0540 -0.3288 -0.2517 -1.5704 -0.0527 -0.0040 -1.6165 -0.1358 -0.5125 -0.2681 -1.4339 -0.0389 -1.7229 -0.0909 -2.2296 -0.0572 -1.5429 -0.3167 -0.0095 -0.0104 -0.7136 -0.5402 -1.1052 -0.3393 -0.2327 -0.6535 -0.3141 -1.1569 -0.0500 -0.0926 -1.6850 -2.0612 -0.3387 -0.0571 -0.2548 -0.7233 -0.3336 -3.1100 -1.8607 -0.2699 -2.3743 -1.4934 -0.3210 -1.2046 -0.3563 -0.6734 -0.4375 -0.2267 -0.5928 -0.6099 -0.7788 -0.2773 -0.2469 -3.4401 -2.1179 -0.3035 -0.2544
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body mass index ; fat mass ; fat-free mass
H-1167	-0.8145232200622559	▁body ▁mass ▁index ▁; HR ▁; ▁fat ▁mass ▁; ▁fat - free ▁mass ▁index
D-1167	-0.8145232200622559	body mass index ;HR ; fat mass ; fat-free mass index
P-1167	-3.2796 -0.6335 -0.1190 -0.4095 -2.6063 -0.4905 -1.6285 -0.4865 -0.4384 -0.8279 -0.3716 -0.6057 -0.2942 -0.2276 -0.3092 -0.3042
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile range ; body mass index ; interquartile range ; copd ; chf ; crf
H-797	-0.8418956398963928	▁inter quart ile ▁range ▁; ▁body ▁mass ▁index ▁; ▁inter quart ile ▁range ▁; ▁COP d ▁; ▁CHF ▁; ▁c RF
D-797	-0.8418956398963928	interquartile range ; body mass index ; interquartile range ; COPd ; CHF ; cRF
P-797	-1.6823 -0.5414 -0.3218 -0.0276 -0.4865 -2.4975 -0.1448 -0.0441 -0.4852 -1.4016 -0.4777 -0.3906 -0.0244 -0.5369 -1.6044 -1.3594 -0.5320 -0.4836 -0.4422 -1.4263 -3.6705 -0.4269 -0.3557
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse remodeling ; ejection fraction ; mortality ; all-cause hospitalizations ; hf ; hospitalizations ; dialysis ; patients
H-911	-0.614946186542511	▁rever se ▁remodel ing ▁; ▁e je ction ▁ fraction ▁; ▁mortal iteit ▁; ▁all - ca use ▁hospital ization s ▁; HF ▁; ▁di al ysis ▁patients
D-911	-0.614946186542511	reverse remodeling ; ejection fraction ; mortaliteit ; all-cause hospitalizations ;HF ; dialysis patients
P-911	-0.3652 -0.1863 -0.1226 -0.1782 -0.4308 -0.1402 -0.4337 -0.1332 -0.3625 -0.0481 -0.4314 -0.3086 -1.8998 -0.4522 -0.8068 -0.1759 -0.2090 -1.5172 -0.3821 -1.6627 -0.5001 -0.4772 -3.0290 -0.4603 -1.0129 -0.0742 -0.0661 -1.8123 -0.4404 -0.3296
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates ; lv contractility ; lvef ; β coefficient ; confidence interval ; systolic blood pressure ; end-systolic volume ; β coefficient
H-1530	-1.1241720914840698	▁eh ▁; ▁LV ▁contract ility ▁; ▁CH ▁; ▁LV EF ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁end - sy sto lic ▁volume ▁; β ▁co e ffi cient ▁; ▁h g
D-1530	-1.1241720914840698	eh ; LV contractility ; CH ; LVEF ; systolic blood pressure ; end-systolic volume ;β coefficient ; hg
P-1530	-0.2665 -0.2020 -2.1372 -0.0566 -0.4748 -0.3474 -5.5676 -0.4857 -2.4484 -1.9513 -0.3619 -7.0983 -0.3121 -0.2097 -1.2380 -1.6077 -0.4302 -3.0722 -0.1972 -1.4312 -1.0309 -0.4738 -0.6351 -0.4264 -1.5767 -0.1879 -0.4139 -0.1858 -0.9938 -0.5967 -0.9042 -0.2507 -0.3597 -0.2904
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography ; dilated lv ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mva
H-348	-0.7361515164375305	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁m l ▁; ▁m 2 ▁; ▁LV ▁; ▁e je ction ▁ fraction ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁significant ▁MS ▁; ▁m va ▁; ▁mean ▁pressure ▁gradi ent ▁; ▁h g
D-348	-0.7361515164375305	echocardiography ; LV ; end-diastolic volume index ; ml ; m2 ; LV ; ejection fraction ; MR ; mitral valve opening ; significant MS ; mva ; mean pressure gradient ; hg
P-348	-1.1497 -0.4050 -0.2272 -0.4690 -0.3435 -0.4252 -2.1477 -0.3774 -2.1322 -0.1217 -0.0071 -0.1767 -0.0966 -0.2259 -0.1165 -0.3511 -0.0523 -4.3992 -0.6004 -0.2518 -0.1952 -0.3544 -3.2026 -0.3063 -0.1828 -0.3627 -0.1902 -0.3831 -0.0268 -0.4001 -1.3441 -0.4257 -0.6977 -0.1051 -0.2807 -0.4577 -0.8762 -0.3400 -0.0234 -2.3803 -0.3544 -0.2609 -4.9914 -0.3955 -2.7916 -0.7530 -0.0385 -1.0937 -0.4269 -0.3168 -0.3416 -0.3834 -0.2569
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind ; clinical ; renal optimization strategies evaluation ; rose ; hospitalized ; patients ; acute heart failure ; renal dysfunction ; estimated glomerular filtration rate ; randomized ; admission
H-74	-0.8757573366165161	▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ROS e
D-74	-0.8757573366165161	acute heart failure ; renal dysfunction ; glomerular filtration rate ;ROSe
P-74	-5.6805 -0.1774 -0.9655 -0.2867 -0.2629 -0.3010 -0.1238 -0.1636 -0.3518 -3.8201 -0.3022 -0.0806 -0.0894 -1.7192 -0.4757 -0.4805 -0.9579 -0.1023 -0.8496 -0.3244
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets ; signal transduction ; pol ii ; transcription factor ; hf ; pathogenesis ; nuclear factor of activated t cells ; nfat ; nuclear factor-κb ; nf-κb ; transcription factor ; gata4
H-1051	-0.7372236847877502	▁molecular ▁analysis ▁; ▁bet s ▁; ▁chr omat in - media ted ▁signal ▁trans duction ▁; ▁Pol ▁II ▁; ▁co - activa ting ▁tran scription ▁factor ▁; ▁ HF ▁path ogen es is ▁; ▁nuclear ▁factor ▁of ▁activa ted ▁t ▁cell s ▁; ▁n FAT ▁; ▁nuclear ▁factor - κ b ▁; NF - κ b ▁; ▁tran scription ▁factor ▁; ▁g ATA 4
D-1051	-0.7372236847877502	molecular analysis ; bets ; chromatin-mediated signal transduction ; Pol II ; co-activating transcription factor ; HF pathogenesis ; nuclear factor of activated t cells ; nFAT ; nuclear factor-κb ;NF-κb ; transcription factor ; gATA4
P-1051	-1.3876 -1.2293 -0.3935 -1.4466 -0.3253 -0.3677 -0.1765 -0.0340 -0.5264 -0.2701 -0.0638 -0.8828 -0.3573 -0.0207 -0.6368 -0.3444 -0.9572 -0.9057 -0.4100 -0.1117 -0.0797 -0.0285 -0.9904 -0.1527 -0.2333 -0.5250 -0.9693 -3.0833 -2.3861 -0.7948 -0.5200 -0.1221 -0.2670 -0.3427 -0.5521 -0.9362 -1.9524 -0.0186 -1.0884 -1.7230 -0.2866 -0.5761 -0.3354 -1.8976 -1.4512 -0.3601 -0.8883 -1.3014 -0.6272 -1.3642 -0.9105 -0.2710 -2.3264 -0.2197 -1.1300 -0.5738 -0.2668 -0.2653 -0.3944 -0.8732 -0.4317 -2.2887 -1.1479 -0.3014 -0.3320 -0.2227
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes ; mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
H-33	-0.7764924764633179	▁mortal iteit ▁; ▁hospital ization ▁; ▁exercise ▁ tolerance ▁; ▁cardiovascular ▁events ▁; ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁ex ace rb ation ▁; ▁ar rhythm ia ▁; ▁cardiac ▁death ▁; ▁hyper tension ▁; ▁ve nous ▁ thro mbo e mbol ic ▁events ▁; ▁ ische mic ▁cerebro vas cular ▁events
D-33	-0.7764924764633179	mortaliteit ; hospitalization ; exercise tolerance ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
P-33	-4.7853 -2.2184 -0.2516 -3.2489 -0.8000 -0.2204 -0.3513 -0.2486 -0.0166 -0.2722 -0.4674 -0.8752 -0.2856 -1.9312 -0.2225 -0.4051 -1.3127 -0.1238 -0.4155 -0.7146 -0.3237 -0.2357 -0.8471 -3.0012 -0.9003 -0.3597 -4.1003 -0.1037 -0.0920 -1.3090 -0.2447 -0.0836 -0.4709 -1.9452 -0.2293 -0.1767 -1.0848 -0.3064 -0.5606 -0.2012 -0.2876 -2.2060 -0.7722 -0.2468 -0.1200 -1.7555 -0.1844 -0.0926 -0.6077 -0.6246 -0.2796 -0.6864 -0.0365 -0.5442 -0.1129 -0.1619 -0.5445 -0.8989 -0.4412 -0.2427
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular mortality ; multivariable adjustment ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-562	-0.9249775409698486	▁cardiovascular ▁mortal iteit ▁; ▁hazard ▁ratio
D-562	-0.9249775409698486	cardiovascular mortaliteit ; hazard ratio
P-562	-0.4023 -0.3204 -2.3816 -0.4439 -1.5518 -0.3260 -1.6693 -0.3046
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus ; diabetes ; patients ; diabetes ; peak vo2 ; patients ; diabetes ; eo-cfus ; peak vo2
H-128	-1.3019436597824097	▁ EO - c FU s ▁; ▁diabetes ▁; ▁diabetes ▁; EO - c FU ▁; ▁VO 2 ▁; ▁diabetes ▁; ▁ EO - c FU s ▁; ▁VO 2
D-128	-1.3019436597824097	EO-cFUs ; diabetes ; diabetes ;EO-cFU ; VO2 ; diabetes ; EO-cFUs ; VO2
P-128	-3.3557 -2.5101 -0.1330 -1.0922 -3.4044 -0.4175 -0.3868 -0.4481 -0.4030 -0.9740 -0.4194 -5.0056 -0.2582 -1.5156 -3.3508 -0.4397 -1.6173 -0.3451 -0.4120 -0.9778 -0.3386 -2.7361 -2.8474 -0.1916 -1.3439 -3.5784 -0.5410 -0.2905 -1.3771 -0.3162 -0.3559 -0.2789
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting ; video edge detection ; epifluorescence microscopy ; myocardial tissues ; cardiomyocytes ; hf
H-1212	-0.6471324563026428	▁immun o blo tting ▁; ▁radio en zy matic - ▁; ▁fluor esc ence ▁res on ance ▁; ▁energy ▁transfer - based ▁as say s ▁; ▁video ▁edge ▁det ection ▁; ▁epi flu o resc ence ▁micro s copy ▁; ▁l - type ▁ca 2 ▁; ▁my o card ial ▁tissu es ▁; ▁cardio my o cy tes ▁; ▁h b
D-1212	-0.6471324563026428	immunoblotting ; radioenzymatic- ; fluorescence resonance ; energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; l-type ca2 ; myocardial tissues ; cardiomyocytes ; hb
P-1212	-0.2043 -0.3074 -0.0556 -1.8817 -0.2573 -0.9783 -0.8101 -0.2718 -0.4258 -0.7592 -2.1292 -0.1484 -1.6382 -2.9674 -0.2189 -0.1849 -0.5435 -0.5159 -0.7500 -0.4171 -0.1814 -0.0616 -0.1626 -0.8461 -0.4775 -0.2729 -1.6489 -0.1656 -0.4433 -1.4575 -0.2817 -0.1488 -0.0492 -0.2029 -0.6226 -3.5703 -0.0604 -0.4227 -1.1656 -0.3258 -0.3111 -0.0988 -0.0070 -0.3073 -0.1303 -0.2759 -1.4059 -0.1372 -0.9191 -1.6610 -0.0976 -0.3561 -0.3241 -0.0661 -1.0501 -0.1854 -0.3466 -0.2728 -0.2625 -1.0415 -2.8119 -0.4195 -0.2494
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east ; early treatment of atrial fibrillation for stroke prevention trial ; randomize ; patients ; stroke ; rhythm control therapy ; prospective ; randomized ; outcome
H-1649	-0.9630686044692993	▁e ast ▁; ▁At rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention ▁tri al ▁; ▁AF ▁; ▁stroke ▁; cha 2 d 2 VAS c ▁; ▁early ▁ rhythm ▁control ▁ therapy
D-1649	-0.9630686044692993	east ; Atrial fibrillation ; Stroke prevention trial ; AF ; stroke ;cha2d2VASc ; early rhythm control therapy
P-1649	-0.7894 -1.6126 -0.3071 -3.8297 -0.0897 -0.6413 -0.1222 -0.4943 -0.2709 -1.7491 -1.4489 -1.5078 -0.1867 -0.5468 -0.1219 -0.4231 -0.5004 -0.2806 -0.3956 -0.2653 -3.6414 -0.2254 -3.2080 -0.2658 -1.0927 -0.2383 -1.0855 -4.2723 -0.2858 -0.4752 -0.8539 -0.9020 -0.1151 -1.1796 -0.2830
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes ; exercise capacity ; peak oxygen consumption ; vo2 ; co-primary outcome ; qol ; minnesota ; heart failure ; heart ; qol ; co-primary outcome
H-1980	-1.2156529426574707	▁Exerci se ▁capacity ▁; ▁oxygen ▁consum p tion ▁; ▁v 2 ▁; ▁Q OL ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁; ▁m w t ▁; ▁Question naire ▁; ▁heart ▁failure - related ▁Q OL
D-1980	-1.2156529426574707	Exercise capacity ; oxygen consumption ; v2 ; QOL ; Minnesota Living with Heart Failure ; mwt ; Questionnaire ; heart failure-related QOL
P-1980	-1.7959 -0.5425 -0.3277 -0.3122 -1.1615 -0.7038 -0.2243 -1.1744 -0.4111 -1.0304 -1.2521 -0.3848 -4.6143 -2.4941 -0.3011 -0.4380 -0.8732 -1.2051 -0.8550 -1.0394 -3.6463 -0.3048 -0.6526 -5.4891 -1.0609 -0.3525 -3.0777 -0.0636 -0.3991 -2.4891 -0.7000 -0.3540 -0.2602 -1.9210 -2.4870 -0.3227 -0.2575
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic ; mitochondrial-targeted peptide ; ss31 ; mitochondrial function ; tac ; clinical ; mitochondrial-targeted peptide ; drugs ; heart failure
H-878	-1.1569669246673584	▁prote om ic ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁; ▁SS 31 ▁; ▁mito cho ndri al ▁function ▁; ▁up stream ▁signal ▁; ▁ TAC ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁; ▁drugs ▁; ▁heart ▁failure
D-878	-1.1569669246673584	proteomic ; mitochondrial-targeted peptide ; SS31 ; mitochondrial function ; upstream signal ; TAC ; mitochondrial-targeted peptide ; drugs ; heart failure
P-878	-0.6566 -0.6361 -0.2712 -1.2574 -0.6079 -3.5376 -1.8767 -0.3510 -0.5132 -2.8781 -2.8737 -0.5819 -2.0117 -0.4869 -0.8208 -0.6402 -0.5283 -0.5456 -0.3123 -0.3888 -1.4644 -0.8508 -0.2209 -0.1508 -0.3006 -4.9386 -0.1340 -1.3663 -0.2783 -1.3155 -1.6138 -0.3048 -0.3194 -2.5661 -2.7684 -0.6491 -0.5309 -2.9969 -3.4520 -0.6740 -3.2487 -0.7699 -1.0536 -0.5167 -0.1980 -0.2494 -2.1133 -0.4725 -0.3203 -0.2345
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients ; left ventricular ejection fraction ; patients ; hf ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient ; epidemic ; medical ; financial costs
H-55	-1.2407476902008057	▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; HF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁hospital ▁; ▁physician s ▁; ▁in patient ▁setting s ▁; ▁financiële ▁kosten
D-55	-1.2407476902008057	low left ventricular ejection fraction ;HF ; left ventricular ejection fraction ; hospital ; physicians ; inpatient settings ; financiële kosten
P-55	-2.9077 -2.3603 -1.2572 -3.1794 -2.2008 -0.8660 -0.9751 -0.5570 -0.8190 -0.1399 -0.3153 -2.6196 -0.3006 -2.6843 -0.8968 -3.3022 -1.6871 -0.9198 -1.1936 -0.7621 -0.7777 -0.1623 -0.3352 -0.9962 -0.6516 -1.0908 -0.3119 -0.4389 -4.8933 -0.4673 -0.7188 -0.1826 -0.3853 -1.5724 -2.4397 -0.3067 -0.2334
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf ; patients ; hfref ; left ventricular ; ejection fraction ; hfpef ; echo-doppler ; n-terminal pro-brain-type natriuretic peptide ; adverse events
H-494	-0.8608762621879578	▁ HF ▁; HF r EF ▁; ▁left ▁vent ri cular ▁; ▁v n ▁; ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁e cho - d opp ler ▁studies ▁; ▁pro - bra in - type ▁na tri ure tic ▁pe pti de ▁assessment
D-494	-0.8608762621879578	HF ;HFrEF ; left ventricular ; vn ; ejection fraction ;HFpEF ; echo-doppler studies ; pro-brain-type natriuretic peptide assessment
P-494	-1.8395 -1.5956 -0.3536 -1.3107 -0.8132 -1.2100 -0.3313 -1.7434 -0.2189 -1.7942 -0.7052 -0.4281 -2.1371 -1.0969 -0.3894 -0.1665 -0.4382 -0.1781 -0.3687 -0.0385 -0.3510 -2.4471 -0.5172 -2.1706 -0.3393 -0.6465 -0.7641 -0.1061 -1.4618 -0.1735 -1.1175 -0.9109 -0.3840 -1.7386 -0.1951 -1.7179 -0.3898 -0.3589 -0.0194 -0.0641 -0.9719 -1.5000 -3.0067 -1.3052 -0.1426 -0.5776 -0.7642 -0.6135 -0.2706
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds ; comorbidities ; hospitalized ; adjusted odds ratio ; aor ; confidence interval ; eds ; aor
H-464	-0.8741929531097412	▁low - volu me ▁ED s ▁; ▁hospital ized ▁; ▁a OR ▁; ▁high - volu me ▁ED s ▁; ▁a OR
D-464	-0.8741929531097412	low-volume EDs ; hospitalized ; aOR ; high-volume EDs ; aOR
P-464	-1.4160 -0.2087 -0.2776 -0.6913 -1.7614 -0.3229 -0.3193 -0.9649 -0.4533 -0.4326 -2.5368 -0.4628 -0.4626 -3.0076 -0.2554 -0.4434 -0.6365 -1.8107 -0.3439 -0.5157 -2.2459 -0.7037 -0.4282 -0.2795
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients ; cardiac transplant ; ecct ; patients ; diabetes mellitus ; chronic kidney disease ; estimated glomerular filtration rate
H-715	-0.7024959325790405	▁cardiac ▁transplant ▁; ▁ec t ▁; ▁diabetes ▁mell itus ▁; ▁chronic ▁ki dne y ▁disease ▁; ▁glo mer ular ▁filtr ation ▁rate
D-715	-0.7024959325790405	cardiac transplant ; ect ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
P-715	-0.3089 -0.2223 -0.4904 -0.3095 -1.9714 -0.3399 -0.2746 -0.0059 -0.0990 -0.4001 -0.6559 -0.0967 -1.6129 -0.5428 -0.8091 -0.4273 -0.5594 -0.3086 -0.1147 -0.0836 -2.2929 -2.1385 -2.4502 -0.3452
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc battery ; health abc hf risk model ; change ; c-index ; net-reclassification-improvement ; hf
H-631	-0.9798946976661682	▁h bc ▁Bat tery ▁score s ▁; ▁Health ▁ABC ▁; HF ▁Risk ▁model ▁; ▁discrimina tion ▁; ▁c - index ▁; ▁ HF
D-631	-0.9798946976661682	hbc Battery scores ; Health ABC ;HF Risk model ; discrimination ; c-index ; HF
P-631	-2.1075 -2.3684 -0.4665 -0.1144 -1.6857 -0.2388 -0.2581 -1.6286 -0.5315 -1.0138 -2.1783 -0.8671 -1.3530 -0.3020 -0.0645 -2.3839 -0.3336 -0.5021 -0.2696 -0.0070 -0.3384 -1.2178 -3.5371 -0.4104 -0.3190
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi ; rmsea ; self-care maintenance ; cfi ; rmsea ; self-care management ; cfi ; rmsea ; self-care confidence
H-1507	-1.3273874521255493	▁c fi ▁; ▁RM se a ▁; ▁Self - car e ▁Main ten ance ▁Scal e ▁; ▁c fi ▁; ▁RM se a ▁; ▁Self - car e ▁management ▁Scal e ▁; ▁c fi ▁; ▁Self - car e ▁Confi den ce ▁scale
D-1507	-1.3273874521255493	cfi ; RMsea ; Self-care Maintenance Scale ; cfi ; RMsea ; Self-care management Scale ; cfi ; Self-care Confidence scale
P-1507	-1.1428 -5.9460 -0.2690 -2.1061 -2.1596 -1.2601 -0.2672 -0.2297 -0.1443 -2.5323 -0.6020 -3.4743 -1.7679 -0.9147 -0.3066 -0.1578 -0.3714 -1.1747 -5.6675 -0.3003 -2.6197 -2.2295 -1.0977 -0.2641 -0.1673 -0.1277 -2.0028 -0.4504 -0.6483 -0.3085 -0.1196 -0.3532 -1.5639 -6.1455 -0.2633 -2.5485 -0.1284 -1.7045 -0.4673 -2.0193 -0.3436 -2.0956 -0.6301 -0.3474 -0.2917
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients ; bat ; patients ; quality-of-life ; nyha functional class ; change
H-1876	-0.8414735198020935	▁BAT ▁; ▁quality - of - life ▁score ▁; ▁w ha ▁; ▁functional ▁class ▁ranking
D-1876	-0.8414735198020935	BAT ; quality-of-life score ; wha ; functional class ranking
P-1876	-0.2807 -0.4079 -1.1517 -0.2971 -0.0808 -0.6122 -1.0209 -1.1237 -0.4488 -4.6902 -1.5361 -0.5688 -0.0975 -0.2193 -0.9698 -0.4552 -0.3444
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients ; preoperative ; hypoalbuminemia ; postoperative ; albumin ; hypoalbuminemia ; albumin ; lvad
H-537	-0.7455935478210449	▁hypo album in emia ▁; ▁post operativ e ▁; ▁album in ▁levels ▁; ▁hypo album in emia ▁; ▁album in ▁levels ▁; ▁l VAD
D-537	-0.7455935478210449	hypoalbuminemia ; postoperative ; albumin levels ; hypoalbuminemia ; albumin levels ; lVAD
P-537	-0.5190 -1.0928 -0.6779 -1.4350 -0.3720 -1.6767 -0.7053 -0.1532 -1.5126 -1.3092 -0.6837 -0.5512 -0.3451 -0.3121 -0.7690 -0.5637 -1.7162 -0.3766 -1.5080 -0.6382 -0.7786 -0.3083 -0.4022 -0.3061 -0.3835 -0.2894
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization ; confidence interval ; acute myocardial infarction ; ami ; complications ; kidney infection ; urinary tract infection ; uti ; complications
H-1717	-0.7459972500801086	▁re hospital ization ▁; ▁cm ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁ki dne y ▁infection ▁; ▁urin ary ▁tract ▁infection ▁; UTI
D-1717	-0.7459972500801086	rehospitalization ; cm ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
P-1717	-1.4881 -0.0589 -1.8322 -0.3381 -4.2117 -0.4819 -0.8822 -0.1865 -1.7437 -0.2251 -0.4519 -0.8412 -0.1077 -0.3838 -0.9407 -0.3102 -1.1080 -0.2951 -1.4411 -0.9854 -0.2509 -1.2383 -0.2894 -0.1028 -0.7664 -0.4604 -0.4456 -0.2425 -0.3694 -0.3489 -0.2979
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients ; heart failure ; hf ; ischemic ; nonischemic cardiomyopathies ; pharmacological ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; right ventricular assist devices
H-54	-0.49999308586120605	▁heart ▁failure ▁; HF ▁; ▁ ische mic ▁; ▁non ische mic ▁cardio my o pathi es ▁; ▁ pharma c ological ▁arma ment arium ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cardiac ▁transplant ation ▁; ▁left ▁; ▁right ▁vent ri cular ▁assist ▁devices
D-54	-0.49999308586120605	heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; left ; right ventricular assist devices
P-54	-5.3789 -0.2694 -0.2529 -1.1862 -0.2277 -0.7108 -0.1570 -0.2791 -0.6661 -0.8378 -0.1029 -0.5670 -0.1877 -0.5830 -0.2787 -0.0413 -0.2237 -0.3415 -1.6022 -0.4415 -0.1910 -0.6370 -0.1863 -0.1007 -0.0049 -0.3386 -1.8049 -0.1471 -0.5014 -0.1317 -0.4473 -0.2420 -0.0883 -0.5305 -0.1279 -0.2872 -0.3769 -0.1585 -0.1357 -0.0607 -0.0133 -0.8357 -0.6464 -0.0483 -0.3346 -0.2166 -0.0508 -1.0947 -0.2692 -0.5605 -0.3735 -1.0478 -0.2027 -1.1902 -0.2503 -0.4457 -0.4747 -0.3536 -0.2571
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf ; catheterization ; central venous pressure ; svr ; cardiac index
H-230	-1.3801201581954956	SAF ▁; ▁ PF ▁; ▁cat heter ization ▁; ▁centrale ▁ve nous ▁pressure ▁; ▁h g ▁; ▁ rv ▁index ▁; ▁dyn ▁; ▁cardiac ▁index
D-230	-1.3801201581954956	SAF ; PF ; catheterization ; centrale venous pressure ; hg ; rv index ; dyn ; cardiac index
P-230	-0.6423 -0.4827 -3.5248 -1.0710 -0.4689 -4.5320 -0.3140 -2.0061 -0.6808 -1.7792 -3.2312 -0.6382 -0.9037 -0.6236 -1.0572 -0.6060 -0.5194 -4.1211 -3.0015 -0.2694 -0.5160 -1.9876 -1.9378 -1.3905 -0.1974 -0.4385 -0.3225
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission ; bnp ; reduced ef ; preserved ef ; bnp ; ef
H-193	-1.4701884984970093	▁ad mission ▁media n ▁b NP ▁; ▁EF ▁; ▁EF ▁; ▁media n ▁b NP ▁; ▁EF ▁; ▁border line
D-193	-1.4701884984970093	admission median bNP ; EF ; EF ; median bNP ; EF ; borderline
P-193	-3.9246 -1.6163 -0.5939 -0.1573 -1.8843 -3.0484 -0.4499 -0.7408 -0.3966 -1.9972 -0.4198 -4.6054 -0.1180 -1.2799 -3.4806 -0.3566 -2.5131 -1.3100 -2.4844 -0.1873 -0.3752 -0.4044
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart failure ; admission ; heart transplantation ; lv assist device ; death ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval ; ischemic ; functional class
H-435	-1.0439655780792236	▁heart ▁failure ▁; ▁heart ▁transplant ation ▁; LV ▁assist ▁device ▁; ▁death ▁; haz ard ▁ratio ▁; ▁all - ca use ▁death
D-435	-1.0439655780792236	heart failure ; heart transplantation ;LV assist device ; death ;hazard ratio ; all-cause death
P-435	-2.6829 -0.9904 -1.6520 -3.0170 -0.1803 -2.1964 -0.3302 -1.8214 -0.6724 -0.2789 -0.2710 -1.1785 -0.3361 -0.4827 -0.2142 -0.4251 -0.3460 -2.3255 -0.1332 -0.1625 -1.9457 -1.1766 -1.9340 -0.3022
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv ejection fraction ; shortening ; systolic elastance ; contractile efficiency ; acf ; acf ; allopurinol ; cardiomyocytes ; extracellular flux analyzer
H-475	-0.5975150465965271	▁LV ▁; ▁e je ction ▁ fraction ▁; ▁circum fer ential ▁short en ing ▁; ▁sy sto lic ▁elastan ce ▁; ▁contract ile ▁efficiency ▁; ▁a CF ▁; ▁a CF ▁; ▁allo puri nol ▁rat s ▁; ▁o 2 ▁consum p tion ▁rate ▁; ▁isola ted ▁cardio my o cy tes ▁; ▁extra cel lular ▁flux ▁anal y zer
D-475	-0.5975150465965271	LV ; ejection fraction ; circumferential shortening ; systolic elastance ; contractile efficiency ; aCF ; aCF ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
P-475	-1.4025 -0.3490 -0.2549 -0.6438 -0.2333 -0.3543 -0.1279 -0.3016 -0.0929 -1.9582 -1.6835 -0.4720 -0.1731 -0.5486 -0.4027 -0.3067 -0.2895 -0.1020 -0.0339 -2.5784 -0.3324 -0.0137 -0.4352 -0.7160 -0.2894 -1.7061 -2.3289 -0.2447 -1.7424 -3.2249 -0.2121 -0.0762 -0.1079 -1.2783 -0.5155 -0.2627 -0.3129 -0.1220 -0.1970 -0.4059 -0.3977 -1.9433 -0.5386 -0.3205 -0.6675 -0.5826 -0.0420 -1.1804 -0.1420 -0.2006 -0.3260 -0.2943 -0.1390 -0.9553 -0.2241 -0.0078 -0.4067 -0.3718 -0.2265 -0.3845 -0.2641
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively ; patients ; hfpef ; lv hypertrophy ; lvh ; relative wall thickness ; rwt ; lvh ; rwt ; lvh ; rwt ; lvh ; rwt
H-1526	-1.0378118753433228	▁ HF p EF ▁; ▁LV ▁; ▁ge ometr y ▁; ▁LV ▁hyper trop hy ▁; LV h ▁; ▁relative ▁wall ▁thi ck ness ▁; ▁r w t ▁; ▁CR ▁; ▁LV h ▁; ▁r w t ▁; ▁eh ▁; ▁v w t
D-1526	-1.0378118753433228	HFpEF ; LV ; geometry ; LV hypertrophy ;LVh ; relative wall thickness ; rwt ; CR ; LVh ; rwt ; eh ; vwt
P-1526	-2.2611 -1.8113 -0.0742 -0.9681 -0.3840 -1.5855 -0.5860 -0.9622 -0.1257 -0.9774 -0.4495 -1.7853 -0.2268 -0.0529 -1.6168 -0.3243 -2.6138 -1.6542 -0.3243 -2.0921 -0.9940 -0.4729 -0.0407 -1.9709 -0.4122 -1.7846 -0.4378 -0.0146 -0.5240 -2.7603 -0.4028 -3.0289 -1.5936 -0.2991 -0.4792 -0.1924 -0.0352 -0.5433 -3.7656 -0.3309 -1.6289 -3.3923 -0.0405 -0.3786 -0.3029
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 ; angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist ; valsartan ; hypertension ; heart failure with preserved ejection fraction ; outcomes ; heart failure with reduced ejection fraction
H-1463	-0.8482410311698914	▁l CZ 696 ▁; ▁ang io ten sin ▁receptor ▁; ▁nepri ly sin ▁inhibi tor ▁; ▁nepri ly sin ▁inhibi tor ▁; ▁pro drug ▁; ▁ang io ten sin ▁receptor ▁anta gon ist ▁val sar tan ▁; ▁hyper tension ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-1463	-0.8482410311698914	lCZ696 ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; preserved ejection fraction ; heart failure ; reduced ejection fraction
P-1463	-0.6949 -2.2058 -0.2826 -0.2895 -1.6072 -3.6856 -0.3382 -3.7064 -0.0672 -0.4244 -0.2318 -1.1474 -2.2163 -0.1373 -0.1454 -0.2763 -0.2039 -1.0248 -2.5562 -0.0975 -0.2194 -0.5190 -2.0379 -0.1244 -0.3333 -1.4535 -2.9897 -0.3180 -3.4707 -0.0493 -0.8862 -0.0117 -0.7379 -0.4461 -0.5878 -0.1013 -0.3182 -0.0892 -0.0639 -0.3033 -1.7710 -0.5276 -0.5285 -1.9157 -0.1810 -1.8954 -0.1149 -0.5694 -0.2703 -0.4407 -0.0618 -0.3264 -2.5526 -0.7883 -0.8811 -3.0741 -0.1628 -0.0608 -0.4173 -0.2419 -0.4428 -0.0531 -0.3627 -0.2481
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood pressure ; mitral valve plasty ; degenerative mr ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; physio ring 30 ; edwards lifesciences ; irvine
H-343	-0.5424359440803528	▁blood ▁pressure ▁; ▁h g ▁; ▁mit ral ▁val ve ▁; ▁de genera tive ▁MR ▁; ▁p 3 ▁pro lapse ▁; ▁chor dal ▁rup tures ▁; ▁tri ang ular ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is ▁; ▁ring ▁ann ulo plast y ▁; ▁Ph y sio ▁ring ▁30 ▁; Ed ward s ▁Life science s ▁; ▁ir vine ▁; ▁CA
D-343	-0.5424359440803528	blood pressure ; hg ; mitral valve ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio ring 30 ;Edwards Lifesciences ; irvine ; CA
P-343	-0.7894 -1.0703 -0.3564 -1.2691 -0.3647 -0.4248 -0.5736 -0.2484 -0.3573 -0.3531 -1.9162 -0.4266 -0.0329 -2.0040 -0.4441 -0.3845 -0.8342 -0.4811 -0.1589 -0.2830 -0.4397 -0.1201 -0.2709 -0.0616 -0.3332 -0.5112 -0.0153 -0.2263 -0.0737 -0.3060 -0.3029 -0.4763 -0.3705 -0.1749 -0.2840 -0.4546 -0.3408 -0.0917 -0.7565 -0.0451 -0.8327 -0.9815 -0.5310 -0.0997 -1.0834 -0.1998 -0.5056 -1.8438 -0.3845 -1.5369 -0.0840 -0.0591 -0.9265 -1.0031 -0.2929 -3.1678 -0.0867 -0.1063 -0.7446 -0.1535 -0.0801 -0.2789 -0.0612 -0.1414 -1.5307 -1.0783 -0.3686 -0.2954
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes ; incremental shuttle walk test ; peak oxygen uptake ; muscular ; echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory ; beck depression inventory ; health-related quality of life ; minnesota living with heart failure questionnaire ; medical outcomes study short-form
H-1320	-0.6772202849388123	▁shu ttle ▁walk ▁test ▁; ▁oxygen ▁up take ▁; ▁muscular ▁strength ▁; ▁e cho car dio graphic ▁; ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁marker s ▁; ▁depression ▁; ▁be ck ▁de pression ▁in ven tory ▁; Min es ota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁Medical
D-1320	-0.6772202849388123	shuttle walk test ; oxygen uptake ; muscular strength ; echocardiographic ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ;Minesota Living with Heart Failure Questionnaire ; Medical
P-1320	-0.2535 -0.0115 -0.6654 -1.0113 -0.2519 -0.9883 -2.3856 -0.5291 -0.3097 -0.2138 -1.1245 -0.3094 -0.4759 -0.3042 -0.1609 -0.9925 -1.3096 -1.6034 -0.3055 -0.9702 -1.0391 -1.4071 -0.8283 -0.1487 -0.4872 -0.3859 -0.0509 -0.4525 -0.5131 -0.0737 -0.2296 -0.3385 -0.4035 -0.2947 -0.5533 -0.0927 -0.1776 -0.4572 -0.3162 -0.7721 -0.1565 -0.4423 -3.2228 -2.6024 -0.2365 -0.7994 -0.7032 -0.6933 -0.3997 -1.4392 -0.6680 -0.0176 -0.2859 -0.7291 -2.0321 -0.2987
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction term analysis ; lvef ; patients ; patients ; mortality ; lvef ; p value
H-116	-1.9893678426742554	▁LV EF ▁; ▁h m ▁; ▁mortal iteit ▁; ▁LV EF ▁; ▁h
D-116	-1.9893678426742554	LVEF ; hm ; mortaliteit ; LVEF ; h
P-116	-2.7606 -1.8357 -0.3496 -3.1747 -5.0472 -0.3834 -2.4301 -2.0126 -0.3879 -2.5226 -1.8851 -0.5009 -4.5583 -1.7105 -0.2813
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto ; zsf1 ; obese ; zsf1 ; obese ; zsf1 ; followed up ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
H-763	-1.0461723804473877	▁we star - K yo to ▁; ▁lean ▁; ▁ nc w t ▁; ▁obes e ▁; ▁ nc w t ▁; ▁obes e ▁; ▁ nc w t ▁; ▁high - fat ▁die t ▁; ▁metabol ic ▁; ▁renal ▁; ▁e cho car dio graphic ▁; ▁hem o dynamic ally ▁; ▁eu than ization
D-763	-1.0461723804473877	westar-Kyoto ; lean ; ncwt ; obese ; ncwt ; obese ; ncwt ; high-fat diet ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
P-763	-1.1143 -0.7745 -0.1788 -2.2162 -0.6194 -0.1290 -0.3382 -0.1471 -2.4069 -1.6126 -6.4877 -0.8446 -2.7559 -0.5584 -0.3960 -0.2689 -1.1608 -1.4680 -5.9134 -1.0248 -2.0643 -0.3184 -0.8239 -0.3062 -1.4660 -1.2891 -6.2055 -0.8515 -1.8974 -0.2709 -1.2441 -0.1626 -0.3754 -1.1841 -0.2333 -0.3138 -0.7220 -0.1432 -0.3139 -0.0321 -0.4552 -0.3895 -0.3661 -0.1123 -0.6168 -1.1237 -0.8598 -0.6940 -0.1875 -0.0985 -1.4576 -0.4895 -0.0051 -0.3374 -1.2654 -0.3243 -0.2158
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier curves ; log-rank testing ; risk stratification ; patients ; patients
H-384	-1.0413607358932495	▁ka plan - me ier ▁cur ves ▁; ▁log - rank ▁testing ▁; ▁UM
D-384	-1.0413607358932495	kaplan-meier curves ; log-rank testing ; UM
P-384	-0.2778 -0.0225 -0.1811 -0.4753 -0.3320 -0.4040 -4.3514 -0.3822 -1.0907 -0.1442 -0.2156 -1.2363 -0.3844 -1.8687 -4.8981 -0.3975
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate cox regression analyses ; hypertension ; sinus rhythm ; hazard ratio ; confidence interval
H-950	-0.9386377930641174	▁multi varia te ▁co x ▁re gression ▁analyse s ▁; ▁AF ▁; ▁AF ▁; ▁hyper tension ▁; ▁sinus ▁ rhythm ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁cm
D-950	-0.9386377930641174	multivariate cox regression analyses ; AF ; AF ; hypertension ; sinus rhythm ;hazard ratio ;HR ; confidence interval ; cm
P-950	-0.5083 -0.5304 -0.4999 -0.0534 -0.5002 -0.0556 -0.0934 -1.8141 -0.5916 -0.4507 -0.8201 -0.7929 -2.2413 -0.3369 -0.2311 -0.1320 -0.3853 -0.6621 -0.2599 -0.7336 -0.3648 -0.0618 -0.0692 -0.0269 -0.3174 -3.9017 -0.4818 -5.4505 -0.2370 -0.3050 -5.6368 -2.1186 -0.3109
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients ; chronic ; hf-ref ; nyha functional class ii ; egfr ; potassium ; eplerenone ; hyperkalemia
H-1228	-1.017978310585022	▁chronic ▁ HF - re f ▁; ▁NY ha ▁; ▁functional ▁class ▁II ▁; ▁e g FR ▁; ▁po tas s ium ▁; ▁e pler en one ▁; ▁hyper kal emia ▁; ▁w RF
D-1228	-1.017978310585022	chronic HF-ref ; NYha ; functional class II ; egFR ; potassium ; eplerenone ; hyperkalemia ; wRF
P-1228	-1.3228 -1.3781 -1.2954 -0.1166 -1.2040 -3.6770 -0.2958 -2.5928 -3.4230 -0.3547 -0.0790 -0.1113 -1.7358 -0.3722 -0.5752 -2.5835 -3.5113 -0.3333 -1.2411 -1.0896 -0.3120 -0.2219 -0.3612 -0.2481 -0.6586 -0.0874 -1.1478 -0.3569 -0.2127 -0.4293 -1.0418 -0.3074 -0.1972 -3.1152 -0.3666 -0.2911
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm ; dual energy x-ray absorptiometry ; dxa ; patients ; chronic heart failure ; chf ; non-cachectic chf ; myocardial
H-12	-0.8411716222763062	▁f m ▁; ▁FM ▁; ▁body ▁fat ▁; ▁dual ▁energy ▁; ▁X - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁non - dia be tic ▁patients ▁; ▁chronic ▁heart ▁failure ▁; ▁ nc w ▁; cc ▁; ▁non - ca che ctic ▁CHF ▁; ▁my o card ial ▁in far ction - bo th
D-12	-0.8411716222763062	fm ; FM ; body fat ; dual energy ; X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ; ncw ;cc ; non-cachectic CHF ; myocardial infarction-both
P-12	-1.7718 -1.6111 -0.3822 -2.2761 -0.4014 -2.5510 -0.3447 -0.9739 -0.8308 -0.7821 -0.8048 -2.4106 -0.2195 -1.2034 -0.0137 -0.8136 -1.0391 -1.2997 -1.6688 -0.3940 -0.3556 -1.8331 -0.4435 -0.9523 -0.1086 -0.0146 -0.2696 -0.6104 -0.8741 -0.9907 -0.7291 -1.0587 -0.3737 -0.3121 -3.6526 -1.6265 -1.2580 -0.3866 -1.2576 -0.4880 -0.5524 -0.0569 -0.1037 -0.8465 -0.4991 -0.2517 -0.3373 -1.8493 -0.2647 -0.6356 -1.2299 -0.1514 -0.3477 -0.8970 -0.6334 -0.0344 -0.8907 -0.4270 -0.2330
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline ; drug ; spironolactone ; combined end point ; death ; hospitalization ; hf ; hazard ratio ; confidence interval ; aas ; hazard ratio ; confidence interval ; p value
H-1707	-0.8557190895080566	▁spi rono lac tone ▁; ▁end ▁point ▁; ▁hospital ization ▁; ▁ HF ▁; haz ard ▁ratio ▁; ▁AA s ▁; haz ard ▁ratio
D-1707	-0.8557190895080566	spironolactone ; end point ; hospitalization ; HF ;hazard ratio ; AAs ;hazard ratio
P-1707	-0.4590 -0.1026 -0.1777 -0.3128 -0.4422 -3.7616 -1.1179 -1.2475 -1.3401 -1.1200 -0.2848 -2.5150 -1.5554 -0.3564 -1.3651 -0.3406 -0.2426 -0.3369 -2.1621 -0.5211 -0.2484 -0.2617 -0.5317 -0.6964 -0.4658 -0.2831
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective study ; patients ; invasively ; diagnosed ; pulmonary arterial hypertension ; inoperable ; chronic thromboembolic pulmonary hypertension ; right ventricular ; pump ; stable ; pulmonary arterial hypertension ; medication ; noninvasive ; stress echocardiography ; cardiopulmonary exercise testing
H-823	-0.6700126528739929	▁invasi ve ly ▁diagnose ▁; ▁pulmonar y ▁arterial ▁hyper tension ▁; ▁in opera ble ▁chronic ▁ thro mbo e mbol ic ▁pulmonar y ▁hyper tension ▁; ▁right ▁vent ri cular ▁pump ▁; ▁pulmonar y ▁arterial ▁hyper tension ▁; ▁medication ▁; ▁stress ▁e cho card i ography ▁; ▁cardio pul mon ary ▁exercise ▁testing
D-823	-0.6700126528739929	invasively diagnose ; pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; right ventricular pump ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise testing
P-823	-2.5225 -0.5232 -0.3068 -0.1735 -2.1431 -0.0676 -1.4237 -0.1328 -0.4182 -0.5199 -0.2050 -0.5867 -0.4377 -2.3642 -0.3632 -0.1598 -0.1473 -1.4975 -0.0516 -0.0555 -0.2052 -0.0868 -1.8180 -0.5783 -0.5194 -0.2077 -1.0390 -0.1485 -1.8049 -0.1895 -0.8314 -0.2552 -2.6113 -1.7486 -0.1619 -0.3996 -0.4841 -0.2140 -0.4662 -0.2366 -0.3988 -0.5157 -0.2540 -0.2085 -0.1928 -0.4046 -0.2898 -0.0453 -0.9182 -1.5494 -1.8059 -0.5018 -1.0049 -0.4468 -0.2084
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular death ; hf ; hospitalization ; randomization ; btes ; btes ; cardiovascular death ; hf ; hospitalization ; exercise ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-1930	-1.0527137517929077	▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁significant ▁; ▁b tes ▁; ▁b tes ▁; ▁cardiovascular ▁death ▁; ▁ HF ▁; ▁hospital ization ▁; ▁exercise ▁group ▁; haz ard ▁ratio
D-1930	-1.0527137517929077	cardiovascular death ; HF hospitalization ; significant ; btes ; btes ; cardiovascular death ; HF ; hospitalization ; exercise group ;hazard ratio
P-1930	-1.4754 -1.7918 -0.2351 -1.2708 -1.3706 -1.9088 -1.5734 -0.3083 -0.0489 -0.6636 -1.7894 -1.0230 -0.2551 -2.7377 -1.0906 -0.2485 -0.5424 -1.8853 -0.2529 -1.2589 -1.8229 -1.0312 -1.1998 -1.4668 -0.2740 -0.6471 -2.0511 -0.2522 -0.2753 -0.3004 -0.4272 -2.9936 -0.2674
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad ; diabetes ; odds ratio ; electrocardiographic q waves ; left bundle branch block ; odds ratio ; nondiabetes ; dyslipidemia ; hypertension ; odds ratio
H-1190	-0.5026102662086487	▁CAD ▁; ▁diabetes ▁; odd s ▁ratio ▁; ▁electro car dio graphic ▁Q ▁wa ves ▁; ▁left ▁bund le ▁bran ch ▁block ▁; odd s ▁ratio ▁; ▁non dia bete s ▁risk ▁factors ▁; ▁dys li pide mia ▁; ▁hyper tension ▁; ▁to ba cco ▁use ▁; odd s ▁ratio
D-1190	-0.5026102662086487	CAD ; diabetes ;odds ratio ; electrocardiographic Q waves ; left bundle branch block ;odds ratio ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco use ;odds ratio
P-1190	-1.1750 -0.1805 -0.2225 -0.2502 -0.4430 -0.1793 -0.2849 -0.3558 -0.0308 -0.0609 -0.3616 -0.5649 -3.0744 -0.0217 -1.8758 -0.2746 -0.4748 -0.1036 -0.8740 -0.0399 -0.2745 -0.3587 -0.2843 -0.4580 -0.1858 -0.3356 -0.3771 -0.8084 -0.0933 -0.5508 -0.2645 -1.3536 -0.4749 -0.3072 -0.0699 -0.1491 -0.1010 -0.7557 -0.3282 -0.0750 -0.0531 -0.3388 -0.3786 -2.2592 -0.8094 -2.0229 -0.2781 -0.0721 -0.2200 -0.5741 -0.4010 -0.2745
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients ; hospitalized ; death ; all-cause readmission ; aor ; eds ; aor
H-466	-0.886189341545105	▁index ▁ED ▁visit ▁; ▁low - volu me ▁ED ▁cases ▁; ▁death ▁; ▁all - ca use ▁read mission ▁; ▁medium ▁; ▁a OR ▁; ▁high - volu me ▁ED s ▁; ▁a OR
D-466	-0.886189341545105	index ED visit ; low-volume ED cases ; death ; all-cause readmission ; medium ; aOR ; high-volume EDs ; aOR
P-466	-0.0762 -0.8389 -1.5308 -0.2737 -0.8244 -0.1991 -0.3004 -0.3559 -1.5202 -2.2101 -0.2975 -2.8128 -0.3534 -1.1184 -0.1218 -0.2233 -0.9831 -0.8267 -0.9657 -0.4146 -1.9697 -0.2998 -1.0898 -0.5842 -0.3659 -3.1818 -0.2005 -0.5250 -0.5430 -1.3422 -0.3989 -0.3817 -3.2978 -0.8399 -0.3766 -0.2593
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients ; implantable cardioverter-defibrillator ; implantation ; engage ; patients ; decisions ; implantable cardioverter-defibrillator
H-1863	-0.893295168876648	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant ation ▁; ▁significant ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1863	-0.893295168876648	implantable cardioverter-defibrillator deactivation ; implantation ; significant ; implantable cardioverter-defibrillator deactivation
P-1863	-1.1626 -0.3989 -0.3442 -0.4177 -1.2659 -0.3376 -0.1641 -0.5521 -3.0674 -0.9800 -0.3809 -0.4735 -0.4677 -2.6670 -0.4333 -0.9342 -2.7372 -0.3264 -0.0301 -0.5757 -3.9019 -0.4016 -0.4684 -0.2719 -1.2297 -0.2907 -0.1007 -0.5971 -2.5413 -0.8440 -0.2676 -0.2978 -0.3063 -2.2536 -0.4376 -0.2322
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac magnetic resonance ; t1 time ; hazard ratio ; confidence interval ; left atrial area ; hazard ratio ; confidence interval ; pulmonary vascular resistance ; hazard ratio ; confidence interval ; cardiac events
H-739	-0.7559149265289307	▁Card iac ▁magnetic ▁res on ance ▁; haz ard ▁ratio ▁; ▁left ▁at rial ▁area ▁; haz ard ▁ratio ▁; ▁pulmonar y ▁vas cular ▁resist ance ▁; haz ard ▁ratio ▁; ▁cardiac ▁events
D-739	-0.7559149265289307	Cardiac magnetic resonance ;hazard ratio ; left atrial area ;hazard ratio ; pulmonary vascular resistance ;hazard ratio ; cardiac events
P-739	-2.5370 -0.7192 -0.2210 -0.2336 -0.9734 -0.8473 -0.5336 -1.3654 -0.3848 -0.4763 -0.3242 -1.3013 -1.7058 -0.9043 -0.8917 -0.2703 -0.8388 -0.5863 -0.4703 -0.3174 -0.2698 -0.9373 -0.1157 -0.3797 -0.7835 -0.3611 -0.3337 -0.7726 -0.6823 -0.6522 -0.3367 -2.0332 -2.1665 -0.4027 -0.3282
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively ; followed up ; hf ; patients ; systolic ; left ventricular ejection fraction ; hf ; stable ; clinical ; conditions ; new york heart association class i ; clinical ; echocardiographic ; cardiopulmonary exercise test
H-1755	-0.8027119636535645	▁ HF ▁; ▁sy sto lic ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁New ▁York ▁Heart ▁association ▁; ▁e cho car dio graphic ▁; ▁cardio pul mon ary ▁exercise ▁test
D-1755	-0.8027119636535645	HF ; systolic ; left ventricular ejection fraction ; HF ; New York Heart association ; echocardiographic ; cardiopulmonary exercise test
P-1755	-1.6971 -1.6540 -0.3834 -0.2430 -0.1321 -0.0710 -0.4243 -3.2810 -0.8932 -0.1956 -1.6783 -0.3891 -0.3560 -0.3386 -0.1988 -0.5792 -0.0189 -0.3176 -2.7463 -2.1779 -0.3050 -2.1055 -1.6769 -1.3206 -0.4910 -0.2679 -0.2363 -0.4216 -0.0639 -0.5769 -0.7355 -0.3229 -0.0765 -0.6972 -1.3517 -1.4035 -0.5116 -0.8793 -0.6404 -0.2489
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients ; end stage heart failure ; abcd classification ; american college of cardiology ; acc ; american heart association ; aha ; new york heart association ; nyha ; heart disease ; symptoms ; heart failure ; physical ; medical treatment
H-1666	-1.278539776802063	▁heart ▁failure ▁; ▁ab d ▁; ▁American ▁college ▁of ▁Card i ology ▁; ▁a cc ▁; American ▁Heart ▁association ▁; AHA ▁; ▁New ▁York ▁Heart ▁association ▁; ▁w ha ▁; ▁structura l ▁heart ▁disease ▁; ▁heart ▁failure ▁; ▁physical ▁ex er tion ▁; ▁medical
D-1666	-1.278539776802063	heart failure ; abd ; American college of Cardiology ; acc ;American Heart association ;AHA ; New York Heart association ; wha ; structural heart disease ; heart failure ; physical exertion ; medical
P-1666	-5.2824 -1.3106 -0.3272 -1.2225 -0.3779 -0.4108 -3.5025 -1.8486 -1.0739 -1.6712 -0.2846 -0.1710 -0.2739 -1.8446 -0.5045 -0.3279 -1.3298 -2.3183 -0.8436 -0.2993 -3.4827 -0.2917 -2.1256 -1.6605 -1.7486 -0.7459 -0.2447 -4.0156 -1.3506 -0.2967 -5.0193 -1.1754 -0.9924 -1.0139 -0.3011 -2.1860 -0.7581 -0.5212 -1.5750 -0.0800 -0.3631 -0.5678 -0.4051 -0.9916 -1.3848 -0.2905
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva ; continuity equation ; lv end-diastolic volume ; lv end-systolic volume ; mitral filling flow ; mva ; mitral filling flow ; continuous wave doppler echocardiography ; mitral valve plasty
H-345	-0.8480573892593384	▁m va ▁; ▁continu iteit ▁e qu ation ▁; ▁v n ▁; ▁end - dia sto lic ▁volume ▁; ▁LV ▁; ▁end - sy sto lic ▁volume ▁; ▁mit ral ▁fill ing ▁flow ▁; ▁m va ▁; ▁veloci ty ▁time ▁; ▁mit ral ▁fill ing ▁flow ▁; ▁continuo us ▁wa ve ▁; ▁do pp ler ▁e cho card i ography ▁; ▁MR ▁; ▁mit ral ▁val ve ▁plast y
D-345	-0.8480573892593384	mva ; continuiteit equation ; vn ; end-diastolic volume ; LV ; end-systolic volume ; mitral filling flow ; mva ; velocity time ; mitral filling flow ; continuous wave ; doppler echocardiography ; MR ; mitral valve plasty
P-345	-0.5594 -3.6700 -0.2719 -1.1769 -2.6955 -0.4820 -0.7320 -2.0110 -0.3429 -0.9420 -0.7698 -0.8350 -2.6955 -0.1253 -0.0562 -0.2062 -0.0928 -0.4664 -0.2756 -1.4244 -0.7669 -1.5842 -0.1333 -2.4515 -0.2521 -0.1819 -0.6696 -0.2561 -1.7966 -0.8715 -1.9733 -0.4758 -2.1805 -0.6019 -0.6452 -4.0313 -0.2971 -0.4974 -0.3252 -1.7065 -0.4163 -1.2461 -0.5156 -1.7181 -0.4276 -1.6533 -0.2341 -0.1539 -1.1671 -0.0260 -0.0737 -0.3980 -0.2954 -0.1744 -1.0132 -0.2746 -0.2075 -0.2347 -0.4805 -0.2980 -0.3663 -0.5337 -0.7225 -1.2701 -0.2999 -1.4339 -0.6874 -0.2598 -1.4735 -0.3578 -0.2704
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance ; rm ; all-cause mortality ; sts ; hh ; cri ; cri ; cri
H-157	-1.641790747642517	▁RM ▁; ▁mortal iteit ▁; ▁s ts ▁ HH ▁; HR ▁; ▁c r i ▁; ▁m t ▁; ▁office ▁hours ▁; HR ▁; ▁Cr i
D-157	-1.641790747642517	RM ; mortaliteit ; sts HH ;HR ; cri ; mt ; office hours ;HR ; Cri
P-157	-2.4022 -0.4125 -0.9471 -1.8108 -0.3754 -1.0688 -1.9876 -1.2138 -1.0335 -0.3547 -4.2138 -0.4817 -3.5471 -0.7085 -3.8409 -0.4288 -5.0420 -1.4302 -0.4488 -0.8207 -0.2965 -0.3760 -5.3291 -0.7728 -0.8260 -3.6825 -1.8266 -0.2918
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi ; hf ; clinic ; outcomes ; hfpsi ; outcomes ; tracking ; patients ; hfpsi
H-381	-1.302418828010559	▁ HF PSI ▁; ▁Ann ▁ar bor ▁Veteran s ' ▁Affairs ▁; ▁ HF ▁clinic ▁; ▁va ▁co hor t ▁; ▁ HF PSI ▁; ▁va - RT ▁co hor t ▁; ▁va ▁patients ▁; ▁ HF PSI
D-381	-1.302418828010559	HFPSI ; Ann arbor Veterans' Affairs ; HF clinic ; va cohort ; HFPSI ; va-RT cohort ; va patients ; HFPSI
P-381	-1.9157 -3.3086 -3.6468 -0.3055 -1.7190 -0.5127 -0.5318 -0.4239 -0.2956 -4.0258 -0.0952 -0.6719 -1.9473 -1.6323 -1.2360 -0.2795 -1.1315 -0.6617 -2.2800 -0.0935 -0.3291 -0.7034 -3.1541 -2.7466 -0.3605 -0.1147 -0.4809 -2.5647 -0.3253 -2.4704 -0.1716 -0.3305 -0.5547 -1.9654 -0.3238 -1.2700 -2.8352 -3.9907 -0.3793 -0.3117
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients ; hfref ; diuretics ; co-morbidities ; 6-mwt ; feet ; nyha class iii
H-243	-0.9935850501060486	▁h Fr EF ▁; ▁di ure tics ▁; ▁co - mor bid ities ▁; ▁mw t ▁; ▁ny ha ▁class ▁III
D-243	-0.9935850501060486	hFrEF ; diuretics ; co-morbidities ; mwt ; nyha class III
P-243	-1.0178 -2.7904 -2.6495 -0.3337 -0.4146 -0.6339 -0.4547 -0.5407 -0.3904 -0.1931 -0.1510 -0.6957 -3.8711 -0.5502 -0.6615 -0.0922 -0.4258 -2.7933 -2.3457 -0.4345 -0.5157 -0.5409 -0.3561
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery ; hf ; postoperative ; echocardiography ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mitral valve area ; mva
H-344	-0.6754664778709412	HF ▁; ▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁LV ▁; ▁e je ction ▁ fraction ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁mit ral ▁val ve ▁area ▁; ▁m va ▁; ▁mean ▁pressure ▁gradi ent ▁; ▁h g
D-344	-0.6754664778709412	HF ; echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mva ; mean pressure gradient ; hg
P-344	-4.6043 -0.3265 -1.3252 -0.7012 -0.2284 -0.4208 -0.4305 -0.4057 -0.9807 -0.3001 -1.8326 -0.1451 -0.0115 -0.1085 -0.0983 -0.1664 -0.0925 -0.3363 -2.9980 -0.2872 -0.1431 -0.6404 -0.1298 -0.3026 -0.0180 -0.4017 -0.8151 -0.4010 -0.8654 -0.3492 -0.9359 -0.7516 -1.9587 -0.3262 -0.5480 -0.4695 -0.6450 -0.6099 -1.0060 -0.3749 -0.2556 -3.5538 -0.3168 -0.8385 -0.6261 -0.0436 -0.5028 -0.3805 -0.2167 -0.3239 -0.3377 -0.2364
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas ; spironolactone ; hyperkalemia ; potassium ; hypokalemia ; potassium
H-1706	-0.724219799041748	▁AA s ▁; ▁spi rono lac tone ▁dose ▁; ▁hyper kal emia ▁; po tas s ium ▁; ▁hypo kal emia ▁; po tas s ium
D-1706	-0.724219799041748	AAs ; spironolactone dose ; hyperkalemia ;potassium ; hypokalemia ;potassium
P-1706	-1.4698 -0.6995 -0.3643 -0.3371 -0.1791 -0.2265 -0.2601 -1.4013 -0.3792 -0.4593 -0.6727 -0.7777 -0.3623 -1.0945 -2.3001 -0.6260 -0.7629 -0.3818 -0.3541 -1.1881 -0.8517 -0.3321 -1.0824 -1.8454 -0.4742 -0.7169 -0.3846 -0.2944
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate analysis ; patients ; preserved lvef ; mortality ; patients ; lvef ; hazard ratio ; lvef ; preserved lvef
H-115	-1.3016819953918457	▁LV EF ▁; ▁long - term ▁mortal iteit ▁; ▁LV EF ▁; haz ard ▁ratio ▁; HR ▁; ▁LV EF ▁; ▁pres er ved ▁LV EF ▁; HR
D-115	-1.3016819953918457	LVEF ; long-term mortaliteit ; LVEF ;hazard ratio ;HR ; LVEF ; preserved LVEF ;HR
P-115	-2.1696 -1.8760 -0.3477 -4.5742 -0.2551 -0.2848 -0.1686 -2.1182 -0.4288 -1.6744 -1.4003 -0.3613 -0.2507 -0.1078 -0.0195 -0.3112 -2.8597 -0.5271 -2.0713 -1.9557 -0.4040 -4.2232 -0.8393 -3.0894 -0.5500 -1.6755 -0.3946 -3.4296 -0.3947 -0.2881
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients ; hfpef ; primary outcome ; odds ratio ; nyha class iii ; 6-minute walk test ; 6-mwt ; feet ; prescribed ; medications
H-242	-0.7893616557121277	▁ HF p EF ▁; ▁male ▁gender ▁; odd s ▁ratio ▁; ▁ny ha ▁class ▁III ▁; ▁walk ▁test ▁; ▁mw t
D-242	-0.7893616557121277	HFpEF ; male gender ;odds ratio ; nyha class III ; walk test ; mwt
P-242	-1.6969 -1.1742 -0.0729 -0.8676 -0.3258 -2.1809 -0.3708 -0.2673 -0.0272 -0.1474 -0.0284 -0.3274 -3.0049 -1.3867 -0.7465 -0.5543 -0.6819 -1.5865 -0.9290 -0.3284 -0.4633 -0.1031 -1.3326 -0.3406
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived pulmonary arterial systolic pressure ; pasp ; right ventricular ; rv ; tricuspid annular plane systolic excursion ; tapse ; diastole ; end-systole ; clinical ; follow-up ; heart failure ; hf ; patients ; cardiac
H-492	-0.5835736393928528	▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁right ▁vent ri cular ▁; ▁v n ▁; ▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; TA PS e ▁; ▁dia stol e ▁; ▁end - sy stol e ▁; ▁heart ▁failure ▁; HF ▁; ▁cardiac ▁risk
D-492	-0.5835736393928528	pulmonary arterial systolic pressure ;PASp ; right ventricular ; vn ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
P-492	-1.2254 -1.4300 -0.0659 -0.0488 -0.2208 -0.2041 -0.8186 -0.2526 -0.9473 -0.8657 -0.3013 -1.2663 -0.1265 -1.5320 -0.2430 -0.3240 -1.7122 -0.5583 -0.4133 -0.0129 -0.3489 -0.1213 -0.8907 -0.0421 -0.8007 -0.0281 -0.1623 -0.2215 -0.3175 -0.1353 -0.3000 -2.3189 -2.3858 -0.3324 -0.2349 -0.0383 -0.3349 -0.2261 -0.2658 -0.6433 -0.1973 -0.9502 -1.0123 -0.1544 -0.3494 -1.8230 -0.4068 -0.2817 -1.3689 -0.2729 -0.3301 -1.0241 -0.3713 -0.2527
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv reverse remodeling ; lv end-diastolic dimension ; longitudinal ; strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial ; right ventricular fractional area ; change
H-432	-1.2980625629425049	▁LV ▁; ▁rever se ▁remodel ing ▁; ▁LV ▁; ▁end - dia sto lic ▁ dimension ▁index ▁; ▁left ▁vent ric le ▁; ▁left ▁at rial ▁area ▁; ▁right ▁vent ri cular ▁; ▁end - dia sto lic ▁area ▁index ▁; ▁right ▁at rial ▁area ▁; ▁right ▁vent ri cular ▁ fraction al ▁area
D-432	-1.2980625629425049	LV ; reverse remodeling ; LV ; end-diastolic dimension index ; left ventricle ; left atrial area ; right ventricular ; end-diastolic area index ; right atrial area ; right ventricular fractional area
P-432	-0.2267 -0.6607 -3.3983 -0.1403 -0.1186 -0.2114 -0.3692 -3.6185 -0.5050 -2.9474 -0.3742 -0.0746 -0.9157 -0.4905 -0.5333 -1.4971 -0.2401 -0.3798 -1.6045 -0.6661 -1.6240 -0.8003 -0.3662 -2.1320 -3.8718 -1.1735 -1.8472 -0.3982 -3.3420 -1.0399 -3.4597 -1.4343 -1.4051 -4.4424 -0.5143 -0.0930 -0.9122 -0.8722 -2.8978 -0.8279 -0.3789 -2.6598 -4.1318 -0.7036 -1.3762 -0.3947 -1.9566 -0.8997 -3.3734 -1.6470 -0.6674 -0.1335 -0.1490 -0.6406 -0.8870 -0.2664
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area under the receiver operating characteristic curve ; auc ; pcwp ; confidence interval ; septal ; p values
H-485	-1.2776000499725342	▁receive r ▁; ▁operating ▁character istic ▁cur ve ▁; ▁ab c ▁; ▁pc w ▁; ▁confidence ▁interval ▁; ▁e / e ▁; sept al ▁; ▁e we an
D-485	-1.2776000499725342	receiver ; operating characteristic curve ; abc ; pcw ; confidence interval ; e/e ;septal ; ewean
P-485	-1.9963 -0.0568 -0.6244 -0.2386 -0.6042 -0.2642 -0.9414 -0.9589 -0.3175 -4.6477 -1.4855 -0.3344 -0.1641 -2.0544 -1.3964 -1.2390 -0.3763 -0.2731 -2.2476 -4.9676 -0.3243 -5.0873 -0.1124 -0.1185 -0.8341 -0.7394 -4.8067 -0.4813 -0.3273 -0.3082
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 ; irs2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; irs1 ; irs2 ; heart-specific irs1 and irs2 gene double-knockout ; h-dko ; liver-specific irs1 and irs2 double-knockout ; l-dko
H-654	-1.1039319038391113	▁i RS 1 ▁; ▁i RS 2 ▁; ▁heart ▁; ▁hyper insu line mia ▁; ▁my o card ial ▁insulin ▁resist ance ▁; ▁cel lular ▁dys function ▁; ▁i RS 2 ▁; ▁heart - specific ▁; ▁i RS 1 ▁; ▁i RS 2 ▁; ▁double - k no ckou t ▁; ▁l - d ko
D-654	-1.1039319038391113	iRS1 ; iRS2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; heart-specific ; iRS1 ; iRS2 ; double-knockout ; l-dko
P-654	-1.7660 -1.5521 -2.7983 -0.4580 -2.5912 -2.2412 -0.1786 -0.3141 -3.1293 -0.3678 -0.1060 -0.0089 -0.0879 -1.1512 -0.3996 -1.3838 -0.3536 -1.4308 -2.2891 -0.1373 -0.2344 -0.2507 -0.3203 -0.7031 -0.0820 -0.0490 -0.1566 -0.3348 -3.5153 -1.4395 -2.1928 -0.3566 -4.5058 -0.1837 -0.3993 -0.5658 -3.8892 -1.3714 -2.9216 -0.3609 -4.9119 -2.1640 -0.2003 -0.5058 -3.3998 -0.2696 -0.8488 -0.4886 -0.4359 -0.1032 -0.2704 -0.7664 -0.0995 -0.4397 -0.7587 -0.3765 -0.3073
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; diagnostic ; stable ; coronary artery disease ; b-type natriuretic peptide ; bnp ; nt-probnp ; ventricular cardiomyocytes ; ventricular ; wall stress ; myocardial ischemia
H-1364	-1.1071876287460327	▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁n - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁corona ry ▁arter y ▁disease ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁b n ▁; ▁n - termin al ▁fragment ▁; ▁ nc - pro b p ▁; ▁vent ri cular ▁cardio my o cy tes ▁; ▁vent ri cular ▁wall ▁stress ▁; ▁my o card ial ▁ ische mia
D-1364	-1.1071876287460327	b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; coronary artery disease ; b-type natriuretic peptide ; bn ; n-terminal fragment ; nc-probp ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
P-1364	-1.5044 -0.4325 -0.0935 -0.1347 -2.5302 -2.5386 -2.0459 -2.2672 -1.3157 -1.2718 -0.3218 -2.8590 -0.0712 -1.4394 -0.0943 -0.9537 -0.1129 -1.6442 -0.3983 -0.0315 -0.1094 -2.1260 -2.5005 -2.3137 -2.6099 -1.2252 -0.9789 -0.3167 -0.9926 -1.9352 -0.0776 -1.8568 -1.0474 -0.3297 -2.4832 -0.8884 -0.0790 -0.1582 -2.0864 -2.5094 -2.6061 -2.6509 -1.5069 -1.4161 -0.3399 -0.6545 -3.0504 -0.4222 -0.6034 -0.0733 -1.7738 -0.0742 -0.3525 -0.2731 -3.1442 -1.1945 -0.1447 -0.2974 -2.1106 -3.6142 -0.3659 -0.1327 -2.4958 -1.7183 -0.1525 -0.9148 -0.1815 -0.2010 -0.4348 -0.3439 -0.0608 -2.9763 -1.7141 -1.9032 -0.2840 -0.2746 -1.0119 -0.1766 -0.7452 -1.0349 -0.3155 -0.0923 -0.8554 -0.4615 -0.2753
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients ; coronary artery disease ; hypertension ; trastuzumab ; administration ; chf
H-680	-1.3896366357803345	▁tras tuz um ab - tre ated ▁patients ▁; ▁HR ▁; ▁corona ry ▁arter y ▁disease ▁; HR ▁; ▁hyper tension ▁; HR ▁; ▁tras tuz um ab ▁administration ▁; HR ▁; ▁CHF
D-680	-1.3896366357803345	trastuzumab-treated patients ; HR ; coronary artery disease ;HR ; hypertension ;HR ; trastuzumab administration ;HR ; CHF
P-680	-2.0677 -0.6890 -0.5853 -2.7298 -1.3732 -0.2716 -2.5227 -2.8788 -0.3714 -5.0725 -0.4020 -0.6898 -2.5021 -0.0192 -1.1861 -0.6083 -0.3377 -3.8688 -0.4063 -0.3585 -0.1697 -0.3257 -3.9761 -0.4763 -1.8098 -0.4638 -0.6796 -2.2380 -3.1240 -0.2868 -4.1812 -0.4817 -0.6788 -0.4328 -0.3719
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef ; clinical ; crt ; crt ; systolic volume index ; lv mass
H-754	-1.359217643737793	▁LV EF ▁; ▁com posit e ▁response ▁; ▁c RT ▁on ▁; ▁c RT ▁OFF ▁; ▁LV ▁; ▁sy sto lic ▁volume ▁index ▁; ▁LV ▁mass
D-754	-1.359217643737793	LVEF ; composite response ; cRT on ; cRT OFF ; LV ; systolic volume index ; LV mass
P-754	-1.2873 -2.7084 -0.3928 -3.2594 -0.3660 -0.0635 -1.2229 -0.4278 -0.7640 -3.2405 -4.2825 -0.5112 -1.3905 -3.9509 -1.1676 -0.4558 -2.6938 -1.3622 -3.3447 -0.1149 -0.2398 -0.4512 -0.1324 -0.4331 -2.8458 -0.2216 -0.4415 -0.2860
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β signaling ; tgf-β receptor type i ; cell ; yield ; epithelial ; mesenchymal ; transition ; pluripotency marker ; nanog ; cell ; cells ; in vitro
H-1343	-0.6973194479942322	▁t bf - β ▁signal ing ▁; ▁t GF - β ▁receptor ▁type ▁I ▁; ▁s mad ▁; ▁small - mo le cule ▁inhibi tors ▁; ▁c - K it + ▁cell ▁yi eld ▁; ▁epi the li al ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker ▁; ▁na nog ▁; ▁c - K it + ▁cell ▁; ▁cardio my o cy te - like ▁cell s
D-1343	-0.6973194479942322	tbf-β signaling ; tGF-β receptor type I ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker ; nanog ; c-Kit+ cell ; cardiomyocyte-like cells
P-1343	-0.8299 -2.6110 -0.1871 -1.2289 -0.4795 -0.5208 -0.2992 -1.5119 -2.5272 -0.1730 -1.2326 -0.0484 -1.9006 -2.4960 -0.3396 -0.4657 -0.2542 -0.2368 -0.5691 -0.1431 -0.3873 -0.3701 -0.1168 -0.1763 -0.6090 -0.3547 -0.0733 -0.3453 -2.6804 -0.4905 -3.9354 -0.4510 -0.0200 -0.0097 -0.3796 -1.3190 -0.4386 -0.1533 -0.0415 -0.5994 -0.1112 -0.3797 -0.5169 -1.3452 -0.1129 -0.1907 -0.3088 -0.3727 -0.1660 -0.2322 -0.0533 -0.0850 -0.9503 -0.1159 -0.3977 -0.3895 -0.0267 -0.1889 -2.6364 -0.5514 -3.3698 -0.4270 -1.4499 -0.6869 -0.9620 -0.5127 -0.2549 -0.2764 -0.6238 -1.0870 -0.5993 -0.3384 -0.6004 -0.2758
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients ; systolic heart failure ; ejection fraction ; randomized ; placebo ; ivabradine ; shift ; systolic heart failure treatment with the if inhibitor ivabradine trial ; patients ; placebo ; ivabradine ; echocardiographic
H-519	-0.8280616402626038	▁sy sto lic ▁heart ▁failure ▁; ej ection ▁ fraction ▁; ▁i va bra dine ▁; ▁SHI ft ▁; ▁sy sto lic ▁Heart ▁failure ▁; ▁Treatment ▁; ▁If ▁in hib itor ▁i va bra dine ▁tri al ▁; ▁i va bra dine ▁; ▁e cho car dio graphic
D-519	-0.8280616402626038	systolic heart failure ;ejection fraction ; ivabradine ; SHIft ; systolic Heart failure ; Treatment ; If inhibitor ivabradine trial ; ivabradine ; echocardiographic
P-519	-0.6738 -0.9709 -0.3147 -1.9470 -0.5668 -0.2424 -0.8272 -0.6415 -0.1616 -0.0213 -0.3456 -0.4418 -0.1176 -1.5712 -2.3230 -0.3139 -0.1060 -2.6832 -0.2686 -1.2558 -0.5614 -0.5073 -2.1425 -1.5986 -0.3737 -0.6725 -0.9603 -2.1925 -0.2028 -0.1054 -1.5381 -1.8554 -0.0838 -1.1693 -1.8204 -0.2873 -0.2221 -0.3150 -0.9726 -0.1569 -1.5286 -1.9929 -0.3219 -0.2689 -0.4105 -0.1053 -0.9245 -1.4088 -0.6658 -0.2441
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence ; transfusion ; mortality ; relative risk ; mortality ; patients ; acute coronary syndrome
H-45	-0.9656604528427124	▁liberal ▁trans fusion ▁; ▁mortal iteit ▁; ▁i 2 ▁; ▁mortal iteit ▁; ▁a cute ▁corona ry ▁syndrome
D-45	-0.9656604528427124	liberal transfusion ; mortaliteit ; i2 ; mortaliteit ; acute coronary syndrome
P-45	-0.2930 -0.0701 -0.3546 -1.4790 -1.2958 -3.0980 -2.2579 -1.5481 -0.0614 -0.3033 -0.3433 -2.8285 -1.5037 -0.1440 -0.0812 -0.1987 -2.7655 -0.0099 -0.3846 -0.2928
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death ; readmission ; patients ; physician ; hazard ratio ; confidence interval ; physician ; follow-up ; patients ; follow-up
H-1419	-1.0033711194992065	▁death ▁; ▁un plan ned ▁read mission ▁; ▁familiar ▁physician ▁; ▁evaluat ed ▁hazard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁cm ▁; ▁early ▁follow - up ▁visit s ▁; ▁follow - up ▁visit s
D-1419	-1.0033711194992065	death ; unplanned readmission ; familiar physician ; evaluated hazard ratio ;HR ; confidence interval ; cm ; early follow-up visits ; follow-up visits
P-1419	-4.8045 -0.2581 -0.0453 -0.0255 -0.3599 -1.5294 -1.1345 -0.4004 -2.2647 -0.6368 -0.2994 -5.2590 -1.4922 -0.2512 -0.0312 -0.2639 -2.0302 -0.3470 -1.9210 -0.2042 -0.2929 -4.9314 -0.4841 -2.8719 -0.0768 -0.4984 -0.0840 -1.0594 -0.2523 -0.3275 -0.6593 -0.3830 -0.0605 -0.8004 -0.2392 -0.2843 -0.2609
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard ratios ; multivariate regression ; tapse ; pasp ; hazard ratio ; tapse ; new york heart association functional class
H-499	-1.5309059619903564	▁Hazard ▁ratio s ▁; ▁p b ▁; haz ard ▁ratio ▁; HR ▁; ▁p b ▁; ▁ nc w ▁Heart ▁association ▁; ▁functional ▁class ▁; HR
D-499	-1.5309059619903564	Hazard ratios ; pb ;hazard ratio ;HR ; pb ; ncw Heart association ; functional class ;HR
P-499	-1.3805 -0.2430 -1.0123 -0.4371 -2.9479 -1.8587 -0.6663 -3.1521 -0.9860 -0.2232 -0.4340 -3.8250 -0.5335 -3.5810 -1.7266 -0.8082 -1.8792 -5.2396 -0.9264 -3.1800 -1.0631 -0.3399 -0.3623 -0.6474 -0.5103 -3.5966 -0.9942 -0.3110
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek ; human embryonic kidney ; cells ; β1ar ; s1pr1 ; β1ar ; downregulation ; sphingosine-1-phosphate ; s1pr1 agonist ; s1pr1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
H-1409	-1.2406384944915771	▁h ek ▁; human ▁em bry o nic ▁ki dne y ▁; ▁β 1 ar ▁; ▁s 1 PR 1 ▁; ▁β 1 ar ▁; ▁down regul ation ▁; ▁sp hing os ine -1 - phos pha te ▁; ▁s 1 PR 1 ▁; ▁ago nist ▁; ▁iso prot eren ol ▁; ▁β - ad r energi c ▁receptor ▁ago nist
D-1409	-1.2406384944915771	hek ;human embryonic kidney ; β1ar ; s1PR1 ; β1ar ; downregulation ; sphingosine-1-phosphate ; s1PR1 ; agonist ; isoproterenol ; β-adrenergic receptor agonist
P-1409	-1.3466 -2.9387 -0.2611 -0.5971 -0.2057 -0.2629 -0.2401 -0.7095 -0.0355 -1.5782 -0.6512 -0.4674 -2.6336 -3.2032 -3.0639 -0.3982 -1.6342 -2.3585 -3.1048 -4.8170 -0.5960 -1.9754 -3.2644 -2.6329 -1.5773 -1.6125 -1.0226 -2.9879 -0.4750 -0.0532 -2.6936 -0.7677 -3.5531 -1.0838 -0.6508 -0.0356 -0.0822 -0.3011 -0.4058 -0.9378 -1.5075 -2.3794 -3.1794 -1.8009 -4.3720 -0.5670 -0.4980 -0.2867 -0.0569 -0.1381 -0.6292 -0.3643 -0.3047 -0.1341 -0.2933 -0.3252 -1.6877 -0.9508 -0.1004 -0.2063 -0.3284 -0.5527 -0.2812
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline ; training ; 6-minute walked distance ; quality of life ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; symptoms ; beck depression inventory ; zung self-rated depression scores ; b-type natriuretic peptide ; endothelial function ; flow-mediated dilatation ; left ventricular diastolic function
H-1330	-0.5398377776145935	▁walked ▁; ▁kan sas ▁City ▁; ▁cards i om yo pathy ▁Question naire ▁; ▁Minnesota ▁; ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁ depressiv e ▁symptoms ▁; ▁be ck ▁de pression ▁in ven tory ▁; ▁depression ▁score s ▁; ▁na tri ure tic ▁pe pti de ▁; ▁en dot heli al ▁function ▁; flow - media ted ▁di la tation ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function
D-1330	-0.5398377776145935	walked ; kansas City ; cardsiomyopathy Questionnaire ; Minnesota ; Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; depression scores ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; left ventricular diastolic function
P-1330	-2.5085 -0.3965 -0.4121 -0.0995 -0.7170 -1.9846 -0.9124 -0.4965 -0.1206 -0.3705 -0.2423 -1.1853 -0.0975 -0.2120 -0.3523 -0.2613 -0.7178 -0.3358 -0.9455 -0.4494 -0.6373 -0.9531 -0.1272 -0.2482 -0.1309 -0.0653 -0.0543 -1.2375 -0.2221 -0.6241 -0.0300 -0.1875 -0.3648 -0.4217 -0.6467 -0.1504 -0.3067 -2.7195 -0.2857 -0.1847 -0.4290 -2.1174 -0.6544 -0.8143 -1.0337 -1.3590 -0.2262 -0.4424 -0.3483 -0.2127 -0.2747 -0.1877 -0.0531 -0.1484 -0.2709 -0.3033 -0.1053 -0.0664 -1.1570 -0.4626 -0.2768 -0.2918 -0.3626 -0.4113 -0.3785 -1.9928 -1.4080 -0.0426 -0.0801 -0.1159 -0.2515 -0.4883 -0.2262
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal function ; the chronic kidney disease epidemiology collaboration ; patients ; estimated glomerular filtration rate ; egfr
H-390	-0.9950960874557495	▁Ren al ▁function ▁; ▁Chro nic ▁Kid ney ▁Disease ▁Epidemi ology ▁Col labora tion ▁e qu ation ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁g bf ▁; ▁m L ▁; ▁m L
D-390	-0.9950960874557495	Renal function ; Chronic Kidney Disease Epidemiology Collaboration equation ; glomerular filtration rate ; gbf ; mL ; mL
P-390	-3.1816 -0.2942 -0.2315 -0.3826 -0.0731 -0.9734 -0.0390 -0.9002 -0.1686 -0.3941 -0.3491 -2.3412 -0.8458 -0.5802 -1.4337 -0.3936 -1.5873 -0.3917 -0.2655 -0.8037 -0.1070 -0.0625 -1.8634 -0.3773 -0.3707 -5.3639 -2.1280 -0.4026 -0.2727 -2.9536 -1.2830 -0.4622 -2.6919 -0.5066 -0.3530
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective ; randomized ; paradigm-hf ; chronic heart failure ; systolic dysfunction ; lv ef ; functional class ; nyha ; elevated ; bnp ; nt-pro bnp ; primary endpoint ; cardiovascular death ; hospitalization ; heart failure ; arni ; lcz696 ; sacubiltril ; valsartan
H-1968	-0.7281516790390015	▁para dig m - HF ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function ▁; ▁v n ▁EF ▁; ▁functional ▁class ▁; ▁ny ha ▁i - III ▁; ▁b np ▁; ▁ nc w ▁; ▁car dio vas cular ▁death ▁; ▁hospital ization ▁; ▁heart ▁failure ▁; ▁ar ni ▁; ▁l z 696 ▁; ▁sa cubi lt ril ▁; ▁val sar tan
D-1968	-0.7281516790390015	paradigm-HF ; chronic heart failure ; systolic dysfunction ; vn EF ; functional class ; nyha i-III ; bnp ; ncw ; cardiovascular death ; hospitalization ; heart failure ; arni ; lz696 ; sacubiltril ; valsartan
P-1968	-0.3538 -1.0842 -1.0385 -0.1143 -0.4322 -0.3586 -1.1615 -2.1320 -0.5430 -0.3562 -0.1010 -0.1566 -0.3105 -0.0158 -0.1155 -0.3366 -2.3788 -0.7808 -1.8611 -0.3248 -0.0898 -0.2283 -0.5036 -0.6027 -1.3658 -0.8722 -0.6578 -0.1201 -0.3319 -1.5710 -2.5290 -0.4314 -2.5500 -0.6287 -0.6713 -1.6766 -1.8865 -0.3422 -0.9240 -0.7874 -1.2194 -0.2550 -0.3494 -0.8320 -0.4343 -1.4700 -0.7085 -0.3877 -0.6746 -1.2498 -0.3891 -0.0277 -3.6383 -0.2298 -0.4735 -0.0857 -0.0927 -0.1097 -0.4353 -0.2886 -0.2666 -0.1422 -0.1788 -0.4241 -0.2411
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia ; outcomes ; african americans ; aas ; new york heart association ; nyha ; hf ; left ventricular dysfunction ; randomized ; spironolactone ; titrated ; placebo ; randomized aldactone evaluation study ; rales
H-1703	-0.8529555201530457	▁hyper kal emia ▁; ▁African ▁American s ▁; ▁AA s ▁; ▁non - AA s ▁; ▁white ▁; ▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁class ▁III ▁; ▁w h ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁spi rono lac tone ▁; ▁al da cto ne ▁evaluat ion ▁Study ▁; RAL es
D-1703	-0.8529555201530457	hyperkalemia ; African Americans ; AAs ; non-AAs ; white ; New York Heart association ;NYha ; class III ; wh ; left ventricular dysfunction ; spironolactone ; aldactone evaluation Study ;RALes
P-1703	-0.4083 -0.8038 -1.5579 -0.3036 -0.7504 -2.4741 -0.5823 -0.2751 -5.2125 -0.4502 -0.2970 -1.0754 -0.0751 -1.3769 -0.2378 -0.2497 -0.7000 -0.3022 -2.1560 -1.3036 -1.3678 -0.4725 -0.2919 -3.0133 -2.2664 -0.3783 -0.6448 -0.1401 -0.9039 -3.2270 -0.9167 -0.3027 -0.2033 -0.2611 -2.2460 -0.6010 -0.0191 -0.2742 -0.4071 -0.1735 -0.0338 -0.1898 -0.1108 -0.3950 -1.9285 -0.2678 -0.2750 -0.8624 -0.4809 -2.4337 -0.8969 -0.2317 -0.1298 -0.2026 -0.3632 -0.2608
2021-01-28 10:48:45 | INFO | fairseq.logging.progress_bar | :    101 / 105 wps=222
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds ratios ; confidence intervals ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; patients ; estimated glomerular filtration rate ; nonsignificant ; acute kidney injury
H-976	-0.5573205947875977	▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁diabetes ▁mell itus ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁stroke ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁a cute ▁ki dne y ▁injury
D-976	-0.5573205947875977	cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate ; acute kidney injury
P-976	-0.6767 -0.9763 -0.3248 -1.5004 -0.3020 -0.7829 -0.1294 -0.6270 -0.3399 -0.8618 -0.3109 -1.9701 -1.1073 -0.3050 -0.2752 -0.2121 -0.5036 -0.0591 -0.3638 -0.1198 -0.0051 -0.1053 -0.2967 -0.2002 -0.2643 -0.6138 -0.2296 -0.4372 -0.2332 -0.5103 -0.3692 -0.8006 -0.2859 -0.7559 -1.1209 -0.0740 -0.4103 -1.2727 -0.3190 -1.5762 -0.5014 -0.2756 -0.1782 -0.3477 -0.3359 -0.3041 -0.0443 -0.0372 -1.9564 -2.0231 -0.3995 -1.5480 -0.8099 -0.0324 -1.1918 -0.4331 -0.1873 -0.4074 -0.2406
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic function ; ea ; ventricular-arterial coupling ; ees ; ea
H-925	-1.1612136363983154	▁dia sto lic ▁function ▁; ▁Ea ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁e a
D-925	-1.1612136363983154	diastolic function ; Ea ; ventricular-arterial coupling ; ea
P-925	-0.0595 -0.4179 -0.1088 -0.2308 -0.5566 -3.9767 -0.5414 -2.3720 -3.2832 -0.8545 -0.4722 -0.1056 -0.4874 -0.1732 -1.3859 -0.5899 -1.9639 -4.6685 -0.6295 -0.3468
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard ratios ; disease risk score ; drs ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
H-1835	-1.4288790225982666	▁disease ▁risk ▁score ▁; ▁d RS ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁ci ▁; ▁sax ag lip tin ▁; ▁pi og lita zone ▁; ▁sax ag lip tin ▁; ▁sul fon yl ure as ▁; ▁sax ag lip tin ▁; ▁insulin
D-1835	-1.4288790225982666	disease risk score ; dRS ; saxagliptin ; sitagliptin ; ci ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
P-1835	-2.9512 -0.6404 -0.4045 -0.2967 -0.0489 -2.7972 -0.3560 -3.7112 -0.2284 -1.6266 -3.8579 -0.4975 -3.4328 -0.3575 -0.6281 -3.2787 -0.4368 -4.5454 -1.9629 -1.9821 -0.2806 -2.2411 -4.2418 -0.4479 -0.6399 -0.0539 -0.0821 -0.6174 -0.4537 -2.4628 -0.4194 -2.0581 -4.2310 -0.3695 -0.1152 -0.2166 -0.6528 -2.0667 -0.3462 -0.3722 -4.7696 -0.4033 -1.6305 -4.2774 -0.3675 -0.0499 -0.3996 -0.2786
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients ; revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline ; electrocardiogram
H-106	-0.9735117554664612	▁IE ▁; ▁re vas cular ization ▁; ▁co ron ary ▁arter y ▁by pass ▁; ▁surgery ▁; HR ▁; ▁per cuta ne ous ▁corona ry ▁intervention ▁; ▁HR ▁; ▁sy sto lic ▁blood ▁pressure ▁; HR ▁; ▁left ▁bund le ▁bran ch ▁block ▁pattern ▁; ▁base line ▁electro card i ogram ▁; ▁h
D-106	-0.9735117554664612	IE ; revascularization ; coronary artery bypass ; surgery ;HR ; percutaneous coronary intervention ; HR ; systolic blood pressure ;HR ; left bundle branch block pattern ; baseline electrocardiogram ; h
P-106	-3.7671 -0.2554 -0.1328 -0.0653 -0.0966 -1.1718 -0.3752 -1.0027 -2.6459 -1.6245 -0.0525 -1.9309 -2.5260 -0.0610 -0.4757 -0.1691 -0.3196 -5.0762 -0.4031 -0.6466 -0.0064 -0.9769 -1.0633 -0.3754 -2.4273 -0.1420 -0.3558 -3.7534 -0.4958 -0.1644 -0.1365 -0.1670 -1.0635 -1.5857 -0.4017 -4.5277 -0.6284 -0.7348 -0.1167 -0.5752 -0.1408 -0.4489 -0.4878 -0.8548 -0.3274 -1.6798 -0.0435 -0.0179 -0.2151 -0.3190 -0.0801 -0.3053 -5.1362 -0.7357 -0.2549
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical ; biomedical ; relative risk ; confidence interval ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1262	-0.9206222295761108	▁bio medic al ▁treatment ▁; ▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁significant ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end
D-1262	-0.9206222295761108	biomedical treatment ; biomedical treatment ; CHm ; significant ; left ventricular ejection fraction ; left ventricular diastolic end
P-1262	-0.0376 -0.3410 -0.0925 -1.9138 -0.4233 -0.0849 -0.6276 -0.0787 -1.4982 -0.3396 -2.9043 -0.4217 -0.3360 -1.3954 -1.1261 -1.5076 -0.7276 -2.5695 -0.9129 -0.5836 -0.4786 -0.4112 -0.8081 -0.1478 -0.3816 -1.2640 -0.9430 -2.8505 -0.9700 -0.1846 -0.2687 -0.2473 -2.6266 -2.3683 -0.3500
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective ; randomized ; crossover study ; outcome ; stable heart failure ; patients ; left ventricular ejection fraction ; homozygous ; haplotype ; β2-receptor ; randomized ; carvedilol ; metoprolol
H-1114	-0.6996027827262878	▁open - label ▁cross over ▁; ▁mask ed ▁outcome ▁assessment s ▁; ▁heart ▁failure ▁; ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ar g 16 ▁; ▁ gt l n 27 ▁; ▁ha plo type ▁; ▁β 2- recept or ▁; ▁car vedi lol ▁; ▁met o pro lol
D-1114	-0.6996027827262878	open-label crossover ; masked outcome assessments ; heart failure ; ventricular ejection fraction ; arg16 ; gtln27 ; haplotype ; β2-receptor ; carvedilol ; metoprolol
P-1114	-2.0742 -0.1798 -0.2378 -0.1534 -0.0313 -1.2497 -1.2510 -0.1265 -0.5598 -0.4139 -0.2952 -0.3348 -3.5476 -0.3519 -0.5144 -3.7285 -1.6997 -0.5748 -0.3105 -0.4485 -0.2165 -0.6535 -0.0227 -0.3024 -0.5509 -0.4259 -0.7470 -0.4187 -1.4571 -2.4973 -0.8731 -0.0636 -0.6597 -0.2535 -3.1906 -0.7569 -0.2364 -0.3704 -0.1785 -0.0728 -0.0732 -0.1568 -0.4549 -0.1404 -0.2303 -0.7469 -0.3455 -0.1216 -0.1823 -0.2353 -1.6714 -0.4498 -0.2400
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; interquartile range ; β-blockers ; interquartile range ; interquartile range
H-665	-0.44236090779304504	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁inter quart ile ▁range ▁; ▁β - block ers ▁; ▁inter quart ile ▁range
D-665	-0.44236090779304504	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; β-blockers ; interquartile range
P-665	-2.4489 -2.0788 -0.1968 -1.9717 -0.5242 -0.0402 -0.2090 -0.3018 -0.0883 -0.0960 -0.0432 -0.5485 -0.3288 -0.0608 -0.1548 -1.3052 -0.0203 -0.4611 -0.3771 -0.4166 -0.0378 -0.1457 -0.2750 -0.0405 -0.4681 -0.2225 -0.0954 -0.4147 -0.5529 -0.4393 -0.0653 -0.2347 -0.2949 -0.0527 -0.5833 -0.3300
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ; ivabradine ; change ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; correlates ; exercise capacity ; therapy ; ivabradine ; correlated ; peak oxygen uptake
H-1177	-0.7947943210601807	▁Therapy ▁; ▁i va bra dine ▁; ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty ▁; ▁exercise ▁capacity ▁; ▁i va bra dine ▁; ▁oxygen ▁up take
D-1177	-0.7947943210601807	Therapy ; ivabradine ; diastolic mitral flow velocity ; diastolic mitral annular velocity ; exercise capacity ; ivabradine ; oxygen uptake
P-1177	-2.7675 -0.6387 -0.2250 -0.0654 -1.1966 -1.9195 -0.2867 -0.8513 -0.3834 -0.2110 -1.3325 -0.6032 -1.2571 -1.9096 -0.8178 -0.3646 -0.2146 -0.6031 -0.2921 -1.2781 -0.7182 -1.0423 -0.1964 -0.1632 -0.5339 -0.4177 -0.6999 -0.3530 -0.3686 -0.6885 -0.0768 -1.2430 -1.9297 -0.3307 -0.8759 -2.4642 -1.1036 -0.2925 -0.2809
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf ; biosynthetic enzymes ; lyso-paf acetyltransferase ; lyso-paf-at ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; paf-cpt ; catabolic isoenzymes ; paf-acetylhydrolase ; paf-ah ; lipoprotein-associated phospholipase a2 ; lp-pla2 ; leukocytes
H-1268	-0.8406683206558228	▁PA f ▁; ▁bio syn the tic ▁enzym es ▁; lys o - pa f ▁; ▁a ce tyl transfer ase ▁; lys o - pa f - at ▁; ▁di thi oth rei tol ▁; ▁d t ▁; ▁ sensitiv e ▁; ▁cd p ▁; ▁cho line ▁; ▁1- al kyl -2 - ace tyl - s n - gly cer ol ▁; ▁cho line phos pho transfer ase ▁; ▁p bf - c p ▁; ▁cata bo lic ▁iso en zy mes ▁; ▁pa f - ace tyl hydro lase ▁; ▁p bf - AH ▁; ▁lipo prote in - as soci ated ▁ phos pho lipa se ▁a 2 ▁; ▁l p - PLA 2] ▁; ▁leuk o cy tes
D-1268	-0.8406683206558228	PAf ; biosynthetic enzymes ;lyso-paf ; acetyltransferase ;lyso-paf-at ; dithiothreitol ; dt ; sensitive ; cdp ; choline ; 1-alkyl-2-acetyl-sn-glycerol ; cholinephosphotransferase ; pbf-cp ; catabolic isoenzymes ; paf-acetylhydrolase ; pbf-AH ; lipoprotein-associated phospholipase a2 ; lp-PLA2] ; leukocytes
P-1268	-1.5329 -2.4668 -0.2763 -0.0477 -0.0989 -0.9276 -1.8720 -0.2915 -0.3883 -0.3247 -0.0706 -1.0371 -0.1825 -0.5178 -2.9282 -1.8667 -0.1705 -1.3877 -1.8796 -0.3242 -3.4139 -0.2651 -0.3788 -0.6120 -0.1800 -0.5358 -2.8212 -0.7350 -0.6941 -0.2450 -0.1979 -0.4353 -1.6262 -0.0473 -1.9123 -0.2911 -0.3647 -0.6861 -0.3979 -3.2961 -0.7845 -0.5723 -2.3938 -0.4956 -0.3673 -0.4234 -0.5517 -0.3090 -1.6012 -0.2455 -0.1042 -0.2306 -0.4262 -0.2195 -3.6395 -0.6775 -0.2025 -0.2652 -0.0698 -0.2307 -0.1773 -0.3209 -0.5704 -0.6783 -0.9672 -0.5628 -0.5904 -1.6745 -1.4512 -2.8347 -0.3200 -2.0523 -2.7094 -0.2925 -0.9679 -3.0191 -0.8071 -0.1723 -0.1178 -0.0277 -0.0520 -0.3374 -0.6689 -1.3504 -0.3054 -2.9550 -3.4230 -0.1223 -0.9000 -1.0559 -0.1027 -0.6728 -0.2770 -2.0362 -3.0338 -0.1783 -2.7706 -0.2421 -0.3419 -0.4787 -0.6360 -0.2183 -0.2251 -0.0638 -2.4632 -0.1158 -0.1651 -0.3221 -0.2940 -0.6349 -1.3289 -0.0285 -0.2254 -0.0094 -0.0466 -0.1915 -0.0184 -1.2326 -1.0451 -1.0401 -0.2771 -0.1377 -0.4761 -0.4277 -0.3048
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients ; death ; hospitalization ; aor ; aor ; aor ; aor
H-465	-1.2119861841201782	▁low - volu me ▁ED ▁cases ▁; ▁death ▁; hospital ization ▁; ED ▁visit ▁; ▁a OR ▁; ▁a OR ▁; ▁high - volu me ▁ED ▁cases ▁; ▁a OR
D-465	-1.2119861841201782	low-volume ED cases ; death ;hospitalization ;ED visit ; aOR ; aOR ; high-volume ED cases ; aOR
P-465	-1.1510 -0.2347 -0.3564 -0.6153 -1.7967 -1.2814 -0.3105 -2.7066 -0.4415 -0.3601 -0.9173 -0.3242 -2.8012 -1.2250 -0.3357 -1.7775 -0.6469 -0.3770 -5.0802 -0.8927 -0.3987 -3.0272 -0.2538 -0.5358 -0.6068 -1.7564 -2.6934 -0.3577 -3.9379 -0.9040 -0.3957 -0.2844
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine ; baseline ; follow-up ; exercise capacity ; mets ; mets ; peak oxygen uptake ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1175	-0.8675761222839355	▁i va bra dine ▁group ▁; ▁follow - up ▁; ▁exercise ▁capacity ▁; ▁oxygen ▁up take ▁; ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1175	-0.8675761222839355	ivabradine group ; follow-up ; exercise capacity ; oxygen uptake ; early diastolic mitral flow velocity ; diastolic mitral annular velocity
P-1175	-0.0979 -0.0498 -1.0062 -1.4519 -2.0197 -0.3461 -1.1495 -0.2624 -0.0523 -1.7354 -1.8504 -0.4654 -0.4864 -1.9801 -2.6011 -1.2085 -0.4166 -1.1054 -0.0611 -0.4200 -0.3106 -1.5906 -0.6449 -1.6976 -2.0811 -1.1551 -0.4667 -0.4639 -0.4268 -0.4672 -1.1787 -0.7285 -1.0143 -0.0753 -0.3506 -0.8431 -0.4351 -0.2715
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health buddy program ; all-cause mortality ; hazard ratio ; confidence interval ; inpatient ; admissions ; baseline
H-1625	-0.7670360803604126	▁Health ▁Budd y ▁Program ▁; ▁mortal iteit ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; CI ▁; ▁in patient ▁ad missions
D-1625	-0.7670360803604126	Health Buddy Program ; mortaliteit ;hazard ratio ;HR ; confidence interval ;CI ; inpatient admissions
P-1625	-1.3821 -0.1904 -0.2534 -1.3433 -0.3663 -1.1686 -2.1085 -0.3807 -0.0571 -0.1763 -0.0382 -0.3042 -1.8106 -0.3727 -0.2829 -0.1367 -0.3495 -5.1565 -0.3467 -0.2004 -0.1777 -1.4935 -0.3980 -0.3635 -0.3182
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted hazard ratios ; dash
H-691	-0.9735495448112488	▁multi vari able - ad just ed ▁hazard ▁ratio s ▁; ▁DAS h ▁; ▁die t ▁score
D-691	-0.9735495448112488	multivariable-adjusted hazard ratios ; DASh ; diet score
P-691	-2.1619 -0.2862 -1.3578 -0.3601 -0.0975 -0.3214 -0.4783 -0.8106 -0.3202 -0.5577 -0.3818 -3.1688 -0.2494 -1.5848 -2.7400 -0.3270 -0.5513 -2.3385 -0.4042
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt ; nt-probnp ; report ; aric ; hf ; systolic blood pressure ; antihypertensive medication ; diabetes ; body mass index ; coronary heart disease ; heart rate ; hf ; area under the receiver operating characteristic curve ; auc ; integrated discrimination improvement ; net reclassification improvement ; nri
H-287	-0.697020947933197	▁c t n t ▁; ▁NT - pro b NP ▁; labora tory ▁report ▁; ▁a RIC ▁ HF ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁anti hy per tensi ve ▁medication ▁; ▁smoking ▁; ▁diabetes ▁; ▁body ▁mass ▁index ▁; ▁corona ry ▁heart ▁disease ▁; ▁heart ▁rate ▁; ▁ HF ▁; ▁receive r ▁; ▁operating ▁character istic ▁cur ve ▁; ▁ab c ▁; ▁discrimina tion ▁improvement ▁; ▁net ▁re class ification ▁improvement ▁; ▁n RI
D-287	-0.697020947933197	ctnt ; NT-probNP ;laboratory report ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; receiver ; operating characteristic curve ; abc ; discrimination improvement ; net reclassification improvement ; nRI
P-287	-0.0788 -0.0679 -0.0752 -0.4400 -0.2476 -0.0672 -0.0804 -0.0636 -1.1409 -1.4839 -0.2977 -0.7218 -0.3005 -0.1576 -0.3015 -0.7463 -2.3562 -1.7537 -1.7445 -0.3015 -0.2080 -0.3505 -0.2322 -0.9326 -1.6536 -0.3820 -0.0517 -0.7484 -0.0486 -0.1745 -0.3021 -0.4356 -0.9530 -0.5623 -0.2636 -0.2626 -0.3099 -0.4555 -0.1442 -0.0337 -0.2981 -0.1708 -2.4222 -0.7128 -1.1351 -0.2569 -1.5165 -1.0141 -0.3488 -3.0469 -3.4707 -0.2936 -2.6307 -0.0535 -0.8384 -0.4754 -0.2361 -0.1852 -0.6260 -0.4132 -0.3286 -3.0081 -1.6750 -0.2956 -0.2640 -1.8808 -1.5462 -0.2377 -0.0273 -0.0671 -0.1407 -0.8018 -0.8746 -0.1940 -0.9640 -0.3451 -0.4020 -0.2391
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; patients ; heart failure and reduced ejection fraction ; hf-ref ; new york heart association ; nyha ; functional class ; estimated glomerular filtration rate ; egfr ; serum potassium
H-1222	-0.9176135659217834	▁e pler en one ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁w RF ▁; ▁EM PHA SIS - HF ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; HF - re f ▁; ▁New ▁York ▁Heart ▁association ▁; ▁ny ha ▁; ▁functional ▁class ▁II ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR ▁; ▁se rum ▁po tas s ium
D-1222	-0.9176135659217834	eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; ejection fraction ;HF-ref ; New York Heart association ; nyha ; functional class II ; glomerular filtration rate ; egFR ; serum potassium
P-1222	-0.0588 -0.1646 -0.0688 -1.2008 -0.3141 -0.2631 -0.8621 -0.5097 -0.3063 -0.1415 -0.3693 -0.2976 -0.3109 -3.8602 -0.3345 -2.3731 -0.3303 -1.9373 -0.1794 -1.2112 -0.3019 -2.4402 -0.4469 -0.2418 -0.9558 -0.5762 -0.0518 -0.4851 -0.0425 -0.3207 -3.1841 -0.2022 -1.1576 -2.9918 -0.2959 -1.5631 -1.0213 -1.0177 -0.5407 -0.2434 -2.9372 -2.8180 -0.3590 -1.9842 -0.6004 -1.5771 -0.3791 -0.8082 -0.4039 -0.0930 -0.0572 -1.9085 -0.5029 -0.3224 -1.4338 -3.5491 -3.3062 -0.4015 -0.7432 -1.1092 -0.3657 -0.7073 -0.2787 -0.1191 -0.3879 -0.2353
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline ; follow-up ; nyha classification ; patients ; patient ; change ; patient ; quality of life ; duke activity status index ; kansas city cardiomyopathy questionnaire ; 6 min walk test
H-1958	-1.2516580820083618	▁follow - up ▁; ▁NY ha ▁classifica tion ▁; ▁class ▁II ▁; ▁patients ▁; ▁class ▁I ▁; ▁Duke ▁Activ iteit ▁Status ▁index ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁walk ▁test ▁distance ▁; SD
D-1958	-1.2516580820083618	follow-up ; NYha classification ; class II ; patients ; class I ; Duke Activiteit Status index ; Kansas City Cardiomyopathy Questionnaire ; walk test distance ;SD
P-1958	-4.5118 -0.2778 -0.0432 -0.4022 -2.2658 -2.2498 -1.1782 -1.1010 -0.4770 -3.7423 -2.9938 -0.6291 -2.3550 -0.5492 -2.3094 -1.7296 -0.7057 -1.9494 -1.0851 -1.5149 -0.7970 -0.9861 -0.3688 -0.5414 -3.1139 -1.2393 -0.0644 -0.2075 -0.3706 -0.2340 -0.7837 -0.1726 -0.5148 -1.6664 -1.5127 -1.3866 -0.4991 -2.9160 -0.2869 -0.3342
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo ; dopamine ; dopamine ; placebo ; change ; cystatin c ; dopamine ; placebo
H-80	-1.3727692365646362	▁place bo ▁; ▁low - dos e ▁dop amine ▁; ▁significant ▁; ▁urin e ▁volume ▁; dop amine ▁; ▁place bo ▁; ▁m L ▁; ▁cyst atin ▁c ▁level ▁; dop amine ▁; ▁place bo
D-80	-1.3727692365646362	placebo ; low-dose dopamine ; significant ; urine volume ;dopamine ; placebo ; mL ; cystatin c level ;dopamine ; placebo
P-80	-6.6137 -0.3916 -0.3143 -1.2193 -0.1365 -0.6448 -0.6072 -0.0934 -0.5961 -0.2733 -0.4852 -1.6232 -0.4588 -0.2006 -0.3761 -0.2636 -2.1620 -1.2934 -0.3518 -5.7293 -0.5260 -0.3215 -4.5367 -4.0207 -0.3757 -0.9466 -0.9826 -1.5703 -0.3010 -0.2602 -2.0329 -1.6865 -0.4163 -7.5796 -0.4383 -0.6157 -0.3481
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide ; nesiritide ; placebo ; change ; cystatin c ; nesiritide ; placebo
H-81	-1.5151938199996948	▁low - dos e ▁nesi riti de ▁; ▁urin e ▁volume ▁; nesi riti de ▁; ▁place bo ▁; ▁m L ▁; ▁cyst atin ▁c ▁level ▁; nesi riti de ▁; ▁place bo
D-81	-1.5151938199996948	low-dose nesiritide ; urine volume ;nesiritide ; placebo ; mL ; cystatin c level ;nesiritide ; placebo
P-81	-7.9805 -0.1796 -0.8668 -0.2553 -0.7343 -0.5270 -0.7052 -0.3442 -2.1578 -0.2432 -0.4593 -0.2945 -3.1326 -1.3588 -0.8580 -0.4342 -5.3195 -0.1836 -0.3721 -4.4732 -4.1241 -0.4591 -1.4706 -0.8870 -1.6862 -0.2673 -0.2565 -3.2044 -1.6748 -0.7611 -0.4396 -5.8581 -0.1519 -0.5482 -0.3634
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking ; functional capacity ; 6mwt ; physical ; activity ; symptoms ; hospital anxiety and depression scale
H-572	-0.7124414443969727	▁Nordic ▁walking ▁; ▁functional ▁capacity ▁; ▁mw t ▁; ▁physical ▁activity ▁; ▁right ▁grip ▁strength ▁; ▁ depressiv e ▁symptoms ▁; Hospital ▁an xie ty ▁; ▁de pression ▁Scal e
D-572	-0.7124414443969727	Nordic walking ; functional capacity ; mwt ; physical activity ; right grip strength ; depressive symptoms ;Hospital anxiety ; depression Scale
P-572	-0.8378 -1.1558 -0.3028 -0.1633 -0.2148 -0.4585 -1.0348 -0.0713 -0.3769 -2.2547 -1.2418 -0.5032 -2.9622 -0.2511 -0.9058 -0.4950 -0.4972 -0.2617 -0.0944 -1.7202 -0.4236 -1.2355 -0.5698 -0.0940 -0.4495 -1.6954 -0.1319 -0.2848 -0.7305 -0.0340 -0.9969 -0.3489
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients ; hyperkalemia ; patients ; diabetes ; egfr ; systolic blood pressure ; potassium ; hyperkalemia ; leading ; hospitalization ; hospitalization ; primary outcome ; hospitalization ; hf ; cardiovascular mortality
H-1225	-1.1159756183624268	▁hyper kal emia ▁; ▁w RF ▁; ▁diabetes ▁; ▁e g FR ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁h g ▁; po tas s ium ▁; ▁hyper kal emia ▁; ▁w RF ▁; hospital ization ▁; ▁ HF ▁; ▁cardiovascular ▁mortal iteit
D-1225	-1.1159756183624268	hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; wRF ;hospitalization ; HF ; cardiovascular mortaliteit
P-1225	-0.5068 -1.1968 -2.2423 -0.2715 -0.2923 -4.1413 -0.3314 -0.2451 -0.3506 -0.6855 -2.5532 -3.1898 -0.3016 -0.2681 -0.2148 -0.2062 -1.1357 -1.8543 -0.3367 -2.3621 -0.6056 -0.3562 -1.3419 -1.2331 -0.2194 -0.1575 -0.3460 -1.8116 -1.5599 -1.9544 -0.3213 -0.6996 -4.5809 -0.3034 -3.1472 -1.5075 -0.2640 -1.5439 -1.7482 -0.2236 -0.0744 -0.1690 -2.8263 -0.3071 -0.2308
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard ratio ; confidence interval ; baseline ; glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; new york heart association class ; atrial fibrillation ; congestive hf ; mortality
H-66	-1.1506859064102173	haz ard ▁ratio ▁; HR ▁; ▁ nc w ▁; ▁base line ▁glo mer ular ▁filtr ation ▁rate ▁; HR ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; HR ▁; ▁diabetes ▁; HR ▁; ▁per i pher al ▁vas cular ▁disease ▁; HR ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁h ▁; ▁i CD ▁shock s ▁; ▁h ▁; ▁New ▁York ▁Heart ▁association ▁; ▁at rial ▁fi bril lation ▁; ▁con ges tive ▁ HF ▁; ▁mortal iteit
D-66	-1.1506859064102173	hazard ratio ;HR ; ncw ; baseline glomerular filtration rate ;HR ; chronic obstructive pulmonary disease ;HR ; diabetes ;HR ; peripheral vascular disease ;HR ; left ventricular ejection fraction ; h ; iCD shocks ; h ; New York Heart association ; atrial fibrillation ; congestive HF ; mortaliteit
P-66	-3.4730 -0.2052 -0.0645 -0.2019 -2.0447 -0.3047 -6.2992 -2.9289 -0.6578 -0.3789 -1.3839 -0.3031 -0.1652 -0.4908 -0.0839 -0.0573 -1.5145 -1.2277 -0.3682 -2.9419 -0.4407 -0.6643 -0.7522 -1.3754 -2.1342 -0.0239 -1.3062 -0.7460 -0.3581 -3.5199 -0.4061 -0.3162 -0.2973 -4.2214 -0.5287 -0.6605 -0.2907 -1.2705 -0.3445 -0.4183 -0.4235 -1.2724 -0.3911 -3.5228 -0.4679 -1.7658 -0.4115 -2.6377 -0.8880 -0.1245 -0.4204 -0.2081 -0.7624 -0.0681 -0.3531 -4.8333 -1.0603 -1.5866 -1.5605 -0.5060 -0.3689 -0.3102 -6.3463 -0.8162 -2.2617 -1.9382 -2.1896 -0.5497 -0.5138 -1.4149 -0.7178 -0.4444 -0.2340 -0.7781 -0.3642 -0.7901 -0.5041 -2.6127 -0.6085 -1.2077 -0.9785 -0.3928 -2.3187 -0.4152 -0.2980
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable analysis ; end point ; peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
H-1761	-0.875184178352356	▁oxygen ▁up take ▁; ▁hazard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁ventilator y ▁efficiency ▁s lope ▁; ▁hem o glob in ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁renal ▁function ▁; ▁renal ▁disease ▁; ▁so dium
D-1761	-0.875184178352356	oxygen uptake ; hazard ratio ;HR ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
P-1761	-1.2414 -3.0986 -1.8244 -0.3431 -1.0302 -0.0863 -0.3041 -3.0705 -0.3925 -0.6169 -0.3589 -0.3737 -4.1272 -1.2699 -0.2475 -0.9354 -0.6979 -0.3644 -1.5635 -0.5496 -0.3090 -0.8803 -0.3798 -2.7546 -0.5849 -2.2428 -0.9778 -0.4225 -0.4642 -0.2126 -0.6949 -0.0963 -0.3728 -0.3514 -0.6655 -0.3445 -0.3857 -1.0682 -0.4319 -0.3805 -0.1935 -0.6294 -0.2935
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute walked distance ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; beck depression inventory ; flow-mediated dilatation ; fes ; placebo ; b-type natriuretic peptide ; mitral
H-1331	-0.7872229814529419	▁Kansas ▁City ▁; ▁Card i om yo pathy ▁Question naire ▁; ▁Minnesota ▁; ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁ zwe ng ▁; ▁flow - media ted ▁di la tation ▁diameter ▁; ▁f es ▁; ▁place bo ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁mit ral ▁; ▁wa ve ▁ratio
D-1331	-0.7872229814529419	Kansas City ; Cardiomyopathy Questionnaire ; Minnesota ; Living with Heart Failure Questionnaire ; Beck depression inventory ; zweng ; flow-mediated dilatation diameter ; fes ; placebo ; b-type natriuretic peptide ; mitral ; wave ratio
P-1331	-0.5824 -2.4174 -0.5409 -1.5260 -0.1390 -0.3339 -0.5129 -0.2071 -2.1009 -0.1052 -0.6354 -0.2794 -0.6210 -0.4532 -0.6453 -1.1359 -0.4706 -1.8378 -1.3580 -0.2461 -0.3189 -0.5963 -0.8578 -0.1426 -0.5299 -0.7609 -0.3261 -0.2917 -0.3761 -3.5774 -3.3643 -0.2519 -0.3660 -0.1213 -0.1450 -1.4175 -0.2130 -0.5299 -0.2829 -0.1365 -0.3269 -1.6969 -2.6664 -0.4195 -2.6835 -0.0345 -0.8133 -2.9540 -0.2740 -0.0427 -0.0277 -0.7269 -1.2236 -1.2965 -0.3693 -0.1517 -1.1645 -0.3487 -1.0621 -0.2334 -0.2902 -1.2956 -0.2114 -0.1625 -0.4571 -0.2696
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate analysis ; chf ; odds ratio ; chest ; hypertension ; genes ; rac2 ; doxorubicin efflux transporter ; abcc2
H-1455	-0.9521896839141846	▁CHF ▁; Od ds ▁Ra tio ▁; ▁h t ▁; ▁che st ▁radi ation ▁; ▁hyper tension ▁; ▁gene s ▁co ding ▁; ▁ NAD - h - oxid ase ▁sub un it ▁ RAC 2 ▁; ▁h bf ▁; ▁do xor ubi cin ▁ eff lux ▁transporter ▁; ▁ab c 2
D-1455	-0.9521896839141846	CHF ;Odds Ratio ; ht ; chest radiation ; hypertension ; genes coding ; NAD-h-oxidase subunit RAC2 ; hbf ; doxorubicin efflux transporter ; abc2
P-1455	-1.2403 -0.3215 -2.4867 -0.3081 -2.0663 -2.7478 -0.3850 -0.9386 -2.4507 -0.5696 -0.2503 -0.1253 -0.2609 -1.8035 -0.4091 -0.3223 -0.3149 -0.3688 -1.1899 -0.5735 -0.3180 -1.1269 -0.3436 -1.4488 -0.1627 -6.2118 -2.5362 -0.6508 -0.0745 -3.1804 -0.2606 -0.3324 -0.7174 -1.4413 -0.5171 -0.8445 -0.3505 -0.7685 -4.4376 -0.3337 -0.2697 -0.2540 -0.1602 -1.0458 -0.2710 -0.1285 -0.1147 -0.2906 -0.4518 -0.2057 -1.3389 -0.9790 -0.3668 -0.3512
2021-01-28 10:48:55 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-28 10:48:55 | INFO | fairseq_cli.generate | Translated 2,024 sentences (36,756 tokens) in 157.2s (12.88 sentences/s, 233.86 tokens/s)
2021-01-28 10:48:55 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 47.35, 68.9/54.7/45.9/38.7 (BP=0.931, ratio=0.933, syslen=36756, reflen=39387)
